6-K
Grifols SA (GRFS)
6-K
2023-02-28
For: 2023-02-28
View Original
Added on
April 05, 2026
UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 OF THESECURITIES EXCHANGE ACT OF 1934
For the month February 2023
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ¨ No x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ¨ No x
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
| Item | Sequential Page Number | |
|---|---|---|
| 1. | Press Release dated February 28,<br> 2023 | 3 |
| 2. | Consolidated Annual Accounts for the year ended December 31,<br> 2022 | 40 |
| Page 1 of 5<br>Full Year 2022 Results<br>Grifols delivers strong 2022 performance and is<br>positioned for sustainable future growth<br>Revenue reaches EUR 6,064 million (+12.4% cc1) and Adjusted EBITDA improves to<br>EUR 1,247 million, both in in line with guidance, while leverage ratio down to 7.1x2<br>exceeding guidance<br>Barcelona, Spain, February 28, 2023- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS)<br>delivered solid and improved operating and financial performance in 2022, while continuing to<br>execute on its top priorities. Total revenue grew by 12.4% cc (+22.9% on a reported basis) compared<br>to 2021, reaching record levels of EUR 6,064.0 million (EUR 5,702.7 million excluding Biotest) mainly<br>driven by Biopharma’s key proteins following strong recovery of plasma supply.<br>Grifols’ co-CEOs Victor Grifols Deu and Raimon Grifols Roura note: “Grifols has closed 2022 by<br>delivering on its commitments, while taking difficult but required actions to further strengthen the<br>organization. We want to thank the Grifols’ team for successfully navigating through a challenging<br>year. Looking at 2023, we believe the company has a solid foundation on which to build Grifols’<br>future. We continue to work and innovate to provide life-saving medicines to patients, while we are<br>committed to driving meaningful impact for all our stakeholders.”<br>1<br> Operating or constant currency (cc) excludes changes rate variations reported in the period<br>2 Leverage ratio consistently calculated based on the credit facilities agreement and including Biotest<br>x Full year revenue growth of 12% cc and 23% on a reported basis driven by Biopharma’s<br>performance (EUR 5,005 million; +20% cc; +31% reported) supported by solid underlying<br>demand, pricing, product mix, Biotest contribution and FX tailwind<br>x Plasma collection volumes increase by 25% vs. 2021<br>x Reported EBITDA improves to EUR 1,198 million, a 21.0% margin (EUR 1,221 million and<br>20.1% including Biotest) backed by operational leverage and cost discipline, although still<br>impacted by high cost per liter<br>x Net profit increases by 10.4% to EUR 208 million<br>x Reported leverage ratio declines to 7.1x by end-year. Liquidity position at EUR 1.6bn<br>x Grifols pursues long-term competitiveness with an operational improvement plan, which<br>will deliver EUR 400 million annualized cash cost savings<br>x The company provides guidance for 2023 showing revenue growth of 8-10% and significant<br>EBITDA margin expansion. Including annualized cost savings, EBITDA stand alone is<br>expected to reach EUR 1.7 billion, representing a 27-28% margin<br>x Board of Directors and Management are fully committed to achieving the guidance and<br>delivering on the top priorities, including the improvement plan and executing on<br>deleveraging in 2023 | ||
| --- | ||
| Page 2 of 5<br>As Alfredo Arroyo, CFO, states, “Superior execution across our key priorities resulted in a year of<br>transformation. We are implementing initiatives to strengthen financial performance and discipline,<br>reflected on the announced operational improvement plan delivering EUR 400 million annualized<br>cash cost savings. We are focused on executing to continue growing our revenue, meaningfully<br>expanding margins and deleveraging.”<br>Biopharma revenue reached EUR 5,005.4 million growing by 19.6% cc (+31.2% on a reported<br>basis) compared to 2021. Underpinning this strong performance were plasma collections, robust<br>underlying demand for key proteins and price increases. Favorable product mix was also a notable<br>driver with subcutaneous immunoglobulin (SCIG) Xembify® sales increasing by +33.7% supported<br>by higher demand and favorable customer mix, as well as ALBUTEIN FlexBag™ gaining traction<br>after its launch in November 2021.<br>Grifols Biopharma’s revenue, excluding Biotest, grew by 5.1% cc (+15.6% on a reported basis) up<br>to EUR 4,644.1 million in 2022, reflecting a sequential acceleration with a 17.5% cc growth in the<br>second half of the year compared to +3.3% cc in the first half of 2022.<br>Plasma collections continued to improve, increasing by 25% in 2022 (+26% in the U.S.) compared<br>to previous year. Growth in plasma collections in 2023 is expected to be supported by efficiencies in<br>centers in terms of digitalization, processes and donor experience, coupled with current plasma<br>momentum, macroeconomic backdrop and the upside from qualified Mexican national donors.<br>Additionally, Grifols is focused on optimizing its plasma-center network by closing or consolidating<br>underperforming centers, having closed 18 centers in the fourth quarter of 2022 and with several<br>additional centers scheduled to be closed or consolidated in the first half of 2023.<br>Diagnostic recorded EUR 671.3 million in revenue in 2022, down 19.7% cc (-13.8% on a reported<br>basis) compared to 2021, primarily due to non-recurring sales of TMA (Transcription-Mediated<br>Amplification) molecular tests, used to detect SARS-CoV-2, and the termination of mandatory Zika-virus testing, partially offset by blood typing solutions’ double-digit-growth across most geographies.<br>Excluding the COVID-19 one-off testing and mandatory Zika-virus screening effects, the decline was<br>4.6% cc, impacted by pricing in NAT Donor Screening and recombinant proteins.<br>Bio Supplies expanded by 13.2% cc (+26.1% on a reported basis) to EUR 146.1 million in 2022,<br>following the acquisition of the remaining 51% capital of Access Biologicals, which positively<br>impacted performance of Bio Supplies Biopharma’s cell culture media and plasma for diagnostics.<br>Gross margin totaled 37.6% in 2022 (36.8% including Biotest) due to a double impact from<br>Biopharma and Diagnostic. On the one hand, high cost per liter resulted from plasma collected in<br>2021 and the first half of 2022, due to inventory accounting (c.9-months lag). This was primarily due<br>to elevated donor commitment compensation (DCC) and inflationary pressures on labor costs. On<br>the other hand, COVID-19 one-off testing and Zika screening adversely impacted gross margin by<br>210bps in 2022 compared to previous year.<br>Grifols is currently focused on margin expansion while achieving desired plasma volumes for 2023,<br>reducing cost per liter to more sustainable levels. To this end, DCC’s drop by 20% in Q4 vs. its peak<br>in July drove a 10% CPL reduction over the same reference period. Other plasma operating costs,<br>accounting approximately for the remaining 65% of the fully-loaded plasma cost, also declined, albeit<br>to a lesser extent, amid the current macroeconomic backdrop. | ||
| --- | ||
| Page 3 of 5<br>The company recently announced operational improvement plan aims to further address these<br>plasma-related costs through a range of measures resulting in at least EUR 300 million annualized<br>cost savings – out of the EUR 400 million targeted for the whole Plan.<br>EBITDA grew to EUR 1,198 million at a 21.0% margin (EUR 1,221 million and 20.1% including<br>Biotest) in 2022, supported by operating leverage, including SG&A cost savings and R+D<br>prioritization, partially offsetting a high cost per liter in the first half, decreased margin from<br>Diagnostic, inflationary pressures, and high Biotest expenses, particularly related to the Biotest Next<br>Level (BNL) project3<br>..<br>Adjusted EBITDA stood at EUR 1,174 million (EUR 1,247 million including Biotest), a 20.6% margin.<br>Excluding the impact of IFRS 164<br>, net financial debt totaled EUR 9,191.3 million, while the reported<br>leverage ratio declined from 9.0x in the first half of 2022 to 7.1x for the full year 2022, following<br>organic EBITDA improvement and enhanced inventory management.<br>As of December 31, 2022, Grifols’ strong liquidity position totaled EUR 1,562 million, including a<br>cash position of EUR 548 million.<br>2023 Guidance<br>Testament to its commitment to enhance communication with its stakeholders, Grifols provides<br>guidance for 2023, signaling robust total and Biopharma revenue growth of 8-10% and 10-12% cc,<br>respectively; as well as significant margin expansion in the second half with a 23-25% EBITDA<br>margin excluding Biotest; supported by a continued increase in plasma collections and a reduction<br>of cost per liter and other costs, including EUR 100 million savings expected to be recognized in the<br>profit and loss account, as part of the operational improvement plan. Including the EUR 400 million<br>annualized cash cost savings, the EBITDA stand-alone is expected to stand at EUR 1.7 billion and<br>27-28% margin.<br>Grifols’ fundamentals remain strong. The company continues to execute on its top priorities with a<br>long-term vision, and is well-positioned for future growth, focused on business performance,<br>operational excellence and delivering value to its stakeholders.<br>CONFERENCE CALL<br>Grifols invites investors to listen to a webcast of a conference call at 2.30 pm CET / 8.30 am EST on<br>Tuesday, February 28, 2023.<br>To listen to the webcast and view the FY22 Results Presentation, visit our web site >> FY2022<br>Earnings Call. Participants are advised to register in advance of the conference call.<br>The transcript and webcast replay of the call will be made available on our web site at<br>www.grifols.com/en/investors within 24 hours after the end of the live conference call.<br>3<br> Biotest Next Level (BNL) project aims to increase production capacity in Dreieich, Germany, and develop three key R&D projects (IgG Next Gen,<br>Trimodulin, Fibrinogen)<br>4 As of December 31, 2022, the impact of IFRS 16 on total debts is EUR 1,016.9 million | ||
| --- | ||
| Page 4 of 5<br>INVESTORS:<br>Grifols Investors Relations & Sustainability<br>inversores@grifols.com - investors@grifols.com<br>sostenibilidad@grifols.com - sustainability@grifols.com<br>Tel. +34 93 571 02 21<br>MEDIA CONTACTS:<br>Grifols Press Office<br>media@grifols.com<br>Tel. +34 93 571 00 02<br>Spain<br>Duomo Comunicación<br>Tel.: +34 91 311 92 89 – +34 91 311 92 90<br>Raquel Lumbreras (Tel. +34 659 572 185)<br>Raquel_lumbreras@duomocomunicacion.com<br>Borja Gómez (Tel. +34 650 402 225)<br>Borja_gomez@duomocomunicacion.com<br>International<br>Finsbury Glover Hering<br>Email: Grifols-global@finsbury.com<br>Tel.: +44 20 7251 3801<br>About Grifols<br>Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and<br>well-being of people around the world. A leader in essential plasma-derived medicines and transfusion<br>medicine, the company develops, produces, and provides innovative healthcare services and solutions in more<br>than 110 countries.<br>Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times<br>life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance<br>quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology,<br>hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.<br>A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest<br>with over 400 across North America, Europe, Africa and the Middle East, and China.<br>As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed<br>to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and<br>diagnostic products. The company also supplies tools, information and services that enable hospitals,<br>pharmacies and healthcare professionals to efficiently deliver expert medical care.<br>Grifols, with more than 26,000 employees in more than 30 countries and regions, is committed to a sustainable<br>business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.<br>In 2022, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also<br>generated 193,000 jobs, including indirect and induced.<br>The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35<br>(MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the<br>U.S. NASDAQ through ADRs (NASDAQ:GRFS).<br>For more information about Grifols, please visit www.grifols.com | ||
| --- | ||
| Page 5 of 5<br>LEGAL DISCLAIMER<br>The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”.<br>Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”,<br> “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future<br>projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the<br>management team at the time of writing this report, and these are subject to a number of factors that mean that the actual<br>results may be materially different. The future results of the Grifols group could be affected by events relating to its own<br>activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor<br>products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the<br>date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of<br>these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or<br>assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly<br>required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares<br>in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October,<br>approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005,<br>of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of<br>purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote<br>or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the<br>external auditors of the Grifols group. | ||
| --- | ||
| 2022<br>Full Year Results<br>February 28, 2023<br>Executing on<br>Key Priorities | ||
| --- | ||
| 2022 Full Year Results - 2 -<br>Important Information<br>This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market<br>Law (Royal Legislative Decree 4/2015, of 23 October, as amended and restated from time to time), Royal Decree 1310/2005, of November 4, and its<br>implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or<br>exchange of securities, nor a request for any vote or approval in any other jurisdiction.<br>Forward-Looking Statements<br>This presentation contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by GRIFOLS<br>management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to<br>capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not<br>historical facts and are generally identified by the words “expected”, “potential”, “estimates” and similar expressions.<br>Although Grifols believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks, uncertainties<br>and other factors could lead to material differences between the actual future results, financial situation, development or performance of the Company and the<br>estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado de Valores and the Securities<br>and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update these forward-looking statements or<br>conform them to future events or developments. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the<br>auditors of Grifols.<br>NON-GAAP Financial Measures<br>This presentation refers to certain non-GAAP financial measures. The presentation of these financial measures is not intended to be considered in isolation, or<br>as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material<br>limitations associated with the use of non-GAAP financial measures as an analytical tool. In addition, these measures may be different from non-GAAP financial<br>measures used by other companies, limiting their usefulness for comparative purposes. We compensate for these limitations by providing specific information<br>regarding GAAP amounts excluded from these non-GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly<br>comparable GAAP financial measures can be found in our Grifols Financial Statements.<br>Legal Disclaimer | ||
| --- | ||
| 2022 Full Year Results - 3 -<br>1. Key Priorities and 2022 Value Drivers<br>2. Performance by Business Unit<br>3. Group Financial Performance and 2023 Guidance<br>4. Final Remarks<br>5. Annex<br>Table of Contents | ||
| --- | ||
| 2022 Full Year Results - 4 -<br>Executing on Our Priorities and Commitments<br>Performance<br>culture<br>Key Priorities<br>Efficient, effective,<br>data-driven, agile and<br>decisive organization<br>Strengthen financial<br>performance,<br>financial discipline<br>and cost control<br>Bolstering innovation<br>and product portfolio<br>to deliver life<br>changing medicines<br>to patients<br>Improve cash flow<br>and expense profile<br>Debt reduction<br>Commercial<br>portfolio/innovation<br>Biotest<br>Modified short-term<br>incentive plans<br>First equity-based long-term incentive plan Delayering and better spans of control<br>Operational<br>improvement plan with<br>EUR 400m annualized<br>cash cost savings<br>Implemented<br>measures to increase<br>operating cash flow<br>Capital<br>allocation discipline<br>Growth plan for SCIG<br>and strengthen<br>positioning in Alpha-1<br>Acceleration of<br>clinical trials<br>Accelerated Biotest’s<br>integration<br>Operational<br>excellence<br>Evaluating<br>transactional<br>alternatives to delever<br>Key priorities Actions underway | ||
| --- | ||
| 2022 Full Year Results - 5 -<br>Delivering Solid Performance While Meeting Guidance<br>2022 Value Drivers<br>961<br>945<br>1,198<br>LTM EBITDA Reported (stand-alone)<br>-9.8%<br>-0.5%<br>11.0%<br>-12.0%<br>3.3%<br>17.5%<br>Total revenue growth (stand-alone)<br>Biopharma revenue growth (stand-alone)<br>H2’21 H1’22 H2’22<br>+5.1% cc (+8.6% in Q4)<br>+15.6% (+22.5% in Q4)<br>Robust sequential revenue growth (at cc)<br>Leverage ratio 7.1x €6,064m<br>Revenue<br>with Biotest<br>Revenue Growth Operating Performance Leverage Ratio<br>+22.9% (+34.7% in Q4)<br>+12.4% cc (+20.9% in Q4)<br> €5,703m<br>Revenue<br>stand-alone<br>EBITDA<br>with Biotest €1,221m<br>Reported Adjusted<br>20.1%<br> €1,247m<br>20.6%<br>EBITDA<br>stand-alone<br> €1,198m<br>21.0%<br> €1,174m<br>20.6%<br>FY21 H1’22 FY22<br>6.2x<br>9.0x<br>7.1x<br>LR (combined)<br>FY21 proforma<br>incl. Biotest<br>H1’22 FY22<br>Solid sequential EBITDA expansion (in million EUR) Significant leverage reduction<br>investment<br>Consistently calculated based on the<br>credit facilities agreement and<br>including Biotest | ||
| --- | ||
| 2022 Full Year Results - 6 -<br>Pivotal Year to Unlock Further Shareholder Value<br>2022 Value Drivers<br>Accounting consolidation beginning May’22<br>Closed a transformational<br>strategic transaction<br>to accelerate growth and innovation<br> • Xembify® (SCIG) approved in several EU countries<br>and Australia for PID and SID<br> • Xembify® (SCIG) in SID-CLL: FDA IND approved<br> • Sign-off of a collaboration agreement with Endpoint<br>Health to develop and commercialize<br>an ATIII therapy in Sepsis<br> • Positive topline results of VISTASEAL™ (fibrin<br>sealant) in biosurgery pediatric use study<br> • Accelerated patient enrollment plan for PRECIOSA<br>(albumin in liver disease) and SPARTA (alpha-1<br>deficiency)<br> • Biotest Yimmugo® (IVIG NextGen) approved in<br>Germany and Austria for patients with<br>immunodeficiencies and immunomodulation<br> • FDA approves AlphaID™ At Home<br> • FDA approves Blood Typing Manager Agreement with CBS to increase Canada’s<br>self-sufficiency in<br>immunoglobulin medicines<br>2.4m IG<br>grams/year<br>provided by 2026<br>Innovation<br> • xx • xx Biopharma Diagnostic<br>FY22 milestones<br>Canadian Blood Services<br>Balancing plasma volumes<br>and cost per liter<br>to expand profitability<br>Plasma collections vs. FY’21 +25%<br>Q4’22 Cost per liter vs. July’22 peak -10%<br>Q4’22 Donor fee vs. July’22 peak -20%<br>Plasma<br>96%+<br>voting rights<br>70%<br>share capital<br> €1,600m<br>Equity Value<br> €2,000m<br>Enterprise Value<br>Unique opportunity U to…<br>* (U.S. data)<br>Accelerate R&D pipeline with two new plasma<br>proteins to boost revenues and margins<br>Balance global footprint, expanding plasma,<br>commercial footprint and operations in EMEA | ||
| --- | ||
| 2022 Full Year Results - 7 -<br>1. Key Priorities & 2022 Value Drivers<br>2. Performance by Business Unit<br>3. Group Financial Performance and 2023 Guidance<br>4. Final Remarks<br>5. Annex<br>Table of Contents | ||
| --- | ||
| 2022 Full Year Results - 8 -<br>Performance by Business Unit<br>Biopharma and Biotest Drive Double-Digit Revenues Growth<br>386<br>518<br>361<br>4,933<br>FY21 Biopharma<br>154<br>Diagnostic<br>15<br>Bio<br>Supplies<br>5<br>Intersegments<br>and others<br>5,185<br>FY22<br>stand-alone (cc)<br>FX FY22<br>stand-alone<br>6,064<br>FY22<br>combined<br>5,703<br>+22.9%<br>(+12.4%<br>at cc) +15.6%<br>+5.1% cc<br>+10.1% -19.7% +13.2%<br>Grifols Biotest Combined<br>Revenues 5,703 361 6,064<br>% growth +15.6% - +22.9%<br>% growth at cc +5.1% - +12.4%<br>Biopharma 4,644 361 5,005<br>% growth +21.7% - +31.2%<br>% growth at cc +10.1% - +19.6%<br>Diagnostic 672 - 672<br>% growth -13.8% - -13.8%<br>% growth at cc -19.7% - -19.7%<br>Bio Supplies 146 - 146<br>% growth +26.1% - +26.1%<br>% growth at cc +13.2% - +13.2%<br>Others & Intersegments 241 - 241<br>% growth +8.1% - +8.1%<br>% growth at cc +1.9% - +1.9%<br>FY22<br>+1.9%<br>(EUR in millions) | ||
| --- | ||
| 2022 Full Year Results - 9 -<br>Alpha-1 &<br>Specialty<br>proteins<br>Performance by Business Unit | Biopharma (stand-alone figures)<br>Robust Growth Supported by Strong Underlying Demand for Key Proteins<br>IG<br>55-60%<br>of revenues<br>Albumin<br>10-15%<br>of revenues<br>25-30%<br>of revenues<br>+29.5%<br>+14.2% cc<br>Q4’22<br>+21.7%<br>+10.1% cc<br>FY22<br> • Solid IVIG performance backed by higher<br>plasma supply and strong demand,<br>coupled with price increase<br> • SCIG gaining traction (+34% in FY22)<br>+13.3%<br>+4.9%<br> • Higher demand in APAC driven by China<br> • Improved product mix supported by<br>albumin in bags launch<br>+6.9%<br> • Sales increased by low-double-digit driven by robust underlying<br>demand and favorable product mix as Xembify® continues to gain<br>weight<br> • Margins impacted by high cost per liter in the first half of 2022;<br>10% cash cost per liter decline in Q4’22 since July’22 peak, driven<br>by donor compensation<br> • Plasma collections grew 25% underpinning growth<br>Revenue performance by protein in FY22 (at cc)<br> • Biotest Yimmugo® (IVIG NextGen) launched in Germany<br> • Market expansion of TAVLESSE® in Norway and Czech Republic; received<br>NICE recommendation in UK<br> • VISTASEAL™ launched in Canada, Italy, Switzerland, Estonia, Latvia,<br>Lithuania and Australia<br>Commercial milestones<br> • Favorable alpha-1 customer mix, higher<br>demand and price increase<br> • Strong demand for Hypers, VISTASEAL™<br>and TAVLESSE®<br> • HyperRAB performing well | |
| --- | ||
| 2022 Full Year Results - 10 -<br>Donor commitment compensation (DCC)<br>Plasma Momentum Continues While Cost Per Liter Declines<br>+25% +26% in U.S<br>FY22 vs. FY21 +32%<br>U.S. Southern border<br>plasma centers<br> • Solid plasma-center network with a focus on improving<br>volumes per center<br> • Operational improvement plan addressing donor<br>commitment compensation and other plasma operating<br>costs through a range of efficiency measures<br> • Focus on increasing profitability per liter while collecting<br>desired plasma volumes<br>Progressive decline mainly driven by donor commitment compensation<br>Cost per liter (CPL)<br>Q4’22<br>Continuous improvement of plasma volumes<br>-10%<br>Q4’22<br>115<br>100<br>85<br>-20%<br>90<br>95<br>100<br>105105<br>100<br>90<br>95<br>Note: Base 100: Q2’22; 3M average moving trend. Figures comparing Q4’22 average vs. July’’22 (U.S. data)<br>Performance by Business Unit | Biopharma | Plasma<br>390+ plasma centers<br>Plasma Collections Cost per Liter |
| --- | ||
| 2022 Full Year Results - 11 -<br>Positioned to Leverage Scale, Strengths and Expertise<br>Pre-Clinical Phase 1 Phase 2 Phase 3 Ph. 4 / Reg. LCM<br>Immunology<br>recIG in PID<br>IVIG-PEG-PID<br>Xembify® in CLL<br>Xembify® – Bi-weekly dosing – PID<br>Xembify® – Prefilled syringes<br>Xembify® – Europe<br>Yimmugo® (IVIG NextGen) in PID<br>Hepatology/<br>Intensive<br>Care<br>PRECIOSA Decompensated Cirrhosis (Albumin-20%)<br>APACHE Acute on Chronic Liver Disease (Albumin-5%)<br>FlexBag® (US, EU)<br>PulmonologyAlpha-1 AT in Non-cystic fibrosis bronchiectasis Alpha-1 AT 15% (SC) in AATD SPARTA – Prolastin-C® Prolastin® 4-5g. vials (EU)<br>Hematology<br>ATIII in Sepsis (partnership with Endpoint Health)<br>Fibrinogen in Cong. Deficiency & severe hypofibrinogen<br>Fibrinogen in Acquired Deficiency<br>Fostamatinib1 in ITP for refractory patients<br>Yimmugo® (IVIG NextGen) in ITP<br>Infectious<br>diseases GIGA 2339 in HBV Trimodulin (IgM) in sCAP Cytotec® Pregnancy in CMV infection<br>Neurology<br>GRF6019 in Alzheimer Disease (AD)<br>GRF6021 in Parkinson Disease (PD) with dementia<br>Aβvac40 in AD2<br>AKST4290 in PD<br>AMBAR-Next in AD<br>Others<br>GIGA564 Anti-CTLA-4 (mAb Oncology)<br>GIGA2328 Anti-CTLA-4 (mAb Oncology)<br>AKST4290 in nAMD & DR<br>VISTASEAL™ (fibrin sealant) in Biosurgery pediatric use<br>projects<br>Commercialization started<br>Performance by Business Unit | Biopharma | Innovation<br>Risk-value balanced pipeline<br>1 Licensed rights from Rigel Pharmaceuticals in EU and other countries; 2 Project of Araclon (Grifols’ invested company)<br>FY23 Key Milestones<br>Commercialization started<br> • Final results of Xembify® bi-weekly dosing<br>study<br> • First patient enrolled and treated in the<br>Xembify® SID-CLL study<br> • Final results of IVIG-PEG study<br> • Finalize enrollment of the PRECIOSA trial<br> • Alpha-1 AT 15% (subcutaneous) Phase 1/2<br>study advancement from single dose to<br>repeat dose phase<br> • Biotest Trimodulin ph.III ESsCAPE trial<br>study initiation<br> • Biotest Yimmugo® BLA FDA submission<br> • Finalize enrolment of the SPARTA study<br> • Biotest Fibrinogen AD ADFIRST trial<br>completed and top line study results<br> • Biotest Cytotect (PreCyssion) last patient<br>expected<br> • GIGA564 IND submission<br> • GIGA2328 pre-IND submission<br>H1’23<br>H2’23 |
| --- | ||
| 2022 Full Year Results - 12 -<br>Performance by Business Unit | Diagnostic<br>Blood Typing Outperformance Partially Offset NAT Donor Screening Decline<br>-8.0%<br>-15.9% cc<br>Q4’22<br>-13.8%<br>-19.7% cc<br>FY22<br>Recombinant<br>proteins<br>NAT Donor<br>Screening<br>55-60%<br>of revenues<br>Blood Typing<br>Solutions<br>(BTS)<br>25-30%<br>of revenues<br>15-20%<br>of revenues<br> • Termination of one-off COVID-19 testing<br>and mandatory Zika screening impacted<br>revenues and profitability<br> • Extended agreement (15-years) with CTS;<br>impact on pricing<br> • Growth in Asia (in particular India, China,<br>Malaysia) and Middle East, coupled with<br>higher plasma and blood donations<br>-32.4%<br>Excl. COVID<br>and Zika<br>-9.4%<br>+16.9%<br> • Significant double-digit-growth across most<br>geographies, highlighting U.S. and Mexico<br> • Gaining market share<br> • Decline primarily resulting from<br>the joint business collaboration<br>on new R&D project<br>15 20%<br>-6.1%<br>Revenue performance by business line in FY22 (at cc)<br> • Excluding one-off COVID-19 and mandatory Zika testing,<br>Diagnostic declined by 4.6% cc in FY22<br> • Blood typing solutions was the main growth driver<br> • One off COVID-19 and mandatory Zika testing impacted total<br>gross margin by 210bps vs. FY21<br> • Launch in Q2’23 of AlphaID™ At Home, an OTC free service to<br>assess genetic risk of developing alpha-1, in the U.S.<br> • Launch of the new DG Gel 8 card in the U.S.<br> • Procleix Plasmodium and Promonitor Quick ADL<br>awarded the CE mark<br>Commercial milestones | |
| --- | ||
| 2022 Full Year Results - 13 -<br> • Vertical integration to achieve higher<br>margins from Grifols’ products<br> • Commercial knowledge to grow in the<br>cell culture market, in-vitro diagnostics<br>and diagnostic R+D solutions<br> • Enhanced and reinforced Bio Supplies<br>portfolio with a more robust offering of<br>biological products<br> • Boost Grifols’ standing as a reputable<br>supplier of biological products<br>Performance by Business Unit | Bio Supplies<br>Integration of Access Biologicals Driving Strong Revenue Growth<br>+51.2%<br>+32.8% cc<br>Q4’22<br>+26.1%<br>+13.2% cc<br>FY22<br>Plasma<br>hyperimmune<br>sales to<br>third parties<br>Bio Supplies<br>Biopharma<br>50-55%<br>of revenues<br>Bio Supplies<br>Diagnostic<br>25-30%<br>of revenues<br>20-25%<br>of revenues<br> • Growth driven by cell culture media due to Access Biologicals<br>acquisition and Intermediates<br> • Partially offset by lower sales of Drug Excipients<br>+7.9%<br>+52.7%<br> • Plasma for diagnostics supported by Access Biologicals and higher<br>market demand in the market<br> • Higher performance of blood-derived products fueled by Access<br>Biologicals acquisition and increase of donations<br>-4.2% • Lower sales due to contract termination<br>Revenue performance by business line in FY22 (at cc)<br>Access Biologicals<br>as a high growth engine | |
| --- | ||
| 2022 Full Year Results - 14 -<br>Table of Contents<br>1. Key Priorities & 2022 Value Drivers<br>3. Group Financial Performance and 2023 Guidance<br>4. Final Remarks<br>5. Annex<br>2. Performance by Business Unit | ||
| --- | ||
| 2022 Full Year Results - 15 -<br>Delivering on Guidance for FY 2022<br>Group Financial Performance<br>1 Sustainable revenue growth<br>Revenue (stand-alone)<br>Guidance FY22<br>2 Capturing operational leverage<br>FY22 Figures<br>Revenue (combined w/ Biotest)<br> €5.6-5.8bn<br> €5.8-6.0bn<br> €5.7bn<br> €6.1bn<br>EBITDA Adj. margin (stand-alone)<br>EBITDA Adj. margin (combined w/ Biotest)<br>3 Strengthening balance sheet<br>Leverage ratio 7.9x<br>20-21%<br>20-21%<br>20.6%<br>20.6%<br>7.1x | ||
| --- | ||
| 2022 Full Year Results - 16 -<br>Accelerated Growth and Improved Profitability Marked FY22 Performance<br>Group Financial Performance<br>Grifols Biotest Combined Grifols Biotest Combined<br>Revenues 1,558 155 1,713 5,703 361 6,064<br>% growth +22.5% - +34.7% +15.6% - +22.9%<br>% growth at cc +8.6% - +20.9% +5.1% - +12.4%<br>Gross Profit 556 43 599 2,142 90 2,232<br>% margin 35.7% 27.6% 35.0% 37.6% 24.9% 36.8%<br>Opex 397 39 436 1,455 97 1,552<br>% growth at cc +7.6% - +7.6% +4.6% - +4.6%<br>EBITDA 276 18 294 1,198 23 1,221<br>% growth at cc +77.3% - +91.5% +14.0% - +16.5%<br>% margin 17.7% 11.8% 17.2% 21.0% 6.4% 20.1%<br>EBITDA Adj. 316 32 348 1,174 73 1,247<br>% margin 20.3% 20.5% 20.3% 20.6% 20.2% 20.6%<br>Net income 20 (0) 20 224 (16) 208<br>% growth n/a - n/a +18.6% - +10.4%<br>Q4’22 FY22<br>Robust revenue growth driven mainly by Biopharma’s key<br>proteins and increased plasma supply; product mix; pricing and<br>FX tailwind; and a notable contribution from Biotest<br>Gross margin impacted by<br>(i) In Biopharma, high cost per liter from the plasma collected<br>in 2021 and the majority of 2022 due to high donor<br>compensation and labor costs, albeit having declined<br>significantly in Q4 and onwards<br>(ii) Loss in Diagnostic driven by one-off COVID testing and<br>mandatory Zika screening, which adversely impacted total<br>gross margin by 100bps vs. Q4’21 and 210bps vs. FY21<br>Operating leverage continues to support greater profitability at<br>EBITDA level backed by SG&A cost savings and R+D<br>prioritization, offsetting inflationary pressures and decreased<br>higher margin from lower Diagnostic revenues<br>Net profit impacted by higher financial expenses<br>(EUR in millions) | ||
| --- | ||
| 2022 Full Year Results - 17 -<br>Sequential EBITDA Improvement Continues<br>Group Financial Performance | EBITDA Stand-alone FY21 vs. FY22<br>62<br>121 67<br>50<br>61<br>102<br>Biopharma<br>13<br>Diagnostic Bio Supplies<br>and others<br>Opex Access<br>Biologicals<br>3<br>Other income FX Adjusted<br>EBITDA<br>FY22<br>One offs<br>24<br>Reported<br>EBITDA FY22<br>961<br>-108<br>1,198 1,174<br>Reported<br>EBITDA<br>FY21<br>19.5%<br>21.0% 20.6%<br>(EUR in millions)<br>COVID-19<br>and Zika tests<br>Excluding loss of COVID testing<br>and mandatory Zika screening,<br>Diagnostic EBITDA growing<br>R+D prioritization and<br>cost savings Primarily Access<br>Biologicals gain and<br>restructuring costs<br>Note: the variations of Biopharma, Diagnostic and Bio Supplies and others refer only to Gross margin | |
| --- | ||
| 2022 Full Year Results - 18 -<br>Operational Performance Enabling a Reduction in Leverage Ratio<br>Group Financial Performance | Leverage<br>FY21<br>Reported<br>Working capital,<br>LTM EBITDA<br>and committed<br>investments<br>LTM H1’22<br>Reported<br>Deleverage path FY22<br>Reported<br>6.2x 1.8x<br>1.0x<br>9.0x<br>1.9x 7.1x<br>Evolution of the leverage ratio<br>Year-end<br>liquidity<br> €1.6bn<br>Year-end cash and<br>cash equivalents<br> €0.5bn<br>Limited exposure to<br>interest rate hikes<br>65%<br>Fixed<br>35%<br>Floating<br>No significant maturities until 2025<br>0.1 0.1<br>2.0<br>0.1<br>4.1<br>2.1<br>0.6<br>Acquisition 1.6x 2023 2024 2025 2026 2027 2028 2029-2036<br>EBITDA & debt 0.2x<br>(EUR in billions)<br>(calculated based on the credit facilities agreement and including Biotest) | |
| --- | ||
| 2022 Full Year Results - 19 -<br>Annualized Cash Savings of Approx. EUR400m; Most Initiatives Implemented by 4Q’23<br>EUR 100m Savings Recognized in P&L and EUR 250m Cash Savings in 2023<br>Group Financial Performance | Operational Improvement Plan<br>Direct and Indirect<br>Procurement<br>Logistics<br>Facilities<br>Pillar Goal Key Initiatives Annualized Savings1<br>Drive down cash cost per liter<br>while creating the most efficient,<br>advanced, donor-friendly,<br>highest quality, world-class<br>plasma procurement<br>operations, and prepare for the<br> ‘center of the future’<br>General &<br>Administrative<br>(G&A)<br>Plasma Cost and<br>Operations<br> • Optimize donor center opening hours and days of operation while<br>maintaining desired volume<br> • Enhance efficiencies through elimination or centralization of positions,<br>digitization and staffing optimization<br> • Continue to optimize donor commitment compensation<br> • Improve capacity utilization and throughput while improving donor<br>experience by de-bottlenecking and decreasing donor cycle time<br> • Streamline overhead and management functions and delayer while<br>offering better support to donor centers<br> • Manage up underperforming centers<br> • Implement digital marketing strategy<br> • Delayering and increased spans of control<br> • Centralize, consolidate and insource support functions<br> • Price and demand management<br> • Reduce IT CAPEX from optimization of capitalized projects<br> • New travel policies and guidelines<br>EUR 300m<br>EUR 60m<br>Streamline corporate<br>functions and reduce<br>indirect spend and headcount<br>in order to increase agility and<br>eliminate redundant activities<br>1 Compared to comparable 2022 full year data | |
| --- | ||
| 2022 Full Year Results - 20 -<br>Direct and Indirect<br>Procurement<br>Group Financial Performance | Operational Improvement Plan<br>Plasma<br>G&A<br>Logistics<br>Facilities<br> • Consolidate suppliers and distributors globally through<br>tenders or negotiation<br> • Minimize number of OEMs via re-sourcing activities<br> • Test market via RFP and identify lower-cost alternatives<br> • Office and laboratory facilities consolidation<br> • Lease renegotiation and sub-leasing<br>EUR 15m<br>EUR 10m<br> • Supply chain flexibility through new routes and optimization<br>of existing routes<br> • Optimize logistics flow from air to ocean freight<br> • Consolidate internal warehouses<br>EUR 15m<br>Strategic sourcing<br>initiatives across five<br>procurement<br>categories<br>Cost improvements<br>largely offsetting<br>additional volume<br>Rationalize real estate<br>footprint<br>One-time restructuring charge of approximately EUR 140 million, to be accrued in Q1’23<br>Pillar Goal Key Initiatives<br>Annualized Cash Savings of Approx. EUR400m; Most Initiatives Implemented by 4Q’23<br>EUR 100m Savings Recognized in P&L and EUR 250m Cash Savings in 2023<br>1 Compared to comparable 2022 full year data<br>Annualized Savings1 | |
| --- | ||
| 2022 Full Year Results - 21 -<br>Strong Sales Growth Driven by Biopharma and Further Margin Expansion in 2H’23<br>Group Financial Performance | 2023 Guidance<br>Revenue (at cc)<br>EBITDA<br>Total revenue +8-10%<br>EBITDA Adjusted Margin<br>(stand-alone)<br>EBITDA Adjusted<br>(combined)<br> • Plasma collections increase in 2022 underpins<br>strong sales growth in 2023 backed by solid<br>underlying volume demand, pricing and<br>product mix<br> • Biotest continues to significantly contribute<br> • H1’23 margins continue to be impacted by<br>high cash CPL in 2022 due to inventory<br>accounting (c.9 months lag)<br> • Significant margin expansion in H2’23 as<br>meaningful cash CPL declines in 4Q’22 and<br>2023 further supported by implementation of<br>operational improvement plan<br>19-20%<br>H1’23 H2’23<br>23-25%<br>Biopharma +10-12%<br>FY23<br>FY23<br>21-23%<br>EUR 1.4bn<br>EBITDA annualizing cost savings<br>(stand-alone)<br>EUR 1.7bn<br>27-28% | |
| --- | ||
| 2022 Full Year Results - 22 -<br>Table of Contents<br>1. Key Priorities & 2022 Value Drivers<br>4. Final Remarks<br>5. Annex<br>2. Performance by Business Unit<br>3. Group Financial Performance and 2023 Guidance | ||
| --- | ||
| 2022 Full Year Results - 23 -<br>Final Remarks<br>Laser-Focused and Committed to Execution in 2023<br>Governance and<br>actions in place to<br>deliver enhanced<br>financial performance<br>and increase<br>shareholder value<br>Operational<br>Improvement<br>Plan<br>Guidance<br>Accelerating<br>Deleverage<br> • Reinforce competitiveness, reduce global cost base, and enhance<br>organizational accountability, agility, efficiency, and effectiveness<br> • Implementation is ongoing to achieve EUR 400 million annualized cash<br>cost savings tackling cost per liter and G&A<br> • Currently project managed, tracked and monitored on a weekly basis<br> • Solid revenues growth driven by Biopharma<br> • Significant margin expansion in 2H’23 as improvement plan advances<br> • EUR 1.7bn at 27-28% margin stand-alone incl. annualized savings in FY23<br> • Biotest will deliver strategic value in the mid and long-term but margin<br>dilutive in the short-term<br> • Organic EBITDA improvement, enhancement of inventory management<br>and cash flow generation in order to reduce leverage ratio<br> • Execute on deleveraging transaction in 2023 | ||
| --- | ||
| 2022 Full Year Results - 24 -<br>Table of Contents<br>1. Key Priorities & 2022 Value Drivers<br>2. Performance by Business Unit<br>3. Group Financial Performance and 2023 Guidance<br>4. Final Remarks<br>5. Annex<br>5.1. Sustainability<br>5.2. Financials | ||
| --- | ||
| 2022 Full Year Results - 25 -<br>Reinforcing Our Sustainability Pillars<br>Sustainability<br>Our People Commitment to Donors and Patients Impact on Society Environmental Responsibility<br>40% 60%<br>90+ nationalities<br>4.7M+<br>training<br>hours<br>800,000+<br>patients treated<br>5.7x<br>improvement in<br>patients’ quality of life<br>in relation to<br>treatment cost<br>The effort and dedication of our people improves<br>patients’ lives and helps create a healthier world<br>2022 Key figures<br>Gender pay gap<br>0.9%<br>3.0%<br>1.4%<br>26,300+ employees<br>(including Biotest)<br>920,000+<br>donors<br> €5.2bn<br>positive impact<br>on donors and local<br>communities<br>80+<br>patient associations<br>supported<br>8,245<br>hemophilia<br>patients treated<br>2014-2021<br>~900<br>workers with<br>disabilities<br>65%+<br>of promotions are<br>women<br>11,500+<br>new hires<br> €23.8bn<br>positive impact<br>for patients<br> €21M<br>product donations<br>Committed to a more human leadership style and to a culture where training,<br>promotion and talent are the driving forces behind professional development<br>Diversity, inclusivity, equal opportunities and parity are unwavering priorities<br>We are the bridge between donor and patient while<br>we work to guarantee blood plasma supply<br>We build strong communities and take great care of our donors<br>Thanks to donors’ generosity and commitment we are able to develop plasma-derived treatments, essential to improve the health of thousands of patients<br>2.8% | ||
| --- | ||
| 2022 Full Year Results - 26 -<br>Reinforcing Our Sustainability Pillars<br>Sustainability<br>Our People Commitment to Donors and Patients Impact on Society Environmental Responsibility<br>The future of people goes hand in hand with the<br>future of the planet<br>Determined to make a positive impact on society, with<br>far-reaching, direct-impact<br>193,000<br>jobs created<br>60+<br>educational<br>initiatives in 5<br>countries<br> €1M+<br>donated to<br>Ukraine<br>3M m3<br>water<br>consumption<br>-8% vs. 2021<br>+35%<br>increase<br>remote<br>working<br>Scope 3<br>SBTi<br>in the last phase<br>of verification<br>74%<br>of production from<br>facilities with ISO<br>14001 certification<br>26%<br>of electricity used<br>comes from<br>renewable sources<br>-49%<br>reduction in<br>air travel<br>vs. 2019<br>Public-private partnerships<br>CBS<br>2021 2022<br>2022 Key figures<br>Social initiatives delivered through our foundations<br>We participate actively in local communities, support local organizations and<br>strive to increase the multiplier effect generated by our activity<br>Actively reducing the impact of our activity on the environment, ensuring<br>efficient resource management<br>Striving to mitigate the impact of climate change<br> €9.6bn<br>total economic<br>impact<br>28+<br>workshops, conferences<br>and seminars €32M<br>social<br>initiatives<br> €34M<br>resources<br>allocated | ||
| --- | ||
| 2022 Full Year Results - 27 -<br>Net Revenue by Division and Region<br>In thousands of euros<br>Grifols Biotest Combined Grifols Biotest Combined Grifols Biotest Combined Grifols Biotest Combined Grifols Biotest Combined<br>Sales 1,267,192 - 1,267,192 1,444,613 98,287 1,542,900 1,433,365 107,766 1,541,131 1,557,558 155,186 1,712,744 5,702,728 361,239 6,063,967<br>% vs. prior year<br>* 7.0% 7.0% 6.9% 14.1% 27.4% 37.0% 22.5% 34.7% 15.6% 22.9%<br>% vs. prior year cc<br>** 1.4% 1.4% (2.2%) 5.1% 13.7% 23.3% 8.6% 20.9% 5.1% 12.4%<br>Biopharma 1,022,508 - 1,022,508 1,192,095 98,287 1,290,382 1,157,415 107,766 1,265,181 1,272,125 155,186 1,427,311 4,644,143 361,239 5,005,382<br>% vs. prior year<br>* 13.5% 13.5% 9.9% 19.0% 36.8% 49.5% 29.5% 45.2% 21.7% 31.2%<br>% vs. prior year cc<br>** 7.1% 7.1% 0.1% 9.2% 21.3% 34.0% 14.2% 30.0% 10.1% 19.6%<br>Diagnostic 169,749 - 169,749 159,687 - 159,687 169,620 - 169,620 172,236 - 172,236 671,292 - 671,292<br>% vs. prior year<br>* (16.5%) (16.5%) (16.9%) 13.5% (13.6%) 47.2% (8.0%) 49.5% (13.8%) 34.7%<br>% vs. prior year cc<br>** (19.8%) (19.8%) (22.4%) 7.1% (20.8%) 31.9% (15.9%) 34.0% (19.7%) 20.9%<br>Bio Supplies 23,747 - 23,747 28,806 - 28,806 44,214 - 44,214 49,309 - 49,309 146,076 - 146,076<br>% vs. prior year<br>* (17.5%) (17.5%) 17.6% 49.5% 47.9% (13.8%) 51.2% (16.7%) 26.1% 13.5%<br>% vs. prior year cc<br>** (22.0%) (22.0%) 7.9% 34.0% 29.9% (19.7%) 32.8% (21.0%) 13.2% 7.1%<br>Others & intersegments 51,188 - 51,188 64,025 - 64,025 62,116 - 62,116 63,888 - 63,888 241,217 - 241,217<br>% vs. prior year<br>* (0.4%) (0.4%) 26.9% 26.9% 18.8% 18.8% (7.5%) (7.5%) 8.1% 8.1%<br>% vs. prior year cc<br>** (2.9%) (2.9%) 20.8% 20.8% 10.5% 10.5% (14.9%) (14.9%) 1.9% 1.9%<br>1Q 2022 2Q 2022 3Q 2022 4Q 2022 2022<br>Sales 1,267,192 - 1,267,192 1,444,613 98,287 1,542,900 1,433,365 107,766 1,541,131 1,557,558 155,186 1,712,744 5,702,728 361,239 6,063,967<br>% vs. prior year<br>* 7.0% 7.0% 6.9% 14.1% 27.4% 37.0% 22.5% 34.7% 15.6% 22.9%<br>% vs. prior year cc<br>** 1.4% 1.4% (2.2%) 5.1% 13.7% 23.3% 8.6% 20.9% 5.1% 12.4%<br>US + CANADA 848,261 - 848,261 967,557 1,165 968,722 993,706 954 994,660 1,043,964 - 1,043,964 3,853,488 2,119 3,855,607<br>% vs. prior year<br>* 14.1% 14.1% 16.1% 16.2% 33.9% 34.0% 25.0% 25.0% 22.2% 22.2%<br>% vs. prior year cc<br>** 6.5% 6.5% 4.2% 4.4% 16.0% 16.1% 7.6% 7.6% 8.4% 8.5%<br>EU 208,768 - 208,768 214,521 50,334 264,855 210,998 57,052 268,050 217,508 73,030 290,538 851,795 180,416 1,032,211<br>% vs. prior year<br>* (10.0%) (10.0%) (2.8%) 20.1% (5.2%) 20.5% (6.0%) 25.5% (6.0%) 13.9%<br>% vs. prior year cc<br>** (10.2%) (10.2%) (3.3%) 19.7% (5.9%) 20.0% (6.6%) 25.1% (6.5%) 13.5%<br>ROW 210,163 - 210,163 262,535 46,788 309,323 228,661 49,760 278,421 296,086 82,156 378,242 997,445 178,704 1,176,149<br>% vs. prior year<br>* 0.3% 0.3% (11.8%) 3.9% 42.9% 74.0% 44.5% 84.6% 14.4% 34.9%<br>% vs. prior year cc<br>** (3.8%) (3.8%) (19.2%) (3.6%) 30.0% 60.9% 30.1% 70.3% 5.1% 25.6%<br>* For comparison purposes, 2021 figures have been reclassified in accordance with new business units; ** Constant currency (cc) excludes exchange rate fluctuations over the period. | ||
| --- | ||
| 2022 Full Year Results - 28 -<br>In thousands of euros 1Q 2022 2Q 2022 3Q 2022 4Q 2022 2022<br>NET REVENUES 1,267,193 1,542,899 1,541,130 1,712,745 6,063,967<br>% vs. prior year 7.0% 14.1% 37.0% 34.7% 22.9%<br>COST OF SALES (772,592) (964,949) (981,260) (1,113,636) (3,832,437)<br>% vs. prior year 18.6% 25.1% 42.6% 29.5% 29.0%<br>GROSS MARGIN 494,601 577,950 559,870 599,109 2,231,530<br>% vs. prior year -7.3% -0.5% 28.2% 45.5% 13.7%<br>% Net revenues 39.0% 37.5% 36.3% 35.0% 36.8%<br>R&D (76,155) (85,127) (93,614) (106,244) (361,140)<br>% vs. prior year 6.1% -1.9% 2.2% 1.4% 1.8%<br>SG&A (259,417) (308,473) (292,823) (329,710) (1,190,423)<br>% vs. prior year 0.9% 23.5% 9.5% 14.8% 12.1%<br>OPERATING EXPENSES (335,572) (393,600) (386,437) (435,954) (1,551,563)<br>% vs. prior year 2.0% 16.9% 7.7% 11.2% 9.5%<br>OTHER INCOME 3,583 925 14,678 3,049 22,235<br>% vs. prior year - - - -81.3% 36.4%<br>(637) 80,096 13,276 10,743 103,478<br>% vs. prior year -107.4% 1152.7% -8.9% 257.5% 217.9%<br>OPERATING RESULT (EBIT) 161,975 265,371 201,387 176,947 805,680<br>% vs. prior year -23.9% 5.9% 118.1% 351.7% 35.4%<br>% Net revenues 12.8% 17.2% 13.1% 10.3% 13.3%<br>FINANCIAL RESULT (79,373) (119,380) (114,830) (129,358) (442,941)<br>% vs. prior year 35.2% 96.6% 78.4% 37.6% 59.4%<br>(435) (271) (64) (712) (1,482)<br>% vs. prior year -101.3% -24.5% -161.1% -31.5% (104.5%)<br>PROFIT BEFORE TAX 82,165 145,722 86,493 46,877 361,257<br>% vs. prior year -56.5% -23.1% 208.1% -183.9% 3.1%<br>% Net revenues 6.5% 9.4% 5.6% 2.7% 6.0%<br>INCOME TAX EXPENSE (20,471) (30,804) (27,320) (11,516) (90,111)<br>% vs. prior year -45.8% -18.7% 386.5% 198.1% 5.9%<br>% of pre-tax income 24.9% 21.1% 31.6% 24.6% 24.9%<br>CONSOLIDATED PROFIT 61,694 114,918 59,173 35,361 271,146<br>% vs. prior year -59.1% -24.2% 163.4% -159.2% 2.2%<br>(8,385) (24,578) (14,614) (15,290) (62,867)<br>% vs. prior year -60.2% 67.0% -33.7% -18.7% (17.9%)<br>GROUP PROFIT 53,310 90,339 44,558 20,072 208,279<br>% vs. prior year -59.0% -34.0% 10220.2% -125.6% 10.4%<br>% Net revenues 4.2% 5.9% 2.9% 1.2% 3.4%<br>EBITDA REPORTED 252,553 365,752 308,360 294,354 1,221,019<br>% variation -398.5% -516.5% -423.0% -385.2% 27.0%<br>% Net revenues 19.9% 23.7% 20.0% 17.2% 20.1%<br>SHARE OF RESULTS OF EQUITY ACCOUNTED<br>INVESTEES - CORE ACTIVITIES<br>SHARE OF RESULTS OF EQUITY ACCOUNTED<br>INVESTEES<br>RESULT ATTRIBUTABLE TO<br>NON-CONTROLLING INTERESTS<br>Profit and Loss | ||
| --- | ||
| 2022 Full Year Results - 29 -<br>Financial Performance | Margins | Grifols EBITDA Combined FY21 vs. FY22<br>62<br>121 67<br>50<br>61<br>102<br>50<br>Reported<br>EBITDA<br>FY21<br>Biopharma<br>13<br>Diagnostic Bio Supplies<br>and others<br>Biotest<br>23<br>961<br>-108<br>1,221<br>FX Biotest<br>BNL1<br>Grifols<br>One offs<br>Other income<br>24<br>Opex<br>3<br>Reported<br>Combined<br>EBITDA FY22<br>Adjusted<br>Combined<br>EBITDA<br>FY22<br>Access<br>Biologicals<br>1,247<br>19.5%<br>20.1% 20.6%<br>(EUR in millions)<br>Stand-alone 21.0% 20.6%<br>Combined Combined<br>Note: the variations of Biopharma, Diagnostic and Bio Supplies and others refer only to Gross margin<br>1 Biotest Next Level (BNL) project is aimed to expand production capacity in Dreieich, Germany, and to develop three key R&D projects (IgG Next Gen, Trimodulin, Fibrinogen)<br>COVID-19<br>and Zika tests<br>Stand-alone |
| --- | ||
| 2022 Full Year Results - 30 -<br>Cash Flow In thousands of euros 2022 2021<br>REPORTED GROUP PROFIT 208,279 188,726<br>DEPRECIATION AND AMORTIZATION 407,864 359,767<br>NET PROVISIONS 69,983 64,092<br>OTHER ADJUSTMENTS AND OTHER CHANGES IN WORKING CAPITAL (99,844) 180,683<br>CHANGES IN INVENTORIES (600,245) (157,474)<br>CHANGES IN TRADE RECEIVABLES (73,518) (39,227)<br>CHANGES IN TRADE PAYABLES 76,614 408<br>CHANGE IN OPERATING WORKING CAPITAL (597,149) (196,293)<br>NET CASH FLOW FROM OPERATING ACTIVITIES (10,867) 596,975<br>BUSINESS COMBINATIONS AND INVESTMENTS IN GROUP COMPANIES (1,533,264) (519,128)<br>CAPEX (297,790) (280,889)<br>R&D/OTHER INTANGIBLE ASSETS (77,770) (34,198)<br>OTHER CASH INFLOW / (OUTFLOW) (69,999) (19,934)<br>NET CASH FLOW FROM INVESTING ACTIVITIES (1,978,823) (854,149)<br>FREE CASH FLOW (1,989,690) (257,174)<br>PROCEEDS FROM / (PAYMENTS) FOR EQUITY INSTRUMENTS (3,459) (125,703)<br>ISSUE / (REPAYMENT) OF DEBT (177,372) 2,746,380<br>DIVIDENDS (PAID) / RECEIVED 10,125 (247,498)<br>OTHER CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES (2,787) (75,500)<br>NET CASH FLOW FROM FINANCING ACTIVITIES (173,493) 2,297,679<br>TOTAL CASH FLOW (2,163,183) 2,040,505<br>CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR 2,675,611 579,647<br>EFFECT OF EXCHANGE RATE CHANGES IN CASH AND CASH EQUIVALENTS 35,551 55,459<br>CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 547,979 2,675,611 | ||
| --- | ||
| 2022 Full Year Results - 31 -<br>December December<br>2022 2021<br>8,457,544 7,317,098<br>119,604 119,604<br>910,728 910,728<br>4,326,436 4,133,388<br> TREASURY STOCK (162,220) (164,189)<br>208,279 188,726<br>727,111 335,352<br>2,327,606 1,793,489<br>11,120,586 8,442,425<br>9,960,562 7,768,950<br>1,160,024 673,475<br>1,955,847 3,474,312<br>795,686 2,438,291<br>1,160,161 1,036,021<br>21,533,977 19,233,835<br> OTHER CURRENT LIABILITIES<br>TOTAL EQUITY AND LIABILITIES<br> OTHER COMPREHENSIVE INCOME<br> NON-CONTROLLING INTERESTS<br>NON-CURRENT LIABILITIES<br> NON-CURRENT FINANCIAL LIABILITIES<br> OTHER NON-CURRENT LIABILITIES<br> SHARE PREMIUM<br> RESERVES<br> CURRENT YEAR EARNINGS<br>CURRENT LIABILITIES<br> CURRENT FINANCIAL LIABILITIES<br>EQUITY<br> CAPITAL<br>December December In thousands of euros<br>2022 2021<br>16,880,390 13,723,555<br>10,858,608 8,661,508<br>3,270,937 2,547,497<br>1,955,177 1,999,776<br>620,745 362,267<br>174,923 152,507<br>4,653,587 5,510,280<br>4,969<br>3,201,357 2,259,354<br>35,154 1,939<br>738,651 499,708<br>43,663 2,029,707<br>81,814 64,079<br>547,979 655,493<br>21,533,977 19,233,835<br> INVESTMENTS IN EQUITY ACCOUNTED INVESTEES<br> NON-CURRENT FINANCIAL ASSETS<br> OTHER NON-CURRENT ASSETS<br> OTHER CURRENT ASSETS<br>CASH AND CASH EQUIVALENTS<br>TOTAL ASSETS<br>ASSETS<br>CURRENT ASSETS<br> INVENTORIES<br> CURRENT CONTRACT ASSETS<br> OTHER CURRENT FINANCIAL ASSETS<br>In thousands of euros<br>NON-CURRENT ASSETS<br> NON CURRENT CONTRACT ASSETS HELD FOR SALE<br> TRADE AND OTHER RECEIVABLES<br> GOODWILL AND OTHER INTANGIBLE ASSETS<br> PROPERTY PLANT & EQUIPMENT<br>Balance Sheet | ||
| --- | ||
| Investor Relations<br> & Sustainability<br>+34 93 571 02 21<br>investors@grifols.com<br>sustainability@grifols.com<br>inversores@grifols.com<br>sostenibilidad@grifols.com | ||
| --- | ||
| Auditor’s Report on<br>Grifols, S.A. and<br>subsidiaries<br><br>(Together with the consolidated annual accounts<br>and consolidated directors’ report of Grifols, S.A.<br>and subsidiaries for the year ended 31 December<br>2022)<br>(Translation from the original in Spanish. In the<br>event of discrepancy, the Spanish-language<br>version prevails.) | ||
| --- | ||
| KPMG Auditores S.L., a limited liability Spanish company and a member firm of the<br>KPMG global organisation of independent member firms affiliated with KPMG<br>International Limited, a private English company limited by guarantee. All rights<br>reserved.<br>Paseo de la Castellana, 259C 28046 Madrid<br>KPMG Auditores, S.L.<br>Torre Realia<br>Plaça d’Europa, 41-43<br>08908 L’Hospitalet de Llobregat<br>(Barcelona)<br>Independent Auditor's Report on the Consolidated Annual<br>Accounts<br>Reg. Mer Madrid, T. 11.961, F. 90,<br>Sec. 8, H. M -188.007, Inscrip. 9<br>N.I.F. B-78510153<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>To the Shareholders of Grifols, S.A.<br>REPORT ON THE CONSOLIDATED ANNUAL ACCOUNTS<br>Opinion __________________________________________________________________<br>We have audited the consolidated annual accounts of Grifols, S.A. (the “Parent”) and subsidiaries<br>(together the “Group”), which comprise the consolidated balance sheet at 31 December 2022, and<br>the consolidated income statement, consolidated statement of comprehensive income, consolidated<br>statement of changes in equity and consolidated statement of cash flows for the year then ended,<br>and consolidated notes.<br>In our opinion, the accompanying consolidated annual accounts give a true and fair view, in all<br>material respects, of the consolidated equity and consolidated financial position of the Group at 31<br>December 2022 and of its consolidated financial performance and its consolidated cash flows for the<br>year then ended in accordance with International Financial Reporting Standards as adopted by the<br>European Union (IFRS-EU) and other provisions of the financial reporting framework applicable in<br>Spain.<br>Basis for Opinion _________________________________________________________<br>We conducted our audit in accordance with prevailing legislation regulating the audit of accounts in<br>Spain. Our responsibilities under those standards are further described in the Auditor's<br>Responsibilities for the Audit of the Consolidated Annual Accounts section of our report.<br>We are independent of the Group in accordance with the ethical requirements, including those<br>regarding independence, that are relevant to our audit of the consolidated annual accounts pursuant<br>to the legislation regulating the audit of accounts in Spain. We have not provided any non-audit<br>services, nor have any situations or circumstances arisen which, under the aforementioned<br>regulations, have affected the required independence such that this has been compromised.<br>We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis<br>for our opinion. | ||
| --- | ||
| 2<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Key Audit Matters ________________________________________________________<br>Key audit matters are those matters that, in our professional judgement, were of most significance<br>in the audit of the consolidated annual accounts of the current period. These matters were<br>addressed in the context of our audit of the consolidated annual accounts as a whole, and in forming<br>our opinion thereon, and we do not provide a separate opinion on these matters.<br>Assessment of the impairment testing on goodwill of the Diagnostic cash-generating<br>unit (CGU)<br>See notes 4 (g) and 6 to the consolidated annual accounts<br>Key audit matter How the matter was addressed in our audit<br>Goodwill amounts to Euros 7,011,909 thousand<br>at 31 December 2022, of which Euros<br>2,773,160 thousand is from the Diagnostic<br>cash-generating unit (CGU). The Group<br>calculates the recoverable amount of goodwill<br>on a yearly basis if there are indications of<br>impairment.<br>We identify the assessment of the impairment<br>testing on goodwill of the Diagnostic CGU as a<br>key audit matter, as it required significant value<br>judgements by the Directors to evaluate the<br>calculation of impairment, which was carried<br>out using the discounted cash flow method.<br>This model includes assumptions regarding<br>future cash flows, the perpetual growth rate<br>and discount rate, as well as the increase in<br>sales for the Blood Typing Solutions (BTS) and<br>Clinical Diagnostics (Cdx) lines of business.<br>Minor changes in these assumptions could give<br>rise to a significant effect on the Group’s<br>measurement of the carrying amount of<br>goodwill.<br>The main procedures we performed to address<br>this key audit matter were as follows:<br> We evaluated the design and<br>implementation and examined the<br>operating effectiveness of certain internal<br>controls relating to the process of<br>assessing the impairment of goodwill,<br>including controls related to the<br>determination of the fair value of the<br>Diagnostic CGU, as well as the<br>determination of the assumptions for<br>projected sales of the BTS and CDx lines of<br>business, the perpetual growth rate and<br>the discount rate.<br> We involved our valuation specialists for<br>the following procedures:<br>- Evaluation of the perpetual growth rate<br>corresponding to the Diagnostic CGU,<br>comparing the consistency of the<br>estimate with market data in the public<br>domain relating to comparable entities.<br>- Evaluation of the discount rate,<br>comparing it with a range of discount<br>rates calculated independently using<br>market data in the public domain<br>relating to comparable entities.<br>- Analysis of the reasonableness of the<br>discounted cash flows valuation<br>methodology used to calculate the<br>recoverable amount. | ||
| --- | ||
| 3<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Assessment of the impairment testing on the equity-accounted investment in Shanghai<br>Raas<br>See notes 4 (a) and 10 to the consolidated annual accounts<br>Key audit matter How the matter was addressed in our audit<br>Investments accounted for using the equity<br>method amount to Euros 1,955,177 thousand<br>at 31 December 2022, of which Euros<br>1,910,428 is the investment in Shanghai Raas,<br>the shares of which are quoted on the<br>Shenzhen stock exchange (China), for which<br>objective evidence of impairment has been<br>identified.<br>At 31 December 2022 the Group has<br>determined the recoverable amount of this<br>investment based on its value in use, using the<br>discounted cash flow method, the result of<br>which has not determined the need to<br>recognise any impairment of this investment.<br>We identify the assessment of the equity-accounted investment in Shanghai Raas for<br>impairment as a key audit matter, as it required<br>significant value judgements by the Directors<br>both in evaluating the existence of indications<br>of impairment and in estimating the value in<br>use, which was carried out using the<br>discounted cash flow method. This method<br>includes assumptions regarding the perpetual<br>growth rate and discount rate.<br>The main procedures we performed to address<br>this key audit matter were as follows:<br> We evaluated the design and<br>implementation and examined the<br>operating effectiveness of certain internal<br>controls relating to the process of<br>assessing the equity-accounted investment<br>in Shanghai Raas for impairment, including<br>controls related to the determination of the<br>value in use of this investment, as well as<br>the determination of the assumptions for<br>the perpetual growth rate and the discount<br>rate.<br> We involved our valuation specialists for<br>the following procedures:<br>- Evaluation of the perpetual growth rate<br>corresponding to the equity-accounted<br>investment in Shanghai Raas,<br>comparing it with market data in the<br>public domain relating to comparable<br>entities.<br> We queried the recoverable amount<br>calculated using a sensitivity analysis<br>regarding the assumptions on the<br>projection for sales of the BTS and CDx<br>lines of business, the perpetual growth rate<br>and the discount rate, comparing the<br>results with the recognised amount.<br> We evaluated the Group’s capacity to<br>calculate the cash flow projections,<br>comparing historical projections with actual<br>results and the business plans approved by<br>the Group’s governing bodies.<br> We assessed whether the disclosures in<br>the consolidated annual accounts meet the<br>requirements of the financial reporting<br>framework applicable to the Group. | ||
| --- | ||
| 4<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Assessment of the impairment testing on the equity-accounted investment in Shanghai<br>Raas<br>See notes 4 (a) and 10 to the consolidated annual accounts<br>Key audit matter How the matter was addressed in our audit<br>Minor changes in these assumptions could<br>have a significant effect on the value in use of<br>the investment, and therefore, on its carrying<br>amount at the reporting date.<br>- Evaluation of the discount rate,<br>comparing it with a range of discount<br>rates calculated independently using<br>market data in the public domain<br>relating to comparable entities.<br>- Analysis of the reasonableness of the<br>discounted cash flows valuation<br>methodology used to calculate the<br>recoverable amount.<br> We queried the recoverable amount<br>calculated using a sensitivity analysis<br>regarding the assumptions for the<br>perpetual growth rate and the discount<br>rate, comparing the results with the<br>recognised amount.<br> We evaluated the Group’s capacity to<br>calculate the cash flow projections,<br>comparing historical projections with actual<br>results and the business plans approved by<br>the Group’s governing bodies.<br> We assessed whether the disclosures in<br>the consolidated annual accounts meet the<br>requirements of the financial reporting<br>framework applicable to the Group.<br>Other Information: Consolidated Directors’ Report __________________________<br>Other information solely comprises the 2022 consolidated directors' report, the preparation of which<br>is the responsibility of the Parent's Directors and which does not form an integral part of the<br>consolidated annual accounts.<br>Our audit opinion on the consolidated annual accounts does not encompass the consolidated<br>directors' report. Our responsibility regarding the information contained in the consolidated directors’<br>report is defined in the legislation regulating the audit of accounts, as follows:<br>a) Determine, solely, whether the consolidated non-financial information statement and certain<br>information included in the Annual Corporate Governance Report and the Annual Report on<br>Directors’ Remuneration, as specified in the Spanish Audit Law, have been provided in the<br>manner stipulated in the applicable legislation, and if not, to report on this matter. | ||
| --- | ||
| 5<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>b) Assess and report on the consistency of the rest of the information included in the consolidated<br>directors’ report with the consolidated annual accounts, based on knowledge of the Group<br>obtained during the audit of the aforementioned consolidated annual accounts. Also, assess and<br>report on whether the content and presentation of this part of the consolidated directors’ report<br>are in accordance with applicable legislation. If, based on the work we have performed, we<br>conclude that there are material misstatements, we are required to report them.<br>Based on the work carried out, as described above, we have observed that the information<br>mentioned in section a) above has been provided in the manner stipulated in the applicable<br>legislation, that the rest of the information contained in the consolidated directors’ report is<br>consistent with that disclosed in the consolidated annual accounts for 2022, and that the content<br>and presentation of the report are in accordance with applicable legislation.<br>Directors' and Audit Committee's Responsibility for the Consolidated Annual<br>Accounts _________________________________________________________________<br>The Parent's Directors are responsible for the preparation of the accompanying consolidated annual<br>accounts in such a way that they give a true and fair view of the consolidated equity, consolidated<br>financial position and consolidated financial performance of the Group in accordance with IFRS-EU<br>and other provisions of the financial reporting framework applicable to the Group in Spain, and for<br>such internal control as they determine is necessary to enable the preparation of consolidated annual<br>accounts that are free from material misstatement, whether due to fraud or error.<br>In preparing the consolidated annual accounts, the Parent's Directors are responsible for assessing<br>the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going<br>concern and using the going concern basis of accounting unless the Directors either intend to<br>liquidate the Group or to cease operations, or have no realistic alternative but to do so.<br>The Parent's audit committee is responsible for overseeing the preparation and presentation of the<br>consolidated annual accounts.<br>Auditor's Responsibilities for the Audit of the Consolidated Annual Accounts<br>Our objectives are to obtain reasonable assurance about whether the consolidated annual accounts<br>as a whole are free from material misstatement, whether due to fraud or error, and to issue an<br>auditor's report that includes our opinion.<br>Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in<br>accordance with prevailing legislation regulating the audit of accounts in Spain will always detect a<br>material misstatement when it exists. Misstatements can arise from fraud or error and are<br>considered material if, individually or in the aggregate, they could reasonably be expected to<br>influence the economic decisions of users taken on the basis of these consolidated annual accounts. | ||
| --- | ||
| 6<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>As part of an audit in accordance with prevailing legislation regulating the audit of accounts in Spain,<br>we exercise professional judgement and maintain professional scepticism throughout the audit. We<br>also:<br> – Identify and assess the risks of material misstatement of the consolidated annual accounts,<br>whether due to fraud or error, design and perform audit procedures responsive to those risks,<br>and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The<br>risk of not detecting a material misstatement resulting from fraud is higher than for one resulting<br>from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or<br>the override of internal control.<br> – Obtain an understanding of internal control relevant to the audit in order to design audit<br>procedures that are appropriate in the circumstances, but not for the purpose of expressing an<br>opinion on the effectiveness of the Group's internal control.<br> – Evaluate the appropriateness of accounting policies used and the reasonableness of accounting<br>estimates and related disclosures made by the Parent's Directors.<br> – Conclude on the appropriateness of the Parent's Directors' use of the going concern basis of<br>accounting and, based on the audit evidence obtained, whether a material uncertainty exists<br>related to events or conditions that may cast significant doubt on the Group's ability to continue<br>as a going concern. If we conclude that a material uncertainty exists, we are required to draw<br>attention in our auditor's report to the related disclosures in the consolidated annual accounts or,<br>if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit<br>evidence obtained up to the date of our auditor's report. However, future events or conditions<br>may cause the Group to cease to continue as a going concern.<br> – Evaluate the overall presentation, structure and content of the consolidated annual accounts,<br>including the disclosures, and whether the consolidated annual accounts represent the<br>underlying transactions and events in a manner that achieves a true and fair view.<br> – Obtain sufficient appropriate audit evidence regarding the financial information of the entities or<br>business activities within the Group to express an opinion on the consolidated annual accounts.<br>We are responsible for the direction, supervision and performance of the Group audit. We<br>remain solely responsible for our audit opinion.<br>We communicate with the audit committee of the Parent regarding, among other matters, the<br>planned scope and timing of the audit and significant audit findings, including any significant<br>deficiencies in internal control that we identify during our audit.<br>We also provide the Parent's audit committee with a statement that we have complied with the<br>applicable ethical requirements, including those regarding independence, and to communicate with<br>them all matters that may reasonably be thought to bear on our independence, and where<br>applicable, related safeguards.<br>From the matters communicated to the audit committee of the Parent, we determine those that<br>were of most significance in the audit of the consolidated annual accounts of the current period and<br>which are therefore the key audit matters. | ||
| --- | ||
| 7<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>We describe these matters in our auditor’s report unless law or regulation precludes public<br>disclosure about the matter.<br>REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS<br>European Single Electronic Format ________________________________________<br>We have examined the digital files of Grifols, S.A. and its subsidiaries for 2022 in European Single<br>Electronic Format (ESEF), which comprise the XHTML file that includes the consolidated annual<br>accounts for the aforementioned year and the XBRL files tagged by the Company, which will form<br>part of the annual financial report.<br>The Directors of Grifols, S.A. are responsible for the presentation of the 2022 annual financial report<br>in accordance with the format and mark-up requirements stipulated in Commission Delegated<br>Regulation (EU) 2019/815 of 17 December 2018 (hereinafter the “ESEF Regulation”). In this regard,<br>they have incorporated the Annual Corporate Governance Report and the Annual Report on<br>Directors’ Remuneration by means of a reference thereto in the consolidated directors’ report.<br>Our responsibility consists of examining the digital files prepared by the Directors of the Parent, in<br>accordance with prevailing legislation regulating the audit of accounts in Spain. This legislation<br>requires that we plan and perform our audit procedures to determine whether the content of the<br>consolidated annual accounts included in the aforementioned digital files fully corresponds to the<br>consolidated annual accounts we have audited, and whether the consolidated annual accounts and<br>the aforementioned files have been formatted and marked up, in all material respects, in accordance<br>with the requirements of the ESEF Regulation.<br>In our opinion, the digital files examined fully correspond to the audited consolidated annual<br>accounts, and these are presented and marked up, in all material respects, in accordance with the<br>requirements of the ESEF Regulation.<br>Additional Report to the Audit Committee of the Parent ____________________<br>The opinion expressed in this report is consistent with our additional report to the Parent's audit<br>committee dated 27 February 2023. | ||
| --- | ||
| 8<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Contract Period __________________________________________________________<br>We were appointed as auditor of the Group by the shareholders at the ordinary general meeting on<br>10 June 2022 for the year ended 31 December 2022.<br>Previously, we had been appointed for a period of three years from 31 July 1990 to 1992, by<br>consensus of the shareholders at their general meeting, and have been auditing the annual accounts<br>since the year ended 31 July 1990.<br>(Signed on original in Spanish)<br>David Hernanz Sayans<br>On the Spanish Official Register of Auditors (“ROAC”) with No. 20236<br>27 February 2023<br>KPMG Auditores, S.L.<br>On the Spanish Official Register of<br>Auditors (“ROAC”) with No. S0702 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Consolidated Annual Accounts<br>31 December 2022 and 2021<br>SUMMARY<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br> ƒ Consolidated financial statements<br> ƒ Consolidated Balance Sheets<br> ƒ Consolidated Statements of Profit and Loss<br> ƒ Consolidated Statements of Comprehensive Income<br> ƒ Consolidated Statements of Cash Flows<br> ƒ Statements of Changes in Consolidated Equity<br> ƒ Notes<br>(1) Nature, Principal Activities and Subsidiaries<br>(2) Basis of Presentation<br>(3) Business Combinations and Sales<br>(4) Significant Accounting Policies<br>(5) Segment Reporting<br>(6) Goodwill<br>(7) Other Intangible Assets<br>(8) Leases<br>(9) Property, Plant and Equipment<br>(10) Equity-Accounted Investees<br>(11) Financial Assets<br>(12) Inventories<br>(13) Contract assets<br>(14) Trade and Other Receivables<br>(15) Cash and Cash Equivalents<br>(16) Equity<br>(17) Earnings per Share<br>(18) Non-Controlling Interests<br>(19) Provisions<br>(20) Financial Liabilities<br>(21) Trade and Other Payables<br>(22) Other Current Liabilities<br>(23) Net Revenues<br>(24) Personnel Expenses<br>(25) Expenses by Nature<br>(26) Finance Result<br>(27) Taxation<br>(28) Other Commitments with Third Parties and Other Contingent<br> Liabilities<br>(29) Financial Instruments<br>(30) Balances and Transactions with Related Parties<br>(31) Environmental Information<br>(32) Other Information<br>(33) Subsequent events | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Consolidated Annual Accounts<br>31 December 2022 and 2021<br>SUMMARY<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br> ƒ Appendices<br> ƒ Appendix I Information on Group Companies, Associates<br>and Others<br> ƒ Appendix II Operating Segments<br> ƒ Appendix III Changes in Other Intangible Assets<br> ƒ Appendix IV Movement in Rights of Use<br> ƒ Appendix V Movement in Property, Plant and Equipment | ||
| --- | ||
| (Free translation from the original Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Assets Reference 31/12/22 31/12/21<br>Goodwill Note 6 7,011,909 6,228,901<br>Other intangible assets Note 7 2,949,147 1,636,950<br>Rights of use Note 8 897,552 795,657<br>Property, plant and equipment Note 9 3,270,937 2,547,497<br>Investment in equity-accounted investees Note 10 1,955,177 1,999,776<br>Non-current financial assets<br>Non-current financial assets measured at fair value 38,570 4,106<br>Non-current financial assets at amortized cost 582,175 358,161<br>Total non-current financial assets Note 11 620,745 362,267<br>Deferred tax assets Note 27 174,923 152,507<br>Total non-current assets 16,880,390 13,723,555<br>Inventories Note 12 3,201,357 2,259,354<br>Non-current assets held for sale 4,969 --<br>Current contract assets Note 13 35,154 1,939<br>Trade and other receivables<br>Trade receivables 608,688 432,197<br>Other receivables 73,181 55,063<br>Current income tax assets 56,782 12,448<br>Trade and other receivables Note 14 738,651 499,708<br>Other current financial assets Note 11<br>Current financial assets measured at fair value 12,629 3,238<br>Current financial assets at amortized cost 31,034 2,026,469<br>Total current financial assets Note 11 43,663 2,029,707<br>Other current assets 81,814 64,079<br>Cash and cash equivalents Note 15 547,979 655,493<br>Total current assets 4,653,587 5,510,280<br>Total assets 21,533,977 19,233,835<br>The accompanying notes form an integral part of the consolidated annual accounts.<br>Consolidated Balance Sheet<br>at 31 December 2022 and 2021<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>(Expressed in thousands of Euros) | ||
| --- | ||
| (Free translation from the original Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Equity and liabilities Reference 31/12/22 31/12/21<br>Share capital 119,604 119,604<br>Share premium 910,728 910,728<br>Reserves 4,326,436 4,133,388<br>Treasury stock (162,220) (164,189)<br>Profit for the year attributable to the Parent 208,279 188,726<br>Total equity 5,402,827 5,188,257<br>Cash Flow hedges (438) 3,130<br>Other comprehensive Income (8,084) (869)<br>Translation differences 735,633 333,091<br>Other comprehensive expenses 727,111 335,352<br>Equity attributable to the Parent Note 16 6,129,938 5,523,609<br>Non-controlling interests Note 18 2,327,606 1,793,489<br>Total equity 8,457,544 7,317,098<br>Liabilities<br>Grants 15,123 15,036<br>Provisions Note 19 110,063 24,122<br>Non-current financial liabilities Note 20 9,960,562 7,768,950<br>Other non-current liabilities 15 333<br>Deferred tax liabilities Note 27 1,034,823 633,984<br>Total non-current liabilities 11,120,586 8,442,425<br>Provisions Note 19 56,339 31,407<br>Current financial liabilities Note 20 795,686 2,438,291<br>Trade and other payables<br>Suppliers 731,918 628,992<br>Other payables 114,730 151,834<br>Current income tax liabilities 15,687 4,516<br>Total trade and other payables Note 21 862,335 785,342<br>Other current liabilities Note 22 241,487 219,272<br>Total current liabilities 1,955,847 3,474,312<br>Total liabilities 13,076,433 11,916,737<br>Total equity and liabilities 21,533,977 19,233,835<br>(*) Restated figures<br>The accompanying notes form an integral part of the consolidated annual accounts.<br>at 31 December 2022 and 2021<br>(Expressed in thousands of Euros)<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Consolidated Balance Sheet | ||
| --- | ||
| (Free translation from the original Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Reference 31/12/22 31/12/21 31/12/20<br>Continuing Operations<br>Net revenue Note 5 and 23 6,063,967 4,933,118 5,340,038<br>Cost of sales (3,832,437) (2,970,522) (3,084,873)<br>Gross Margin 2,231,530 1,962,596 2,255,165<br>Research and development (361,140) (354,881) (294,216)<br>Selling, general and administration expenses (1,190,423) (1,061,508) (985,616)<br>Operating Expenses (1,551,563) (1,416,389) (1,279,832)<br>Other Income 22,235 16,302 --<br>Profit of equity accounted investees with similar activity to that of the Group Note 10 103,478 32,555 20,799<br>Operating Result 805,680 595,064 996,132<br>Finance income 33,859 11,551 8,021<br>Finance costs (496,524) (277,994) (249,639)<br>Change in fair value of financial instruments 11,999 246 55,703<br>Impairment of financial assets at amortized cost -- -- --<br>Exchange differences 7,725 (11,602) 8,246<br>Finance result Note 26 (442,941) (277,799) (177,669)<br>Profit/(loss) of equity accounted investees Note 10 (1,482) 33,188 60,166<br>Profit before income tax from continuing operations 361,257 350,453 878,629<br>Income tax expense Note 27 (90,111) (85,126) (169,639)<br>Profit after income tax from continuing operations 271,146 265,327 708,990<br>Consolidated profit for the year 271,146 265,327 708,990<br>Profit attributable to the Parent 208,279 188,726 618,546<br>Profit attributable to non-controlling interest Note 18 62,867 76,601 90,444<br>Basic earnings per share (Euros) Note 17 0.31 0.28 0.90<br>Diluted earnings per share (Euros) Note 17 0.31 0.28 0.90<br>The accompanying notes form an integral part of the consolidated annual accounts.<br>at 31 December 2022, 2021 and 2020<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Consolidated Statements of Profit and Loss<br>(Expressed in thousands of Euros) | ||
| --- | ||
| (Free translation from the original Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Reference 31/12/22 31/12/21 31/12/20<br>Consolidated profit for the year 271,146 265,327 708,990<br>Items for reclassification to profit or loss<br>469,551 811,683 (747,221)<br>Note 10 30,771 (95,939) 21,916<br>Cash flow hedges - effective portion of changes in fair value 40,052 5,306 --<br>Cash flow hedges - amounts taken to profit or loss (44,809) (1,133) --<br>Tax effect 1,189 (1,043) --<br>(7,215) 286 (252)<br>Other comprehensive income for the year, after tax 489,539 719,160 (725,557)<br>Total comprehensive income for the year 760,685 984,487 (16,567)<br>Total comprehensive income attributable to the Parent 600,038 797,762 1,408<br>160,647 186,725 (17,975)<br>The accompanying notes form an integral part of the consolidated annual accounts.<br>Total comprehensive income attributable to non-controlling interests<br>Equity accounted investees / Translation differences<br>Other<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Consolidated Statements of Comprehensive Income<br>for the years ended 31 December 2022, 2021 and 2020<br>(Expressed in thousands of Euros)<br>Translation differences | ||
| --- | ||
| Reference 31/12/22 31/12/21 31/12/20<br>Cash flows from operating activities<br>Profit before tax 361,257 350,453 878,629<br>Adjustments for: 780,436 574,493 409,766<br>Amortization and depreciation Note 25 407,864 359,767 321,533<br>Other adjustments: 372,572 214,726 88,233<br>(Profit) / losses on equity accounted investments Note 10 (101,996) (65,744) (80,965)<br>Impairment of assets and net provision charges 69,982 64,091 (17,148)<br>(Profit) / losses on disposal of fixed assets Notes 7, 8 and 9 (1,731) 1,196 1,067<br>Government grants taken to income (16,440) (5,608) (1,683)<br>Finance cost / (income) 445,027 246,189 170,535<br>Other adjustments (22,270) (25,398) 16,427<br>Change in operating assets and liabilities (609,219) (140,908) 106,283<br>Change in inventories (600,245) (157,474) 164,631<br>Change in trade and other receivables (80,170) (16,806) (35,429)<br>Change in current financial assets and other current assets (9,010) (7,075) (20,600)<br>Change in current trade and other payables 80,206 40,447 (2,319)<br>Other cash flows used in operating activities (543,341) (187,063) (284,342)<br>Interest paid Note 20d (350,387) (155,120) (155,788)<br>Interest received 4,054 407 3,773<br>Income tax paid (196,436) (30,595) (131,510)<br>Other paid (572) (1,755) (817)<br>Net cash from/used in operating activities (10,867) 596,975 1,110,336<br>Cash flows from investing activities<br>Payments for investments (2,073,480) (876,678) (858,387)<br>Group companies, associates and business units Notes 3 and 10 (1,533,264) (519,128) (468,589)<br>Property, plant and equipment and intangible assets (375,560) (315,088) (362,560)<br>Property, plant and equipment Note 7 (266,491) (247,373) (280,154)<br>Intangible assets Note 9 (109,069) (67,715) (82,406)<br>Other financial assets (164,656) (42,462) (27,238)<br>Proceeds from the sale of investments 94,657 22,529 272<br>Group companies, associates and business units Notes 3 and 10 91,373 20,399 --<br>Property, plant and equipment 3,284 639 272<br>Other financial assets -- 1,491 --<br>Net cash used in investing activities (1,978,823) (854,149) (858,115)<br>Cash flows from financing activities<br>Proceeds from and payments for equity instruments (3,459) (125,703) --<br>Payments for treasury stock (3,459) (125,703) 0<br>Proceeds from and payments for financial liability instruments (177,372) 2,746,380 (243,373)<br>Issue 1,134,168 3,324,399 108,541<br>Redemption and repayment (1,207,253) (495,327) (272,877)<br>Lease payments (104,287) (82,692) (79,037)<br>Dividends and interest on other equity instruments 10,125 (247,498) (103,075)<br>Dividends paid (592) (258,946) (113,230)<br>Dividends received Note 10 10,717 11,448 10,155<br>Other cash flows used in financing activities (2,787) (75,500) (7,953)<br>-- (78,165) (9,227)<br>Other amounts from / (used in) financing activities (2,787) 2,665 1,274<br>Net cash from/(used in) financing activities (173,493) 2,297,679 (354,401)<br>Effect of exchange rate fluctuations on cash 35,551 55,459 (60,155)<br>Net increase / (decrease) in cash and cash equivalents (2,127,632) 2,095,964 (162,335)<br>Cash and cash equivalents at beginning of the year 2,675,611 579,647 741,982<br>Cash and cash equivalents at year end Note 15 547,979 2,675,611 579,647<br>The accompanying notes form an integral part of the consolidated annual accounts.<br>Financing costs included in the amortized cost of the debt<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Consolidated Statements of Cash Flows<br>for the years ended 31 December 2022, 2021 and 2020<br>(Expressed in thousands of Euros)<br>(Free translation from the original Spanish. In the event of discrepancy, the Spanish-language version prevails) | ||
| --- | ||
| (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Equity<br>Profit attributable Other attributable Non-controlling<br>Share Share Reserves to Interim Treasury Translation comprehensive Cash flow to interests Equity<br>Reference Capital Premium Parent dividend Stock differences income hedges Parent<br>Balance at 31 December 2019 119,604 910,728 3,009,599 625,146 (136,828) (49,584) 344,357 (903) -- 4,822,119 2,023,649 6,845,768<br>Translation differences -- -- -- -- -- -- (616,886) -- -- (616,886) (108,419) (725,305)<br>Other comprehensive income -- -- -- -- -- -- -- (252) (252) -- (252)<br>Other comprehensive income / (expense) for the year -- -- -- -- -- -- (616,886) (252) -- (617,138) (108,419) (725,557)<br>Profit/(loss) for the year -- -- -- 618,546 -- -- -- -- 618,546 90,444 708,990<br>Total comprehensive income / (expense) for the year -- -- -- 618,546 -- -- (616,886) (252) -- 1,408 (17,975) (16,567)<br>Net change in treasury stock Note 16 (d) -- -- -- -- -- 5,850 -- -- -- 5,850 -- 5,850<br>Acquisition / Divestment of non-controlling interests Note 16 (c) -- -- 405,698 -- -- -- -- -- -- 405,698 (405,698) --<br>Other changes -- -- (13,453) -- -- -- -- -- -- (13,453) 11,687 (1,766)<br>Distribution of 2019 profit:<br>Reserves -- -- 488,318 (488,318) -- -- -- -- -- -- -- --<br>Dividends -- -- (113,230) -- -- -- -- -- -- (113,230) -- (113,230)<br>Interim dividend -- -- -- (136,828) 136,828 -- -- -- -- -- -- --<br>Operations with shareholders or owners -- -- 767,333 (625,146) 136,828 5,850 -- -- -- 284,865 (394,011) (109,146)<br>Balance at 31 December 2020 119,604 910,728 3,776,932 618,546 -- (43,734) (272,529) (1,155) -- 5,108,392 1,611,663 6,720,055<br>Translation differences -- -- -- -- -- -- 605,620 -- -- 605,620 110,124 715,744<br>Cash flow hedges -- -- -- -- -- -- -- -- 3,130 3,130 -- 3,130<br>Other comprehensive income -- -- -- -- -- -- -- 286 -- 286 -- 286<br>Other comprehensive income / (expense) for the year -- -- -- -- -- -- 605,620 286 3,130 609,036 110,124 719,160<br>Profit/(loss) for the year -- -- -- 188,726 -- -- -- -- -- 188,726 76,601 265,327<br>Total comprehensive income / (expense) for the year -- -- -- 188,726 -- -- 605,620 286 3,130 797,762 186,725 984,487<br>Net change in treasury stock Note 16 (d) -- -- -- -- -- (120,455) -- -- -- (120,455) -- (120,455)<br>Acquisition / Divestment of non-controlling interests Note 16 (c) -- -- (1,611) -- -- -- -- -- -- (1,611) 1,522 (89)<br>Other changes -- -- (8,036) -- -- -- -- -- -- (8,036) 82 (7,954)<br>Distribution of 2020 profit:<br>Reserves -- -- 618,546 (618,546) -- -- -- -- -- -- -- --<br>Dividends -- -- (252,443) -- -- -- -- -- -- (252,443) (6,503) (258,946)<br>Interim dividend -- -- -- -- -- -- -- -- -- -- -- --<br>Operations with shareholders or owners -- -- 356,456 (618,546) -- (120,455) -- -- -- (382,545) (4,899) (387,444)<br>Balance at 31 December 2021 119,604 910,728 4,133,388 188,726 -- (164,189) 333,091 (869) 3,130 5,523,609 1,793,489 7,317,098<br>Translation differences -- -- -- -- -- -- 402,542 -- -- 402,542 97,780 500,322<br>Cash flow hedges Note 29 -- -- -- -- -- -- -- -- (3,568) (3,568) -- (3,568)<br>Other comprehensive income -- -- -- -- -- -- -- (7,215) -- (7,215) -- (7,215)<br>Other comprehensive income / (expense) for the year -- -- -- -- -- -- 402,542 (7,215) (3,568) 391,759 97,780 489,539<br>Profit/(loss) for the year -- -- -- 208,279 -- -- -- -- -- 208,279 62,867 271,146<br>Total comprehensive income / (expense) for the year -- -- -- 208,279 -- -- 402,542 (7,215) (3,568) 600,038 160,647 760,685<br>Net change in treasury stock Note 16 (d) -- -- -- -- -- 1,969 -- -- -- 1,969 -- 1,969<br>Acquisition / Divestment of non-controlling interests -- -- -- -- -- -- -- -- -- -- 373,468 373,468<br>Other changes -- -- 4,322 -- -- -- -- -- -- 4,322 2 4,324<br>Distribution of 2021 profit:<br>Reserves -- -- 188,726 (188,726) -- -- -- -- -- -- -- --<br>Dividends -- -- -- -- -- -- -- -- -- -- -- --<br>Interim dividend -- -- -- -- -- -- -- -- -- -- -- --<br>Operations with shareholders or owners -- -- 193,048 (188,726) -- 1,969 -- -- -- 6,291 373,470 379,761<br>Balance at 31 December 2022 119,604 910,728 4,326,436 208,279 -- (162,220) 735,633 (8,084) (438) 6,129,938 2,327,606 8,457,544<br>The accompanying notes form an integral part of the consolidated annual accounts.<br>Statement of Changes in Consolidated Equity<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Accumulated other comprehensive income<br>(Expressed in thousands of Euros)<br>for the years ended 31 December 2022, 2021 and 2020<br>Attributable to shareholders of the Parent | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>1<br>(1) Nature, Principal Activities and Subsidiaries<br>Grifols, S.A. (hereinafter the Company) was incorporated with limited liability under Spanish law on 22 June 1987.<br>Its registered and tax offices are in Jesús i Maria, 6, 08022, Barcelona. The Company's statutory activity consists of<br>providing corporate and business administrative, management and control services, as well as investing in assets and<br>property. Its principal activity involves rendering administrative, management and control services to its subsidiaries.<br>On 17 May 2006 the Company completed its flotation on the Spanish securities market, which was conducted through<br>the public offering of 71,000,000 ordinary shares of Euros 0.50 par value each and a share premium of Euros 3.90<br>per share. The total capital increase (including the share premium) amounted to Euros 312.4 million, equivalent to a<br>price of Euros 4.40 per share.<br>The Company’s shares were floated on the Spanish stock exchange IBEX-35 index on 2 January 2008.<br>All of the Company’s shares are listed on the Barcelona, Madrid, Valencia and Bilbao securities markets and on the<br>Spanish Automated Quotation System (SIBE/Continuous Market). On 2 June 2011, Class B non-voting shares<br>(ADRs) were listed on the NASDAQ (USA) and on the Spanish Automated Quotation System (SIBE/Continuous<br>Market).<br>Grifols, S.A. is the Parent of the subsidiaries listed in Appendix I of this note to the consolidated annual accounts.<br>Grifols, S.A. and subsidiaries (hereinafter the Group) act on an integrated basis and under common management and<br>their principal activity is the procurement, manufacture, preparation and sale of therapeutic products, especially<br>hemoderivatives.<br>The main factory locations of the Group’s Spanish companies are in Parets del Vallés (Barcelona) and Torres de<br>Cotilla (Murcia), while the US companies are located in Los Angeles (California), Clayton (North Carolina),<br>Emeryville (California), and San Diego (California).<br>(2) Basis of Presentation<br>The consolidated annual accounts have been prepared on the basis of the accounting records of Grifols, S.A. and of<br>the Group companies. The consolidated annual accounts for 2022 have been prepared under International Financial<br>Reporting Standards as adopted by the European Union (IFRS-EU) which for Grifols Group purposes, are identical<br>to the standards as issued by the International Accounting Standard Board (IFRS-IASB) to present fairly the<br>consolidated equity and consolidated financial position of Grifols, S.A. and subsidiaries at 31 December 2022, as<br>well as the consolidated results from their operations, consolidated cash flows and consolidated changes in equity for<br>the year then ended.<br>At their meeting held on 23 February 2023 the Board of Directors of Grifols, S.A. authorized for issue the 2022<br>consolidated annual accounts.<br>The consolidated annual accounts are presented in thousands of Euros, which is the functional and presentation<br>currency of the Parent.<br>These consolidated annual accounts for 2022 show comparative figures for 2021 and voluntarily show figures for<br>2020 from the consolidated statement of profit and loss, consolidated statement of comprehensive income,<br>consolidated statement of changes in equity and consolidated statement of cash flows and their corresponding notes<br>thereto. For the purposes of comparing the consolidated statement of profit and loss for 2022, 2021 and 2020 and the<br>consolidated balance sheet for 2022 and 2021, the effects of the application new standards described in note 2 must<br>be taken into account.<br>The Group adopted IFRS-EU for the first time on 1 January 2004 and has been preparing its annual accounts under<br>International Financial Reporting Standards, as adopted by the European Union (IFRS-EU) as required by Spanish | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>2<br>capital market regulations governing the presentation of financial statements by companies whose debt or own equity<br>instruments are listed on a regulated market.<br>In accordance with the provision of section 357 of the Irish Companies Act 2014, the Company has irrevocably<br>guaranteed all liabilities of an Irish subsidiary undertaking, Grifols Worldwide Operations Limited (Ireland) (see<br>Appendix I), for the financial year ended 31 December 2022 as referred to in subsection 1(b) of that Act, for the<br>purposes of enabling Grifols Worldwide Operations Limited to claim exemption from the requirement to file their<br>own annual accounts in Ireland.<br>(a) Relevant accounting estimates, assumptions and judgments used when applying accounting principles<br>The preparation of the consolidated annual accounts in conformity with IFRS-EU requires management to make<br>judgments, estimates and assumptions that affect the application of Group accounting policies. The following<br>notes include a summary of the relevant accounting estimates and judgments used to apply accounting policies<br>which have the most significant effect on the amounts recognized in the consolidated annual accounts.<br>x Determination of the fair value of assets, liabilities and contingent liabilities in relation to business<br>combinations. The fair value methods used by the Group are detailed in note 3<br>x Assumptions used to test non-current assets and goodwill for impairment. Relevant cash generating units<br>are tested annually for impairment. These are based on risk-adjusted future cash flows discounted using<br>appropriate interest rates. The key assumptions used are specified in note 6. Assumptions relating to risk-adjusted future cash flows and discount rates are based on business forecasts and are therefore inherently<br>subjective. Future events could cause a change in business forecasts, with a consequent adverse effect on<br>the future results of the Group. To the extent considered a reasonably possible change in key assumptions<br>could result in an impairment of goodwill, a sensitivity analysis has been disclosed to show the effect of<br>changes to these assumptions and the effect of the cash generating unit (CGU) on the recoverable amount.<br>x Evaluation of the capitalization of development costs (see note 4(d)). The key assumption is related to the<br>estimation of sufficient future economic benefits of the projects.<br>x The calculation of the income tax expense requires tax legislation interpretations in the jurisdictions where<br>Grifols operates. The decision as to whether the tax authority will accept a given uncertain tax treatment<br>and the expected outcome of outstanding litigation requires significant estimates and judgements. Likewise,<br>Grifols recognizes deferred tax assets, mainly from tax credits and rights to deduct to the extent that it is<br>probable that sufficient taxable income will be available against which temporary differences can be<br>utilized, based on management assumptions regarding amount and payments of future taxable profits (see<br>notes 4(q) and 27).<br>x Determination of chargebacks made to certain customers in the United States (see note 4 (p)).<br>No changes have been made to prior year judgments relating to existing uncertainties.<br>The Group is also exposed to interest rate and currency risks. Refer to sensitivity analysis in note 29.<br>(b) Basis of consolidation<br>Appendix I shows details of the percentages of direct or indirect ownership of subsidiaries by the Company at<br>31 December 2022, 2021 and 2020, as well as the consolidation method used in each case for preparation of the<br>accompanying consolidated annual accounts.<br>Subsidiaries in which the Company directly or indirectly owns the majority of equity or voting rights have been<br>fully consolidated. Associates in which the Company owns between 20% and 50% of share capital and over<br>which it has no control but does have significant influence, have been accounted for under the equity method. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>3<br>Although the Group holds 49% of the shares with voting rights of Grifols Malaysia Sdn Bhd, it controls the<br>majority of the economic and voting rights of Grifols Malaysia Sdn Bhd through a contract with the other<br>shareholder and a pledge on its shares. As a consequence, it has been fully consolidated.<br>Grifols (Thailand) Ltd. has two classes of shares and it grants the majority of voting rights to the class of shares<br>held by the Group. As a consequence, it has been fully consolidated.<br>Changes in associates and jointly controlled entities are detailed in note 10.<br>Changes in subsidiaries<br>In 2022:<br>x Albimmune, S.L.<br>On 13 January 2022, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies<br>Limited, Inc., reached an agreement to acquire 51% of the shares of Albimmune, S.L. for a total amount of Euros<br>3,000.<br>x VCN Biosciences, S.L.<br>On 10 March 2022, Grifols, together with the other shareholders, reached an agreement to sell one hundred<br>percent of the issued and outstanding shares of VCN Bioscience, S.L. for US Dollars 7,700 thousand.<br>As a result of this divestment, the Group has recognized income of Euros 7,557 thousand in the statement of<br>profit and loss of profit and loss.<br>x Biomat USA, Inc.<br>Effective 1 April 2022, Biomat USA Inc. and Talecris Plasma Resources, Inc. entered into a merger agreement,<br>and the resulting company was Biomat USA, Inc.<br>x Biotest AG and Grifols Biotest Holdings GmbH<br>On 25 April 2022, and once all regulatory approvals had been obtained, Grifols completed the acquisition of<br>70.18% of the share capital of Biotest AG and the entire share capital of Tiancheng (Germany) Pharmaceutical<br>Holdings AG, whose current corporate name is Grifols Biotest Holdings GmbH, for Euros 1,460,853 thousand<br>(see note 3).<br>x Access Biologicals Inc.<br>On 15 June 2022, Grifols, through its wholly owned subsidiary Chiquito Acquisition Corp., reached an<br>agreement to acquire all the shares of Access Biologicals LLC, exercising the call option for the remaining 51%<br>for a total of US Dollars 142 million (see note 3 and 10).<br>x Grifols México, S.A. de C.V.<br>Effective 15 December 2022, Grifols México, S.A. de C.V. and Logística Grifols, S.A. de C.V. entered into a<br>merger agreement, and the resulting company was Grifols México, S.A. de C.V.<br>In 2021:<br>x Grifols Pyrenees Research Center, SL<br>Grifols, through its wholly-owned subsidiary Grifols Innovation and New Technologies Limited (“GIANT”),<br>owns 80% of the company Grifols Pyrenees Research Center, SL, which was created to develop and manage a<br>new research center specializing in immunology, which will enhance the knowledge of the human immune | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>4<br>system and develop new immunological therapies. The contribution made by the Group amounted to Euros 2<br>thousand.<br>The remaining 20% belongs to the Government of Andorra, through its economic promotion office Andorra<br>Desenvolupament i Inversió.<br>x Gigagen, Inc.<br>On 8 March 2021, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies<br>Limited ("GIANT"), reached an agreement to acquire all of the shares of Gigagen, Inc. for a total consideration<br>of US Dollars 90.5 million.<br>With the acquisition of 100% of the shareholding, Grifols obtained control over Gigagen and, therefore, it is<br>considered a group company and started to be consolidated under the full integration method. Until that date, the<br>previous shareholding of 43.96% was accounted for by the equity method. The difference between the fair value<br>of the previous shareholding and the value recognized in books was Euros 34,525 thousand (US Dollars 41,758<br>thousand), recognizing a gain for this amount "Profit/Loss of equity accounted investees” in the statement of<br>profit and loss (see note 3).<br>x Prometic Plasma Resources, Inc.<br>On 31December 2021, Grifols, through its wholly owned subsidiary Grifols Canada Therapeutics Inc., reached<br>an agreement to acquire all of the shares of Prometic Plasma Resources Inc. for a total consideration of US<br>Dollars 8,805 thousand (see note 3).<br>x Grifols Escrow Issuer, S.A.<br>On August 26, 2021, Grifols, S.A. acquired all of the shares of Grifols Escrow Issuer, S.A. for a total<br>consideration of US Dollars 60 thousand.<br>x Araclon Biotech, SL<br>On October 2021 Araclon Biotech, S.L carried out a share capital increases of Euros 10 million. After the latter<br>capital increase Grifols’ interest rises to 75.85%.<br>x Haema Plasma Kft.<br>On 1 February 2021, Scranton Plasma B.V. acquired 100% of the shares of Haema Plasma Kft. (see note 3 (b)).<br>The following companies were incorporated during 2021 and were included in the consolidated Grifols Group.<br>x Grifols Middle East&Africa, LLC<br>x Grifols Bio North America, LLC<br>x Biomat Holdco, LLC<br>x Biomat Newco, Corp<br>In 2020:<br>x Grifols Diagnostic Solutions, Inc.<br>On 30 March 2020, Grifols closed a share exchange agreement with Shanghai RAAS Blood Products Co. Ltd.<br>(hereinafter SRAAS), through which Grifols delivered 90 shares of its US subsidiary Grifols Diagnostic<br>Solutions Inc. (hereinafter GDS) (representing 45% of the economic rights and 40% of the voting rights), and in<br>exchange received 1,766 million SRAAS shares (representing 26.2% of the share capital). Thus, Grifols became<br>the largest shareholder of SRAAS, while maintaining operational, political and economic control of GDS (see<br>note 10). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>5<br>x Plasmavita Healthcare GmbH<br>On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder<br>contribution in Plasmavita. The equity shares of 50% has remained unaffected after the contribution. However,<br>in assessing the existence of control due to the new shareholders’ agreement signed on this date, it can be<br>concluded that Grifols has control over Plasmavita and, therefore, it is considered part of the group and it has<br>been fully consolidated (see note 3).<br>x Alkahest, Inc.<br>On 2 September 2020, the Group reached an agreement with the shareholders of Alkahest Inc. (“Alkahest”) to<br>acquire 57.55% of Alkahest’s shares for a total price of US Dollars 146 million, on a debt free basis (see note<br>3).<br>x Green Cross<br>On 20 July 2020, Grifols executed share purchase arrangements with the South Korean-based GC Pharma<br>(Group) (“GC Pharma”) and other investors for the purchase of a plasma fractionation facility and two<br>purification facilities located in the city of Montreal, Canada, (the “Factories”) and 11 plasma collection centers<br>located in the United States (“the “Donation Centers”), for a total price of Euros 387,917 thousands (US Dollars<br>457,160 thousand), on a debt free basis. Grifols will not require supplementary financing for this transaction. On<br>1 October 2020, the transaction was closed (see note 3).<br>x VCN Biosciences, S.L.<br>On 2 December 2020, VCN Biosciences, S.L. carried out a share capital increase of Euros 5 million.<br>Consequently, the Group interest rises from 81.34% to 86.83%.<br> (c) Amendments to IFRS in 2022, 2021 and 2020<br>In accordance with IFRS, the following should be noted in connection with the scope of application of IFRS and<br>the preparation of these consolidated annual accounts of the Group.<br>Effective in 2020<br>Standards EU effective date IASB effective date<br>IAS 1<br>IAS 8 Definition of Material (issued on 31 October 2018) 1 January 2020 1 January 2020<br>Various<br>Amendments to Reference to the Conceptual Framework in<br>IFRS Standards (issued on 29 March 2018) 1 January 2020 1 January 2020<br>IFRS 3 Amendment to IFRS 3 Business Combination (issued on 22<br>October 2018) 1 January 2020 1 January 2020<br>IFRS 9<br>IAS 39<br>IFRS 7<br>Interest rate Benchmark Reform (issued on 26 September 2019) 1 January 2020 1 January 2020<br>IFRS 16 Covid 19 - Related Rent concessions (issued on 28 May 2020) 1 June 2020 1 June 2020<br>Mandatory application for annual periods<br>beginning on or after: | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>6<br>Effective in 2021<br>Standards EU effective date IASB effective date<br>IFRS 4<br>Amendments to IFRS 4 Insurance Contracts – deferral of IFRS 9<br>(issued on 25 June 2020) 1 January 2021 1 January 2021<br>Various<br>Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16<br>Interest Rate Benchmark Reform – Phase 2 (issued on 27<br>August 2020)<br>1 January 2021 1 January 2021<br>IFRS 16 Amendment to IFRS 16 Leases Covid 19-Related Rent<br>Concessions beyond 30 June 2021 (issued on 31 March 2021) 1 April 2021 1 April 2021<br>Mandatory application for annual periods<br>beginning on or after:<br>Effective in 2022<br>The following standards published by the IASB and the IFRS Interpretations Committee and adopted by the<br>European Union for application in Europe came into force in 2022 and, therefore, have been taken into account<br>in the preparation of these consolidated annual accounts:<br>Standards EU effective date IASB effective date<br>Various<br>Amendments issued 14 May 2020 to:<br>- IFRS 3 Business Combinations: references to the Conceptual<br>Framework;<br>- IAS 16 Property, Plant and Equipment: Proceeds before<br>Intended Use;<br>- IAS 37 Provisions, Contingent Liabilities and Contingent<br>Assets: Onerous Contracts — Cost of Fulfilling a Contract ; and<br>- Annual Improvements to IFRSs 2018-2020: IFRS 1, IFRS 9,<br>IFRS 16 and IAS 41.<br>1 January 2022 1 January 2022<br>Mandatory application for annual periods<br>beginning on or after:<br>The application of these standards and interpretations has had no significant impact on these consolidated annual<br>accounts.<br>Standards issued but not effective in 2022<br>At the date these consolidated annual accounts were authorized for issue, the following IFRS and amendments<br>have been published by the European Union but their application is not mandatory until the future periods<br>indicated below: | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>7<br>Standards EU effective date IASB effective date<br>IAS 1<br>Amendments to IAS 1 Presentation of Financial Statements:<br>- Classification of Liabilities as Current or Non-current Date<br>(issued on 23 January 2020);<br>- Classification of Liabilities as Current or Non-current - Deferral<br>of Effective Date (issued on 15 July 2020); and<br>- Non-current Liabilities with Covenants (issued on 31 October<br>2022)<br>pending 1 January 2024<br>IFRS 16 Amendments to IFRS 16 Leases: Lease Liability in a Sale and<br>Leaseback (issued on 22 September 2022) pending 1 January 2024<br>IFRS 17 Insurance Contracts (issued on 18 May 2017); including<br>Amendments to IFRS 17 (issued on 25 June 2020) 1 January 2023 1 January 2023<br>IAS 8<br>Amendments to IAS 8 Accounting policies, Changes in<br>Accounting Estimates and Errors: Definition of Accounting<br>Estitmates (issued on 12 February 2021)<br>1 January 2023 1 January 2023<br>IAS 1<br>Amendments to IAS 1 Presentation of Financial Statements and<br>IFRS Practice Statement 2: Disclosure of Accounting policies<br>(issued on 12 February 2021)<br>1 January 2023 1 January 2023<br>IAS 12<br>Amendments to IAS 12 Income Taxes: Deferred Tax related to<br>Assets and Liabilities arising from a Single Transaction (issued on<br>7 May 2021)<br>1 January 2023 1 January 2023<br>IFRS 17<br>Amendments to IFRS 17 Isurance contracts: Initial Application of<br>IFRS 17 and IFRS 9 - Comparative Information (issued on 9<br>December 2021)<br>1 January 2023 1 January 2023<br>Mandatory application for annual periods<br>beginning on or after:<br>The Group has not applied any of these standards or interpretations in advance of their effective date.<br>The application of these standards and interpretations has had no significant impact on these consolidated<br>financial statements.<br>(3) Business Combinations and Divestments<br>2022<br>a) Prometic Plasma Resources, Inc.<br>On 31 December 2021, Grifols, through its wholly owned subsidiary Grifols Canada Therapeutics, Inc., acquired<br>all the shares of Prometic Plasma Resources Inc. for a total of Canadian Dollars 11,127 thousand (Euros 7,757<br>thousand).<br>Aggregate details of the cost of the business combination, the provisional fair value of the net assets acquired<br>and the goodwill at the acquisition date are shown below:<br>Reference Thousands of Euros Thousands of<br>Canadian Dollars<br>Cost of the business combination<br>Consideration paid 7,757 11,127<br>Total consideration paid 7,757 11,127<br>Fair value of net assets acquired 4,933 7,075<br>Goodwill (excess of the cost of the business combination<br>over the fair value of net assets acquired) Note 6 2,824 4,052 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>8<br>The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as<br>follows:<br>Thousands of Euros Thousands of Canadian<br>Dollars<br>Other Intangible Assets 551 791<br>Rights of Use 238 341<br>Property, plant and equipment 36 51<br>Inventories 71 102<br>Trade and other reeceivables 4,603 6,602<br>Other current assets 9 13<br>Cash and cash equivalents 32 46<br>Total Assets 5,540 7,946<br>Non-current financial liabilities (32) (46)<br>Current financial liabilities (264) (379)<br>Trade and other payables (311) (446)<br>Total Liabilities (607) (871)<br> Total net assets acquired 4,933 7,075<br>Fair Value<br>The resulting goodwill has been allocated to the Biopharma segment and includes the donor database, licenses<br>and workforce.<br>b) Haema Plasma Kft.<br>On 1 February 2021, Scranton Plasma B.V. acquired 100% of the shares of Haema Plasma Kft. Scranton is a<br>shareholder of Grifols.<br>On 1 February 2021 the Group signed a call option on the shares of Haema Plasma kft, exercisable by the Group<br>only 12 months after signing and with an expiry of 48 months from the date on which the option becomes<br>exercisable. The option price was set at thirteen times EBITDA minus net debt.<br>The Group has potential voting rights arising from the option to purchase the shareholding and these are<br>substantive, based on:<br> • A call option for Grifols which gives it the irrevocable and exclusive right (not an obligation) to acquire the<br>Haema Plasma Kft shareholding at any time after 1 February 2022.<br> • Grifols is committed to providing support services in the business of collecting, processing and distributing<br>plasma from the donation centres. There is also a Plasma Supply Agreement whereby the plasma produced by<br>these entities will be used almost entirely to cover Grifols' needs. There is no sales exclusivity.<br> • There are no shareholder agreements that provide for relevant decisions to be approved in a manner other than<br>by majority vote.<br>The above are indicators of the power that Grifols acquires over this entity, considering that the call option is<br>likely to be exercised and Grifols will have the financial capacity to carry it out.<br>Consequently, at the time the option becomes exercisable, the option empowers Grifols, even though it has not<br>yet been exercised, and Haema Plasma Kft. is therefore included in Grifols' consolidated financial statements<br>from 2022. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>9<br>Aggregate details of the cost of the business combination, the provisional fair value of the net assets acquired<br>and the provisional goodwill at the acquisition date are shown below:<br>Reference Thousands of<br>Euros<br>Thousands of<br>Hungarian Forint<br>Call option price 16,948 6,228,796<br>Total consideration 16,948 6,228,796<br>Fair value of net assets acquired 2,209 812,371<br>Goodwill (excess of the cost of the business combination<br>over the fair value of net assets acquired) Note 6 14,739 5,416,425<br>The provisional amounts determined at the date of consolidation of the assets, liabilities and contingent liabilities<br>acquired are as follows:<br>Thousands of Euros Thousands of Hungarian<br>Forint<br>Other Intangible assets 37 13,620<br>Rights of Use 3,421 1,257,286<br>Property, plant and equipment 1,301 478,222<br>Other non-current assets 302 110,810<br>Deferred tax assets 13 4,742<br>Inventories 2,784 1,022,926<br>Trade and other receivables 357 131,821<br>Other current assets 252 92,769<br>Cash and cash equivalents 3,343 1,228,356<br>Total Assets 11,810 4,340,552<br>Provisions (169) (61,946)<br>Non-current financial liabilities (2,517) (925,074)<br>Current financial liabilities (4,281) (1,573,216)<br>Trade and other payables (2,100) (771,861)<br>Other current liabilities (534) (196,084)<br>Total Liabilities and contingent liabilities (9,601) (3,528,181)<br> Total net assets acquired 2,209 812,371<br>Fair Value<br>The resulting goodwill has been allocated to the Biopharma segment and includes the donor database, licences<br>and workforce.<br>c) VCN Biosciences, S.L.<br>On 10 March 2022, Grifols, together with the other shareholders, reached an agreement to sell one hundred<br>percent of the issued and outstanding shares of VCN Bioscience, S.L. for US Dollars 7,700 thousand. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>10<br>As a result of this divestment, the Group has recognized an income of Euros 7,557 thousand under “other<br>income” in the statement of profit and loss of profit and loss. VCN’s net assets were derecognised from the<br>consolidated group as of the indicated date.<br>d) Biotest AG<br>On 25 April 2022, and once all regulatory approvals were obtained, Grifols completed the acquisition of 70.18%<br>of the share capital of Biotest AG for Euros 1,460,853 thousand. The transaction was structured as follows:<br>x Grifols acquired the entire share capital of Tiancheng (Germany) Pharmaceutical Holdings AG for Euros<br>1,090,518 thousand. This amount included a loan from Tiancheng (Germany) Pharmaceutical Holdings AG,<br>whose current corporate name is Grifols Biotest Holdings GmbH, to Biotest AG of Euros 317,876 thousand.<br>The Biotest shares were valued at Euros 43.00 per ordinary share (17,783,776 shares) and Euros 37.00 per<br>preference share (214,581 shares).<br>x At the same time as the transaction, Grifols closed the voluntary takeover bid to all shareholders, which<br>involved the payment of 370,335 thousand of euros for 1,435,657 ordinary shares at 43.00 euros per share<br>and 8,340,577 preference shares at 37.00 euros per share.<br>The investment in Biotest will significantly strengthen Grifols' capabilities, including its scientific and technical<br>capabilities, helping to strengthen the availability of plasma medicines, its commercial presence and its R&D<br>pipeline. With the opening of 2 new centres, Biotest now has 28 plasma donation centres in Europe.<br>Aggregate details of the cost of the business combination, the provisional fair value of the net assets acquired<br>and the provisional goodwill at the acquisition date are shown below:<br>Reference Thousands of Euros<br>Cost of the business combination<br>Consideration paid 1,460,853<br>Total consideration paid 1,460,853<br>Fair value of net assets acquired 1,157,229<br>Goodwill (excess of the cost of the business combination over the<br>fair value of net assets acquired) Note 6 303,624<br>The resulting goodwill has been allocated to the Biopharma segment | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>11<br>The provisional amounts determined at the date of consolidation of the assets, liabilities and contingent liabilities<br>acquired are as follows:<br>Fair Value<br>Thousand of Euros<br>Other Intangible Assets 1,172,582<br>Rights of Use 25,256<br>Property, plant and equipment 545,667<br>Other non-current assets 13,969<br>Deferred Tax Assets 9,109<br>Inventories 259,316<br>Contract Assets 35,319<br>Trade and other receivables 88,249<br>Other current assets 25,644<br>Cash and cash equivalents 94,662<br>Total assets 2,269,773<br>Non-controlling interests (356,386)<br>Non-current provisions (120,298)<br>Non-current financial liabilities (182,761)<br>Other non-current liabilities (9)<br>Deferred tax liabilities (347,192)<br>Current Provisions (18,239)<br>Current financial liabilities (35,052)<br>Trade and other payables (40,489)<br>Other current liabilities (12,118)<br>Total Liabilities and contingent liabilities (1,112,544)<br> Total net assets acquired 1,157,229<br>As part of the purchase price allocation, the company has determined that identifiable intangible assets are the<br>research and development projects in progress, the current product portfolio as well as certain distribution<br>agreements.<br>The fair value of intangible assets has been estimated using an income approach and the projected cash flows<br>have been discounted using rates between 8.6% and 11%. The cash flows have been based on estimates used to<br>establish the transaction price and the discount rates applied have been compared with reference to the implied<br>rate of return of the transaction model and the weighted average cost of capital.<br>The fair value of research and development projects in progress involving plasma therapies (Fibrinogen, IgM<br>and IgG) has been estimated in accordance with an income approach based on the Multiple-Period Excess<br>Earnings Method for the application of which the results of such projects have been adjusted for the probability<br>of success according to the clinical phase of the project at the date of the transaction.<br>The current product portfolio comprises regulatory approvals, trademarks, patient relationships and physician<br>relationships related to products currently marketed by Biotest. The distribution agreements identified as<br>intangible assets relate to the distribution of certain products in different geographic regions. In both cases, the<br>fair value has been determined using the Multiple-Period Excess Earnings Method.<br>Research and development projects in progress, the current product portfolio and distribution agreements are<br>amortized on a straight-line basis over an average period of 20, 30 and 7.5 years, respectively. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>12<br>If the acquisition had taken place as of January 1, 2022, the revenue would have changed by Euros 154,846<br>thousand and the group result by Euros (15,434) thousand.<br>The Group has recognized under operating expenses in the consolidated statement of profit and loss an amount<br>of Euros 23,600 thousand of transaction costs.<br>e) Access Biologicals Inc.<br>On 15 June 2022, Grifols, through its wholly owned subsidiary Chiquito Acquisition Corp., reached an<br>agreement to acquire all the shares of Access Biologicals LLC, exercising the call option for the remaining 51%<br>for a total of US Dollars 142 million. With the acquisition of 100% of the stake, Grifols obtains control over<br>Access Biologicals LLC and is therefore considered a group company and consolidated under the full<br>consolidation method. The difference between the fair value of the previous shareholding and the recognised<br>carrying amount is Euros 72,984 thousand (US Dollars 77,209 thousand), and a gain of this amount is recognised<br>under " Profit/(loss) of equity accounted investees " in the statement of profit and loss of profit or loss (see note<br>10).<br>Access Biologicals' core business is the collection and manufacture of an extensive portfolio of biological<br>products. Combined with a closed materials sourcing process, it provides support services for different markets<br>such as in-vitro diagnostics, biopharmaceuticals, cell culture and diagnostic research and development.<br>Aggregate details of the cost of the business combination, the provisional fair value of the net assets acquired<br>and the provisional goodwill at the acquisition date are shown below:<br>Reference Thousands of Euros Thousands of US<br>Dollars<br>Cost of the business combination<br>First share purchase 48,218 51,010<br>Second share purchase (present value) 134,742 142,544<br>Total consideration paid 182,960 193,554<br>Gain on the previously held investment 72,984 77,209<br>Accumulated gain for equity method before acquisition date 8,256 8,735<br>Step-up of the previously held investment 81,240 85,944<br>Fair value of net assets acquired (83,366) (88,193)<br>Goodwill (excess of the cost of the business combination over<br>the fair value of net assets acquired) Note 6 180,834 191,305<br>The provisional amounts determined at the date of consolidation of the assets, liabilities and contingent liabilities<br>acquired are as follows: | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>13<br>Thousands of<br>Euros<br>Thousands of US<br>Dollars<br>Other Intangible Assets 82,080 86,832<br>Property, plant and equipment 2,589 2,739<br>Other non-current assets 75 79<br>Inventories 16,836 17,811<br>Trade and other receivables 7,522 7,958<br>Other current assets 1,529 1,618<br>Cash and cash equivalents 2,987 3,160<br>Total Assets 113,618 120,197<br>Trade and other payables (7,249) (7,669)<br>Deferred tax liabilities (22,981) (24,312)<br>Other non-current liabilities (22) (23)<br>Total Liabilities and contingent liabilities (30,252) (32,004)<br> Total net assets acquired 83,366 88,193<br>Fair Value<br>The resulting provisional goodwill has been allocated to the Bio-Supplies segment.<br>As part of the purchase price allocation, the Company has determined that identifiable intangible assets are<br>customer relationships.<br>Customer relationships have been valued using the Multiple-Period Excess Earnings Method, for the application<br>of which a discount rate of 8.1% has been considered and a decline rate resulting in an average useful life of 14<br>years. The cash flows have been based on estimates used to establish the transaction price and the discount rate<br>applied has been compared with reference to the implied rate of return of the transaction model and the weighted<br>average cost of capital. The excess of the purchase price over the estimated fair value of the net assets acquired<br>has been recorded as goodwill. The factors contributing to its recognition have been the acquired workforce as<br>well as the expected benefits from the combination of the Group's activities.<br>If the acquisition had taken place as of January 1, 2022, the revenue would have changed by Euros 4,402<br>thousand and the group result by Euros 1,819 thousand.<br>The Group has recognized under operating expenses in the consolidated statement of profit and loss an amount<br>of Euros 486 thousand of transaction costs.<br>f) Goetech, LLC<br>In July 2022, Grifols closed an agreement to sell in cash substantially all of the assets of its subsidiary Goetech<br>LLC, whose trade name is MedKeeper, for a US Dollars 91,635 thousand Enterprise Value (Euros 90,002<br>thousand). MedKeeper develops and markets innovative mobile and cloud-based IT applications aimed at<br>helping hospital pharmacies boost productivity, process safety and compliance.<br>As a consequence of this divestment, the Group has recognized an income of Euros 23,106 thousand in the profit<br>and loss account. Goetech’s net assets were derecognized from the consolidated group as of the indicated date. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>14<br>2021<br>x Gigagen, Inc.<br>On 8 March 2021, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies<br>Limited ("GIANT"), reached an agreement to acquire all of the shares of Gigagen, Inc. for a total consideration<br>of US Dollars 90.5 million.<br>GigaGen is a U.S. biotechnology company specializing in the discovery and early development of recombinant<br>biotherapeutic drugs. GigaGen's research focuses on the discovery of new biological treatments based on<br>antibodies derived from millions of donor-derived immune system cells.<br>With the acquisition of 100% of the shareholding, Grifols obtained control over Gigagen and, therefore, it was<br>considered a group company and is consolidated under the full consolidation method. Until that date, the<br>previous shareholding of 43.96% was accounted for using the equity method. The difference between the fair<br>value of the previous shareholding and the value recognized in books was Euros 34,525 thousand (US Dollars<br>41,758 thousand), recognizing a profit for this amount under "Profit/(loss) of equity accounted investees " in the<br>statement of profit and loss.<br>From the total amount agreed, as of 31 December 2021, an amount of Euros 38,201 thousand was paid in cash<br>and Euros 36,591 thousand were payable. This amount was presented under "Current financial liabilities" in the<br>balance sheet and it was paid in March 2022.<br>The Group recognized an amount of Euros 404 thousand of transaction costs under operating expenses in the<br>consolidated statement of profit and loss.<br>Aggregate details of the cost of the business combination, the fair value of the net assets acquired and the<br>goodwill at the acquisition date are shown below:<br>Reference Thousands of<br>Euros<br>Thousands of<br>US Dollars<br>Consideration paid<br>First share purchase 38,201 46,203<br>Second share purchase (present value) 35,227 42,608<br>Total consideration paid 73,428 88,811<br>Fair value of the previous investment in the company 50,792 61,434<br>Fair value of net assets acquired 18,760 22,691<br>Goodwill (excess of the cost of the business combination over the fair<br>value of net assets acquired) Note 6 105,460 127,554 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>15<br>The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as<br>follows:<br>Fair value<br>Reference Thousands of<br>Euros<br>Thousands of<br>US Dollars<br>Development costs in progress Note 7 24,027 29,061<br>Property, plant and equipment Note 7 1,168 1,413<br>Non-current financial assets 151 183<br>Trade and other receivables 56 68<br>Other current assets 2,368 2,864<br>Cash and cash equivalents 12,389 14,985<br> Total assets 40,159 48,574<br>Non-current liabilities (17,792) (21,520)<br>Current liabilities (3,607) (4,363)<br> Total liabilities and contingent liabilities (21,399) (25,883)<br> Total net assets identified 18,760 22,691<br>The fair value of the R&D projects in progress was estimated based on market approach of comparable<br>transactions.<br>The resulting goodwill was allocated to the others segment and includes the specialized R&D workforce and the<br>portfolio of future early stage products.<br>The acquired business generated consolidated results for the Group during the period from the acquisition date<br>to year-end in the amount of Euros 4,350 thousand.<br>If the acquisition had occurred as of 1 January 2021, the Group's net revenues and results would not have changed<br>significantly.<br>x BPL Plasma, Inc.<br>On 28 February 2021, Biomat USA, Inc. the Group's American subsidiary, acquired 25 plasma donation centers<br>in the United States from BPL Plasma, Inc. a subsidiary of Bio Products Laboratory Holdings Limited, for US<br>Dollars 385 million.<br>The transaction received the necessary regulatory approvals and was financed with its own resources, without<br>issuing debt.<br>Grifols will obtain approximately one million liters of plasma per year from these centers.<br>The Group recognized transaction costs of Euros 2,764 thousand in operating expenses in the consolidated<br>statement of profit and loss of profit and loss. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>16<br>Aggregate details of the cost of the business combination, the definitive fair value of the net assets acquired and<br>the definitive goodwill at the acquisition date are shown below:<br>Reference Thousands of Euros Thousands of US<br>Dollars<br>Consideration paid<br>First payment made 9,921 12,000<br>Cash paid at the transaction closing date 308,016 372,548<br>Total consideration paid 317,937 384,548<br>Fair value of net assets acquired 15,039 18,190<br>Goodwill (excess of the cost of the business combination<br>over the fair value of net assets acquired) Note 6 302,898 366,358<br>The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as<br>follows:<br>Reference Thousands of<br>Euros<br>Thousands of<br>US Dollars<br>Property, plant and equipment Note 9 14,406 17,424<br>Non-current financial assets 85 103<br>Inventories 557 674<br> Total assets 15,048 18,201<br>Current liabilities (9) (11)<br> Total liabilities and contingent liabilities (9) (11)<br> Total net assets identified 15,039 18,190<br>Fair value<br>The resulting goodwill was allocated to the Biopharma segment and included the donor database, licenses and<br>workforce.<br>x Acquisition of plasma centers from Kedplasma, LLC.<br>On 31 March 2021, Biomat USA, Inc., the Group's American subsidiary, acquired 7 plasma donation centers in<br>the United States from the company Kedplasma, LLC for US Dollars 55.2 million. All the centers acquired are<br>licensed by the U.S. Food and Drug Administration (FDA) and the European authorities.<br>Grifols will have immediate access to the plasma obtained at these centers, which obtain approximately 240,000<br>liters of plasma per year.<br>The transaction received the necessary regulatory approvals and was financed with equity without issuing debt.<br>The Group recognized transaction costs of Euros 625 thousand in operating expenses in the consolidated<br>statement of profit and loss of profit and loss. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>17<br>Aggregate details of the cost of the business combination, the definitive fair value of the net assets acquired and<br>the definitive goodwill at the acquisition date are shown below:<br>Reference Thousands of Euros Thousands of US<br>Dollars<br>Consideration paid<br>Cash paid 45,638 55,200<br>Total consideration paid 45,638 55,200<br>Fair value of net assets acquired 2,692 3,256<br>Goodwill (excess of the cost of the business combination<br>over the fair value of net assets acquired) Note 6 42,946 51,944<br>The amounts determined at the acquisition date of the assets, liabilities and contingent liabilities acquired are as<br>follows:<br>Reference Thousands of<br>Euros<br>Thousands of US<br>Dollars<br>Property, plant and equipment Note 9 2,448 2,961<br>Inventories 244 295<br> Total assets 2,692 3,256<br> Total net assets identified 2,692 3,256<br>Fair value<br>The resulting goodwill was allocated to the Biopharma segment and included the donor database, licenses and<br>workforce.<br>x Prometic Plasma Resources, Inc.<br>On 31 December 2021, Grifols, through its wholly owned subsidiary Grifols Canada Therapeutics Inc., acquired<br>all of the shares of Prometic Plasma Resources Inc. for a total consideration of US Dollars 8,805 thousand (see<br>note 2).<br>The purchase price has been assigned provisionally to Goodwill in the consolidated balance sheet, considering<br>that the initial accounting has not been completed at the end of the reporting period.<br>2020<br><br>(a) Plasmavita<br>In November 2017, Grifols established Plasmavita Healthcare GmbH (hereinafter Plasmavita), a joint venture<br>between Grifols (50%) and two other partners (50%) for the construction and operation of 10 plasma donor<br>centers in Germany.<br>On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder<br>contribution in Plasmavita. The equity share of 50% has remained unchanged after the contribution. However,<br>in assessing the existence of control due to new shareholder agreement signed on this date, the following was<br>concluded: | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>18<br>- Grifols has a casting vote for any decision, determination and approval, with respect to the annual budget<br>of Plasmavita and the distribution of dividends. Grifols has the power to make key business decisions.<br>- Grifols is involved in the decision-making related to exposure or rights to variable returns from the investee.<br>- Grifols has the casting vote to distribute dividends.<br>Considering the above, it was concluded that Grifols has control over Plasmavita and, therefore, it is considered<br>part of the group and it has been fully consolidated.<br>Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at<br>the acquisition date are provided below:<br>Reference Thousands of Euros<br>Consideration paid<br>Cash paid 10,000<br>Total consideration paid 10,000<br>Fair value of the previous investment in the business 10,674<br>Fair value of net assets acquired 21,374<br>Non-controlling interests (10,687)<br>Goodwill (excess of the cost of the business combination over the<br>fair value of net assets acquired) Note 6<br>9,987<br>The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities acquired are as<br>follows:<br>Fair Value<br>Reference Thousands of Euros<br>Intangible assets Note 7 177<br>Rights of use Note 8 7,856<br>Property, plant and equipment Note 9 6,506<br>Investment in group companies 9,548<br>Non-current financial assets 5,017<br>Inventories 1,114<br>Trade and other receivables 811<br>Other current assets 333<br>Cash and cash equivalents 359<br> Total assets 31,721<br>Deferred tax liabilities (1,364)<br>Other non-current liabilites (7,575)<br>Current liabilities (1,408)<br> Total liabilities and contingent liabilities (10,347)<br> Total net assets acquired 21,374<br>The resulting goodwill was allocated to the Biopharma segment, and it included the donor data base, licenses<br>and workforce.<br>If the acquisition had taken place on 1 January 2020, the net amount of the Group´s revenue and profit would<br>not have differed significantly. The revenue and consolidated profit generated by Plasmavita between the<br>acquisition date and 31 December 2020 are not significant for the Group. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>19<br>The difference between the fair value of the previous investment and the book value amounted to Euros 5,357<br>thousand and has been recognized as income under “Profit/(loss) of equity accounted investees with similar<br>activity to that of the Group” in the consolidated statement of profit and loss. The minority interest’s share of<br>the contribution made amounts to Euros 5 million and has been recognized as a loss under the same line item.<br>(b) Alkahest, Inc.<br>On 2 September 2020, Grifols signed an agreement to acquire all the shares of Alkahest Inc. ("Alkahest") for a<br>total amount of Euros 123,425 thousand (US Dollars 146,000 thousand), which was subject to approval by<br>regulatory authorities. As part of the agreement, the Group had:<br>x Grifols has a casting vote for any decision, determination and approval, with respect to the annual budget of<br>Alkahest and the distribution of dividends. Grifols has the power to decide on key business decisions.<br>x Grifols is involved in the decision-making related to exposure or rights to variable returns from the investee.<br>Considering the above, it was concluded that Grifols has control over Alkahest and, therefore, it is considered<br>part of the group and it has been fully consolidated. Until that date, the previous 42.45% stake in Alkahest was<br>recorded using the equity method. The difference between the fair value of the previous investment and the book<br>value amounted to Euros 86,743 thousand (US Dollars 102,552 thousand) and has been recognized as income<br>under “Profit/(loss) of equity accounted investees” in the consolidated statement of profit and loss.<br>On 15 October 2020, and as a result of the aforementioned share purchase agreement, Grifols proceeded to<br>acquire 57.55% of the capital of Alkahest. After the transaction, the Group owns 100% of the company's share<br>capital. Given that Grifols already had control of Alkahest, the transaction has been recorded as an agreement<br>with the non-controlling interest, which has meant the recognition of a liability at amortized cost of Euros<br>121,149 thousand (US Dollars 143,706 thousand) and a decrease in "Non-controlling interests” in the amount of<br>Euros 121,486 thousand (US Dollars 143,307 thousand), net of recorded losses and “Other reserves ”in the<br>amount of Euros 337 thousand (US Dollars 399 thousand).<br>At 31 December 2020, the amount payable totaled Euros 100,492 thousand and was presented under the line<br>item “Current financial liabilities”. This amount was settled on 1 February 2021 (see note 20).<br>Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at<br>the acquisition date are provided below:<br>Thousands of Euros Thousands of US<br>Dollars<br>Cost of the business combination<br>First repurchase of non-controlling interests 18,797 22,235<br>Second repurchase of non-controlling interests (present value) 104,628 123,765<br>Total business combination cost 123,425 146,000<br>Fair value of the previous investment in the business 91,023 107,671<br>Fair value of net assets acquired 140,076 165,696<br>Goodwill (excess of the cost of the business<br>combination over the fair value of net assets acquired) 74,372 87,975 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>20<br>The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities acquired are as<br>follows:<br>Thousands of Euros Thousands of<br>US Dollars<br>Other Intangible Assets 265,617 314,198<br>Property, plant and equipement 4,970 5,879<br>Other non-current assets 178 210<br>Trade and other receivables 2,552 3,019<br>Other current assets 1,609 1,904<br>Cash and cash equivalents 7,563 8,946<br>Total assets 282,489 334,156<br>Non-current financial liabilities (42,269) (50,000)<br>Deferred tax liabilities (74,372) (87,975)<br>Other non-current liabilities (19,644) (23,237)<br>Trade and other payables (1,863) (2,204)<br>Other current liabilities (4,265) (5,044)<br>Total Liabilities (142,413) (168,460)<br>Fair value of net assets acquired 140,076 165,696<br>Fair Value<br>The resulting goodwill was allocated to the Others segment and it mainly includes the workforce.<br>The fair value of research and clinical development projects in progress that include products for<br>neurodegenerative disorders, neuromuscular and ophthalmologic diseases have been estimated according to an<br>income approach based on risk-adjusted discounted free cash flows.<br>Had the acquisition taken place on 1 January 2020, the net amount of the Group´s revenue would not have<br>changed significantly, and the net profit would have decreased by Euros 30,045 thousand. The profit of Alkahest<br>between the acquisition date and 31 December 2020 amounted to Euros (12,317) thousand. The amount of net<br>revenue has not changed significantly.<br>(c) Green Cross<br>On 20 July 2020, Grifols signed share purchase arrangements with the South Korean based GC Pharma Group<br>and other investors for the acquisition of a plasma fractionation facility and two purification facilities located in<br>the city of Montreal, Canada, and 11 plasma collection centers located in the United States, for a total<br>consideration of Euros 387,917 thousand (US Dollars 457,160 thousand), on a debt free basis. On 1 October<br>2020, the transaction was closed.<br>The consideration was paid with Grifols' own cash resources, and at the close of the Transaction certain equity,<br>working capital and cash targets were guaranteed.<br>The factories are currently in the process of obtaining the required licenses and regulatory approvals from the<br>competent health authorities for the manufacturing of plasma-derived products. When licensed and approved,<br>Grifols will become the only commercial manufacturer of plasma products in Canada, with a fractionation<br>capacity of 1.5 M liters.<br>Grifols plans to be ready to manufacture IVIG and Albumin at the factories to be able to supply the Canadian<br>market starting in 2023. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>21<br>The collection centers achieved a collection volume of 350,000 liters of plasma in 2019.<br>Upon the execution of the Transaction, and by means of a plasma supply agreement, the Group has also<br>committed to supplying certain output of plasma arising out of the collection centers to GC Pharma for a 24-<br>month period.<br>Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at<br>the acquisition date are provided below:<br>Thousands of Euros Thousands of US<br>Dollars<br>Consideration paid<br>Cash paid 387,917 457,160<br>Total consideration paid 387,917 457,160<br>Fair value of net assets acquired 194,227 228,897<br>Goodwill (excess of the cost of the business combination<br>over the fair value of net assets acquired) 193,690 228,263<br>The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows:<br>Thousands of Euros Thousands of US<br>Dollars<br>Other Intangible Assets 2,877 3,390<br>Rights of Use 11,642 13,720<br>Property, plant and equipement 158,148 186,377<br>Deferred tax assets 33,081 38,986<br>Other non current assets 122 144<br>Inventories 2,999 3,534<br>Trade and other receivables 3,484 4,106<br>Other current assets 943 1,111<br>Cash and cash equivalents 6,053 7,133<br>Total assets 219,349 258,501<br>Non-current financial liabilities (13,150) (15,497)<br>Current financial liabilities (797) (939)<br>Trade and other payables (11,175) (13,168)<br>Total Liabilities (25,122) (29,604)<br>Fair value of net assets acquired 194,227 228,897<br>Fair Value<br>The resulting goodwill was allocated to the Bioscience segment, and it includes the donor data base, current<br>licenses and future authorizations and workforce<br>Had the acquisition taken place on 1 January 2020, the net amount of the Group´s revenue would have increased<br>by Euros 31,197 thousand and the net profit would have decreased by Euros 32,423 thousand. The revenue and | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>22<br>profit of Green Cross between the acquisition date and 31 December 2020 amounted to Euros 4,625 thousand<br>and Euros (5,023) thousand respectively.<br><br>(4) Significant Accounting Policies<br> (a) Consolidation<br>Dependents<br>Subsidiaries are considered to be those over which the Group exercises control. A subsidiary is controlled when, due to<br>its involvement in it, it is exposed, or has the right, to variable returns and has the capacity to influence such returns<br>through the power it exercises over it.<br>The income, expenses and cash flows of subsidiaries are included in the consolidated financial statements from the date<br>of acquisition, which is the date on which the Group effectively obtains control of the subsidiaries. Subsidiaries are<br>excluded from consolidation from the date on which control is lost.<br>Transactions and balances with Group companies and unrealized gains or losses have been eliminated in consolidation.<br>The accounting policies of the subsidiaries have been adapted to the Group's accounting policies for transactions and<br>other events that, being similar, have occurred in similar circumstances.<br>The financial statements of the subsidiaries used in the consolidation process are as of the same reporting date and for the<br>same period as those of the Parent Company.<br>Appendix I includes information on the subsidiaries included in the Group's consolidation.<br>Business combinations<br>The acquisition method is used to account for the acquisition of subsidiaries in a business combination. The acquisition<br>date is the date on which the Group obtains control of the acquired business.<br>The acquisition cost of a subsidiary is determined at the acquisition date and comprises (i) the fair values of assets<br>delivered, (ii) liabilities incurred or assumed, (iii) equity instruments issued, (iv) the fair value of any asset or liability<br>resulting from a contingent consideration arrangement and (v) the fair value of any previous interest in the subsidiary.<br>Any disbursement that is not part of the exchange for the acquired business is excluded.<br>Acquisition-related costs are expensed as incurred.<br>The Group recognizes identifiable assets acquired and liabilities and contingent liabilities assumed at fair value at the<br>acquisition date. Assets held for sale, liabilities for employee compensation, transactions with payments based on equity<br>instruments, deferred tax assets and liabilities and right-of-use assets and liabilities and lease liabilities are excluded from<br>the application of this criterion.<br>The excess of the consideration transferred, the amount of any non-controlling interest in the acquired subsidiary and the<br>acquisition-date fair value of any previous interest in the acquired subsidiary over the fair value of the identifiable net<br>assets is recorded as goodwill. If these amounts are less than the fair value of the identifiable net assets of the acquired<br>subsidiary, the difference is recognized in profit or loss as a bargain purchase.<br>When settlement of any part of the cash consideration is deferred, amounts payable in the future are discounted to their<br>present value at the date of exchange.<br>Contingent consideration is classified as equity or a financial liability. Amounts classified as a financial liability are<br>subsequently remeasured at fair value with changes in fair value recognized in profit or loss.<br>When the business combination could only be determined on a provisional basis, the identifiable net assets are initially<br>recorded at their provisional values, recognizing the adjustments made during the measurement period as if they had been | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>23<br>known at the acquisition date, restating comparative figures for the previous year, if applicable. The adjustments to the<br>provisional values only incorporate information relating to facts and circumstances that existed at the acquisition date and<br>which, had they been known, would have affected the amounts recognized at that date. The measurement period should<br>not exceed twelve months from the date of acquisition.<br>If the business combination is carried out in stages, the acquisition-date carrying amount of the previously held equity<br>interest of the acquiree is remeasured at its acquisition-date fair value, with any resulting gain or loss recognized in profit<br>or loss.<br>Non-controlling interests<br>Non-controlling interests in subsidiaries are recorded at the acquisition date at their percentage of interest in the fair value<br>of the identifiable net assets, without considering potential voting rights. In addition, the profit or loss for the year and<br>each component of other comprehensive income allocated to the non-controlling interest is allocated in proportion to its<br>percentage of ownership.<br>Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of<br>profit and loss, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and<br>the consolidated balance sheet, respectively.<br>The increase and reduction of non-controlling interests in a subsidiary while maintaining control is recognized as an<br>equity transaction in reserves.<br>Associated<br>Associated entities are those over which the Group exercises significant influence, understood as the capacity to intervene<br>in financial and operating decisions, without the existence of control or joint control.<br>Investments in associates are initially recognized at acquisition cost, including costs directly attributable to the acquisition<br>and any active or passive contingent consideration that depends on future events or the fulfillment of certain conditions.<br>Subsequently, investments in associates are accounted for by the equity method from the date on which significant<br>influence is exercised until the date on which the Company can no longer justify the existence of significant influence.<br>The excess between the cost of the investment and the Group's share of the fair values of the identifiable net assets is<br>recorded as goodwill, which is included in the carrying amount of the investment. The shortfall, once the amounts of the<br>cost of the investment and the identification and valuation of the net assets of the associate have been evaluated, is<br>recorded as income in the determination of the investor's share in the results of the associate for the year in which it was<br>acquired.<br>The accounting policies of the associated companies have been subject to time and valuation homogenization in the same<br>terms as those referred to in the subsidiaries.<br>The Group's share in the profits or losses of associates obtained from the date of acquisition is recorded as an increase or<br>decrease in the value of the investments with a credit or debit to " Profit/(loss) of equity accounted investees ". Likewise,<br>the Group's share in the other comprehensive income of associates obtained since the acquisition date is recorded as an<br>increase or decrease in the value of the investments in associates, with the balancing entry by nature being recognized in<br>other comprehensive income. Dividend distributions are recorded as decreases in the value of investments. To determine<br>the Group's share of profits or losses, including impairment losses recognized by associates, income or expenses arising<br>from the acquisition method are considered.<br>When the Group's share of losses on an equity accounted investment equals or exceeds its interest in the entity, the Group<br>does not recognize additional losses unless it has incurred obligations or made payments on behalf of the other entity.<br>The Group's share in the profits or losses of associates and changes in equity is determined on the basis of the ownership<br>interest at year-end, without considering the possible exercise or conversion of potential voting rights. However, the<br>Group's share is determined considering the possible exercise of potential voting rights and other derivative financial | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>24<br>instruments that, in substance, grant current access to the economic benefits associated with ownership interests, i.e. the<br>right to participate in future dividends and changes in the value of associates.<br>After applying the equity method, the Group assesses whether there is objective evidence of impairment of the net<br>investment in the associate. The impairment calculation is determined by comparing the carrying amount of the net<br>investment in the associate with its recoverable amount, where recoverable amount is the higher of value in use or fair<br>value less costs of disposal. In this regard, the value in use is calculated based on the Group's share of the present value<br>of the estimated cash flows from ordinary activities and the amounts that could result from the final disposal of the<br>associate. The recoverable amount of the investment in an associate is assessed in relation to each associate (see note 10),<br>unless it does not constitute a cash-generating unit (CGU). Impairment losses are not allocated to goodwill or other assets<br>implicit in the investment in associates arising from the application of the acquisition method. In subsequent years,<br>reversals of the value of investments are recognized against income, to the extent that there is an increase in the<br>recoverable value. Impairment losses are presented separately from the Group's share in the results of associates.<br>Appendix I includes information on subsidiaries and associates included in the Group's consolidation.<br>Joint agreements<br>Joint arrangements are those in which there is a contractual agreement to share control over an economic activity, so that<br>decisions on the relevant activities require the unanimous consent of the Group and the other operators. Investments in<br>joint arrangements are classified as joint operations or joint ventures, depending on the contractual rights and obligations<br>of each investor, rather than the legal structure of the joint arrangement.<br>Interests in joint ventures are accounted for by the equity method, after initially being recognized at cost in the<br>consolidated balance sheet.<br>(b) Transactions and balances in foreign currencies<br><br>Transactions in foreign currencies are translated to the functional currency using the average exchange rate of the previous<br>month provided that it does not differ significantly from the exchange rate at the date of the transaction. Foreign currency<br>gains and losses resulting from the settlement of these transactions and from the translation of monetary assets and<br>liabilities denominated in foreign currencies at closing exchange rates are recognized in profit or loss except when there<br>are qualified cash flow hedges and qualified net investment hedges that are deferred to equity.<br>The effect of exchange rate changes on cash and cash equivalents denominated in foreign currencies is presented<br>separately in the statement of cash flows as "Effect of exchange rate changes on cash".<br>The translation of foreign operations whose functional currency is not that of a hyperinflationary country has been made<br>by applying the following criteria:<br> • Assets and liabilities, including goodwill and adjustments to net assets arising from the acquisition of businesses,<br>are translated at the closing exchange rate at each balance sheet date;<br> • Revenues and expenses are translated at the average exchange rate of the previous month, as an approximation<br>of the exchange rate at the date of the transaction;<br> • Translation differences resulting from the application of the above criteria are recognized in other comprehensive<br>income.<br>(c) Goodwill<br>After initial recognition, goodwill is recorded at cost, less any accumulated impairment loss, which is not reversible.<br>Goodwill is not amortized, but is tested for impairment on an annual basis or more frequently in the event that events<br>indicative of a potential loss in the value of the asset have been identified. For these purposes, goodwill resulting from<br>business combinations is allocated to each of the cash generating units (CGUs) or groups of CGUs that are expected to | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>25<br>benefit from the synergies of the combination and the criteria referred to in note 6 are applied. CGUs or groups of CGUs<br>are identified at the lowest level that goodwill is controlled for the purpose of internal management (Note 6).<br>(d) Intangible assets<br>Intangible assets are recorded at cost (acquisition or development) or at fair value when acquired in a business<br>combination, less accumulated amortization and any accumulated impairment losses.<br>Any expenses incurred during the research phase of projects are recognized as an expense when incurred.<br>Costs related to development activities for internally generated intangible assets are capitalized to the extent that:<br> • The Group has technical studies that justify the viability of the production process;<br> • There is a commitment by the Group to complete production of the asset so that it is in a condition for sale or<br>internal use;<br> • The asset will generate sufficient economic benefits;<br> • The Group has the technical and financial resources to complete the development of the asset and has developed<br>budget control and analytical accounting systems that make it possible to monitor the budgeted costs, the modifications<br>introduced and the costs actually charged to the various projects.<br>These development costs are recorded as income under the heading "self-constructed non-current assets" in the<br>consolidated statement of profit and loss when they are capitalized. Development costs previously recognized as an<br>expense are not recognized as an asset in a subsequent period.<br>The Group amortizes its intangible assets with finite useful lives by distributing the cost of the assets on a straight-line<br>basis according to the following criteria:<br><br>Amortisation method Rates<br>Development expenses Straight line 10%<br>Concessions, patents, licenses, trademarks and similar Straight line 4% - 20%<br>Computer software Straight line 33%<br>Currently marketed products Straight line 3% - 10%<br>Intangible assets with indefinite useful lives are not subject to amortization but are tested for impairment at least once a<br>year.<br>The Group reviews the useful lives of intangible assets at the end of each year. Changes in the initially established criteria<br>are recognized as a change in estimate.<br>(e) Property, plant and equipment<br>Property, plant and equipment are stated at cost, less accumulated depreciation and, if applicable, accumulated impairment<br>losses.<br>Cost includes, among other items, direct labor costs used in the construction of the asset and a portion of the costs<br>indirectly attributable to the asset. These two items are recorded as income under the heading "Self-constructed non-current assets" in the consolidated statement of profit and loss, when capitalized. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>26<br>Finance costs incurred that are directly attributable to the acquisition or construction of the asset until the asset is ready<br>for use also form part of the cost.<br>Likewise, expansion or improvement costs are included as an increase in the value of the asset when they represent an<br>increase in its capacity or an extension of its useful life. However, maintenance costs are recognized in income when<br>incurred.<br>Depreciation of property, plant and equipment is provided on a straight-line basis over the estimated useful lives of the<br>assets, less their residual value.<br>Depreciation of property, plant and equipment is determined by applying the following criteria:<br>Depreciation method Rates<br>Buildings Straight line 1% - 3%<br>Other property, technical equipment and machinery Straight line 4%-10%<br>Other property, plant and equipment Straight line 7% - 33%<br>The Group reviews the residual value, useful life and depreciation method of property, plant and equipment at the end of<br>each reporting period. Changes in the initially established criteria are recognized as a change in estimate.<br>(f) Leases<br>Lessee<br>The determination of whether a contract is or contains a lease is based on an analysis of the contractual arrangement and<br>requires an assessment of whether the lessee has the right to control the use of the identified asset and to obtain all of the<br>economic benefits from the use of the asset throughout the lease term.<br>The lease term is the non-cancelable period considering the initial term of each contract unless the Group has a unilateral<br>extension or termination option and there is reasonable certainty that such option will be exercised in which case the<br>corresponding extension or early termination term will be considered.<br>In lease contracts where the Group acts as lessee, it is recognized at the lease commencement date (i.e. the date on which<br>the underlying asset is available for use):<br> • A liability for the present value of the installments to be paid over the lease term, using the incremental borrowing<br>or implicit interest rate as the discount rate when expressly indicated in the contract and,<br> • A right-of-use asset representing the right to use the underlying leased asset during the term of the lease.<br>Lease liabilities include fixed lease payments less any incentives, as well as variable payments that depend on an index<br>or interest rate known at the date of inception of the lease. Also included is the exercise price of the purchase option when<br>the lessee is reasonably certain of exercising it. After initial recognition, the liability is increased by the interest on the<br>lease liability and reduced by the payments made. The liability is also remeasured if there are changes in the amounts<br>payable and the lease terms. Payments included in the lease payments corresponding to maintenance, electricity, water,<br>gas, security, cleaning, among others, are not part of the lease liability and are recognized as an expense.<br>The incremental borrowing rate is determined taking into account: (i) geographic areas, (ii) financial term, (iii) lease term,<br>(iv) risk-free rate as reference rate and (v) financial spread.<br>Rights-of-use assets are measured at cost, less accumulated amortization and impairment losses (if any) and adjusted as<br>a result of the remeasurement of the lease liability. Cost includes the amount of the initial valuation of the lease liability,<br>as well as any amounts previously paid to the lessor prior to or at the commencement date of the lease less any incentives | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>27<br>received by the lessor and estimated costs to decommission the leased asset. Amortization of rights of use is provided on<br>a straight-line basis over the shorter of the estimated useful life of the asset or the lease term.<br>The Group applies the exception to recognition for those contracts where the lease term is 12 months or less or where the<br>value of the leased asset (individually) when new, is less than US Dollars 5,000 or its equivalent in another currency.<br>Consequently, in these cases, the amounts accrued will be recognized as an expense during the lease term.<br>Lessor<br>When the Group acts as lessor, it classifies contracts between operating and finance leases. Leases in which the Group<br>acts as lessor while retaining a significant portion of the risks and rewards incidental to ownership of the leased asset are<br>treated as operating leases. Otherwise, the lease is treated as a finance lease.<br>(g) Impairment of non-financial assets<br>Goodwill and intangible assets that have an indefinite useful life are not subject to amortization and are tested for<br>impairment annually, or more frequently in the event of events or changes in circumstances that indicate that they may<br>be impaired.<br>Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount<br>may not be recoverable.<br>When the recoverable amount is less than the carrying amount of the asset, an impairment loss is recognized in the<br>consolidated statement of profit and loss for the difference between both amounts.<br>The recoverable amount is the higher of an asset's fair value less costs of disposal and the estimated value in use based<br>on discounted future cash flows expected to arise from the use of the asset. The estimate of value in use considers<br>expectations about possible variations in the amount or timing of cash flows, the time value of money, the price to be paid<br>for bearing the uncertainty related to the asset and other factors that affect the valuation of future cash flows related to the<br>asset.<br>For the purpose of assessing impairment losses, assets are grouped at the lowest levels for which there are separately<br>identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets (cash-generating units). Impairment losses on non-financial assets (other than goodwill) are reviewed for possible reversal at<br>the end of each reporting period.<br>Losses related to the impairment of CGUs are initially allocated to reduce, if applicable, the value of goodwill attributed<br>to the CGU and then to the other assets of the CGU, pro rata based on the carrying amount of each asset, with the limit<br>for each asset being the higher of its fair value less costs of disposal, its value in use and zero.<br>Impairment losses related to goodwill are not reversible.<br>(h) Financial instruments<br>Financial assets<br>Ranking<br>The classification of financial assets is determined based on the characteristics of the contractual cash flows of those<br>assets and the business model that represents how the financial assets are managed to achieve a particular business<br>objective. In determining whether the cash flows are obtained through the receipt of contractual cash flows from the<br>assets, consideration is given to the frequency, value and timing of sales in prior periods, the reasons for those sales and<br>expectations regarding future sales activity. This information provides indicative data on how the Group's stated objective<br>regarding the management of financial assets is achieved and, more specifically, how cash flows are obtained.<br>Therefore, financial assets are classified according to the following valuation categories based on the business model and<br>are only reclassified when, and only when their business model for managing them changes: | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>28<br>a) Financial assets at amortized cost: includes financial assets, including those admitted to trading on an organized<br>market, for which the Group holds the investment under a business model whose objective is to hold financial assets to<br>receive cash flows from the execution of the contract, and the contractual terms of the asset give rise, at specified dates,<br>to cash flows that are solely collections of principal and interest on the principal amount outstanding.<br>In general, the following are included in this category:<br>i) Trade receivables: arising from the sale of goods or the rendering of services for trade transactions with deferred<br>payment, and<br>ii) Receivables from non-trade operations: these arise from loans or credits granted by the Group whose collections are<br>of a determined or determinable amount.<br>b) Financial assets at fair value through other comprehensive income: this category includes financial assets whose<br>contractual conditions give rise, at specified dates, to cash flows that are solely collections of principal and interest on the<br>principal amount outstanding, and are held within the framework of a business model whose objective is achieved by<br>obtaining contractual cash flows and selling financial assets. Investments in equity instruments irrevocably designated by<br>the Group at the time of their initial recognition are also included in this category, provided that they are not held for<br>trading and are not to be valued at cost.<br>c) Financial assets at fair value through profit or loss: includes financial assets held for trading and those financial<br>assets that have not been classified in any of the above categories. Also included in this category are financial assets that<br>are optionally designated by the Group at the time of initial recognition, which otherwise would have been included in<br>another category, because such designation eliminates or significantly reduces a valuation inconsistency or accounting<br>missmatch that would otherwise arise.<br>Initial measurement<br>Financial assets are recorded, in general terms, initially at the fair value of the consideration given plus directly attributable<br>transaction costs. However, transaction costs directly attributable to assets recorded at fair value through profit or loss are<br>recognized in the statement of profit and loss for the year.<br>Trade accounts receivable are initially recognized at the amount of the consideration that is unconditional, unless they<br>contain significant financial components, in which case they are recognized at fair value.<br>Subsequent measurement<br>Financial assets at amortized cost are recorded by applying this valuation criterion, charging to the statement of profit and<br>loss the interest accrued by applying the effective interest rate method.<br>Financial assets included in the fair value category through other comprehensive income are recorded at fair value, without<br>deducting any transaction costs that may be incurred in their disposal. Changes in fair value are recorded directly in equity<br>until the financial asset is derecognized or impaired, at which time the amount so recognized is taken to the statement of<br>profit and loss.<br>Financial assets at fair value through profit or loss are measured at fair value and the result of changes in fair value is<br>recorded in the statement of profit and loss.<br>Disposals of financial assets<br>Financial assets are derecognized when the rights to receive cash flows related to them have expired or have been<br>transferred and the Group has substantially transferred the risks and rewards of ownership. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>29<br>Impairment<br>The Group assesses, on a prospective basis, the expected credit losses associated with its debt instruments carried at<br>amortized cost and at fair value through other comprehensive income The methodology applied for impairment depends<br>on whether there has been a significant increase in credit risk.<br>For trade receivables, the Group applies the simplified approach permitted by IFRS 9 which requires expected losses to<br>be recorded from the initial recognition of the receivables, so that the Group determines expected credit losses as a<br>probability-weighted estimate of such losses over the expected life of the financial instrument.<br>The practical solution used is the use of a provisioning matrix based on segmentation into homogeneous asset groups,<br>applying historical information on default rates for these groups and applying reasonable information on future economic<br>conditions.<br>Default rates are calculated based on current default experience over the past year, as it is a very dynamic market, and are<br>adjusted for differences between current and historical economic conditions and considering projected information, which<br>is reasonably available.<br>Financial liabilities<br>Financial liabilities assumed or incurred by the Group are classified in the following measurement categories:<br>(a) Financial liabilities at amortized cost: are those debits and payables of the Group that have arisen from the<br>purchase of goods and services for trading operations, or those which, without having a commercial origin, not being<br>derivative instruments, arise from loan or credit operations received by the Group.<br>These liabilities are initially measured at the fair value of the consideration received, adjusted for directly attributable<br>transaction costs. Any difference between the amount received and its repayment value is recognized in the consolidated<br>statement of profit and loss during the repayment period of the debt, applying the effective interest rate method.<br>(b) Financial liabilities at fair value through profit or loss.<br>Liability derivative financial instruments are measured at fair value, following the same criteria as those corresponding<br>to financial assets at fair value through profit or loss described in the preceding section.<br>The Group derecognizes financial liabilities when the obligations that generated them are extinguished.<br>Assets and liabilities are presented separately in the balance sheet and are only presented at their net amount when the<br>Group has the enforceable right to offset the recognized amounts and, in addition, intends to settle the amounts on a net<br>basis or to realize the asset and settle the liability simultaneously.<br>Equity instruments<br>The Group holds financial assets, mainly equity instruments, which are measured at fair value. When Group management<br>has opted to present gains and losses in the fair value of equity investments in other comprehensive income, after initial<br>recognition, the equity instruments are measured at fair value, recognizing the gain or loss in other comprehensive income.<br>Amounts recognized in other comprehensive income are not reclassified to profit or loss, but are reclassified to reserves<br>when the instruments are derecognized. Dividends from such investments continue to be recognized in profit or loss as<br>other income when the Group's right to receive payments is established.<br>(i) Derivative financial instruments and hedging activities<br>Financial derivatives are recognized at fair value at the date of the contract and at each year-end. The method for<br>recognizing the gain or loss depends on whether the derivative is classified as a hedging instrument, and if so, the nature<br>of the hedged asset. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>30<br>For accounting purposes, they are classified as follows:<br>(i) Derivatives qualifying for cash flow hedge accounting<br>Hedging effectiveness<br>Hedge effectiveness is determined at the inception of the hedging relationship, and through periodic prospective<br>effectiveness assessments to ensure that there is an economic relationship between the hedged item and the hedging<br>instrument.<br>In derivatives such as the euro/dollar cross-currency swap, the Group uses the hypothetical derivative method to assess<br>effectiveness. This hypothetical derivative is constructed without the inclusion of credit risk and currency spread. Under<br>the hypothetical derivative method, the cumulative change in the fair value of the actual currency swap, excluding the<br>effect of the currency spread, will be compared to the cumulative change in the fair value of the hypothetical swap.<br>Therefore, the hypothetical derivative is constructed as a cross-currency swap with fixed euro payment, fixed U.S. dollar<br>receipt without the inclusion of credit risk and foreign currency spread and with a fair value of zero at the date of<br>designation.<br>Recognition<br>At the inception of the hedging relationship, the Group documents the economic relationship between the hedging<br>instruments and the hedged items, including whether changes in cash flows of the hedging instruments are expected to<br>offset changes in cash flows of the hedged items. The Group documents its risk management objective and strategy for<br>undertaking its hedging transactions.<br>The effective portion of changes in the fair value of derivatives designated and classified as cash flow hedges is recognized<br>in equity under "Cash flow hedge reserve". In the case of cross-currency swaps, the currency spread of the hedging<br>relationship is excluded and treated as hedging costs in equity. The gain or loss corresponding to the ineffective portion<br>is recognized immediately in profit or loss for the year under the heading "Change in fair value of financial instruments".<br>Amounts accumulated in the hedging reserve included in shareholders' equity are transferred to profit or loss when the<br>hedged item affects profit or loss or when ineffectiveness is identified.<br>The fair value of derivatives designated as hedges is detailed in note 29. Movements in the hedging reserve included in<br>shareholders' equity are shown in note 16 (c).<br>(ii) Derivatives that do not qualify for hedge accounting<br>When derivatives do not meet the criteria for hedge accounting, they are classified as "held for trading". Changes in fair<br>value are recognized immediately in the consolidated statement of profit and loss.<br>(j) Own equity instruments<br>The acquisition of treasury stock is recorded at acquisition cost, reducing equity until the time of disposal. Gains or losses<br>on the disposal of treasury stock are recorded under "Reserves" in the consolidated balance sheet. Transaction costs related<br>to own equity instruments, net of taxes, are recorded as a reduction of equity.<br>(k) Inventories<br>Inventories are stated at the lower of weighted average cost or net realizable value. Net realizable value is the estimated<br>selling price in the normal course of business, less the estimated costs to complete production and those necessary to<br>make the sale. For raw materials and other supplies it is the replacement cost.<br>The cost includes direct materials, direct labor and an appropriate proportion of indirect variable and fixed costs, the latter<br>being allocated on the basis of the normal working capacity of the means of production. The cost of plasma stocks includes<br>the amount delivered to donors, or the amount invoiced by the seller when purchased from third parties, as well as the<br>cost of products and devices used in the collection process, and rental and storage costs. The costs of purchased inventories | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>31<br>are determined after deducting discounts and rebates when it is probable that the conditions determining their concession<br>will be met. Indirect costs such as management and administrative overheads are recognized as expenses in the period in<br>which they are incurred.<br>Any previously recognized inventory impairment adjustment is reversed against income under "Cost of sales" when the<br>circumstances that caused the impairment no longer exist or when there is clear evidence of an increase in the net<br>realizable value as a result of a change in economic circumstances. The reversal of the write-down is limited to the lower<br>of cost and the new net realizable value of inventories.<br>(l) Cash and cash equivalents<br>Cash and cash equivalents include cash on hand, demand deposits with banks, other short-term highly liquid investments<br>with an original maturity of three months or less that are readily convertible to known amounts of cash and which are<br>subject to an insignificant risk of changes in value.<br>(m) Government grants<br>Government grants are recognized when there is reasonable assurance that the conditions attached to the grant will be<br>met and that the grant will be collected.<br>Non-refundable capital grants are recorded on the liability side of the consolidated balance sheet at the original amount<br>granted and are recognized in the consolidated statement of profit and loss as the related assets financed are depreciated.<br>Grants received as compensation for expenses or losses already incurred or for the purpose of providing immediate<br>financial support not related to future expenses are credited to the consolidated statement of profit and loss.<br>Financial liabilities that incorporate implicit aid in the form of the application of below-market interest rates are<br>recognized initially at fair value. The difference between this value, adjusted where appropriate for the costs of issuing<br>the financial liability and the amount received, is recorded as a government grant based on the nature of the grant.<br>(n) Employee benefits<br>(i) Defined contribution plans<br>The Group records the contributions to be made to defined contribution plans as they accrue. The amount of accrued<br>contributions is recorded under "Personnel expenses" in the consolidated statement of profit and loss in the year to which<br>the contribution relates.<br>(ii) Defined benefit plans<br>The liability recognized corresponds to the present value of the obligation at the consolidated balance sheet date less the<br>fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected<br>unit credit method. The present value of the obligation is determined by discounting the estimated future cash flows at<br>interest rates of bonds denominated in the currency in which the benefits will be paid and with maturities similar to those<br>of the related obligations. Actuarial gains and losses arising from changes in actuarial assumptions or differences between<br>assumptions and reality are recognized in equity under "Other comprehensive income". Past service costs are recognized<br>in the consolidated statement of profit and loss under "Personnel expenses".<br>(iii) Termination benefits<br>Termination benefits are recognized on the earlier of the following dates: (a) when the Group can no longer withdraw the<br>offer or (b) when the Group recognizes costs of a restructuring within the scope of IAS 37 and this results in the payment<br>of termination benefits.<br>(iv) Short-term employee benefits | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>32<br>The Group recognizes the expected cost of short-term compensation in the form of paid leave whose rights accrue as<br>employees render the services that entitle them to receive it. If the leave is not accrued, the expense is recognized as the<br>leave is taken.<br>The Group recognizes the expected cost of profit sharing or employee incentive plans when there is a present legal or<br>constructive obligation as a result of past events and a reliable estimate can be made of the value of the obligation.<br>(v) Share-based payments<br><br>The Group grants share-based payments to certain employees who are rendering services to the company.<br>The fair value of services received is estimated by estimating the fair value of the shares granted at the grant date. Since<br>the equity instruments granted become vested when the employees complete a certain period of service, the services<br>received are recognized during the vesting period in the statement of profit and loss as an expense for the year with a<br>corresponding credit to equity. The amount recognized corresponds to the amount that will be settled once the agreed<br>conditions are met and will not be reviewed or revalued during the vesting period, as the commitment is settled in shares.<br>If an employee resigns from his/her position before the end of the vesting period, he/she will only receive the agreed<br>incentive in shares, being the Company's choice its settlement in cash or through equity instruments.<br>(o) Provisions<br>Provisions are recognized when the Group has a present legal or constructive obligation as a result of a past event, it is<br>probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable<br>estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses.<br>The amount of the provision corresponds to the best estimate at the closing date of the disbursements required to settle<br>the present obligation, after taking into account the risks and uncertainties related to the provision and, when significant,<br>the financial effect of discounting, provided that the disbursements to be made in each period can be reliably determined.<br>(p) Revenue recognition<br><br>Revenue from the sale of goods or services is recognized at an amount that reflects the consideration the Group expects<br>to be entitled to receive in exchange for transferring goods or services to a customer, at the time the customer obtains<br>control of the goods or services rendered, i.e. when the customer has the ability to direct the use of the goods or services.<br>The consideration committed in a contract with a customer may include fixed amounts, variable amounts, or both. The<br>amount of consideration may vary due to discounts, rebates, incentives, performance bonuses, penalties or other similar<br>items. Contingent consideration is only included in the transaction price when it is highly probable that the amount of<br>revenue recognized will not be subject to significant future reversals. Revenue is presented net of value added tax and<br>any other amounts or taxes, which in substance correspond to amounts received on behalf of third parties.<br>(i) Sales of goods<br>Revenue from the sale of goods is recognized when the Group satisfies the performance obligation by transferring the<br>committed goods to the customer. An asset is transferred when the customer obtains control of that asset. In assessing the<br>satisfaction of the performance obligation, the Group considers the following indicators of the transfer of control, which<br>include, but are not limited to, the following:<br> • The Group has a present right to payment for the asset.<br> • The customer has the legal right to the asset<br> • The Group has transferred the physical possession of the asset<br> • Customer has the significant risks and rewards of asset ownership<br> • The customer has accepted the asset<br>The nature of the assets that the Group undertakes to transfer are mainly: sale of goods, sale of equipment, toll contracts,<br>maintenance and technical service contracts, training, licenses, royalties and know-how and engineering contracts, among<br>others. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>33<br>In determining the transaction price, it is assumed that the goods and/or services are transferred in accordance with the<br>terms of the contract. The consideration committed to a customer may include fixed amounts, variable amounts, or both.<br>The price should be estimated taking into account the effect of variable consideration (as applicable) for returns,<br>chargebacks/volume discounts or other incentives, provided that the same is highly probable.<br>The Group participates in state Medicaid programs in the United States. Provision for Medicaid rebates is recorded at the<br>time the sale is recorded in an amount equal to the estimated Medicaid rebate claims attributable to such sale. The Group<br>determines the estimate of the accrual for Medicaid rebates primarily based on historical Medicaid rebate experience,<br>legal interpretations of applicable laws related to the Medicaid program and any new information regarding changes in<br>Medicaid program guidelines and regulations that could affect the amount of the rebates. The Group considers pending<br>Medicaid claims, Medicaid payments, and inventory levels in the distribution channel and adjusts the provision<br>periodically to reflect actual experience. Although rebate payments typically occur with a lag of one to two quarters,<br>adjustments for actual experience have not been material.<br>As is standard industry practice, certain customers have entered into contracts with the Group for purchases that are<br>eligible for a price discount based on a minimum purchase quantity, volume discounts or cash discounts. These discounts<br>are accounted for as a reduction in sales and accounts receivable in the same month in which the sales are invoiced based<br>on a combination of the customer's actual purchase data and historical experience when the customer's actual purchase<br>data is later known.<br>In the United States, the Group enters into agreements with certain customers to establish contractual prices for products,<br>which these entities purchase from the authorized wholesaler or distributor (collectively, "wholesalers") of their choice.<br>Accordingly, when these entities purchase the products from the wholesalers at the contractual price which is lower than<br>the price charged by the Group to the wholesaler, the Group provides the wholesaler with a credit known as a chargeback.<br>The Group accounts for the accrual of chargebacks at the time of sale. The allowance account for chargebacks is based<br>on the Group's estimate of the wholesaler's inventory levels and the expected direct sale of the products by the wholesalers<br>at the contract price based on past chargeback history and other factors. The Group periodically monitors factors<br>influencing the provision for rebates and applies adjustments when it believes that actual rebates may differ from the<br>established allowance accounts. These adjustments occur over a relatively short period of time. As these refunds are<br>typically settled within 30 to 45 days of sale, adjustments for actual amounts have not been material.<br>The amount at closing for the remaining discounts is settled in the following year within 90 to 180 days depending on the<br>type of provision.<br>(ii) Provision of services<br>Revenue from the rendering of services is recognized by reference to the stage of completion of the transaction at the<br>reporting date when the outcome of the transaction can be estimated reliably. This circumstance occurs when the amount<br>of revenue, the stage of completion, costs already incurred and costs to be incurred can be reliably measured and it is<br>probable that the economic benefits derived from the rendering of the service will be received.<br>In the case of services rendered for which the final result cannot be reliably estimated, revenue is recognized only up to<br>the limit of the recognized expenses that are recoverable.<br>(q) Income tax<br><br>The income tax expense or tax credit for the year comprises both current tax and deferred tax.<br>Current tax is the amount payable on the taxable income for the current year based on the applicable tax rate for each<br>jurisdiction. It is calculated on the basis of the laws enacted or about to be enacted at the balance sheet date in the countries<br>where subsidiaries and associates operate and generate taxable income. The Group periodically evaluates the positions<br>taken in tax returns with respect to situations where the applicable tax regulations are subject to interpretation and<br>establishes provisions, if necessary, based on the amounts expected to be paid to the tax authorities, the provision for<br>which is included in taxable income (loss). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>34<br>Deferred taxes are recognized on temporary differences arising between the tax bases of assets and liabilities and their<br>carrying amounts in the consolidated annual accounts. It is determined using tax rates (and laws) enacted or about to be<br>enacted at the balance sheet date that are expected to apply when the related deferred tax asset is realized or the deferred<br>tax liability is settled.<br>Deferred taxes are not recognized if they arise from the initial recognition of an asset or liability in a transaction, other<br>than a business combination, that at the time of the transaction affects neither accounting nor taxable income. Deferred<br>tax assets and liabilities are also not recognized for temporary differences between the carrying amount and tax base of<br>investments in foreign operations when the company is able to control the date on which the temporary differences will<br>reverse and it is probable that the temporary differences will not reverse in the foreseeable future. Likewise, deferred tax<br>liabilities are not recognized if they arise from the initial recognition of goodwill. Lastly, deferred tax assets are only<br>recognized if it is probable that sufficient future taxable profit will be available against which they can be utilized.<br>Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and<br>liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and liabilities are<br>offset when the entity has a legally enforceable right to offset and intends either to settle on a net basis or to realize the<br>asset and settle the liability simultaneously.<br>Current or deferred income tax is recognized in profit or loss, unless it arises from a transaction or economic event that<br>has been recognized in other comprehensive income or directly in equity. In such cases, the tax is also recognized in other<br>comprehensive income or directly in equity, respectively.<br>The Group periodically evaluates the positions taken in tax returns with respect to situations where the applicable tax<br>regulations are subject to interpretation and establishes provisions, if necessary, based on the amounts expected to be paid<br>to the tax authorities, the provision for which is included in taxable income (loss).<br>(r) Segment reporting<br>An operating segment is a component of the Group that engages in business activities from which it may earn revenues<br>and incur expenses, whose operating results are regularly reviewed by the Group's chief operating decision maker in order<br>to decide on the resources to be allocated to the segment, evaluate its performance and for which discrete financial<br>information is available.<br>(s) Environment<br>The Group carries out operations whose main purpose is to prevent, reduce or repair damage to the environment as a<br>result of its activities.<br><br>Items of property, plant and equipment acquired for the purpose of being used on a lasting basis in its activity and whose<br>main purpose is the minimization of environmental impact and the protection and improvement of the environment,<br>including the reduction or elimination of future pollution from the Group's operations, are recognized as assets through<br>the application of measurement, presentation and disclosure criteria consistent with those mentioned in note 4(e).<br>(5) Segment Reporting<br>In accordance with IFRS 8 “Operating Segments”, financial information for operating segments is reported in the<br>accompanying Appendix II, which forms an integral part of this note to the consolidated annual accounts.<br>Group companies are divided into four areas: companies from the industrial area, companies from the commercial<br>area, companies from the services area and companies from the research area. Within each of these areas, activities<br>are organized based on the nature of the products and services manufactured and marketed.<br>Assets, liabilities, income and expenses for segments include directly and reliably attributable items. Items which are<br>not attributed to segments by the Group are:<br>x Balance sheet: equity, cash and cash equivalents and loans and borrowings. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>35<br>x Statement of profit and loss: finance result and income tax.<br>(a) Operating segments<br>The operating segments defined by the steering committee are as follows:<br>x Biopharma (formerly Bioscience): concentrates all activities related to products derived from human plasma for<br>therapeutic use.<br>x Diagnostic: including the marketing of diagnostic testing equipment, reagents and other equipment,<br>manufactured by Group or other companies.<br>x Bio Supplies: this groups together transactions related to biological products for non-therapeutic use. The part<br>relating to sales of plasma to third parties has been reclassified from Bio Supplies to Other.<br>x Others: includes the provision of manufacturing services to third parties, plasma sales to third parties and research<br>activities. It also includes pharmaceutical products manufactured by the Group and intended for hospital<br>pharmacies, as well as the marketing of products that complement the Group's own products.<br>Details of sales by groups of products for 2022, 2021 and 2020 are as follows:<br>31/12/2022 31/12/2021 (*) 31/12/2020 (*)<br>Haemoderivatives 5,005,382 3,814,983 4,242,502<br>Transfusional medicine 640,604 712,238 714,164<br>Other diagnostic 21,740 23,625 27,630<br>146,076 115,811 133,221<br>Others 250,165 266,461 222,521<br>6,063,967 4,933,118 5,340,038<br>* As a consequence of the review of transactions and balances allocations by segments, the comparative figures for the<br>fiscal year 2021 and 2020 have been adjusted accordingly.<br>Thousands of Euros<br>Bio supplies<br>Total<br>Biopharma<br>Diagnostic<br>At 31 December 2022, 97.6% of the income from the sale of goods and services has been recognized at a certain<br>point-in-time (97.4% in 2021 and 97.5% in 2020).<br>The Group has concluded that hemoderivative products are sufficiently alike to be considered as a whole for the<br>following reasons:<br>x All these products are human plasma derivatives and are manufactured in a similar way.<br>x The customers and methods used to distribute these products are similar.<br>x All these products are subject to the same regulations regarding production and the same regulatory<br>environment.<br>(b) Geographical information<br>Geographical information is grouped into four areas:<br>x United States of America and Canada<br>x Spain<br>x Rest of the European Union<br>x Rest of the world | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>36<br>The definition of these four segments is mainly due to the geographical level that Group management sets to<br>manage its revenue as they respond to specific economic scenarios. The main framework of the Group is<br>consistent with this geographical segment grouping, including the monitoring of its commercial operations and<br>its information systems.<br><br>The financial information reported for geographical areas is based on sales to third parties in these markets as well<br>as the location of assets.<br>(c) Main customers<br>In 2022, no customer has accounted for more than 10% of the Group's gross revenues, and nor was the case in<br>2021. In 2020, 10.38% of the Group's gross revenues corresponded to revenues from a customer in the Biopharma<br>segment. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>37<br>(6) Goodwill<br>Details of and movement in this caption of the consolidated balance sheet at 31 December 2022 were as follows:<br>Balance at Business Translation Balance at<br>Segment Reference 31/12/2021 Combination differences 31/12/2022<br>Net value<br>Grifols UK.Ltd. (UK) Biopharma 8,185 -- -- -- (438) 7,747<br>Grifols Italia.S.p.A. (Italy) Biopharma 6,118 -- -- -- -- 6,118<br>Biomat USA, Inc.(USA) Biopharma 676,321 -- -- 175,920 47,707 899,948<br>Grifols Australia Pty Ltd.<br>(Australia) / Medion<br>Diagnostics AG<br>(Switzerland)<br>Diagnostic 9,752 -- -- -- 107 9,859<br>Grifols Therapeutics, Inc.<br>(USA) Biopharma 1,962,024 -- -- -- 121,408 2,083,432<br>Progenika Biopharma, S.A.<br>(Spain) Diagnostic 40,516 -- -- -- -- 40,516<br>Grifols Diagnostic (Novartis<br> & Hologic) (USA, Spain and<br>Hong Kong)<br>Diagnostic 2,565,493 -- -- -- 157,292 2,722,785<br>Kiro Grifols S.L. (Spain) Others 24,376 -- -- -- -- 24,376<br>Goetech LLC (USA) Others Note 3 59,590 -- (63,798) -- 4,208 --<br>Haema AG (Germany) Biopharma 190,014 -- -- -- -- 190,014<br>BPC Plasma, Inc. (formerly<br>Biotest Pharma Corp; USA) Biopharma 151,584 -- -- -- 9,380 160,964<br>Interstate Blood Bank, Inc.<br>(USA) Biopharma 171,184 -- -- (175,920) 4,736 --<br>Plasmavita Healthcare<br>GmbH (Germany) Biopharma 9,987 -- -- -- -- 9,987<br>Alkahest, Inc (USA) Others 77,675 -- -- -- 4,806 82,481<br>Grifols Canada<br>Therapeutics, Inc (formerly<br>Green Cross<br>Biotherapeutics, Inc.)<br>(Canada)<br>Biopharma 155,755 -- -- -- (980) 154,775<br>GigaGen, Inc (USA) Others 112,621 -- -- -- 6,969 119,590<br>Prometic Plasma Resources,<br>Inc. (Canada) Biopharma Note 3 7,706 (4,894) -- -- (10) 2,802<br>Haema Plasma Kft.<br>(Hungary) Biopharma Note 3 -- 14,739 -- -- (1,210) 13,529<br>Grifols Biotest Holdings<br>GmbH / Biotest AG<br>(Germany)<br>Biopharma Note 3 -- 303,624 -- -- -- 303,624<br>Access Biologicals, LLC<br>(USA) Bio Supplies Note 3 -- 180,834 -- -- (1,472) 179,362<br>6,228,901 494,303 (63,798) -- 352,503 7,011,909<br>(See note 3)<br>Thousands of Euros<br>Disposal<br>s<br>Transfers | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>38<br>Details of and movement in this caption of the consolidated balance sheet at 31 December 2021 are as follows:<br>Balance at Business Translation Balance at<br>Segment Reference 31/12/2020 Combination differences 31/12/2021<br>Net value<br>Grifols UK.Ltd. (UK) Biopharma 7,674 -- -- 511 8,185<br>Grifols Italia.S.p.A. (Italy) Biopharma 6,118 -- -- -- 6,118<br>Biomat USA, Inc.(USA) Biopharma 234,791 345,844 51,364 44,322 676,321<br>Grifols Australia Pty Ltd.<br>(Australia) / Medion<br>Diagnostics AG (Switzerland)<br>Diagnostic 9,538 -- -- 214 9,752<br>Grifols Therapeutics, Inc.<br>(USA) Biopharma 1,816,404 -- -- 145,620 1,962,024<br>Araclon Biotech, S.L. (Spain) Diagnostic 6,000 (6,000) -- -- --<br>Progenika Biopharma, S.A.<br>(Spain) Diagnostic 40,516 -- -- -- 40,516<br>Grifols Diagnostic (Novartis &<br>Hologic) (USA, Spain and<br>Hong Kong)<br>Diagnostic 2,376,978 -- -- 188,515 2,565,493<br>Kiro Grifols S.L. (Spain) Others 24,376 -- -- -- 24,376<br>Goetech LLC (USA) Others 55,167 -- -- 4,423 59,590<br>Haema AG (Germany) Biopharma 190,014 -- -- -- 190,014<br>BPC Plasma, Inc. (formerly<br>Biotest Pharma Corp; USA) Biopharma 140,334 -- -- 11,250 151,584<br>Interstate Blood Bank, Inc.<br>(USA) Biopharma 158,479 -- -- 12,705 171,184<br>Plasmavita Healthcare GmbH<br>(Germany) Biopharma 9,987 -- -- -- 9,987<br>Alkahest, Inc (USA) Others 71,910 -- -- 5,765 77,675<br>Grifols Canada Therapeutics,<br>Inc (formerly Green Cross<br>Biotherapeutics, Inc.) (Canada)<br>Biopharma Note 3 134,569 16,667 -- 12,225 163,461<br>GCAM, Inc (formerly Green<br>Cross America Inc.) (USA) Biopharma 49,416 -- (51,364) 1,948 --<br>GigaGen, Inc (USA) Others Note 3 -- 105,460 -- 7,161 112,621<br>5,332,271 461,971 0 434,659 6,228,901<br>Transfers<br>Thousands of Euros<br>Impairment testing:<br>CGUs correspond to the reporting segments except for the Others segment which corresponds to Kiro Grifols and<br>GigaGen as separated GGU.<br>As a result of the acquisition of Talecris in 2011, and for impairment testing purposes, the Group combines the CGUs<br>allocated to the Biopharma segment, grouping them together at segment level, because substantial synergies were<br>expected to arise on the acquisition of Talecris, and due to the vertical integration of the business and the lack of an<br>independent organized market for the products. Because the synergies benefit the Biopharma segment globally they<br>cannot be allocated to individual CGUs. The Biopharma segment represents the lowest level to which goodwill is<br>allocated and is subject to control by Group management for internal control purposes.<br>As a result of the acquisition of Novartis’ Diagnostic business unit in 2014, the Group decided to combine Araclon,<br>Progenika, Australia and Hologic’s share of NAT donor screening unit acquisition into a single CGU for the<br>Diagnostic business as the acquisition is supporting not only the vertically integration business but also cross-selling<br>opportunities. In addition, for management purposes, the Group’s management is focused on the business more than<br>geographical areas or individual companies. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>39<br>The Hospital division is no longer a reportable segment since it does not meet any of the quantitative thresholds<br>described in IFRS 8 Operating Segments. The segment information included in the Hospital CGU in previous years<br>is currently grouped into an Others segment.<br>In addition, due to the acquisition of the remaining 51% stake in Access Biologicals, a new CGU for the Bio Supplies<br>business has been identified (see note 3).<br>The CGUs established by Grifols management are:<br>x Biopharma<br>x Diagnostic<br>x Bio Supplies<br>x Kiro Grifols<br>x GigaGen<br>The recoverable amount of the Biopharma CGU and Bio Supplies CGU has been calculated based on its value in use<br>calculated as the present value of the five-year future cash flows discounted at a discount rate considering the related<br>inherent risk.<br>The recoverable amount of the Diagnostic CGU has been calculated based on its fair value less costs to sell calculated<br>as the present value of future cash flows approved by Management discounted at a discount rate considering the<br>inherent risk.. Due to the reorganization to boost the business units, a long term strategic plan has been approved in<br>order to transform the Diagnostic business unit by investments which will lead to a beyond five year growth.<br>Consequently, management has estimated future cash flows for the period 2023-2033.<br>The recoverable amount of the Kiro Grifols CGU has been calculated based on its fair value less costs to sell<br>calculated as the present value of the five-year cash flows discounted at a discount rate considering the related<br>inherent risk.<br>For the calculation of the recoverable amount, management has considered:<br>x Gross margin based on historical performance and actual situation<br>x Development prospects in the international market<br>x Current investments<br>x Investments which will imply a significant growth of the production capacity for those cases whose fair<br>value has been considered<br>Cash flows estimated as of the year in which stable growth in the CGU has been reached are extrapolated using the<br>estimated growth rates indicated below. Perpetual growth rates are consistent with the forecasts included in industry<br>reports.<br>The recoverable amount of the GigaGen CGU has been determined based on the fair value less costs to sell, calculated<br>as the present value of the future cash flows mainly of a research and development project that have been approved<br>by management, adjusted by the probability of success and discounted at a discount rate that includes their inherent<br>risk. Cash flows have been estimated taking into consideration a useful life of 20 years from the product launch and<br>their reduction as of the sixth year.<br>The key assumptions used in calculating impairment testing of the CGUs for 2021 were as follows:<br>Perpetual Growth rate Pre-tax discount rate<br>Bioscience 2.0% 9.0%<br>Diagnostic 2.0% 9.3% | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>40<br>The key assumptions used in calculating impairment testing of the CGUs for 2022 have been as follows:<br>Additionally, the following key assumptions have been used for the GigaGen CGU impairment testing:<br>Likewise, for the impairment test of the Diagnostic CGU, the sales of Blood Typing Solution (BTS) and those of<br>the Clinical Diagnostic have been considered as key assumptions.<br>The discount rate used reflects specific risks relating to the CGUs and the countries in which they operate. The main<br>assumptions used for determining the discount rate are as follows:<br> • Risk free rate: normalized government bonds at 10 years<br> • Market risk premium: premium based on market research<br> • Unlevered beta: average market beta<br> • Debt to equity ratio: average market ratio<br>In 2021, the reasonably possible changes considered for the CGUs impairment testing were a variation in the discount<br>rate, as well as in the estimated perpetual growth rate, , with independent movements of each other, as follows:<br>In 2022, and according to the current economic context, the reasonably possible changes considered for the CGUs<br>impairment testing are a variation in the discount rate, as well as in the estimated perpetual growth rate, with<br>independent movements of each other, as follows:<br>Additionally, for the impairment test of the Diagnostic CGU, two scenarios of sensitivity to variations in the sales of<br>the Blood Typing Solutions (BTS) business line and the Clinical Diagnostics (CDx) business line have also been<br>considered. In the first case, sales projections were estimated to be approximately 10% lower than initially projected,<br>on average, each year. In the second case, a projection has been estimated so that Clinical Diagnostics sales from<br>2029 onwards represent on average 80% of the initially estimated sales.<br>Perpetual Growth rate Pre-tax discount rate<br>Biopharma 1.9% 10.9%<br>Diagnostic 1.9% 9.7%<br>Bio Supplies 1.9% 10.9%<br>Kiro Grifols 1.5% 11.6%<br>GigaGen N/A 19.6%<br>Sink rate Success rate<br>GigaGen 5.0% 20.0%<br>Perpetual Growth rate Pre-tax discount rate<br>Bioscience +/- 50 bps +/- 50 bps<br>Diagnostic +/- 50 bps +/- 50 bps<br>Perpetual Growth rate Pre-tax discount rate<br>Biopharma +/- 50 bps +/- 50 bps<br>Diagnostic +/- 50 bps +/- 50 bps<br>Bio Supplies +/- 50 bps +/- 50 bps<br>Kiro Grifols +/- 50 bps +/- 50 bps<br>GigaGen No aplica +/- 100 bps | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>41<br>In addition, the following reasonably possible changes have been considered for the GigaGen CGU impairment<br>testing with independent movements of each other:<br>The reasonably possible changes in key assumptions considered by management in the calculation of the recoverable<br>amount of the Biopharma, Bio Supplies, Kiro Grifols and GigaGen CGU’s would not cause the carrying amount to<br>exceed its recoverable amount.<br>The reasonably possible changes in key assumptions considered by management in the calculation of the Diagnostic<br>CGU recoverable amount would cause the carrying amount to exceed its recoverable amount as follows:<br>% of asset value<br>Perpetual Growth rate -1%<br>Pre-tax discount rate -4%<br>Sensitivity to BTS sales -1%<br>Sensitivity to CDx sales -4%<br>At 31 December 2022 Grifols’ stock market capitalization totals Euros 6,636 million (Euros 9,834 million at 31<br>December 2021).<br>(7) Other Intangible Assets<br>Details of other intangible assets and movement during the years ended 31 December 2022 and 2021 are included in<br>Appendix III, which forms an integral part of these notes to the consolidated annual accounts.<br>Intangible assets acquired from Talecris mainly include currently marketed products. Identifiable intangible assets<br>correspond to Gamunex and have been recognized at fair value at the acquisition date of Talecris and classified as<br>currently marketed products. Intangible assets recognized comprise the rights on the Gamunex product, its<br>commercialization and distribution license, trademark, as well as relations with hospitals. Each of these components<br>is closely linked and fully complementary, are subject to similar risks and have a similar regulatory approval process.<br>Intangible assets acquired from Progenika mainly include currently marketed products. Identifiable intangible assets<br>correspond to blood, immunology and cardiovascular genotyping. These assets have been recognized at fair value at<br>the acquisition date of Progenika and classified as currently marketed products.<br>The cost and accumulated amortization of currently marketed products acquired from Talecris and Progenika at 31<br>December 2022 was as follows:<br>Balance at Translation Balance at<br>31/12/2021 Additions differences 31/12/2022<br>Cost of currently marketed products - Gamunex 1,059,509 -- 65,561 1,125,070<br>Cost of currently marketed products - Progenika 23,792 -- -- 23,792<br>Accumulated amortisation of currently marketed<br>products - Gamunex (373,772) (37,833) (22,798) (434,403)<br>Accumulated amortisation of currently marketed<br>products - Progenika (21,012) (2,379) -- (23,391)<br>Carrying amount of currently marketed products 688,517 (40,212) (22,798) 691,068<br>Thousands of Euros<br>Sink rate Success rate<br>GigaGen +/- 100 bps +/- 100 bps | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>42<br>The cost and accumulated amortization of currently marketed products acquired from Talecris, Progenika and<br>Gigagen at 31 December 2021 was as follows:<br>Balance at Translation Balance at<br>31/12/2020 Additions differences 31/12/2021<br>Cost of currently marketed products - Gamunex 980,873 -- 78,636 1,059,509<br>Cost of currently marketed products - Progenika 23,792 -- -- 23,792<br>Accumulated amortisation of currently marketed products -<br>Gamunex (313,335) (33,610) (26,827) (373,772)<br>Accumulated amortisation of currently marketed products -<br>Progenika (18,633) (2,379) -- (21,012)<br>Carrying amount of currently marketed products 672,697 (35,989) 51,809 688,517<br>Thousandss of Euros<br>The estimated useful life of the currently marketed products acquired from Talecris is considered limited, has been<br>estimated at 30 years on the basis of the expected life cycle of the product (Gamunex) and is amortized on a straight-line basis.<br>At 31 December 2022 the residual useful life of currently marketed products is 18 years and 5 months (19 years and<br>5 months at 31 December 2021).<br>The estimated useful life of the currently marketed products acquired from Progenika is considered limited, has been<br>estimated at 10 years on the basis of the expected life cycle of the product and is amortized on a straight-line basis.<br>At 31 December 2022 the residual useful life of currently marketed products acquired from Progenika is 2 months (1<br>year and 2 months at 31 December 2021).<br>(a) Self – constructed intangible assets<br>At 31 December 2022 the Group has recognized Euros 37,214 thousand as self – constructed intangible assets<br>(Euros 34,034 thousand at 31 December 2021).<br>(b) Purchase commitments<br>At 31 December 2022 the Group has intangible asset purchase commitments amounting to Euros 69 thousand<br>(Euros 431 thousand at 31 December 2021).<br>(c) Intangible assets with indefinite useful lives and other intangibles in progress<br>At 31 December 2022 the Group recognizes plasma center licenses with indefinite useful lives under intangible<br>assets for a carrying amount of Euros 31,054 thousand (Euros 29,394 thousand at 31 December 2021).<br><br>The Group has also an amount of Euros 486,364 thousand as development costs in progress (Euros 432,534<br>thousand at 31 December 2021).<br>(d) Results on disposal of intangible assets<br>The total losses on disposals and sale of intangible assets amounts to Euros 1,082 thousand in 2022 (losses of<br>Euros 30 thousand in 2021). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>43<br>(e) Impairment testing<br>Indefinite-lived intangible assets have been allocated to the cash-generating unit (CGU) of the Biopharma<br>segment. These assets have been tested for impairment together with goodwill (see note 6).<br>Impairment testing has been analyzed for each of the intangible assets in progress by calculating its recoverable<br>amount based on their fair value.<br>(8) Leases<br>Details of leases in the consolidated balance sheet at 31 December 2022 and 2021 are as follows:<br>Right-of-use assets<br>31/12/2022 31/12/2021<br>Land and buildings 885,050 782,125<br>Machinery 3,017 5,283<br>Computer equipment 1,026 2,044<br>Vehicles 8,459 6,205<br>897,552 795,657<br>Lease liabilities<br>31/12/2022 31/12/2021<br>Non-current 914,588 825,157<br>Current 102,356 48,567<br>1,016,944 873,724<br>Thousands of Euros<br>Thousands of Euros<br>The composition of lease liabilities as of 31 December 2022 and 2021 is shown below. Undiscounted future payments<br>classified on a maturity basis are presented together with the effect of the financial discount:<br>31/12/2022 31/12/2021<br>Maturity:<br>Within one year 102,356 85,972<br>In the second year 97,823 82,923<br>In the third to fifth years 270,876 224,378<br>After the fifth year 996,655 872,926<br>1,467,710 1,266,199<br>Discounting effect 450,766 392,475<br>Total lease liabilities 1,016,944 873,724<br>Thousands of Euros<br>Details by maturity of lease liabilities are shown under “Liquidity risk” in note 29.<br>At 31 December 2022, the Group has recognized an amount of Euros 141,973 thousand related to additions of right-of- use assets (Euros 133,442 thousand at 31 December 2021). Movement at 31 December 2022 and 2021 is included<br>in Appendix IV, which forms an integral part of these notes to the consolidated annual accounts. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>44<br>At 31 December 2022 and 2021, the amounts recognized in the consolidated statement of profit and loss related to<br>lease agreements are:<br>Right-of-use depreciation<br>31/12/2022 31/12/2021<br>Buildings 72,214 57,901<br>Machinery 1,983 2,120<br>Computer equipment 1,432 2,269<br>Vehicles 4,869 4,430<br>80,498 66,720<br>Thousands of Euros<br>Reference 31/12/2022 31/12/2021<br>Finance lease expenses Note 26 45,198 35,786<br>45,198 35,786<br>Thousands of Euros<br>31/12/2022 31/12/2021<br>Expenses related to short-term contracts 1,739 3,106<br>Expenses related to low-value contracts 13,435 13,404<br>Other operating lease expenses 23,820 16,435<br>38,994 32,945<br>Thousands of Euros<br>At 31 December 2022, the Group has paid a total of Euros 104,287 thousand related to lease contracts (Euros 82,692<br>thousand at 31 December 2021).<br>The total amount recognized in the balance sheet corresponds to lease contracts in which the Group is the lessee.<br>(9) Property, Plant and Equipment<br>Details of property, plant and equipment and movement in the consolidated balance sheet at 31 December 2022 and<br>2021 are included in Appendix V, which forms an integral part of this note to the consolidated annual accounts.<br>Property, plant and development under construction at 31 December 2022 and 2021 mainly comprise investments<br>made to extend the companies’ equipment and to increase their productive capacity.<br>In 2022, the Group has capitalized interests for a total amount of Euros 25,184 thousand (Euros 18,636 thousand in<br>2021) (see note 26).<br>a) Insurance<br>Group policy is to contract sufficient insurance coverage for the risk of damage to property, plant and equipment.<br>At 31 December 2022 the Group has a combined insurance policy for all Group companies, which more than<br>adequately covers the carrying amount of all the Group’s assets.<br>b) Losses on disposal of property, plant and equipment<br>Total losses incurred on disposals of property, plant and equipment for 2022 amount to Euros 6,817 thousand<br>(losses of Euros 2,720 thousand in 2021). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>45<br>c) Self – constructed property, plant and equipment<br>At 31 December 2022 the Group has recognized Euros 87,656 thousand as self -constructed property, plant and<br>equipment (Euros 87,885 thousand at 31 December 2021).<br>d) Purchase commitments<br>At 31 December 2022 the Group has property, plant and equipment purchase commitments amounting to Euros<br>41,680 thousand (Euros 40,596 thousand at 31 December 2021).<br>e) Impairment testing<br>As a result of the reorganization of the USA donor center network, an impairment for some tangible assets<br>allocated to the relocated donor centers has been recognized for a total amount of Euros 5.7 million as an expense<br>in the consolidated statement of profit and loss for 2022.<br>As a result of the discontinuation of the Blood Collection Systems activity, an impairment for some of the tangible<br>assets allocated to this business activity was recognized for a total amount of Euros 11.5 million as an expense in<br>the consolidated statement of profit and loss for 2021.<br>Impairment testing for the tangible assets has been analyzed by calculating its recoverable amount based on their<br>fair value.<br>f) Transfers<br>At 31 December 2022, transfers include the reclassification of Euros 5,159 thousand to "non-current assets held<br>for sale" related to agreement that the Group has reached for the sale of the installations owned by Grifols Brasil,<br>Lda.<br>(10) Equity-Accounted Investees<br>Details of this caption in the consolidated balance sheet at 31 December 2022 and 2021 are as follows:<br>Thousands of Euros Thousands of Euros<br>% ownership 31/12/2022 % ownership 31/12/2021<br>Access Biologicals LLC 100.00% -- 49.00% 53,264<br>Shanghai RAAS Blood Products Co., Ltd. 26.20% 1,910,428 26.20% 1,909,596<br>Grifols Egypt Plasma Derivatives 49.00% 36,111 49.00% 31,847<br>BioDarou P.J.S. Co. 49.00% 5,051 0.00% --<br>Total equity accounted investees with similar<br>activity to that of the Group 1,951,590 1,994,707<br>Albajuna Therapeutics, S.L 49.00% 622 49.00% 1,910<br>Mecwins, S.A. 24.59% 2,965 24.99% 3,159<br>Total of the rest of equity accounted investees 3,587 5,069<br>Total equity-accounted investees 1,955,177 1,999,776 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>46<br>Movement in the investments in equity-accounted investees for the year ended 31 December 2022 is as follows:<br>Access<br>Biologicals LLC<br>Shanghai RAAS<br>Blood Products<br>Co., Ltd.<br>Grifols Egypt<br>Plasma<br>Derivatives<br>BioDarou P.J.S.<br>Co. Total<br>Albajuna<br>Therapeutics,<br>S.L<br>Mecwins, S.A. Total Total<br>Balance at 1 January 53,264 1,909,596 31,847 -- 1,994,707 1,910 3,159 5,069 1,999,776<br>Acquisitions -- -- -- 4,534 4,534 -- -- -- 4,534<br>Transfers (129,459) -- -- -- (129,459) -- -- -- (129,459)<br>Share of profit / (losses) 76,895 26,680 865 (962) 103,478 (1,288) (194) (1,482) 101,996<br>Share of other comprehensive income /<br>translation differences 3,028 (18,859) (16,419) 1,479 (30,771) -- -- -- (30,771)<br>Collected dividends (3,728) (6,989) -- -- (10,717) -- -- -- (10,717)<br>Others -- -- 19,818 -- 19,818 -- -- -- 19,818<br>Balance at 31 December -- 1,910,428 36,111 5,051 1,951,590 622 2,965 3,587 1,955,177<br>Thousands of Euros<br>2022<br>Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>47<br>Movement in the investments in equity-accounted investees for the year ended 31 December 2021 is as follows:<br>Access<br>Biologicals LLC<br>Shanghai RAAS<br>Blood Products<br>Co., Ltd.<br>Grifols Egypt<br>Plasma<br>Derivatives<br>Total<br>Albajuna<br>Therapeutics,<br>S.L<br>GigaGen, Inc. Mecwins, S.A. Total Total<br>Balance at 1 January 46,782 1,800,578 -- 1,847,360 3,378 15,677 2,605 21,660 1,869,020<br>Acquisitions -- -- 30,454 30,454 -- -- 860 860 31,314<br>Transfers -- -- -- -- -- (50,794) -- (50,794) (50,794)<br>Share of profit / (losses) 8,298 24,835 (578) 32,555 (1,463) 34,957 (306) 33,188 65,743<br>Share of other comprehensive income /<br>translation differences 3,929 89,886 1,971 95,786 (5) 160 -- 155 95,941<br>Collected dividends (5,745) (5,703) -- (11,448) -- -- -- -- (11,448)<br>Balance at 31 December 53,264 1,909,596 31,847 1,994,707 1,910 -- 3,159 5,069 1,999,776<br>Thousands of Euros<br>2021<br>Equity accounted investees with similar activity to that of the Group Rest of equity accounted investees<br>Movement in the investments in equity-accounted investees for the year ended 31 December 2020 is as follows:<br>Access<br>Biologicals<br>LLC<br>Plasmavita<br>Healthcare<br>Shanghai<br>RAAS Blood<br>Products Co.,<br>Ltd.<br>Total Alkahest, Inc.<br>Albajuna<br>Therapeutics,<br>S.L<br>GigaGen, Inc. Mecwins, S.A. Medcom Advance, S.A Total Total<br>Balance at 1 January 49,922 10,368 -- 60,290 14,708 5,228 23,997 2,338 7,912 54,183 114,473<br>Acquisitions -- -- 1,807,351 1,807,351 -- -- -- -- -- -- 1,807,351<br>Transfers -- (10,674) -- (10,674) (91,023) -- -- -- -- (91,023) (101,697)<br>Share of profit / (losses) 8,962 306 11,531 20,799 76,414 (1,878) (6,725) 267 -- 68,078 88,877<br>Share of other comprehensive income /<br>translation differences (4,160) -- (16,090) (20,250) (99) 28 (1,595) -- -- (1,666) (21,916)<br>Impairment losses -- -- -- -- -- -- -- -- (7,912) (7,912) (7,912)<br>Collected dividends (7,942) -- (2,214) (10,156) -- -- -- -- -- -- (10,156)<br>Balance at 31 December 46,782 -- 1,800,578 1,847,360 -- 3,378 15,677 2,605 -- 21,660 1,869,020<br>Thousands of Euros<br>2020<br>Equity accounted investees with similar activity to that of the<br>Group Rest of equity accounted investees | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>48<br>The main movements of the equity-accounted investees with similar activity to that of the Group are explained below:<br>Grifols Egypt for Plasma Derivatives (S.A.E.)<br>On 29 July 2021, a cooperation agreement was signed with the National Service Projects Organization (NSPO) to<br>help build a platform to bring self-sufficiency in plasma-derived medicines to Egypt. The Company made a first<br>contribution of US Dollars 36,750 thousand (equivalent to Euros 30,454 thousand at the date of integration), and in<br>exchange received GEPD shares representing 49% of its share capital, which amounts to US Dollars 300 million.<br>The Company has undertaken to make the contributions for the outstanding amount corresponding to its interest as<br>the capital requirements are approved. As a result, the Group made a further capital contribution of US Dollars 22<br>million during 2022, equivalent to 49% of the total capital contribution made (US dollars 45 million).<br>Shanghai RAAS Blood Products Co. Ltd.<br>In March 2019, Grifols entered into a share exchange agreement with Shanghai RAAS Blood Products Co. Ltd.<br>(hereinafter SRAAS), through which Grifols would deliver 90 shares of its US subsidiary Grifols Diagnostic<br>Solutions Inc. (hereinafter GDS) (representing 45% of the economic rights and 40% of the voting rights), and in<br>exchange would receive 1,766 million of SRAAS shares (representing 26.2% of the share capital).<br>After receiving all relevant authorizations, at 31 December 2019, Grifols delivered 90 shares of its subsidiary GDS<br>in exchange for a contractual right to receive equity instruments in an associate (equivalent to 1,766 million of<br>SRAAS shares), because at that date no shares of SRAAS were received. As a consequence, at 31 December 31 2019,<br>SRAAS was the minority shareholder owning 45% of GDS. Grifols recorded the aforementioned contractual right<br>for the fair value of the GDS shares delivered and subsequently, the right was measured based on its fair value through<br>profit or loss.<br>On 30 March 2020, the share exchange agreement was closed and Grifols received SRAAS shares corresponding to<br>26.2% of its share capital. Therefore, Grifols became the largest shareholder of SRAAS, while maintaining<br>operational, voting and economic control of GDS.<br>Consequently, the consolidated balance sheet at 31 December 2020, did not longer show any financial asset related<br>to the contractual right, but the interest in SRAAS was recorded as an investment in an associate company because<br>the Group exercises significant influence in accordance with the criteria established in IAS 28 – Investment in<br>Associates and Joint Ventures. SRAAS’ equity-accounted investment was recognized at the value of the shares at the<br>closing date of the transaction. The difference between the contractual right value recognized at 31 December 2019<br>and SRAAS quoted value at 30 March 2020 was Euros 56,526 thousand which was recognized as Change in fair<br>value of financial instruments in the consolidated statement of profit and loss (see note 26).<br>The impact on the consolidated statement of profit and loss related to the equity method result was included in the<br>Operating Result under “Profit/(loss) of equity accounted investees with similar activity to that of the Group”, since<br>SRAAS is a company dedicated to the plasma product sector.<br>The transaction costs were recognized as part of the investment value and totaled Euros 34,088 thousand.<br>As of 31 December 2022, the quoted value of SRAAS shares was CNY 6.34. As a result of the prolonged decline in<br>the fair value of the associate Shanghai RAAS (hereinafter referred to as SRAAS) below its cost, there is an indication<br>of impairment.<br>31/12/2022 31/12/2021 Date of acquisition<br>SRAAS Share price CNY 6.34 CNY 6.80 CNY 7.91 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>49<br>The recoverable amount of the investment in SRAAS has been determined based on its value in use calculated as the<br>present value of future cash flows discounted at a discount rate that reflects the inherent risk.<br>Management has determined the gross margin based on past performance and the current situation, ongoing<br>investments and its expectations of market development without considering new business.<br>Cash flows have been estimated over 14 years since SRAAS operates in an emerging market where current<br>investments are estimated to result in long-term growth beyond 5 years. Cash flows from the fourth year onwards are<br>extrapolated for a further 10 years using growth rates that reduce the fourth year growth rate to the long-term growth<br>rate shown below to better reflect medium-term growth estimates. Perpetual growth rates are consistent with forecasts<br>included in industry and country reports.<br>The key assumptions used to perform the impairment test of the investment in SRAAS for 2022 are as follows:<br>Perpetual Growth rate Pre-tax discount rate<br>SRAAS 3.3% 9.2%<br>The discount rates used reflect the specific risks related to SRAAS and the country where it operates. The main<br>assumptions used to determine the discount rate are as follows:<br>x Risk-free rate: Standardized 10-year government bonds.<br>x Market risk premium: Premium based on market studies.<br>x Unleveraged beta: Average beta of the market.<br>x Debt-to-equity ratio: market average ratio.<br>In the actual economic context, the reasonably possible changes considered for SRAAS are a variation in the discount<br>rate, as well as in the estimated perpetual growth rate, with independent movements of each other, as follows:<br>Perpetual Growth rate Pre-tax discount rate<br>SRAAS +/- 50 bps +/- 50 bps<br>Reasonably possible changes in key assumptions considered by management in calculating the recoverable amount<br>of SRAAS would cause the carrying amount to exceed its recoverable amount as follows:<br>Pre-tax discount rate +50 bps<br>SRAAS -2% .<br>Plasmavita Healthcare GmbH<br>In 2017, Grifols established PLASMAVITA GmbH, a joint venture between Grifols (50%) and two European<br>partners (50%). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>50<br>On 14 April 2020, Grifols made a contribution of Euros 10 million in cash that was recognized as a shareholder<br>contribution in Plasmavita. The equity share of 50% remained unchanged after the contribution. However, in<br>assessing the existence of control due to the new shareholder agreement signed on that date, it was concluded that<br>Grifols has control over Plasmavita and, therefore, it was considered part of the group and it has been fully<br>consolidated (see note 3).<br>Access Biologicals LLC.<br>On 12 January 2017, the group announced the acquisition of 49% of the voting rights in Access Biologicals LLC, a<br>company based in San Diego, California, USA, for the amount of US Dollars 51 million. Grifols entered into an<br>option agreement to purchase the remaining 51% voting rights in five years, in 2022. Grifols also signed a supply<br>agreement to sell biological products not meant for therapeutic use to Access Biologicals.<br>The principal business activity of Access Biologicals is the collection and manufacturing of an extensive portfolio of<br>biological products. Combined with closed-loop material sourcing, it provides critical support for various markets<br>such as in-vitro diagnostic manufacturing, biopharmaceutical, cell culture and diagnostic research & development.<br>On 15 June 2022, Grifols, through its wholly-owned subsidiary Chiquito Acquisition Corp., reached an agreement to<br>acquire all the shares of Access Biologicals LLC, exercising the call option for the remaining 51%, for a total of US<br>Dollars 142 million. With the acquisition of 100% of the shares, Grifols obtains control over Access Biologicals LLC<br>and, therefore, it is considered a group company and is consolidated under the full consolidation method (see note<br>3).<br>BioDarou P.J.S. Co.<br>On 25 April 25 2022, and after obtaining all regulatory approvals, Grifols closed the acquisition of 70.18% of the<br>share capital of Biotest AG for Euros 1,460,853 thousand (see note 3). Biotest AG is the parent company of a<br>consolidated group of companies, which includes a joint venture investment corresponding to a 49% interest held by<br>Biotest Pharma GmbH in BioDarou P.J.S. Co, whose registered office is in Tehran, Iran, and which is accounted for<br>using the equity method.<br>The company's goal is to collect plasma, process it into immunoglobulins, factors and human albumin through Biotest<br>AG and then sell the finished products in Iran.<br>The main movements for the rest of the equity-accounted investees are explained below:<br>Alkahest, Inc.<br>On 2 September 2020, Grifols signed an agreement to acquire all the shares of Alkahest Inc. ("Alkahest") for a total<br>amount of Euros 123,425 thousand (US Dollars 146,000 thousand), which was subject to approval by regulatory<br>authorities.<br>Likewise, as a result of agreements between shareholders, Grifols obtained control of Alkahest on 2 September 2020.<br>Until that date, the previous 42.45% stake in Alkahest was equity accounted. The difference between the fair value<br>of the previous stake and the book value was Euros 86,743 thousand (US Dollars 102,552 thousand), recognizing a<br>profit for such amount under "Profit/(loss) of equity accounted investees" in the statement of profit and loss.<br>As from this date, Alkahest was incorporated into the Group's consolidation perimeter by the full consolidation<br>method.<br>Medcom Advance, S.A.<br>In February 2019, the Group completed the acquisition of 45% of the shares in Medcom Advance, S.A. for an amount<br>of Euros 8,602 thousand. Medcom Advance, S.A. is a company dedicated to research and development with a view<br>to create proprietary patents using nanotechnology. The company was equity-accounted. At 31 December 2021 and<br>2022, this investment is fully impaired. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>51<br>Mecwins, S.A.<br>On 22 October 2018 Grifols allocated Euros 2 million to the capital increase of Mecwins through Progenika<br>Biopharma, reaching 24.99% of the total capital.<br>Mecwins is a spin-off of the Institute of Micro and Nanotechnology of the Center for Scientific Research (CSIC),<br>specialized in the development of innovative nanotechnological analysis tools for the diagnosis and prognosis of<br>diseases.<br>Mecwins has developed ultrasensitive optical reading immunoassay technology from nanosensors for the detection<br>of protein biomarkers in blood. This technology has potential applications in fields such as oncology, cardiovascular<br>and infectious diseases.<br>The injection of capital, in which CRB Inverbio also participated with an additional Euros 2 million, will enable<br>Mecwins to start developing pre-commercial prototypes of this technology and for Grifols to position itself in the<br>field of nanotechnology applied to diagnosis.<br>GigaGen Inc.<br>On 5 July 2017, Grifols through its 100% subsidiary Grifols Innovation and New Technologies Limited (“GIANT”)<br>acquired a 43.96% shareholding in GigaGen, Inc., a company based in San Francisco (USA) for the amount of US<br>Dollars 35 million.<br>GIANT and GigaGen entered into a Research and Collaboration Agreement whereby in exchange of a collaboration<br>fee of US Dollars 15 million in the aggregate, GigaGen will commit to carry out research activities to develop<br>recombinant polyclonal immunoglobulin therapies derived from human B cells for the treatment of human diseases.<br>On 8 March 2021, Grifols, through its wholly owned subsidiary Grifols Innovation and New Technologies Limited<br>("GIANT"), reached an agreement to acquire all of the shares of Gigagen, Inc. for a total amount of US Dollars 90.5<br>million. With the acquisition of the 100% stake, Grifols obtains control over Gigagen and, therefore, becomes a group<br>company and is consolidated under the full consolidation method (see note 3).<br>The most recent financial statements available of the main equity-accounted investments of Grifols are as follows:<br>Balance sheet:<br>Thousands of Euros<br>31/12/2022<br>SRAAS SRAAS Access Biologicals<br>Non-current assets 3,028,641 2,877,382 2,707<br>Current assets 648,415 549,977 23,287<br>Cash and cash equivalents 430,655 401,117 3,790<br>Non-current liabilities (2,645) (3,313) (36)<br>Non-current financial liabilities (292) (453) --<br>Current liabilities (193,289) (191,133) (3,615)<br>Current financial liabilities -- -- (2,649)<br>Net assets 3,911,485 3,633,577 23,484<br>31/12/2021<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>52<br>P&L:<br>Thousands of Euros<br>31/12/2022<br>SRAAS SRAAS Access Biologicals<br>Net revenue 700,831 395,812 45,689<br>Profit for the year 227,000 181,395 17,380<br>Thousands of Euros<br>31/12/2021<br>As previously mentioned, on 15 June 2022, Grifols acquired all of Access Biologicals LLC shares and is therefore<br>considered a group company. Consequently, the company’s financial statements for 2022 are no longer detailed.<br>(11) Financial Assets<br>Details of non-current financial assets on the consolidated balance sheet at 31 December 2022 and 2021 are as<br>follows:<br>Reference 31/12/2022 31/12/2021<br>Financial investments in listed shares 11,540 2,038<br>Non-current derivatives Note 29 27,030 2,068<br>Total Non-current financial assets measured at fair value 38,570 4,106<br>Non-current guarantee deposits 9,277 7,763<br>Other non-current financial assets (a) 476,361 261,294<br>Non-current loans to related parties Note 30 96,537 89,104<br>Total Non-current financial assets measured at amortized cost 582,175 358,161<br>Thousands of Euros<br>Details of current financial assets on the consolidated balance sheet at 31 December 2022 and 2021 are as follows:<br>Thousands of Euros<br>Reference 31/12/2022 31/12/2021<br>Current derivatives Note 29 12,629 3,238<br>Total Non-current financial assets measured at fair value 12,629 3,238<br>Reference 31/12/2022 31/12/2021<br>Deposits and guarantees 359 561<br>Other current financial assets (a) 30,627 2,025,869<br>Current loans to third parties 48 39<br>Total other current financial assets measured at amortized<br>cost 31,034 2,026,469<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>53<br>(a) Other non-current and current financial assets<br>Details of other non-current and current financial assets are as follows:<br>Reference 31/12/2022 31/12/2021<br>Other financial assets with related parties Note 30 318,890 220,947<br>Other financial assets with third parties 188,098 2,066,216<br>Total other non-current and current financial assets 506,988 2,287,163<br>Thousands of Euros<br>In 2021 Grifols closed a collaboration agreement with the U.S. firm ImmunoTek Bio Centers, LLC, specialized in<br>the opening and construction of plasma centers, to open 21 plasma centers in the United States. At 31 December<br>2022, the Group has made advanced payments related to this project for an amount of Euros 124.1 million (Euros<br>42.3 million).<br>At 31 December 2021 “Other financial assets with third parties” was mainly composed of the cash received from<br>the new bond issue, which has been used in 2022 to acquire the existing share capital of Tiancheng (Germany)<br>Pharmaceutical Holdings AG, whose current corporate name is Grifols Biotest Holdings GmbH, owner of<br>approximately 90% of Biotest ordinary shares and 1% of Biotest preferred shares (see note 15 and 20).<br>(12) Inventories<br>Details of inventories at 31 December 2022 and 2021 are as follows:<br>31/12/2022 31/12/2021<br>Goods for resale 138,909 137,887<br>Raw materials and supplies 1,064,776 657,060<br>Work in progress and semi-finished goods 1,331,644 721,088<br>Finished goods 666,028 743,319<br>3,201,357 2,259,354<br>Thousands of Euros<br>Movement in the inventory provision was as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Balance at 1 January 158,724 122,613 104,251<br>Net charge for the year (66,647) 28,092 42,255<br>Cancellations for the year (12,155) (269) (189)<br>Translation differences 4,818 8,288 (23,704)<br>Balance at 31 December 84,740 158,724 122,613<br>Thousands of Euros<br>As a result of the discontinuation of the Blood Collection Systems activity, an impairment of some inventory was<br>recognized for a total amount of Euros 5 million as an expense in the consolidated statement of profit and loss for<br>2021. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>54<br>(13) Contract assets<br>Contract assets from contract fractionation relate to contingent claims for the complete fulfilment of contractual<br>obligations from contract fractionation agreements entered into by Biotest AG. The resulting performance obligations<br>are generally fulfilled by Biotest over a period of up to 12 months. Receivables from this business, which usually<br>have a due date of between 90 and 120 days, are recognized when the right to receive the consideration becomes<br>unconditional. This is the case when the biological drugs produced from the blood plasma provided by the customer<br>are delivered to the customer. These are service transactions that are valued at the corresponding costs of sales<br>incurred plus profit margin, if it can be estimated.<br>Details of contract assets at 31 December 2022 and 2021 are as follows:<br>31/12/2022 31/12/2021<br>Contract assets (gross) 35,467 1,939<br>Allowances for expected credit losses (313) --<br>Contract assets (net) 35,154 1,939<br>Thousands of Euros<br>Default risks are accounted for by making value adjustments to the contract assets. The allowance for expected credit<br>losses is calculated as the difference between the nominal amount of the contract assets and the estimated recoverable<br>amount. An independent expert has examined the portfolio of contract assets that do not show any concrete<br>indications of impairment in individual cases.<br>Movement in allowance for expected credit losses corresponding to contract assets is included in note 29.<br>(14) Trade and Other Receivables<br>Details at 31 December 2022 and 2021 are as follows:<br>Reference 31/12/2022 31/12/2021<br>Trade receivables 478,597 324,442<br>Receivables from associates Note 30 162,382 131,764<br>Impairment losses Note 29 (i) (32,291) (24,009)<br>Trade receivables 608,688 432,197<br>Other receivables Note 29 (i) 10,050 11,014<br>Personnel 770 654<br>Advance payments Note 29 (i) 19,033 6,210<br>Taxation authorities, VAT recoverable 38,719 35,389<br>Other public entities 4,609 1,796<br>Other receivables 73,181 55,063<br>Current income tax assets 56,782 12,448<br>Total trade and other receivables 738,651 499,708<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>55<br>Other receivables<br>During 2022, 2021 and 2020 the Grifols Group has sold receivables without recourse to some financial institutions<br>(factors), to which the risks and benefits inherent to the ownership of the assigned credits are substantially transferred.<br>Also, the control over the assigned credits, understood as the factor's ability to sell them to an unrelated third party,<br>unilaterally and without restrictions, has been transferred to the factor. The main conditions of these contracts include<br>the advanced collection of the assigned credits that vary between 70% and 100% of the nominal amount and a<br>percentage of insolvency risk coverage on the factor side that varies between 90% and 100% of the nominal of the<br>assigned credits.<br>These contracts have been considered as without recourse factoring and the amount advanced by the factors has been<br>derecognized from the balance sheet.<br>Likewise, in financial years 2022 and 2021, some receivables assignment contracts were signed with a financial<br>institution, in which Grifols retains the risks and benefits inherent to the ownership of the assigned credits. These<br>contracts have been considered as with resource and the assigned amount remains in the consolidated balance sheet<br>at 31 December 2022 and a short-term debt has been recognized for an amount equal to the consideration received<br>from the factor for the assignment. The amount recognized is Euros 16,546 thousand at 31 December 2022 (Euros<br>23,450 thousand at 31 December 2021).<br>Total receivables without recourse sold to financial institutions through the aforementioned contracts in 2022 amount<br>to Euros 3,174,308 thousand (Euros 2,975,343 thousand in 2021 and Euros 2,735,973 thousand in 2020).<br>The financial cost of credit rights sold for the Group totals Euros 18,201 thousand which has been recognized under<br>finance costs in the consolidated statement of profit and loss for 2022 (Euros 10,292 thousand in 2021 and Euros<br>10,964 thousand in 2020) (see note 26).<br>Details of balances with related parties are shown in note 30.<br>The volume of invoices sold without recourse to various financial institutions which, based on their due date would<br>not have been collected at 31 December 2022, totals Euros 445,185 thousand (Euros 317,054 thousand at December,<br>2021).<br>(15) Cash and Cash Equivalents<br>Details of this caption of the consolidated balance sheet at 31 December 2022 and 2021 are as follows:<br>31/12/2022 31/12/2021<br>Current deposits 5 --<br>Cash in hand and at banks 547,974 655,493<br>Total cash and cash equivalents recognized in the balance sheet 547,979 655,493<br>Restricted cash -- 2,020,118<br>Total cash and cash equivalents recognized in the statement of cash<br>flows 547,979 2,675,611<br>Thousands of Euros<br>As mentioned in note 20, during 2021 the Group issued a bond in two tranches for amounts of Euros 1,400 million<br>and US Dollars 705 million. These funds were held in an escrow account and were released once the transaction with<br>Tiancheng (Germany) Pharmaceutical Holdings AG, whose current corporate name is Grifols Biotest Holdings<br>GmbH, became effective. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>56<br>(16) Equity<br>Details of consolidated equity and movement are shown in the consolidated statement of changes in equity.<br>(a) Share capital<br>At 31 December 2022 and 2021, the Company’s share capital amounts to Euros 119,603,705 and comprises:<br>x Class A shares: 426,129,798 ordinary shares of Euros 0.25 par value each, subscribed and fully paid and of<br>the same class and series.<br>x Class B shares: 261,425,110 non-voting preference shares of 0.05 Euros par value each, of the same class<br>and series, and with the preferential rights set forth in the Company’s by-laws.<br>The main characteristics of the Class B shares are as follows:<br>x Each Class B share entitles its holder to receive a minimum annual preferred dividend out of the distributable<br>profits at the end of each year equal to Euros 0.01 per Class B share provided that the aggregate preferred<br>dividend does not exceed the distributable profits of that year and, subject, according to the commercial law,<br>to the approval of the distribution of dividends by the Company’s shareholders. This preferred dividend is<br>not cumulative if sufficient distributable profits are not obtained in the period.<br>x Each Class B share is entitled to receive, in addition to the above-mentioned preferred dividend, the same<br>dividends and other distributions as for one Grifols ordinary share.<br>x Each Class B share entitles the holder to its redemption under certain circumstances, if a takeover bid for all<br>or part of the shares in the Company has been made, except if holders of Class B shares have been entitled<br>to participate in the bid on the same terms as holders of Class A shares. The redemption terms and conditions<br>reflected in the Company’s by-laws limit the amount that may be redeemed, requiring that sufficient<br>distributable reserves be available, and limit the percentage of shares to be redeemed in line with the ordinary<br>shares to which the bid is addressed.<br>x In the event the Company were to be wound up and liquidated, each Class B share entitles the holder to<br>receive, before any amounts are paid to holders of ordinary shares, an amount equal to the sum of (i) the par<br>value of the Class B share, and (ii) the share premium paid for the Class B share when it was subscribed. In<br>addition to the Class B liquidation preference amount, each holder is entitled to receive the same liquidation<br>amount that is paid for each ordinary share.<br>These shares are freely transferable.<br>Since 23 July 2012 the ADSs (American Depositary Shares) representing Grifols’ Class B shares (non-voting<br>shares) have had an exchange ratio of 1:1 in relation to Class B shares, ie.1 ADS represents 1 Class B share. The<br>previous rate was 2 ADS per 1 Class B share.<br>The Company’s knowledge of its shareholders is based on information provided voluntarily or in compliance<br>with applicable legislation. According to the information available to the Company, there are no interests<br>representing more than 10% of the Company’s total capital at 31 December 2022 and 2021.<br>At 31 December 2022 and 2021, the number of outstanding shares is equal to the total number of Company<br>shares, less treasury stock. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>57<br>Movement in outstanding shares during 2022 is as follows:<br>Reference Class A shares Class B shares<br>Balance at 1 January 2022 422,185,368 256,354,580<br>(Acquisition) / disposal of treasury stock Note 16 (d) -- (129,254)<br>Balance at 31 December 2022 422,185,368 256,225,326<br>Movement in outstanding shares during 2021 is as follows:<br>Reference Class A shares Class B shares<br>Balance at 1 January 2021 426,129,798 258,412,946<br>(Acquisition) / disposal of treasury stock Note 16 (d) (3,944,430) (2,058,366)<br>Balance at 31 December 2021 422,185,368 256,354,580<br><br>(b) Share premium<br>Movement in the share premium is described in the consolidated statement of changes in equity, which forms an<br>integral part of this note to the consolidated annual accounts.<br>(c) Reserves<br>The drawdown of accumulated gains is subject to legislation applicable to each of the Group companies.<br>At 31 December 2022, Euros 18.908 thousand equivalent to the carrying amount of development costs<br>pending amortization of certain Spanish companies (Euros 29,486 thousand at 31 December 2021) are, in<br>accordance with applicable legislation, a distribution limitation until these development costs have been<br>amortized.<br>The movement in this caption of the consolidated balance sheet during the years ended at 31 December 2022,<br>2021 and 2020 is reflected in the consolidated statement of changes in equity, the most significant movements<br>being detailed below:<br>On 30 March 2020, the share exchange agreement was closed and Grifols received SRAAS shares corresponding<br>to 26.2% of its share capital. Therefore, Grifols became the largest shareholder of SRAAS, while maintaining<br>operational, voting and economic control of GDS (see notes 10 and 18). This transaction generated an impact of<br>Euros 408 million on reserves.<br>Legal reserve<br>Companies in Spain are obliged to transfer 10% of each year‘s profits to a legal reserve until this reserve reaches<br>an amount equal to 20% of share capital. This reserve is not distributable to shareholders and may only be used<br>to offset losses if no other reserves are available. Under certain conditions it may be used to increase share capital<br>provided that the balance left on the reserve is at least equal to 10% of the nominal value of the total share capital<br>after the increase.<br>At 31 December 2022 and 2021 the legal reserve of the Parent amounts to Euros 23,921 thousand which<br>corresponds to 20% of the share capital.<br>Distribution of the legal reserves of Spanish companies is subject to the same restrictions as those of the Company<br>and at 31 December 2022 and 2021 the balance of the legal reserve of other Spanish companies amounts to Euros<br>2,066 thousand. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>58<br>Other foreign Group companies have a legal reserve amounting to Euros 4,137 thousand at 31 December 2022<br>(Euros 3,805 thousand at 31 December 2021).<br>Hedging reserve<br>The hedging reserve includes the cash flow hedge reserve and the costs of hedging reserve, see note 4(i) for<br>details. The cash flow hedge reserve is used to recognise the effective portion of gains or losses on derivatives<br>that are designated and qualify as cash flow hedges, as described in note 29.<br>The group defers the changes in the forward element of forward contracts and the time value of option contracts<br>in the costs of hedging reserve.<br>(d) Treasury stock<br>The Parent held Class A and B treasury stock equivalent to 1.3% of its capital at 31 December 2022 (1.3% of its<br>capital in Class A and B treasury stock at 31 December 2021).<br>Treasury stock Class A<br>Movement in Class A treasury stock during the year ended 31 December 2022 is as follows:<br>No. of Class A<br>shares Thousands of Euros<br>Balance at 1 January 2022 3,944,430 89,959<br>Disposal Class A shares -- --<br>Balance at 31 December 2022 3,944,430 89,959<br>Movement in Class A treasury stock during the year ended 31 December 2021 is as follows:<br>No. of Class A<br>shares Thousands of Euros<br>Balance at 1 January 2021 -- --<br>Disposal Class A shares -- --<br>Acquisition Class A shares 3,944,430 89,959<br>Balance at 31 December 2021 3,944,430 89,959<br>At the meeting held on 11 March 2021, the Board of Directors agreed to implement a program to buy back<br>Grifols' treasury stock for the purpose of using it as consideration in possible future acquisitions. This Buyback<br>Program began on 12 March 2021 and has been in force until 14 June 2021 and its execution was entrusted to<br>an independent bank. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>59<br>Treasury stock Class B<br>Movement in Class B treasury stock during 2022 was as follows:<br>No. of Class B<br>shares Thousands of Euros<br>Balance at 1 January 2022 5,070,530 74,230<br>Disposal Class B shares (370,746) (5,428)<br>Acquisition Class B shares 500,000 3,459<br>Balance at 31 December 2022 5,199,784 72,261<br>Movement in Class B treasury stock during 2021 is as follows:<br>No. of Class B<br>shares Thousands of Euros<br>Balance at 1 January 2021 3,012,164 43,734<br>Disposal Class B shares (361,530) (5,248)<br>Acquisition Class B shares 2,419,896 35,744<br>Balance at 31 December 2021 5,070,530 74,230<br>In March 2022, the Group delivered 370,746 treasury stocks (Class B shares) to eligible employees as<br>compensation under the Restricted Share Unit Retention Plan.<br>In March 2021, the Group delivered 361,530 treasury stocks (Class B shares) to eligible employees as<br>compensation under the Restricted Share Unit Retention Plan.<br>(e) Distribution of profit and dividends<br>The profits of Grifols, S.A. and subsidiaries will be distributed as agreed by respective shareholders at their<br>general meetings.<br>The proposed distribution of profit of the Parent Grifols, S.A. for the years ended 31 December 2022, and the<br>distribution of profit approved for 2021, presented at the general meeting held on 10 June 2022, is as follows:<br>31/12/2022 31/12/2021<br>Voluntary reserve (266,296) (140,728)<br>Profit of the Parent (266,296) (140,728)<br>Thousands of Euros<br>The distribution of profit corresponding to the year ended 31 December 2022 and 2021 are presented in the<br>statement of changes in consolidated equity.<br>During 2022 no dividend has been paid. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>60<br>The following dividends were paid in 2021:<br>At the general meeting held on 21 May 2021 the shareholders of Grifols S.A. approved the distribution of a<br>preferred dividend of Euros 0.01 for every Class B non-voting share, together with the approval of an ordinary<br>dividend of Euros 0.36 for Class A and Class B share charged to voluntary reserves of the Company for an<br>amount of Euros 247,520 thousand.<br>During 2022 and 2021 no interim dividend has been paid.<br>(f) Restricted Share Unit Retention Plan<br>The Group has set up a Restricted Share Unit Retention Plan (hereinafter RSU Plan) for certain employees (see<br>note 28). This commitment will be settled using equity instruments and the cumulative accrual amounts to Euros<br>7,304 thousand at 31 December 2022 (Euros 9,838 thousand at 31 December 2021).<br>(17) Earnings Per Share<br>(a) Basic Earnings per share<br>The calculation of basic earnings per share is based on the profit for the year attributable to the shareholders of the<br>Parent divided by the weighted average number of ordinary shares in circulation throughout the year, excluding<br>treasury stock.<br>Details of the calculation of basic earnings per share are as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Profit for the year attributable to shareholders of the<br>Parent (Thousands of Euros) 208,279 188,726 618,546<br>Weighted average number of ordinary shares outstanding 679,805,142 681,556,937 685,515,740<br>Basic earnings per share (Euros per share) 0.31 0.28 0.90<br>Thousands of Euros<br>% of par value Euros per share Thousands of Euros<br>Ordinary shares 146% 0.36 154,005<br>Non-voting shares 729% 0.36 93,515<br>Non-voting shares (preferred dividend) 20% 0.01 2,614<br>Total dividends paid 250,134<br>31/12/2021 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>61<br>The weighted average number of ordinary shares outstanding (basic) is as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Issued shares outstanding at 1 January 679,598,330 685,601,126 685,198,238<br>Effect of shares issued -- -- --<br>Effect of treasury stock 206,812 (4,044,189) 317,502<br>Weighted average number of ordinary shares outstanding (basic)<br>at 31 December 679,805,142 681,556,937 685,515,740<br>Number of shares<br>(b) Diluted Earnings per share<br>Diluted earnings per share are calculated by dividing profit for the year attributable to shareholders of the Parent by<br>the weighted average number of ordinary shares in circulation considering the diluting effects of potential ordinary<br>shares.<br>The RSU Plan granted by the Group and payable in shares, assumes the existence of dilutive potential shares. Diluted<br>earnings per share have been calculated as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Profit for the year attributable to shareholders of the<br>Parent (Thousands of Euros) 208,279 188,726 618,546<br>Weighted average number of ordinary shares outstanding<br>(diluted) 679,292,729 681,404,922 685,142,749<br>Diluted earnings per share (Euros per share) 0.31 0.28 0.90<br>Thousands of Euros<br>The weighted average number of ordinary shares outstanding diluted has been calculated as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Ordinary shares outstanding at 1 January 679,598,330 685,601,126 685,198,238<br>Shares committed under RSU plan (512,413) (152,015) (372,991)<br>Effect of shares issued -- -- --<br>Effect of treasury stock 206,812 (4,044,189) 317,502<br>Weighted average number of ordinary shares outstanding (diluted)<br>at 31 December 679,292,729 681,404,922 685,142,749<br>Number of shares | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>62<br>(18) Non-Controlling Interests<br>Details of non-controlling interests and movement at 31 December 2022 are as follows:<br>Reference Balance at<br>31/12/2021 Additions<br>Business<br>combinations<br>/ Perimeter<br>additions<br>Other<br>movements<br>Translation<br>differences<br>Balance at<br>31/12/2022<br>Grifols (Thailand) Pte Ltd 4,417 282 -- (23) 103 4,779<br>Grifols Malaysia Sdn Bhd 3,059 593 -- -- 11 3,663<br>Araclon Biotech, S.A. 240 (833) -- -- -- (593)<br>VCN Bioscience, S.L 97 0 -- (97) -- 0<br>Kiro Grifols, S.L. 284 (312) -- 3 -- (25)<br>Haema AG 233,542 (4,858) -- -- -- 228,684<br>BPC Plasma, Inc 305,276 30,086 -- -- 19,140 354,502<br>Grifols Diagnostics Solutions Inc. 1,234,850 46,719 -- 111 71,994 1,353,674<br>Plasmavita Healthcare 11,724 (1,590) -- -- -- 10,134<br>Haema Plasma Kft -- (4,074) 17,080 -- (1,067) 11,939<br>G Pyrenees Research Cntr -- (7) 1 -- -- (6)<br>Albimmune SL -- (742) 1 -- -- (741)<br>Biotest AG Note 3 -- (2,397) 356,386 8 7,599 361,596<br>1,793,489 62,867 373,468 2 97,780 2,327,606<br>Thousands of Euros<br>On 25 April 2022, the Group acquired 70.18% of the shares in Biotest AG. Consequently, the information relating<br>to Biotest, AG corresponds to the period from 1 May to 31 December 2022.<br>Details of non-controlling interests and movement at 31 December 2021 are as follows:<br>Balance at<br>31/12/2020 Additions<br>Business<br>combinations /<br>Perimeter<br>additions<br>Dividends paid Translation<br>differences<br>Balance at<br>31/12/2021<br>Grifols (Thailand) Pte Ltd 4,338 218 -- -- (139) 4,417<br>Grifols Malaysia Sdn Bhd 2,923 810 (843) -- 169 3,059<br>Araclon Biotech, S.A. (1,088) (1,119) 2,447 -- -- 240<br>VCN Bioscience, S.L 316 (219) -- -- -- 97<br>Kiro Grifols , S.L. 598 (314) -- -- -- 284<br>Haema AG 231,284 2,258 -- -- -- 233,542<br>BPC Plasma, Inc (formerly Biotest US<br>Corporation) 274,995 8,014 -- -- 22,267 305,276<br>Grifols Diagnostic Solutions, Inc. 1,087,632 65,894 -- (6,503) 87,827 1,234,850<br>Plasmavita Healthcare 10,665 1,059 -- -- -- 11,724<br>1,611,663 76,601 1,604 (6,503) 110,124 1,793,489<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>63<br>At 31 December 2022 and 2021, the main items of the statement of financial positions of the most significant non-controlling interests are as follows:<br>Thousands of Euros<br>Biotest, AG Grupo GDS Haema AG BPC Plasma, Inc Grupo GDS Haema AG BPC Plasma,<br>Inc<br>Non-current assets 585,282 4,175,839 126,051 345,906 3,796,855 121,309 263,921<br>Current assets 619,513 286,153 40,308 30,242 291,371 57,985 74,206<br>Total Assets 1,204,795 4,461,992 166,359 376,148 4,088,226 179,294 338,127<br>Non-current liabilities 701,613 292,416 19,673 54,131 278,620 27,137 53,715<br>Current liabilities 130,193 93,474 72,675 60,638 91,299 84,117 83,592<br>Total Liabilities 831,806 385,890 92,348 114,769 369,919 111,254 137,307<br>Total equity 372,989 4,076,102 74,011 261,379 3,718,307 68,040 200,820<br>Profit/(loss) for the year (16,036) 140,678 5,972 48,132 198,416 8,100 34,333<br>Thousands of Euros<br>31/12/2022 31/12/2021<br>Detail of cash flows of the most significant non-controlling interests is as follows:<br>31/12/2021<br>Biotest, AG GDS Group GDS Group<br>Net cash flows from operating activities (39,881) 220,566 274,202<br>Net cash flows from investing activities (29,358) (222,612) (247,441)<br>Net cash flows from financing activities 91,219 1,914 (26,682)<br>21,980 (132) 79<br>Thousands of Euros<br>31/12/2022<br>(19) Provisions<br>Details of provisions at 31 December 2022 and 2021 are as follows:<br>31/12/2022 31/12/2021<br>Provisions for pensions and similar obligations (a) 94,071 6,717<br>Other provisions 15,992 17,405<br>Non-current provisions 110,063 24,122<br>Trade provisions 56,339 31,407<br>Current provisions 56,339 31,407<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>64<br>The movement in non-current and current provisions is as follows:<br>Reference 31/12/2022 31/12/2021 31/12/2020<br>Opening balance 55,529 38,446 61,139<br>Business combinations Note 3 138,476 32 954<br>Net charges 12,588 15,664 414<br>Net reversal -- -- (21,998)<br>Net cancellations (9,091) (794) (422)<br>Transfers (33,575) (673) 468<br>Translation differences 2,475 2,854 (2,109)<br>Closing balance 166,402 55,529 38,446<br>Thousands of Euros<br>(a) Pension plan<br>At 31 December 2022, 2021 and 2020, the balance of provisions for pensions and similar mainly includes a<br>provisions made by the Biotest Group in relation to retirement benefit obligations and foreign personal commitments<br>with employment.<br>Benefits are based on the employee’s length of service and salary. Retirement benefit obligations relate mainly to<br>employees of the Group’s German companies. Similar obligations are foreign obligations payable in a lump sum on<br>retirement and obligations of the Biotest pension savings plan. These plans are voluntary pension plans not subject<br>to statutory or legal obligations. The amount of the pension obligations is mainly dependent on interest rate<br>movements and the life expectancy of the participants.<br>Assets of Euros 5,676 thousand were held by a trustee, company of the group, in financial year 2022 under a<br>contractual trust arrangement (CTA) as external insolvency insurance for portions of the occupational pension<br>scheme. Since the transferred funds qualify as plan assets in accordance with IAS 19, provisions for pensions and<br>similar obligations were netted with the transferred assets. As a result, provisions for pensions and similar obligations<br>were reduced accordingly.<br>At 31 December 2022, the net defined benefit liability of the Biotest Group comprises the following:<br>Thousands of Euros<br>Net present value of defined benefit obligations 31/12/2022<br>From pension plans 80,445<br>From similar obligations 11,046<br>91,491<br>Fair value of plan assets<br>For pension plans (4,222)<br>For similar obligations (1,454)<br>(5,676)<br>Net defined benefit liability<br>From pension plans 76,223<br>From similar obligations 9,592<br>85,815 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>65<br>The costs for the defined benefit plans consist of the following components:<br>Thousands of Euros<br>31/12/2022<br>Current service cost 3,517<br>Net interest expenses 766<br>Total expenses recognised in profit and loss 4,283<br>Actuarial losses due to experience adjustments 1,294<br>Actuarial gains due to changes in financial assumptions (34,754)<br>Actuarial gains from changes in demographic assumptions (6)<br>Return on plan assets (excluding amounts included in net interest expense) 755<br>Revaluation recognised directly in other comprehensive income (32,711)<br>Defined benefit costs (28,428)<br>In financial year 2022, actuarial gains of Euros 32,711 thousand are recognised in other comprehensive income. Of<br>this amount, Euros 34,754 thousand resulted from changes in actuarial assumptions, which is mainly due to the<br>increase in the actuarial interest rate in the main plans in Germany from 1.1% to 3.9%.<br>The following table shows the reconciliation of the net present value of the defined benefit obligation (DBO):<br>Thousands of Euros<br>31/12/2022<br>Net present value of defined benefit obligation at 1 May 122,880<br>Current service cost 3,517<br>Interest expense 816<br>Expenses recognised in the statement of profit and loss 4,333<br>Actuarial losses due to experience adjustments 1,294<br>Actuarial gains due to changes in financial assumptions (34,754)<br>Actuarial gains from changes in demographic assumptions (6)<br>Revaluation recognised directly in other comprehensive income (33,466)<br>Pension benefits paid (2,256)<br>Net present value of defined benefit obligations at 31 December 91,491 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>66<br>The following table shows the reconciliation of the fair value of plan assets:<br>Thousands of Euros<br>31/12/2022<br>Fair value of plan assets as of 1 May 4,560<br>Interest income 50<br>Income recognised in the consolidated statement of income 50<br>Return on plan assets (excluding amounts included in net interest expenses) (755)<br>Revaluations recognised directly in the statement of comprehensive income (755)<br>Contribution by the employer 1,821<br>Payments from plan assets --<br>Fair value of plan assets as of 31 December 5,676<br>The following payments are expected to be made in subsequent years based on the current pension obligations of<br>the Biotest group:<br>Thousands of Euros<br>31/12/2022<br>In the next 12 months 4,394<br>Between 2 and 5 years 21,629<br>Between 5 and 10 years 31,124<br>After 10 years 112,888<br>Total expected payments 170,035<br>The weighted average term of the defined benefit plans is 11.7 years as of 31 December 2022.<br>Plan assets of the Biotest group were invested in the following asset classes as of the reporting date:<br>Thousands of Euros<br>31/12/2022<br>Cash and cash equivalents 187<br>Financial investment 1,000<br>Fund shares 4,489<br>Total expected payments 5,676<br>The plan assets transferred to Biotest Vorsorge Trust e.V are invested in accordance with defined investment<br>principles, whereby the maturity or termination option of the financial instruments must always be selected in such<br>a way that the association can meet its payment obligations. In accordance with the investment principles, the assets<br>can be invested in Euro time deposits as well as domestic government bonds, mortgage bonds or fund units in money<br>market funds or corporate bonds, all in Euro. Loans can also be issued to the Biotest Group companies against the<br>corresponding guarantees. A minimum rating of A- is required for all financial instruments. The expected<br>contributions to plan assets amount to Euros 1,896 thousand. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>67<br>Of the provisions for pensions and similar obligations in the Biotest group, Euros 90,783 thousand relate to pension<br>plans. The calculation of the pension plans is based on the following actuarial assumptions:<br>31/12/2022<br>Discount rate 3.9%<br>Expected return on plan assets 1.1%<br>Rate of increase for wages and salaries 3.4%<br>Rate of interest for pensions 2.2%<br>Employee turnover rate 3.0%<br>Actuarial assumptions are mainly based on historical empirical values with the exception of the discount rate. The<br>calculation was based on the published Heubeck 2018 G mortality tables.<br>Under IAS 19.145, the effect of any possible changes to parameters for the underlying assumptions used to calculate<br>the pension obligations must be disclosed in the sensitivity analysis. Only changes that are realistically expected to<br>occur in the following financial year are to be considered.<br>The actuarial rate of interest, salary trend, pension trend and life expectancy are regarded as material assumptions.<br>These parameters are shown in the following overview together with information on the parameter changes and their<br>impact on the net present value calculation as of 31 December 2022.<br>Thousands of Euros<br>Parameter change Impact on the pension<br>obligation<br>Rate of interest Increase by 50 basis points (4,906)<br>Rate of interest Decrease by 50 basis points 5,414<br>Salary trend Increase by 50 basis points 171<br>Salary trend Decrease by 50 basis points (166)<br>Pension trend Increase by 100 basis points 6,227<br>Pension trend Decrease by 100 basis points (5,310)<br>Life expectancy Increase by one year 2,916<br>An amount of Euros 11,844 thousand was recognized as expense for defined contribution plans and is broken down<br>as follows:<br>Thousands of Euros<br>31/12/2022<br>Defined contribution plans of the Company 134<br>Employer contributions to statutory pension scheme 11,710<br>11,844 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>68<br>(20) Financial Liabilities<br>This note provides information on the contractual conditions of the Group’s financial liabilities, which are measured<br>at amortized cost, except for the financial derivatives that are valued at fair value. For further information on exposure<br>to interest rate risk, currency risk and liquidity risk and the fair values of financial liabilities, please refer to note 29.<br>Details at 31 December 2022 and 2021 are as follows:<br>Financial liabilities Reference 31/12/2022 31/12/2021<br>Non-current bonds (a) 4,638,444 2,577,465<br>Senior secured debt (b) 3,419,058 3,296,025<br>Other loans (b) 336,530 480,836<br>Other non-current financial liabilities (c) 887,707 838,826<br>Non-current financial derivatives Note 29 4,003 --<br>Non-current lease liabilities Note 8 914,588 825,157<br>Loan transaction costs (239,768) (249,359)<br>Total non-current financial liabilities 9,960,562 7,768,950<br>Current bonds (a) 150,512 2,270,474<br>Senior secured debt (b) 8,904 --<br>Other loans (b) 477,065 165,139<br>Other current financial liabilities (c) 113,680 43,234<br>Current financial derivatives Note 29 733 875<br>Current lease liabilities Note 8 102,356 48,567<br>Loan transaction costs (57,564) (89,998)<br>Total current financial liabilities 795,686 2,438,291<br>Thousands of Euros<br>(a) Senior Notes<br>Detail of Senior Notes at 31 December 2022 are as follows:<br>Thousands of Euros<br>Issue date Company Nominal value Currency Annual coupon Maturity<br>18/04/2017 Grifols, S.A. 1,000,000 Euros 3.20% 2025<br>05/10/2021 Grifols Escrow<br>Issuer S.A. 1,400,000 Euros 3.875% 2028<br>05/10/2021 Grifols Escrow<br>Issuer S.A. 705,000 US dollar 4.750% 2028<br>15/11/2019 Grifols, S.A. 770,000 Euros 2.25% 2027<br>15/11/2019 Grifols, S.A. 905,000 Euros 1.625% 2025<br>Unsecured senior notes<br>Secured senior notes<br>The bonds issued by Grifols, S.A. in 2017 and 2019 were admitted to listing on the Irish Stock Exchange on the same<br>issue date. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>69<br>On 5 October 2021, Grifols Escrow Issuer, S.A. closed the issuance of a senior unsecured corporate bond (Senior<br>Unsecured Notes) in two tranches for amounts of Euros 1,400 million and US Dollars 705 million. Both tranches<br>mature in 2028, accrue an annual coupon of 3.875% and 4.750%, respectively and are listed on the Irish Stock<br>Exchange.<br>The proceeds from the bonds were used to finance the Euros 1100 million acquisition of the entire share capital of<br>Tiancheng (Germany) Pharmaceutical Holdings AG, whose current corporate name is Grifols Biotest Holdings<br>GmbH, which holds 89.88% of the ordinary shares of Biotest AG and 1.08% of the preferred shares. In addition, the<br>proceeds will also be used to finance the voluntary public offering for the remaining ordinary and preferred shares of<br>Biotest AG.<br>Details of movement in the Senior Notes at 31 December 2022 are as follows:<br>Opening<br>outstanding balance<br>01/01/22<br>Cancellation Exchange<br>differences<br>Closing outstanding<br>balance 31/12/22<br>Senior unsecured corporate notes 2017 1,000,000 -- -- 1,000,000<br>Senior secured corporate notes 2019 1,675,000 (97,535) -- 1,577,465<br>Senior unsecured corporate notes Euros 2021 1,400,000 -- -- 1,400,000<br>Senior unsecured corporate notes US Dollars 2021 622,462 -- 38,517 660,979<br>4,697,462 (97,535) 38,517 4,638,444<br>Thousands of Euros<br>On 2 December 2021, Grifols, S.A. announced a repurchase offer for the same price plus unpaid accrued interests of<br>the mentioned bonds, up to the equivalent in Euros of US Dollars 110,317 thousand. The agreement with the<br>bondholders was closed in January 2022.<br>Details of movement in the Senior Notes at 31 December 2021 are as follows:<br>Opening<br>outstanding balance<br>01/01/21<br>Issue Exchange<br>differences<br>Closing outstanding<br>balance 31/12/21<br>Senior unsecured corporate notes 2017 1,000,000 -- -- 1,000,000<br>Senior secured corporate notes 2019 1,675,000 -- -- 1,675,000<br>Senior unsecured corporate notes Euros 2021 -- 1,400,000 -- 1,400,000<br>Senior unsecured corporate notes US Dollars 2021 -- 598,970 23,492 622,462<br>2,675,000 1,998,970 23,492 4,697,462<br>Thousands of Euros<br>At 31 December 2022 and 2021 the current obligations caption includes the issue of bearer promissory notes to Group<br>employees, as follows: | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>70<br>31/12/2022 31/12/2021<br>Issue date 04/05/2022 04/05/2021<br>Maturity date 04/05/2023 04/05/2022<br>Nominal amount of promissory notes (Euros) 3,000 3,000<br>Interest rate 3.00% 2.50%<br>Promissory Notes subscribed 120,054 119,325<br>Buy-backs or redemptions (1,938) (1,740)<br>Interest pending accrual (1,176) (975)<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>71<br>(b) Loans and borrowings<br>Details of loans and borrowings at 31 December 2022 and 2021 are as follows:<br>Credit Currency Interest rate Date awarded Maturity date Amount extended Carrying amount Amount extended Carrying amount<br>Senior debt - Tranche B Euros Euribor + 2.25% 15/11/2019 15/11/2027 1,360,000 1,255,285 1,360,000 1,258,554<br>Senior debt - Tranche B US Dollars Libor + 2.00% 15/11/2019 15/11/2027 2,343,896 2,163,773 2,227,171 2,037,471<br>Total senior debt 3,703,896 3,419,058 3,587,171 3,296,025<br>EIB Loan Euros 2.40% 20/11/2015 20/11/2025 100,000 21,250 100,000 31,875<br>EIB Loan Euros 2.02% 22/12/2017 22/12/2027 85,000 42,500 85,000 53,125<br>EIB Loan Euros 2.15% 25/09/2018 25/09/2028 85,000 53,125 85,000 63,750<br>Total EIB Loan 270,000 116,875 270,000 148,750<br>Revolving Credit US Dollars Libor + 1.5% 15/11/2019 15/11/2025 937,559 -- 882,924 330,000<br>Total Revolving Credit 937,559 -- 882,924 330,000<br>Other non-current loans Euros<br>1.76% - Euribor<br>+ 6.70% 235,000 219,655 10,000 2,086<br>Loan transaction costs -- (163,476) -- (197,703)<br>Non-current loans and borrowings 5,146,455 3,592,112 4,750,095 3,579,158<br>Thousands of Euros<br>31/12/2022 31/12/2021 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>72<br>Credit Currency Interest rate Date awarded Maturity date<br>Amount<br>extended<br>Carrying<br>amount<br>Amount<br>extended<br>Carrying<br>amount<br>Senior debt - Tranche B Euros Euribor + 2.25% 15/11/2019 15/11/2027 (*) 3,269 (*) --<br>Senior debt - Tranche B US Dollars Libor + 2.00% 15/11/2019 15/11/2027 (*) 5,635 (*) --<br>Total senior debt -- 8,904 -- --<br>EIB Loan Euros 2.40% 20/11/2015 20/11/2025 (*) 10,625 (*) 10,625<br>EIB Loan Euros 2.02% 22/12/2017 22/12/2027 (*) 21,250 (*) 21,250<br>Total EIB Loan -- 31,875 -- 31,875<br>Other current loans 0.10% - 3.75% 481,163 445,190 211,901 133,265<br>Loan transaction costs -- (36,559) -- (37,245)<br>Current loans and borrowings 481,163 449,410 211,901 127,895<br>(*) See amount granted under non-current debt<br>31/12/2022 31/12/2021<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>73<br>Current loans and borrowings include accrued interest amounting to Euros 12,592 thousand at 31 December<br>2022 (Euros 7,682 thousand at 31 December 2021).<br>Between 2015 and 2018, the Group arranged three long-term loans with the European Investment Bank totaling<br>Euros 270,000 thousand (divided into two loans of Euros 85,000 thousand and one loan of Euros 100,000<br>thousand) to support its investments in R&D, mainly focused on the search for new therapeutic indications for<br>plasma-derived protein therapies. The financial terms include a fixed interest rate, a maturity of 10 years with a<br>grace period of 2 years. At 31 December 2022, the carrying amount of the loans obtained from the European<br>Investment Bank amounts to Euros 148,750 thousand (Euros 180,625 thousand at 31 December 2021).<br>Senior Secured debt<br>The Senior Secured debt consists of an eight-year loan divided into two tranches: US Tranche B and Tranche B<br>in Euros. The terms and conditions of both tranches are as follows:<br> ƒ US Dollar Tranche B:<br>x Original principal amount of US Dollars 2,500 million.<br>x Applicable margin of 200 basis points (bp) pegged to US Libor.<br>x Quasi-bullet repayment structure.<br>x Maturity in 2027.<br> ƒ Tranche B in Euros:<br>x Original principal amount of Euros 1,360 million.<br>x Applicable margin of 225 basis points (bp) pegged to Euribor.<br>x Quasi-bullet repayment structure.<br>x Maturity in 2027.<br>Details of Tranche B by maturity at 31 December 2022 are as follows:<br>Currency Principal in Thousands<br>of US Dollars<br>Principal in Thousands<br>of Euros Currency Principal in Thousands of<br>Euros<br>Maturity<br>2023 US Dollars 6,015 5,635 Euros 3,269<br>2024 US Dollars 24,058 22,557 Euros 13,076<br>2025 US Dollars 24,058 22,557 Euros 13,076<br>2026 US Dollars 24,058 22,557 Euros 13,076<br>2027 US Dollars 2,235,700 2,096,101 Euros 1,216,058<br>Total US Dollars 2,313,889 2,169,407 Euros 1,258,555<br>US Tranche B Tranche B in Euros<br>The borrowers of the total Senior secured debt are Grifols, S.A. and Grifols Worldwide Operations USA, Inc.<br>At 31 December 2021, the Group redeemed in advance an amount of Euros 74,246 thousand from Tranche B in<br>Euros and Euros 124,798 thousand from Tranche B in US Dollars, using part of the amount received from GIC<br>(sovereign wealth fund in Singapore).<br>Revolving credit facility<br>On 7 May 2020, the Group concluded the upsize of the multi-currency revolving credit facility from US Dollars<br>500 million to US Dollars 1,000 million with maturity in 2025 and an applicable margin of 150 basis points (bp)<br>pegged to US Libor. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>74<br>Movement in the Revolving Credit Facility is as follows:<br>31/12/2022 31/12/2021<br>Drawn opening balance 330,000 0<br>Drawdowns 591,537 829,636<br>Repayments (916,958) (525,979)<br>Translation differences (4,579) 26,343<br>Drawn closing balance 0 330,000<br>Thousands of Euros<br>The costs of refinancing the revolving credit facility in 2020 amounted to Euros 9.3 million.<br>Guarantors<br>The Notes, the Senior Term Loans and the Revolving Loans are secured by Grifols, S.A. and certain significant<br>subsidiaries of Grifols, S.A., which together with Grifols, S.A., represent, in the aggregate, at least 60% of the<br>consolidated EBITDA of the Group.<br>The Notes are guaranteed on a senior secured basis by subsidiaries of Grifols, S.A. that are guarantors and co-borrower under the New Credit Facilities. The guarantors are Grifols Worldwide Operations Limited, Grifols<br>Biologicals Inc., Grifols Shared Services North America, Inc., Grifols Therapeutics, Inc., Instituto Grifols, S.A.,<br>Grifols Worldwide Operations USA, Inc., Grifols USA, Llc. and Grifols International, S.A.<br>(c) Other financial liabilities<br>Details of other financial liabilities at 31 December 2022 and 2021 are as follows:<br>Other financial liabilities Reference 31/12/2022 31/12/2021<br>Non-current debt with GIC (sovereign wealth fund in Singapore) (i) 833,664 829,937<br>Non-current preferential loans 4,943 7,029<br>Other non-current financial liabilities (iii) 49,100 1,860<br>Total other non-current financial liabilities 887,707 838,826<br>Current debt with GIC (sovereign wealth fund in Singapore) (i) 86,284 --<br>Current preferential loans 1,633 2,607<br>Outstanding payments of acquisitions (ii) -- 39,075<br>Other current financial liabilities (iii) 25,763 1,552<br>Total other current financial liabilities 113,680 43,234<br>Thousands of Euros<br>(i) Debt with GIC – Singapore sovereign wealth fund<br>In November 2021 approval was received from the pertinent authorities to close the agreement with GIC<br>(Sovereign Fund of Singapore), announced in June 2021, whereby the Group received an amount of US Dollars<br>990 million in exchange for 10 ordinary Class B shares in Biomat USA and nine ordinary Class B shares in a<br>new sub-holding, Biomat Newco, created for this purpose. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>75<br>The main terms and conditions of the agreement with GIC were:<br><br>x The distribution of annual preferential dividends to GIC equivalent to US Dollar 4,168 thousand per share,<br>following majority approval of the Board of Directors of Biomat USA and Biomat Newco;<br>x The redemption right with respect to Class B stock for US Dollars 52,105 thousand per share, is subject to<br>unilateral approval of the Class B stockholders (with one share annually redeemable starting as of 31<br>December 2022). At 31 December 2022 no shares have been redeemed.<br>x From 1 December 2036, holders of Class B shares of Biomat USA will have the right to request Biomat USA<br>to redeem up to the total of the Class B shares they hold at a value of US Dollars 52,105,263.16 per share.<br>Class B shareholders of Biomat Newco will have the same right with respect to Biomat Newco.<br>x In the event that the dividends or the annual redemption at Biomat USA or Biomat NewCo, where applicable,<br>is not approved, is partially paid, or is otherwise not paid, GIC holds the right to obtain in exchange thereof<br>an undetermined number of shares among the following alternatives (i) an additional number of shares in<br>Biomat USA, in lieu of the non-payment occurred at Biomat USA, (ii) an additional number of shares in<br>Biomat NewCo, in lieu of the non-payment occurred at Biomat NewCo; or (iii) a number of ADRs of Grifols,<br>S.A. in lieu of either (i) or (ii).<br><br>x Grifols holds the right to redeem all of the Class B stock from the fifth year onwards;<br><br>x In the event of liquidation of Biomat USA and Biomat Newco, GIC shall have the right to the preferential<br>liquidation of US Dollars 52,105 thousand per share, but shall not have any rights over the liquidation of net<br>assets of these companies.<br>Current debt with GIC includes Euros 37,432 thousand of accrued interests plus Euros 48,852 thousand related<br>to the share redemption right.<br>Grifols did not have the discretional right to avoid payment in cash and therefore, the instrument was recorded<br>as a financial liability at 31 December 2022 and at 31 December 2021.<br><br>The Group does not lose control of Biomat USA and continues overseeing all aspects of the Biomat Group’s<br>administration and operations.<br>(ii) Outstanding payments of acquisitions<br>At 31 December 2021, the balance corresponded to the outstanding amount payable relating to the Gigagen, Inc.<br>acquisition (see note 3).<br>(iii) Other non-current and current financial liabilities<br>At 31 December 2022, “other non-current financial liabilities” include mainly an unsecured long-term loan in<br>the amount of Euros 44.3 million and a repayment obligation arising from a supply contract amounting to Euros<br>5.9 million, both corresponding to Biotest, AG, a company acquired by the Group on 25 April 2022 (see note 3).<br>At 31 December 2022, “other current financial liabilities” include mainly distributor commission liabilities of<br>Euros 15.5 million corresponding to Biotest, AG, a company acquired by the Group on 25 April 2022 (see note<br>3). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>76<br>Details of the maturity of other financial liabilities are as follows:<br>31/12/2022 31/12/2021<br>Maturity at:<br> Up to one year 113,680 43,234<br> Two years 54,506 88,144<br> Three years 50,086 88,947<br> Four years 50,408 89,027<br> Five years 49,483 88,871<br> Over five years 683,224 483,837<br>1,001,387 882,060<br>Thousands of Euros<br>(d) Changes in liabilities derived from financing activities<br>Reference Bonds Senior Secured<br>debt & Other loans<br>Finance lease<br>liabilities<br>Other financial<br>liabilities Total<br>Carrying amount at 1 January 2020 2,677,202 3,687,739 740,690 101,749 7,207,380<br>New financing 116,352 -- -- -- 116,352<br>Refunds (105,564) (66,047) (79,037) (22,681) (273,329)<br>Interest accrued 81,880 124,840 35,084 2,073 243,877<br>Other movements -- (10,468) 88,867 4,837 83,236<br>Interest paid/received (60,355) (95,433) -- -- (155,788)<br>Business combinations Note 3 -- -- -- 34,778 34,778<br>Foreign exchange differences -- (172,246) (52,105) (5,443) (229,794)<br>Balance at 31 December 2020 2,709,515 3,468,385 733,499 115,313 7,026,712<br>New financing 2,126,979 329,555 -- 829,937 3,286,471<br>Refunds (114,480) (266,659) (82,692) (3,507) (467,338)<br>Interest accrued 100,948 130,327 35,786 2,165 269,226<br>Other movements (33,920) 5,445 135,697 729 107,951<br>Interest paid/received (64,031) (91,089) -- -- (155,120)<br>Business combinations Note 3 -- -- -- (64,749) (64,749)<br>Foreign exchange differences 18,523 131,084 51,434 3,047 204,088<br>Balance at December 31, 2021 4,743,534 3,707,048 873,724 882,935 10,207,241<br>New financing 112,557 990,537 -- 16,448 1,119,542<br>Refunds (217,058) (944,386) (104,287) (15,685) (1,281,416)<br>Interest accrued 176,317 206,901 43,640 84,586 511,444<br>Other movements 744 (744) 123,792 -- 123,792<br>Interest paid/received (150,595) (156,461) -- (43,331) (350,387)<br>Business combinations Note 3 (1,804) 121,597 30,290 31,016 181,099<br>Foreign exchange differences 27,965 117,029 49,785 50,154 244,933<br>Balance at 31 December 2022 4,691,660 4,041,521 1,016,944 1,006,123 10,756,248<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>77<br>(21) Trade and Other Payables<br>Details are as follows:<br>31/12/2022 31/12/2021<br>Suppliers 731,918 628,992<br>VAT payable 11,133 13,011<br>Taxation authorities, withholdings payable 7,986 7,267<br>Social security payable 23,627 39,191<br>Other public entities 71,984 92,365<br>Other payables 114,730 151,834<br>Current income tax liabilities 15,687 4,516<br>862,335 785,342<br>Thousands of Euros<br>Suppliers<br>Details of balances with related parties are shown in note 30.<br>The Group’s exposure to currency risk and liquidity risk associated with trade and other payables is described in note<br>29.<br>In accordance with the provision of Law 18/2022 that amends Law 15/2010 of 5 July, for fiscal years 2022 and 2021<br>information concerning the average payment period to suppliers is included.<br>Information concerning the average payment period to suppliers is as follows:<br>31/12/2022 31/12/2021<br>Average payment period to suppliers 69.03 68.35<br>Paid invoices ratio 70.06 69.4<br>Outstanding invoices ratio 62.29 61.96<br>31/12/2022 31/12/2021<br>Total invoices paid 656,465 669,899<br>Total outstanding invoices 100,302 104,804<br>Days<br>Thousands of Euros<br>Information concerning invoices paid in a period of less than the established by the Law is as follows:<br>31/12/2022 31/12/2021<br>Monetary volume paid in euros (thousands of Euros) 250,490 251,127<br>Percentage of total monetary payments to suppliers 38.16% 37.49%<br>Number of paid invoices 23,274 21,724<br>Percentage of the total number of invoices paid to suppliers 25.98% 23.84%<br>Days | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>78<br>(22) Other Current Liabilities<br>Details at 31 December are as follows:<br>At 31 December 2022, and 31 December 2021, the advances received are contract liabilities relate to unperformed<br>performance obligations for which Grifols has received a consideration from the customer.<br>(23) Net Revenues<br>Net revenues are mainly generated from the sale of goods.<br>The distribution of net consolidated revenues for 2022, 2021 and 2020 by segment is as follows:<br>31/12/2022 31/12/2021 (*) 31/12/2020 (*)<br>Biopharma 5,005,382 3,814,983 4,242,502<br>Diagnostic 671,292 779,108 775,889<br>Bio supplies 146,076 115,811 133,221<br>Others 250,165 266,461 222,521<br>Intersegments (8,948) (43,245) (34,095)<br>6,063,967 4,933,118 5,340,038<br>Thousands of Euros<br>* As a consequence of the review of transactions and balances allocations by segments, the comparative figures for the<br>fiscal year 2021 and 2020 have been adjusted accordingly.<br>The geographical distribution of net consolidated revenues is as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>USA and Canada 3,855,607 3,154,549 3,599,746<br>Spain 320,631 362,407 339,169<br>European Union 711,579 544,042 495,323<br>Rest of the world 1,176,150 872,120 905,800<br>Consolidated 6,063,967 4,933,118 5,340,038<br>Thousands of Euros<br>31/12/2022 31/12/2021<br>Salaries payable 199,584 175,710<br>Other payables 4,069 23<br>Deferred income 27,642 32,970<br>Advances received 10,192 10,569<br>Other current liabilities 241,487 219,272<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>79<br>Details of discounts and other reductions in gross income are as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Gross sales 7,720,463 6,234,277 6,806,005<br> Chargebacks (1,402,218) (1,101,896) (1,247,153)<br> Cash discounts (76,547) (60,019) (68,912)<br> Volume rebates (66,280) (49,043) (57,858)<br> Medicare and Medicaid (64,438) (53,440) (61,089)<br> Other discounts (47,013) (36,761) (30,955)<br>Net sales 6,063,967 4,933,118 5,340,038<br>Thousands of Euros<br>Movement in discounts and other reductions in gross income during 2022 is as follows:<br>Chargebacks Cash<br>discounts<br>Volume<br>rebates<br>Medicare /<br>Medicaid<br>Other<br>discounts Total<br>Balance at 31 December 2021 159,846 5,701 21,246 25,614 10,585 222,992<br>Current estimate related to sales made in<br>current and previous periods 1,402,218 76,547 66,280 64,438 47,013 1,656,496 (1)<br>(Actual returns or credits in current period<br>related to sales made in current period) (1,196,670) (69,960) (43,494) (43,332) (28,818) (1,382,274) (2)<br>(Actual returns or credits in current period<br>related to sales made in prior periods) (109,726) (6,442) (21,501) (21,271) (2,935) (161,875) (3)<br>Translation differences 8,845 338 1,034 1,587 138 11,942<br>Balance at 31 December 2022 264,513 6,184 23,565 27,036 25,983 347,281<br>(2) Amounts credited and posted against provisions for current period<br>(3) Amounts credited and posted against provisions for prior period<br>Thousands of Euros<br>(1) Net impact in income statement: estimate for the current year plus prior years' adjustments. Adjustments made during the year<br>corresponding to prior years' estimates have not been significant. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>80<br>Movement in discounts and other reductions to gross income during 2021 was as follows:<br>Chargebacks Cash<br>discounts<br>Volume<br>rebates<br>Medicare /<br>Medicaid<br>Other<br>discounts Total<br>Balance at 31 December 2020 190,869 6,795 29,670 28,451 11,763 267,548<br>Current estimate related to sales made in<br>current and previous periods 1,101,896 60,019 49,043 53,440 36,761 1,301,159 (1)<br>(Actual returns or credits in current period<br>related to sales made in current period) (1,080,304) (54,554) (29,617) (42,890) (27,036) (1,234,401) (2)<br>(Actual returns or credits in current period<br>related to sales made in prior periods) (65,681) (6,964) (29,304) (15,422) (11,057) (128,428) (3)<br>Translation differences 13,066 405 1,454 2,035 154 17,114<br>Balance at 31 December 2021 159,846 5,701 21,246 25,614 10,585 222,992<br>Thousands of Euros<br>Movement in discounts and other reductions to gross income during 2020 was as follows:<br>Chargebacks Cash<br>discounts<br>Volume<br>rebates<br>Medicare /<br>Medicaid<br>Other<br>discounts Total<br>Balance at 31 December 2019 90,488 5,897 28,705 18,911 15,071 159,072<br>Current estimate related to sales made in<br>current and previous periods 1,247,153 68,912 57,858 61,089 30,955 1,465,967 (1)<br>(Actual returns or credits in current period<br>related to sales made in current period) (1,033,053) (61,387) (27,798) (34,564) (30,509) (1,187,311) (2)<br>(Actual returns or credits in current period<br>related to sales made in prior periods) (97,504) (6,030) (26,481) (14,526) (3,615) (148,156) (3)<br>Translation differences (16,215) (597) (2,614) (2,459) (139) (22,024)<br>Balance at 31 December 2020 190,869 6,795 29,670 28,451 11,763 267,548<br>Thousands of Euros<br>(24) Personnel Expenses<br>Details of personnel expenses by function are as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Cost of sales 1,343,991 999,347 1,058,132<br>Research and development 159,766 138,629 110,682<br>Selling, general & administration expenses 472,413 401,390 383,851<br>1,976,170 1,539,366 1,552,665<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>81<br>Details by nature are as follows:<br>Reference 31/12/2022 31/12/2021 31/12/2020<br>Wages and salaries 1,600,617 1,231,812 1,234,761<br>Contributions to pension plans Note 28 40,994 31,757 33,226<br>Other social charges 33,506 27,387 27,462<br>Social Security 301,053 248,410 257,216<br>1,976,170 1,539,366 1,552,665<br>Thousands of Euros<br>The average headcount during 2022 and 2021, by department, was approximately as follows:<br>The headcount of the Group employees and the Company’s directors at 31 December 2021, by gender, was as<br>follows:<br>Man Women<br>Total Number of<br>Employees<br>Directors 8 4 12<br>Manufacturing 6,976 11,759 18,735<br>Research&development - technical area 427 661 1,088<br>Administration and others 954 655 1,609<br>General management 152 161 313<br>Marketing 81 122 203<br>Sales and Distribution 666 619 1,285<br>9,264 13,981 23,245<br>31/12/2021<br>31/12/2022 31/12/2021<br>Manufacturing 19,180 17,006<br>R&D - technical area 1,160 1,083<br>Administration and others 1,730 1,615<br>General management 285 326<br>Marketing 181 201<br>Sales and Distribution 1,376 1,279<br>23,912 21,510<br>Average headcount | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>82<br>The headcount of the Group employees and the Company’s directors at 31 December 2022, by gender, is as follows:<br>(25) Expenses by Nature<br>(a) Amortization and depreciation<br>Expenses for the amortization and depreciation of intangible assets, right of use assets and property, plant and<br>equipment, incurred during 2022, 2021 and 2020 classified by functions are as follows:<br>Thousands of Euros<br>31/12/2022 31/12/2021 31/12/2020<br>Cost of sales 275,512 211,676 198,310<br>Research and development 44,295 55,311 32,814<br>Selling, general & administration expenses 88,057 92,780 90,409<br>407,864 359,767 321,533<br>(b) Other operating income and expenses<br>Other operating income and expenses incurred during 2022, 2021 and 2020 by function are as follows:<br>Thousands of Euros<br>31/12/2022 31/12/2021 31/12/2020<br>Cost of sales 682,636 535,058 500,415<br>Research and development 164,229 165,884 156,994<br>Selling, general & administration expenses 579,067 532,056 499,218<br>1,425,932 1,232,998 1,156,627<br>Man Women Undeclared<br>Total Number<br>of Employees<br>Directors 8 4 -- 12<br>Manufacturing 8,047 13,153 35 21,235<br>Research&development - technical area 528 741 2 1,271<br>Administration and others 1,103 766 1 1,870<br>General management 145 157 -- 302<br>Marketing 53 114 -- 167<br>Sales and Distribution 742 726 1 1,469<br>10,626 15,661 39 26,326<br>31/12/2022 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>83<br>Details by nature are as follows:<br>Thousands of Euros<br>Reference 31/12/2022 31/12/2021 31/12/2020<br>Changes in trade provisions 8,743 4,844 (14,059)<br>Professional services 305,215 258,371 265,539<br>Commissions 40,397 28,671 27,147<br>Supplies and auxiliary materials 251,120 197,893 187,370<br>Operating leases Note 8 38,994 32,945 28,176<br>Freight 190,692 148,797 137,466<br>Repair and maintenance expenses 218,971 150,308 147,039<br>Advertising 90,652 71,280 55,073<br>Insurance 46,090 38,724 30,776<br>Royalties 13,646 48,446 40,634<br>Travel expenses 49,356 30,334 23,005<br>External services 83,296 74,858 71,240<br>R&D Expenses 94,903 106,873 101,410<br>Gains on disposal of assets (22,236) -- --<br>Other 16,093 40,654 55,811<br>Other operating income&expenses 1,425,932 1,232,998 1,156,627<br>(26) Finance Result<br>Details are as follows:<br>Reference 31/12/2022 31/12/2021 31/12/2020<br>Finance income 33,859 11,551 8,021<br>Finance costs from Senior Unsecured Notes (181,149) (104,944) (85,182)<br>Finance costs from senior debt Note 20 (b) (161,466) (111,719) (119,140)<br>Finance costs from other financial liabilities (81,914) -- --<br>Finance costs from sale of receivables Note 14 (18,201) (10,292) (10,964)<br>Capitalized interest Note 9 25,184 18,636 16,606<br>Finance lease expenses Note 8 (45,198) (35,786) (35,205)<br>Other finance costs (33,780) (33,889) (15,754)<br>Finance costs (496,524) (277,994) (249,639)<br>Change in fair value of financial instruments 11,999 246 55,703<br>Exchange differences 7,725 (11,602) 8,246<br>Finance result (442,941) (277,799) (177,669)<br>Thousands of Euros<br>The finance costs from other financial liabilities heading for 2022 includes finance costs related to the interest on<br>the funds received by GIC amounting 81,914 thousand (see note 20 (c)).<br>During 2022 the Group has capitalized interest at a rate of between 4.43% and 5.44% based on the financing received<br>(between 3.71% and 4.15% during 2021). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>84<br> “Change in fair value of financial instruments” at 31 December 2020 includes the difference between the contractual<br>right value recognized at 31 December 2019 and the quoted value of SRAAS at 30 March 2020 for an amount of<br>Euros 56,526 thousand (see note 10).<br>(27) Taxation<br>Grifols, S.A. is authorized to file consolidated tax returns in Spain with Grifols Movaco, S.A., Laboratorios Grifols,<br>S.A., Instituto Grifols, S.A., Biomat, S.A., Grifols Viajes, S.A., Grifols International, S.A., Grifols Engineering, S.A.,<br>Gripdan Invest, S.L., Araclon Biotech, Aigües Minerals de Vilajuiga, S.A. and VCN Biosciences, S.L. Grifols, S.A.,<br>in its capacity as Parent, is responsible for the filing and settlement of the consolidated tax return. Under prevailing<br>tax law, Spanish companies pay 25% tax, which may be reduced by certain deductions.<br>The North American company Grifols Shared Services North America, Inc. is also authorized to file consolidated<br>tax returns in the USA with Grifols Biologicals Inc., Grifols USA, LLC., Biomat USA, Inc., Grifols Therapeutics<br>Inc., Talecris Plasma Resources, Inc, Interstate Blood Bank, Inc. and Goetech, LLC.. The profits of the companies<br>domiciled in the USA, determined in accordance with prevailing tax legislation, are subject to tax of approximately<br>22% of taxable income, which may be reduced by certain deductions.<br>Grifols assesses the effect of uncertain tax treatments and recognizes the effect of the uncertainty on taxable earnings.<br>At 31 of December 2022 and 2021, the potential obligations deriving from tax claims are properly covered. There<br>are no lawsuits or uncertain tax treatments that are individually material.<br>Law 38/2022 has incorporated a temporary measure with effect for tax periods beginning in 2023, limiting the amount<br>of the individual tax losses of each of the entities comprising the tax group for corporate income tax purposes by<br>50%. Under the terms in which this measure has been approved, it will have an impact on the use of tax loss<br>carryforwards by the consolidated tax group Grifols S.A. The group is currently evaluating the impact of this measure<br>and the alternatives that may mitigate this effect, although it is not possible to quantify this impact at this time.<br>The Pilar 2 Law proposes to establish a worldwide minimum taxation of 15% in Corporate Income Tax (IS) for those<br>companies with a turnover of more than 750 M€. The group is currently evaluating the impact of this measure;<br>however it is not expected to have a significant impact on its consolidated financial statements.<br>(a) Reconciliation of accounting and taxable income<br>Details of the income tax expense and income tax related to profit for the year are as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Profit before income tax from continuing<br>operations 361,257 350,453 878,629<br>Tax at 25% 90,313 87,613 219,657<br>Permanent differences (30,796) 2,503 (7,181)<br>Effect of different tax rates 9,953 (8,720) (30,686)<br>Tax credits (deductions) 3,667 (14,998) (14,980)<br>Prior year income tax expense 12,685 18,908 517<br>Other income tax expenses/(income) 4,289 (180) 2,312<br>Total income tax expense 90,111 85,126 169,639<br>Deferred tax (15,138) 17,754 43,138<br>Current tax 105,249 67,372 126,501<br>Total income tax expense 90,111 85,126 169,639<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>85<br>The effect of the different tax rates is basically due to a change of country mix in profits<br>(b) Deferred tax assets and liabilities<br>Details of deferred tax assets and liabilities are as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Assets<br> Provisions 20,511 8,387 3,942<br> Inventories 67,557 47,908 59,129<br> Tax credits (deductions) 33,921 26,425 57,896<br> Tax loss carryforwards 58,159 51,750 53,063<br> Other 6,197 19,993 11,004<br> Subtotal, assets 186,345 154,463 185,034<br> Goodwill (3,063) (2,106) (30,040)<br> Fixed assets, amortisation and depreciation (16) 3,151 (3,011)<br> Intangible assets (1,349) (3,001) (2,062)<br> Other (6,994) -- --<br> Subtotal, net liabilities (11,422) (1,956) (35,113)<br>Deferred assets, net 174,923 152,507 149,921<br>Liabilities<br> Goodwill (337,948) (272,596) (215,907)<br> Intangible assets (669,316) (288,819) (270,145)<br> Fixed assets (92,811) (86,899) (78,325)<br> Debt cancellation costs (50,666) (61,543) (66,720)<br>Subtotal, liabilities (1,150,741) (709,857) (631,097)<br>Tax loss carryforwards 2,993 2,160 12,024<br> Tax credits (deductions) 14,578 -- --<br>Inventories 652 5,532 1,673<br> Provisions 70,206 37,671 36,663<br> Other 27,489 30,510 23,924<br>Subtotal, net assets 115,918 75,873 74,284<br>Net deferred Liabilities (1,034,823) (633,984) (556,813)<br>Tax effect | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>86<br>Movement in deferred tax assets and liabilities is as follows:<br>Deferred tax assets and liabilities 31/12/2022 31/12/2021 31/12/2020<br>Balance at 1 January (481,477) (406,892) (340,803)<br>Movements during the year 15,138 (17,754) (43,138)<br>Business combination (note 3) (361,051) (16,400) (47,988)<br>Translation differences (32,510) (40,431) 25,037<br>Balance at 31 December (859,900) (481,477) (406,892)<br>Thousands of Euros<br>The Spanish companies have opted to apply accelerated depreciation to certain additions to property, plant and<br>equipment, which has resulted in the corresponding deferred tax liability.<br>The remaining assets and liabilities recognized in 2022, 2021 and 2020 were recognized in the statement of profit<br>and loss.<br>Estimated net deferred tax assets to be reversed in a period of less than 12 months amount to Euros 112,274<br>thousand at 31 December 2022 (Euros 57,183 thousand at 31 December 2021).<br>The majority of the tax deductions pending application from Spanish companies related mainly to research and<br>development, mature in 18 years. Likewise, the Group estimates that practically the entire amount will be applied<br>in five years.<br>Tax loss carryforwards pending to be offset derived from the US companies are available for 20 years from their<br>date of origin whilst tax losses carryforwards pending to be offset from Spanish companies registered in the<br>Basque Country are available for 15 years and there is no maturity date for other remaining Spanish companies.<br>The Group estimates that of the total amount of tax credits for tax losses recognized in the balance sheet at 31<br>December 2022 for an amount of Euros 61,152 thousand, approximately Euros 48,453 thousand will be<br>recovered in a period of less than 5 years.<br>The Group has not recognized as deferred tax assets the tax effect of the unused tax loss carryforwards of Group<br>companies, which amount to Euros 121,486 thousand (Euros 123,407 thousand at 31 December 2021). The<br>amount of unrecognized deferred tax liabilities associated with investments in subsidiaries amounted to Euros<br>78,947 thousand as of 31 December 2022 (Euros 52,119 thousand as of 31 December 2021).<br>The commitments from Spanish companies from the reversal of deferred tax related to provisions of investments<br>in subsidiaries are not significant.<br>(c) Years open to inspection<br>Under prevailing legislation, taxes cannot be considered to be definitively settled until the returns filed have been<br>inspected by the taxation authorities, or the prescription period has elapsed.<br>The main tax audits currently open in the Group are as follows:<br>x Certain companies of the Group domiciled in Spain were subject to an inspection by the Spanish State Tax<br>Administration Agency in relation to Corporate Income Tax for the years 2014, 2015 and 2016 and Value<br>Added Tax for the years 2015 and 2016.<br>As a result of said procedure, the State Tax Administration Agency issued assessments containing the results<br>of the inspection, where it is indicated that the treatment of certain transactions and computations mainly<br>related to Transfer Pricing should be adjusted, taking into consideration different interpretations related to<br>the allocation of taxable bases between different jurisdictions. With respect to Corporate Income Tax, the<br>deductibility of certain expenses for the computation of the tax payable has been questioned. These | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>87<br>assessments were signed in conformity by the Group on 8 November 2021. It should be noted that no<br>penalties were imposed on any of the Group companies for any of the taxes subject to verification.<br>The results of the inspection did not have a significant impact on the Group's consolidated annual accounts,<br>and the differences determined by the State Tax Administration Agency were recorded as part of the current<br>tax included under the heading "Current tax liabilities" in the Consolidated Balance Sheet as of 31 December<br>2021.<br>If the result of the procedure is considered to be replicable to years not reviewed and open to inspection, the<br>Group estimated that it was not necessary to record provisions in the consolidated annual accounts mainly<br>because the number of transactions that gave rise to the aforementioned assessments has significantly<br>decreased since the years in which they were inspected.<br>Likewise, having adjusted the allocation of taxable income in accordance with the aforementioned<br>assessments for the purposes of their consideration for the determination of Transfer Pricing, the Group now<br>has a legal right to recover certain amounts from the corresponding Administration, in accordance with the<br>provisions of the European Convention on International Commercial Arbitration with respect to international<br>double taxation. The minimum amount to be recovered, upon which its realization is virtually certain, was<br>recorded as a non-current receivable included in the caption "other payable” as of 31 December 2021.<br>x Grifols Shared Services North America, Inc. and subsidiaries: In 2020 notification of an inspection was<br>received relating to the State Income Tax for the fiscal years 2017 and 2018.<br>x Certain Group companies domiciled in Spain were notified in July 2022 of the inspection by the Spanish<br>State Tax Administration Agency in relation to Corporation Tax for the years 2017 to 2019 and Value Added<br>Tax, personal income tax, non-resident income and capital income for the years 2018 and 2019.<br>Group management does not expect any significant liability to derive from these inspections.<br>Based on its experience of the different tax inspections in the different jurisdictions in which Grifols operates,<br>the Group considers it unlikely that there will be a scenario of discrepancy with the taxation authorities that will<br>require significant adjustments to be made to the tax result or to the asset and/or liability balances relating to<br>corporate income tax.<br>(28) Other Commitments with Third Parties and Other Contingent Liabilities<br>(a) Guarantees<br>The Group has no significant guarantees extended to third parties.<br>(b) Guarantees committed with third parties<br>The Group has no significant guarantees extended to third parties, except for those described in note 20.<br>(c) Obligations with personnel<br>The Group’s annual contribution to defined contribution pension plans of Spanish Group companies for 2022<br>has amounted to Euros 1,033 thousand (Euros 948 thousand for 2021).<br>In successive years this contribution will be defined through labor negotiations.<br>In the event that control is taken of the Company, the Group has agreements with 45 employees/directors<br>whereby they can unilaterally rescind their employment contracts with the Company and are entitled to<br>termination benefits ranging from two to five years’ salary. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>88<br>The Group has contracts with six executives entitling them to termination benefits ranging from one to four years<br>of their salary in different circumstances.<br>Restricted Share Unit Retention Plan<br>For the annual bonus, the Group established a Restricted Share Unit Retention Plan (RSU Plan), for eligible<br>employees. Under this plan, employees can choose to receive up to 50% of their yearly bonus in non-voting<br>Class B ordinary shares (Grifols Class B Shares) or Grifols American Depositary Shares (Grifols ADS), and the<br>Group will match this with an additional 50% of the employee’s choice of RSUs.<br>Grifols Class B Shares and Grifols ADS are valued at grant date.<br>These RSU’s will have a vesting period of 2 years and 1 day and, subsequently, the RSU's will be exchanged for<br>Grifols Class B Shares or Grifols ADS (American Depositary Share representing 1 Class B Share).<br>If an eligible employee leaves the Company or is terminated before the vesting period, he/she will not be entitled<br>to the additional RSU’s.<br>At 31 December 2022, the Group has settled the RSU plan of 2019 for an amount of Euros 9,381 thousand<br>(Euros 7,782 thousand at 31 December 2021 corresponding to the RSU plan of 2018).<br>This commitment is treated as equity instrument and the amount totals Euros 7,304 thousand at 31 December<br>2022 (Euros 9,838 thousand at 31 December 2021).<br>Savings plan and profit-sharing plan<br>The Group has a defined contribution plan (savings plan), which qualifies as a deferred salary arrangement under<br>Section 401 (k) of the Internal Revenue Code (IRC). Once eligible, employees may elect to contribute a portion<br>of their salaries to the savings plan, subject to certain limitations. The Group matches 100% of the first 4% of<br>employee contributions and 50% of the next 2%. Group and employee contributions are fully vested when<br>contributed. The total cost of matching contributions to the savings plan was US Dollars 34.1 million in 2022<br>(US Dollars 31.8 million in 2021).<br>Other plans<br>The Group has a defined benefit pension plan for certain former Talecris Biotherapeutics, GmbH employees in<br>Germany as required by statutory law. The pension cost relating to this plan is not material for the periods<br>presented.<br>(d) Purchase commitments<br>Details of the Group’s raw material purchase commitments at 31 December 2022 are as follows:<br>Thousands of Euros<br>2023 409,984<br>2024 413,283<br>2025 352,805<br>2026 230,625<br>2027 219,034<br>More than 5 years 281,951 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>89<br>(e) Judicial procedures and arbitration<br>Details of legal proceedings in which the Company or Group companies are involved are as follows:<br>x ABBOTT LABORATORIES v. GRIFOLS DIAGNOSTIC SOLUTIONS INC., GRIFOLS WORLDWIDE<br>OPERATIONS LIMITED AND NOVARTIS VACCINES AND DIAGNOSTICS, INC.<br>Served: 8 October 2019<br>US District Court, Northern District of Illinois<br>Patent Infringement, Civil Action No. 1:19-cv-6587<br>Abbott Laboratories (“Abbott”), GDS, GWWO and Novartis Vaccines and Diagnostics, Inc. are in dispute over<br>unpaid royalties payable by Abbott to GDS and Ortho-Clinical Diagnostics (“Ortho”) under an HIV License and<br>Option agreement dated 16 August 2019 (the “HIV License”). On 12 September 2019, GDS and Ortho filed Notice<br>of Arbitration. On 3 October 2019, Abbott terminated the HIV License and filed for Declaratory Relief seeking<br>to invalidate the licensed patent. On March 16, 2020, Grifols and Ortho filed an answer and counterclaim to the<br>litigation, while simultaneously pursuing arbitration for the pre-termination amount owed by Abbott. The<br>arbitration hearing was 15-16 June 2020. Grifols/Ortho were awarded US Dollars 4 Million.<br>NEXT ACTION: Expert Discovery was concluded on 14 October 2022, and the parties filed dispositive motions,<br>including a motion for summary judgement by Abbott and an opposition filed by GDS, the Court has yet to rule<br>on the motion for summary judgement filed by Abbott. GDS and Ortho contend that the patent is valid and they<br>believe that Abbott will be unsuccessful in its Declaratory Relief action and Motion for Summary Judgment in<br>attempting to invalidate the patent.<br>x SIEMENS HEALTHCARE DIAGNOSTICS, INC. v. ORTHO-CLINICAL DIAGNOSTICS, INC.,<br>GRIFOLS DIAGNOSTIC SOLUTIONS INC.<br>Served: 10 November 2020<br>Contract Dispute<br>Siemens initiated dispute resolution against Ortho and GDS under the Supply Agreement alleging overpayments<br>after an audit by Siemens.<br>OUTCOME: Decision by the Panel issued on 27 September 2022. The Panel denied all claims by Siemens<br>except for the cost of an audit, which resulted in a payment to Siemens in the amount of US Dollars 171,000.<br>x RAMIREZ-VIVAR, ALFONSO v. GRIFOLS DIAGNOSTIC SOLUTIONS, INC.<br>Served: 11 March 2021<br>Superior Court, CA County of Alameda<br>Case No.: RG21089519<br>Wage & Hour Class Action<br>Plaintiff claiming violation of CA wage & hour statutes.<br>NEXT STEP: The Hearing on the class certification motion was heard on 28 October 2022. Court recently granted<br>class certification to a very limited portion of the class relating to only two of the ten claims alleged in the class<br>action lawsuit. Defense counsel has reviewed the claims and provided an analysis of exposure and discuss options<br>pertaining to defense and potential mediation. Plaintiff's counsel has requested mediation and GDS is cautiously<br>optimistic that a settlement is possible in the coming weeks/months. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>90<br>CLASS POTENTIAL: Approximately 300 GDS employees in California for payroll/wage & hour violations per<br>pay period for 4 years.<br>x BRIAN VAUGHAN, JASON DARNELL, FEBBIE MINNIEFIELD, and ADRIEL VEGA, individually and<br>on behalf of others similarly situated v. BIOMAT USA, INC., TALECRIS PLASMA RESOURCES, INC.,<br>and INTERSTATE BLOOD BANK, INC.<br>Served: 22 June 2020<br>Circuit Court of Cook County<br>Case No. 2020CH04519<br>Removed to Federal Court 17 July 2020, Northern District of Illinois, Case No. 20-cv-4241<br>Illinois Biometric Information Privacy Act<br>Former donors allege violations of IL Biometric Information Privacy Act in a putative class action. Plaintiffs<br>donated plasma at one of Defendants’ Illinois-based plasma donation centers. They were required to scan at least<br>one fingerprint to donate plasma to track their identity. Plaintiffs allege that Defendants failed to comply with the<br>BIPA’s requirements when they collected their fingerprint data. Specifically, they allege that Defendants violated<br>the BIPA by (i) failing to develop a publicly data-retention policy and guidelines for permanently destroying<br>biometric data, and (b) collecting, using, and storing their donors’ biometric data without obtaining informed<br>written consent. Defendants, for their part, deny Plaintiffs’ allegations, that they have violated the BIPA, they are<br>subject to the BIPA, or that any biometric data of donors were disclosed to any unauthorized third parties.<br>Defendants had many defenses including the federal preemption, arguments to be made to defeat class certification,<br>and most relevant is that Class Members signed a consent form authorizing the use of fingerprinting as biometric<br>authentication of their identity as part of the automated screening process.<br>NEXT ACTION: The Parties have settled this class action in the amount of $16,750,000. At the time of this<br>settlement, discovery was beginning. The Group has properly accrued a total amount of US Dollars 6 million, and<br>the remainder will be funded by the insurer. The Parties agreed to settle this litigation now without any admission<br>or determination of liability or the strength of the Parties’ claims and defenses, in order to avoid further risk and<br>expenses to Plaintiffs and the Defendants. The Parties have signed a settlement agreement and the Plaintiffs have<br>now filed a Motion for Preliminary Approval of Class Action Settlement, and the request for a Final Approval<br>Hearing is pending with the Court. When approved by the Court, the Parties will provide notice to the class and<br>proceed with the settlement procedures.<br>CLASS MEMBERS: The settlement class is 66,822 individuals.<br>x CERUS CORPORATION v. LABORATORIOS GRIFOLS, S.A.<br>Cerus Corporation ("Cerus") and Laboratorios Grifols, S.A. ("Grifols") entered into a Manufacturing and Supply<br>Agreement executed in 2016, pursuant to which Grifols was to manufacture and supply to Cerus processing and<br>filters sets to be used by Cerus in its own product (the "Agreement"). As a result of Grifols' decision to discontinue<br>the manufacturing, sale and support of its blood bag product business worldwide, Grifols was unable to comply<br>with the Agreement.<br>In December 2021, Cerus filed a notice of arbitration in the UK pursuant to the terms of the Agreement alleging<br>wrongful termination of the Agreement by Grifols. Furthermore, in January 2022, Cerus filed injunctive measures<br>with the Courts of Rubí (Barcelona) requiring the suspension of the closure of Grifols' blood bags production<br>facility until the arbitration proceedings is finalized.<br>NEXT ACTION: In September the parties agreed to further suspend both the arbitration and the hearing on the<br>injunctive measures until 28 February 2023. In the meantime, the companies are applying efforts to amicably solve<br>technical vicissitudes in order to continue with their commercial relationship (manufacturing and supply<br>agreement) on satisfactory terms for both parties. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>91<br>x THE STATE CO. FOR MARKETING DRUGS AND MEDICAL APPLIANCES IN IRAQ (KIMADIA) v.<br>LABORATORIOS GRIFOLS, S.A.<br>The State Co. for Marketing Drugs and Medical Appliances in Iraq ("KIMADIA") awarded a tender for the supply<br>of blood bags to Laboratorios Grifols, S.A. ("Grifols"). Grifols, through Hali/Tiba (its agent in Iraq), informed<br>KIMADIA on Grifols' inability to supply the blood bags pursuant to the tender awarded, due to its decision to<br>discontinue the manufacturing, sale and support of its blood bag product business.<br>The tender documents set forth a list of penalties and compensations in case the awardee is unable to supply the<br>products to KIMADIA. Further, Hali/Tiba also claims Grifols a compensation for the services performed in<br>relation to the tender.<br>NEXT ACTION: Grifols has received verbal information that KIMADIA has been able to have sourced alternative<br>product for an agreeable pricing and that discussions among Hali/Tiba and KIMADIA have not continue on the<br>topic of possible sanctions. However, Grifols is still waiting to obtain written confirmation on the latter or<br>assurance that its possible claim has expired.<br>(29) Financial Instruments<br>(a) Classification<br>Below is a breakdown of the financial instruments by nature, category and fair value. The Group does not provide<br>details of the fair value of certain financial instruments as their carrying amount is very similar to their fair value<br>because of its short term. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>92<br>Financial assets at<br>amortised costs<br>Financial assets<br>at FVTPL<br>Financial assets<br>at FV through<br>OCI<br>Hedges Financial liabilities at amortised cost Other financial liabilities Total Level 1 Level 2 Level 3 Total<br>Non-current financial assets -- 7 11,533 -- -- -- 11,540 7 -- 11,533 11,540<br>Derivative instruments -- -- -- 39,659 -- -- 39,659 -- 39,659 -- 39,659<br>Trade receivables -- -- 236,076 -- -- -- 236,076 -- 236,076 -- 236,076<br>Financial assets measured at fair value -- 7 247,609 39,659 -- -- 287,275<br>Non-current financial assets 582,175 -- -- -- -- -- 582,175<br>Other current financial assets 31,034 -- -- -- -- -- 31,034<br>Trade and other receivables 445,793 -- -- -- -- -- 445,793<br>Cash and cash equivalents 547,979 -- -- -- -- -- 547,979<br>Financial assets not measured at fair value 1,606,981 -- -- -- -- -- 1,606,981<br>Derivatives instruments -- (4,736) -- -- -- -- (4,736) -- (4,736) -- (4,736)<br>Financial liabilities measured at fair value -- (4,736) -- -- -- -- (4,736)<br>Senior Unsecured & Secured Notes -- -- -- -- (4,572,720) -- (4,572,720) (4,122,656) -- -- (4,122,656)<br>Promissory Notes -- -- -- -- (118,940) -- (118,940)<br>Senior secured debt -- -- -- -- (3,227,926) -- (3,227,926) -- (3,286,662) -- (3,286,662)<br>Other bank loans -- -- -- -- (813,595) -- (813,595)<br>Lease liabilities -- -- -- -- (1,016,944) -- (1,016,944)<br>Other financial liabilities -- -- -- -- (1,001,387) -- (1,001,387)<br>Other non-current debts -- -- -- -- -- (15) (15)<br>Trade and other payables -- -- -- -- (846,648) -- (846,648)<br>Other current liabilities -- -- -- -- -- (241,487) (241,487)<br>Financial liabilities not measured at fair<br>value -- -- -- -- (11,598,160) (241,502) (11,839,662)<br>1,606,981 (4,729) 247,609 39,659 (11,598,160) (241,502) (9,950,142)<br>Thousands of Euros<br>31/12/2022<br>Carrying amount Fair Value | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>93<br>Financial assets at<br>amortised costs<br>Financial assets<br>at FVTPL<br>Financial assets<br>at FV through<br>OCI<br>Hedges Financial liabilities at amortised cost Other financial liabilities Total Level 1 Level 2 Level 3 Total<br>Non-current financial assets -- 7 2,031 -- -- -- 2,038 7 -- 2,031 2,038<br>Derivative instruments -- -- -- 5,306 -- -- 5,306 -- 5,306 -- 5,306<br>Trade receivables -- -- 216,433 -- -- -- 216,433 -- 216,433 -- 216,433<br>Financial assets measured at fair value -- 7 218,464 5,306 -- -- 223,777<br>Non-current financial assets 358,161 -- -- -- -- -- 358,161<br>Other current financial assets 2,026,469 -- -- -- -- -- 2,026,469<br>Trade and other receivables 270,827 -- -- -- -- -- 270,827<br>Cash and cash equivalents 655,493 -- -- -- -- -- 655,493<br>Financial assets not measured at fair value 3,310,950 -- -- -- -- -- 3,310,950<br>Derivatives instruments -- (875) -- -- -- -- (875) -- (875) -- (875)<br>Financial liabilities measured at fair value -- (875) -- -- -- -- (875)<br>Senior Unsecured & Secured Notes -- -- -- -- (4,626,919) -- (4,626,919) (4,697,328) -- -- (4,697,328)<br>Promissory Notes -- -- -- -- (116,610) -- (116,610)<br>Senior secured debt -- -- -- -- (3,061,078) -- (3,061,078) -- (3,262,901) -- (3,262,901)<br>Other bank loans -- -- -- -- (645,975) -- (645,975)<br>Lease liabilities -- -- -- -- (873,724) -- (873,724)<br>Other financial liabilities -- -- -- -- (882,060) -- (882,060)<br>Other non-current debts -- -- -- -- -- (333) (333)<br>Trade and other payables -- -- -- -- (780,826) -- (780,826)<br>Other current liabilities -- -- -- -- -- (219,272) (219,272)<br>Financial liabilities not measured at fair<br>value -- -- -- -- (10,987,192) (219,605) (11,206,797)<br>3,310,950 (868) 218,464 5,306 (10,987,192) (219,605) (7,672,945)<br>Thousands of Euros<br>31/12/2021<br>Carrying amount Fair Value | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>94<br>(b) Measurement of fair value<br>In order to determine the fair value of financial assets or liabilities, the Group uses the following hierarchy<br>based on the relevance of the variables used:<br>x Level 1: estimations based on quoted prices of the instrument.<br>x Level 2: estimations based on significant observable variables coming directly from the market.<br>x Level 3: estimations based on valuation techniques other than observable variables in the market,<br>mainly discounted cash flows.<br>(c) Financial risk management<br>This item provides information on the Group’s exposure to risk associated with the use of financial<br>instruments, the Group’s objectives and procedures to measure and mitigate this risk, and the Group’s capital<br>management strategy.<br>The Group is exposed to the following risks:<br>x Credit risk<br>x Liquidity risk<br>x Market risk: includes interest rate risk, currency risk and other price risks.<br>The Group’s risk management policies are established to identify and analyze the risks faced by the Group,<br>define appropriate risk limits and controls and to control risks and comply with limits. Risk management<br>policies and procedures are reviewed regularly so that they reflect changes in market conditions and the<br>Group's activities. The Group’s management procedures and rules are designed to create a strict and<br>constructive control environment in which all employees understand their duties and obligations.<br>The Group’s Audit Committee supervises how management controls compliance with the Group’s risk<br>management procedures and policies and reviews whether the risk management policy is suitable considering<br>the risks to which the Group is exposed. This committee is assisted by Internal Audit which acts as supervisor.<br>Internal Audit performs regular and ad hoc reviews of the risk management controls and procedures and<br>reports its findings to the Audit Committee.<br>(i) Credit risk<br>Credit risk is the risk to which the Group is exposed in the event that a customer or counterparty to a financial<br>instrument fails to discharge a contractual obligation, and mainly results from trade receivables and the<br>Group’s investments in financial assets.<br>Trade receivables<br>The Group does not predict any significant insolvency risks as a result of delays in receiving payment from<br>some European countries due to their current economic situation. The main risk in these countries is that of<br>late payments, which is mitigated through the possibility of claiming interest as foreseen by prevailing<br>legislation. No significant bad debt or late payment issues have been detected for sales to private entities.<br>The Group recognizes impairment based on its best estimate of the expected losses on trade and other<br>receivables. The main impairment losses recognized are due to specific losses relating to individually<br>identified risks. At year end, these impairment losses are immaterial.<br>Concentration of credit risk | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>95<br>For trade receivables the Group uses the simplified approach, estimating lifetime expected credit losses, while<br>for all other financial assets the Group uses the general approach for calculating expected credit losses. In<br>both cases, due to the customers' credit rating, as well as the internal classification systems currently in place<br>for new customers and considering that collection periods are mostly under 30 days, there is no significant<br>impact for the Group.<br>Exposure to credit risk<br>The carrying amount of financial assets represents the maximum exposure to credit risk. At 31 December<br>2022 and 2021 the maximum level of exposure to credit risk is as follows:<br>Carrying amount Reference 31/12/2022 31/12/2021<br>Non-current financial assets Nota 11 620,745 362,267<br>Other current financial assets Nota 11 43,663 2,029,707<br>Contractual assets Nota 13 35,154 1,939<br>Trade receivables Nota 14 608,688 432,197<br>Other receivables Nota 14 29,083 17,224<br>Cash and cash equivalents Nota 15 547,979 655,493<br>1,885,312 3,498,827<br>Thousands of Euros<br>The maximum level of exposure to risk associated with receivables and contractual assets at 31 December<br>2022 and 2021, by geographical area, is as follows.<br>Carrying amount 31/12/2022 31/12/2021<br>Spain 53,145 62,108<br>EU countries 69,003 40,897<br>United States of America 139,721 110,624<br>Other European countries 16,030 25,163<br>Other regions 395,026 212,568<br>672,925 451,360<br>Thousands of Euros<br>Impairment losses | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>96<br>A breakdown of the trade and other receivables and contractual assets net of the impairment losses by ageing<br>at 31 December 2022 is as follows:<br>Thousands of Euros<br>ECL Rate Total gross carrying<br>amount Provision<br>Total net third<br>party trade<br>receivables<br>Not matured 0.19% 550,131 (48) 550,083<br>Past due 0-30 days 0.19% 44,779 (425) 44,354<br>Past due 31-60 days 0.62% 16,000 (163) 15,837<br>Past due 61-90 days 2.03% 6,029 (133) 5,896<br>Past due 91-180 days 3.01% 17,407 (295) 17,112<br>Past due 181-365 days 8.52% 10,747 (187) 10,560<br>More than one year 100.00% 9,994 (9,994) --<br>--<br>Customers with objective evidence of impairment 21,046 (21,046) --<br>676,133 (32,291) 643,842<br>A breakdown of the trade and other receivables and contractual assets net of the impairment losses by ageing<br>as of 31 December 2021 is as follows:<br>Thousands of Euros<br>ECL Rate Total gross carrying<br>amount Provision<br>Total net third<br>party trade<br>receivables<br>Not matured 0.19% 364,538 (445) 364,093<br>Past due 0-30 days 0.19% 32,623 (51) 32,572<br>Past due 31-60 days 0.62% 14,144 (79) 14,065<br>Past due 61-90 days 2.03% 6,556 (133) 6,423<br>Past due 91-180 days 3.01% 11,000 (311) 10,689<br>Past due 181-365 days 8.52% 6,543 (249) 6,294<br>More than one year 100.00% 3,911 (3,911) --<br>Customers with objective evidence of impairment 18,830 (18,830) --<br>458,145 (24,009) 434,136<br><br> Unimpaired receivables that are past due mainly relate to public entities.<br><br>Movement in the bad debt provision was as follows:<br>31/12/2022 31/12/2021 31/12/2020<br>Opening balance 24,009 22,985 22,291<br>Net charges for the year 14,074 6,471 2,436<br>Net cancellations for the year (6,949) (6,269) (124)<br>Transfers 53 -- (29)<br>Translation differences 1,104 822 (1,589)<br>Closing balance 32,291 24,009 22,985<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>97<br>(ii) Liquidity risk<br>Liquidity risk is the risk that the Group cannot meet its financial obligations as they fall due. The Group’s<br>approach to managing liquidity is to ensure where possible, that it always has sufficient liquidity to settle its<br>obligations at the maturity date, both in normal conditions and in times of tension, to avoid incurring<br>unacceptable losses or tarnishing the Group’s reputation.<br>The Group manages liquidity risk on a prudent basis, based on availability of cash and sufficient committed<br>unused long-term credit facilities, enabling the Group to implement its business plans and carry out operations<br>using stable and secure sources of financing.<br>At 31 December 2022 the Group has total cash and cash equivalents of Euros 547,979 thousand (Euros 655,493<br>thousand at 31 December 2021). The Group also has approximately Euros 987,340 thousand in unused credit<br>facilities (Euros 621,989 thousand at 31 December 2021), including Euros 937,559 thousand on the revolving<br>credit facility (Euros 534,429 thousand at 31 December 2021).<br>The Group is able to provide sufficient liquidity to fund its current obligations based on cash flows from<br>operations combined with cash balances and availability of unused credit lines, and it is committed to<br>maintaining elevated and adequate levels of liquidity through internally generated cash flows, and a decrease<br>in dividend payments in the medium term. Additionally, currently the Group does not generate significant<br>cash in any country that might have restrictions on the repatriation of funds.<br>As in previous years, the Group continues with its quarterly program for optimization of working capital,<br>which is mainly based on contracts to sell receivables without recourse.<br>The main contractual obligations existing at the end of the fiscal year comprise mainly long-term financial<br>debt obligations with capital repayments and interest payments (see note 20).<br>Details of the contractual maturity dates of financial liabilities including committed interest calculated using<br>interest rate forward curves are as follows:<br>Carrying amount Reference<br>Carrying<br>amount at<br>31/12/22<br>Contractual<br>flows<br>6 months or<br>less<br>6 - 12<br>months 1-2 years 2- 5 years More than<br>5 years<br>Financial liabilities<br>Bank loans Note 20 4,041,522 5,193,051 527,770 148,914 488,105 4,028,262 --<br>Other financial liabilities Note 20 1,001,387 1,685,824 169,278 18,656 124,822 441,933 931,135<br>Bonds and other<br>marketable securities Note 20 4,691,659 5,468,068 190,453 75,951 147,903 5,053,761 --<br>Lease liabilities Note 20 1,016,944 1,016,944 51,088 51,268 57,695 218,384 638,509<br>Payable to suppliers Note 21 731,918 731,918 731,675 243 -- -- --<br>Other current liabilities Note 22 14,261 14,262 11,364 2,898 -- -- --<br>Financial derivatives Note 29 (d) 4,736 4,736 733 -- 12 3,991 --<br>Total 11,502,427 14,114,803 1,682,361 297,930 818,537 9,746,331 1,569,644<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>98<br>Carrying amount Reference<br>Carrying<br>amount at<br>31/12/21<br>Contractual<br>flows<br>6 months or<br>less<br>6 - 12<br>months 1-2 years 2- 5 years More than<br>5 years<br>Financial liabilities<br>Bank loans Note 20 3,707,053 4,309,621 476,397 78,524 102,070 3,641,777 10,853<br>Other financial liabilities Note 20 882,060 1,294,873 41,934 1,300 164,718 448,161 638,760<br>Bonds and other<br>marketable securities Note 20 4,743,529 5,663,320 2,215,138 170,572 48,538 3,145,255 83,817<br>Lease liabilities Note 20 873,724 873,723 24,640 23,927 47,595 184,032 593,529<br>Payable to suppliers Note 21 628,992 628,992 622,091 6,901 -- -- --<br>Other current liabilities Note 22 43,562 43,562 42,387 1,175 -- -- --<br>Financial derivatives Note 29 (d) 875 875 875 -- -- -- --<br>Total 10,879,795 12,814,966 3,423,462 282,399 362,921 7,419,225 1,326,959<br>Thousands of Euros<br>(iii) Currency risk<br>The Group operates internationally and is therefore exposed to currency risk when operating with foreign<br>currencies, especially with regard to the US Dollar. Currency risk is associated with future commercial<br>transactions, recognized assets and liabilities, and net investments in foreign operations.<br>The Group holds significant investments in foreign operations, the net assets of which are exposed to currency<br>risk. The conversion risk affecting net assets of the Group’s foreign operations in US Dollars is mitigated<br>primarily through borrowings in this foreign currency.<br>The Group’s main exposure to currency risk is with regard to the US Dollar, which is used in a significant<br>percentage of transactions in foreign functional currencies.<br>The financing obtained in Euros represents 60% of the total debt of the Group and amounts to Euros 5,563<br>million at 31 December 2022 (69% and Euros 5,962 million at 31 December 2021).<br>As mentioned in note 20, part of the US dollar debt of the Group is covered by a currency swap to hedge the<br>exposure to the associated currency risk.<br>The Group applies the cost of hedging method. This method enables the Group to exclude the currency basis<br>spread from the designated hedging instrument and, subject to certain requirements, changes in their fair value<br>attributable to this component are recognized in other comprehensive income.<br>Details of the Group’s exposure to currency risk is as follows:<br>Euros (*) US Dollars (**)<br>Trade receivables 2,116 58,331<br>Receivables from Group companies 132,645 11,542<br>Loans to Group companies 4,548,142 33<br>Cash and cash equivalents 11,154 1,989<br>Trade payables (17,297) (20,870)<br>Payables to Group companies (77,367) (29,277)<br>Loans from Group companies (4,414,879) --<br>Bank loans (31,875) --<br>Balance sheet exposure 152,639 21,748<br>(*) Balances in Euros in subsidiaries with US Dollars functional currency<br>(**) Balances in US Dollars in subsidiaries with Euros functional currency<br>Thousands of Euros<br>31/12/2022 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>99<br>Euros (*) US Dollars (**)<br>Trade receivables 2,023 14,800<br>Receivables from Group companies 141,285 7,101<br>Loans to Group companies 464,789 21<br>Cash and cash equivalents 25,766 82<br>Trade payables (27,098) (23,349)<br>Payables to Group companies (62,930) (6,480)<br>Loans from Group companies (11,495) (3)<br>Bank loans (372,500) --<br>Balance sheet exposure 159,840 (7,828)<br>(*) Balances in Euros in subsidiaries with US Dollar functional currency<br>(**) Balances in US Dollar in subsidiaries with Euros functional currency<br>Thousands of Euros<br>31/12/2021<br>The most significant exchange rates applied at 2022 and 2021 year ends are as follows:<br>Euros 31/12/2022 31/12/2021<br>US Dollars 1.0666 1.1326<br>Closing exchange rate<br>A sensitivity analysis for foreign exchange fluctuations is as follows:<br>Had the US Dollar strengthened by 10% against the Euro at 31 December 2022, equity would have increased<br>by Euros 892,806 thousand (Euros 812,285 thousand at 31 December 2021) and profit due to foreign exchange<br>differences would have increased by Euros 17,439 thousand (increase of Euros 15,201 thousand at 31<br>December 2021). This analysis assumes that all other variables are held constant, especially that interest rates<br>remain constant.<br>A 10% weakening of the US Dollar against the Euro at 31 December 2022 and 2021 would have had the<br>opposite effect for the amounts shown above, all other variables being held constant.<br>The Group uses hedge accounting to partially hedge the currency risk exposure (See note 29 (d)).<br>(iv) Interest rate risk<br>The Group’s interest rate risks arise from current and non-current borrowings. Borrowings at variable interest<br>rates expose the Group to cash flow interest rate risks. Fixed-rate borrowings expose the Group to fair value<br>interest rate risk.<br>The objective of the management of interest rate risk is to achieve a balance in the structure of the debt, keeping<br>part of the external resources issued at a fixed rate and covering part of the variable rate debt through hedges.<br>A significant part of the financing obtained accrues interest at fixed rates, representing 63% of the total debt<br>of the Group at 31 December 2022 (58% at 31 December 2021). It mainly includes corporate senior notes,<br>European Investment Bank loans, as well as the agreement with GIC (Sovereign Fund of Singapore) (see note<br>20).<br>Variable-rate debt represents 37% of the total debt at 31 December 2022 (42% at 31 December 2021) and<br>includes mainly the senior secured debt (see note 20 (b)). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>100<br>To date, the profile of interest on interest-bearing financial instruments is as follows:<br>31/12/2022 31/12/2021<br>Fixed-interest financial instruments<br> Financial liabilities (5,835,492) (4,878,087)<br>(5,835,492) (4,878,087)<br>Variable-interest financial instruments<br> Financial liabilities (3,486,460) (3,296,025)<br>(3,486,460) (3,296,025)<br>(9,321,952) (8,174,112)<br>Thousands of Euros<br>Had the interest rate been 100 basis points higher at 31 December 2022, the interest expense would have<br>increased by Euros 34,688 thousand (Euros 35,449 thousand at 31 December 2021). As the Group does not<br>have any hedging derivatives in place, the net effect on cash interest payments would have increased by the<br>same amount.<br>(v) Market price risk<br>Price risk affecting raw materials is mitigated by the vertical integration of the hemoderivatives business in a<br>highly concentrated sector.<br>(d) Financial derivatives<br>At 31 December 2022 and 2021 the Group has recognized the following derivatives:<br>Financial derivatives Currency<br>Notional<br>amount at<br>31/12/2022<br>Notional<br>amount at<br>31/12/2021<br>Value at<br>31/12/22<br>Value at<br>31/12/21 Maturity<br>Cross currency interest rate<br>swap<br>US Dollar 500,000,000 500,000,000 35,296 5,306 15/10/2024<br>Cross currency interest rate<br>swap<br>US Dollar 205,000,000 -- 3,216 -- 15/10/2024<br>Foreign exchange rate forward Swiss Franc 5,500,000 -- 71 -- 28/02/2023<br>Foreign exchange rate forward Canadian dollar 4,416,667 -- 165 -- 2023 and 2024<br>Foreign exchange rate forward Pound Sterling 27,100,000 -- 805 -- 2023<br>Foreign exchange rate forward US Dollar 23,720,000 -- 104 -- 2023<br>Embedded derivative Euro 160,000,000 -- 2 -- 2024<br>Total assets (note 11) 39,659 5,306<br>Cross currency interest rate<br>swap<br>US Dollar 205,000,000 -- (3,990) -- 15/10/2024<br>Foreign exchange rate forward Canadian dollar -- 51,000,000 -- (875) 25/07/2022<br>Foreign exchange rate forward US Dollar 60,000,000 -- (594) -- 30/01/2023<br>Foreign exchange rate forward Canadian dollar 8,000,001 -- (145) -- 2024 and 2025<br>Foreign exchange rate forward US Dollar 15,300,000 -- (6) -- 2023<br>Embedded derivative Euro 65,000,000 -- (1) -- 2024<br>Total liabilities (note 20) (4,736) (875)<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>101<br>(i) Hedging derivative financial instruments<br>On 5 October 2021, the Group subscribed three cross currency interest-rate swaps with an aggregate value of US<br>Dollars 500 million to hedge part of the Euro equivalent value of the US Dollar unsecured notes issued in October<br>2021. It is a fixed-to-fixed USD/EUR cross currency swap with the following characteristics:<br>- The Group receives a loan of Euros 431.6 million at a nominal interest rate of 3.78%.<br>- The Group grants a US Dollars 500 million loan at a nominal interest rate of 4.75%.<br>On 28 June 2022, the Group subscribed one cross currency interest-rate swap of US Dollars 205 million to hedge<br>the remaining part of the Euro equivalent value of the US Dollar unsecured notes issued in October 2021. It is a<br>fixed-to-fixed USD/EUR cross currency swap with the following characteristics:<br>- The Group receives a Euros 194 million loan at a nominal interest rate of 3.1046%.<br>- The Group grants a US Dollars 205 million loan at a nominal interest rate of 4.75%.<br>The derivative complies with the criteria required for hedge accounting. See further details in notes 4 (i).<br>The movement in derivative financial instruments is as follows:<br>31/12/2022 31/12/2021<br>Initial balance 4,431 --<br>Business combination (1,255) --<br>Changes in fair value recognized in equity (4,757) 3,130<br>Transfer to profit or loss 12,552 1,895<br>Transfer to profit or loss - translation differences 32,954 3<br>Tax effect 6,170 --<br>Collections / Payments (15,172) (597)<br>Ending balance 34,923 4,431<br>Thousands of Euros<br>(ii) Derivative financial instruments at fair value through profit and loss<br>The Group has subscribed various foreign exchange forwards to partially hedge the foreign currency value of<br>intercompany loan. Since the Group chooses not to apply hedge accounting criteria, gains or losses resulting<br>from changes in the fair value of derivatives are taken directly to “Change in fair value of financial<br>instruments” in the consolidated statement of profit and loss. At 31 December 2022, the Group has recognized<br>a net finance cost of Euros 2,407 thousand (Euros 280 thousand of net finance cost at 31 December 2021).<br>(e) Capital management<br>The directors’ policy is to maintain a solid capital base in order to ensure investor, creditor and market<br>confidence and sustain future business development. The board of directors defines and proposes the level of<br>dividends paid to shareholders.<br>The capital structure is periodically reviewed through the preparation of strategic plans focused mainly on a<br>sequential improvement of EBITDA (Earnings before interests, tax, amortization and depreciation), | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>102<br>generation of operating cash and discipline in the allocation of capital; with the objective and commitment to<br>reduce the leverage ratio.<br>In accordance with the senior secured debt contract, the Group is subject to compliance with some covenants.<br>At 31 December 2022 and 2021, the Group complies with the covenants in the contract.<br>The credit rating of the Group is as follows:<br>September 2022 December 2021 September 2021<br>Moody's Investors Corporate rating B1 B1<br>Senior secured debt Ba3 Ba3<br>Senior Unsecured debt B3 B3<br>Perspective Negative Negative<br>Standard & Poor's Corporate rating B+ BB-Senior secured debt BB- BB<br>Senior Unsecured debt B- B<br>Perspective Stable Negative<br>Fitch Ratings Corporate rating BB- BB-Senior secured debt BB+ BB+<br>Senior Unsecured debt B+ B+<br>Perspective Stable Stable<br>The Parent held Class B treasury stock equivalent to 1.33% of its capital at 31 December 2022 (1.31% at 31<br>December 2021).<br>(30) Balances and Transactions with Related Parties<br>Details of balances with related parties are as follows:<br>Carrying amount Reference 31/12/2022 31/12/2021<br>Receivables from associates and joint ventures 14 162,382 131,764<br>Current contract assets from associates and joint ventures 3,880 --<br>Trade payables associates and joint ventures (91) (3)<br>Loans to other related parties 96,537 89,104<br>Other financial assets with other related parties 11 318,890 220,947<br>Debts with key management personnel (5,534) (6,644)<br>Payables to other related parties (4,810) (3,824)<br>571,254 431,344<br>Thousands of Euros<br>Payables are included in trade and other payables (see note 21). | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>103<br> “Other financial assets with other related parties" mainly includes a loan with a related party with maturity 2024 and<br>an interest rate of 3.75% (see note 11).<br>(a) Group transactions with related parties<br>Group transactions with related parties during 2022 are as follows:<br>Associates & joint<br>ventures<br>Key management<br>personnel Other related parties Board of directors of<br>the Company<br>Net sales 339,170 -- -- --<br>Purchases (9) -- -- --<br>Other service expenses (34) -- (4,343) --<br>Remuneration -- (13,891) -- (5,316)<br>Payments for rights of use -- -- (6,300) --<br>Purchase of property, plant<br>and equipment -- -- 3,464 --<br>Dividends paid/received 10,717 -- -- --<br>349,844 (13,891) (7,179) (5,316)<br>Thousands of Euros<br>Group transactions with related parties during 2021 were as follows:<br>Associates & joint<br>ventures<br>Key management<br>personnel Other related parties Board of directors of<br>the Company<br>Net sales 220,808 -- -- --<br>Purchases (613) -- -- --<br>Other service expenses (2,709) -- (3,963) --<br>Remuneration -- (15,136) -- (4,417)<br>Payments for rights of use -- -- (5,332) --<br>Purchase of property, plant<br>and equipment -- -- 7,326 --<br>Finance income 2 -- -- --<br>Dividends paid/received 2,636 -- -- --<br>220,124 (15,136) (1,969) (4,417)<br>Thousands of Euros | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>104<br>Group transactions with related parties during 2020 were as follows:<br>Associates & joint<br>ventures<br>Key management<br>personnel Other related parties Board of directors of<br>the Company<br>Net sales 10,522 -- -- --<br>Purchases (459) -- -- --<br>Other service expenses (15,010) -- (10,344) --<br>Remuneration -- (17,164) -- (4,966)<br>Payments for rights of use -- -- (5,137) --<br>Purchase of property, plant<br>and equipment -- -- (13,500) --<br>Finance income 783 -- -- --<br>Dividends paid/received 10,156 -- -- --<br>5,992 (17,164) (28,981) (4,966)<br>Thousands of Euros<br>Every year the Group contributes 0.7% of its profits before tax to a non-profit organization.<br> “Other service expenses” include contributions to non-profit organizations totaling Euros 3,833 thousand in 2022<br>(Euros 3,963 thousand in 2021 and Euros 10,344 thousand in 2020).<br>On 28 December 2018, the Group sold BPC Plasma, Inc and Haema, AG to Scranton Enterprises B.V<br>(shareholder of Grifols) for US Dollars 538,014 thousand (see note 3). For the payment of the mentioned amount<br>of the sale, Scranton signed a loan contract dated 28 December 2018 for an amount of US Dollars 95,000<br>thousand (Euros 82,969 thousand) with Grifols Worldwide Operations Limited. The compensation is<br>2%+EURIBOR and due on 28 December 2025.<br>Directors representing shareholders´ interests have received remuneration of Euros 965 thousand in 2022 (Euros<br>965 thousand in 2021).<br>The Group has not extended any advances or loans to the members of the board of directors or key management<br>personnel nor has it assumed any guarantee commitments on their behalf. It has also not assumed any pension<br>or life insurance obligations on behalf of former or current members of the board of directors or key management<br>personnel. In addition, certain Company directors and key management personnel have termination benefit<br>commitments (see note 28).<br>(b) Conflicts of interest concerning the directors<br>The Company’s directors and their related parties have not entered into any conflict of interest that should have<br>been reported in accordance with article 229 of the revised Spanish Companies Act.<br>(31) Environmental Information and Climate Change<br>The Group carries out operations whose main purpose is to prevent, reduce or minimize the potential impact of<br>its activities on the environment.<br>Grifols' environmental management is based on the concept of circular economy. Priority is given to the efficient<br>use of material resources, water and energy, and waste generation is reduced, taking into account the different<br>stages of the life cycle of products and services. This strategy integrates the transition towards a low-carbon<br>economy which minimizes the impact on climate change. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>105<br>Grifols has a climate risk map through which it has analyzed the resilience of its strategy based on a climate<br>scenario of a potential maximum rise of 2ºC, following the recommendations of the TCFD. The result of this<br>analysis has enabled Grifols to assess the financial impact of the most significant risks:<br>x Reduction in the availability of water resources: Grifols has facilities in areas where, under the simulated<br>scenario, there could be a reduction in the availability of water resources, causing supply problems with<br>impacts that include an increase in the price of water and production restrictions at industrial facilities. This<br>risk can translate into increased costs associated with obtaining own water resources (well water), cleaning<br>and proper maintenance or use of water-dependent infrastructures and industrial processes.<br>The possible financial impact has taken into account the possibility of production stoppage and the increase<br>in the price per m3 of water in areas with a negative price elasticity of demand. The financial impact is<br>estimated to result in an non-relevant increase in expenditure.<br>The results of the exposure analysis indicate that the plants that may be most exposed to this risk are those<br>located in Barcelona and Los Angeles (USA). For each, Grifols' management of the risk varies. In Los<br>Angeles, Grifols would have the capacity to transfer production to other plants in the group, while in<br>Barcelona, the company has several connections to the mains water supply and also has well water<br>extraction. Moreover, as in Los Angeles, a possible temporary stoppage of production (5 to 20 days) could<br>be made up for by transferring production to other plants. The costs of transporting the plasma and other<br>intermediate pastes, 50% to the Clayton plant and 50% to the Barcelona plant, would not be relevant.<br>x New legal requirements regarding the reduction of GHG emissions: Grifols is committed to achieving<br>carbon neutrality by 2050. Until then, new requirements could be established to reduce GHG emissions that<br>would require greater investments for the reduction of direct emissions (Scope 1 and 2) through the<br>installation of renewable generation technologies or changes in electricity supplies for electricity from<br>renewable sources, among others.<br>In the event of not being able to make such investments, Grifols expects to invest further in carbon credits<br>to offset its carbon footprint. The projected potential financial impact to 2040 from carbon footprint<br>reduction under current targets, would have to be assumed by the Group.<br>The 2020-2022 Environmental Program includes the reduction of emissions through the use of 68 million<br>kWh of renewable electricity through PPAs (Power Purchasing Agreements), the construction of two new<br>photovoltaic plants (Barcelona and Murcia) and the construction of new refrigeration plants with refrigerant<br>gases with a global warming potential equal to '0'. By 2022, more than 81% of the actions of this program<br>related to climate change have already been carried out.<br>Grifols will update this program starting in 2023 to include more ambitious reduction targets. Some of these<br>new targets will be science-based, in accordance with the Science-based Target Initiative methodology.<br>Exposure to this risk is expected to decrease as Grifols meets the established targets.<br>Failing that, the answer would be to invest in carbon credits to offset the carbon footprint.<br>x Variation in the availability of plasma resources: According to the sixth IPCC report, anthropogenic<br>climate change would contribute to extreme precipitation, which could become more frequent in most<br>regions due to global warming.<br>The regions most vulnerable to these types of events which could have an impact on Grifols are the states<br>of Texas and North Carolina, USA. The potential impact of restrictions on access to factories - with a<br>temporary shutdown of production - and laboratories could be offset by transferring plasma to other<br>facilities. However, plasma donation centres could suffer alterations in the plasma collection processes, as<br>a consequence of the difficulties that donors could have in accessing them.<br>The financial impact of reduced plasma collection in the donation centres most exposed to extreme weather<br>events is estimatednot to be relevant. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>106<br>The results of the exposure analysis indicate that plasma centres may be the most exposed to this risk.<br>However, the fact that they are widely spread over several regions allows dilution of any potential impact.<br>The analysis was conducted taking into account the centres most exposed to an increase in the severity of<br>weather events such as hurricanes and tropical storms. In the worst-case scenario of centre closures,<br>production would not be substantially affected, so the impact would be limited to the temporary<br>unavailability of plasma in the directly affected centres, resulting in reduced availability of plasma drugs.<br>x Transition to low-emission technologies: In the geographical areas in which Grifols operates, meeting the<br>2030 decarbonization targets is based on the principles of technological neutrality and cost-efficiency,<br>requiring high investments in innovation and infrastructure. Of particular note are the major investments<br>associated with the installation of air conditioning, boiler and renewable energy generation technologies<br>aimed at reducing Grifols' emissions and increasing energy efficiency. The technologies present in the<br>production plants which contribute most to the carbon footprint are boilers, which use fossil fuels in their<br>operation, and their potential impact is their replacement with low-emission options.<br>With the aim of replacing the most polluting technologies, Grifols regularly analyses the technological<br>options available on the market, with a special focus on technologies that increase its climate resilience.<br>Currently, there is no consensus on a single technology that can generate the heat needed on an industrial<br>scale without using fossil fuels. Grifols is aware that renewable hydrogen could be a valuable energy vector<br>for end uses, being an alternative for obtaining good yields at a reasonable cost. At present, the use of<br>renewable hydrogen is in its infancy, although Grifols is monitoring its development in order to study its<br>viability in the near future.<br>In the simulated scenario, Grifols recognizes that in order to manage this risk in its entirety, the replacement<br>of boilers must be carried out progressively and will depend on the progress and availability of these<br>technologies on the market. It also takes into account heat generation processes using electrical technologies<br>such as thermocompression.<br>The investment in environmental assets during the year ended 31 December 2022 is Euros 8,372 thousand (Euros<br>7,363 thousand in the year ended 31 December 2021 and Euros 2,751 thousand in the year ended 31 December<br>2020), mainly intended to optimize water consumption, improvements in wastewater treatment, eco-efficiency<br>projects in the use of energy and the replacement of refrigerant gases with others with a lower environmental<br>impact.<br>The expenses incurred by the Group for the protection and improvement of the environment in 2022 amounted<br>to approximately Euros 25,787 thousand (Euros 20,642 thousand in 2021 and Euros 20,495 thousand in 2020).<br>With the procedures currently in place, the Group considers that environmental risks are adequately controlled.<br>The Group's strategy is aligned with the objectives of the Paris Agreement, and has been considered in the<br>evaluation of the useful lives of assets and in the impairment analysis of non-financial assets. The Group does<br>not anticipate impairment of assets before the established amortization periods.<br>The Group has not received any environmental subsidies during fiscal years 2022, 2021 and 2020. | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>Notes to the Consolidated Annual Accounts<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>107<br>(32) Other Information<br>Audit fees:<br>KPMG Auditores, S.L. has invoiced the following fees for professional services during 2022 and 2021:<br>31/12/2022 31/12/2021<br>Audit services 1,778 1,717<br>Other assurance services 560 1,025<br>2,338 2,742<br>Thousands of Euros<br><br>Amounts included in table above, include the total amount of fees related to services incurred during 2022 and<br>2021 without considering the invoice date.<br>Other assurance services in 2022 include limited reviews of the interim financial statements, the audit of the<br>consolidated financial statements under PCAOB, as well as conducting audits under AICPA. Additionally, it<br>included comfort letters in relation to debt issuances, provided by KPMG Auditores, S.L. to Grifols, S.A. and<br>subsidiaries in 2021.<br>Other entities affiliated to KPMG International have invoiced the Group for the following fees for professional<br>services during 2022 and 2021:<br>31/12/2022 31/12/2021<br>Audit services 4,115 2,734<br>Other assurance services 1,013 1,033<br>Tax advisory services 3 9<br>Other services 206 107<br>5,337 3,883<br>Thousands of Euros<br>Other audit firms have invoiced the Group for the following fees for professional services during 2022 and 2021:<br>31/12/2022 31/12/2021<br>Audit services 84 88<br>84 88<br>Thousands of Euros<br>(33) Subsequent events<br>On 15 February 2023, the Group announced a comprehensive operational improvement plan with significant<br>cost savings. The plan includes the optimization of plasma costs and operations, streamlining corporate functions,<br>and enhancing other efficiencies across the organization. It also includes a workforce optimization to be<br>implemented in 2023 that will affect approximately 8% of the company’s employees, primarily in the U.S.<br>plasma operations. The Group estimates one-time restructuring charge of approximately Euros 140 million to be<br>accrued in the first quarter of 2023. | ||
| --- | ||
| Acquisition /<br>Registered Incorporation<br>Name Office date Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect<br>Diagnostic Grifols, S.A. 1987 Industrial Development and manufacture of diagnostic equipment, instruments and reagents. --- 100.000% --- 100.000% --- 100.000%<br>Instituto Grifols, S.A.<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>1987 Industrial Plasma fractioning and the manufacture of haemoderivative pharmaceutical products. 99.998% 0.002% 99.998% 0.002% 99.998% 0.002%<br>Laboratorios Grifols, S.A.<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>1989 Industrial Production of glass- and plastic-packaged parenteral solutions, parenteral and enteral nutrition products<br>and blood extraction equipment and bags.<br>100.000% --- 98.600% 1.400% 98.600% 1.400%<br>Biomat, S.A.<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>1991 Industrial Analysis and certification of the quality of plasma used by Instituto Grifols, S.A. It also provides transfusion centres with plasma virus inactivation services (I.P.T.H). 99.900% 0.100% 99.900% 0.100% 99.900% 0.100%<br>Grifols Engineering, S.A.<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>2000 Industrial<br>Design and development of the Group’s manufacturing installations and part of the equipment and<br>machinery used at these premises. The company also renders engineering services to external<br>companies.<br>99.950% 0.050% 99.950% 0.050% 99.950% 0.050%<br>Biomat USA, Inc.<br>2410 Lillyvale Avenue<br>Los Angeles (California)<br>United States<br>2002 Industrial Procuring human plasma. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Biologicals, LLC.<br>5555 Valley Boulevard<br>Los Angeles (California)<br>United States<br>2003 Industrial Plasma fractioning and the production of haemoderivatives. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Australia Pty Ltd.<br>Unit 5/80 Fairbank<br>Clayton South<br>Victoria 3149<br>Australia<br>2009 Industrial Distribution of pharmaceutical products and the development and manufacture of reagents for<br>diagnostics.<br>100.000% --- 100.000% --- 100.000% ---<br>Medion Grifols Diagnostic AG<br>Bonnstrasse,9<br>3186 Dügingen<br>Switzerland<br>2009 Industrial Development and manufacturing activities in the area of biotechnology and diagnostics. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Therapeutics, LLC.<br>4101 Research Commons<br>(Principal Address),<br>79 T.W. Alexander Drive,<br>Research Triangle Park,<br>North Carolina 277709,<br>United States<br>2011 Industrial Plasma fractioning and the production of haemoderivatives. --- 100.000% --- 100.000% --- 100.000%<br>Talecris Plasma Resources, Inc. (merged with Biomat USA,<br>Inc.)<br>4101 Research Commons<br>(Principal Address),<br>79 T.W. Alexander Drive,<br>Research Triangle Park,<br>North Carolina 277709,<br>United States<br>2011 Industrial Procurement of human plasma. --- --- --- 100.000% --- 100.000%<br>Grifols Worldwide Operations Limited<br>Grange Castle Business Park,<br>Grange Castle , Clondalkin,<br>Dublin 22,<br>Ireland<br>2012 Industrial Packaging, labelling, storage, distribution, manufacture and development of pharmaceutical products<br>and rendering of financial services to Group companies.<br>100.000% --- 100.000% --- 100.000% ---<br>Progenika Biopharma, S.A.<br>Parque Tecnológico de Vizcaya,<br>Edificio 504<br>48160 Derio (Vizcaya)<br>Spain<br>2013 Industrial Development, production and commercialisation of biotechnological solutions. 91.875% 8.125% 91.880% 8.120% 91.880% 8.120%<br>Grifols Diagnostics Solutions, Inc.<br>4560 Horton Street<br>94608 Emeryville, California<br>United States<br>2013 Industrial Manufacture and sale of blood testing products --- 55.000% --- 55.000% --- 55.000%<br>Grifols Worldwide Operations USA Inc.<br>13111 Temple Avenue, City of<br>Industry, California 91746-1510<br>Estados Unidos<br>2014 Industrial Manufacture, warehousing, and logistical support for biological products. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Asia Pacific Pte, Ltd<br>501 Orchard Road nº20-01<br>238880 Wheelock Place,<br>Singapore<br>2003 Commercial Distribution and sale of medical and pharmaceutical products. 100.000% --- 100.000% --- 100.000% ---<br>Grifols Movaco, S.A.<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>1987 Commercial Distribution and sale of reagents, chemical products and other pharmaceutical specialities, and of<br>medical and surgical materials, equipment and instruments for use by laboratories and health centres.<br>99.999% 0.001% 99.999% 0.001% 99.999% 0.001%<br>Grifols Portugal Productos Farmacéuticos e Hospitalares,<br>Lda.<br>Rua de Sao Sebastiao,2<br>Zona Industrial Cabra Figa<br>2635-448 Rio de Mouro<br>Portugal<br>1988 Commercial Import, export and commercialisation of pharmaceutical and hospital equipment and products,<br>particularly Grifols products.<br>0.010% 99.990% 0.010% 99.990% 0.010% 99.990%<br>Grifols Chile, S.A.<br>Avda. Americo Vespucio, 2242<br>Comuna de Conchali<br>Santiago de Chile<br>Chile<br>1990 Commercial Development of pharmaceutical businesses, which can involve the import, production,<br>commercialisation and export of related products.<br>99.000% --- 99.000% --- 99.000% ---<br>Grifols USA, LLC.<br>2410 Lillyvale Avenue<br>Los Angeles (California)<br>United States<br>1990 Commercial Distribution and marketing of company products. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Argentina, S.A.<br>Bartolomé Mitre 3690/3790,<br>CPB1605BUT Munro<br>Partido de Vicente Lopez<br>Argentina<br>1991 Commercial Clinical and biological research. Preparation of reagents and therapeutic and diet products.<br>Manufacture and commercialisation of other pharmaceutical specialities.<br>95.010% 4.990% 95.010% 4.990% 95.010% 4.990%<br>Grifols s.r.o.<br>Calle Zitna,2<br>Prague<br>Czech Republic<br>1992 Commercial Purchase, sale and distribution of chemical-pharmaceutical products, including human plasma. 100.000% --- 100.000% --- 100.000% ---<br>Grifols (Thailand) Ltd<br>191 Silom Complex Building,<br>21st Follor, Silom Road, Silom,<br>Bangrak<br>10500 Bangkok<br>Thailand<br>2003 Commercial Import, export and distribution of pharmaceutical products. --- 48.000% --- 48.000% --- 48.000%<br>APPENDIX I<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Information on Group Companies, Associates and others for the years ended 31 December 2022, 2021 and 2020<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>Fully Consolidated Companies<br>31/12/2020<br>% shares<br>31/12/2021<br>% shares<br>31/12/2022<br>% shares<br>This appendix forms an integral part of note 2 to the consolidated annual accounts. | ||
| --- | ||
| Acquisition /<br>Registered Incorporation<br>Name Office date Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect<br>APPENDIX I<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Information on Group Companies, Associates and others for the years ended 31 December 2022, 2021 and 2020<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Fully Consolidated Companies<br>31/12/2020<br>% shares<br>31/12/2021<br>% shares<br>31/12/2022<br>% shares<br>Grifols Malaysia Sdn Bhd<br>Level 18, The Gardens North<br>Tower, Mid Valley City,<br>Lingkaran Syed Putra<br>59200 Kuala Lumpur<br>Malaysia<br>2003 Commercial Distribution and sale of pharmaceutical products. --- 49.000% --- 49.000% --- 30.000%<br>Grifols International, S.A.<br>Polígono Levante<br>Calle Can Guasch, s/n<br>08150 Parets del Vallès<br>(Barcelona) Spain<br>1997 Commercial Coordination of the marketing, sales and logistics for all the Group’s subsidiaries operating in other<br>countries.<br>99.998% 0.002% 99.998% 0.002% 99.998% 0.002%<br>Grifols Italia S.p.A<br>Via Carducci, 62d<br>56010 Ghezzano<br>Pisa, Italy<br>1997 Commercial Purchase, sale and distribution of chemical-pharmaceutical products. 100.000% --- 100.000% --- 100.000% ---<br>Grifols UK Ltd.<br>Gregory Rowcliffe & Milners, 1<br>Bedford Row, London WC1R<br>4BZ<br>United Kingdom<br>1997 Commercial Distribution and sale of therapeutic and other pharmaceutical products, especially haemoderivatives. 100.000% --- 100.000% --- 100.000% ---<br>Grifols Brasil, Lda.<br>Rua Umuarama, 263<br>Condominio Portal da Serra<br>Vila Perneta<br>CEP 83.325-000 Pinhais<br>Paraná, Brazil<br>1998 Commercial Import and export, preparation, distribution and sale of pharmaceutical and chemical products for<br>laboratory and hospital use, and medical-surgical equipment and instruments.<br>100.000% --- 100.000% --- 100.000% ---<br>Grifols France, S.A.R.L.<br>Arteparc, Rue de la Belle du<br>Canet, Bât. D, Route de la Côte<br>d'Azur, 13590 Meyreuil<br>France<br>1999 Commercial Commercialisation of chemical and healthcare products. 99.990% 0.010% 99.990% 0.010% 99.990% 0.010%<br>Grifols Polska Sp.z.o.o. Grzybowska 87 street00-844 Warsaw, Poland 2003 Commercial Distribution and sale of pharmaceutical, cosmetic and other products. 100.000% --- 100.000% --- 100.000% ---<br>Logística Grifols, S.A. de C.V. (merged with Grifols México,<br>S.A. de C.V.)<br>Calle Eugenio Cuzin, nº 909-913<br>Parque Industrial Belenes Norte<br>45150 Zapopán<br>Jalisco, Mexico<br>2008 Commercial Manufacture and commercialisation of pharmaceutical products for human and veterinary use. --- --- 99.990% 0.010% 99.990% 0.010%<br>Grifols México, S.A. de C.V.<br>Calle Eugenio Cuzin, nº 909-913<br>Parque Industrial Belenes Norte<br>45150 Zapopán<br>Jalisco, Mexico<br>1993 Commercial<br>Production, manufacture, adaptation, conditioning, sale and purchase, commissioning, representation<br>and consignment of all kinds of pharmaceutical products and the acquisition of machinery, equipment,<br>raw materials, tools, movable goods and property for the aforementioned purposes.<br>100.000% --- 99.980% 0.020% 99.980% 0.020%<br>Grifols Nordic, AB<br>Sveavägen 166<br>11346 Stockholm<br>Sweden<br>2010 Commercial Research and development, production and marketing of pharmaceutical products, medical devices and<br>any other asset deriving from the aforementioned activities.<br>100.000% --- 100.000% --- 100.000% ---<br>Grifols Colombia, Ltda<br>Carrera 7 No. 71 52 Torre B piso<br>9<br>Bogotá. D.C.<br>Colombia<br>2010 Commercial<br>Sale, commercialisation and distribution of medicines, pharmaceutical (including but not limited to<br>haemoderivatives) and hospital products, medical devices, biomedical equipment, laboratory<br>instruments and reagents for diagnosis and/or healthcare software.<br>99.990% 0.010% 99.990% 0.010% 99.990% 0.010%<br>Grifols Deutschland GmbH<br>Lyoner Strasse 15, D-60528 Frankfurt am Main<br>Germany<br>2011 Commercial<br>Procurement of the official permits and necessary approval for the production, commercialisation and<br>distribution of products deriving from blood plasma, as well as the import, export, distribution and sale<br>of reagents and chemical and pharmaceutical products, especially for laboratories and health centres<br>and surgical and medical equipment and instruments.<br>100.000% --- 100.000% --- 100.000% ---<br>Grifols Canada, Ltd.<br>5060 Spectrum Way, Suite 405<br>(Principal Address)<br>Mississauga,<br>Ontario L4W 5N5<br>Canada<br>2011 Commercial Distribution and sale of biotechnological products. 100.000% --- --- 100.000% --- 100.000%<br>Grifols Pharmaceutical Technology (Shanghai) Co., Ltd.<br>Unit 901-902, Tower 2, No.<br>1539, West Nanjing Rd.,<br>Jing’an District, Shanghai<br>200040<br>China<br>2013 Commercial Pharmaceutical consultancy services (except for diagnosis), technical and logistical consultancy<br>services, business management and marketing consultancy services.<br>100.000% --- 100.000% --- 100.000% ---<br>Grifols Switzerland AG<br>Steinengraben, 5<br>40003 Basel<br>Switzerland<br>2013 Commercial Research, development, import and export and commercialisation of pharmaceutical products, devices<br>and diagnostic instruments.<br>--- --- --- --- 100.000% ---<br>Grifols (H.K.), Limited<br>Units 1505-7 BerKshire House,<br>25 Westlands Road<br>Hong Kong<br>2014 Commercial Distribution and sale of diagnostic products. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Japan K.K.<br>Hilton Plaza West Office Tower,<br>19th floor. 2-2, Umeda 2-chome,<br>Kita-ku Osaka-shi<br>Japan<br>2014 Commercial Research, development, import and export and commercialisation of pharmaceutical products, devices<br>and diagnostic instruments.<br>100.000% --- 100.000% --- 100.000% ---<br>Grifols India Healthcare Private Ltd<br>Regus Business Centre<br>Pvt.Ltd.,Level15,Dev Corpora,<br>Plot No.463,Nr. Khajana<br>East.Exp.Highway,Thane (W),<br>Mumbai - 400604,<br>Maharashtra<br>India<br>2014 Commercial Distribution and sale of pharmaceutical products. 99.984% 0.016% 99.984% 0.016% 99.984% 0.016%<br>Grifols Diagnostics Equipment Taiwan Limited<br>8F., No.367, Fuxing N. RD.,<br>Songshang Dist., Taipei City<br>10543, Taiwan<br>2016 Commercial Distribution and sale of diagnostic products. 100.000% --- 100.000% --- 100.000% ---<br>Grifols Viajes, S.A.<br>Can Guasch, 2<br>08150 Parets del Vallès<br>Barcelona, Spain<br>1995 Services Travel agency exclusively serving Group companies. 99.900% 0.100% 99.900% 0.100% 99.900% 0.100%<br>Squadron Reinsurance Designated Activity Company<br>The Metropolitan Building, 3rd<br>Fl.<br>James Joyce Street, Dublin<br>Ireland<br>2003 Services Reinsurance of Group companies’ insurance policies. --- 100.000% --- 100.000% --- 100.000%<br>Grifols Shared Services North America, Inc.<br>2410 Lillivale Avenue<br>90032 Los Angeles, California<br>United States<br>2011 Services Support services for the collection, manufacture, sale and distribution of plasma derivatives and related<br>products.<br>100.000% --- 100.000% --- 100.000% ---<br>Gripdan Invest, S.L Avenida Diagonal 477 Barcelona, Spain 2015 Services Rental of industrial buildings 100.000% --- 100.000% --- 100.000% ---<br>Araclon Biotech, S.L.<br>Paseo de Sagasta, 17 2º izqda.<br>Zaragoza, Spain 2012 Research Creation and commercialisation of a blood diagnosis kit for the detection of Alzheimer's and development of effective immunotherapy (vaccine) against this disease. --- 75.850% --- 75.850% --- 75.100%<br>This appendix forms an integral part of note 2 to the consolidated annual accounts. | ||
| --- | ||
| Acquisition /<br>Registered Incorporation<br>Name Office date Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect<br>APPENDIX I<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Information on Group Companies, Associates and others for the years ended 31 December 2022, 2021 and 2020<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Fully Consolidated Companies<br>31/12/2020<br>% shares<br>31/12/2021<br>% shares<br>31/12/2022<br>% shares<br>VCN Bioscience, S.L.<br>Avenida de la Generalitat 152<br>Sant Cugat del Valles<br>(Barcelona)<br>Spain<br>2012 Research Research and development of therapeutic approaches for tumours for which there is currently no<br>effective treatment.<br>--- --- --- 86.830% --- 86.830%<br>Grifols Innovation and New Technologies Limited<br>Grange Castle Business Park,<br>Grange Castle , Clondalkin,<br>Dublin 22,<br>Ireland<br>2016 Research Biotechnology research and development --- 100.000% --- 100.000% --- 100.000%<br>Kiro Grifols S.L Polígono Bainuetxe, 5, 2º planta, Aretxabaleta, Guipúzcoa<br>Spain<br>2014 Research Development of machines and equipment to automate and control key points of hospital processes, and<br>hospital pharmacy processes.<br>90.000% --- 90.000% --- 90.000% ---<br>Chiquito Acquisition Corp.<br>2711 Centerville Road Suite 400,<br>Wilmington, Delaware, New<br>Castle County, United States<br>2017 Corporate Engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware, as amended from time to time (the "DGCL"). --- 100.000% --- 100.000% --- 100.000%<br>Aigües Minerals de Vilajuiga, S.A. Carrer Sant Sebastià, 2, 17493 Vilajuïga, Girona, Spain 2017 Industrial Collection and use of mineral-medicinal waters and obtaining of all necessary administrative concessions for the optimum and widest use of these. 99.990% 0.010% 99.990% 0.010% 99.990% 0.010%<br>Goetech LLC (D/B/A Medkeeper)<br>7600 Grandview Avenue, Suite 2<br>10, Arvada, CO 80002, United<br>States<br>2018 Industrial Development and distribution of web and mobile-based platforms for hospital pharmacies --- 100.000% --- 100.000% --- 100.000%<br>Interstate Blood Bank, Inc.<br>5700 Pleasantville Road<br>Memphis, Tennessee<br>United States<br>2016 Industrial Procurement of human plasma. --- 100.000% --- 100.000% --- 100.000%<br>Haema, AG LandsteinerstraBe 1, 04103 Leipzig - Germany 2018 Industrial Procurement of human plasma. --- --- --- --- --- ---<br>BPC Plasma, Inc (formerly Biotest Pharma Corp) 901 Yamato Rd., Suite 101, Boca Raton FL 33431 - USA 2018 Industrial Procurement of human plasma. --- --- --- --- --- ---<br>Alkahest, Inc.<br>3500 South DuPont Hwy,<br>Dover, County of Kent<br>United States<br>2015 Research Development of novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS). --- 100.000% --- 100.000% --- 42.450%<br>Plasmavita Healthcare GmbH Colmarer Strasse 22, 60528<br>Frankfurt am Main - Germany<br>2018 Industrial Procurement of human plasma. --- 50.000% --- 50.000% --- 50.000%<br>Plasmavita Healthcare II GmbH Garnisongasse 4/12, 1090 Vienna<br>, Austria<br>2019 Industrial Procurement of human plasma. --- 50.000% --- 50.000% --- 50.000%<br>Grifols Canada Therapeutics Inc. (formerly Green Cross<br>Biotherapeutics; Inc)<br>2911 Avenue Marie Curie,<br>Arrondissement de Saint-Laurent, Quebec<br>Canada<br>2020 Industrial Conducting business in Pharmceuticals and Medicines Industry 0.020% 99.980% 100.000% --- --- 100.000%<br>GCAM, Inc. (merged with Biomat USA, Inc.)<br>1561 E Orangethorpe Ave #205,<br>Fullerton, CA 92831<br>USA<br>2020 Industrial<br>Engage in any lawful act or activity for which corporations may be organized under the General<br>Corporation Law of Delaware and engaging in any and all activities necessary or incidental to the<br>foregoing.<br>--- --- --- --- --- 100.000%<br>Grifols Laboratory Solutions, Inc<br>Corporation Trust Center, 1209,<br>Orange Street, Wilmington, New<br>Castle Country, Delaware, 19801<br>Estados Unidos<br>2020 Services Engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware --- 100.000% --- 100.000% --- 100.000%<br>Grifols Korea Co., Ltd.<br>302 Teheran-ro, Gangnam-gu,<br>Seoul (Yeoksam-dong)<br>Korea<br>2020 Commercial Import, export of diagnostic in vitro products and solutions. 100.000% --- 100.000% --- 100.000% ---<br>Grifols Middle East & Africa LLC<br>Office No. 534, 5th floor,<br>NamaaBuilding No.155, Ramses<br>Extension Street, Al Hay Al<br>Sades, Nasr City, Cairo<br>Egypt<br>2021 Services Providing consultation (except for those stipulated in Article 27 of the Capital Market Law and its<br>executive regulations) and carry out those commercial activities that are permitted by the law.<br>99.990% 0.010% 99.990% 0.010% --- ---<br>GigaGen Inc.<br>407 Cabot Road<br>South San Francisco, CA 94080,<br>United States<br>2017 Industrial Engage in any lawful act or activity for which corporations may be organized under General<br>Corporation Law.<br>--- 100.000% --- 100.000% --- 43.960%<br>Grifols Pyrenees Research Center, S.L.<br>C/ Prat de la Creu, 68-76, Planta<br>3ª, Edifici Administratiu del<br>Comú d'Andorra la Vella<br>Andorra<br>2021 Industrial Constitution, development and management of operations of a research and development center in all<br>areas of immnology, dedicated to find possible solutions for therapeutic applications.<br>--- 80.000% --- 80.000% --- ---<br>Grifols Bio North America LLC<br>251 Little Falls Drive,<br>Wilmington, New Castle County,<br>19808, Delaware<br>United States<br>2021 Industrial Engage in any lawful business permitted by the Act or the laws of any jurisdiction in which the<br>Company may do business.<br>--- 100.000% --- 100.000% --- ---<br>Biomat Holdco, LLC.<br>251 Little Falls Drive,<br>Wilmington, New Castle County,<br>Delaware, 19808<br>United States<br>2021 Services Engage in any lawful act or activity for which corporations may be organized under General<br>Corporation Law of Delaware.<br>--- 100.000% --- 100.000% --- ---<br>Biomat Newco, Corp.<br>251 Little Falls Drive,<br>Wilmington, New Castle County,<br>Delaware, 19808<br>United States<br>2021 Services Engage in any lawful act or activity for which corporations may be organized under General<br>Corporation Law of Delaware.<br>--- 100.000% --- 100.000% --- ---<br>Grifols Escrow Issuer, S.A.<br>Parque Empresarial Can Sant<br>Joan, Avda de la Generalitat, 152-<br>156, Sant Cugat del Vallès,<br>08174, Barcelona<br>Spain<br>2021 Services Administration, management and control services for companies and businesses, as well as investment<br>in property, as well as providing advisory services of any investee entities or group companies.<br>100.000% --- 100.000% --- --- ---<br>Prometic Plasma Resources, Inc.<br>531 Boul. Des Prairies, Building<br>15<br>Laval, Quebec H7V 1B7<br>Canada<br>2021 Industrial Procurement of human plasma. --- 100.000% 100.000% --- --- ---<br>Access Biologicals, LLC 955, Park Center Drive, Vista, CA 92801, USA 2017 Industrial Manufacture of biological products such as specific serum and plasma reagents that are used by biotechnological and biopharmaceutical companies for in-vitro diagnosis, cell culture and research and development in the field of diagnostics. --- 100.000% --- 49.000% --- 49.000%<br>Access Biologicals IC-DISC, Inc. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. --- 100.000% --- 49.000% --- 49.000%<br>This appendix forms an integral part of note 2 to the consolidated annual accounts. | ||
| --- | ||
| Acquisition /<br>Registered Incorporation<br>Name Office date Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect<br>APPENDIX I<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Information on Group Companies, Associates and others for the years ended 31 December 2022, 2021 and 2020<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Fully Consolidated Companies<br>31/12/2020<br>% shares<br>31/12/2021<br>% shares<br>31/12/2022<br>% shares<br>Access Cell Culture, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. --- 100.000% --- 49.000% --- 49.000%<br>Access Plasma, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. --- 100.000% --- 49.000% --- 49.000%<br>Albimmune, S.L.<br>Parque Empresarial Can Sant<br>Joan, Avda de la Generalitat, 152-<br>156, Sant Cugat del Vallès,<br>08174, Barcelona<br>España<br>2022 Research The purpose of the company is the research, development and exploitation of a project on the application of the use of albumin as a medicine --- 51.000% --- --- --- ---<br>Biotest, AG Landsteinerstr. 5, D-63303 Dreieich, Germany 2022 Industrial<br>Development, manufacture and distribution of biological, chemical, pharmaceutical, human and<br>veterinary medical, cosmetic and dietary products as well as containers, devices, machines and<br>accessories for medical, pharmaceutical and analytical purposes, as well as research in these fields.<br>Furthermore the activity (especially research development, production and distribution) in the field of<br>plant protection and plant breeding, the field of testing and purification of soil, water and air and in the<br>field of products, materials and techniques used in space.<br>24.700% 45.480% --- --- --- ---<br>Biotest Austria, GmbH Einsiedlergasse 58, A-1050, Vienna, Austria 2022 Industrial Distribution of pharmaceutical products. --- 70.180% --- --- --- ---<br>Biotest Italia, S.R.L.<br>Via Leonardo da Vinci 43, I-20090 Trezzano sul Naviglio MI,<br>Italia<br>2022 Industrial Distribution of pharmaceutical products. --- 70.180% --- --- --- ---<br>Biotest (UK) Ltd.<br>17 High Street, B31 2UQ<br>Longbridge Birmingham, United<br>Kingdom<br>2022 Industrial Distribution of pharmaceutical products. --- 70.180% --- --- --- ---<br>Biotest (Schweiz) AG Schützenstrasse 17, CH-5102 Rupperswil, Switzerland 2022 Industrial Distribution of pharmaceutical products. --- 70.180% --- --- --- ---<br>Biotest Hungaria Kft Torbágy utca 15/ A, Törökbálint 2045, Hungary 2022 Industrial Procurement of human plasma. --- 70.180% --- --- --- ---<br>Biotest Farmacêutica LTDA<br>Rua José Ramos Guimarães, 49<br>A Centro, 12955-000, Bom<br>Jesus dos Perdões – SP, Brasil<br>2022 Industrial Distribution of pharmaceutical products. --- 70.180% --- --- --- ---<br>Biotest Hellas M.E.P.E. 45 Michalakopoulou Str., 11528<br>Athens, Greece 2022 Research Research and development of solutions in the Biopharma area. --- 70.180% --- --- --- ---<br>Biotest France SAS 45/47 rue d'Hauteville, 75010<br>Paris, France 2022 Servicios The purpose of the company is to act as an agent and support the group companies. --- 70.180% --- --- --- ---<br>Biotest Pharmaceuticals Ilaç Pazarlama Anonim Sirketi<br>Nishstanbul, Cobançesme<br>Mahallesi, 34197 Bahçeliever,<br>Istanbul, Turkey<br>2022 Research Research and development of solutions in the Biopharma area. --- 70.180% --- --- --- ---<br>Biotest Medical, S.L.U.<br>C/ Frederic Mompou, nº 5, 6º 3ª<br>A, 08960 Sant Just Desvern,<br>Barcelona, Spain<br>2022 Industrial Distribution of pharmaceutical products. --- 70.180% --- --- --- ---<br>Biotest Pharma, GmbH Landsteinerstr. 5, D-63303 Dreieich, Germany 2022 Industrial Carry out the development and production activities in the Biopharma area. --- 70.180% --- --- --- ---<br>BioDarou PLC Sarparast St., Italia St. Felestin<br>Ave, 1416653163 Tehran, Iran 2022 Industrial Procurement of human plasma. --- 70.180% --- --- --- ---<br>Biotest Grundstücksverwaltungs GmbH Landsteinerstr. 5, D-63303 Dreieich, Germany 2022 Servicios Management of own assets. --- 70.180% --- --- --- ---<br>Plasma Service Europe GmbH Landsteinerstr. 5, D-63303 Dreieich, Germany 2022 Industrial Procurement of human plasma. --- 70.180% --- --- --- ---<br>Cara Plasma s.r.o.<br>Jungmannova 745/24 - Nové<br>Město, 110 00 Praha 1 , Czech<br>Republic<br>2022 Industrial Procurement of human plasma. --- 70.180% --- --- --- ---<br>Plazmaszolgálat Kft Torbágy utca 15/ A, Törökbálint 2045, Hungary 2022 Industrial Procurement of human plasma. --- 70.180% --- --- --- ---<br>Grifols Biotest Holdings GmbH Colmarer Str. 22, 60528 Frankfurt am Main, Germany 2022 Services Management of own assets as well as the acquisition, sale, holding and management of shares in other companies in Germany and abroad in the company's own name and on its own account (not third parties), in particular in Biotest AG with registered offices in Dreiech. 100.000% --- --- --- --- ---<br>This appendix forms an integral part of note 2 to the consolidated annual accounts. | ||
| --- | ||
| Name Registered Office<br>Acquisition /<br>Incorporation<br>date<br>Activity Statutory Activity Direct Indirect Direct Indirect Direct Indirect<br>Equity-accounted investees and others<br>Aradigm Corporation<br>3929 Point Eden Way<br>Hayward, California<br>United States<br>2013 Research Development and commercialisation of drugs delivered by inhalation for the prevention and treatment of<br>severe respiratory diseases.<br>--- --- --- 35.130% --- 35.130%<br>Mecwins, S.L.<br>Avenida Fernandos Casas<br>Novoa, 37<br>Santiago de Compostela,<br>Spain<br>2013 Research Research and production of nanotechnological, biotechnological and chemical solutions. --- 24.590% --- 24.990% --- 24.990%<br>Albajuna Therapeutics, S.L<br>Hospital Germans Trias i<br>Pujol, carretera de Canyet,<br>s/n, Badalona<br>Spain<br>2016 Research Development and manufacture of therapeutic antibodies against HIV. --- 49.000% --- 49.000% --- 49.000%<br>Singulex, Inc.<br>4041 Forest Park Avenue<br>St. Louis, Missouri<br>United States<br>2016 Research Development of the Single Molecule Counting (SMC™) technology for clinical diagnostic and scientific discovery. --- --- --- 19.330% --- 19.330%<br>Access Biologicals, LLC. (becomes part<br>of the group)<br>995 Park Center Dr, Vista,<br>CA 92081, USA<br>2017 Industrial<br>Manufacture of biological products, including specific sera and plasma-derived reagents, which are used<br>by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and<br>development in the diagnostic field.<br>--- --- --- 49.000% --- 49.000%<br>Access Biologicals IC-DISC, Inc. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. --- --- --- 49.000% --- 49.000%<br>Access Cell Culture, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. --- --- --- 49.000% --- 49.000%<br>Access Plasma, LLC. 995 Park Center Dr, Vista, CA 92081, USA 2017 Industrial Manufacture of biological products, including specific sera and plasma-derived reagents, which are used by biotechnology and biopharmaceutical companies for in-vitro diagnostics, cell culture, and research and development in the diagnostic field. --- --- --- 49.000% --- 49.000%<br>GigaGen Inc.<br>407 Cabot Road<br>South San Francisco, CA<br>94080, USA<br>2017 Industrial Engage in any lawful act or activity for which corporations may be organized under General Corporation<br>Law.<br>--- --- --- --- --- 43.960%<br>Medcom Advance, S.A Av. Roma, 35 Entresuelo 1, 08018 Barcelona; Spain 2019 Research Research and development of nanotechnological solutions. --- 45.000% --- 45.000% --- 45.000%<br>Shanghai RAAS Blood Products Co.<br>Ltd.<br>2009 Wangyuan Road,<br>Fengxian District, Shanghai<br>2020 Industrial<br>Introducing advanced and applicable technologies, instruments and scientific management systems for<br>manufacturing and diagnosis of blood products, in order to raise the production capacity and enhance<br>quality standards of blood products to the international level.<br>26.200% --- 26.200% --- 26.200% ---<br>Grifols Egypt for Plasma Derivatives<br>(S.A.E.)<br>Tolip El Narges Hotel,<br>Teseen Streett, Fifth<br>Settlement, Cairo<br>Egypt<br>2021 Industrial Establish and operate a plasma fractionation plant, regardless of whether the plasma is collected locally or<br>imported, as well as its filling and packaging.<br>49.000% --- 49.000% --- --- ---<br>This appendix is part of note 2 from the consolidated annual accounts.<br>APPENDIX I<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Information on Group Companies, Associates and others for the years ended 31 December 2022, 2021 and 2020<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>31/12/2020<br>% shares<br>31/12/2021<br>% shares<br>31/12/2022<br>% shares | ||
| --- | ||
| 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*)<br>Revenues from external customers 5,005,382 3,814,983 4,242,502 671,292 779,108 775,889 146,076 115,811 133,221 250,165 266,461 222,521 (8,94 (43,245) 8) (34,095) -25,386 6,063,967 4,933,118 5,340,038<br>Total operating income 3,814,983 5,005,382 4,242,502 671,292 779,108 775,889 146,076 115,811 133,221 250,165 266,461 222,521 (8,948) (43,245) (34,095) (25,386) 6,063,967 4,933,118 5,340,038<br>Profit/(Loss) for the segment 791,339 681,925 967,415 129,968 152,948 215,793 114,397 39,901 36,142 (46,809) (83,482) (43,960) 35,419 (10,896) 4,428 (305) 1,024,314 780,396 1,179,818<br>Unallocated expenses (185,332) (218,634) (183,686)<br>Operating profit/(loss) 805,680 595,064 996,132<br>Finance result (277,799) (442,941) (177,669)<br>Share of profit/(loss) of equity-accounted investee -- -- -- -- -- -- -- -- -- (1,482) 33,188 60,166 -- -- -- -- 33,188 (1,482) 60,166<br>Income tax expense (85,126) (90,111) (169,639)<br>Profit for the year after tax 271,146 265,327 708,990<br>Segment assets 13,187,651 9,467,378 7,975,667 3,681,632 3,513,991 3,371,125 341,876 47,446 251,551 766,139 827,371 641,341 (6,997) (39,963) (26,773) 17,970,301 13,816,223 12,212,911<br>Equity-accounted investments 41,162 31,847 -- -- -- -- -- 53,264 46,782 1,914,015 1,914,665 1,822,238 -- -- -- 1,955,177 1,999,776 1,869,020<br>Unallocated assets -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 1,608,499 3,417,836 1,192,845<br>Total assets 21,533,977 19,233,835 15,274,776<br>Segment liabilities 2,317,191 1,521,634 1,222,664 425,693 397,869 372,461 43,264 27,596 120,787 222,565 199,095 153,513 -- -- -- 3,008,713 2,146,194 1,869,425<br>Unallocated liabilities -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 10,067,720 9,770,543 6,685,296<br>Total liabilities 13,076,433 11,916,737 8,554,721<br>Other information:<br>Allocated amortisation and depreciation 294,156 228,114 201,087 64,682 88,557 63,053 5,759 2,948 21,846 20,367 19,043 15,263 -- -- -- 338,662 384,964 301,249<br>Unallocated amortisation and depreciation -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 21,105 22,900 20,284<br>Allocated expenses that do not require cash payments 26,051 (71,964) 38,955 13,639 4,446 (21,335) 120 73 3 (206) 3,349 (2,448) -- -- -- 33,919 (58,411) 15,175<br>Unallocated expenses that do not require cash<br>payments<br> -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 4,991 (10,770) 4,924<br>Allocated additions for the year of property, plant &<br>equipment, intangible assets and rights of use 402,672 349,890 289,062 49,890 19,991 34,516 98 13,836 10,915 30,192 28,597 12,698 -- -- -- 482,852 412,314 347,191<br>Unallocated additions for the year of property, plant<br> & equipment, intangible assets and rights of use<br> -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 59,866 55,380 107,178<br>* As a consequence of the review of transactions and balances allocations by segments, the comparative figures for the fiscal year 2021 and 2020 have been adjusted accordingly.<br>This appendix forms an integral part of note 5 to the consolidated annual accounts.<br>Consolidated<br>APPENDIX II<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Operating Segments for the years ended 31 December 2022, 2021 and 2020<br>(Expressed in thousands of Euros)<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Biopharma Diagnostic Bio Supplies Others Intersegments<br>1 of 2 | ||
| --- | ||
| 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020<br>Net Revenue 320,631 362,407 339,169 711,579 544,042 495,323 3,855,607 3,154,549 3,599,746 1,176,150 872,120 905,800 6,063,967 4,933,118 5,340,038<br>Assets by geographical area 1,156,068 1,092,435 1,117,647 6,600,264 5,393,407 2,927,198 11,561,068 10,525,140 9,138,360 2,216,577 2,222,853 2,091,571 21,533,977 19,233,835 15,274,776<br>Other information:<br>Additions for the year of property, plant &<br>equipment, intangible assets and rights of use 60,503 71,022 93,787 107,030 91,388 92,873 363,034 295,526 253,442 12,151 9,758 14,267 542,718 467,694 454,369<br>This appendix forms an integral part of note 5 to the consolidated annual accounts.<br>Consolidated<br>APPENDIX II<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>for the years ended 31 December 2022, 2021 and 2020<br>(Expressed in thousands of Euros)<br> Reporting by geographical area<br>Spain Rest of European Union USA + Canada Rest of World<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>2 of 2 | ||
| --- | ||
| (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Balance at Business Translation Balance at<br>31/12/2021 Additions combinations Transfers Disposals differences 31/12/2022<br>Development costs 801,606 39,835 943,857 -- (3,372) 40,159 1,822,085<br>Concessions, patents, licenses brands & similar 244,558 36,612 3,762 97 (3,907) 11,036 292,158<br>Computer software 330,491 31,299 50 1,881 (34,429) 11,699 340,991<br>Currently marketed products 1,083,301 65,561 1,148,862<br>Other intangible assets 156,009 1,323 307,927 (55) (77,825) 12,418 399,797<br>Total cost of intangible assets 2,615,965 109,069 1,255,596 1,923 (119,533) 140,873 4,003,893<br>Accum. amort. of development costs (168,366) (28,160) -- -- 663 (3,581) (199,444)<br>Accum. amort of concessions, patents, licenses, br (64,176) (12,321) (332) -- 2,200 (2,702) (77,331)<br>Accum. amort. of computer software (200,291) (30,357) (12) 140 16,813 (6,598) (220,305)<br>Accum. amort. of currently marketed products (394,784) (40,212) (22,798) (457,794)<br>Accum. amort. of other intangible assets (81,298) (12,603) -- -- 799 (4,687) (97,789)<br>Total accum. amort intangible assets (908,915) (123,653) (344) 140 20,475 (40,366) (1,052,663)<br>Impairment of other intangible assets (70,100) (638) -- 79 76,302 (7,726) (2,083)<br>Carrying amount of intangible assets 1,636,950 (15,222) 1,255,252 2,142 (22,756) 92,781 2,949,147<br>(See note 3)<br>This appendix forms an integral part of note 7 to the consolidated annual accounts.<br>APPENDIX III<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Changes in Other Intangible Assets<br>for the year ended<br>31 December 2022<br>(Expressed in thousands of Euros)<br>1 of 2 | ||
| --- | ||
| (Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>Balance at Business Translation Balance at<br>31/12/2020 Additions combinations Transfers Disposals differences 31/12/2021<br>Development costs 701,390 34,671 24,027 -- (5,679) 47,197 801,606<br>Concessions, patents, licenses brands & similar 228,023 57 -- -- -- 16,478 244,558<br>Computer software 279,651 33,516 -- 3,315 (208) 14,217 330,491<br>Currently marketed products 1,004,665 -- -- -- -- 78,636 1,083,301<br>Other intangible assets 156,644 -- -- -- (12,146) 11,511 156,009<br>Total cost of intangible assets 2,370,373 68,244 24,027 3,315 (18,033) 168,039 2,615,965<br>Accum. amort. of development costs (125,875) (44,612) -- (60) 5,679 (3,498) (168,366)<br>Accum. amort of concessions, patents, licenses, br (51,197) (9,909) -- -- -- (3,070) (64,176)<br>Accum. amort. of computer software (167,124) (25,474) -- (101) 178 (7,770) (200,291)<br>Accum. amort. of currently marketed products (331,968) (35,989) -- -- -- (26,827) (394,784)<br>Accum. amort. of other intangible assets (71,430) (4,265) -- -- -- (5,603) (81,298)<br>Total accum. amort intangible assets (747,594) (120,249) 0 (161) 5,857 (46,768) (908,915)<br>Impairment of other intangible assets (65,129) (73) -- -- -- (4,898) (70,100)<br>Carrying amount of intangible assets 1,557,650 (52,078) 24,027 3,154 (12,176) 116,373 1,636,950<br>(See note 3)<br>This appendix forms an integral part of note 7 to the consolidated annual accounts.<br>APPENDIX III<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Changes in Other Intangible Assets<br>for the year ended<br>31 December 2021<br>(Expressed in thousands of Euros)<br>2 of 2 | ||
| --- | ||
| Balance at Business Translation Balance at<br>31/12/2021 Additions combinations Transfers Disposals differences 31/12/2022<br>Land and buildings 941,955 130,475 27,620 (455) (35,924) 50,983 1,114,654<br>Machinery 9,076 5,055 347 (1,189) (6,849) 224 6,664<br>Computer equipment 8,519 278 263 (568) (1,848) 175 6,819<br>Vehicles 15,760 6,165 1,279 (10) (2,527) 291 20,958<br>Total cost of rights of use 975,310 141,973 29,509 (2,222) (47,148) 51,673 1,149,095<br>Accum. depr. of land and buildings (159,831) (72,214) (359) 106 9,782 (7,088) (229,604)<br>Accum. depr. of machinery (3,792) (1,983) (236) 894 1,361 109 (3,647)<br>Accum. depr. of computer equipment (6,475) (1,432) -- 573 1,719 (178) (5,793)<br>Accum. depr. of vehicles (9,555) (4,869) -- 4 2,157 (236) (12,499)<br>Total accum. Depr. of rights of use (179,653) (80,498) (595) 1,577 15,019 (7,393) (251,543)<br>Carrying amount of rights of use 795,657 61,475 28,914 (645) (32,129) 44,280 897,552<br>This appendix forms an integral part of note 8 to the consolidated annual accounts.<br>(Expressed in thousands of Euros)<br>(Free translation from the original in Spanish. In the event of any discrepancy, the Spanish-language version prevails)<br>APPENDIX IV<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Movement in Rights of Use<br>for the year ended<br>31 December 2022<br>1 de 2 | ||
| --- | ||
| Balance at Business Translation Balance at<br>31/12/2020 Additions combinations Transfers Disposals differences 31/12/2021<br>Land and buildings 759,120 125,112 4,611 3,337 (3,603) 53,378 941,955<br>Machinery 5,907 3,412 -- (495) (89) 341 9,076<br>Computer equipment 8,228 641 -- (629) (7) 286 8,519<br>Vehicles 14,152 4,277 -- (407) (2,887) 625 15,760<br>Total cost of rights of use 787,407 133,442 4,611 1,806 (6,586) 54,630 975,310<br>Accum. depr. of land and buildings (94,118) (57,901) -- (3,337) 3,605 (8,080) (159,831)<br>Accum. depr. of machinery (2,236) (2,120) -- 587 87 (110) (3,792)<br>Accum. depr. of computer equipment (4,640) (2,269) -- 629 7 (202) (6,475)<br>Accum. depr. of vehicles (7,717) (4,430) -- 407 2,581 (396) (9,555)<br>Total accum. depr. of rights of use (108,711) (66,720) -- (1,714) 6,280 (8,788) (179,653)<br>Carrying amount of rights of use 678,696 66,722 4,611 92 (306) 45,842 795,657<br>This appendix forms an integral part of note 8 to the consolidated annual accounts.<br>(Expressed in thousands of Euros)<br>(Free translation from the original in Spanish. In the event of any discrepancy, the Spanish-language version prevails)<br>APPENDIX IV<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Movement in Rights of Use<br>for the year ended<br>31 December 2021<br>2 de 2 | ||
| --- | ||
| Balances at Translation Balances at<br>31/12/2021 Additions<br>Business<br>combination Transfers Disposals differences 31/12/2022<br>Cost:<br>Land and buildings 860,447 4,636 236,732 11,374 (864) 43,081 1,155,406<br>Plant and machinery 2,527,744 50,025 316,946 115,070 (50,958) 110,196 3,069,023<br>Fixed Assets under construction<br>763,787<br>237,015 -- (147,240) -- 24,853 878,415<br>4,151,978 291,676 553,678 (20,796) (51,822) 178,130 5,102,844<br>Accumulated depreciation:<br>Buildings<br>(148,082)<br>(27,757) -- 1,553 57 (7,108) (181,337)<br>Plant and machinery<br>(1,442,434)<br>(175,956) (4,044) 3,201 41,061 (59,834) (1,638,006)<br>(1,590,516) (203,713) (4,044) 4,754 41,118 (66,942) (1,819,343)<br>(13,965) (7,396) -- 9,383 340 (926) (12,564)<br>Carrying amount 2,547,497 80,567 549,634 (6,659) (10,364) 110,262 3,270,937<br>(See note 3)<br>This appendix forms an integral part of note 9 to the consolidated annual accounts.<br>APPENDIX V<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Movement in Property, Plant and Equipment<br>for the year ended<br>Impairment of other property, plant<br>and equipment<br>(Expressed in thousands of Euros)<br>(Free translation from the original in Spanish. In the event of any discrepancy, the Spanish-language version prevails)<br>31 December 2022<br>1 of 2 | ||
| --- | ||
| Balances at Translation Balances at<br>31/12/2020 Additions<br>Business<br>combination Transfers Disposals differences 31/12/2021<br>Cost:<br>Land and buildings 780,180 3,361 660 24,830 (123) 51,539 860,447<br>Plant and machinery 2,200,429 42,747 10,381 171,894 (24,960) 127,253 2,527,744<br>Fixed Assets under construction 704,582 219,900 (7,300) (199,943) -- 46,548 763,787<br>3,685,191 266,008 3,741 (3,219) (25,083) 225,340 4,151,978<br>Accumulated depreciation:<br>Buildings (122,948) (19,388) -- 2,583 123 (8,452) (148,082)<br>Plant and machinery (1,235,483) (153,408) -- (2,609) 18,808 (69,742) (1,442,434)<br>(1,358,431) (172,796) -- (26) 18,931 (78,194) (1,590,516)<br>(2,653) (11,246) -- -- -- (66) (13,965)<br>Carrying amount 2,324,107 81,966 3,741 (3,245) (6,152) 147,080 2,547,497<br>(See note 3)<br>This appendix forms an integral part of note 9 to the consolidated annual accounts.<br>(Expressed in thousands of Euros)<br>(Free translation from the original in Spanish. In the event of any discrepancy, the Spanish-language version prevails)<br>Impairment of other property, plant<br>and equipment<br>APPENDIX V<br>GRIFOLS, S.A. AND SUBSIDIARIES<br>Movement in Property, Plant and Equipment<br>for the year ended<br>31 December 2021<br>2 of 2 | ||
| --- | ||
| 2022<br>CONSOLIDATED<br>DIRECTORS’<br>REPORT | ||
| --- | ||
| In This Report<br>INTRODUCTION<br>LETTER FROM THE CHAIRMAN OF HONOUR 5<br>LETTER FROM THE EXECUTIVE CHAIRMAN AND CO-CEOs 6<br>HIGHLIGHTS 8<br>MILESTONES 9<br>ABOUT US 10<br>INNOVATION 70<br>ENVIRONMENTAL RESPONSIBILITY 124<br>COMMITMENT TO DONORS AND PATIENTS 26<br>OUR PEOPLE 86<br>FINANCIAL PERFORMANCE 146<br>ETHICAL COMMITMENT 48<br>IMPACT ON SOCIETY 108<br>ABOUT THIS REPORT 164 | ||
| --- | ||
| Dr. Josep Antoni Grífols i Roig founds<br>the Instituto Central de Análisis<br>Clínicos, Bacteriológicos y Químicos<br>in Barcelona<br>2016<br>Acquisition of Hologic’s NAT<br>donor screening unit<br>2014<br>Acquisition of Novartis<br>transfusion diagnostic<br>business unit<br>2011<br>Third largest manufacturer<br>of plasma-derived medicines<br>following the acquisition<br>of Talacris Biotherapeutics<br>Laboratorios Grifols is<br>born<br>Founded in Barcelona by Dr. Grífols i<br>Roig and his sons, Josep and Víctor<br>Grífols i Lucas<br>Production of the first lyophilized<br>plasma in Europe<br>Acquisition of SeraCare (Biomat) and<br>its 43 plasma donation centers<br>Grifols acquires Alpha Therapeutic<br>Corporation Mitsubishi assets,<br>including its Los Angeles-based<br>plasma fractionation plant<br>Operations of Spain’s first fractionation<br>facility commence<br>Inicio de la cotización en<br>el Nasdaq<br>Grifols becomes the first non-U.S.<br>company to earn FDA approval for<br>its installations and a biological<br>medicine (albumin)<br>Dr. Josep Antoni Grífols i Lucas<br>develops the plasmapherisis technique<br>Our history shapes our future<br>Industry pioneers<br>A listed<br>company<br>Internationalization<br>Our journey<br>begins<br>More than 100 years of history built on passion,<br>innovation and teamwork, allowing us to continue<br>creating value and forging a more sustainable future<br>Global expansion<br>1940<br>1909<br>2022<br>1943<br>2002<br>2003<br>1958<br>Stock market launch in<br>Spain<br>2006<br>2011<br>1995<br>1951 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 5 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>New challenges.<br>New opportunities.<br>Almost four decades ago, I followed in my father’s footsteps and took up the helm of what was, at that time, a family business, embarking upon a<br>journey that would see me spearhead and witness one of the great transformations of Grifols. It was back in the 80s, and flanked by a loyal, highly<br>motivated team, we started to expand our production capacity, seek out new business opportunities and take the company global. In 2006 we took<br>the company public to compete on a level playing field with the big industry names, and in 2011 the acquisition of Talecris positioned us as one of the<br>indisputable sector leaders.<br>It was a time of sacrifice, just as this present time is. A time of strategic decision-making, just as this year has been. And above all, it was a time to<br>prioritize what was best for Grifols, as always. Because one thing we know for sure is that what is best for Grifols is what is best for thousands of<br>patients, donors and healthcare professionals. It is what is best for our people, our shareholders, and society. We have been safeguarding people’s<br>health and well-being for 115 years and we will continue to do so, with the utmost responsibility and great optimism.<br>In October 2022 I decided to step down from my role as Chairman of the Board of Directors of Grifols, though I shall stay on as Chairman of Honour, The<br>Executive Chairman, the current CEOs and rest of the management make a formidable team; one which is fully equipped to take Grifols into the future<br>and, as it has already demonstrated, to reverse the situation triggered by COVID-19, a global pandemic with a severe long-term impact.<br>This is not the first storm we have weathered. There have been plenty of times in Grifols’ history when we have had to give it our all and work harder<br>and better to build a stronger company.<br>The transformation is underway, and we have taken all the necessary measures to remain positioned as a top global player which is fully committed to<br>improving the health and well-being of people all over the world. Now, with the integration of Biotest, our new strategic plans and our enhanced capacity<br>to deliver, I can assure you that at Grifols, the best is yet to come.<br>VÍCTOR GRÍFOLS ROURA<br>CHAIRMAN OF HONOUR OF GRIFOLS<br> “What is best for Grifols is what is best for<br>thousands of patients, donors and healthcare<br>professionals. It is what is best for our people,<br>our shareholders, and society. As Chairman of<br>Honour, I will make sure this never changes” | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 6<br> “Grifols has robust fundamentals and a clear roadmap<br>to build an even stronger position going forward.<br>Growth, sustainability and a long-term approach are<br>the hallmarks of our business”<br>VÍCTOR GRÍFOLS DEU, CO-CEO<br>Transformational spirit<br>For Grifols, 2022 brought a burgeoning recovery and an<br>improving operating and financial performance, even against a<br>macroeconomic backdrop of inflation, uncertainty and volatile<br>financial markets.<br>The decisions made in previous years to enhance our plasma<br>supply capacity drove a consistent increase in donations,<br>particularly in the US market, with donations up 25% over the year<br>to stand at record 2019 levels.<br>Over the course of the year we have implemented operational<br>improvement plans and an internal reorganization based on more<br>independent business units – Plasma Procurement, Biopharma,<br>Diagnostic and Bio Supplies – with a view to improving our<br>competitive position.<br>We took a close look this year at all of our business areas and<br>functions to see where we can deliver better organizational<br>efficiency and become more responsive and proactive. Sadly, these<br>changes will give rise to an 8% reduction in our workforce, which<br>will largely impact our US Plasma Procurement unit.<br>We also undertook a comprehensive review of our innovation<br>projects to ensure we are channeling our efforts into the most<br>viable, high-potential ideas, as well as designing a new structure<br>to drive faster progress on these projects. This allowed us to<br>successfully optimize our R&D pipeline and investments as well as<br>delivering an improvement in terms of risk-opportunity profile.<br>In April, we completed the acquisition of Biotest AG. This major<br>milestone will allow us to increase the availability of plasma-derived therapies, expand our product portfolio to better respond<br>to patients’ needs, step up our innovation strategy and grow our<br>global footprint. It has also allowed us to create Europe’s largest<br>private network of plasma donation centers.<br>The outstanding results reported in 2022 clearly evidence the<br>effort we have all put in to generating growth and improving our<br>operational performance. We want to extend our thanks to every<br>member of the Grifols team for their hard work and constant<br>dedication. Without their commitment, we could never have forged<br>a new strategic partnership with Canadian Blood Services, secured<br>FDA clearance for the AlphaID™ At Home Genetic Health Risk<br>Service, opened a new albumin filling plant in Ireland or launched<br>our subcutaneous immunoglobulin treatment Xembify in Europe, to<br>name but a few of this year’s achievements. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 7<br> “Our 2022 results are a clear reflection of the<br>effort and hard work put in by every member of<br>the Grifols team in recent years. Donors, patients<br>and our team are our constant priority”<br>RAIMON GRIFOLS ROURA, CO-CEO<br>In addition to these transformational measures, it is important to<br>highlight that Grifols’ business activity is geared towards improving<br>patients’ lives and contributing decisively to sustainability, because<br>in our view, a project which is sustainable and profitable over the<br>long term must also be ethically, socially and environmentally<br>responsible.<br>We are determined to reinforce our position as one of the world’s<br>most sustainable companies. In 2022, Grifols was included for the<br>third year running in the Dow Jones Sustainability Index (DJSI), the<br>world’s leading sustainability benchmark. We also made significant<br>inroads in deploying our ESG strategy, which is underpinned by the<br>six core pillars and 30 specific goals comprising the Grifols 2030<br>Agenda. We are proud of the progress made, while we continued<br>support for the UN Global Compact and its ten principles.<br>We responded successfully to other challenges this year, too.<br>We increased training hours to nearly 220 hours per employee,<br>secured progress in equality, diversity and inclusion, and delivered<br>an overall improvement in our gender pay gap.<br>We took environmental action, paring down our greenhouse gas<br>emissions and working on using natural resources more efficiently,<br>as well as moving ever closer to our target of using energy from<br>renewable sources only by 2030. We also continue to roll out<br>ambitious, far-reaching social investment initiatives with donors,<br>patients and patients’ associations, as well as supporting the<br>endeavors of our three foundations.<br>This year 2022 brought great change, but thanks to our<br>transformational spirit, sustainable leadership and responsible<br>growth, we forged ahead with integrity, rigor and an unwavering<br>commitment to the values and ethical principles that have guided<br>us for 115 years.<br>Thank you for believing in us.<br>Sustainable leadership<br> CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’Report · 8<br>Highlights<br>FINANCIAL PERFORMANCE TALENT AND DIVERSITY COMMITMENT<br>INNOVATION<br>REVENUE EBITDA<br>6,064 1,221<br>MILLION EUROS<br>+12.4% CC1<br>MILLION EUROS<br>HUMAN CAPITAL<br>26,314<br>PEOPLE<br>4.7<br>MILLION TRAINING HOURS<br>920,000+<br>DONORS<br>800,000+<br>PATIENTS<br>65%+<br>OF PROMOTIONS WENT TO WOMEN<br>R&D+i NET INVESTMENT R&D+i WORKFORCE<br>351 1,200+<br>MILLION EUROS PEOPLE<br>CREATED VALUE FOR DONORS<br>AND COMMUNITIES<br>5,150<br>MILLION EUROS<br>VALUE CREATED FOR PATIENTS<br>23,810<br>MILLION EUROS<br>6 3<br>THERAPEUTIC AREAS INNOVATION HUBS<br>60% 40%<br>(1) Operating or cc excludes rate fluctuations over the period | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 9 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 9<br>Milestones<br>Biotest investment<br>Grifols completes its strategic investment<br>in Biotest, a transformational transaction<br>that will increase its availability of plasma-derived therapies, expand and accelerate<br>its R+D pipeline, and bolster revenue and<br>margins.<br>Strategic Alliance with<br>Canadian Blood Services<br>FDA clearance of<br>AlphaIDTM At Home<br>New facility in Ireland<br>Grifols inaugurates a new production plant<br>in Dublin dedicated to the sterile dosing<br>and filling of albumin in a flexible bag.<br>Growth<br>Commitment to patients<br>Innovation<br>Sustainability<br>Under this agreement, Grifols will use<br>Canadian plasma to manufacture<br>immunoglobulins (Ig) at its Montreal<br>facility exclusively for CBS, accelerating<br>the country’s efforts to attain 50%<br>self-sufficiency in this essential plasma<br>protein.<br>European launch of Yimmugo®<br>One of the world’s most sustainable companies<br>Recognition as a Great Place to Work<br>Alliance with<br>Endpoint Health<br>Grifols signs a collaboration<br>agreement with Endpoint<br>Health to develop and<br>commercialize antithrombin<br>III to treat sepsis, a life-threatening medical<br>emergency.<br>Grifols’ AlphaID™ At Home Genetic<br>Health Risk Service receives FDA<br>clearance.This service will allow<br>people to assess their genetic risk or<br>developing alpha-1-related lung and/or<br>liver diseases without a prescription.<br>After receiving approval from<br>the German and Austrian<br>health authorities, the<br>commercialization of this<br>innovative new intravenous<br>immunoglobulin has begun in<br>Germany.<br>Grifols is included in the Dow Jones Sustainability World Index for the second consecutive<br>year and in the Dow Jones Sustainability Europe Index for the third year running in<br>recognition of its leadership and commitment to ESG issues.<br>The company received three awards from Forbes in 2022, two<br>in the United States and the other in Spain.<br>50th anniversary of Grifols<br>in Parets<br>Since establishing its Parets del Vallès<br>(Barcelona) facility in 1972, Grifols has<br>expanded its operations to include a total<br>of 23 manufacturing plants.<br>Changes in the top<br>leadership<br>Steven F. Mayer is appointed as<br>Grifols Executive Chairman in October,<br>following Victor Grífols Roura’s decision<br>to retire and continue as Chairman of<br>Honour of Grifols Board of Directors. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 10 1<br>About us<br>Improving<br>people’s health | ||
| --- | ||
| We are Grifols<br> Business units<br>Grifols is dedicated to enhancing the health and well-being of people around the world.<br>Since 1909, we have strived to promote innovation and advance plasma science to make<br>a positive social impact. Guided by our longstanding solid values and ethical principles,<br>we integrate responsible and sustainable business practices in all of our operations.<br>Making strides<br> • A bridge between<br>patients and donors<br>More treatments thanks to donors’<br>generosity<br> • Sustainable business<br>model<br>We create economic, social and<br>environmental value<br> • Solid corporate<br>governance<br>Reinforced leadership team<br> • Transformation in<br>progress<br>Progress based on strategic priorities<br> • Commitment with the<br>UN Global Compact<br>We work to build a more sustainable<br>future<br> • Roadmap for Grifols 2030<br>Agenda<br>30 objectives based on 6 SDG-aligned pillars<br>Plasma Procurement and Biopharma<br>Plasma procurement, production and<br>commercialization of plasma and non-plasma solutions<br>83% % over revenue<br> Bio Supplies<br>High-quality biological products for<br>non-therapeutic use<br>2% % over revenue<br> Diagnostic<br>Leading-edge diagnostic solutions for blood and<br>plasma analyses<br>11% % over revenue<br> Others<br>Specialty pharmaceuticals and hospital<br>management solutions<br>4% % over revenue<br>AMONG THE WORLD’S MOST SUSTAINABLE COMPANIES<br>2023 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 12<br>We address the needs of thousands of patients<br>Grifols strives to generate long-term sustainable value for all of its stakeholder groups,<br>with a clear emphasis on patients and donors, whose generosity makes our plasma-derived therapies possible.<br>Immunology and<br>Neurology Pulmonology Hematology Hepatology / Intensive Care<br>Immunodeficiencies and<br>autoimmune disorders<br>Alpha-1 antitrypsin deficiency Hemophilia and other bleeding and<br>clotting disorders<br>Hypovolemia and hypoalbuminemia in liver<br>diseases, cardiac surgery,<br>severe infection, etc.<br>FlexBag<br>Therapeutic areas<br>6<br>Treatments<br>Plasma and<br>non-plasma therapies<br>Diagnostic solutions<br>Transfusional and Clinical | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 13 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>Joining forces with Biotest<br>Since Grifols closed its Biotest investment in April 2022, both companies have closely<br>collaborated to increase the availability of plasma therapies for the benefit of patients.<br>Immunology and<br>Neurology Hematology Hepatology / Intensive Care Innovation<br>Fibrinogen<br>IgM (Trimodulin)<br>New indication for Cytotect®<br>Workforce<br>+2,300<br>Donor plasma centers<br>+33<br>Production capacity<br>+3M liters/plasma<br>STRATEGIC PROJECTS ADVANCED<br>3<br>+ More details in Innovation, Our People and Financial Performance chapters. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 14<br>North America<br>Clayton<br>Denver<br>Emeryville<br>Los Angeles<br>San Diego<br>Memphis<br>Montreal<br>North Carolina Hub<br>Research Triangle Park<br>California Hub<br>Emeryville<br>San Carlos<br>South San Francisco<br>Los Angeles<br>San Diego<br>US 298<br>Canada 1<br>Clayton<br>Los Angeles<br>Montreal<br>Raleigh-Durham<br>Emeryville<br>Raleigh-Durham<br>San Diego<br>Memphis Denver<br>Corporate Headquarters<br>Industrial Facilities<br>R&D Centers<br>Biopharma Centers<br>Diagnostic Centers<br>Bio Supplies Centers<br>Others Centers<br>Plasma Donor Centers<br>Denver<br>Memphis<br>Montreal<br>Emeryville<br>San Carlos<br>South San Francisco<br>Los Angeles<br>San Diego<br>Raleigh-Durham<br>Clayton<br>Research Triangle Park<br>NORTH CAROLINA HUB CALIFORNIA HUB<br>2022 Informe Anual Integrado y de Sostenibilidad · 14<br>Our global footprint<br>GRI 2-1 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 15 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>Europe<br>China<br>Melbourne<br>Egypt<br>EUROPEAN HUB<br>Barcelona Germany 57<br>Hungary 18<br>Czech Republic 13<br>Austria 3<br>Barcelona<br>Bilbao<br>Dublin<br>Düdingen<br>Dreieich<br>Leipzig<br>Murcia<br>San Sebastian<br>Europe Hub<br>Dublin<br>Andorra<br>Barcelona<br>Bilbao<br>Zaragoza<br>Düdingen<br>Barcelona<br>Dublin<br>Barcelona<br>Bilbao<br>Düdingen<br>Leipzig Barcelona<br>Murcia<br>San Sebastian<br>Barcelona<br>Bilbao<br>Zaragoza<br>San Sebastian<br>Murcia<br>Andorra<br>Dublin<br>Düdingen<br>Leipzig<br>Dreieich<br>Melbourne China Melbourne Egypt 2<br>China 41<br>RoW<br>GRI 2-1 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 16<br>Our business model creates value<br>2022 Consolidated Directors’ R eport· 16<br>STRATEG CI V SI OI N<br><br><br><br><br>RISK MANAGEMENT<br>STRATEG<br>CI V<br>SI<br>OI N<br>RISK<br>MANAGEMENT<br>DONORS<br>MANUFACTURING<br>INPUT<br>GOAL<br>Enhancing global health<br>Helping people live longer<br>and better lives<br>SUSTAINABILITY PLAN<br>STRATEGIC PILLARS<br>VALUE CHAIN<br>Honesty Ethics<br> Integrity HR**<br> Safety & Quality VALUES<br>DONORS<br>920,000+ donors<br>+25% plasma donations<br>390+ plasma centers<br>TEAM<br> 26,314 employees*<br>60% women<br> 90+ nationalities<br>51% 30-50 years<br>INNOVATION<br>Robust ecosystem<br>6 therapeutic areas<br> RESOURCES<br> €351M net R+D investment*<br> €298M CAPEX<br> €1.5Bn+ acquisitions<br> €21.2Bn+ in assets<br>PLANET<br> 34M€ environmental<br>3Mm3+ water consumption<br>965M kWh+ energy consumption<br>+26% renewable energy<br>GOVERNANCE<br> New leadership<br> 33% women on Board of Directors<br>* Including Grifols and Biotest<br>** Human rights<br>INNOVATION | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 17 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>2022 ConsolidatedDirectors’ Report · 17<br>STRATEG CI V SI OI N<br><br><br><br><br>RISK MANAGEMENT<br>DISTRIBUTION<br>PATIENTS<br>VALUE CREATION<br> Commitment to patients and donors<br> Employee pool<br> Social impact<br> Environmental responsibility<br>AMBITION<br>Increase our positive impact<br>to strengthen our sustainable<br>business model<br>Transparency Compliance<br>Independence Sustainability<br>PATIENTS<br> 800,000+ treated<br> €23.8Bn value creation<br> 5.7x quality of life improvement**<br> €21M access to treatment<br> 80+ patient organizations<br>TEAM<br> 193,000 jobs created<br> 4.7M+ training hours<br> 899 disabled employees<br> 98% permanent contracts<br>70% training hours delivered to women<br>WE CONTRIBUTE TO 10 SDGs<br>RESOURCES<br> €9.6Bn economic impact generated<br> €6.1Bn revenue<br> €1.2Bn EBITDA<br> €719M total tax contributions<br> €11M community investments<br>PLANET<br> -28% GHG reduction per unit<br> of production<br> +8% energy efficiency per unit<br> of production<br> 8% water savings<br>** In relation to plasma-derived medicines costs.<br>ETHICAL COMMITMENT<br>ECO<br>N<br>O<br>M<br>C<br>I<br>P<br>E<br>R<br>FO<br>RMANCE -24% carbon footprint in Scopes 1 and 2 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 18<br>We are a listed company<br>Shareholder structure No extra-statutory or concerted actions<br>Grifols S.A. share capital currently stands at EUR 119,603,705 and<br>is represented by:<br>O Class A shares: 426,129,798 ordinary shares with voting rights<br>and par value of EUR 0.25, listed on the Barcelona, Madrid,<br>Valencia and Bilbao stock exchanges and the Continuous Market<br>(SIBE).<br>O Class B shares: 261,425,110 shares with non-voting rights<br>but some economic preferential rights and par value of<br>EUR 0.05, listed on the Barcelona, Madrid, Valencia and Bilbao<br>stock exchanges and the Continuous Market (SIBE). These shares<br>have a preferred dividend of EUR 0.01 per share.<br>Grifols has two American Depository Receipt (ADR) programs in the<br>U.S: Level I ADR for its Class A Shares and Level III ADR for Class<br>B Shares. Level I ADR are listed in U.S. dollars on the OTC markets<br>and Level III ADRs are traded in U.S. dollars on the NASDAQ<br>exchange.<br>On the other hand, there are no extra-statutory agreements or<br>concerted actions between shareholders. Furthermore, there are no<br>restrictions (statutory, legislative or otherwise) on the transferability<br>of securities and/or any restriction on voting rights.<br>Source: Annual corporate governance Report 2022<br>+ More details on Grifols’ shareholder composition: www.grifols.com<br>O Related Shareholders and Board of Directors<br>O Treasury stock<br>O Europacific Growth Fund<br>O Capital Research and Management Company<br>O Blackrock<br>O Free float<br>62%<br>30.1%<br>56.1%<br>5.7%<br>3.0%<br>3.8%<br>1.3%<br>38%<br>Class A<br>Class B<br>Legal framework<br>Grifols is a publicly traded company in Spain and<br>the United States and complies with all applicable<br>legislation in both countries. The company’s<br>regulations are frequently reviewed to align with<br>and incorporate new guidelines and best practices<br>into its regulatory frameworks.<br>External regulatory framework<br>O Spanish Company Act (Ley de Sociedades de<br>Capital), Securities Market Act (Ley del Mercado<br>de Valores) and other applicable Spanish<br>regulations<br>O Spain’s National Securities Market Commission’s<br>(CNMV) Good Governance Code of Listed<br>Companies<br>O CNMV’s Technical Guide 3/2017 on Audit<br>Committees at Public-Interest Entities<br>O CNMV’s Technical Guide 1/2019 on Nomination<br>and Remuneration Committees<br>O U.S. Securities and Exchange Commission (SEC)<br>guidelines<br>O NASDAQ Corporate Governance Requirements<br>O U.S. Sarbanes-Oxley Act of 2002<br>Internal regulatory framework<br>O Articles of associations<br>O General Shareholders’ Meeting regulations<br>O Board of Directors regulations<br>O Internal codes and regulations<br>O Corporate policies | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 19 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>with a solid corporate governance<br>As a global company, Grifols creates long-term value through a solid and strategic corporate<br>governance structure<br>Board of Directors<br>18 meetings<br>94% attendance<br>Audit Committee<br>8 meetings<br>92% attendance<br>Appointments and Remuneration<br>Committee<br>8 meetings<br>100% attendance<br>Sustainability Committee<br>4 meetings<br>100% attendance<br>The General Shareholders’ Meeting is the sovereign governing body representing Grifols ownership. The Board of Directors is its highest<br>decision-making body.<br>Grifols publishes an Annual Corporate Governance Report, subject to approval by the Board of Directors. This report includes information<br>on its management framework and ownership structure, among other issues.<br>Lead Independent<br>Director Board of Directors Executive Chairman CO-CEOs<br>Appointments &<br>Remunerations<br>Committee<br>Audit Committee Sustainability Committee<br>Sustainability Steering<br>Committee<br>Executive Team<br>GENERAL SHAREHOLDERS’ MEETING | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 20<br>Strong leadership<br>NURIA MARTÍN BARNÉS<br>SECRETARY - NON-MEMBER<br>APPOINTMENTS AND REMUNERATION COMMITTEE - SECRETARY - NON-MEMBER<br>SUSTAINABILITY COMMITTEE - SECRETARY - NON-MEMBER<br>AUDIT COMMITTEE - SECRETARY - NON-MEMBER<br>The appointments of Víctor Grifols Roura as Chairman of Honour and Steven F. Mayer as executive<br>chairman were approved by the board on September 30, 2022.<br>Subsequent to the year-end, Steven F. Mayer resigned as Executive Chairman for health and<br>personal reasons. On February 21, 2023, the Board of Directors appointed Thomas Glanzmann as<br>new Executive Chairman.<br>58%<br>Independent directors<br>33%<br>Women board members<br>The Board of Directors appointed an<br>Executive Chairperson to reinforce<br>Grifols’ leadership, accelerate the<br>execution of the company’s strategic<br>plan and to increase value for all<br>shareholders.<br>VÍCTOR GRÍFOLS ROURA<br>PROPIETARY DIRECTOR<br>CHAIRMAN OF HONOUR<br>STEVEN F. MAYER<br>EXECUTIVE DIRECTOR<br>EXECUTIVE CHAIRMAN<br>RAIMON GRÍFOLS ROURA<br>EXECUTIVE DIRECTOR<br>CO-CEO<br>VÍCTOR GRÍFOLS DEU<br>EXECUTIVE DIRECTOR<br>CO-CEO<br>TOMÁS DAGÁ GELABERT<br>OTHER EXTERNAL<br>VICE SECRETARY<br>AUDIT COMMITTEE<br>APPOINTMENTS AND REMUNERATION COMMITTEE<br> ÍÑIGO SÁNCHEZ-ASIAÍN<br>MARDONES<br>INDEPENDENT DIRECTOR<br>AUDIT COMMITTEE - CHAIRPERSON<br>ENRIQUETA FELIP FONT<br>INDEPENDENT DIRECTOR<br>SUSTAINABILITY COMMITTEE<br>JAMES COSTOS<br>INDEPENDENT DIRECTOR<br>APPOINTMENTS AND<br>REMUNERATION COMMITTEE - CHAIRPERSON<br>CARINA SZPILKA LÁZARO<br>LEAD INDEPENDENT DIRECTOR<br>AUDIT COMMITTEE<br>THOMAS GLANZMANN<br>OTHER EXTERNAL<br>VICE CHAIRMAN NON-EXECUTIVE<br>SUSTAINABILITY COMMITTEE - CHAIRPERSON<br>MONTSERRAT MUÑOZ<br>ABELLANA<br>INDEPENDENT DIRECTOR<br>SUSTAINABILITY COMMITTEE<br>SUSANA GONZÁLEZ RODRÍGUEZ<br>INDEPENDENT DIRECTOR<br>APPOINTMENTS AND REMUNERATION COMMITTEE<br>Board of Directors<br>1<br>Lead independent director<br>+ More information on Grifols’ Board of Directors and its functions, board evaluations<br>and committees: www.grifols.com<br>+ More information on remunerations: Annual Remuneration Report and Directors’<br>Remuneration Policy. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 21 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>ALFREDO ARROYO GUERRA<br>CHIEF FINANCIAL OFFICER<br>JORDI BALSELLS VALLS<br>PRESIDENT PLASMA PROCUREMENT<br>DAVID BELL<br>CHIEF CORP DEV, LEG&DP OFFICER<br>VICENTE BLANQUER TORRE<br>CHIEF QUALITY OFFICER<br>MARÍA PÍA D’URBANO<br>PRESIDENT BIOPHARMA<br>DANIEL FLETA COIT<br>CHIEF INDUSTRIAL SERVICES OFFICER<br>MONTSERRAT GAJA LLAMAS<br>CHIEF HUMAN RESOURCES OFFICER<br>ALBERT GRÍFOLS COMA-CROS<br>CHIEF SCIENTIFIC INNOVATION OFFICER<br>ALBERTO GRÍFOLS ROURA<br>PRESIDENT, BIO-SUPPLIES<br>FRANCISCO JAVIER GUIX HUGUET<br>VP, HEALTHCARE SOLUTIONS<br>ANTONIO MARTÍNEZ MARTÍNEZ<br>PRESIDENT, DIAGNOSTIC<br>LLUIS PONS GÓMEZ<br>SVP, STRATEGY<br>IGNACIO RAMAL SUBIRA<br>CHIEF INT. AUDIT & ENTERPRISE RISK MGMT<br>MARÍA TERESA RIONÉ LLANO<br>CHIEF COMMUNICATIONS OFFICER<br>FERNANDO SEBASTIÁN RODRÍGUEZ HARO<br>EVP, TRANSFORMATION<br> Executive team<br>DIVERSE COMPETENCIES AND EXPERIENCE:<br>Broad sector experience<br>In Business management and science<br>In Sustainability<br>In Science and innovation<br>In Digital transformation<br>All committees are comprised by non-executive<br>directors, at least two of whom are independent. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 22<br>PLASMA<br>O Ensure plasma supply and access to treatments<br>O Boost a diversified network of plasma centers and maximize<br>their efficiency<br>INNOVATION<br>O Prioritize critical innovation projects<br>O Focus on differentiated products through in-house and investee<br>initiatives projects<br>O Integrate innovation and digital transformation projects that help<br>streamline processes and add value to the business model<br>DONORS AND PATIENTS O Intensify our commitment to patients, healthcare professionals<br>and donors<br>TALENT<br>O Foster a culture based on talent recognition and development<br>O Advocate and promote diversity, inclusion and equal opportunity<br>O Promote employee health and well-being<br>FINANCIAL<br>PERFORMANCE<br>O Reduce debt<br>O Financial discipline and cost control<br>O Sustainable growth<br>NEW BUSINESS MODELS<br>AND GLOBAL EXPANSION<br>O Promote public-private collaborations to bolster countries’ self-sufficiency in plasma-derived medicines<br>O Establish strategic high-potential alliances in core markets<br>SUSTAINABILITY<br>O Continue forging a culture of Sustainability throughout the<br>organization<br>O Maintain a robust Sustainability strategy and roadmap<br>O Increase the integration of ESG analyses and evaluations in<br>decision-making processes<br>Our management team: core priorities<br>New governance<br>New organizational<br>structure<br>New strategic plan<br>Redefined plasma<br>center model<br>Efficiency and<br>cost-savings plan<br>Biotest synergies<br>STRENGTHENING OUR BUSINESS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 23 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>Sustainability as a roadmap<br>Grifols has made significant strides in recent years to integrate<br>Sustainability into its business model and boost the positive impact<br>and value generated by its operations.<br>This ambition is reflected in Grifols’ Sustainability Policy<br>and 2021-23 Sustainability Master Plan, incorporated in its Strategic<br>Plan and aligned with the United Nations Sustainable Development<br>Goals (SDGs).<br>Based on an in-depth analysis of the company’s relevant or material<br>aspects, the Sustainability Master Plan outlines the 30 corporate<br>objectives that form Grifols 2030 Agenda.<br>Overview of Grifols’ relevant aspects<br>In 2022, Grifols identified its relevant aspects based on<br>their current or potential impact in the short, medium and<br>long term (impact materiality), as well as those that might<br>generate financial risks or opportunities and therefore affect<br>the company’s value in the short, medium and long term<br>(financial materiality).<br>This double analysis (double materiality) led to an objective<br>and strategic matrix, allowing Grifols to update its ESG sheet.<br>IMPACT MATERIALITY<br>FINANCIAL MATERIALITY<br>5<br>4<br>3<br>2<br>1 12345<br>1. Minimum 2. Low 3. Medium 4. High 5. Very high<br>1 Circular economy and resource management<br>2 Climate change<br>3 Energy efficiency<br>4 Human rights<br>5 Health contribution (patients and society)<br>6 Employee commitment<br>7 Data protection and cybersecurity<br>8 Innovation and knowledge generation<br>9 Contribution to society<br>10 Product safety and quality<br>11 Plasma and donors<br>12 Ethical code and good business practices<br>4<br>10<br>8<br>7 6<br>9<br>5<br>11<br>1<br>3<br>2<br>12<br>GRI 3-1, GRI 3-2 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 24<br>Grifols 2030 Agenda<br>Commitment to Donors and Patients Intermediate Status<br>O Achieve EUR 18 million per year in donations to support patient programs €13M/year<br>O Increase donations of clotting factors to 240 million IU 90M IU<br>O Achieve 90% approval among donors for positive customer service (good or excellent<br>rating) n/a<br>O Attain 80% referral rate from active donors n/a<br>O Increase ratings via the Donor Hub by 45% Same 2030 target<br>Social Impact Intermediate Status<br>O Increase the number of social outreach initiatives and investments by 50%<br>35%+ (initiatives)<br>13%+ (investments)<br>O Allocation of 25% of social initiatives for STEM scholarships for women 20%<br>O Reach $1 million in donations of products and medicines for emergency relief efforts 750k$<br>O Increase funds for José Antonio Grífols Lucas Foundation by 10% 10%<br>O Increase by 10% the amount allocated to bioethics grants and by 20% number of activities<br>developed by Víctor Grífols i Lucas Foundation 10%<br>Environmental responsibility Intermediate Status<br>O 55% decline in GHG emissions per unit of production -15%<br>O 15% increase in energy efficiency per unit of production +5%<br>O 100% electricity consumed from renewable sources 27%<br>O Promote decarbonization in business travel and work commutes Same 2030 target<br>O Increase circular economy measures at each stage of the operational life cycle Same 2030 target<br>O Protect biodiversity in the company’s natural areas to capture CO2 Same 2030 target<br>Ethical commitment Intermediate Status<br>O Implement ESG criteria among suppliers up to 60-80% of total spending volume 25%<br>O Maintain Biopharma claims ratio in ) 1/50,000 Same 2030 target<br>O Maintain <1 critical deficiencies identified by external audits (health regulatory authorities) Same 2030 target | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 25 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>Grifols is firmly committed to its strategic roadmap.<br>In 2022, we continued to advance at a progress rate of over<br>90%, evidence of our headway toward meeting our Agenda<br>2030 objectives.<br>* Plasma workforce excluded.<br>Our People Intermediate Status<br>O Impart 100 hours of training hours/year/person Same 2030 target<br>O Deliver annual training to 70-80% of the workforce Same 2030 target<br>O Increase percentage of women in Senior Manager roles to 50% 41%<br>O Increase percentage of people with disabilities to 3-5% of total employee pool Same 2030 target<br>O Ensure women comprise 50% of interviews for managerial positions 45%<br>O Maintain employee turnover rate below industry average* Same 2030 target<br>O Achieve 70% overall employee engagement rate per department 63%<br>O 75% increase in installations certified as healthy workplaces 54%<br>O 15% decrease in LTIFR (lost time injury frequency rate) 5,3%<br>O 75% of installations with ISO 45001 certification 54%<br>Innovation Intermediate Status<br>O Promote in-house and external innovation in core<br>therapeutic areas<br>O Achieve 80%+ of milestones defined in key<br>innovation projects<br>O Allocate at least 75% of R+D investment to<br>new products and market development<br> Z | ||
| --- | ||
| Commitment to<br>donors and patients<br>Building<br>bridges<br>2 | ||
| --- | ||
| We are health<br>Our priorities<br>WE SUBSCRIBE TO THE PRINCIPLES OF BIOETHICS<br>We work to guarantee the supply of plasma and advance countries’ self-sufficiency to assure access to plasma-based treatments. Our standards of<br>quality, safety, transparency and engagement are industry references as the<br>health and well-being of thousands of people depend upon us.<br>Roadmap for Grifols<br>2030 Agenda<br> • Increase donations to<br>patient programs<br> • Increase donations<br>of clotting factors in<br>developing countries<br> • Boost product donations<br>for emergency relief<br>efforts<br> • Achieve service<br>ratings from donors of<br> “excellent” or “good”<br> • Encourage more donors<br>to recommend the<br>donation process to<br>family and friends<br> • Increase ratings on donor<br>applications<br>Donors<br>Patient associations<br>Self-sufficiency<br>Patients<br>AUTONOMY<br>Each person is able to make decisions freely and independently.<br>JUSTICE<br>Healthcare resources are allocated equitably and fairly.<br>BENEFICENCE<br>We work to optimize benefits for patients and diminish<br>potential harm.<br>NON-MALEFICENCE<br>Our actions cannot intentionally create a harm or injury<br>to the patient. | ||
| --- | ||
| “I like helping people. Donating plasma has a positive impact, and I feel good knowing I<br>contribute to saving people’s lives.”<br>Trent H., Texas, United States<br>1,586 donations<br>Committed donors<br>O Donations are via plasmapheresis<br>O Plasma is only collected from qualified<br>donors who regularly donate in centers<br>routinely inspected by health authorities<br>O Donating plasma is safe<br>2,600 M€<br>positive impact on donors<br>920,000+<br>donors<br>Makes up 55% of whole blood<br>Contains 90% water<br>7% are essential proteins:<br>Grifols transforms donor plasma into life-sustaining<br>medicines, ensuring responsible operations at every stage of<br>the value chain.<br>Donors Plasma<br>ALPHA ALBUMIN<br>AND BETA<br>GLOBULINS<br>IMMUNO<br>GLOBULINS<br>CLOTTING FIBRINOGEN<br>FACTORS<br>1% 3% 15% 21% 60%<br>2022 Consolidated Directors’ Report · 28 | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 29<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 29<br> “It took me 21 years for a correct diagnosis of Alpha-1. Because<br>donors donate their plasma, I am able to live a better life; I am<br>on my feet and moving most of the time.”<br>Matteo - Italia. Alpha 1-antitrypsin deficiency (AADT) patient<br>Improving patients’ lives<br>O Suitable plasma<br>O Protein fractionation and purification<br>O Viral inactivation and sterile filling<br>O Maximum product control via holographic seal and<br>PEDIGRI® system<br>60<br>day inventory hold<br>10+<br>screening analyses per donation<br>O Dozens of diseases are treated with plasma therapies<br>O Proactive promotion of access to treatment<br>O Numerous patient support programs<br>800,000+<br>patients treated<br>On average, nine to 12 months are needed to<br>convert this raw material into essential<br>plasma-based therapies for patients.<br>Value chain Patients<br>23,810 M€<br>positive impact on patients | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 30<br>Efforts to guarantee<br>plasma supply<br>Greater awareness<br>O Campaigns and collaborations in the U.S. and Europe<br>O Promotion of International Plasma Awareness Week (IPAW),<br>organized by the Plasma Protein Therapeutics Association (PPTA)<br>O Cooperation with patient authorities and associations<br>O Support of the U.S. Plasma Donation Awareness Act<br>O Support for EU policies that promote strategic<br>self-sufficiency of plasma<br>+ More information in Chapter 6: Impact on Society<br>More plasma centers<br>O Grifols operates the largest network of plasma centers<br>in the world<br>O 390+ plasma centers<br>O Global and diversified operations<br>O Acquisition of first plasma center in Canada in 2022<br>O Opening of two plasma centers in Egypt out of the 20 planned<br>by 2023<br>O 33 Biotest centers<br>Greater self-sufficiency<br>O Consolidation of the strategic alliance in Egypt<br>O New alliance with Canadian Blood Services<br>+ More information in Chapter 6: Social Impact.<br>Museu Grifols: spotlighting the value of plasma for 25 years<br>In 2022, Museu Grifols marked the 25th anniversary of its Barcelona inauguration. Located in the former headquarters of<br>Laboratorios Grifols, this unique space has welcomed more than 11,000 people to better understand and appreciate the vital role<br>of plasma in global healthcare systems. Through visually appealing exhibits, visitors learn more about plasma and the production<br>of plasma-based therapies, and how they enhance the health and well-being of people worldwide. In addition to Barcelona, Museu<br>Grifols also has headquarters in Los Angeles and permanent exhibitions in other U.S. cities. | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 31<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Program to boost plasma self-sufficiency:<br>leading the change<br>A strategic alliance with Canada<br>In 2022, Grifols reached a long-term collaboration agreement with Canadian Blood Services (CBS) to<br>accelerate the country’s immunoglobulin self-sufficiency from 15% to 50% in the shortest timeframe<br>possible. Grifols will produce immunoglobulins exclusively for CBS at its new fractionation plant in<br>Montreal.<br>This is the first time CBS has signed this type of agreement. Based on Grifols’ leadership in establishing<br>private-public-sector partnerships, this is the best way to ensure countries’ plasma self-sufficiency.<br>Canada has high Ig consumption, currently importing up to 85% of this plasma protein.<br>To help address the country’s needs, Grifols is creating a vertical supply chain with new plasma donation<br>centers to be opened in the coming years and already-acquired production facilities, including its<br>manufacturing plant in Montreal and a plasma donation center in Winnipeg. The manufacturing process will<br>take place in Grifols’ Clayton (North Carolina) plant until the Montreal plant is fully operational in 2026.<br>Egypt, pioneering in the Middle East<br>and Africa<br>Grifols signed a strategic alliance with the Egyptian government in 2020 to promote the self-supply of<br>plasma medicines through a public-private partnership model. Under this innovative alliance, Grifols is<br>helping develop the first integrated platform in the Middle East and Africa to supply plasma therapies on<br>national and regional levels.<br>Grifols Egypt currently has two operational plasma centers, with the aim of opening 20 centers in total.<br>The company continues to make inroads on the construction of the remaining production installations,<br>including plasma fractionation and purification plants, and analysis and storage facilities. These<br>installations are expected to be operational by 2025. In the meantime, all collected plasma (up to a<br>million liters per year) will be processed in Spain and returned to Egypt as finished product.<br>The World Health Organization (WHO), Council of Europe and other institutions all agree on the urgent need for countries to increase their self-sufficiency of plasma-derived medicines for the sake of patients who<br>need them. Under the umbrella of its “Self-sufficiency Program,” Grifols closely collaborates with countries to advance this crucial objective, helping them improve their healthcare systems and reduce their reliance<br>on third parties. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 32<br>8 commitments to donors 8 commitments to donors<br>Safeguard donors’ health, safety and well-being<br>Respect donors’ human rights and ensure equal treatment following the principles of non-discrimination<br>Ensure donors provide informed consent before donating plasma<br>Respect legislation in each country regarding donor compensation and the frequency of plasma donations<br>Support local communities where donor centers are located<br>Comply with personal data legal requirements and implement all necessary measures to protect donors’ privacy and personal data<br>Promote open communication and awareness about the uses of plasma medicines<br>Ensure every interaction with donors is professional, respectful, helpful and engaging<br>Our commitment<br>to donors<br>Respect for dignity and human rights underpin all Grifols’ activities in alignment with the core principles of the Universal Declaration of Human Rights (1948), Declaration<br>of Helsinki (1964), and UNESCO Universal Declaration of Bioethics and Human Rights (2005).<br>As defined in Grifols’ Code of Ethics, all company interactions with stakeholders, including donors, are founded on a deep-seated respect for human rights. This principle<br>is articulated in the Grifols Donor Policy, which also underlines respect for country-specific legal regulations, non-discrimination and measures to protect donors’ health<br>and safety as fundamental commitments. | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 33<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 33<br>Grifols donors represent a cross-section of society<br>DONOR SATISFACTION RATE *<br>94%<br>Active donors who recommend<br>the donation process to family<br>and friends<br>86%<br>Active donors who rate Grifols’<br>attention as good or excellent<br>BALANCED DISTRIBUTION EDUCATION AND EMPLOYMENT<br>41% 59%<br>31%<br>18 to 25<br>61%<br>college graduates<br>* Based on the 2021 survey of approximately 5,000 active donors (last donation in the last 60 days)<br>27%<br>current<br>university<br>students<br>95%<br>full-time employees<br>12%<br>high school<br>graduates<br>31%<br>26 to 35<br>6%<br>56 to 65<br>13%<br>46 to 55<br>19%<br>36 to 45<br>AGE<br>Grifols provides clear and reliable information for donors at every stage of the donation<br>process, and prior informed consent is essential. Interactions with donors are founded on the<br>utmost respect for human rights and the principles of bioethics and transparency. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 34<br>Donors and donations<br>Donation regulations<br>Plasma can be procured from whole blood donations (recovered plasma) or via plasmapheresis<br>(sourced plasma).<br>Plasma collection for fractionation is strictly regulated by various global healthcare authorities and good<br>manufacturing practices (GMP). In the United States, the regulatory authority is the FDA and, in Europe,<br>it is the European Agency for Medicine (EMA). The Plasma Protein Therapeutics Association (PPTA)<br>defines and monitors additional quality standards as part of its voluntary IQPP (International Quality<br>Plasma Program) certification.<br>Plasma donation is an extremely safe process, with few to no side effects. Using the plasmapheresis<br>technique, plasma is extracted from whole blood and blood cells, platelets and other components are<br>returned to the donor. The body can regenerate the volume of collected proteins in less than 24 hours, a<br>far shorter recovery compared to whole blood donations.<br>Quality control in plasma donation centers<br>Grifols’ donation centers follow the highest quality and safety standards and undergo ongoing regulatory<br>inspections to guarantee the safety and quality of donated plasma.<br>Plasma cannot be synthetically produced or created in a laboratory. Hundreds of donors<br>and donations are needed to provide a single year’s supply of plasma-derived medicines<br>for just one patient.<br>No administrative<br>action** in 2022<br>REGULATORY INSPECTIONS IN GRIFOLS’<br>PLASMA DONATION CENTERS<br>No. of inspection days<br>2022 2021<br>FDA* 119 80<br>EMA 182 196<br>CLIA-COLA 108 145<br>PPTA 123 117<br>TOTAL 532 538<br>Including Biotest<br>(*) More than 95% of FDA inspections resulted in 0 observations.<br>(**) Suspension, revocation or loss of any license or certification; warning letter, imposed suspension of any regulated activity.<br>Plasmapheresis, a safe procedure for<br>donating plasma<br>WHOLE-BLOOD COLLECTION<br>BLOOD AND<br>PLASMA SEPARATION<br>RED AND WHITE BLOOD<br>CELLS ARE RETURNED<br>ONLY PLASMA IS DONATED | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 35<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Donation criteria<br>When is donating plasma not allowed?<br>Grifols follows all the regulatory requirements of the<br>health authorities. Additionally, has comprehensive<br>processes, using the evidence based medicine approach,<br>to establish the eligibility criteria an ensure whether a<br>donor can donate. If medical evaluations reveal abnormal<br>levels or irregular parameters, donors must postpone the<br>donation process to ensure these are not indicative of an<br>underlying health issue. Biomarkers include:<br>O Irregular heartbeat<br>O High body temperature<br>O High or low hematocrit<br>O High or low total protein<br>O Lipemic plasma<br>We protect donors’ health<br>Grifols only uses plasma from qualified donors, never<br>from occasional donors. Once deemed suitable, donors<br>undergo physical exams and assessments of their<br>medical, surgical, social and travel history. They are also<br>subject to medical history before every donation.<br>This information is recorded in the donor’s file, which<br>is confidential and in compliance with Grifols’ data<br>protection policy.<br>Before each donation, a specialized Grifols staff member<br>checks the donor’s vital signs and weight, as well as<br>blood and plasma protein levels to confirm they can<br>safely donate.<br>Grifols’ regular medical assessments helps enhance the<br>overall health and well-being of its donors, one of its<br>corporate priorities.<br>Qualified donors<br>O Donate at least twice over the last 6 months<br>O Maximum 2 times every 7 days<br>O 18-69 years old<br>O 50+ kg<br>O Normal limits medical exam<br>DOCUMENTATION<br>O Valid ID picture: driver’s license, passport, etc.<br>O Proof of Social Security Number<br>O Proof of address<br>Blood analysis with every donation<br>O HCV, HBV, VHA, HIV and B19 virus detection<br>O Hepatitis B, Hepatitis C and HIV antibodies<br>O Other periodic tests<br>Specific controls<br>O Weight, blood pressure, pulse, temperature, anemia and protein<br>levels<br>Plasmavigilance: safe donations<br>Grifols’ plasmavigilance data in 2021 indicates<br>minimal donor adverse events (DAE)* in line with<br>previous years. Only 0.2% of donations caused<br>side effects per 10,000 donations. These levels are<br>similar to those of previous years. Most adverse<br>effects were minor, resulting in hypotensive events<br>or phlebotomy-related injuries like hematomas.<br>Severe reactions requiring medical assistance were<br>extremely rare, representing only 0.005% of Grifols’<br>total donations.<br>Data on donor side effects continues to confirm the<br>safety of plasma donation.<br>*Grifols publishes plasmavigilance data one year after the study<br>following the criteria outlined in the “IQPP Standard for Donor<br>Adverse Events” and the nine categories included in Plasma Protein<br>Therapeutics Association (PPTA) guidelines.<br>Hematomas<br>49.2%<br>Hypotension<br>42.9%<br>Other 3%<br>Hyperventilation 0.5%<br>Citrate reactions 1.7%<br>Allergic reactions 1.6%<br>Aeroembolism 0.06% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 36<br>Donor health is our top priority<br>STUDY ON PLASMAVIGILANCE IN THE U.S.<br>The rate of side effects from plasma donations via<br>plasmapheresis is not significant<br>More than 1.1 million donors – who together account for 72% of the U.S. source plasma collected<br>for a four-month – participated in the first industry-wide, multi company study of the incidence,<br>frequency and type of adverse effects of plasmapheresis. Promoted by the PPTA in cooperation<br>with diverse industry firms, the study confirmed the overall safety of plasmapheresis. Following FDA<br>standards of collection volumes and donation frequency, the rate of adverse events (AE) was 1.58 per<br>10,000 donations. Moreover, 90% of AEs were minor, such as hypotension and phlebotomy-related<br>hematomas, and there were no reports of serious or severe adverse events. The scientific journal<br>Transfusion published the study’s findings in 2021.<br>IRON LEVELS<br>Plasma donation has no effect on iron reserves<br>This study found no loss of iron or decline in ferritin levels a a result of regular plasma donations –<br>even in the case of long-term donors – as opposed to whole blood donations. In light of these findings,<br>there is no need to monitor donors’ iron levels or recommend iron supplements.<br>CHOLESTEROL LEVELS<br>Research findings suggest that cholesterol levels may decline<br>Apheresis or low-density lipoprotein extraction is used to treat patients with familial<br>hypercholesterolemia. Similarly, the low-volume plasmapheresis used in plasma donations may also<br>lower cholesterol levels in some donors. This research initiative examined the effect of plasmapheresis<br>on total LDL and HDL cholesterol levels in a healthy plasma donor population. Based on its findings,<br>total and LDL cholesterol levels may decline in donors with elevated baseline cholesterol levels<br>following regular voluntary plasmapheresis. In donors with low baseline HDL levels, HDL cholesterol<br>levels may increase.<br>BLOOD PRESSURE<br>The results suggest a beneficial effect for donors with high<br>blood pressure<br>Grifols conducted a study to determine the potential effects of plasmapheresis on blood pressure.<br>The results suggest a beneficial effect among donors with high baseline blood-pressure levels, with<br>significant decreases in both systolic and diastolic blood pressure when donation intervals are under<br>14 days. No decline in blood pressure was observed among donors with baseline normal blood<br>pressure levels.<br>+ Access to all studies: Plasmavigilance: Source Plasma Joins the Call to Arms - Cho - 2021 - Transfusion - Wiley Online Library. Prospective Multicentre Study of the Effect of Voluntary Plasmapheresis on Plasma Cholesterol Levels in Donors. Frequent Source Plasma<br>Donors Are Not at Risk of Iron Depletion. The Effect of Plasmapheresis on Blood Pressure in Voluntary Plasma Donors - PubMed (nih.gov).<br>Grifols directly supports and promotes the research of diverse scientific institutions and<br>associations to better understand the potential effects of plasmapheresis on donors as part<br>of its commitment to donor health and safety. | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 37<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Donation centers<br>in dedicated<br>communities<br>In 2022, Grifols operated 298 plasma centers in the U.S. and 91 in<br>Europe, all located in communities dedicated to driving positive change. Its<br>U.S. plasma donation centers are geographically diverse, with no particular<br>concentration in specific areas.<br>In its search for suitable sites for plasma centers, Grifols considers areas<br>with a solid commitment to community progress, active chambers of<br>commerce, and a strong vocation to advancing social progress. For Grifols,<br>a community’s active participation in the plasma donation process is<br>paramount to securing patients’ access to life-sustaining plasma-based<br>therapies.<br>Grifols’ plasma-center employees take proactive steps to forge ties with<br>local residents by organizing educational, social and awareness-raising<br>events on the vital need for plasma donations. Plasma centers also<br>collaborate with local businesses and non-governmental organizations to<br>help raise awareness on plasma and the manufacturing process of<br>plasma therapies.<br>The company considers other criteria when choosing where to establish<br>plasma donation centers, including low viral markers, below-average crime<br>statistics and community heterogeneity, critical to ensuring a diverse donor<br>pool.<br>Our commitment creates value<br>A win-win commitment<br>In 2022, Grifols once again measured the socioeconomic impact of its plasma donation centers in the United<br>States and Germany using the input-output methodology.<br>Total economic impact<br> €4,550M<br>+49% higher than 2021<br>Total jobs created<br>122,500<br>+43% higher than 2021 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 38<br> A differential value chain<br>PLASMA<br>COLLECTION<br>ANALYSIS OF<br>DONATED<br>PLASMA<br>INVENTORY<br>HOLD<br>PLASMA PROCUREMENT<br>Only qualified<br>donors<br> • Screenings for virus<br>antigens or antibodies<br> 10+ analyses per unit of<br> plasma: hepatitis A, B and<br> C, HIV, parvovirus B19, etc.<br> • Use of highly sensitive<br>techniques like NAT and<br>ELISA<br> • Laboratories approved by<br>FDA, EMA and other health<br>authorities<br> • Minimum 60-day<br>inventory hold before<br>used in production<br> • New verification of<br>samples to guarantee<br>the absence of viral or<br>pathogenic markers<br>PLASMA<br>Internal Control Framework<br>Grifols’ robust safety system encompasses a highly trained staff; rigorous process and product designs; innovative Grifols-engineered<br>technologies; and complete traceability, from plasma donation to commercialization.<br>Grifols’ Quality Area monitors the diverse materials and procedures that intervene in the supply chain. This supervision includes controls in<br>both manufacturing processes and final products to assure the quality, safety and efficacy of each lot, as well as the review and follow-up<br>of manufacturing procedures to guarantee compliance with GMPs and ongoing improvements. It also oversees systems to escalate relevant<br>events and take corrective actions through Grifols Quality Committees, which evaluate key performance indicators (KPIs) and quality markers.<br>Grifols forms part of the National Donor Deferral Registry (NDDR), the industry’s voluntary self-regulatory initiative to verify the quality<br>and safety of plasma applicable to all U.S. donors.<br>Supplier Audit System<br>Under Grifols’ Supplier Qualification Management System, and softgoods<br>are subject to strict and ongoing evaluation processes, including plasma<br>from external suppliers and critical non-plasma suppliers. Grifols<br>conducts routine supplier audits to guarantee compliance with GMP<br>regulations and quality standards.<br>+ More information: https://www.pptaglobal.org/safetyquality/nationaldonor-deferral-registry + A detailed breakdown of supply audits is available in Chapter 3: Ethical commitment.<br>Plasma Procurement Regulation<br>O WHO: recommendations for the manufacture, control and regulation of human plasma for<br>fractionation (WHO Technical Report Series, No. 941)<br>O Directive 2002/98/CE, which establishes standards for the quality and safety of the processes<br>related to human blood and its components<br>O EMA Guideline on Plasma-Derived Medicinal Products<br>O 21CFR Part 640: additional standards for human blood and blood products<br>O Local regulations in countries where hemoderivatives are distributed<br>O PPTA standards that Grifols voluntarily adheres to<br>O European Pharmacopoeia<br>Biopharma Regulation<br>O Good Pharmacovigilance Practices, EMA<br>O Code of Federal Regulations (CFR): 21 CFR 11, 21 CFR 210, 21 CFR 211, 21 CFR 600, 601, 610,<br>630 and 640<br>O Good Manufacturing Practices, Pharmaceutical Inspection Co-operation Scheme (PIC/S)<br>O European Pharmacopoeia<br>O United States Pharmacopeia<br>O Local regulations in countries where hemoderivatives are distributed | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 39<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>QUALITY MANAGEMENT<br>SYSTEMS IN<br>MANUFACTURING<br>FACILITIES<br>Production with suitable<br>plasma<br>Production stages:<br>fractionation or separation of<br>proteins, purification, specific stages<br>of viral inactivation,<br>dosage and conditioning Adherence<br>to Good Manufacturing Practices<br>(GMP)<br>ELIMINATION OF VIRUSES AND<br>OTHER PATHOGENS<br>Carried out throughout the<br>manufacturing process<br>Testing and elimination processes for<br>potential pathogens, viral inactivation and<br>virus removal techniques<br>May also include pasteurization, heat<br>treatment, solvent/detergent treatment<br>and/or nanofiltration, depending on the<br>product<br>ASEPTIC FILLING<br>Once purified<br>Sterilization and dosing<br>carried out using an exclusive<br>system developed by Grifols<br>Engineering<br>PRODUCT TRACKING AND<br>TRACEABILITY<br>Vial identification with a unique code<br>Packaging with a holographic seal to assure<br>inviolability and authenticity<br>System for assigning unique and traceable<br>numerical series to prevent counterfeiting<br>PEDIGRI® system to provide healthcare<br>professionals with detailed information on<br>specific plasma used<br>BIOPHARMA<br>MANUFACTURING POST-SALES<br>External certifications<br>The quality systems of all Grifols’ medicine and medical device production facilities are certified by external<br>bodies<br> • Certifications of Good Business Manufacturing Practices from the European Union, the United States and<br>other countries where required.<br> • IQPP & QSEAL Certifications from the Plasma Protein Therapeutics Association (PPTA).<br> • International Quality Plasma Program (IQPP) Certification, a voluntary standards program including the<br>management of donors and plasma centers.<br> • Quality Standards of Excellence, Assurance and Leadership (QSEAL) Certification, with voluntary<br>membership and certification, applicable to the manufacture of plasma-derived medicines.<br>100% of the employees subject to quality control and product safety receive training in this area.<br>Internal and external quality audits<br> • Grifols management establishes and maintains the quality management system. Internal<br>auditors periodically audit plasma centers, laboratories, production facilities and warehouses to<br>monitor quality standards and GMP compliance.<br> • The quality audit area conducts routine reviews of all operations.<br> • All plasma centers, manufacturing plants, warehouses and laboratories are periodically<br>inspected by health authorities in the U.S. (FDA), Europe (EMA) and other countries in<br>accordance with current regulations.<br> • Plasma centers and fractionation plants are subject to regular PPTA inspections.<br>+ https://www. pptaglobal.org/safety-quality/standards/iqpp<br>+ A detailed breakdown of supply audits is available in Chapter 3. Ethical commitment. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 40<br>Guided by the greatest respect for human rights, Grifols has<br>three unwavering commitments that oversee its interactions<br>with patients and patient organizations:<br>Our commitment to patients<br>Patient notification system<br>Grifols has supported and participated in the Plasma<br>Protein Therapeutics Association’s (PPTA) Patient<br>Notification System (PNS) since 1998. Using this free<br>system, patients and registered persons are notified<br>of information relating to the voluntary or mandatory<br>withdrawal of plasma medicines. The service is<br>confidential and limited to registered users such as<br>patients, doctors, family members and pharmaceutical<br>professionals.<br>+ More information: https://www.pptaglobal.org/advocacy/patient-notification-system<br>We subscribe to international<br>principles:<br>O International Bill of Human Rights (includes the<br>Universal Declaration of Human Rights, International<br>Covenant on Civil and Political Rights, and International<br>Covenant on Economic, Social and Cultural Rights)<br>O Declaration of Helsinki<br>O UNESCO Universal Declaration on Bioethics and Human<br>Rights<br>O United Nations Guiding Principles on Business and<br>Human Rights<br>O OECD Guidelines for Multinational Enterprises<br>O United Nations Global Compact<br>O Delivery of the best possible therapies,<br>products and services through<br>continuous innovation and leadership in<br>safety and quality standards.<br>O Engagement and support of patients<br>and organizations by serving as a<br>reliable and transparent source of<br>information.<br>O Advocacy and support of the principles<br>of justice and equality in healthcare,<br>with a special focus on access to<br>plasma therapies.<br>Safety and quality Transparency and independence Access to treatment | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 41<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>ALBUMIN<br> – Liver cirrhosis<br> – Surgery (cardiac and major)<br> – Intensive care (e.g. sepsis, burns)<br>IMMUNOGLOBULINS<br> – Immunodeficiencies<br> – Primary (PIDD)<br> – Secondary (SID)<br> – Neurological conditions<br> – Chronic inflammatory demyelinating<br>polyradiculoneuropathy (CIDP)<br> – Acute demyelinating polyneuropathy<br>(Guillain Barré)<br> – Multifocal motor neuropathy (MMN)<br> – Hematological conditions<br> – Immune thrombocytopenia (immune<br>thrombocytopenic purpura or ITP)<br> – Neuromuscular diseases<br> – Myasthenia Gravis (MG)<br> – Post-exposure prophylaxis for rabies<br> – Post-exposure prophylaxis and treatment<br>for tetanus<br> – Immunoprophylaxis of hepatitis B<br>ALPHA-1 ANTITRYPSIN<br> – Alpha-1 antitrypsin deficiency disorder<br>(AATD) (genetic emphysema)<br>CLOTTING FACTORS<br> – Bleeding disorders<br> – Hemophilia A and B<br> – Von Willebrand disease (VWD)<br> – Rare clotting factor deficiencies<br> – Trauma/injury-related hemorrhaging<br> – Overdose of anticoagulants or toxic<br>substances that induce bleeding<br>ALBUMIN<br>25g<br>IMMUNOGLOBULINS<br>4g<br>ALPHA-1 ANTITRYPSIN<br>0,15-0,30g<br>CLOTTING FACTORS<br>Factor VIII: 300 a 450 UI<br>Factor IX: 180 a 200 UI<br>An estimated two million people in Europe1 suffer from one of the 12 most common rare diseases, including hemophilia and<br>primary immunodeficiency (PIDD).These conditions are treated and managed with plasma-derived therapies.<br>The potential benefits of plasma therapies for high-prevalence diseases continues to grow in line with scientific advances. Plasma<br>proteins are also used in everyday medical treatments, emergency services and surgical interventions, among other uses.<br>(1) - Silvia Rohr and Rianne Emst “Key Economic and Value Consideration for Plasma-Derived Medicinal Products (PDMPs) in Europe” for the PPTA.<br>Patients benefitted in 2022<br>800,000+<br>Immunodeficiencies and<br>neurological conditions<br>Bleeding disorders Alpha-1 antitrypsin<br>deficiency<br>Increase in life expectancy O OO<br>Improvement in quality of life O OO<br>Prevention of infections OFor PIDD and SID<br>Positive impact on disease progression O OO<br>Prevalence<br>PIDD: 1/13,500 CIDP: 1/200,000 in<br>children 1-7/100,000 in adults<br>PTI: 9.5/100,000<br>Hemophilia A: 25/100.000<br>Hemophilia B: 5/100.000<br>EvW: 1/8,500-1/50,000<br>AADT: 123,7/100,000<br>Essential treatments<br>Benefits of plasma-based therapies by disease<br>Diseases treated | ||
| --- | ||
| 2022 Informe Anual Integrado y de Sostenibilidad · 42<br>Access to treatments<br>Patient support initiatives in the U.S.<br>Grifols works actively to promote patient access to the treatments they need, especially when<br>extraordinary circumstances may affect or limit this access. Since 2006, the company implemented<br>initiatives to support patients who are treated with its plasma medicines during lapses in medical<br>insurance coverage. It also provides treatment to patients who need short-term help.<br>4,185<br>Patients benefitted in 2022<br> €11.8M<br>value* of support provided in 2022<br>* Includes product value and financial support. | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Informe Anual Integrado y de Sostenibilidad · 43<br>World Federation of Hemophilia<br>8,245 patients treated 2014-2021*<br>4,459 patients treated in 2021*<br>30+ countries<br>33.5 million IU donated in 2022<br>Approximately 400,000 people around the world suffer from severe hemophilia, yet 75% do not receive<br>treatment. Grifols has collaborated with the World Federation of Hemophilia (WFH) Humanitarian Aid<br>Program since 2014 by donating clotting factors for hemophilia patients in need of treatment.<br>Grifols donations also support the WFH’s Global Alliance for Progress (GAP) program. In its second<br>decade, this initiative aims to increase the number of patients diagnosed and treated for bleeding<br>disorders, especially in the world’s poorest countries.<br>Support in emergency situations<br>Grifols collaborates with Direct Relief to provide medical resources to healthcare professionals following<br>natural disasters and other humanitarian emergencies. In 2022, the company updated its donation<br>procedures with Direct Relief to expedite the delivery of donated products.<br>*Source: WFH data/ **IU = international units<br>Global Aid Program<br> €2.0 M<br>million in plasma medicines donated 2019-2022<br> €0.7 M<br>value of product donations in 2022<br>218M+<br>IU clotting factors<br>2022-2030 Commitment<br>Donate 240 million IU**,<br>which provides 10,300 doses to<br>treat 3,000 patients per year | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 44<br>Patient associations and advocacy groups play a fundamental role in global healthcare systems by giving patients a voice. Coordinated by<br>Global Patient Affairs team, these organizations are an essential component of Grifols’ corporate actions and decision-making process.<br>The company’s interactions with patient associations respect country-specific regulations and transparency principles. Grifols has<br>standardized operating procedures to internally regulate collaboration agreements, grants and donations by establishing eligibility,<br>compliance, ethics and transparency guidelines. These criteria are outlined in the Patient and Patient Organizations Policy.<br>Broad scope in 2022<br>Grifols engaged more than 80 global patient organizations in core therapeutic areas. In 2022 Grifols allocated nearly €21 M to product<br>donations* and to support 50 of these associations through various programs and activities. Europe has been the main focus of the<br>company's activity.<br>Patient associations<br>+ * More details: Access to treatments section<br>How we collaborate<br>O Awareness: We support initiatives to increase awareness<br>of specific diseases<br>O Boosting diagnostic rates: We promote early diagnosis<br>O Education: We contribute to educate patients, families<br>and caretakers<br>O Communication: We facilitate communication between<br>patients, medical professionals and policymakers<br>O Access: We promote better access to treatment<br>and healthcare<br>Grifols patient interactions: guiding<br>principles<br>O Mutual benefit: Demonstrate a clear benefit for patients<br>O Transparency: Public disclosure of financial contributions to<br>patient associations and encouragement that they<br>do likewise<br>O Integrity: Commitment always in alignment with corporate<br>objectives and priorities<br>O Compliance: Compliance with all legal norms, rules and<br>guidelines, as well as Grifols policies<br>O Independence: The right not to support Grifols’ actions<br>+ More information on Grifols Patient and Patient Organization Policy:<br>www.grifols.com<br>North America:<br>O Focus on the U.S.,<br>Canada and Mexico<br>Europe:<br>O Focus on Spain,<br>France, Germany, Italy<br>and Scandinavia<br>Latin America:<br>O Focus on Brazil and<br>Argentina<br>Asia:<br>O Focus on Australia<br>Therapeutic<br>Areas/Diseases<br>4<br>geographic regions<br>Interaction with 80+ patient associations<br>Pulmunology<br>Immunology<br>Neurology<br>Alzheimer’s disease<br>Liver disease<br>Bleeding disorders | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 45<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Collaborations and programs<br>Donation program to patient associations<br>The company supports the projects and initiatives spearheaded by patient organizations around four strategic lines:<br>O Education and empowerment: Efforts to involve patients in making decisions about their health. In the case of rare diseases, training<br>medical professionals is also key to reduce the time to diagnosis and improve the approach to these conditions. To this end, Grifols<br>collaborates in various seminars and scientific conferences.<br>O Greater awareness and visibility: Initiatives to give visibility to patient communities and commemorate their related International<br>Days to forge community ties and help get their needs and challenges included on political agendas. Grifols takes part in creating and<br>maintaining different communication channels and informational collateral.<br>O Patient experience and welfare: Grifols collaborates with projects aimed at improving disease management and patient experience,<br>including programs to facilitate the administration of treatments and promote healthy lifestyle and nutritional habits, among others. In<br>2022, the company supported Spanish hemophilia associations to offer patients physiotherapy services to address their musculoskeletal<br>challenges and improve functional capacity, as well as psychological support programs for pediatric and adult patients of various<br>associations.<br>O Advocacy and access: Patient organizations ensure equity in access to treatment, and in the case of plasma derivatives, they also<br>promote plasma sufficiency through a single donor-patient link. The shortage of plasma-based medicines remains an urgent global<br>challenge despite a greater focus during the COVID-19 crisis. In 2022, Grifols continued to support plasma awareness and educational<br>campaigns in Europe led by various primary immunodeficiency patient organizations.<br>Plasma education program for European<br>patient associations<br>This initiative was launched in 2022 to educate and empower<br>patient communities. Two editions of the program have been carried<br>out with the participation of the main patient organizations in<br>Austria, Germany, Spain and Switzerland.<br>Building community<br>Grifols strives to forge trusting relationships, educate and<br>support the patient communities it serves. The “Open House”<br>educational program, launched in the United States, is among<br>the initiatives that reflects this commitment. In 2022, Grifols<br>launched a program in Europe, bringing together, for the first<br>time, 18 representatives from 10 different patient organizations<br>in Spain in the first edition, and 12 representatives from 6<br>German-speaking organizations (plus two plasma donors) in the<br>second edition, at the Grifols Museum and production plants in<br>Barcelona. In addition to promoting education, “Open House”<br>also aims to reinforce ties with patient associations by building<br>a sense of community, promoting joint efforts and increasing<br>their visibility.<br>We support patients’ needs<br>The Spanish Association of Primary Immune Deficiencies<br>(AEDIP) leads the “Spanish Consensus for the Sufficiency<br>of Plasma and Its Related Treatments” to promote a<br>national strategy for plasma and plasma-based treatments<br>in collaboration with patient associations, clinical experts,<br>scientific societies, donor organizations and other market<br>agents. The AEDIP aspires to make Spain a benchmark in the<br>collection, management and use of plasma, ensuring patients a<br>sufficient supply of plasma therapies and fast, fair access<br>to treatment. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 46<br>FINANCIAL STABILITY<br>Donors have more income to meet<br>their day-to-day needs and cover<br>their monthly living expenses.<br>HEALTHIER LIVES<br>Their health improves since they are able to<br>afford better-quality food and exercise more<br>frequently.<br>PHYSICAL AND PSYCHOLOGICAL<br>WELL-BEING<br>Donors feel better about themselves,<br>enjoy a better social life and spend<br>more time with family and friends.<br>EDUCATIONAL EXPENSES<br>Donors are more confident about their future<br>since they can better afford tuition and pay<br>for other college-related expenses.<br>HEALTHCARE ACCESS<br>A healthier community since donors must<br>be in good health in order to donate. More<br>people benefit from plasma-derived proteins.<br>ECONOMIC IMPACT IN DONOR<br>COMMUNITIES<br>A sizeable amount of money reverts back<br>to the community, with around 87% of<br>compensations injected within a<br>20-mile radius.<br>TOTAL SROI*<br>2.7x<br>* Total SROI is a term to reflect both the Investment and the Social Value created<br> €2,550M<br>Local Communities<br> €2,600M<br>Donors<br>POSITIVE IMPACT ON<br>DONORS AND LOCAL<br>COMMUNITIES<br> €5,150M<br>How we contribute | ||
| --- | ||
| CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 47<br>1<br>About Grifols<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Positive impact of Grifols’ 4 main plasma proteins on patients treated for the<br>primary diseases for which they were developed<br> €735M<br>Alpha-1 antitrypsin<br> €120M<br>Factor VIII<br> €9,340M<br>Inmunoglobulinas<br> €13,525M<br>Albúmina<br>POSITIVE IMPACT ON<br>PATIENTS<br> €23,810M<br>5.7X<br>IMPROVEMENT IN QUALITY<br>OF LIFE IN RELATION<br>TO PLASMA-DERIVED<br>MEDICINES COST<br>ONGOING VALUE CREATION FOR<br>DONORS AND PATIENTS<br>In 2022, Grifols once again measured the value<br>generated by its U.S. and European donation<br>centers and main plasma medicines as treatment<br>indications for alpha-1 antitrypsin to treat DAAT;<br>immunoglobulins for primary immunodeficiencies<br>(PIDD), secondary immunodeficiencies (SID), chronic<br>inflammatory demyelinating polyneuropathy (CIDP),<br>primary immune thrombocytopenia (ITP), Guillain<br>Barré Syndrome and Myasthenia Gravis (MG);<br>clotting factor VIII; and albumin to treat acute liver<br>disease, hepatorenal syndrome and spontaneous<br>bacterial peritonitis (SBP).<br>Grifols used the SROI (Social Return on Investment)<br>methodology to determine the value generated in<br>2022 for donors, local communities and patients,<br>and to estimate the global cost-benefit of its<br>treatments.<br>+ More details on the analysis in Chapter 9: About This Report | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 48<br>Ethical commitment<br>Adding value<br>3 | ||
| --- | ||
| We are trust<br> Our principles<br>At Grifols, we are firm believers in the value-creating power of a job well<br>done. Our core values and principles are tightly interwoven into our corporate<br>governance systems and internal codes and regulations. Every day, we work to<br>ensure they are applied at every level of the organization.<br>WE FOLLOW UN GLOBAL PACT PRINCIPLES<br>PRINCIPLE 1. We support and respect the protection of internationally<br>proclaimed human rights in our areas of influence.<br>PRINCIPLE 2. We do everything possible to ensure our operations are not<br>complicit in human rights abuses.<br>PRINCIPLE 10. We work against corruption in all its forms, including extorsion<br>and bribery.<br>Honesty<br>Transparency<br>Human Rights<br>Independence<br>Ethics<br>Integrity<br>Sustainability<br>Legal Compliance<br>Safety and Quality<br>Roadmap for<br>Grifols 2030 Agenda<br> • Suppliers evaluated<br>by ESG criteria<br> • Maintaining<br>Biopharma claims ratio<br> • No Critical issues detected<br>in external audits | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 50<br>Ethical Foundation<br>Code of conduct<br>O Adherence by all employees via written consent<br>O Specific training for new hires<br>O The code is public and accessible to the entire workforce in Spanish and English on Grifols’<br>corporate website and the employee portal<br>O Any compliance issue is considered a serious breach and may lead to disciplinary actions,<br>including dismissal<br>Code of ethics<br>O Model of conduct extends to the entire workforce, including senior-level executives and<br>corporate governance bodies<br>O Explicitly endorsed every year by board members, senior executives, directors and area<br>managers<br>O Any breach of Grifols’ ethical principles may lead to disciplinary actions, including dismissal<br>+ All of Grifols’ corporate policies and internal codes and regulations are publicly available on www.grifols.com<br>New corporate policies<br>Mental Health Policy<br>Designed to prevent, protect and promote employee mental health and well-being, as well as support workers<br>dealing with mental health issues<br>Climate Change Policy<br>Establishes a framework to articulate Grifols’ strategy and business model regarding its commitment to fight<br>climate change<br>Procurement Policy<br>Includes guidelines and common procedures for purchasing processes and supply strategies | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 51 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Human rights:<br>a core pillar<br>Integrated into our business<br>model, the global human<br>rights strategy continuously<br>evolves through ongoing<br>improvement procedures<br>and serves as the basis<br>of employee training and<br>engagement at every<br>organizational level.<br>Respect for the intrinsic rights and dignity of every person is an<br>essential prerequisite for Grifols. The key principles of bioethics guide<br>Grifols in the research, development, manufacturing and marketing<br>of its products, with the overarching aims of protecting the safety<br>and dignity of everyone involved in the process, and ensuring the<br>advancement of scientific progress within an ethical framework.<br>Various regulations, declarations and codes govern the adoption of<br>these principles, including the Universal Declaration of Human Rights<br>(1948), the Helsinki Declaration (1964) and the UNESCO International<br>Declaration of Bioethics and Human Rights (2005).<br>In line with the foremost international benchmarks (United Nations<br>Global Compact, United Nations Guiding Principles of Business and<br>Human Rights, OECD guidelines for multinationals, and the ILO<br>Declaration for Multinationals), Grifols has developed a comprehensive<br>strategy to promote and guarantee responsibility and commitment to<br>human rights throughout all its activities.<br>Promoting and safeguarding human rights in Grifols’ top leadership<br>We are working on the establishment of a Human Rights Committee<br>to strengthen our governance bodies to promote, implement and ensure<br>compliance with the Human Rights Policy, in addition to integrating and<br>coordinating the reporting of non-Financial and sustainability information,<br>among others.<br>Board of Directors<br>Sustainability Committee | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 52<br>Four areas of action<br>In 2022, Grifols further analyzed and reviewed its due-diligence processes to progressively<br>implement a global model, integrating both internal and external best practices.<br>+ Grifols’ Human Rights Policy is available on the corporate website<br>Reinforced governance Increase in awareness and education Greater transparency Concrete and measurable action plans<br>Culture of understanding and respect for Human Rights<br>O Compiles and updates the values outlined in the Code of Conduct,<br>which governs the behavior of everyone who works and collaborates with<br>the Group.<br>O Establishes the foundational principles on human rights<br>governance and a general framework to detect, prevent, mitigate and<br>correct current or potential negative impacts.<br>O Outlines clear principles to forge a culture of respect for human<br>rights that governs all of Grifols’ stakeholder interactions.<br>O Identification and prioritization of impacts<br>O Impact analysis<br>O Management to minimize and mitigate<br>impacts<br>O Grifols Ethic Helpline<br>Human Rights Policy Due Diligence Remediation and<br>grievance procedures | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 53 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 53<br>Due Diligence<br>Measures to address identified impacts<br>The company defined the following salient human-rights issues as most severe and likely to impact<br>its operational scope based on its human-rights due-diligence processes and United Nations Guiding<br>Principle 24.<br>In 2022, Grifols focused due-diligence process on defining the most relevant human-rights issues.<br> As part of these efforts, it implemented a series of measures and processes to prevent impacts<br>related to the main identified risks, defining quantifiable indicators for each. In 2023, the company<br>will initiate a protocol to review its compliance, and work to advance human-rights management at<br>every stage of the value chain in its countries of operation.<br>Grifols has a communication channel (Grifols Ethics Helpline) available to all employees and third-party to confidentially report any concerns of ethical misconduct, including those that may violate or<br>undermine human rights. This system strengthens the due-diligence process and helps identify and<br>address negative human-rights effects.<br>Most relevant human-rights impacts<br>Patients’ right to healthcare:<br>access to medicines<br>Donor rights: protection of<br>vulnerable groups<br>Patient safety: counterfeit<br>medicines<br>Employee rights: non-discrimination, equality and<br>diversity<br>Occupational health and<br>safety<br>Non-harassment workplace<br>Employee training and<br>development<br>Human rights in the value<br>chain | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 54<br>Grifols’ ultimate goal when processing stakeholders’ personal data<br>is to build relationships of trust by preserving their privacy, and<br>preventing data breaches. The company complies with all<br>applicable data-protection laws and regulations, and works with<br>suppliers that provide sufficient assurances in protecting data<br>integrity and privacy.<br>The company’s Global Data Privacy and Data Protection Policy<br>defines a framework for processing personal data, as well as all<br>pertinent data protection and security principles. Its compliance is<br>mandatory for the entire workforce.<br>Training and awareness are key to privacy. All employees receive<br>training on the Global Privacy and Data Protection Policy, and teams<br>that regularly process personal data undergo additional instruction.<br>In 2022, Grifols assured access to training and awareness sessions<br>Data protection and<br>cybersecurity<br>Right to privacy Cybersecurity<br>for all employees likely to process personal data. In particular over<br>18,000 employees globally had access to privacy training.<br>Grifols’ rigorous privacy-related safety, technical and organizational<br>measures, protect its organizational assets and users in a cyber-environment, while vouching for the confidentiality of personal data<br>of all our stakeholders, including medical information collected<br>in plasma donor centers and clinical trials. The company has<br>diverse processes and systems in place to protect against the loss,<br>unauthorized access, misuse and modification of personal data of<br>plasma donors and clinical-trial participants. All clinical trials adhere<br>to the guidelines established by the European Medicines Agency’s<br>Good Clinical Practice ICH E6 (R2) and the U.S. Food and Drug<br>Administration. In addition, audits performed on both clinical trials<br>and pharmacovigilance procedures include a compliance review of<br>applicable privacy regulations.<br>Grifols has both internal and external cyber-protection measures.<br>Its internal safety and cybersecurity policy develops and defines<br>a regulatory framework, decision-making and control bodies,<br>and cybersecurity and cyber risk-management functions, while<br>specialized external services effectively protect the safety of the<br>information and assets involved in Grifols’ operations.<br>The company makes sure its organizational environment wholly<br>supports its business objectives and cybersecurity goals. Its<br>rigorous procedures, tools, technological innovations and insurance<br>policies protect the organization’s assets and users. Grifols<br>regularly reviews the risks associated with the use of third-party<br>and cloud-based services, ensuring they comply with all security,<br>privacy and legal norms. It also has a robust IT incident-response<br>system, including contingency plans to ensure the continuity of its<br>operations in the event of an attack.<br>In 2022, Grifols recorded no relevant cyberattacks, cyber-related<br>thefts, loss of sensitive data or physical damages affecting the<br>normal development of its operations. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 55 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>We promote integrity<br>Crime prevention policy and<br>criminal risk management<br>system<br>The Crime Prevention Policy establishes Grifols’ unequivocal<br>rejection of the commission of criminal offenses or other types<br>of unethical conduct, and its determination to prevent and<br>combat them. This policy is developed through the Criminal Risk<br>Management System (CRMS), which defines the appropriate<br>measures to prevent crimes and significantly reduce the risk<br>of their commission. The CRMS is routinely reviewed by an<br>independent expert.<br>Anti-competition practices<br>Grifols’ Competition Policy prohibits its members from any conduct<br>that has the purpose or may have the effect of limiting or distorting<br>free competition in the market against the interests of other<br>competitors and, more serious, against the interests of consumers<br>and users. Such prohibited conducts include, among others,<br>collusive practices or agreements, such as, for example, sharing<br>market or sources of supply, collective boycott, resale pricing, or the<br>application of unequal commercial conditions, among others; and<br>abuse of a dominant position, such as denying production or supply,<br>imposing predatory prices, or forcing the purchase of unrelated<br>related products, among others.<br>Money laundering<br>Grifols has mechanisms, procedures and policies to prevent, detect<br>and respond to possible money laundering breaches in the course<br>of its business operations.<br>Prevention<br>As part of its CRMS criminal risk analysis, Grifols assesses its<br>exposure to the risk of money laundering and terrorist financing,<br>identifying activities with higher associated risks and primary<br>mechanisms to mitigate them.<br>Detection<br>Grifols detects possible breaches through routine CRMS reviews.<br>The Grifols Ethics Helpline allows people to confidentially report<br>potential instances of unethical behavior or irregularities.<br>Reaction and response<br>Grifols has an investigation protocol, as well as a sanctioning<br>system.<br>In 2022, Grifols reported no confirmed cases of anti-competitive<br>practices in its regions of operation. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 56<br>Anti-corruption policy<br>Extensive to all employees and third-party collaborators, Grifols’<br>Anti-Corruption Policy outlines the standards of conduct and<br>interactions with civil servants and public-sector organizations and<br>agents, as well as private-sector organisms and entities.<br>The company has diverse review processes to ensure compliance<br>as part of its overall anti-corruption program.<br>Grifols has zero tolerance for acts of bribery and corruption, and<br>works towards the goal of maintaining zero cases of corruption.<br>The company does not tolerate any form of retaliation against<br>those who in good faith report a possible violation of applicable<br>laws, rules and regulations, or non-compliance with internal<br>policies and procedures. Grifols has internal procedures that<br>explicitly define the acts considered as bribery and corruption, and<br>that include a list of the applicable disciplinary actions if a violation<br>of its Anti-Corruption Policy is detected, including the possibility of<br>dismissal.<br>Integrated anti-corruption model<br>Training sessions<br>To ensure compliance with anti-corruption policies and procedures,<br>Grifols holds regular training sessions for both current staff and new<br>recruits. Those employees who, due to their duties, interact more<br>frequently with public officials or perform functions related to the<br>marketing of Grifols products or services, receive additional and<br>reinforced training.<br>Review process<br>Compliance with the Anti-Corruption Policy is reinforced by a series<br>of review processes according to the type of interaction (articulated<br>through various internal procedures), under the supervision of the<br>compliance function. While special attention is given to higher risk<br>operations, reviews of interactions with government officials, public<br>agencies, healthcare professionals and/or healthcare organizations<br>include the analysis and management of potential conflicts of<br>interest. The review processes are intended to cover the full range<br>of Grifols’ activities in the market.<br>+ Grifols’ Anti-corruption Policy is available on: www.grifols.com<br>Confirmed cases of<br>corruption in 2022<br>0<br>Number of interactions reviewed between Grifols employees<br>and government officials or other professionals in 2022<br>4,730<br>Anti-corruption measures for third-party<br>collaborations<br>Grifols’ anti-corruption global program includes control mechanisms<br>for third parties interested in entering a business or commercial<br>relationship with the company. Before entering any commercial<br>relationship with Grifols, third parties are subject to a thorough<br>two-part verification process: a first phase, where Grifols establishes<br>the legitimacy of the potential commercial transaction, and a second<br>phase of due diligence, which includes an in-depth analysis of the<br>third-party’s organizational structure, key employees, business<br>approach and corporate reputation, among other aspects.<br>Third-party contracts include current anti-corruption obligations, as<br>well as an annex summarizing Grifols’ Anti-Corruption Policy. At least<br>once a year, they are required to certify full compliance with the<br>ethical standards outlined in this policy.<br>In certain cases, third-party collaborators such as international<br>distributors are also required to complete periodic online training<br>on anti-corruption issues, for example, the U.S. Foreign Corrupt<br>Practices Act (FCPA).<br>The contracts with third parties also include a clause giving Grifols<br>the right to perform audits and terminate commercial relations in the<br>case of non-compliance with these norms.<br>Internally, employees are responsible for constantly monitoring the<br>day-to-day activities of the third parties under their management<br>area. Both the potential violations alerts system and the continuous<br>monitoring process aim at detecting possible red flags and, as such,<br>manage and resolve these adequately and as promptly as possible. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 57 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 57<br>Training sessions<br>98% ~90%<br>Informed<br>before<br>2022<br>Informed<br>during<br>2022 Total<br>O Executives 4 15 19<br>O Directors 19 85 104<br>O Senior Management 23 155 178<br>O Management 25 172 197<br>O Senior Professionals 27 329 356<br>O Professional staff 16 194 210<br>O Administrative staff / manufacturing workers 7 57 64<br>Total 121 1,007 1,128<br>Audits<br>The company’s Internal Auditing Department conducts routine1 audits<br>on corporate areas and business units, including the review and<br>control of compliance with the Anti-Corruption Policy in all companies<br>that have risk of corruption. External and independent audits are also<br>carried out on different aspects of Grifols’ Global Anti-Corruption<br>Program.<br>If a potential case of corruption is identified, an internal investigation<br>is always initiated with the involvement of external legal advisors.<br>The Global Compliance Review Committee assists the Audit<br>Committee, which reports to the Board of Directors, regarding its<br>supervision of the Global Anti-Corruption Program.<br>of Grifols’ employees most likely to witness cases of corruption<br>have been informed of anti-corruption policies and procedures<br> have undergone specific training<br>EMPLOYEES MOST LIKELY TO OBSERVE CASES OF CORRUPTION WHO HAVE BEEN INFORMED ON<br>ANTI-CORRUPTION POLICIES AND PROCEDURES BY PROFESSIONAL CATEGORIES<br>NUMBER OF EXECUTIVES INFORMED ON ANTI-CORRUPTION POLICIES AND PROCEDURES<br>Informed before<br>2022<br>Informed during<br>2022 TOTAL<br>1 3 3<br>17 18<br>EMPLOYEES MOST LIKELY TO OBSERVE CASES<br>OF CORRUPTION WHO HAVE RECEIVED SPECIFIC<br>ANTI-CORRUPTION TRAINING<br>81<br>274<br>351<br>73<br>229<br>9<br>154<br>503<br>360<br>Trained before<br>2022<br>Trained during<br>2022 TOTAL<br>EMPLOYEES MOST LIKELY TO OBSERVE CASES OF<br>CORRUPTION WHO HAVE BEEN INFORMED ON ANTI-CORRUPTION POLICIES AND PROCEDURES<br>Informed before<br>2022<br>Informed during<br>2022 TOTAL<br>14<br>17<br>91 368 459<br>146<br>493<br>160<br>510<br>OEurope O U.S. O Others<br>(1) The periodicity of these audits is established according to the risk assigned.<br>8%<br>15%<br>33%<br>19%<br>6%<br>1%<br>17% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 58<br>Grifols’ interactions with global healthcare professionals and<br>organizations broaden its knowledge and awareness of patient<br>behavior and disease management, critical to enhancing the quality<br>of patient care and expanding treatment options. Conducted with<br>maximum integrity and transparency, these relations are regulated<br>by The Global Compliance Program.<br>Grifols’ Gifts and Hospitality policy provides guidance to Grifols<br>employees on the appropriate standards and established limits<br>for managing transfers of value and hospitality to healthcare<br>professionals, public officials and others subject to the Grifols Gift<br>and Hospitality policy.<br>U.S.<br>In the U.S., the Sunshine Act (PPS Act) requires manufacturers<br>and group purchasing organizations (GPO) of pharmaceuticals,<br>biologicals, medical devices and medical supplies to itemize all<br>information relating to payments and transfers of value to specific<br>professionals and healthcare organizations, including physicians,<br>mid-level practitioners and teaching hospitals. Every year in June,<br>the Centers for Medicare and Medicaid Services (CMS) publishes<br>information extracted from these reports.<br>We are transparent<br>Interactions with healthcare professionals and healthcare organizations<br>Europe<br>In Europe,1 Grifols voluntarily adopted practices outlined in Chapter<br>5 of the European Federation of Pharmaceutical Industries and<br>Associations (EFPIA) Code, and made them extensive to all<br>corporate divisions and operations in 2015. In 2022, for the seventh<br>consecutive year, Grifols disclosed all payments and transfers of value<br>to healthcare organizations and professionals in various European<br>countries as defined by EFPIA, in alignment with its policies and<br>procedures on its transparency program and in compliance with this<br>initiative. As a member of MedTech Europe, Grifols’ Code of Ethical<br>Business Practice likewise reflects these transparency guidelines,<br>including the disclosure of Training Grants carried out in 2021. The<br>company also discloses all information related to country-specific<br>transfers of value in compliance with local regulations.<br>(1) The following countries are included within the EFPIA Code: Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland,<br>France, Germany, Greece, Hungary, Ireland, Iceland, Italy, Latvia, Lithuania, Malta, North<br>Macedonia, Norway, the Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia,<br>Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and United Kingdom.<br>Grifols has a specific policy and procedure in place that describes its<br>transparency program and how it complies with U.S. federal and state<br>reporting obligations.<br>In the U.S., Grifols adheres to the Pharmaceutical Research and<br>Manufacturers of America (PhRMA) and the Advanced Medical<br>Technology Association (AdvaMed) Codes on Interactions with<br>Healthcare Providers and continues to develop its compliance<br>systems to reflect code updates (PhRMA in January 2022 and<br>AdvaMed en June 2022). Both codes aspire to bolster the ethical<br>norms and principles in interactions with the healthcare community.<br>In accordance with these principles, healthcare companies like<br>Grifols can hire external consultants or advisors under the following<br>conditions: the selection process is based on qualifications and<br>experience and for a specific need; financial compensation reflects<br>fair market value established for these services; and the relationship<br>is formalized through a written contract.<br>Grifols maintains a transparency-training program for all employees<br>whose roles include regular interactions with U.S. healthcare<br>organizations and professionals. In 2022, 75 U.S.-based employees<br>received training on transparency reporting.<br>+ Grifols’ corporate website includes a methodology note and specific reports on transfers of value to healthcare professionals and organizations in concrete countries: www.grifols.com | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 59 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Aggregate total transfers of value<br>Under the Open Payment Program, U.S.<br>transfers of value<br>$12.0M<br>+64% vs 2021<br>+ More detail on the transfers of value made according to the EFPIA Code: www.grifols.com<br>In accordance with<br>EFPIA criteria<br> €18.9M<br>+41% vs 2021 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 60<br>Public affairs management<br>Grifols’ European involvement<br>Grifols participates in health policy discussions with a broad network<br>of EU stakeholders to help improve people’s access to healthcare.<br>In 2022, the company actively participated in the following public<br>consultations:<br>O 2023 targeted consultation on EU4Health priorities<br>O Proposal for a regulation on Substances of Human Origin<br>SoHO: proposed regulation on substances of<br>human origin<br>Grifols welcomed the European Commission’s proposal for a<br>regulation on the standards of quality and safety for Substances<br>of Human Origin (SoHO). The proposal could be an important<br>step forward in modernizing the regulatory framework and should<br>potentially increase the supply of essential plasma-derived therapies<br>to treat rare, chronic and life-threatening conditions. Grifols looks<br>forward to working with the different institutions involved to boost<br>Europe’s plasma supply.<br>+ https://health.ec.europa.eu/blood-tissues-cells-and-organs/overview/proposal-regulation-substances-human-origin_en<br>Review of EU pharmaceutical legislation<br>In 2023, the European Commission will release a proposal to update<br>general pharmaceutical legislation. Grifols hopes to work with the<br>different institutions involved to ensure the legislative proposal<br>promotes greater access to healthcare and recognizes the unique<br>nature of plasma medicines.<br>+ https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12963-<br>Revision-de-la-legislacion-general-farmaceutica-de-la-Union_es<br>Advocacy is a legitimate and essential component of the democratic<br>process, allowing people to share their perspectives and concerns<br>with public officials. For Grifols, advocacy entails reaching out<br>to political circles to raise awareness among policymakers on<br>the singular nature of plasma-derived medicines and the vital<br>importance of their unrestricted access in healthcare centers. The<br>Grifols Code of Conduct and Anti-Corruption Policy offers guidelines<br>and standards of interaction between Grifols and public officials.<br>Grifols follows the highest ethical standards in its interactions<br>with public officials, including the obligation to act with the utmost<br>integrity and transparency. In the U.S., Grifols complies with all<br>federal, state and local regulations, including regularly submitting<br>transparency reports outlining its lobbying-related expenses to the<br>U.S. Congress as required by the Lobbying Disclosure Act (LDA).<br>Grifols lobbying disclosure reporting requirements are governed by<br>standard operating procedures covering Grifols activities in the U.S.<br>and EU. The company makes neither direct nor indirect campaign<br>contributions to political candidates or government officials.<br>Grifols is part of the European Union’s Lobby Transparency Register<br>since 2019, and adheres to the rules of conduct governing relations<br>with European Union institutions, articulated in its code of conduct.<br>Through this registry, the company discloses its activities to EU<br>institutions and has the option of submitting feedback on public<br>consultations. These are mainly focused on legislation and policies<br>related to blood and plasma, as well as on patient access to care.<br>The company is also a member of three other EU organizations:<br>Plasma Protein Therapeutics Association (PPTA), European<br>Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and<br>MedTech Europe.<br>+ More details at the end of this chapter | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 61 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Grifols Ethics Helpline<br>The Grifols Ethics Helpline is available for employees and external collaborators to anonymously<br>and confidentially raise any concerns regarding legal non-compliance or misconduct.<br>All allegations follow a standard operating procedure to make sure they are properly channeled<br>and investigated, and to determine if any corrective measures are required. Grifols has a<br>designated Ombudsperson to ensure this process is properly followed.<br>Grifols does not tolerate retaliatory measures of any kind against those who in good faith report<br>possible violations of applicable laws, rules and regulations or non-compliance with internal<br>policies and procedures. Retaliation could lead to disciplinary action, including dismissal.<br>In 2022, the Grifols Ethics Helpline received 355 allegations (290 allegations in 2021): 328 in<br>North America, 22 in Europe and 5 in other countries. After their investigation, 4 allegations<br>related to human rights violations were substantiated. In all cases, the appropriate disciplinary<br>measures were taken. In addition, no allegations of corruption were received in 2022.<br>+ More information on the Grifols Ethics Helpline: http://grifols.ethicspoint.com<br>O General concern<br>O Workplace harassment<br>O Misconduct or inappropriate behavior<br>O Improper employment or disciplinary action<br>O Discrimination<br>O Conflict of interest<br>O Health, Safety and environment<br>O Failure to comply with quality, regulatory or manufacturing standards<br>O Sexual harassment<br>O Others<br>GRIFOLS’ ETHICS HELPLINE 2022<br>29%<br>9%<br>27%<br>3%<br>5%<br>4%<br>1%<br>2%<br>2%<br>18% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 62<br>A responsible<br>value chain<br>Our understanding of safety and quality<br>As a leading healthcare organization, Grifols makes every effort to achieve the highest levels of quality<br>and safety of its products and services. This core commitment is driven by senior management,<br>ratified in the Code of Ethics and extensive to the entire organization. The Chief Quality Officer (CQO)<br>verifies the effective implementation and management of all safety and quality control processes.<br>Given its critical organizational role, the CQO reports directly to the co-CEOs and serves in the<br>corporate management committee.<br>Grifols has a Corporate Quality Policy that establishes its commitment to conduct all its operations<br>in accordance with the highest safety and quality standards to improve people’s health and create<br>long-term sustainable value for patients, donors, the healthcare community, collaborators and society<br>in general.<br>Each business unit has robust policies and procedures in place to guarantee the maximum quality,<br>safety and efficacy throughout the value chain. Grifols’ quality-assurance system encompasses all<br>corporate operations and includes continuous training and development to ensure all employees can<br>successfully fulfill their roles to the highest quality and safety standards. Various internal committees<br>routinely evaluate corporate processes and quality systems, including the monitoring of key<br>performance and quality indicators.<br>In 2022, Grifols received audits and inspections with favourable outcome by global health authorities<br>and organizations, evidence of its commitment to quality and safety. The company reported no cases<br>of regulatory non-compliance, monetary penalties, warnings or non-compliance with voluntary codes<br>in 2022.<br>Grifols’ sustainable and responsible value chain is promoted through a range of policies and<br>procedures, advocating quality and safety standards that go far beyond regulatory compliance.<br>Reflecting its ongoing quest for excellence, the company also integrates due diligence into its strategy<br>to prevent or mitigate negative existing or potential repercussions on human rights or<br>the environment. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 63 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Grifols’ newly implemented Corporate Procurement Policy<br>establishes common guidelines and procedures for purchasing<br>processes and supply strategies, ensuring all acquired goods<br>and services are grounded in transparent, objective, timely and<br>cost-effective decision making. This policy contributes to more<br>structured, consistent and homogeneous purchasing processes,<br>enabling enhanced risk management and strict compliance with all<br>policies, procedures and internal and external controls.<br>This policy incorporates ethical, social, environmental and<br>privacy criteria in alignment with the company’s health, safety<br>and environmental policies. At the same time, it promotes the<br>principles of sustainable procurement and maximum transparency<br>in supplier relations, in accordance with Grifols’ Human Rights and<br>Sustainability Policies.<br>Supplier relations<br>Continuous supplier evaluation process<br>All Grifols’ business units have qualified vendors whose technical,<br>management and control capabilities have been previously<br>evaluated and approved by the Quality Area. The company takes<br>social and environmental aspects into account when evaluating<br>suppliers, and previously qualifies those whose goods or services<br>could affect product quality.<br>The company has procedures to regularly evaluate suppliers based<br>on the risk level of the material or service they supply and/or its<br>impact on the value chain. The evaluation of new suppliers and<br>their follow-up includes routine audits, with concrete questions<br>regarding their environmental impact. Specific environmental and<br>occupational health and safety issues, among other criteria, are<br>used to assess transportation companies. Supplier evaluation<br>includes the verification of suppliers’ environmental certifications,<br>such as ISO 14001 (for environmental management systems)<br>and OSHAS (for occupational health and safety management) as<br>additional elements in the selection and qualification of suppliers.<br>All transport companies are evaluated, including specific<br>environment-related parameters (ISO 14001, biodiesel or new<br>generation fuel certifications).<br>Ethical compliance and respect for human rights is one of Grifols’<br>fundamental pillars, which is why everyone involved in the<br>procurement process, whether employees or external collaborators,<br>must adhere to a series of core principles. These include compliance<br>with rules and regulations; integrity, impartiality and fairness;<br>transparency, confidentiality; and due diligence, among others.<br>The policy also promotes the inclusion of social and environmental<br>requirements, specifications and other criteria in Grifols procurement<br>systems.<br>The company continues its efforts to improve supplier evaluation and<br>due-diligence processes, including vendors’ progress in integrating<br>ESG factors into their operations.<br>+ More details at the end of this chapter | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 64<br>Confidence for patients and healthcare providers<br>Health, safety and pharmacovigilance measures<br>Under its Quality and Safety Policy, Grifols identifies the critical<br>attributes of its products and conducts exhaustive controls on the<br>quality of raw materials, manufacturing processes, and finished<br>product testing. All medical devices are assessed in accordance<br>with the European REACH (Registration, Evaluation, Authorization<br>and Restriction of Chemicals) regulation.<br>Grifols’ pharmacovigilance system monitors for any adverse effects<br>or reactions resulting from its plasma-derived medicines, as well<br>as a surveillance system to monitor adverse reactions stemming<br>from the use of its medical and in vitro devices. Both programs<br>have systems to report any safety issues and suspected cases of<br>adverse reactions.<br>All activities and requirements of the pharmacovigilance system<br>and the medical and in vitro device vigilance system are defined<br>in Grifols’ standard operating procedures and subject to routine<br>reviews. The company conducts regular internal audits of these<br>systems as part of its quality compliance protocols, which are also<br>subject to external inspections by the competent health authorities.<br>Grifols’ pharmacovigilance and medical and in vitro device<br>surveillance activities are never outsourced to third-party<br>companies.<br>Labels and product inserts<br>The information in product leaflets and labels complies with<br>the standards and regulations applicable in Grifols’ countries of<br>operation, including Directive 2001/83/EC for medicines marketed<br>in Europe and Title 21 Code of Federal Regulations (CFR) in the<br>United States, as well as local regulations applicable in<br>other markets.<br>In the case of medical devices and in vitro medical devices, their<br>labeling, instructions for the use of reagents, and instrument user<br>and software manuals comply with country-specific regulations<br>(EN ISO 15223, among others), and include mitigating measures<br>identified via medical-device risk management systems (EN ISO<br>14971:2012 Medical Devices) or in accordance with heath-authority requirements. All printed material is translated into the<br>corresponding languages, updated as required and accessible<br>to users.<br>Ensuring maximum safety<br>and quality of our products is<br>part of our commitment. Our<br>quality standards, safety and<br>sustainability go beyond strict<br>regulatory requirements.<br>+ More details at the end of this chapter | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 65 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Product Recall System<br>The claims and recall systems are outlined in Grifols’ standard<br>operating procedures and internally audited to confirm their<br>effectiveness and compliance with current legislation. They are also<br>subject to inspections by the competent healthcare authorities.<br>All Grifols teams involved in possible product recalls, whether<br>voluntary or mandatory, receive specific training to effectively<br>manage possible incidents. The company also runs periodic<br>product-recall drills to make sure all crisis-management<br>procedures and protocols work smoothly, and identify any areas<br>for improvement.<br>The product claims and recall systems include procedures to<br>notify healthcare authorities, patient associations and healthcare<br>professionals regarding the potential risks of a recalled product.<br>Grifols has a customer service call center and dedicated webpages<br>for specific products to communicate potential risks. The company<br>also prohibits the use of any recalled product in clinical trials.<br>In 2022, Grifols had no product recalls, either mandatory or<br>voluntary pertaining to the discretionary withdrawal of products<br>that fail to meet its safety and quality standards.<br>Claims System<br>Through its claims system, Grifols registers and reviews all<br>notifications received from healthcare centers, patients and users<br>related to consumer appraisals of possible defects in product<br>quality. The management system for technical services for medical<br>devices is linked with the claims management system to make sure<br>all client requests are assessed.<br>When a subsidiary or an authorized call center receives a complaint<br>related to a Grifols medicinal product, it immediately notifies the<br>appropriate manufacturing facility, ensuring all complaints are<br>properly evaluated in accordance with the claims system.<br>Biopharma<br>1<br>units distributed<br>out of77,806<br>Diagnostic<br>1<br>diagnostic tests<br>out of482,302<br>Others* (Medicines)<br>1<br>units distributed<br>out of5,848,478<br>Others* (Medical devices)<br>1<br>units distributed<br>out of31,210<br>The quality area of each organization is responsible for evaluating<br>complaints. As part of this process, they conduct the relevant<br>investigations; ensure the implementation of corrective and<br>preventive actions, if necessary; notify the health authorities,<br>if applicable; and inform the customer of the investigation’s<br>conclusions.<br>*Others: primarily includes the former Hospital Division. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 66<br>Counterfeit drug prevention system<br>Counterfeit medicines pose a serious health risk. Plasma medicines<br>are prescription drugs and administered mainly in hospital settings.<br>Grifols collaborates with regulatory authorities in the investigation<br>and analysis of suspected counterfeit products. The company has<br>an internal policy with guidelines to prevent, detect and report<br>counterfeit products. Suspicious and identified cases of counterfeit<br>medicines are mandatorily reported on time and in due form to<br>the relevant authorities in accordance with the applicable local<br>regulations.<br>The company uses track and trace technology to adhere to<br>concrete product serialization and aggregation requirements, a<br>reflection of its total commitment to prevent counterfeiting and<br>fully comply with country- and region-specific norms. These<br>requirements include marking vials with a unique code before<br>any plasma product is sold, and including a holographic seal on<br>containers to guarantee their inviolability and authenticity.<br>Grifols is unaware of any actions in 2022 that resulted in raids,<br>seizures, arrests and/or the filing of criminal charges related to<br>counterfeit products.<br>Responsible marketing practices<br>Grifols ensures its promotional and educational collateral complies<br>with applicable laws and regulations; aligns with industry<br>policies and voluntarily adopted codes; adequately addresses the<br>target audience and end users; and contains truthful, accurate,<br>comprehensive and balanced information.<br>The Grifols Review Process (GRP) is a standard operating procedure<br>that defines the activities and responsibilities related to the approval,<br>review and control of promotional and educational materials used<br>to communicate its products and services. Representatives from<br>the legal, medical and regulatory departments review and approve<br>Grifols’ marketing materials using an electronic system adapted to<br>the GRP. The material and content are solely approved for specific<br>uses and countries, and can only be used without any alterations.<br>The contents of all promotional and educational materials are<br>regularly reviewed to confirm their validity and compliance with<br>current standards and codes.<br>The company imparts appropriate training on responsible marketing<br>and sales practices in line with its Code of Conduct and Anti-Corruption Policy.<br>In 2022, the company received no claims of counterfeit materials,<br>and thus incurred no related monetary losses.<br>MATERIALS REVIEWED<br>MATERIALS APPROVED<br>2020 2021 2022<br>2020 2021 2022<br>We are working to integrate due diligence into our strategy,<br>aimed at continuing to move towards excellence in<br>management, preventing or mitigating possible negative<br>effects - actual or potential - that could impact human rights<br>or the environment.<br> 3,731<br>3,489<br> 3,746<br>3,370<br>3,637<br>3,321 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 67 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 67<br>(*) Includes inspections by health authorities and accredited inspection bodies, as well as in-house inspections.<br>(**) Suspension, revocation or loss of any license or certification; warning letter, imposed suspension of any regulated activity.<br>***Former Bioscience Division<br>**** Others: includes Former Hospital Division<br>Good Manufacturing Practices - Grifols<br>380<br>8<br>Biopharma<br>2 358 Others<br>Plasma Procurement<br>10<br>Diagnostic<br>Good Manufacturing Practices - Biotest<br>2<br>Biopharma 15<br>Plasma Procurement<br>Incidents**<br>0<br>SUMMARY OF AUDITS AND INSPECTIONS<br>PLASMA PROCUREMENT BIOPHARMA***<br>Grifols Grifols Biotest Biotest<br>DIAGNOSTIC BIO SUPPLIES OTHERS****<br>304 25 57 14 51<br>Internal audits<br>58<br>Internal audits<br>441 16 8 4<br>Routine inspections by<br>10<br>official institutions<br>2<br>Routine inspections by<br>official institutions<br>10<br>Routine inspections by<br>official institutions<br>27<br>100% favorable<br>supplier audits<br>79 22 47 16<br>100% favorable<br>10<br>supplier audits<br>Evolution of audits and inspections*<br>Internal audits Internal audits<br>Inspections by healthcare authorities<br>and accredited inspection organisms<br>Inspections by healthcare authorities<br>and accredited inspection organisms<br>100% favorable supplier audits 100% favorable supplier audits<br>2<br>Bio Supplies | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 68<br>EUROPE1<br>2021 2020 2019<br>Euros % Euros % Euros %<br>Services 1,006,669 5% 539,293 4% 1,113,493 7%<br>Contribution toward cost of events HCO 57,272 0% 21,443 0% 436,741 3%<br>Contribution toward cost of events HCP 1,978,053 11% 1,334,663 10% 2,361,468 15%<br>Grants 280,272 1% 199,827 2% 409,521 3%<br>R&D collaboration with third parties2 15,609,633 83% 11,346,476 84% 11,339,366 72%<br>TOTAL 18,931,899 100% 13,441,702 100% 15,660,589 100%<br>(1) Transfers of value in Europe in accordance with the definition of the EFPIA disclosure code.<br>(2) Includes research grants. Research data is included in accordance with the definition of the Disclosure Code of EFPIA, do not reflect the total amount invested by Grifols in R&D.<br>U.S.<br>2021 2020 2019<br>USD % USD % USD %<br>Services 4,128,833 34% 649,483 9% 1,017,565 17%<br>Contribution toward cost of events HCP 344,243 3% 290,127 4% 671,040 11%<br>Grants 0 0% 0 0% 15,000 0%<br>R&D collaboration with third parties 7,025,507 59% 4,552,923 63% 3,890,209 66%<br>Investigator sponsored research 483,866 4% 1,772,579 24% 355,383 6%<br>TOTAL 11,982,449 100% 7,265,112 100% 5,949,196 100%<br>MANAGEMENT OF PUBLIC AFFAIRS<br>2021 2020 2019<br>Lobbying Expenditures in the U.S. as Reported Under the LDA. These amounts reference lobbying expenses, not political<br>campaign contributions. Grifols does not make political campaign contributions in the U.S. USD 590,000 USD 510,000 USD 550,000<br>Estimated annual costs related to activities covered by the European Transparency Register EUR 100,000 - 199,000 EUR 100,000 - 199,000 EUR 50,000 - 99,000<br>GRIFOLS’ ETHICS HELPLINE<br>2022 2021 2020<br>General concern 29% 17% 24%<br>Workplace harassment 9% 17% 20%<br>Misconduct or inappropriate behavior 27% 22% 11%<br>Improper employment or disciplinary action 3% 3% 6%<br>Discrimination 5% 9% 8%<br>Conflict of interest 2% 2% 0%<br>Health, safety and environment 4% 8% 10%<br>Failure to comply with quality, regulatory or manufacturing standards 1% 2% 1%<br>Sexual harassment 2% 3% 2%<br>Others 18% 17% 18%<br>TRANSFERS OF VALUE BY TYPE | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 69 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>MEASURES APPLIED BY BUSINESS UNIT 2022<br>Business Unit Type of product Pharmacovigilance system Medical device surveillance system<br>Biopharma Medicines Applicable Not applicable<br>Diagnostic Medical devices Not applicable Applicable<br>Others Medicines and medical devices Applicable Applicable<br>SUMMARY OF AUDITS - GRIFOLS 2022<br>Business Unit Type of supplier Nª of quality audits Favorable Not favorable Pending evaluation and final report<br>Plasma Procurement<br>Raw material suppliers 68 65 0 3<br>Distributors 3 3 0 0<br>Transport companies 3 3 0 0<br>Services suppliers 8 8 0 0<br>Biopharma<br>Raw material suppliers 54 42 0 12<br>Transport companies 2 2 0 0<br>Services suppliers 3 3 0 0<br>Diagnostic Raw material suppliers 25 22 0 3 Services suppliers 9 5 0 4<br>Grifols global subsidiaries<br>Raw material suppliers 2 2 0 0<br>Distribuitors 32 25 4 3<br>Transport companies 16 16 0 0<br>Services suppliers 15 15 0 0<br>Others Raw material suppliers 8 7 0 1 Services suppliers 3 3 0 0<br>SUMMARY OF SUPPLIER AUDITS - BIOTEST 2022<br>Business Unit Type of supplier Nª of quality audits Favorable Not favorable Pending evaluation and final report<br>Plasma Procurement Raw material suppliers 58 19 0 39 Services suppliers 7 3 0 4<br>Biopharma Raw material suppliers 19 8 0 11 Services suppliers 27 8 0 19<br>PROMOTIONAL AND EDUCATIONAL MATERIALS<br>2022 2021 2020<br>Materials reviewed 3,746 3,489 3,731<br>Materials approved 3,370 3,321 3,637 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 70<br>Innovation<br>Broadening<br>horizons<br>4 | ||
| --- | ||
| We are pioneers<br> Main therapeutic areas Our priorities<br>Guided by its ethical approach and utmost respect for human rights, the<br>company leads as a forerunner in the plasma-science field, promotes scientific<br>cooperation to advance knowledge, and works to elevate healthcare education<br>and research capabilities at all levels.<br>Immunology<br>Pulmonology<br>Hematology<br>Infectious Diseases<br>Other<br>Neurology<br>Hepatology & Intensive Care<br>Roadmap for<br>Grifols 2030 Agenda<br> • Innovators<br>Promote plasma and non-plasma<br>advances through in-house and external<br>initiatives in the main therapeutic areas<br>ACCELERATE PROGRESS<br>O New therapies, products and solutions<br>O Improvements and new indiciations for existing products<br>SUPPORT<br>O Healthcare systems<br>O Competitiveness<br>COOPERATE<br>O Support scientific cooperation, education and research capabilities to drive<br>progress in scientific knowledge<br>OPTIMIZE<br>O Achieve greater efficiencies<br>O Improve in-house productivity | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 72<br>DIGITAL<br>TRANSFORMATION<br>COMMITTEE<br>IN-HOUSE REACH<br>COMMITTEES FOR THE<br>ANALYSIS OF R&D+I<br>PROJECTS<br>GRIFOLS ENGINEERING<br>DIGITAL INNOVATION NEW PLATFORMS<br>GRIFOLS SCIENTIFIC<br>INNOVATION OFFICE<br>A robust innovation ecosystem<br>Our innovation ecosystem fosters scientific knowledge and the pursuit of new opportunities<br>and collaborations<br>3 key objectives in 2022<br>Accelerate and prioritize<br>projects<br>Optimize the organizational<br>structure of innovation<br>Build new innovation<br>models<br>Grifols promotes scientific advances and new discoveries with the<br>overarching aim of enhancing people’s health and well-being.<br>In this regard, it encourages scientific cooperation, supports the<br>teaching of health sciences and research skills at all levels via<br>in-house initiatives, investee companies, public-private partnerships<br>and financial contributions to third-party programs. As part of its<br>commitment to sustainable innovation, it continuously strives to<br>optimize efficiency and productivity internally.<br>EXTERNAL REACH<br> • Co-innovation programs<br> • Sponsorship of research programs<br> • Investment in research companies<br> • Collaborations with excellence centers<br> • Scholarships and awards: Grifols Scientific Awards<br> • Strategic alliances<br> • Academic collaborations | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 73 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>A solid organizational structure<br>SIO IN 2022:<br>Greater efficiency<br>O Continuous evaluation of new advances<br>and opportunities<br>O A spotlight on control<br>O Two-pronged approach<br>Results-oriented<br>O Promotion of Biotest projects<br>Centralized and global<br>O Led by the Chief Scientific Innovation<br>Officer<br>Through the Grifols Scientific Innovation Office (SIO) we manage our R&D+i. In 2022 we<br>reorganized and streamlined its functions to accelerate our main projects<br>First innovation summits<br>Grifols Scientific Innovation Office<br>(SIO) works to promote collaboration<br>in the R&D+i teams. In 2022, the first<br>Discovery Research and Bioinformatics<br>Summits were held in the United<br>States and Spain, providing an<br>enriching forum to share knowledge of<br>ongoing high-profile research projects.<br>Discovery<br>Plasma<br>Discovery<br>Recombinant<br> Drug<br>Development<br>External<br>Innovation<br>Scientific &<br>Medical Affairs<br>Scientific Business<br>Development Global IP Controlling PMO & Strategy<br>RESEARCH AREAS<br>SUPPORT AREAS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 74<br>R&D+i INVESTMENTS<br> €351M<br>PATENTS<br>3,487<br>patents<br>RESOURCES<br>5.8%<br>of total revenue<br> €1,550M+<br>invested over the last 5 years<br>1,250+<br>People dedicated to R&D+i<br>100+<br>External research 970<br>patent applications<br>1,435<br>patents that expire in the next 10 years<br>R&D+i resource allocations<br>Including Biotest figures | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 75 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 75<br>Research Platforms<br>O Plasma proteomics, fractionation and purification<br>O Single-cell transcriptomics<br>O Machine learning AI platform for target discovery<br>O Neuronal functional assay platform<br>O Therapeutic target selection and validation<br>O Polyclonal recombinant expression and manufacturing<br>O Mammalian cell line for site-directed integration<br>O Platform for discovery monoclonal antibodies<br>Investee Companies<br>AlbaJuna Therapeutics - Spain<br>O Development of a promising antibody treatment to<br>neutralize HIV and viral reservoirs at the cellular level<br>Araclon - Spain<br>O Specialized in the research and development of new<br>treatments and diagnostic tests for Alzheimer’s disease<br>New Diagnostic Excellence<br>Center in China<br>Through this path-breaking initiative, Grifols will advance<br>diagnostic knowledge and innovation in Asia by broadening<br>its comprehensive solutions and activities.<br>California Hub<br>Emeryville. San Carlos and South San Francisco<br>Biopharma and Diagnostic<br>Los Angeles and San Diego<br>Biopharma and Diagnostic<br>North Carolina Hub<br>Research Triangle<br>Park<br>Biopharma<br>European Hub<br>Dublin<br>Biopharma<br>Andorra<br>Biopharma -<br>Inmunology<br>Dreieich<br>Biotest<br>Barcelona, Bilbao and<br>Zaragoza, Spain<br>Biopharma and<br>Diagnostic<br>Düdingen, Switzerland<br>Diagnostic | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 76<br>An integral R&D+i strategy<br>Harnessing Biotest’s full potential<br>Acceleration of Biotest’s R&D+i projects that<br>complement and strengthen Grifols’ innovation<br>portfolio to expand plasma-based treatment<br>options for patients around the world.<br>Of note this is the phase III study Adfirst<br>(Adjusted Fibrinogen Replacement<br>Strategy) in patients with high blood<br>loss during spinal surgery, or during<br>abdominal surgery as a treatment for<br>pseudomyxoma peritonei (PMP).<br>A new polyclonal antibody preparation<br>with high content of immunoglobulins<br>(IgM, IgA and IgG) as a treatment for<br>severe community acquired pneumonia<br>(sCAP).<br>Hyperimmunoglobulin approved to<br>prevent cytomegalovirus (CMV) infection<br>in immunocompromised patients.<br>Currently in phase III clinical trials<br>for use to prevent mother-to-child<br>transmission of CMV.<br>+ More information: Pipeline (biotest.com)<br>FIBRINOGEN TRIMODULIN CYTOTECT® | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 77 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>6 main therapeutic areas<br>+ More information on Grifols’ research projects: https://www,grifols,com/es/key-therapeutic-areas<br>1 Partnership with Endpoint Health; 2 Licensed rights from Rigel Pharmaceuticals in EU and other countries; 3 Project of Araclon (Grifols’ invested company)<br>** Commercialization started<br> Projects Biotest<br>Pre-Clinical Phase 1 Phase 2 Phase 3 Phase 4 /<br>Reg.<br>LCM<br>Immunology<br>recIG – PID<br>IGIV-PEG-PID<br>Xembify® in CLL<br>Xembify® – Bi-weekly dosing - PID<br>Xembify® – Prefilled syringes<br>Xembify® – Europe<br>Yimmugo® (IGIV NextGen) in PID **<br>Hepatology/<br>Intensive Care<br>PRECIOSA Decompensated Cirrhosis (Albumin-20%)<br>APACHE Acute on Chronic Liver Disease (Albumin-5%)<br>FlexBag® (U.S., EU)<br>Pulmonology<br>Alpha-1 AT in Non-cystic fibrosis bronchiectasis<br>Alpha-1 AT 15% (SC) in AATD<br>SPARTA – Prolastin-C® - AATD<br>Prolastin® 4-5g. vials (EU)<br>Hematology<br>ATIII in Sepsis1<br>Fibrinogen in Cong. Deficiency & severe hypofibrinogen<br>Fibrinogen in Acquired Deficiency<br>Fostamatinib2 in ITP for refractory patients<br>Yimmugo® (IGIV NextGen) in ITP **<br>Infectious<br>diseases<br>GIGA 2339 in HBV<br>Trimodulin (IgM) in sCAP<br>Cytotec® Pregnancy in CMV infection<br>Neurology<br>GRF6019 in Alzheimer Disease (AD)<br>GRF6021 in Parkinson Disease (PD) with dementia<br>A`vac40 in AD3<br>AKST4290 in PD<br>AMBAR-Next in AD<br>Others<br>GIGA564 Anti-CTLA-4 (mAb Oncology)<br>GIGA2328 Anti-CTLA-4 (mAb Oncology)<br>AKST4290 in nAMD & DR<br>VISTASEAL™ (fibrin sealant) in Biosurgery pediatric use | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 78<br>Ethics, science and innovation<br>For Grifols, advances in the life-science domain cannot be separated from their<br>essential humanistic component. Scientific progress must occur within an ethical and<br>social framework. The company translates this commitment into action through the<br>Víctor Grífols Lucas Foundation.<br>Analysis committees in the Grifols Scientific Innovation Office supervise and monitor<br>all issues related to clinical trials, including their ethical considerations.<br>Grifols subscribes to three fundamental and universal principles, which together<br>govern the ethics of its clinical trials as defined in its Human Rights Policy.<br>Respect for people<br>Respect for an individual’s ability to make decisions freely and independently, and<br>protection of at-risk groups of people who may participate in research. In research<br>processes, this principle is expressed through an informed consent form.<br>Welfare<br>Guarantee the health of people who participate in clinical trials. Risks must be<br>minimized and benefits maximized for all participants. For Grifols, protecting people’s<br>health takes precedence over professional and personal interests, the search for<br>knowledge and research advances.<br>Justice<br>Research must strike a balance between benefits and risks. The principles and<br>outcomes of research projects must be analyzed and participants must be selected<br>homogeneously. Under this principle, participants are never exposed to unsafe<br>situations to benefit another person. There is an obligation to safeguard the rights of<br>vulnerable groups.<br>+ More information on Grifols’ Human Rights Policy: www.grifols.com | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 79 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 79<br>Our commitments<br>Clinical trials<br>Grifols is committed to protecting the rights, safety and well-being of patients who take part in<br>the clinical trials it conducts or sponsors. All clinical research led by the company or on its behalf<br>complies with the standards defined in the International Conference on Harmonization of Good<br>Clinical Practice (ICH GCP); the protection of human beings under the Declaration of Helsinki<br>(1964); and applicable local laws and regulations.<br>Clinical trials are described in a detailed protocol and sent to regulatory authorities and external ethics<br>committees for evaluation. They only begin once a favorable decision has been confirmed.<br>Participants submit a written, signed and dated informed consent form. The lead researcher (or<br>assigned healthcare professional) provides appropriate information, resolves any doubts and gives<br>potential clinical-trial subjects sufficient time to make an informed decision on their participation.<br>Grifols implements standard operating procedures to maintain quality control and ensure the<br>proper execution of clinical trials, and provides correct documentation and reporting of trial data in<br>alignment with the protocol, the ICH GCP and applicable regulatory requirements. The company has<br>additional procedures in place to enable clinical staff to detect and document potential fraud<br>or misconduct.<br>The company also has measures to safeguard subjects’ anonymity and promote the transparency<br>of its clinical trial data. More information on the protocol, status and results stemming from Grifols’<br>clinical trials are disclosed on publicly accessible registries, including www.clinicaltrials.gov. In<br>addition, the findings of clinical trials carried out within the framework of the European Medicines<br>Agency (EMA) are registered on the EudraCT website. The company releases the findings of many<br>of its clinical trials in international conferences and scientific journals.<br>Responsible testing<br>Grifols is committed to the responsible use of laboratory animals when animal testing is essential<br>for the development of new life-saving therapies.<br>Whether studies are carried out in university settings or in outsourced external laboratories,<br>Grifols scientists work closely with regulatory agencies and the Institutional Animal Care and Use<br>Committee (IACUC) to ensure the safe and ethical treatment of research animals.<br>All facilities are approved by the competent authorities where research is conducted. In the<br>United States, Grifols facilities are certified by the Association for Assessment and Accreditation of<br>Laboratory Animal Care (AAALAC) or equivalent organizations and hold the highest accreditation<br>possible for animal-testing laboratories. In Europe, laboratories comply with Directive 2010/63/<br>EU relating to the protection of animals used for scientific purposes and undergo country-specific<br>inspections by the competent authorities.<br>In parallel, the company also adheres to the “Alternatives and the 3Rs” (Replacement, Reduction<br>and Refinement) protocol, which advocates (i) completely avoiding the use of animals or replacing<br>them with alternative techniques; (ii) minimizing the number of animals used; and (iii) refining how<br>experiments are performed to ensure animals suffer as little as possible.<br>+ More information: ClinicalTrials,gov and EudraCT, | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 80<br>Treatment innovations<br>Main projects in development<br>Clinical trial on the use of subcutaneous immunoglobulin Xembify® to prevent infection in patients with<br>chronic lymphocytic leukemia, a disease affecting more than 375,000 people in the U.S. alone.<br>Fibrinogen is the first clotting factor missing when major blood loss occurs during surgery or trauma. Its<br>replenishment is essential, with standard treatments including fresh plasma or cryoprecipitate. Ongoing<br>phase III study in severe spinal surgery and peritoneal pseudomyxoma surgery.<br>Awaiting the start of a clinical trial to apply artificial intelligence technology and Endpoint’s proprietary<br>diagnostic test to identify septic patients most likely to respond to Grifols AT-III treatment, with a potential<br>of more than 140,000 cases/year in the U.S. alone.<br>A very rare, inherited bleeding disorder (1:106 people) in which the body’s ability to form blood clots is<br>impaired. Fibrinogen is used for the treatment and prophylaxis of bleeding episodes in these patients.<br>PHASE III<br>DOUBLE-BLIND TRIAL<br>380+<br>Participants<br>88-100<br>Health Centers<br>JOINT EFFORTS: GRIFOLS & ENDPOINT<br>PHASE I/III CLINICAL TRIAL<br>COMPLETED<br>WORLD’S LARGEST TRIAL OF<br>CONGENITAL FIBRINOGEN<br>DEFICIENCY: 175 HD* IN 36<br>PATIENTS<br>RESULTS CONFIRM HIGH<br>EXPECTATIONS OF ITS<br>EFFICACY AND SAFETY<br>TREATMENT FOR ADULTS AND<br>CHILDREN<br>PHASE III TRIAL IN MAJOR SPINAL<br>SURGERY AND PERITONEAL<br>PSEUDOMYXOMA SURGERY<br>NON-INFERIORITY STUDY OVER<br>STANDARD TREATMENT<br>SUCCESSFUL INTERIM ANALYSIS<br>WITH 120 PATIENTS<br>PATIENT ENROLLMENT<br>OBJECTIVE REACHED<br>XEMBIFY® TO TREAT LEUKEMIA<br>ACQUIRED FIBRINOGEN DEFICIENCY<br>ANTITHROMBIN III FOR SEPSIS<br>CONGENITAL FIBRINOGEN DEFICIENCY<br>*HD: hemorrhagic episode | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 81 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Milestones and product launches<br>Launch of Yimmugo® (IgG Next<br>Generation)<br>This innovative new intravenous<br>immunoglobulin was successfully launched<br>in Germany after earning approvals from<br>its respective health authorities. Yimmugo®<br>is the first Ig produced in Biotest’s new<br>plant, enabling Grifols to expand its<br>portfolio of plasma therapies for patients<br>with congenital and acquired immune<br>deficiencies.<br>+ Más Información Sobre Yimmugo,<br>Approval of Xembify® (IgSC)<br>in Europe and Australia<br>Grifols 20% subcutaneous immunoglobulin<br>(IgSC) Xembify, indicated for primary<br>immunodeficiencies and certain secondary<br>immunodeficiencies, earned several<br>approvals from European and Australian<br>health authorities. The product is expected<br>to launch in Wales (United Kingdom), Spain<br>and Australia in 2023 and in France<br>in 2024.<br>Market expansion of TAVLESSE®<br>(fostamatinib) in Europe<br>TAVLESSE® (fostamatinib), indicated to<br>treat immune thrombocytopenia (ITP) in<br>adult patients who are refractory to other<br>treatments, was launched in the Czech<br>Republic and Norway. Grifols’ first non-plasma treatment, it was also endorsed by<br>the United Kingdom’s National Institute for<br>Health and Care Excellence (NICE).<br>VISTASEAL™ broadens its<br>market presence<br>The biological sealant VISTASEAL™, used<br>to control surgical bleeding episodes,<br>was effectively launched in Canada, Italy,<br>Switzerland, Estonia, Lithuania, Latvia and<br>Australia. VISTASEAL™ combines two<br>plasma proteins (fibrinogen and thrombin),<br>and is administered with Ethicon’s airless<br>spray device technology. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 82<br>Other initiatives<br>for neurogenerative<br>diseases<br>Other advances in plasma<br>therapies<br>GigaGen, non-plasma<br>innovations<br>O Grifols continues to drive new knowledge via Alkahest of<br>the plasma proteome to determine which plasma proteins<br>are connected with aging, a discovery that could extend its<br>therapeutic benefit to various diseases, including those related to<br>the central nervous system.<br>O Launch of two clinical programs with plasma fractions and<br>small molecules in patients with Alzheimer’s, Parkinson’s and<br>dementia.<br>O Araclon Biotech’s active immunotherapy, ABvac40, is in phase II<br>clinical trials.<br>+ More information: About Araclon / Clinical Progress - Alkahest<br>Grifols’ leadership in the plasma protein sector is founded on<br>its continual pursuit of new therapeutic applications for existing<br>plasma-derived products, the discovery of new proteins, and the<br>development of manufacturing innovations to improve the efficacy<br>and safety of its products.<br>GigaGen is dedicated to the discovery and development<br>of recombinant polyclonal antibody-based drugs to treat<br>immunodeficiencies, infectious diseases and immunotherapy-resistant cancers. Its proprietary technology platforms accelerate<br>the discovery of potent monoclonal antibody therapeutics and a<br>new class of drugs: recombinant polyclonal antibodies.<br>In 2022, GigaGen published research in the scientific journal mAbs<br>on its application of machine learning to create these therapeutic<br>antibodies. This method was initially employed in two oncology<br>targets, PD-1 and CTLA-4, with two pre-clinical phase trials<br>underway, although its application could potentially extend to other<br>diseases. Grifols has wholly owned GigaGen Inc. since 2021.<br>+ More details: GigaGen - Antibody Drug Discovery With Single Cell Technology<br>Recombinant therapy for Hepatitis B<br>Recombinant polyclonal antibody therapy for chronic hepatitis B<br>virus (HBV) infection developed on GigaGen’s proprietary platform,<br>with a neutralizing potential far greater than currently available<br>therapies and vaccines.<br>Highly prevalent disease<br>296M+<br>people suffer from chronic HBV<br>IN THE PRE-CLINICAL PHASE<br>R&D PROJECTS ACCORDING TO THEIR<br>DEVELOPMENT PHASE<br>2022* 2021 2020<br>Discovery 19 21 15<br>Pre-clinical 28 30 26<br>Clinical 23 22 25<br>Post-commercialization<br>studies 39 9 11<br>Other projects 14 14 19<br>Total Biopharma<br>R&D projects 123 96 96<br>*it includes Biotest data | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 83 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Diagnostic innovation<br>Milestones and launches<br>CE mark for Procleix<br>Plasmodium<br>The Procleix® Plasmodium assay allows<br>NAT tests to detect plasmodium, a<br>mosquito-borne parasite that causes<br>malaria, in whole blood samples,<br>allowing European blood banks to boost<br>transfusion safety.<br>U.S. launch of the new DG<br>Gel 8 Direct Coombs card<br>The new DG Gel 8 Direct Coombs card<br>is used in direct antiglobulin tests to<br>investigate hemolytic disease in new-borns, transfusion reactions and autoim-mune hemolytic anemia. Following FDA<br>approval, it was successfully introduced<br>in the U.S. market.<br>Blood Typing Manager<br>obtains FDA approval<br>This blood typing tool, designed to<br>enhance efficiency and productivity<br>in transfusion laboratories, is set to<br>launch in the United States, Europe, the<br>Middle East and Africa (EMEA) in 2023.<br>In the U.S., FDA approval has also<br>been obtained for automated antibody<br>titration techniques in Grifols IH instru-ments, used to detect the presence and<br>quantity of antibodies against red blood<br>cell antigens. This information is critical<br>to monitor solid organ transplants with<br>ABO incompatibility and hemolytic<br>disease of the fetus and newborn.<br>FDA clearance for AlphaID™<br>At Home<br>AlphaID™ At Home Genetic Health Risk<br>Service is a free service allowing U.S.<br>adults to assess their genetic risk of de-veloping alpha-1 without a prescription.<br>Using the innovative AlphaID™ oral test,<br>it enables detection through a saliva<br>sample. The service will be available in<br>the United States in the second quarter<br>of 2023.<br>Promonitor Quick ADL is<br>awarded the CE mark<br>Indicated for Crohn’s disease, ulcerative<br>colitis and several rheumatic diseases,<br>this rapid test quantifies the presence<br>of the biologic drug adalimumab using a<br>drop of blood. Available in all European<br>markets that accept this certification,<br>this product responds to the clinical<br>need of proper follow-up. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 84<br>Digital innovation<br>The current market landscape and growth opportunities continue<br>to underscore digital innovation as a transversal axis for Grifols.<br>In light of its pivotal role, the company created the Digitalization<br>Steering Committee (DSC) to continuously explore, evaluate and<br>promote novel digital tools that add value to its business model.<br>The committee includes diverse cross-functional teams and groups<br>that work together to drive the Grifols’ digital transformation.<br>Milestones<br>Blockchain technology comes to Grifols<br>Grifols is a pioneer in the development of blockchain technology<br>to replace EDI messaging, an important step to better protect<br>corporate information. In the long term, this digital transformation<br>initiative aims to increase the accuracy in choosing prices/<br>contracts among commercial partners, leading to an enhanced<br>customer experience in contract and reimbursement processes.<br>Research using AI solutions<br>Grifols incorporated AI technology to examine the molecular<br>mechanisms of immunoglobulin in several autoimmune and<br>inflammatory diseases that show diverse responses to IVIg<br>treatment. Frontiers in Immunology, one of the most cited journals<br>in the field of immunology, featured the research findings. This was<br>the first Grifols study using artificial intelligence to be published.<br>Grifols Innovation and Google Academy alliance<br>Grifols Innovation with Google Academy (GIGA) aims to accelerate<br>innovation by fostering a digital culture and mindset throughout<br>the organization. Among its main areas of focus are computational<br>drug discovery, artificial intelligence/machine learning (AI/ML) for<br>image processing, clinical data incorporation and harmonization,<br>remote care and home-based clinical trials, and proteomics and<br>transcriptomics research.<br>Commercial<br>Clients<br>+ value<br>Industrial<br>Value chain and operations<br>+ optimization<br>Plasma<br>Donors<br>+ experience<br>+ efficiency<br>R&D<br>New sources of value<br>Quality<br>+ safety<br>Corporate<br>+ processes<br>+ employee experience | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 85 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Research support<br>and collaboration<br>Grifols helps advance scientific knowledge of plasma proteins by supporting pre-clinical and clinical<br>research through the ISR program.<br>$8M+<br>allocated to research over the past 5 years<br>to complement public-sector investments<br>Sponsorship: ISR Program<br>+ More information: www.grifols.com<br>These recognitions support and recognize innovative proposals designed to improve people’s overall<br>health and quality of life.<br> €4M<br>over the last 5 years toward<br>scientific awards and research<br>grants<br> Grifols Scientific Awards and research grants<br>+ More information: www.grifols.com<br>In 2015, Grifols founded The Grifols Chair for the Study of Cirrhosis, a private initiative with a global<br>reach aimed at generating research and raising awareness of liver diseases, cirrhosis in particular. The<br>project is led by Prof. Vicente Arroyo through the European Foundation for the Study of Chronic Liver<br>Failure (EF-CLIF), whose executive board includes a Grifols representative.<br> €17M<br>invested over the last 5 years<br>in liver disease research<br>The Grifols chair for the study of cirrhosis<br>+ More information: Grifols Chair for Translational Research | EF Clif | European Foundation for the Study of Chronic Liver Failure<br>Grifols promoted the creation of Plasmatology, the first scientific journal dedicated to plasma science.<br>This leading-edge publication showcases the most relevant and high-impact research in the field, from<br>basic research to clinical application, with the aim of becoming a reference in the international<br>scientific community.<br>23<br>articles published since its<br>launch in March 2021<br>Plasmatology Journal<br>+ Plasmatology: SAGE Journals (sagepub.com) |
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 86<br>Our people<br>Our most<br>valuable asset<br>5 | ||
| --- | ||
| We are a team<br> Our principles<br>We strive to cultivate long-term relationships with our employees by offering<br>training, promotion and talent development opportunities that promote their<br>professional growth in a safe and healthy work environment. At the same time,<br>we make ongoing efforts to advance diversity, inclusion, equal opportunities and<br>gender parity.<br>WE ADHERE TO UNITED NATIONS<br>GLOBAL COMPACT PRINCIPLES<br>PRINCIPLE 3<br>We uphold the freedom of association and<br>the effective recognition of the right to<br>collective bargaining.<br>PRINCIPLE 4<br>We support the elimination of all forms of<br>forced and compulsory labor.<br>PRINCIPLE 5<br>We support the eradication of all forms of<br>child labor.<br>PRINCIPLE 6<br>We support the elimination of discrimination<br>in respect of employment and occupation.<br>Equality<br>Flexibility Ongoing Dialogue<br>Training Diversity & Inclusion<br>Health & Well-Being<br>Roadmap for<br>Grifols 2030 Agenda<br> • More training<br>Increase annual training hours per<br>employee<br> • Organization-wide training<br>Increase the percentage of employees<br>who take part in training initiatives<br> • Shared responsibility<br>Increase the number of women in Grifols<br>Senior Management<br> • Integration<br>Incorporate more people with disabilities<br>into the talent pool<br> • Equality<br>Ensure an equal number of male and<br>female candidates in internal promotion<br>processes for managerial roles<br> • Employee turnover<br>Decrease the overall rate to below the<br>industry average<br> • Commitment<br>Increase the overall rate per department<br> • Health and well-being<br>Increase the number of companies<br>certified as “Healthy Company”<br> • Efficiency<br>Reduce lost time injury frequency rate<br>(LTIFR)<br> • Occupational health<br>and safety<br>Increase number of ISO 45001-certified<br>work centers<br>RECOGNIZED AMONG THE WORLD’S BEST EMPLOYERS: | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 88<br>Act in a responsible and sustainable manner while engaging Grifols teams<br>Uphold diversity, inclusion and equal opportunity<br>Ensure occupational health, wellness and safety<br>Maintain open lines of communication<br>Drive innovation by working as a team<br>Offer training adapted to each employee<br>Support a professional development model that detects both strengths and areas for growth<br>Guarantee competitive compensation packages<br>Our commitment<br>to employees<br>8 commitments to employees<br>Grifols does its utmost to ensure equal opportunities, foster a diverse and<br>inclusive talent pool, and promote the personal and professional growth of its<br>employees. A range policies, guidelines and other management tools reflect<br>our organization-wide employee commitment. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 89<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 89<br>Our priorities in 2022<br>In 2022, the company continued to develop and implement action plans to address the needs detected in the 2020 Grifols<br>Employee Survey, in addition to strategies to better navigate the current economic landscape.<br>Worth highlighting is the “Caring for U” project, an umbrella initiative of several strategic action lines to boost corporate competitiveness.<br>Grifols works to ensure all employees have access to continuous development through in-person or online formats. At the<br>same time, it continues its efforts to enhance diversity, equality, inclusion, health and well-being, and foster a positive employee<br>experience, linchpins to attracting and retaining stellar talent.<br>O Global Recruitment and Selection Policy: guarantees a<br>systematic approach to recruitment, legal compliance and<br>alignment with corporate values to ensure zero discrimination<br>in the recruitment process on the basis of age, marital status,<br>disability, gender, family status, race, religion or sexual<br>orientation.<br>O Occupational Health and Safety Policy: focused on<br>the ongoing application of rigorous health, safety and risk-prevention criteria in the workplace, ensuring the active<br>participation and fluid communication with all stakeholders.<br>O Mental Health Policy: Designed to prevent, protect and<br>promote employee mental health and well-being, as well as<br>support workers dealing with mental health issues.<br>O Global Diversity and Inclusion Policy: recognizes and<br>values the contribution of people with different abilities,<br>experiences and perspectives.<br>O Harassment Prevention Policy: defines harassment as<br>a form of discrimination and defines the types of behavior<br>explicitly prohibited by the organization, underlining its<br>commitment to providing a harassment-free workplace.<br>O Global Training Policy: establishes training commitments<br>and responsibilities, and offers a framework to develop and<br>implement strategic and long-term employee development<br>plans.<br>O “Flexibility for U” Policy: extensive to all Grifols employees,<br>it defines the criteria for remote work, additional flexibility<br>measures and best practices in digital disconnection to promote<br>better work-life balance.<br>O Corporate Internship Policy: establishes and regulates the<br>procedures and benefits for students who carry out internships<br>in Grifols’ Spanish installations.<br>O Grifols Performance System (GPS): annual assessment<br>tool to systematically evaluate employee performance using<br>objective criteria.<br>+ More information on corporate policies: www.grifols.com<br>+ Actions corresponding to these programs are presented throughout this chapter.<br>Policies, guidelines and management tools:<br>4 main programs:<br>Flexibility<br>Trust & Care<br>Wellbeing Health & Care<br>Recognition<br>Care<br>Development<br>Learning & Care<br>Trust and flexibility to continue promoting an optimal work-life balance.<br>The health and well-being of our employees is important to us.<br>A new program to recognize top contributors .<br>Development programs with a long-term vision. Talent Program as a core initiative in 2022. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 90<br>Growing with<br>our team<br>WE PROMOTE EQUALITY **<br>65%+<br>promotions are women<br>72%<br>of new hires are women<br>41%<br>of directors are women<br>197 / +11%<br>47%<br>of management are women<br>630 / +4%<br>TOTAL TALENT POOL *<br>26,314 60% 40%<br>Incorporation of 2,300+ Biotest employees<br>Grifols’ vast experience in integrating teams and talent pools was key<br>to its successful Biotest acquisition. Grifols is currently working on<br>the integration of people, as well as on continuing to foster synergies<br>and align objectives to fully exploit the alliance’s potential and<br>contributions to the global plasma industry.<br>Early in the acquisition process, the company set up committees to<br>facilitate team integration and internal communications with the aim<br>of consolidating strengths and minimizing uncertainty.<br>** Biotest data not included - increase compared to 2021<br>*Total workforce including Grifols and Biotest<br>54% 46%<br>COMMITMENT TO JOB CREATION<br>11,568<br>new hires<br>99% permanent contracts<br>51% between 30-50 years old<br>90+ nationalities<br>milestones | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 91<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Diversity and inclusion<br>Pride in our diverse workforce<br>In the United States, Grifols increased the ethnic representation of its employee pool via agreements with<br>Johnston Community College in Clayton, North Carolina and collaborations with the Black Employee Alliance.<br>Internally, we gave greater visibility to Black History Month, Hispanic Heritage Month and Veterans Day, as<br>well as International Day of Persons with Disabilities (global), International Women’s Day (global), and Pride<br>Month. The company also promoted the U.S. Women’s Leadership Initiative.<br>FOCUS ACTIONS<br>Grifols considers diversity key to generating new ideas, insights and innovation, a core commitment articulated through its Diversity and Inclusion Action Plan, whose objectives are:<br>U.S. Spain + RoW<br>2021 Representation of minorities Inclusion of people with disabilities<br>O Commitment of top management<br>O Inclusive leadership<br>O Review of people management policies and processes<br>O Corporate culture and communication<br>2022 Work values across generations Work values across generations<br>O Comprehensive training<br>O Promotion of intergenerational actions<br>O Awareness and educational campaign<br>O Information on benefits<br>2023 Inclusion of people with disabilities Representation of minorities<br>1. Reflect the diversity in Grifols’<br>communities of operation.<br>2. Continue promoting diversity<br>and inclusion in Grifols’<br>corporate culture and work<br>practices.<br>3. Position Grifols as a global<br>benchmark of diversity and<br>inclusion.<br>O White/Caucasian 41.9%<br>O Hispanic 23.2%<br>O African American 22.3%<br>O Asian 5.0%<br>O Two or more races 3.9%<br>O Unspecified 2.6%<br>O Native Americans/Alaska Natives 0.7%<br>O Hawaiian/Pacific Islander 0.4%<br>RACIAL DIVERSITY IN THE U.S. EMPLOYEE POOL - 2022 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 92<br>The company has zero tolerance for any type of harassment or discrimination. In 2022, its affirmative action plans translated into 110<br>measures, compared to 96 in 2021 and 83 in 2020.<br>Grifols’ strategic development plan includes prevention training initiatives such as the Equal Opportunity Plan course, and others to manage<br>complaints, including the Grifols Ethics Helpline course. Both courses are mandatory for all employees.<br>The company received 36 incidents of discrimination reports in 2022 out of 23,947 employees, compared to 52 incident reports in 2021<br>and 23,234 employees, and 53 incidents in 2020 out of 23,655 employees. All of these complaints were thoroughly investigated and<br>evaluated. While none were deemed discriminatory in legal terms, the company took measures to ensure a discrimination-free environment.<br>Anti-discrimination principles and actions<br>ZERO TOLERANCE FOR HARASSMENT<br>Harassment is a form of discrimination. Established in 2021, Grifols Harassment Prevention Policy aims to eliminate any<br>offensive verbal, physical or visual behavior and actions directed at employees on the basis of gender, color, race, ethnicity,<br>religion, national origin, age, disability, pregnancy, sexual orientation, gender identity or expression that create an intimidating,<br>offensive or hostile work environment or undermine employees’ professional performance.<br>This policy has been translated into 11 languages and adapted to local regulations, reflecting the Grifols’ commitment to three<br>fundamental pillars:<br>1. Guarantee of a non-harassment workplace.<br>2. Fair treatment of employees based on mutual respect.<br>3. Cultivation of a workplace culture accepting of individual differences.<br>The Harassment Prevention Policy outlines specific behaviors prohibited by the organization.<br>These are underscored in employee training initiatives to prevent, correct and discipline behaviors in breach of this policy.<br>Adherence to:<br>O Principles of the International Labour Organization (ILO),<br>created to promote social justice, human rights and the<br>recognition of core labor standards.<br>O The principles of equal opportunity and non-discrimination<br>prevail in Grifols’ hiring processes and its selection of new<br>employees.<br>O U.S. Department of Labor’s Office of Federal Contract<br>Compliance Programs (OFCCP) regulation, which requires<br>active measures to ensure equal employment opportunity and<br>prevent discrimination on the basis of race, gender, religion,<br>age, sexual identity, disability and other factors.<br>O U.S. Department of Labor’s Office of Federal Contract<br>Compliance Programs (OFCCP) regulation, which requires<br>active measures to ensure equal employment opportunity and<br>prevent discrimination on the basis of race, gender, religion,<br>age, sexual identity, disability and other factors.<br>Training in Harassment Prevention Policy:<br>29,267 people 19,347 plasma-center employees | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 93<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Grifols is committed to employing people with disabilities and only<br>adopts alternative measures when their employment is technically<br>or organizationally infeasible, as defined by the General Disability<br>Law applicable to privately and publicly owned firms in Spain.<br>In the U.S., Grifols complies with the employment provisions of<br>the Americans with Disabilities Act (ADA), a federal law aimed<br>at preventing discrimination and providing equal access and<br>opportunities for people with disabilities.<br>As part of its Strategic Plan for Diversity, the company created three<br>global teams in Ireland, Germany and Spain to attract diverse talent<br>and enhance the employee experience of people with disabilities.<br>Highlights in 2022 included:<br>O Greater participation in specialized forums, university<br>collaborations and partnerships to detect and incorporate<br>diverse talent.<br>O New internship program for people with disabilities in Grifols’<br>Engineering Department in Spain.<br>O Enhanced communication and adaptation of the corporate<br>web’s job board to ensure accessibility.<br>O Training on inclusion of people with disabilities for recruitment<br>managers in Spain.<br>Grifols’ has an equal opportunities plan for men and women<br>extensive to its entire Spanish workforce. Its implementation was<br>negotiated with employee representatives in accordance with<br>Organic Law 3/2007 for the effective equality of men and women,<br>and Regulation 901/2020.<br>The equal opportunities plan includes 41 concrete measures<br>to promote equality between male and female employees.<br>These include efforts to guarantee equal pay and opportunities<br>in selection processes and internal promotions, and ensure<br>harassment-free workplaces, among others.<br>Grifols promotes gender equality along several dimensions,<br>including ongoing reviews of promotion processes to detect<br>opportunities for improvement; the use of inclusive language in<br>internal communications; efforts to promote women in STEM; and<br>participation in volunteering programs to advance the employability<br>of women at risk of social exclusion.<br>Incorporating people with<br>disabilities<br>Equal opportunities plan<br>A holistic approach to<br>equality<br>We promote universal accessibility<br>Grifols promotes universal accessibility for people with<br>disabilities in various ways, including the elimination of<br>architectural barriers and compliance with legal standards<br>in its new buildings and installations. Wherever necessary,<br>the company also carries out reforms in existing structures<br>to ensure access for people with reduced mobility.<br>People with disabilities<br>899 employees<br>758 in the United States, 82 in Spain,<br>58 in Germany and 1 in Ireland<br>+16% compared to 2021 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 94<br>We develop talent<br>Our values<br>O We believe people are our most<br>critical asset to drive corporate<br>growth<br>O We recognize our employees’<br>contributions to the group<br>O We seek professionals who support<br>our corporate culture<br>Our objectives<br>O Talent recruitment<br>O Training and development<br>O Performance management<br>O Employee commitment and retention<br>O Internal growth<br>O Talent and succession<br>In 2022, the company made<br>a concerted effort to address<br>the organizational needs and<br>improvements detected in<br>the 2020 Grifols Employee<br>Survey. The upcoming study<br>will feature an in-depth<br>assessment of its progress<br>to date.<br>4 core initiatives<br>Performance management<br>Redesign of Grifols’ Performance System (GPS) to help managers recognize and identify top performers, as well as<br>improve overall corporate performance by encouraging growth, development and team engagement. These efforts include<br>streamlining processes, facilitating more feedback opportunities and specific global projects.<br>Efforts to build a new organization<br>Grifols rolled out organizational development (OD) interventions to facilitate change management during its organizational<br>restructuring. These OD initiatives allowed teams to focus on critical professional development issues, as well as implement<br>strategies and actions to boost employee performance and organizational growth.<br> Global recognition program<br>Efforts to foster a work environment that recognizes and rewards employees’ contributions, job performance and conduct<br>in alignment with Grifols’ values. The program focuses on three chief aspects: corporate values, work anniversaries and<br>outstanding performance. Over 19,000 awards have been granted since its July 2022 launch.<br>Talent Program: Leading the Future<br>Designed to build and develop Grifols next-generation leaders, the first edition of this 12-month program identified<br>100 high-potential employees in diverse business units and departments. Their leadership development includes<br>personalized plans, specialized training sessions, rotations in different functional areas, and mentoring with a senior<br>Grifols leader. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 95<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Grifols made significant strides in 2022 to elevate its talent<br>recruitment and retention, critical to its plasma recovery in its U.S.<br>donation centers and manufacturing plants. This positive trend is<br>even more remarkable when considering the widespread labor<br>dissatisfaction and high levels of employee turnover affecting the<br>U.S. market.<br>As of December 2022, the company was able to fill over 14,000<br>positions despite the tight job market, leading to upswings in<br>production and economic performance. Talent recruitment has<br>become more agile thanks to greater awareness and recognition of<br>Grifols as an employer.<br>In this regard, the Grifols Employer Branding Initiative was key,<br>reflecting the company’s coordinated effort to attract, develop and<br>retain talent, improve brand recognition, and enhance employee<br>engagement.<br>In terms of talent recruitment, Grifols worked to strengthen its<br>collaboration network with U.S. educational entities employment<br>centers; participate in more career recruitment events; and<br>spearhead internal and external communication and awareness<br>campaigns.<br>Grifols collaborates with several universities and educational<br>institutions to offer corporate internships to their students. Through<br>these experiences, interns gain hands-on training and new<br>capabilities to complement their classroom learning and prepare for<br>their future careers.<br>Created in 2017, Grifols’ internship policy assigns a company tutor<br>or representative to each intern, who supports them throughout<br>their learning journey. Corporate internships are six to 18 months<br>in duration.<br>Attracting and developing<br>talent<br>Corporate internship<br>22%<br>of open positions covered by internal<br>promotions<br>Notable contribution of<br>Grifols Employer Branding<br>803<br>interns since 2017<br>18%<br>join the Grifols workforce<br>250<br>interns in 2022 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 96<br>Continuous development<br>Employee training is a core component of Grifols’ professional and<br>talent development. The company works to ensure all employees<br>have access to continuous training and learning opportunities, as<br>outlined in the global training and development strategy.<br>Reflecting Grifols’ corporate objectives, this strategy offers a<br>framework for annual training planning to address the needs<br>identified in individual, team, business and organizational areas.<br>Learning innovations<br>O New manufacturing training center. Located in Parets del Vallès (Barcelona, Spain), this center employs process and<br>procedural simulations to train personnel in areas outside regular manufacturing domains, allowing them to acquire new skills in<br>risk-free environments.<br>O First virtual reality training centers. Grifols operates virtual reality training centers in Barcelona and Dublin. Using this<br>leading-edge technology, the company offers new hires immersive experiences as part of the employee onboarding process.<br>All training activities are evaluated based on learners’ degree of<br>satisfaction and their practical application to their specific roles.<br>Grifols’ professional development opportunities foster a learning<br>culture of personal accountability, and are continuously adapted to<br>reflect its evolving business priorities, emerging trends and global<br>economic landscape.<br>Promoting a culture of learning<br>Online training:<br>O 94% of 2022 training sessions<br>O +4% compared to 2021<br>O Commitment to online and in-person<br>development opportunities<br>On-demand learning:<br>O Carried out via an online platform<br>O +220% increase in the U.S.<br>O Global rollout of the Skillsoft platform<br>More technology:<br>O Virtual reality (VR) to simulate activities<br>and processes<br>O Augmented reality and gamification in the<br>Sales Area<br>O E-learning and VR for new hires<br>Greater multicultural sensitivity:<br>O Centered on multicultural differences and<br>business protocols.<br>O 2022 launch of “Doing Business in China”<br>Grifols offers<br>on-demand learning<br>options to give<br>employees the flexibility<br>of choosing the training<br>resources they need. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 97<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>*Data reflects 96% of Grifols’ workforce.<br>2022 Consolidated Directors’ Report· 97<br>*Data reflects 96% of Grifols’ workforce.<br>Total hours %<br>O Executives 1,861 0.04<br>O Directors 15,367 0.33<br>O Senior Management 19,927 0.42<br>O Management 46,173 0.98<br>O Senior Professionals 102,459 2.17<br>O Professionals 195,447 4.14<br>O Administrative Staff / Manufacturing Technicians 4,337,580 91.92<br>TRAINING HOURS BY PROFESSIONAL CATEGORY<br>Total hours and % over total hours.<br>TRAINING HOURS BY REGION<br>PROFESSIONAL DEVELOPMENT IN BIOTEST<br>Grifols’ training at a glance<br>4,718,814<br>training hours* 2022<br>70%<br>training hours delivered to women<br>30%<br>training hours delivered to men<br>170,000+<br>training hours on occupational health, safety<br>and environmental issues<br>4,310,060<br>U.S.<br>269,409<br>Spain<br>139,345<br>RoW<br>56%<br>delivered to<br>44%<br>delivered to<br>5,200+<br>training hours dedicated to<br>occupational safety, health<br>and environmental issues<br>51,700<br>training hours 2022 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 98<br>Professional development programs<br>DEVELOPMENT OF EXECUTIVES<br>EDUCATIONAL EXPENSES REIMBURSEMENT PROGRAM<br>Focus on continuous reinforcement of leadership and coaching skills.<br>In 2022, Grifols has concentrated on change management, adaptation to new roles and structures and<br>communication skills.<br>Main programs:<br>O Grifols Leadership Exchange Program, designed for manufacturing managers.<br>O Center Leadership Development Program (CLDP), aimed at new leaders of Grifols plasma donation<br>centers. Accredited by the Institute for Credential Excellence (ICE) for its ethical approach.<br>O Short, ad hoc programs imparted globally: “Leadership by Objectives in Flexible Environments” and<br> “The Development and Performance Interview.”<br>New programs:<br>O Evolving Leadership”: a 6-month program to bolster the leadership skills of 20 mid-level managers in<br>Ireland, bolster the leadership pipeline and facilitate the execution of the subsidiary’s strategic priorities.<br>O “Talent Program: Leading the Future”: 12-month global initiative designed to prepare Grifols’ future<br>leadership team.<br>Grifols also gives employees the option of taking part in professional development opportunities outside<br>the company, contributing to its culture of ongoing learning and improvement. This initiative gives<br>employees the necessary flexibility and financial support to earn official higher education degrees and<br>professional certifications.<br>NUMBER OF MANAGERS TRAINED IN LEADERSHIP<br>2020 2021 2022<br>583<br>481<br>594<br>UNIVERSITY TRAINING<br>The Grifols Academy joined the College for America program in 2013. Led by Southern New<br>Hampshire University, it offers scholarships to help Grifols employees earn college degrees.<br>111<br>graduates since 2013<br>GRADUATES (Nº OF EMPLOYEES)<br>2020 2021 2022<br>6<br>8 8<br> €1.3M<br>allocated | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 99<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>The Grifols Academy<br>Offers employees training and professional development to reinforce their corporate<br>competencies and values. Its three core training areas include: corporate competency<br>development, leadership development and onboarding initiatives.<br>The company launched The Grifols Academy in 2009 in reflection of its commitment<br>to continuous development. The Academy comprises three distinct entities, each<br>with a specific educational focus. Through this initiative, Grifols promotes employees’<br>educational and professional development, fosters corporate values, and offers<br>resources and services to medical professionals worldwide to help them offer better<br>patient care.<br>Delivers general and specialized training on plasma science in the core areas of<br>leadership, quality, operations and medicine as part of its efforts to advance the<br>professional and educational development of U.S.-based employees.<br>The Grifols Academy of Plasmapheresis received a five-year approval from The<br>Accrediting Commission of the Accrediting Council for Continued Education and Training<br>(ACCET), valid until December 2024. It was first accredited in 2015.<br>The Grifols Academy continued to develop its portfolio in 2022 by incorporating in-person, hybrid and virtual formats to reach more Grifols employees and adapt to their<br>learning needs.<br>The Grifols Academy of Transfusion Medicine imparts educational programs to<br>professionals around the world to contribute to scientific process and enhance patient<br>care.<br>2,001<br>participants<br>4,468<br>training hours<br>13,736<br>participants<br>39,099<br>training hours<br>5,518<br>participants<br>23<br>training actions<br>+ More information: The Grifols Academy | Grifols | |
| --- | ||
| 2022 Consolidated Directors’ Report · 100<br>Fair compensation practices<br>Grifols is firmly committed to effective equality by providing equal opportunities and equal pay regardless<br>of gender. Every year, the company carries out a gender pay gap analysis, both adjusted and unadjusted,<br>as part of its continuous efforts to promote equality. In 2022, Grifols received external support from the<br>global consulting firm EY to ensure the utmost rigor and transparency in the analysis.<br>The unadjusted wage gap is calculated as the percentage differential between men’s and women’s<br>gross wages per hour worked. That said, the adjusted wage gap is considered a more accurate measure<br>since it employs econometric models to isolate factors in men’s and women’s wages stemming from<br>differences in socioeconomic attributes (ex. age, seniority, geographical area and educational level) and<br>job characteristics (work schedule modality, type of activity and professional category).<br>This report examines the gender pay gap in Spain, the United States, Ireland and Germany, which<br>combined account for over 90% of the group’s employee base. Based on the 2022 World Economic<br>Forum’s Global Gender Gap Report, Grifols’ unadjusted pay gap is below national averages in Spain,<br>Germany and Ireland. The company’s results by professional category highlight its progress in increasing<br>the presence of women in leadership roles and advancing pay equality, with concrete metrics outlined in<br>the 2021-2023 Global Diversity Plan.<br>Guided by these objectives, Grifols has bolstered the proportion of women in senior positions in recent<br>years. In 2022, female representation in the Directors category grew to 41.1% compared to 34.8% in<br>2019. In addition, the Grifols 2030 Agenda includes a target of 50% women in Senior Management<br>roles, which at the close of 2022 stood at nearly 39%. The company foresees a positive impact on wage<br>gap differentials as a result of this progressive upswing in women-led leadership roles.<br>For Grifols, another critical factor in advancing wage parity is bolstering women’s participation in<br>STEM (Science, Technology, Engineering and Mathematics), a field where they have been traditionally<br>underrepresented. The company spearheads various initiatives and measures to identify STEM roles and<br>foster greater access for women.<br>Equal pay between men and women<br>+ More details on remuneration data are available at the end of this chapter.<br>GENDER PAY GAP<br>Spain U.S. Ireland Germany<br>Salary gap by country * 38.4% 22.8% 29.7% 41.4%<br>Grifols<br>Adjusted pay gap** 3% 0.9% 2.8% 1.4%<br>Unadjusted pay gap*** 12.1% 24.6% 15.8% 14.5%<br>*Source: Global Gender Gap Report 2022 – https://www3.weforum.org/docs/WEF_GGGR_2022.pdf<br>** Details and comments on the methodology and its calculation are available in Chapter 9 “About this Report.”<br>*** Difference between men’s and women’s salaries calculated as the percentage differential between the average gross salary per each hour<br>worked by men and women ([average gross salary for men - average gross salary for women] / average gross salary for men), under Law 11/2018 of<br>28 December and the Global Reporting Initiative standards (GRI 405).<br>In addition to its action plan to advance these two aforementioned factors -both directly related to the<br>gender pay gap- the company has also rolled out measures to improve its recruitment, salary review<br>and promotion processes, ensuring these reflect individual performance evaluations based on common,<br>transparent and gender-neutral criteria. As part of Grifols 2030 Agenda, the company aims to ensure<br>women account for 50% of candidate interviews for managerial roles and higher. In parallel, it also<br>promotes flexible work schedules for both men and women and professional development actions to<br>bolster its pipeline of female talent for top-leadership positions.<br>Grifols worked to achieve greater female<br>representation in leadership roles – women<br>hold 41% of director positions and 33% of board<br>membership – while narrowing its gender pay<br>gap close to parity. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 101<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 ConsolidatedDirectors’ Report · 101<br>SPAIN<br>Gross pay gap well below the<br>national average<br>Grifols’ adjusted pay gap in Spain was 3.0%<br>in 2022 (3.2% in 2021), evidence of its<br>commitment to pay parity. Pay-gap declines in<br>the Director (-10.7%) and Management (-1.9%)<br>categories were especially noteworthy.<br>The company continued to adapt its existing<br>equality measures to the new requirements<br>defined in Royal Decree 902/2020 of<br>October 13, 2019, which included additional<br>transparency obligations for compensation<br>audits. Grifols carried out a pay analyses in line<br>with this new regulation, which was presented<br>to the Equality Plan Negotiating Committee<br>in Spain. This study complements the gender<br>gap study and provides further information to<br>reinforce the company’s action plan.<br>In 2022, the unadjusted pay gap in Spain stood<br>at 38.4%, far higher than Grifols’ 12.1% gap.<br>This gap has progressively narrowed from the<br>12.4% reported in 2021 and 14.3% recorded<br>in 2020. Worth highlighting were Grifols’<br>narrower pay gaps in its Directors (-3.9%) and<br>Management (-1.1%) categories.<br>THE U.S.<br>Gross gap very close to the<br>national parity<br>In 2022, Grifols continued to advance pay parity<br>and promote women’s access to leadership<br>roles, reducing its adjusted pay gap in the U.S.<br>to 0.9%. Declines in the adjusted pay gaps in<br>Directors (-1.3%), Senior Professional (-2.3%),<br>Professional (-1.2%) and Administrative staff/<br>Manufacturing operators (-1.0%) categories<br>were particularly noteworthy.<br>The country’s unadjusted pay gap fell<br>significantly last year, from 32.2% in 2021<br>to 22.8% in 2022. In recent years, the U.S.<br>unadjusted pay gap was especially high due<br>to cyclical circumstances stemming from the<br>healthcare crisis.<br>While impacted by a challenging U.S. labor<br>market, Grifols reduced the gross pay gap<br>by 3.5% in 2022 to 24.6% after effectively<br>implementing a series of measures.<br>IRELAND<br>Gross pay gap below the<br>national average<br>In 2022, the adjusted gap stood at 2.8%.<br>The employee pool grew by 21.5% last year,<br>attaining greater female representation in the<br>Directors, Management and Senior Professional<br>categories.<br>In light of the sharp upturn in total employees,<br>the company is unable to conduct an adjusted<br>pay-gap analysis with sufficient statistical<br>reliability, both in overall terms and by<br>professional categories as the 2022 sample is<br>not comparable with 2021 levels.<br>The unadjusted pay gap for Grifols in Ireland<br>was 15.8%, compared to the country’s overall<br>29.7% gap. The company’s 2022 figure reflects<br>a 1.6% decline compared to 2021, reflecting<br>its ongoing efforts to ensure fair remuneration<br>conditions for men and women when performing<br>the same role.<br>GERMANY<br>Gross pay gap well below the<br>national average<br>In Germany, Grifols’ adjusted pay gap is 1.4%,<br>and women hold 56% of team leadership roles,<br>a 1% upturn over 2021.<br>The unadjusted pay gap is 14.5%, far below the<br>41.4% national average. In 2022, Germany’s<br>pay gap grew by roughly 2.8% in 2022, while<br>Grifols’ gross pay gap decreased by 3.8%.<br>EQUALITY AND THE GENDER PAY GAP<br>17.6%<br>over total workforce<br>44.5%<br>women<br>69.9%<br>over total workforce<br>63.7%<br>women<br>1.4%<br>over total workforce<br>43.8%<br>women<br>5.8%<br>over total workforce<br>72.5%<br>women | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 102<br>Grifols’ remuneration philosophy promotes meritocracy and equal<br>opportunities, compensating employees for their professional<br>performance and contribution toward advancing the company’s<br>sustainable development and strategic objectives.<br>Grifols guarantees non-discrimination because of gender, age, race,<br>religion, sexual orientation or other personal factors.<br>The company’s remuneration policy strives to objectively<br>compensate employees based on their level of responsibility and<br>performance.<br>In line with Grifols’ corporate policies, each country offers fair and<br>competitive compensation packages adapted to their local market.<br>Compensation model:<br>O Fixed salary based on the level of responsibility of the position,<br>the employee’s career path and labor market practices in<br>alignment with country-specific regulations. Salaries have<br>defined ranges for each position and are reviewed every year.<br>O Variable retribution as bonds or monetary incentives linked to<br>the achievement of concrete and measurable objectives, which<br>are previously established and communicated.<br>Remuneration system<br>O Compensation packages aligned with market trends and<br>employee needs. Grifols offers a range of social benefits in all of<br>its countries of operation, establishing diverse programs adapted<br>to the local context. These include medical insurance policies,<br>pension plans, life and/or accident insurance, travel insurance,<br>tuition grants, well-being plans and product/service discounts.<br>As outlined in the Remuneration Policy, an external competitiveness<br>remuneration analysis is carried out every year to assess Grifols’<br>compensation practices and ensure thy reflect industry best<br>practices.<br>+ More details on savings plans in chapter 9. About this report.<br>+ More information on remuneration by professional category, age and gender is available in the tables included in chapter 9. About this report.<br>SOCIAL RELATIONSHIPS: BUILDING TRUST<br>Social dialogue<br>For Grifols, engaging in social dialogue with worker representatives is critical to jointly address transversal issues requiring collective bargaining in its various workplaces. In Spain, the labor-relations system<br>establishes two types of representation in companies: trade union representation and unitary or elective representation. These people include members of trade unions, company committees and personnel<br>delegates, with whom Grifols holds regular meetings to address issues affecting the workforce. In other countries such as France and Germany, the company routinely meets with workers’ legal representation.<br>In Italy, company decisions that could impact collective working conditions are discussed with trade union organizations.<br>Collective labor agreements<br>Grifols’ employees in Spain, Germany, Italy, France, Argentina and Brazil work under collective agreements. In 2022, 4,474 employees were covered by these agreements, representing 18.7% of Grifols’<br>workforce. In the United States, industry-level collective bargaining does not exist and is carried out at the company level. The Taft-Hartley Act regulates industry-specific benefit plans and provides that federal<br>courts have jurisdiction to enforce collective bargaining agreements.<br>Workers representation committees<br>In Spain, Chile and Germany, where labor committees are established by law, Grifols assigns managers to oversee the prevention of occupational health and safety risks. In 2022, the majority of employees in<br>Spain were represented by a joint committee comprised by employees and occupational health and safety managers. In Chile and Germany, 100% of employees were represented by these committees. There<br>is no formal representation in the remaining Grifols subsidiaries. In these markets, the company regularly communicates and consults with its specific workforces, which establish committees that welcome<br>employees’ participation and proposals. Each subsidiary defines the frequency of these meetings and subsequent follow-up of the committee’s specific plans, actions and measures. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 103<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Grifols’ Occupational Health and Safety area establishes annual<br>health and safety objectives, as well as oversees an audit program<br>to supervise the health and safety management systems of its<br>subsidiaries. In 2022, a new corporate health and safety policy<br>was launched to improve employees’ health through their active<br>participation and consultation.<br>Grifols has an occupational health and safety structure in all of<br>its countries of operation, in addition to a corporate Occupational<br>Health and Safety Department that serves the entire group.<br>Occupational health and well-being<br>Comprehensive health and safety management<br>Management<br>system<br>Grifols workplaces in Spain are all<br>ISO 45001-certified. A three-year<br>plan is under way to earn ISO 45001<br>certification for all U.S. manufacturing<br>plants by 2030. Outside the U.S. and<br>Spain, international subsidiaries have<br>country-specific systems in accordance<br>with corporate policy and standards.<br>In 2022, Grifols developed a new<br>corporate health and safety manual,<br>incorporating five new health and<br>safety standards extensive to all Grifols<br>companies.<br>Hazard identification and<br>risk minimization<br>Integrated into the design phase of<br>manufacturing plants, process changes<br>and the acquisition of new equipment.<br>Occupational health<br>and safety training and<br>awareness programs<br>The entire Grifols’ workforce<br>receives training and information<br>on occupational health and safety<br>issues, starting from the onboarding<br>phase to changes in the job function<br>and throughout their tenure at the<br>company. In 2022, specific training<br>on ISO 45001 was delivered in the<br>U.S. for occupational health and safety<br>managers. Health & Safety Officers also<br>received training on the new corporate<br>occupational health and safety manual<br>and new standards.<br>Promoting employee<br>health and well-being<br>Grifols heads several programs in its<br>core countries of operation. In 2022,<br>the company launched the “Take<br>Care of Your Heart” program, a three-year wellness plan extensive to all<br>subsidiaries focused on preventing<br>cardiovascular diseases. Globally, it<br>led educational campaigns, training<br>programs and informational sessions<br>to address the importance of mental<br>health and physical exercise as<br>complements to local country-specific<br>actions.<br>Management of<br>contractors<br>Grifols’ production centers have<br>concrete management procedures<br>in place regarding contractor<br>management. In Spain, contractors<br>provide informational regarding<br>occupational risk prevention through a<br>computerized document management<br>platform in order to gain access to<br>Grifols facilities. The procedures for<br>each company are audited by HS<br>Corporate Audits.<br>Progress in occupational health and safety<br>training in 2022<br>O New policy<br>O New manual and standards<br>O Specific training: system management and internal audits<br>Control of corporate occupational health<br>and safety:<br>O Monthly monitoring of key performance health and safety<br>indicators<br>O Assessment visits to all companies and monitoring of<br>preventive plans<br>O Corporate audits based on the annual plan: 6 in 2022 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 104<br>We value our employees<br>Mental health<br>Grifols promoted several actions in 2022 to ensure employees’ emotional equilibrium, including<br>monthly sessions on mental health issues and mindfulness master classes. In Spain and Ireland,<br>the company also offered small-group emotional and sessions led by expert clinical psychologists.<br>Grifols’ Spanish operations incorporated two new tools in employee health revisions–the PHQ-4<br>questionnaire and Goldberg test–to continuously monitor the organization’s psycho-emotional<br>condition and detect situations that might lead to anxiety or depression.<br>186<br>participants in<br>stress management<br>program<br>9<br>in mindfulness<br>course<br>66<br>in emotional<br>intelligence<br>program<br>1,106<br>participants<br> 97<br>teams<br>35+<br>million steps<br>Physical exercise<br>Monthly support meetings; a global daily-steps campaign organized virtually and by teams, with five<br>stages in different Grifols offices. The “Grifols Worldwide Challenge,” a charity run for individuals and<br>teams to promote moderate physical exercise as a healthy way to prevent cardiovascular conditions.<br>STRATEGIC WELLNESS PLAN: TAKE CARE OF YOUR HEART<br>A 3-year plan that addresses two distinct cardiovascular risks per year. In 2022, mental health and exercise. In 2023, alcohol abuse and nutrition. And in 2024, restorative sleep and tobacco addiction. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 105<br> CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Performance in occupational<br>health and safety<br>Grifols employees in the United States, Spain, Ireland and Germany<br>represent roughly 95% of its total workforce. Each subsidiary<br>monitors its own country-specific indicators, including accident<br>rates and new health metrics.<br>The company investigates all accidents with and without leaves,<br>minor incidents and commuting accidents in countries where<br>these are regulated. In parallel, it works continuously to improve its<br>occupational health and safety systems.<br>The group’s manufacturing facilities report low rates of work-related<br>illnesses. All work processes, including the collection and handling<br>of plasma donations, follow a rigorous protocol encompassing<br>technical, organizational and personal measures. Grifols has a<br>program to control the exposure to identified risk factors in order to<br>prevent accidents and take actions when necessary.<br>Absenteeism<br>Work-life balance<br>The health, safety and well-being of Grifols’ employees directly<br>impact its incidence of absenteeism. The company uses an<br>absenteeism management model with defined benchmarks to<br>quantify its cost impact. In order to minimize some of the most<br>common absenteeism causes, Grifols has several measures in<br>place to promote overall employee health and well-being.<br>These include a 24-hour physiotherapy service in Spain to prevent<br>musculoskeletal injuries, evaluate employees’ psychosocial risks<br>and develop specific wellness plans. The company also carries out<br>awareness sessions, return-to-work interviews following extensive<br>leaves, and communication protocols for employee absences.<br>In today’s global labor markets, employees place a high value on<br>work environments grounded in trust and flexibility, which enable<br>them to thrive in their professional roles while achieving a positive<br>work-life balance.<br>As part of Grifols’ Flexibility Policy, the “Flexibility for U” initiative<br>aspires to promote the mutual trust and responsibility between the<br>company and its global talent pool.<br>The program includes a range of actions to reflect the diverse<br>profiles within the Grifols workforce. By 2022, 74% of eligible<br>employees had taken part in this initiative, which includes:<br>O Possibility of teleworking 40-80% of total hours per week,<br>depending on the job function.<br>O Flexible 3-hour window on either side of the employee’s core<br>hours.<br>O Possibility of more remote work positions.<br>O Implementation of intensive work schedule on Fridays in labor<br>markets where this is a common practice.<br>These options are in addition to those already in place, such as the<br>previously implemented “right to disconnect” measure.<br>+ More details on Grifols’ absenteeism rates are available in the tables in<br>chapter 9. About this report<br>Occupational safety as a core<br>commitment<br>Grifols’ work centers in Spain have been ISO<br>45001:2018-certified since 2021. This certification<br>recognizes the company’s efforts to guarantee a safe<br>and healthy work environment for all employees, helping<br>advance the safety, health and good management<br>processes that underlie all Grifols operations. The<br>management team’s leadership and commitment, level of<br>employee engagement, risk-and-opportunity action plans,<br>and operational control were among the aspects evaluated. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ R eport · 106<br>Impact on society<br>Joining<br>forces<br>6 | ||
| --- | ||
| We are community<br> Our principles Our stakeholders<br>We are committed to making a positive impact on society and actively engaging in<br>communities where we operate to increase the multiplier effect of our activity in terms<br>of job creation, social impact and social benefit. We strive to promote more sustainable<br>public healthcare systems and, through our foundations, to expand our social outreach.<br>Engage<br>Advocate Support<br>Making a positive impact<br>Educate<br>Roadmap for<br>Grifols 2030 Agenda<br> • Increase social-outreach initiatives and<br>investments<br> • More social initiatives that<br>grant STEM scholarships<br>for women<br> • More donations allocated<br>to emergency-relief<br>medicines and products<br> • Increase contributions<br>from the José Antonio<br>Grífols Lucas Foundation<br>to local initiatives<br> • Increase contributions<br>from the Victor Grifols<br>i Lucas Foundation to<br>bioethics grants and<br>number of activities<br>The company’s commitments are directed at<br>various stakeholder groups<br>Donors<br>Employees Research community<br>Local communities<br>Public Officials<br>Patients and patient associations<br>Public healthcare systems<br>Foundations and NGOs | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 108<br>Our social reach<br>Grifols’ Sustainability Policy outlines its core principles,<br>commitments and actions to impact society. For its part, the<br>Sustainability Master Plan, in alignment with the 2030 Agenda and<br>United Nations Sustainable Development Goals, underscores Grifols<br>staunch commitment to promoting sustainable development beyond<br>economic impact.<br>Grifols’ social contribution<br> €32.1M<br>12.0 9.2 2.4<br>Million euros<br>Product<br>donations<br>Million euros<br>Patient advocacy<br>groups and programs<br>Million euros<br>Scientific awards, research<br>and education<br>2.7 1.6 4.2<br>Million euros<br>Special projects,<br>sponsorships and other<br>initiatives<br>Million euros<br>Social action<br>and community<br>investment<br>Million euros<br>Foundations<br>+ More information on product donations and contributions to patient organizations and programs, see chapter Commitment to donors and patients.<br>+ More information on scientific awards and research, see chapter Innovation. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 109 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Promoting more sustainable<br>public health systems<br>Improving health system costs<br>Outside its core operations, Grifols puts its facilities, technology, knowhow and technical expertise at the disposal of public donation centers<br>and health organizations to process their surplus plasma, purify the proteins and return them as plasma-derived medicines. Offered in<br>Spain, Italy and Canada through regulated by fractionation service agreements, these collaborations generate significant cost savings for<br>public healthcare systems.<br>Important strides in Spain: 400,000+<br>liters of plasma collected to make<br>plasma-derived medicines<br>In 2022, more than 400,000 liters of plasma were collected<br>in Spain for the fractionation and manufacture of plasma<br>derivatives. This volume represents roughly 40% of the<br>country’s needs to produce plasma-based therapies. In terms<br>of geographic distribution, Andalusia and Catalonia contributed<br>over 50% of collected plasma.<br>This significant upturn in Spain’s plasma collection is thanks<br>to the collective efforts of numerous entities and organizations<br>united by a common commitment: improving the health and<br>well-being of patients.<br>Spain<br> €73M<br> savings in 2022<br>400,000+<br> liters of plasma in 2022<br> €270M+<br> savings since 2019<br>THE VALUE OF OUR<br>CONTRIBUTIONS<br>Public-private collaborations<br>We help countries achieve their self-sufficiency in plasma<br>medicines to ensure patients have access to essential<br>treatments.<br>+ More information, see chapter Commitment to donors and patients.<br>Improving health costs<br> We promote public-private partnerships that promote savings for<br>public health systems.<br>Awareness<br>We collaborate with blood banks to educate and promote plasma<br>donation to help promote Spain’s self-sufficiency of plasma<br>medicines. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 110<br>An integral solution encompassing the entire logistics of<br>plasma (collection, transport, control and analysis) through<br>its fractionation, purification, dosage and delivery as a<br>finished product.<br>Collaborative solution<br>Safety throughout the<br>value chain<br>Integrated quality<br>control<br>Patient focused<br>Savings for global<br>healthcare systems<br>Greater self-sufficiency<br>Supporting blood banks<br>Grifols has various programs designed to collaborate and assist in meeting the need of blood banks.<br>O Transport and plasma storage services to guarantee the quality of transfusion plasma, including the Contingency Program for<br>refrigeration equipment issues; the IPTH Program, which offers additional viral safety measures; and the Secure Program, focused on the<br>collection, storage and recovery of frozen plasma.<br>O Plasma for hemoderivatives, including the Apheresis Program, a collaborative effort with blood banks and transfusion centers to<br>encourage plasma donation through plasmapheresis.<br>O Laboratory service through the Biolab Program, which offers sample analysis, immunohematology and plasma quality-control<br>services, among others.<br>O Quality services including the Quality Program, which provides expert advice on management systems and quality assurance; and<br>the Academy Program, which includes plasma-related training, workshops and educational programs.<br>O Grifols Plasma Management Service, an in-house development to improve, accelerate and facilitate communication among the<br>various parties that intervene in industrial plasma fractionation contracts.<br>OUR INDUSTRIAL<br>FRACTIONATION<br>PROGRAMS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 111 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>bout<br>his report<br>Social action and<br>community investment<br>The principles and guidelines in Grifols’ Sustainability Policy inform<br>its Corporate Social Action and Community Investment Policy, both<br>of which fall under the umbrella of its Sustainability Master Plan.<br>Grifols’ social action is an opportunity to contribute to the United<br>Nations 2030 Agenda for Sustainable Development by investing<br>in initiatives that create shared value and support sustainable<br>development. The company’s social action is carried out directly by<br>Social Impact Committees and through foundations.<br>Grifols’ decisions on investments and donations to social-impact<br>activities are governed by its Code of Conduct guidelines. Its local<br>social impact committees follow specific procedures to guarantee<br>the transparency of these activities and their alignment with the<br>Grifols’ corporate mission and the Social Action and Community<br>Investment Policy.<br>In 2022, the Social Impact Committees collectively allocated over<br>USD 400,000 to relative projects and initiatives.<br>+ More information on Grifols’ social action and community investment policy.<br>*Including plasma center initiatives<br>Grifols’ grant committees review and ensure the rigor and transparency<br>In 2022, the EU/UK Committee was created to coordinate European grants allocated to countries other than Ireland, Germany and Spain.<br>9<br>A<br>th<br>Emeryville<br>Los Angeles<br>San Diego<br>Barcelona<br>Dublin<br>Frankfurt<br>Merlbourne<br>Clayton<br>Direct social-action<br>initiatives<br>Actions* in 2022 Grants for initiatives Participants<br> €1.6M 2,700+ 100+ 2,000+ volunteers | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 112<br>4 AREAS OF INITIATIVES*<br>Health and well-being<br> We aspire to improve access to healthcare and<br>promote healthy lifestyle habits.<br>Local development<br> We support local development in our communities<br>of operation by creating job opportunities and<br>improving residents’ quality of life.<br>Education<br> We promote equality in education among young<br>people and the research community via in-kind<br>donations, grants, and scholarship programs.<br>Environmental issues<br>We recover and enhance the natural environment<br>through in-house initiatives and collaborations with<br>environmental-action groups.<br>16% of initiatives 33% of initiatives 36% of initiatives 16% of initiatives<br>Humanitarian support for Ukraine<br>Grifols collaborates with the Ukrainian Ministry of Health, international and local organizations to provide medicines and assistance to those<br>affected by current conflict. The company has provided serum, Ringer’s solution, albumin, saline and glucose solutions, among others. Additionally,<br>Grifols delivered anti-tetanus immunoglobulins and clotting factors to hemophilia refugees in Germany through the World Health Organization.<br>Grifols donation centers in Germany mobilized to raise funds for the Ukrainian people: for every blood and plasma donation collected at one of<br>the plasma-collection centers, 1 EUR is donated to the German charity Aktion Deutschland Hilft that provide emergency aid to people affected by<br>the Ukrainian conflict. The Probitas Foundation website included a section linked to Grifols internal portal, allowing employees to easily donate to<br>various humanitarian organizations.<br> €1M+<br>donated to Ukraine<br>* Breakdown of initiatives, excluding plasma center activities. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 113 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Health and well-being<br>For the fourth consecutive year, Grifols led a food drive and fundraising campaign for<br>Feeding America through the “Box Out Hunger” initiative, with the generous participation<br>of U.S. employees and donors.<br>Support in 2022<br>1 million meals USD 150,000<br>Annual toy drive in the U.S. by Grifols’ employees and donors in benefit of children<br>from low-income families<br>Support in 2022<br>9,000+ donated toys<br>Core collaborations Other initiatives<br>SPAIN<br>The donations to the Twin families program<br>from the Christmas baskets of 362 employees<br>for an amount of €24,951 provided a daily<br>meal and socio-educational support to 30<br>vulnerable teenagers during the school year.<br>AUSTRALIA<br>Dedicated to providing healthy meals to people<br>with limited resources, Fair Share transforms<br>vacant lots into community gardens to grow<br>vegetables to complement its food baskets.<br>Grifols employees participate in the corporate<br>garden, which prepares around 5,000 meals<br>per day.<br>AUSTRALIA & U.S.<br>Ronald McDonald House Charities provide aid<br>programs for sick children and their families.<br>Grifols takes part in the “Adopt a Room”<br>initiative.<br>A core component of Grifols’ social action, it focuses on supporting and promoting actions<br>that contribute to improving the health and well-being of people.<br>GERMANY<br>Donation of food and basic necessities for<br>groups at risk of exclusion in the Frankfurt area<br>through Frankfurten Tafel, an association serving<br>more than 27,000 people every month. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 114<br>Grifols aspires to maximize positive impacts and opportunities in its<br>communities of operation.<br>Our plasma centers: drivers of local development<br>Grifols’ steadfast commitment to donors extends to the communities where its donation centers are located. The company organizes community-outreach<br>events, offers donations and leads volunteer activities both directly and through the J.A. Grifols Foundation.<br>+ More information Home - JAG Foundation - Grifols (joseantoniogrifolsfoundation.org)<br>Activities Donor-center network,<br>participation<br>Employees Hours dedicated to our<br>communities<br>~2,600 90%+ 1,800+ 25,000+<br>Local development<br>SPONSORSHIP<br>Supporting women’s football<br>Grifols signed a four-year contract as<br>an official sponsor of the UEFA (Union of<br>European Football Associations) women’s<br>football team, starting in the 2021-22<br>season until the completion of competitions<br>in 2025. Through this partnership, Grifols<br>stands out as the only healthcare company<br>to sponsor UEFA women’s football at all<br>levels of competition, including the UEFA<br>Women’s Champions League, UEFA<br>Women’s Euro, Sub 19 and Sub 17 Women’s<br>European Championship, Women’s European<br>Indoor Football Championship, and the<br>campaign “Together #WePlayStrong”.<br>As women’s soccer continues to gain<br>traction and attract new female players and<br>fans across Europe, Grifols’ sponsorship is<br>further testament to its support of women’s<br>sports and commitment to advancing<br>gender equality.<br>Plasma Possibilities<br>This non-profit initiative offers plasma donors the chance to<br> “give back twice” by donating plasma and by partially or totally<br>contributing their donor remuneration to a participating charity<br>organization. More than USD 120,000 (USD 17,000 in 2022) for<br>18 U.S. charitable organizations (10 in 2022) have been raised<br>since its launch in 2017. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 115 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Since 2014, Grifols and Habitat for Humanity have worked together to build and<br>improve safe, decent and healthy homes in communities in across the United States.<br>Support in 2022<br>180+<br>volunteers<br>1,240+<br>hours<br>250,000<br>USD<br>Partnership with the United Service Organizations (USO), a national non-profit whose<br>mission is to care for America’s military service members by keeping them connected<br>to their environment throughout their service. The partnership helps build ties between<br>Grifols Employees and local USO affiliates.<br>Support in 2022<br>120+<br>volunteers<br>500+<br>hours<br>150,000<br>USD<br>Core collaborations Other Initiatives<br>U.S. U.S.<br>Grifols supports and volunteers at various<br>events in El Sereno, a community of roughly<br>43,000 residents.<br>This organization provides safety services to<br>homeless veterans and other unhoused<br>individuals, offering them shelter, housing,<br>food and comprehensive support services.<br>GERMANY<br>Support organization for people with<br>intellectual challenges and multiple<br>disabilities to help them live as independently<br>as possible.<br>SPAIN<br>Toys and educational material collection to<br>meet the needs and demands of families in<br>vulnerable situations. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 116<br>Promoting science and STEM are among Grifols’ main educational priorities.<br>Education<br>Engagement with Charles R. Drew University of Medicine<br>and Science (CDU) Saturday Science Academy that<br>exposes students to science and STEM to motivate them<br>to pursue careers in the health industry.<br>Support in 2022<br>USD 150,000<br>Collaboration with Historically Black College and North<br>Carolina A&T University, to help to prepare students for<br>their careers.<br>Support in 2022<br>USD 50,000<br>Collection of school supplies at schools in<br>the United States and Germany.<br>Support in 2022<br>USD 60,000 90 beneficiary schools<br>Core collaborations 60+ educational initiatives in 5 countries<br>U.S. SPAIN<br>Grifols aims to spark a love of science and create<br>opportunities for young people by promoting<br>diversity, equity and inclusion in STEM education.<br>The company supports the Steps 2-STEM<br>program, which provides resources for African-American, Native American and POC collectives<br>from 11 schools in the Los Angeles, CA area<br>access to STEM careers<br>Sponsored by the U.S. government, international<br>governments and private-sector companies,<br>Fulbright grants are offered to recent college<br>graduates interested in earning doctoral or<br>master’s degrees at U.S. universities. Grifols<br>has collaborated with the prestigious Fulbright<br>program since 2013.<br>AUSTRALIA<br>This foundation offers resources to at-risk<br>youth to keep them engaged with their<br>education and create a better future. Grifols<br>supports the back-to-school program, which<br>provides educational resources, textbooks<br>and school supplies to students with limited<br>resources.<br>U.S.<br>This initiative provides after-school STEM<br>programs for girls from disadvantaged<br>communities. Grifols sponsors a biology<br>curriculum for four schools in California’s East<br>Bay area, benefiting 550-600 girls. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 117 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Actions focused on raising awareness of the importance of fighting against climate<br>change and knowledge of the natural environment and its biodiversity.<br>Environmental Issues<br>Core collaboration Other initiatives<br>U.S. – PRESERVATION<br>OF NATURE TRAINS<br>SPAIN - KNOWLEDGE OF THE<br>NATURAL ENVIRONMENT AND<br>BIODIVERSITY<br>North East Trees designs and develops parks, creating green spaces<br>and promoting water conservation projects in Los Angeles. Grifols<br>sponsors its environmental education program along the Riparian<br>Nature Trail, located between roads and pedestrian paths. The trail<br>includes information on the area’s history, culture and vegetation.<br>A walk to promote knowledge of the natural environment and<br>its biodiversity among Grifols employees and their families through<br>itineraries through the forest and garden of the Can Catà farmhouse,<br>within the Collserola Natural Park, close to Grifols’ facilities.<br>240+ people<br>U.S. – SCIENCE IN SERVICE OF THE ENVIRONMENT<br>Grifols collaborates with the Triangle Land Conservancy, a U.S. association that leads various<br>programs to make the region healthier from an environmental standpoint. Specifically, Grifols supports<br>the “Pathways to Natural Environments and Science” program, created to increase high school<br>students’ knowledge on the need to conserve and protect natural resources.<br>Creation of parks and green spaces in the U.S.<br>to promote healthier communities, with the<br>participation of employees and donors in park<br>clean-ups and rebuilding projects.<br>Support in 2022<br>13 volunteers<br>25 hours<br>USD 150,000 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 118<br>Support for NGOs<br>and foundations<br>Probitas Foundation:<br>improving the health of the most vulnerable<br>The Probitas Foundation was created in 2008 to promote the physical, psychological and emotional health, and equality to opportunities in<br>low-income populations. The foundation works in local Spain communities to improve the nutrition and emotional well-being of at-risk youth.<br>On a global level, it focuses on improving public health systems in low-income countries, leveraging Grifols’ expertise in medical care and<br>clinical diagnostics. The Probitas Foundation receives an annual allocation of 0.7% of Grifols corporate profits.<br>CHILDREN, TEENAGERS AND FAMILIES<br>PROFESSIONALS AND REFERENTS<br>WELFARE CRC<br>(CONVENTION ON THE RIGHTS OF THE CHILD)<br>Professional development<br>As part of the RID program, the PEM (Teacher in Mind)<br>training project, which has trained 62 teachers in mental<br>health, stands out.<br>Healthy lifestyles study<br>Collaboration with the second edition of the Gasol<br>Foundation’s “Pasos Study”, which evaluates the physical<br>activity, lifestyles and obesity patterns of roughly 3,000<br>children in Spain.<br>Community health programs<br>The new laboratory at Saint Joseph Hospital in Monrovia,<br>Liberia, is fully operational. Also launched, was a community<br>health program to address the high maternal and infant<br>mortality. In total, 488 women benefited from the program’s<br>awareness-raising and support activities.<br> “Twin Families” initiative<br>Club Joventut Badalona coaching staff and players,<br>participated in an online campaign to promote healthy habits<br>on the club’s social networks. The campaign formed part of<br>the Probitas Foundation’s “Twin Families Initiative,” a solidarity<br>project that matches families to ensure at-risk children have<br>at least one healthy meal at their school lunchrooms.<br>Local impact: access to health and well-being programs for at-risk youth<br>Three lines of action<br>INTERVENTION<br>AWARENESS,<br>RESEARCH AND<br>TRAINING<br>AWARENESS,<br>RESEARCH AND<br>TRAINING<br>Health<br>education<br>(APE)<br>Access to<br>specialized<br>healthcare<br>(SIT)<br>Training and<br>development<br>(RID)<br>The foundation promotes the healthy development of children and teenagers in vulnerable situations and/or at risk of social exclusion by<br>offering comprehensive support with food, socio-educational and health resources in three areas of action: | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 119 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>The Probitas Foundation’s International Cooperation Program shines<br>a spotlight on neglected tropical diseases (NTDs) and their negative<br>ramifications on global social and economic development. To this end,<br>it promotes fair access to healthcare through WHO’s “One Health”<br>approach, reaffirming its support in 2022 to reinforce the monitoring and<br>eradication of NTDs.<br>Meanwhile, the company also worked to improve clinical diagnostics<br>through its Global Laboratory Initiative, created to boost the capacities of<br>laboratories in the world’s most vulnerable regions.<br>International impact: improving access to healthcare in emerging economies<br>ALLIANCES WITH LABORATORIES<br>COMMUNITY HEALTH PROGRAMS<br>RESEARCH & INNOVATION<br>ONE HEALTH<br>UNIVERSAL HEALTH COVERAGE GLI. Improving laboratory diagnostics PCI. Support for neglected tropical diseases<br>APE: MAIN PROGRAMS<br>23,695 beneficiaries, +400 projects in 61 communities in collaboration with 99<br>organizations, 187 schools and social services<br>SIT: HEALTH, INNOVATION AND THERAPIES<br>312 beneficiaries in 4 projects<br>RID. RESEARCH AND DEVELOPMENT<br>122 people trained and 3,885 participants in a study on childhood obesity<br>GLI. GLOBAL LABORATORY INITIATIVE<br>Created in 2010, the GLI included 33 diagnostic labs in 14 countries in 2022<br>(2 opened in 2022)<br>897,539 direct beneficiaries<br>PCI. INTERNATIONAL COOPERATION PROGRAM<br>In 2022, 8 projects and 162,780 direct beneficiaries<br>Community health training for 1,267 technicians and over 1,500 awareness-raising<br>sessions in 8 countries<br>YAKAAR PROGRAM<br>10 entrepreneurship scholarships in Senegal and 6 training scholarships in Barcelona<br>Commitment to the sustainable development goals Main Programs<br>SDG*<br>APE<br>Health<br>Education<br>Program start year 2012 2018 2010 2010 2019<br>Countries Spain Spain 14 Countries 41 Countries Spain/ Senegal<br>Priority<br>End hunger, achieve food security and<br>improved nutrition<br>Ensure healthy lives and promote well-being for all at all ages<br>Reduce inequalities within and among<br>countries<br>Relevant<br>Inclusive and equitable quality education<br>Ensure availability and sustainable<br>management of water and sanitation for all<br>Access to affordable, reliable and<br>sustainable energy<br>TransversalEnd poverty in all its forms everywhere Achieve gender equality and empower all women and girls Strengthen global Partnership for<br>Sustainable Development<br>+ More information on the Probitas Foundation: www.fundacionprobitas.org<br>*Classification according to the degree of Probitas’contribution | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 120<br>Victor Grífols i Lucas Foundation: Bioethics as a principle<br>The Víctor Grifols i Lucas Foundation was created in 1998 to spotlight the importance of bioethics and create dialogue among specialists<br>from different areas of knowledge. The Foundation aims to promote an ethical attitude among organizations, companies and individuals<br>whose activities are related to human health. For that reason, it offers a platform for debate that constitutes a meeting place for the approach<br>of different perspectives in everything related to ethics, science and healthcare.<br>Workshops, conferences and seminars Participants Publications Scholarships Granteds Research awards granted<br>28+ 2,500+ 3 6 7<br>II International Bioethics Conference<br>The Foundation’s bioethics training and research activities are<br>organized through the Grifols Foundation Chair of Bioethics at<br>the University of Vic-Central University of Catalonia (UVIC-UCC).<br>Its initiatives in 2022 included the 2nd International Congress on<br>Bioethics under the theme “Horizons of Bioethics”.<br>Activities in 2022<br>Publications and articles<br>The Foundation has three editorial collections: “Foundation<br>Notebooks” to communicate upcoming conferences, debate seminars<br>and workshops; “Reports,” featuring results and recommendations<br>on current research; and “Ethical Enquiries,” which includes expert<br>reflections and conclusions on ethical debates. The foundation also<br>collaborates with publishing houses for the dissemination of high-impact books and manuals on bioethics.<br>The conference explored four main issues:<br>1. The impact of biotechnologies on people’s health and well-being<br>2. Applied ethics in a society between pandemics<br>3. Challenges of bioethics pedagogy<br>4. Discomfort with death: transhumanism versus euthanasia | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 121 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Awards<br>Every year, the Foundation awards prizes and research grants<br>to promote the study and dissemination of bioethics. In 2022, it<br>awarded six grants for research projects in bioethics, an audiovisual<br>prize, three prizes for research by high school students, and three<br>prizes for educational centers.<br>Education<br>Advancing the study of bioethics in the education sector is among<br>the Foundation’s core objectives. In 2022, it organized film and<br>debate sessions for high school students, participated once again in<br>the Barcelona International Young Scientific Challenge (BIYSC), and<br>held educational webinars for teachers with insights on how they<br>could incorporate bioethics into the classroom based on the new<br>high school curriculum.<br>Institutional collaborations<br>The Foundation collaborates with other institutions to design and<br>develop training programs and organize activities, as well as to<br>serve as a bioethics advisor in diverse healthcare committees.<br>These collaborations include public institutions such as the<br>Department of Health of the Generalitat de Catalunya; healthcare<br>organizations like the Unió Catalana d’Hospitals, Althaia and the<br>MUTUAM group; universities, professional groups and cultural<br>associations. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 122<br>José Antonio Grífols Lucas Foundation: supporting donor communities<br>Created in 2008, the José Antonio Grifols Lucas Foundation aspires to enhance the health and well-being of plasma donors and their communities. These efforts raise awareness of the importance of plasma,<br>recognize the generosity of donors and generate a positive ripple effect in donor communities.<br>The Foundation’s efforts are currently focused in the United States, although could expand to other countries in the future.<br>Support for local organizations Community investments<br>17 USD 385,000+<br>Grants, awards and scholarships<br>The Foundation’s Board of Directors includes patients, donors and<br>Grifols representatives, who meet on a regular basis. In 2022, the<br>board approved 17 grants amounting to over USD 385,000 to<br>support community-oriented civic, social and educational programs.<br>Beneficiary organizations address an array of social challenges,<br>from poverty eradication to promoting equal opportunity and<br>support resources for at-risk youth.<br>Employees at Grifols plasma donation centers contribute to these<br>partnerships by volunteering their time and taking part in their<br>initiatives. At present, the Foundation is developing a new initiative:<br>a donor emergency relief program to launch in 2023.<br> “Bags of Hope” for foster children<br>The José Antonio Grifols Lucas Foundation has partnered with<br>CASA, a non-profit organization in Peoria, Illinois that offers support<br>services for foster children whose parents are going through the<br>court system. The Foundation’s grant will support the recruitment<br>of 100 CASA volunteers to serve as court advocates for children,<br>manage the application process for needed resources, and help<br>find safe and permanent homes. The grant supports CASA’s “Bags<br>of Hope” program by providing funds for 300 suitcases of items for<br>children transitioning into foster care.<br>To maximize the Foundation’s impact, three Grifols centers in Peoria<br>collected items to fill more than 100 suitcases.<br>+ More information on the José Antonio Grífols Lucas Foundation: www.joseantoniogrifolsfoundation.org<br>+ More information, see “Local Development” section. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 123 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>Some of our collaborations<br>Health and well-being Local development Education Environment<br>Promise Community Homes offers<br>safe, affordable and accessible homes for<br>adults with intellectual disabilities in the<br>St. Louis, Missouri, metropolitan area. The<br>organization renovated two bathrooms to<br>make them handicap-accessible thanks to<br>Grifols’ support.<br>Grifols sponsors the “Safe Families for<br>Children” program, which offers support<br>to parents experiencing difficulties in<br>caring for themselves or their children. The<br>initiative connects beneficiaries with a wide<br>community of support in the Pittsburgh,<br>Pennsylvania, area to encourage and<br>empower them.<br>This organization matches children with<br>university students for tutoring services.<br>Most children (72%) are from low-income<br>households, while most tutors (71%) are<br>first-generation college students. The<br>grant supports tutoring programs at Butler<br>University, Marian University and the<br>University of Indianapolis.<br>The Athens Land Trust in Georgia works<br>to promote education in sustainable<br>agriculture, increase access to healthy food,<br>and support economic and entrepreneurial<br>opportunities for young people and adults<br>from low-income families. Grifols supports<br>two interrelated projects: Young Urban<br>Farmers Program and Community<br>Gardens Network. | ||
| --- | ||
| Environmental<br>responsibility<br>Minimizing our<br>environmental<br>impact<br>7 | ||
| --- | ||
| We are planet<br> Three priorities<br>At Grifols, we strive to minimize the environmental impact of our operations<br>through efficient resource management and a solid commitment to sustainable<br>development. To this end, we systematically evaluate the impact and evolution<br>of our environmental performance, defining both concrete objectives and<br>opportunities for improvement.<br>Climate action Circular economy Biodiversity<br>Roadmap for<br>Grifols 2030 Agenda<br> • Reduce greenhouse gas<br>emissions per unit of<br>production*.<br> • Increase energy<br>efficiency per unit of<br>production.<br> • Consume all electrical<br>energy from renewable<br>sources.<br> • Accelerate<br>decarbonization by<br>cutting down on business<br>trips and employee travel.<br> • Implement more circular<br>economy measures<br>throughout the business<br>life cycle.<br> • Protect biodiversity<br>through the Grifols<br>Wildlife Program.<br>*Scopes 1 and 2.<br>Drive the<br>decarbonization<br>of our activity<br>Minimize our<br>environmental impact<br>Promote biodiversity<br>and the conservation<br>of natural areas<br>2050: net zero<br>emissions | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 126<br>Environmental management at Grifols<br>A cross-cutting and comprehensive approach<br>Awards and recognitions<br>Sustainability policy<br>Establishes the organization’s core environmental<br>and social responsibility principles and commitments,<br>and serves as a framework for their comprehensive<br>integration into the business model<br>Environmental policy<br> Defines the company guidelines, principles and<br>commitments in order to monitor and minimize<br>environmental impact<br>Climate change policy<br> Approved in 2023, it establishes Grifols’ specific climate-action commitments<br>Energy policy<br> Defines corporate guidelines and principles to minimize<br>energy demand and promote the use of renewable<br>energies<br>+ See environmental policies: Corporate Stewardship Reports (grifols.com)<br>POLICIES<br>Eco-efficiency<br>O Integration of environmental criteria when designing new projects, products and services, and review of existing ones.<br>O R+D, Engineering Department and Grifols Engineering apply the most eco-efficient alternatives to new products and projects and review<br>existing ones.<br>O Application of Grifols’ “Guidelines for the Design of Containers and Packaging with Environmental Criteria.”<br>Prevention<br>O Routine review of preventive measures to mitigate the impact of environmental risks.<br>O Periodic drills at production plants to simulate response to environment-related emergencies and incidents.<br>O Specific employee training.<br>Legal compliance<br>O Implementation of legislative monitoring system and periodic compliance audits.<br>Proactivity: short- and medium-term action plans<br>O Six environmental commitments for the 2030 Agenda.<br>O Commitment to net zero emissions by 2050.<br>O Progress to meet SBTi objectives.<br>O 2020-2022 Environmental Plan.<br>O New 2023-2026 Environmental Plan.<br>Environmental communication and awareness<br>O Promotion of communication channels with main stakeholders.<br>O Specific internal and external communication procedures.<br>O Awareness initiatives on environmental preservation.<br>O Training and educational activities on environmental management.<br>Commitment to environmentally sustainable suppliers<br>O Collaboration with environmentally friendly suppliers and partners to help expand sustainable practices. | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 127<br>Management Sustainably designed and eco-efficient installations<br>ISO 14001 ISO 50001 LEED* Certification GREEN GLOBES** ZERO WASTE TO LANDFILL***<br>O All manufacturing, engineering, logistics and<br>commercial companies<br>O Corporate headquarters in<br>Barcelona<br>O Biopharma’s Clayton (NC) facility<br>O Raleigh (NC) offices<br>O Diagnostic facilities in Emeryville (CA)<br>O Clayton (NC) office building<br>O Clayton (NC) raw materials<br>warehouse<br>O Clayton purification and<br>filling plant (NC)<br>O Clayton fractionation<br>plant (NC)<br>O Clayton (NC) production plants<br>O Montreal (Canada) facility - in<br>progress<br>O Dreieich production facilities<br>(Germany)<br>Environmental certifications<br>Grifols’ Environmental Management System is ISO 14001-certified,<br>evidence of its effective efforts to identify and meet all applicable<br>environmental legislation; recognize the environmental impacts of<br>its processes and products; implement preventive and corrective<br>measures; and establish objectives to boost its environmental<br>performance. This comprehensive system includes the Corporate<br>Environmental Manual, which offers an organization-wide framework<br>for the company’s environmental management.<br>Each certified company, or company in the process of being certified,<br>has an environmental committee led by its respective senior<br>management team. This committee is the most important decision-making body in terms of establishing environmental guidelines and<br>* Leadership in Energy Efficiency and Environmental Design.<br>** Green Globes, certified by the Green Building Initiative.<br>*** Zero Waste to Landfill, awarded by Underwriters Laboratories (UL).<br>assuring the correct execution and maintenance of the Environmental<br>Management System, including the allocation of requisite human and<br>economic resources. By the end of 2022, Grifols’ ISO 14001-certified<br>plants accounted for 74% of its total production and applied to 73%<br>of its manufacturing personnel.<br>Grifols prioritizes the certification process of its manufacturing<br>plants by starting with those with larger production output and<br>progressively taking steps to certify those with smaller production<br>volumes and/or a lesser environmental impact. All certified plants<br>are audited by TÜV Rheinland, an independent certification body.<br>Grifols also ensures its buildings and facilities are designed with<br>sustainability in mind. In 2022, it was awarded Gold in the LEED<br>(Leadership in Energy and Environmental Design) certification for<br>its new corporate headquarters in Sant Cugat del Vallès (Barcelona,<br>Spain). LEED is the world’s largest scale rating system for<br>sustainable buildings.<br>In 2022, Grifols was awarded a B rating from the Carbon Disclosure<br>Project (CDP) Climate Change. As the world’s leading environmental<br>reporting platform, the CDP annually assesses companies’ climate-change strategies and performance.<br>Spain<br>U.S.<br>CANADA<br>BIOTEST | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 128<br>A global organization to manage<br>environmental risks<br>As an organization with a vast global reach, Grifols spearheads broad-based efforts to control, prevent and manage environmental risks.<br>All Grifols’ facilities have robust management systems to minimize<br>and mitigate environmental risks, including those derived from its<br>operations (anthropogenic activity) and those produced by nature<br>(natural), such as extreme weather and climate events.<br>Each facility has concrete self-protection plans to define the necessary<br>actions in the event of an environmental emergency, as well as the<br>teams responsible for their implementation.<br>Everyone involved in environmental risk management receives relevant<br>training in accordance with the company’s continuous development<br>strategy.<br>CORPORATIVE<br>DEPARTMENT<br>SUBSIDIARY<br>COORDINATORS<br>ENVIROMENTAL<br>COMMITTEES<br>ENVIRONMENTAL<br>TEAMS<br>1 20 11 4<br>Spain Mexico<br>Brazil<br>Chile<br>Argentina<br>Poland<br>Czech Republic<br>Germany<br>Switzerland<br>France<br>United Kigdom<br>Ireland<br>Portugal<br>Italy<br>Japan<br>China<br>Hong Kong<br>Indonesia<br>Thailand<br>Singapore<br>Australia<br>U.S. (3)<br>Spain<br>Provisions and guarantees for<br>environmental risks<br>Grifols’ civil liability insurance covers accidental environmental<br>pollution, defined as the disturbance of the natural state of<br>the air, water, soil, flora or fauna (or any other situation legally<br>deemed as environmental pollution) caused by emissions<br>from Grifols’ facilities as a result of accidental, sudden and<br>unforeseen events. This insurance policy covers all Grifols’<br>companies, production facilities and offices in all its regions<br>of operation.<br>In 2022, no relevant economic sanctions were issued in relation<br>to adverse environmental impact.<br>NORTH AMERICA<br>Canada<br>U.S.<br>LATIN AMERICA<br>Mexico<br>Colombia<br>Brazil<br>Chile<br>Argentina<br>EUROPE<br>Spain<br>Poland<br>Czech Republic<br>Germany<br>Switzerland<br>France<br>United Kigdom<br>Ireland<br>Portugal<br>Italy<br>Slovakia<br>Japan China<br>Hong Kong<br>Thailand<br>Singapore<br>india<br>Dubai<br>Australia<br>Indonesia<br>Taiwan<br>Industrial facilities | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 129<br>Resources allocated to environmental<br>management and climate change<br>Resource allocation*<br> €34M<br> €85M<br>+22% vs 2021<br>over 3 years<br>58% 27% 15%<br>waste management water cycle reducing atmospheric<br>emissions, energy and others<br>Grifols allocated significant resources to bolster its environmental<br>performance last year and advance on its 2020-2022 Environmental<br>Plan despite the 2020 and 2021 global economic downturn. In 2022,<br>it increased its environment-related resources by 22% to EUR 34.2<br>million.<br>Investments in environmental assets totaled EUR 8.4 million in 2022<br>compared to EUR 7.4 million in 2021, denoting a more than 13%<br>increase. Of these investments, 60% were earmarked to optimize the<br>water cycle and waste management, eco-efficiency projects in energy<br>use, and the replacement of refrigerant gases with more eco-friendly<br>alternatives.<br>Total environmental expenditures stood at EUR 25.8 million,<br>representing a 25% increase on 2021. Waste management across all<br>Grifols’ facilities accounted for 68% of this expenditure.<br>*Includes costs and investments | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 130<br>Climate action<br>Grifols sets targets to effectively reduce atmospheric emissions; it gauges the impacts it has on climate change, identifies risks and opportunities, and develops a policy and strategy to reduce this impact and capitalize on<br>opportunities.<br>The impact of climate change on Grifols’ operations<br>In 2022, Grifols updated figures regarding its climate-change impact and exposure, including the risks and opportunities identified in 2019 in line with recommendations from the Task Force on Climate-Related Financial<br>Disclosures (TCFD). In parallel, it redefined specific metrics and targets to quantify and manage each climate risk and opportunity along four key dimensions -Governance, Risk Management, Strategy, and Metrics and<br>Objectives- as well as its ability to exceed TCFD recommendations. The company continues to work to integrate climate-related risks into its current decision-making process and strategic planning, including assumptions<br>and objectives.<br>The climate commitment is led by the Board of Directors<br>Potential financial impact of the most relevant climate risks Main indicators<br>1. Reduced availability of water resources<br>O Increase in operating costs derived from water consumption due to a higher price per m3.<br>O Income reduction due to a decrease in production capacity due to cuts in the water supply.<br>O Increase in operating costs due to the transfer of production to plants not affected by this risk.<br>Water consumption (m3)<br>Water costs (€) per installation<br>Production capacity (liters of plasma in Biopharma and sales in Diagnostic)<br>2. New legal requirements related to the reduction of GHG emissions<br>O Increased investment to offset the carbon footprint in the event of non-compliance with decarbonization targets. Carbon footprint / Atmospheric emissions (tCO2 e)<br>Carbon price (€/tCO2 e)<br>3. Variation in the availability of resources<br>O Reduction of income due to a lower collection of plasma in the donation centers. Income per liter of plasma (€/l)<br>Number of days that the primary donation centers were closed in the last year.<br>4. Transition to low-emission technologies<br>O Increased investment to replace the most polluting technologies used in production processes. Electricity consumption (MWh)<br>Electricity costs per plant (€)<br>Natural gas consumption (MWh)<br>Natural gas costs per plant (€)<br>Residual price of replaced technology (€)<br>+ More details on “Risk Opportunities Management related to Climate Change” on www.grifols.com | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 131<br>Governance<br>Grifols’ Board of Directors establishes a series of<br>commitments to minimize climate risks. Diverse<br>environmental programs, as well as oversight by<br>the Sustainability Committee, Sustainability Steering<br>Committee and Environment Committee, ensure<br>these commitments are implemented in line with<br>the Sustainability Master Plan. The Chief Industrial<br>Officer (CIO) is responsible for environmental<br>performance and climate change issues. Finally,<br>the Risk Committee, which reports to the Board<br>of Directors, is responsible for developing the risk<br>management model and overseeing the most<br>relevant risks, including those related to climate<br>change.<br>Risks and opportunities<br>This process involves updating the climate risk<br>map and analyzing the qualitative and quantitative<br>resilience of the company’s strategy based on a<br>potential maximum rise of 2°C. A simulation of<br>the climate scenarios proposed by the IPCC was<br>carried out to reflect the SSP2-RCP4.51 scenario.<br>The exposure study included Grifols’ most relevant<br>industrial facilities and plasma centers. An<br>assessment was made to evaluate the estimated<br>time frame, the probability of occurrence and the<br>inherent and residual potential impact for each of<br>the 29 climate risks detected. While the risks and<br>opportunities identified are not yet significant, the<br>company nonetheless reassessed the suitability of<br>the management plans defined in 2022.<br>Strategy<br>Business optimization and innovation are two<br>fundamental cornerstones of Grifols’ corporate<br>strategy. Both are underpinned by objectives<br>related to climate change, which are set out in the<br>company’s Environment Program and promoted<br>through various corporate policies, including climate<br>action. Climate risks and opportunities form an<br>integral part of Grifols’ strategy and decision-making process.<br>Climate risks and opportunities have a direct impact<br>on Grifols’ business and financial strategy and<br>planning, especially in areas related to industrial,<br>operations, products and services. For this reason,<br>climate change is included in operational cost<br>planning and capital allocations, mainly in terms of<br>implementing eco-efficiency and emission reduction<br>measures. Grifols fully abides by existing and future<br>regulatory requirements, implementing procedures<br>to ensure compliance (EV-SOP-000004),<br>which undergo biannual audits. The company’s<br>Environmental Committees monitor these processes<br>and define any further action measures.<br>Metrics and targets<br>Grifols evaluates and monitors when it has reached<br>Environmental Plan targets2 and their impact on<br>mitigating relevant physical risks and leveraging<br>key opportunities. Regarding the link between<br>the remuneration policy and the performance<br>indicators, the Energy Manager is offered incentives<br>related to improving the energy efficiency of<br>company processes. Finally, it should be noted<br>that the company is not subject to any emissions<br>trading scheme. Grifols participates annually in<br>the Carbon Disclosure Project (CDP)3, a program<br>which assesses the organization’s strategy and<br>performance in terms of climate change.<br>(1) Details of the study, including the specific list of climate risks<br>under the SSP2- RCP4.5 scenario, the specific impact, etc. are<br>available at Corporate Responsibility Reports (grifols.com).<br>(2) More details on compliance with the Environmental and<br>Master Plans in “Progress and Compliance with Environmental<br>Commitments in 2022”.<br>(3) Access to Grifols Environmental CDP performance results | <br>Grifols<br>Board of<br>Directors<br>Sustainability<br>Committee<br>Risk Committee Environmental Committee<br>Sustainability<br>Steering<br>Committee<br>Grifols is a member of several high-profile business associations committed to mitigating<br>climate change<br>The Biotechnology Innovation Organization (BIO) is an advocacy association focused on biotechnological solutions in four key areas:<br>sustainable biomass production, promoting sustainable production, developing lower carbon products and improving carbon capture.<br>Grifols also belongs to other global organizations such as MedTech Europe, Asebio, Cambra de Comerç de Barcelona and SIGRE, which<br>prioritize climate change on their agendas.<br>+ More details on partnerships: Chapter 9 “About this Report” | |
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Informe Anual Integrado y de Sostenibilidad · 132 132<br>Emissions<br>Grifols uses the international standard GHG Protocol Corporate<br>Accounting and Reporting Standard methodology to calculate its<br>carbon footprint and identify the greenhouse gas emissions (GHG)<br>generated by its business activity. The data reported includes<br>all Grifols’ global facilities, as well as acquisitions in 2022 and<br>commercial subsidiaries with more than 10 employees.<br>Since 2011, Grifols has published its Scope 1, Scope 2 and some<br>Scope 3 CO2 emissions, where data was available. Throughout 2022,<br>Grifols calculated 2021 figures for all Scope 3 emissions internally,<br>also identifying those considered irrelevant. This year, those for 2022<br>have been calculated.<br>Key impacts:<br>O Scope 1 improved by 36% vs 2021 to 95,000 tCO2e due to lower natural gas<br>consumption primarily at Biopharma’s Barcelona cogeneration facility, as well as a 75%<br>decrease in refrigerant gas leaks, mainly in the U.S. facilities.<br>O In Scope 2, emissions decreased by 30%* to 105,000 tCO2e due to a significant<br>rise in renewable electricity consumption, accounting for 26% of the total. Electricity<br>consumption rose slightly, although below the increase in production.<br>O Scope 3 exceeds 1.4 million tCO2e. Category 1, Purchase of goods and services<br>accounts for more than 50% of emissions, followed by transportation contracted by<br>Grifols (15%) and capital investments (14%).<br>O By geographic area, more than 70%** originate in the U.S., where 67% of Biopharma’s<br>activity takes place. The remaining 30% is divided between Spain and the rest of the world.<br>O In all plants, air emissions of other pollutants such as NOx, CO and SO2, generated by<br>the natural gas combustion in boilers and cogeneration engines, are below the limits<br>established by the relevant environmental authorities.<br>Grifols is reducing its GHG emissions by increasing its use of<br>renewable energies, which already account for 26.4% of its<br>electricity consumption.<br>In 2022, Grifols’ 10-year power purchase agreement (PPA)<br>to acquire clean energy from RWE’s Casa Valdés photovoltaic<br>plant became operational, furthering the company’s efforts<br>to reduce its carbon footprint. Under the agreement, Grifols<br>will acquire 26 million kWh per year from RWE, avoiding the<br>emission of 5,200 tones of CO2.<br>In the United States, more than 80 million kWh of electricity<br>was consumed from renewable sources, while in Ireland more<br>than 11.5 million kWh.<br>SCOPE 1<br>Direct emissions: generated by the business<br>activity itself. Includes direct emissions<br>generated by combustion sources or direct<br>greenhouse gas (GHG) emissions.<br>SCOPE 2<br>Indirect emissions: generated by energy<br>production, mainly electricity, consumed by the<br>organization.<br>SCOPE 3<br>Other indirect emissions: generated by other<br>supplier companies throughout the life cycle<br>of our products or services. Includes business<br>travel, employee transportation and commutes,<br>raw materials, among others.<br>We measure the scope of our emissions (tCO2e)<br>Committed to renewables<br>2020 2021 2022<br>*Scope 2 (location-based). A change has been made in calculating Scope 2 emissions. The cogeneration plant at the Barcelona facility discharges the electricity generated into the grid and Grifols purchases the electricity it needs at any given time from the grid. Previously it<br>was considered that the emissions generated for the production of this electricity were already accounted for through the combustion of natural gas from cogeneration and therefore the electricity produced and sold was discounted from the electricity consumed. In 2022, both<br>the emissions from natural gas for cogeneration and those corresponding to all the electricity purchased have been accounted for.<br>** Scope 1 + 2<br>TOTAL EMISSIONS<br>200,310 tCO2 e<br>Scope 1 and 2<br>-32.8% vs 2021<br>in absolute value<br> Scope 1 Scope 2 (Location-based) Scope 3<br> 111,435<br> 127,596<br> 1,416,451 1,323,454<br> 148,129<br> 150,276<br> 95,242<br> 105,068 | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 2022 Informe Anual Integrado y de Sostenibilidad · 133 133<br>Our action plan is bringing us closer to our goal of reducing GHG emissions by 55% per unit of production by 2030<br>Cutting back on air travel<br>Fell by 49% compared to pre-pandemic levels in 2019. However, compared to 2021, it increased by 44%. The number of<br>videoconferences in 2022 was 31% higher than in 2019 and 3% lower than 2021. New ways of working have helped to minimize<br>travel among Grifols’ various global work centers.<br>Increase in remote work<br>Grifols “Flexibility for U”, implemented in 2022, regulates the rules on remote work. Last year, remote work increased by 35%<br>compared to 2021, averaging over 2,900 connections per day.<br>Optimizing logistics<br>Grifols has been working to optimize its plasma transport network in Europe since 2021. Through these efforts, the company has<br>reduced its contracted transport services by over 290,000 km. These measures include adjusting the frequency of plasma collection<br>routes in European workplaces; promoting full truckloads between plasma collection points, warehouses and the Barcelona<br>manufacturing complex; increasing the storage capacity of plasma collection containers; and using larger U.S. pallets to maximize<br>storage and transport, among others.<br>Minimizing the impact of employee commutes<br>Grifols works to reduce the impact of emissions resulting from employee commutes. The Parets del Vallès facility offers an employee<br>bus service to coincide with different shift times, while in North Carolina, Grifols co-funds a shared transport service. In recent years,<br>electric vehicle charging stations have been installed in the main workplaces. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 C onsolidated Directors’ R eport · 134<br>Energy sources<br>Total energy consumption remained at similar<br>levels to 2021, declining slightly by 1%.<br>Gradual progress is being made to optimize<br>energy consumption at Grifols’ Biopharma<br>installations.<br>Production and sales recovered in 2022,<br>as production has continued to stabilize in<br>production facilities.<br>The positive impact resulted in a 14% decrease<br>in consumption relative to sales.<br>TOTAL ENERGY CONSUMPTION<br>890<br>Million kWh<br>-1% vs 2021<br>CONSUMPTION RELATIVE TO SALES<br>156.151<br>Million kWh/M€<br>-14% vs 2021<br>51% 48% 1%<br>natural gas electricity other fuels | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 135<br>Although to a lesser extent, Biopharma also consumes other fuels besides natural gas, including<br>diesel, gasoline and propane to run its own generators, equipment and vehicles. This accounted for<br>15.2 million kWh of consumption in 2022. Some of Grifols’ German installations use district heating<br>for hot water and heating, which consumed 10.2 million kWh in 2022.<br>Other fuels<br>Natural gas<br>Significant fall in consumption<br>Increased eco-efficiencies<br>EVOLUTION OF TOTAL NATURAL GAS CONSUMPTION (MILLIONS kWh)<br>Favorable impact of Biopharma<br>O Consumes 85% of all Grifols’ natural gas usage.<br>O Total consumption fell by 6.4% due to the decrease in natural gas used in the cogeneration plant.<br>O In relation to production*, it decreased by 8% and in relation to sales* by 22%.<br>O The increase in total Plasma Procurement consumption stems from the expansion of Grifols’ network<br>of plasma centers.<br>Diagnostic decreases its consumption<br>O Total consumption for Diagnostic decreased by 11.3%, although it increased in relation to production<br>and sales by around 2.9%.<br>Variations at country level<br>O In Spain and RoW, consumption is on a downward trend<br>O U.S. production increased by 3.2%, mainly due to the Biopharma plant, which increased production by 7%.<br>TOTAL CONSUMPTION<br>452M<br> kWh consumed<br>-4.7% vs 2021<br>*In terms of consumption relative to production and sales, Biopharma includes the Plasma Procurement and Biopharma business<br>units, which together would be comparable to the former Bioscience Division.<br>2020 2021 2022<br> Total Biopharma Diagnostic Plasma procurement Others Bio Supplies<br>23<br>0.4 1<br>18<br>17<br>27<br>410<br>474<br>421<br>359<br>26<br>21<br>14<br>1<br>21<br>24<br>384<br>452 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 136<br>Electricity<br>Consumption remains stable in a context of<br>rising output<br>By 2030, 100% of the electricity consumed<br>will come from renewable energy sources<br>Positive impact of Biopharma<br>O Consumed 61% of all electrical energy used.<br>O Total consumption decreased by 5.7%.<br>O 22.5% decrease relative to sales*.<br>O 2.7% relative to production*.<br>O The increase in total energy consumption at Plasma Procurement is directly related to the expansion<br>of Grifols’ plasma center network.<br>Diagnostic reduced its overall consumption<br>O 7.8% decrease.<br>O 7% increase relative to production and sales due to lower manufacturing and sales volumes.<br>Variations at country level<br>O In Spain and RoW, consumption is on a downward trend.<br>O 3.1% increase in the U.S. due largely to the impact of plasma donation centers.<br>TOTAL CONSUMPTION<br>451M<br>kWh consumed<br>+0.5% vs 2021<br>* In terms of consumption relative to production and sales, Biopharma includes the Plasma Procurement and Biopharma business<br>units, which together would be comparable to the former Bioscience Division. Total Biopharma Diagnostic Plasma procurement Others Bio Supplies<br>428<br>263<br>291<br>448 451<br>274<br>108<br>102<br>120<br>30<br>33<br>33<br>13 14 20<br>10 9 5<br>2020 2021 2022 | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 137<br>RENEWABLE ENERGIES<br>26.4% of Grifols’ electricity consumption derives from renewable energy sources<br>In 2022, Grifols consumed a total of 118.8 million kWh of renewable electricity, representing 26.4% of total electricity consumption.<br>Spain consumed 26.5 million kWh of renewable electrical energy<br>In 2022, Grifols’ 10-year power purchase agreement (PPA) with RWE to acquire clean energy from its Casa Valdés photovoltaic plant became<br>operational. In addition, Biopharma’s photovoltaic power plant in Barcelona continued to create energy for self-consumption, generating<br>311,399 kWh in 2022. In total, 454,381 kWh of photovoltaic energy was generated at Biopharma and Others’ own facilities for self-consumption in Barcelona and Murcia.<br>Renewable electricity agreements in the U.S. and Ireland<br>By region, 71% of the group’s electrical energy is consumed in the United States, home to several of its industrial complexes and the majority<br>of its plasma donation centers. In the U.S., 80 million kWh of electricity was consumed with a guarantee of renewable energy, and more than<br>11.5 million kWh in Ireland. Together, they account for 20.3% of electricity consumption. The company is working to reach PPA agreements in<br>the U.S. in the coming years.<br>COGENERATION<br>6% of total electricity consumption from the cogeneration plant in Barcelona<br>Biopharma’s Barcelona installations include a 6.1 MW cogeneration plant that generates electricity sold back to the grid, as well as producing<br>useful heat for Grifols’ own facilities. This plant was not operating at full capacity in 2022, generating 27.6 million kWh of electricity (33% less<br>than 2021) and 20.6 million kWh of useful heat.<br>Artificial intelligence (AI) is helping Grifols’ facilities work<br>much more efficiently. Integrating this technology has<br>led to a more than 15% fall in energy consumption in air<br>conditioning in the production rooms of the Parets del<br>Vallès (Barcelona, Spain) Diagnostic Unit.<br>Air conditioning is one of the company’s main sources<br>of electricity consumption, and technology can offer<br>ways of reducing it. This led to the launch of the “Energy<br>efficiency through (artificial intelligence)” pilot project<br>in 2022.<br>The company is working to replicate this initiative in other<br>areas with high demand for air conditioning and also in<br>the production of cold for Biopharma’s fractionation and<br>purification processes.<br>Artificial intelligence to reduce<br>consumption | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 138<br>Circular economy<br>Grifols’ environmental management is based on the concept of the circular economy, which endeavors to reduce the consumption of raw materials, water and energy sources in the production cycle. The company<br>prioritizes the efficient use of resources and works to reduce waste by focusing on the different stages in the product life cycle. The goal of this strategy is to embrace the transition to a low-carbon economy and minimize<br>the impact on climate change.<br> • Rationalization of cardboard, plastic and caustic soda consumption<br> • Maximum utilization of raw materials<br> • Promoting local suppliers<br> • Route optimization<br> • Environmental criteria in engineering projects<br> • Eco-design of equipment (diagnostic & engineering)<br> • Environmental criteria in R&D<br> • Container and packaging design<br> • Residual waste recovery<br> • Energy recovery from waste<br> • Anaerobic digestion<br> • Zero Waste to Landfill initiative<br> • In-house treatment of wastewater<br> • Minimization of atmospheric emissions<br> • Water recovery systems<br> • Optimized water consumption<br> • Energy efficiency<br> • Renewable energy consumption<br> • Cogeneration plant<br> • LEED/Green Globes building certification<br> • Recycling of recoverable waste<br> • Internal reuse of ethanol<br> • Recovery of intermediate products<br> • New biological products marketed<br>by the Bio Supplies Business Unit<br> • Optimization of packaging<br> • Recycled/recyclable packaging materials<br> • Certification of transport companies<br> • Optimization of routes and means of transportation<br> • SIGRE – Integrated Management System for drugs out<br>of specification<br> • Collection and management of electric and electronic<br>equipment placed in the market<br> • Reuse of ethanol in production processes<br> • Intermediate products: PEG + sorbitol<br> • Grifols Engineering machine manuals<br> • Equipment manuals (diagnostic)<br>ALCANCE<br>INTERNO<br>Design<br>Collection<br>Recycling<br>Residual Waste<br>Raw Materials<br>Distribution<br>Production, Remanufacturing<br>Consumption, Use, Reuse, Repair<br>Economía<br>circular | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 139<br>Consumption of raw materials<br>Plasma is the main raw material consumed by Biopharma, accounting for more than 80% of Grifols’ activity in terms of sales revenue. Ethanol,<br>polyethylene glycol and sorbitol are primarily used in the fractionation and purification process of the different plasma proteins. Plasma fractionation<br>enables proteins with therapeutic properties to be extracted and subsequently marketed by Grifols. This process involves subjecting the plasma to<br>successive temperature, pH and ethanol concentration adjustments, each of which facilitates the precipitation of one of these proteins.<br>In the Diagnostic Business Unit, the main raw material is the plastic used in the production of its diagnostic cards (DG-Gel®), in addition to the<br>base plates to manufacture auto-analyzers, and red blood cell reagents for diagnostic kits.<br>Maximum repurposed of plasma<br>Most of the plasma unsuitable for fractionation is marketed through<br>Bio Supplies to produce diagnostic and analytical reagents for<br>research purposes. By 2022, more than 135,000 liters of plasma<br>had been sold, resulting in the annual reuse of 135 tons of raw<br>materials and consequently, the same volume in waste reduction. The<br>remaining plasma is discharged in authorized incineration plants with<br>energy recovery.<br>Once all the plasma proteins for therapeutic purposes have been<br>obtained, the remaining paste is disposed of as waste and managed<br>according to its composition and country: plants producing substitute<br>solid fuel for pastes with a high calorific value; anaerobic digestion for<br>the production of biogas; composted, controlled landfills for<br>non-hazardous waste; or autoclave treatment and subsequent<br>landfill disposal.<br>Management of intermediate products<br>A solution of polyethylene glycol (PEG) and sorbitol is used to separate<br>and obtain Flebogamma® DIF intravenous immunoglobulin. After<br>use, this solution is concentrated at Grifols’ Barcelona facilities and<br>marketed to additive manufacturers for use in the cement industry. By<br>2022, approximately 33,000 tons of aqueous solution of polyethylene<br>glycol and sorbitol had been transformed into 11,136 tons of product<br>sold as raw material for other uses.<br>+ More details on raw material consumption are available in the tables<br>in Chapter 9. About this report. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 140<br>Water cycle<br>Grifols rationalizes water consumption<br>despite expanding its industrial activity.<br>Savings measures implemented in 74% of<br>production facilities, representing 90% of<br>production<br>EVOLUTION OF TOTAL WATER CONSUMPTION (Thousand m3) Positive impact of Biopharma<br>O Consumed 82% of total water consumed<br>O Reducing its total consumption by 9.5% and 11.5% in relation to production*.<br>Diagnostic decreased its consumption<br>O Reducing by 15.3% overall and 2% in relation to production.<br>We take care of water resources<br>O Water-stressed regions accounted for 20.0% of the company’s water consumption, maintaining similar<br>levels recorded in previous years.<br>O Of the total water consumed, 88.3% comes from the municipal network and the remaining 11.7%, from<br>wells located at the Barcelona production facilities.<br>O Water is extracted from wells under regulations set by the water basin manager, which controls all<br>permits and water usage. Grifols monitors these extractions to ensure that the authorized limits are not<br>exceeded.<br>O In 2022, further progress was made to reduce Grifols’ water consumption. The new albumin plant in<br>Ireland was the first to incorporate Building Information Modeling (BIM) technology to conserve water<br>and energy resources.<br>TOTAL CONSUMPTION<br>3M<br>m3 consumed<br>-8% vs 2021<br>*In terms of consumption relative to production and sales, Biopharma includes the Plasma Procurement and Biopharma business<br>units, which together would be comparable to the former Bioscience Division.<br>Grifols operates in regions where water conservation<br>is essential. The company applies water-saving<br>measures when designing new facilities, in addition to<br>implementing solutions in existing installations. These<br>include the recovery of clean water from production<br>processes for use in auxiliary processes, the installation<br>of automated cleaning systems (CIP) to reduce the<br>amount of water used to clean reactors and equipment,<br>and reduced consumption in water treatment systems<br>such as reverse osmosis.<br> Total Biopharma Diagnostic Plasma procurement Others Bio Supplies<br>2020 2021 2022<br>2,425<br>3,057<br>19<br>130 110<br>217<br>178<br>165<br>197<br>251<br>198<br>2,487<br>2,857<br>2,747<br>3,124<br>227<br>11<br>12 | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 141<br>Improving the quality of<br>discharged water<br>Construction of a new anaerobic treatment plant with<br>UASB technology (Upflow Anaerobic Sludge Bed Reactor)<br>was completed at Biopharma’s Barcelona complex. This<br>treatment process is carried out in a highly efficient<br>reactor that reduces 85% of the organic pollutant<br>load in the absence of oxygen, with very low energy<br>consumption, generating biogas of renewable origin.<br>Once treated, this biogas is used as fuel for the plant’s<br>steam production boilers, thus reducing natural gas<br>consumption and CO2 emissions into the atmosphere.<br>This facility will double the plant’s current wastewater<br>treatment capacity in order to reduce the current final<br>discharge parameters or maintain them in the event of<br>production increases.<br>At Biopharma’s North Carolina facility, a new wastewater<br>treatment plant is in the process of being validated. This<br>uses membrane bioreactor (MBR) technology and a<br>sludge treatment line to improve discharge parameters.<br>This plant, which will begin operating in 2023, is set<br>to treat between 3,500 and 7,000 m3/day to serve the<br>facility for the next 15 years.<br>Wastewater and discharge management<br>Grifols adheres to all applicable national and local regulations and<br>permits regarding the disposal and treatment of wastewater at its<br>installations. All wastewater is sent to local sewage systems, where it<br>is treated by municipal or regional facilities. Grifols’ industrial plants<br>pre-treat the water to suitably purify it before its disposal, and all are<br>located in areas where the local authorities monitor water discharge.<br>Manufacturing plants with environmental management systems and/<br>or certified companies have instructions on how to prevent, control<br>and monitor the quality of wastewater. Commercial offices and<br>warehouses discharge wastewater into the municipal sewage system.<br>In 2022, 2.3 million m3 of wastewater was discharged to public<br>sewers. In U.S. plants, stormwater is conveyed to public waterways,<br>including the Los Angeles River, the Neuse River and San Francisco<br>Bay. Approximately 23% of water is consumed in auxiliary processes<br>-such as cooling towers- or incorporated into the product, while 77%<br>is discharged to the sewer. In 2022, the Barcelona and Clayton (North<br>Carolina) facilities treated 873,892 m3 of wastewater using biological<br>systems prior to discharge, representing 37% of total discharge and<br>an improvement over 2021. Projects are underway to expand these<br>treatments at both plants, as set out in the 2020-2022 Environmental<br>Plan.<br>In water-stressed areas, the distribution of discharges corresponds to<br>water consumption, with no significant variations from previous years.<br>Chemical Oxygen Demand (COD) is the most significant discharge<br>parameter in Grifols plants. This is defined as the amount of organic<br>and inorganic matter susceptible to oxidation. In 2022, 2,525 tons of<br>COD were discharged, most of which corresponded to Biopharma’s<br>production facilities. In addition, 357 tons of suspended solids were<br>discharged.<br>Grifols does not work with genetically modified organisms or with<br>products capable of generating persistent organic compounds, and<br>consequently, generates no discharge of this nature. The contribution<br>of nitrogen or phosphorous to the wastewater is insignificant since it<br>comes mainly from sanitary and non-production-related discharges.<br>In 2022, Biopharma’s facilities in Barcelona were fined € 750 for<br>exceeding one of the established discharge parameters.<br>23% water<br>incorporated<br>into the product<br>and used or<br>consumed<br>in auxiliary<br>processes<br>77% is<br>discharged to<br>the sewers<br>Total water<br>discharge<br>2,3 M m3<br>-4,2%<br>48% of<br>Biopharma’s<br>wastewater<br>is treated<br>prior to being<br>discharged<br>-8% COD<br>discharge and<br>-17% suspended<br>solids discharge | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 142<br>Waste<br>Grifols’ waste management strategy prioritizes waste prevention and reduction, and favors waste<br>recovery over landfill or incineration. The company remains committed to waste management<br>treatments with recycling initiatives, anaerobic digestion and material and energy recovery.<br>Recycling<br>31%<br>Landfill<br>29%<br>Anaerobic<br>digestion and other methods*<br>14%<br>Other<br>options<br>20%<br>Compost<br>5% Reused<br>1%<br>El<br>m<br>i<br>n<br>i<br>a<br>ted Rec<br>o<br>v<br>e<br>red<br>49% 51%<br>WASTE RECOVERED<br>22,751<br>metric tons<br>51% of the total waste<br>generated<br>Grifols reduced the total waste sent to landfill, which now stands at<br>29%.<br>The industrial facilities generated 20,310 tons of waste, of which<br>74% is waste recovered (reuse, recycling, composting, energy<br>recovery or by-products).<br>The volume of waste at other facilities such as donation centers and<br>offices amounts to 24,644 tons, 31% of which is recovered.<br>*Including anaerobic digestion, other methods with energy recovery and by-products | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 143<br>We prevent 99% of our waste from reaching landfills<br>Biopharma’s industrial facilities in North Carolina avoid 99% of waste from reaching landfills and uses<br>incineration with energy recovery for a maximum of 5% of its waste. It therefore maintains the highest rating<br>in the “Zero Waste to Landfill Gold Operations” certification.<br>The facilities in Spain have made headway in waste recovery by changing the final destination of a large part<br>of general waste, which is currently managed as solid recovered fuel. All recoverable waste fractions are<br>now managed separately, and only waste that cannot be recovered or recycled due to its composition and<br>applicable legislation is sent to landfill or incinerated.<br>This change has reduced the amount of waste disposed in landfills to 29%, compared to 31.4% in<br>2021. Waste is sent to authorized waste management companies and regular audits are performed by<br>independent specialist auditors.<br>Medication waste management<br>Most Grifols products are used in hospitals, which have their own recycling and disposal criteria established<br>by local health authorities. Grifols products designed for domestic use are dispensed in pharmacies or by<br>hospital suppliers, each of which has its own procedures regarding the safe collection and disposal of self-injectable devices. Grifols participates in various drug waste management programs.<br> • Spain: the SIGRE program manages the collection of household medicine packaging and waste to ensure<br>it is safely treated to protect the environment.<br> • United States: the Pharmaceutical Product Stewardship Working Group (PPSWG) serves as a platform to<br>organize and present science-based data on safe disposal practices for pharmaceuticals and implements<br>industry efforts to raise awareness of appropriate disposal methods.<br>For medicines that end up not being marketed or returned, Grifols uses waste handlers who separate and<br>classify medicine packaging (paper, cardboard, glass, plastics, etc.) to be recycled by specialized companies.<br>The medicines themselves are disposed of through an authorized waste management company, using<br>incineration methods and incineration with energy recovery.<br>Grifols’ main products are plasma medicines for intravenous or intramuscular administration in healthcare<br>centers. The biological origin of plasma medicines limits their impact on the environment since waste is<br>primarily generated from their containers and packaging, most of which can be recycled. The drug package<br>leaflets indicate the correct waste management practices for country-specific legislation. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 144<br>Projects underway<br>Under these programs, several different voluntary projects<br>and activities are carried out throughout the year, aimed<br>at biodiversity protection and for educational purposes.<br>There are currently seven active projects underway:<br>Biodiversity<br>Grifols is firmly committed to protecting biodiversity on its own land through the Grifols Wildlife programs. These include the launch of various<br>initiatives in the Clayton (North Carolina) protected natural area, and the collaboration agreement in the Besòs river basin in Barcelona. The<br>collaboration agreement for the promotion of actions in the Besós River basin in Barcelona for the period 2020-2022 is also still in force.<br>Natural protected area in North Carolina<br>Grifols owns over 121 hectares of forest adjacent to its production facilities in Clayton, North Carolina. This is an ideal habitat for many aquatic<br>and terrestrial species and is certified by the Wildlife at Work and Corporate Lands for Learning programs, both of which were launched by the<br>Wildlife Habitat Council (WHC).<br>Conservation projects* carried out in 2022 include:<br>O Installation and maintenance of bird houses for bluebirds, taking into account their territorial nature. Contributes to favoring the nesting,<br>breeding and shelter of this native species.<br>O Protection of an extensive wooded area adjacent to the Grifols facilities as a habitat for wildlife, which was land earmarked for<br>development, maintaining it as a recreational area for environmental education for the workforce. In 2022, bridges were repaired and made<br>accessible for disabled users; the trails were cleaned and generally maintained; and invasive plant species were controlled and removed.<br>Contributes to preserving forest-dependent fauna, plant diversity, and eliminating invasive species in the area.<br>O Continuation of the internship program for students at North Carolina State University (NCSU) to supervise and manage the<br>Grifols Wildlife Habitat Area, a unique space for environmental and conservation internships. Interns are responsible for coordinating projects<br>related to habitat (forest, prairie, wetlands, etc.) and species (pollinator gardens), as well as monitoring and designing improvement initiatives.<br>Internships have been evaluated since 2020 and are supported by Grifols personnel. Contribution in 2022: 380 hours of student time.<br>O Management of prairie flora and fauna, including the installation of nesting boxes for bluebirds and bats and the elimination of non-native<br>plant species. Contributes to preserving dependent fauna, plant diversity in the area and eliminating invasive species.<br>O Improvement and maintenance of a pollinator garden for the development of five active beehives. In 2022, a small fence was<br>placed around the garden, and a solar pump and hoses installed. Contributes to fauna and plant diversity in the area.<br>O Around 30 Grifols employees were trained in the care of bees and beehives. Contributes to raising awareness and maintaining diversity.<br>O Drainage of the wetland to prevent the possible breach of a listed “high risk” dam, which would have released water and sediment<br>into the nearby stream and forest, leading to animal deaths and the disturbance of the flora and fauna. The dam was breached and the pond<br>will be allowed to return to a natural state.<br>*Main actions carried out for each of the programs.<br>Bluebird Boxes<br>Avian<br>Clayton WHC forest area<br>Forest<br>Internship program<br>Formal learning<br>Clayton WHC meadow<br>Grassland<br>Clayton WHC pollinator garden<br>Landscape<br>Clayton WHC bee training for<br>employee<br>Training<br>Clayton WHC wetlands and<br>waterbodies of water<br>Wetlands and water bodies<br>We conserve 121+ hectares,<br>equivalent to 150+ football<br>fields | ||
| --- | ||
| CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 145<br>Besòs river basin in Barcelona<br>In 2019, Grifols signed a collaboration agreement with the RIVUS Foundation to fund two lines of research and support conservation and environmental education projects in river systems over a three-year period from<br>2020-2022. Several projects were launched in 2022, including research studies to monitor the otter and fish at the RIVUS Observatory, and environmental education, communication and training initiatives.<br>Otter monitoring<br>In 2014, images of an otter were captured in the Tenes River. Shortly<br>thereafter, Grifols signed a collaboration agreement to carry out more<br>research on this species in the Besòs and Tordera river basins. Both<br>rivers are considered the last frontiers of expansion and recovery of<br>the otter in Catalonia after practically disappearing at the end of the<br>last century. Over the last two years, the project has reached its core<br>objective: otters have reproduced in both basins for the first time<br>since becoming extinct in the region. By 2022, seven otter families<br>had been sighted, with an estimated population of at least 34 otters<br>between both basins.<br>The large volume of data and the knowledge generated since the<br>project’s inception has allowed for more in-depth research on otter<br>population trends and dynamics. In 2022, research began to identify<br>the necessary preservation spaces and habitat elements to conserve<br>otter populations and their ecological community for the long term.<br>Fish monitoring<br>Fish are excellent bioindicators of the quality of river systems, and<br>electrofishing is the primary research method used to study their<br>populations. The RIVUS Observatory is one of the few long-term<br>monitoring organizations for Iberian inland fishes. This monitoring is<br>exceptional in Spain in terms of length of the time series and breadth<br>of the taxonomy groups in question.<br>Sampling was carried out throughout 2022 at 22 stations (12 in the<br>Besòs basin and 10 in the Tordera basin), including three annual<br>campaigns covering spring, summer and autumn seasons. The data<br>collected will advance knowledge of fish communities in both areas<br>and provide continuity for their monitoring.<br>Education, promotion and communication<br>In addition to promoting research and initiatives on otters and fish<br>species, Grifols also participated in various environmental education,<br>promotional and communication activities, including the production of<br>audiovisual material, multimedia awareness campaigns, promotional<br>materials, and teaching sessions in academic institutions, universities<br>and conferences. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ Report · 146<br>Financial performance<br>Strengthening<br>our position<br>8 | ||
| --- | ||
| We are growth<br> Our Top Priorities Milestones in 2022<br>We are a global healthcare company with strong fundamentals and a clear vision to further strengthen our<br>position in the future. We remain committed to boosting our financial performance to continue creating<br>value and leveraging our multiple strengths, business opportunities and Biotest synergies, all pillars of our<br>sustainable and long-term growth strategy.<br>Biotest<br>Capture market opportunities<br>Debt reduction<br>Financial discipline and cost control<br>Operational excellence<br>Robust and sustainable<br>revenue growth<br>Notable upswing in<br>plasma donations<br>+12.4% cc1 +25%<br>Deleveraging Liquidity position<br>7.1x €1.6Bn<br>Positive evolution of<br>plasma cost per liter<br>Limited exposure to<br>interest rate hikes<br>(1) Operating or cc excludes rate fluctuations over the period | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 148<br>Committed to value creation<br>The execution of our strategic plan and new roadmap make us stronger as a company and prepare us to take on new challenges. We remain committed to bolstering our financial performance and creating shareholder value.<br>Top priorities Enablers<br>Performance Culture<br>Efficient, effective, data-driven,<br>agile and decisive organization<br>O Emphasis on planning and execution to boost operational performance<br>O Enhanced accountability<br>O Streamlined, leaner and more cost-effective organization<br>Improve Cash Flow<br>and Expense Profile<br>Financial discipline and cost<br>control<br>O Initiatives to drive down plasma cost per liter while collecting optimal<br>volume<br>O Lower fixed costs through greater efficiencies, capacity optimization, and<br>strategic use of technology and data<br>O Focus on working capital and CAPEX<br>Debt Reduction<br>Deleveraging balance sheet<br>O Evaluation of diverse levers<br>O Alternatives under consideration to optimize the broad base of global assets<br>O Equity issuance is not favored at the valuation implied by the current<br>trading price<br>Capture Commercial<br>Opportunities<br>Untap further value from<br>product portfolio<br>O Significant opportunities to expand key existing products including SCIG,<br>alpha-1, etc.<br>O Robust innovation pipeline to widen the commercial portfolio in the<br>mid-term<br>Biotest<br>Solid plan to realize substantial<br>value<br>O Focus on approvals and launches of novel proteins<br>O New Biopharma leader with solid launch and commercialization experience<br>O Significant opportunities to capture synergies and further expand margins<br>ENHANCING<br>TRANSPARENCY<br>AND<br>COMMUNICATIONS<br>REMAINING<br>CONSISTENT TO<br>CORE VALUES AND<br>SUSTAINABILITY | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 149 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>Significant revenue growth<br>Grifols Biotest Combined1<br>Revenue 5,703 361 6,064<br> % variation +15.6% - +22.9%<br> % variation cc1 +5.1% - +12.4%<br>Gross margin 2,141 90 2,232<br> % margin 37.6% 24.9% 36.8%<br>Operational expenses 1,455 97 1,552<br>% variation cc1 +4.6% - +4.6%<br>EBITDA 1,198 23 1,221<br> % margin 21.0% 6.4% 20.1%<br>EBITDA adjusted 1,174 73 1,247<br> % margin 20.6% 20.2% 20.6%<br>Group profit 224 (16) 208<br>% variation +18.6% (16) +10.4%<br>Strong revenue growth driven by the upward<br>sales trend of Biopharma’s main proteins, thanks to higher<br>plasma donations, favorable exchange rates, product mix and<br>pricing, and the notable contribution of Biotest.<br>Gross margin continues to be impacted by the high<br>cost per liter of plasma in the first half of 2022 due to<br>increased donor compensation and labor costs.<br>Gross margin performance also affected by the<br>discontinuation of sales of COVID and mandatory Zika tests.<br>Higher EBITDA profitability thanks to improved<br>operating leverage, cost savings and R+D project prioritization,<br>offsetting inflationary pressures.<br>Profit impacted by high financial costs. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 150<br>Our business unit contribution<br>Positive performance of Biopharma<br>Strong performance of main proteins following the recovery of plasma donations, robust<br>underlying demand and price increases<br>TOTAL REVENUE<br> €5,005 M<br>+31%<br>20% cc<br>GRIFOLS<br> €4,644 M<br>+22%<br>+10% cc<br>BIOTEST CONTRIBUTION<br> €361 M<br>IMMUNOGLOBULINS<br>+13.3%<br>55-60% of revenue<br>ALBUMIN<br>+4.9%<br>10-15% of revenue<br>ALPHA-1 & SPECIALTY PROTEINS<br>+6.9%<br>25-30% of revenue<br>O Strong performance of IVIg thanks to an<br>upswing in plasma donations, allowing Grifols<br>to respond to rising demand<br>O SCIg continues to gain traction and report<br>higher demand<br>O Higher demand in Asia Pacific region driven<br>by China<br>O The launch of albumin in a flexible bag<br>continues to enhance the product mix<br>O Favorable alpha-1 customer mix, higher<br>demand and price increase<br>O Robust demand for Hypers, VISTASEAL™ and<br>TAVLESSE®<br>O Strong HyperRAB sales growth<br>Commercial milestones in 2022<br>German market launch of<br>Yimmugo®, Biotest’s<br>new-generation intravenous<br>immunoglobulin<br>Market expansion of TAVLESSE®<br>in Norway and the Czech Republic,<br>and endorsement of UK health<br>authorities (NICE)<br>Launch of the biological sealant<br>VISTASEAL™ in Canada, Italy,<br>Switzerland, Estonia, Latvia,<br>Lithuania and Australia | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 151 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 151<br>Plasma as a priority<br>INCREASE IN VOLUME<br>+25%<br>vs 2021<br>U.S.<br>+26%<br>PLASMA CENTERS<br>390+<br>Various factors led to higher plasma volume<br>O More than 10% increase (vs 2019) in the number of unique plasma donors to more than 920.000<br>and a higher frequency of donations.<br>O Donations resumed at the U.S. border. Mexican donors with B1-B2 visas were able to donate again<br>in September. Upside potential to double plasma volume collections at these centers.<br>O Deployment of new more efficient plasmapheresis equipment.<br>O Enhanced donor experience through better use of technology, including digital marketing initiatives.<br>Several measures helped improve the plasma cost per liter<br>O Optimized compensation to donors for their time.<br>O Improved operating costs, including greater efficiencies in plasma centers.<br>O Streamlined organizational structure for plasma collection: more agile, efficient and results oriented.<br>O Closure and consolidation of underperforming plasma centers (around 25 centers).<br>IMPROVEMENT IN COST<br>COST PER LITER (CPL) DONOR COMMITMENT COMPENSATION<br>Jun 21 Dec 22 Jun 21 Dec 22<br>Note: Base 100: Q2’22; 3M average moving trend. Figures comparing Q4’22 average vs. July’’22 (U.S. data)<br>-10%<br>Q422<br>-20%<br>Q422 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 152<br>Diagnostic<br>Higher sales of blood typing solutions and developments in China partially offset the end of<br>one-off sales of COVID and mandatory Zika screening tests<br>NAT TECHNOLOGY<br>-32.4%<br>Excl. COVID and Zika<br>-9.4%<br>55-55% of revenue<br>BLOOD TYPING SOLUTIONS<br>+16.9%<br>25-30% of revenue<br>RECOMBINANT PROTEINS<br>-6.1%<br>15-20% of revenue<br>O Impact following the end of COVID and<br>Zika tests sales<br>O Upward trend in Asia (India, China and<br>Malaysia) and the Middle East, along with<br>an upturn in plasma and blood donations<br>O Notable growth in all countries, especially<br>the U.S. and Mexico<br>O Sales uptick of gel cards in EMEA<br>O Sales decline due mainly from a joint business<br>collaboration on a new R+D project<br>Commercial milestones in 2022<br>U.S. authorization for AlphaID™<br>At Home, a free service to<br>detect the genetic risk of<br>developing alpha-1 deficiency.<br>Market launch in Q2’23<br>U.S. launch of new DG Gel 8<br>card for blood group typing and<br>irregular antibody research<br>CE mark for Procleix Plasmodium, used<br>to detect the presence of this malaria-transmitting parasite in whole blood, and<br>Promonitor Quick ADL, used to measure<br>levels of the biologic drug adalimumab in<br>whole blood<br>TOTAL REVENUE<br> €671 M<br>-14%<br>-20% cc | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 153 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>Bio Supplies<br>Significant contributions from Access Biologicals and third-party hyperimmune plasma sales<br>TOTAL REVENUE<br> €4,500 M<br>+26%<br>+13.2% cc<br>BIO SUPPLIES BIOPHARMA<br>+7.9%<br>55-55% of revenue<br>BIO SUPPLIES DIAGNOSTIC<br>+52.7%<br>25-30% of revenue<br>HYPERIMMUNE<br>-4.2%<br>20-25% of revenue<br>O Upturn driven by cell culture medium<br>following the Access Biologicals<br>acquisition, in addition to intermediary<br>products<br>O Partially offset by lower sales of drug<br>products<br>O Increased demand for plasma for<br>diagnostics and contributions from<br>Access Biologicals<br>O Higher performance of blood products<br>driven by Access Biologicals acquisition<br>and upswing in plasma donations<br>O Lower sales following contract<br>terminations | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 154<br>Stronger balance sheet<br>TOTAL ASSETS CASH POSITION EQUITY<br> €21,180.5 M<br>+10.1%<br>2021: €19,233.8 M<br> €548 M €8,207.2 M<br>+12.2%<br>2021: €7,317.1 M<br>Inventory control, collection<br>and payment periods<br>Inventories increased to EUR 3,202.4 million, with a turnover of 299<br>days (278 days in December 2021) because of the higher cost per liter<br>of plasma and higher donation volumes.<br>Average collection and payment periods remained stable at 31 days (32<br>days in 2021) and 53 days (58 days in 2021).<br>Average payment period of 69.7 days to suppliers of the Spanish<br>companies in the Group, similar to the previous year (68.3 days).<br>Operational improvements<br>and cost savings plan<br>Announced in 2023, this plan is designed to reduce the cost base,<br>improve operating cash flow and boost financial performance.<br>Annualized cost savings of EUR 400 million are expected relative to<br>2022. Most savings will stem from measures implemented in the fourth<br>quarter of 2023. Roughly EUR 100 million will be recognized in 2023<br>due to Grifols’ inventory cycle and implementation schedule, although<br>most will be reflected in the 2024 income statement.<br>A solid balance sheet with<br>investments already made<br>EUR 21,180 million at December 31, 2022 compared to EUR 19,234<br>million at December 2021. Grifols’ strategic investments in recent years<br>to boost plasma procurement and accelerate innovation played a critical<br>role in strengthening its growth. The company currently operates under a<br>long-term business plan, with no need for additional capital.<br>Optimized working capital management<br>for solid financial health<br>Optimized management of working capital remained a core lever to<br>bolster the company’s financial strength. At December 31, 2022, Grifols<br>had a robust liquidity position of EUR 1,570 million, including a cash<br>position of EUR 548.0 million and EUR 1,014 million in undrawn lines of<br>credit.<br>Equity<br>At December 31, 2022, shareholders’ equity<br>amounted to EUR 8,207.2 million. Grifols share capital<br>is represented by 426,129,798 ordinary shares (Class<br>A), with a nominal value of EUR 0.25 per share, and<br>261,425,110 non-voting shares (Class B), with a<br>nominal value of EUR 0.05 per share.<br>Grifols ordinary shares (Class A) are listed on the<br>Spanish stock market and form part of the IBEX-35<br>(GRF). Non-voting shares (Class B) are also listed on<br>the Spanish stock market (GRF.P) and on NASDAQ<br>(GRFS) through ADRs (American Depositary Receipts).<br>As announced in September 2021 following the<br>Biotest acquisition agreement, the company will refrain<br>from distributing cash dividend payments until its debt<br>ratio is below 4x/EBITDA.<br>Our commitment to sustainable growth is clear | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 155 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>Liquidity and capital resources<br>Debt leverage ratio falls to 7.1x and liquidity position stands at €1.6 Bn<br>Cash flow from operating activities<br>In 2022, net cash flows from operating activities totaled EUR -10.9 million (EUR 597 million in 2021), due<br>largely to a EUR 942 million increase in inventory levels to EUR 3,201 million resulting from the higher<br>cost per liter of plasma and upsurge in plasma donations. This context also affected working capital,<br>which fell by EUR 609 million. Operating cash flows are expected to increase thanks to the cost savings<br>plan announced at the onset of 2023.<br>Cash flow from investment activities<br>Net cash flows for investment activities totaled EUR -1,978.8 million. The most significant operations<br>were the Biotest acquisition, execution of the call option to acquire the remaining 51% share of Access<br>Biologicals capital, and EUR 297.8 million allocated to capital investments. CAPEX focused mainly on<br>new Biopharma manufacturing facilities, including the new albumin plant in Dublin; the upgrade of the<br>Montreal (Canada) plasma fractionation, immunoglobulin purification and albumin plants; and several IT<br>and digitalization-related projects.<br>Cash flow for financing activities<br>Cash flow from financing activities decreased to EUR -173.5 million due primarily to debt repayment.<br>Capital resources and credit ratings<br>At December 31, 2021, Grifols’ net financial debt totaled EUR 9,191.3 million, excluding the impact IFRS 161.<br>The company actively worked to reduce its leverage ratio in 2022. The net financial debt to EBITDA ratio<br>stands at 7.1x, below the 7.9x estimated for the year.<br>Grifols continues with its plans to divest non-strategic business lines and contain operating expenses. In<br>this regard, it recently announced the rollout of a new operational improvement plan for 2023 including a<br>cost savings initiative of EUR 400 million annualized2.<br>The company also worked to optimize its financial structure in 2022, with nearly 65% of its debt linked to<br>a fixed interest rate at the close of this report. Grifols’ financial structure is limiting the impact of interest<br>rate hikes, although it has no significant debt maturities before 2025 or financial covenants.<br>The company aims to further boost its position and respond to the needs of the current environment<br>through a long-term growth strategy focused on maximizing efficiency and effectiveness. Grifols will<br>continue to monitor potential impacts on its operations and take all necessary mitigation measures.<br>Current Credit Ratings Fitch Standard & Poor’s Moody’s<br>Corporate rating BB- B+ B1<br>Senior secured debt BB+ BB- Ba3<br>Senior unsecured debt B+ B- B3<br>Outlook Stable Stable Negative<br>(1) As of December 31, 2022, the impact of IFRS 16 on debt totaled EUR 1.016,9 million.<br>(2) Estimated savings compared to 2022 GAAP before inflationary impacts. Approximately EUR 100 million of savings will be recognized in the 2023 income statement, and most of the cost savings annualized in the 2024 income statement. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 156<br>CAPEX and industrial activity<br>In 2022, Grifols continued to make progress on its capital investment, with a focus on expanding and improving its business units’ production<br>facilities. The company allocated EUR 297.8 million to CAPEX in 2022 (EUR 280.9 million in 2021), enabling it to undertake and complete its<br>planned investments. Grifols’ main industrial investments had already been made by the end of 2022, with plans to maintain strict discipline<br>in capital resource allocations moving forward.<br>United States · New fractionation plant ·<br>+6 million liters of plasma per year<br>Start-up of the new plasma fractionation plant in North Carolina,<br>with a capacity to fractionate 6 million liters of plasma per year.<br>Also under way is the construction of the world’s first sterile<br>purification, dosing and filling plant of immunoglobulin in a<br>flexible container, expected to open in 2023 and produce a<br>capacity of 6 million liters of plasma equivalent.<br>Ireland · New albumin purification plant<br>In Dublin, Grifols inaugurated its new sterile purification, dosing<br>and filling plant for albumin in a flexible bag, which will triple<br>the company’s annual filling capacity in this format. The plant<br>features the latest eco-efficiency technologies to conserve<br>energy and water, testament to Grifols’ industry-leading design<br>and engineering.<br>Spain · Construction continues on the fibrin<br>and topical thrombin plant<br>In 2022, Grifols continued to advance on the construction of<br>its fibrin and topical thrombin adhesive production plant in<br>Barcelona. Once completed, the facility will expand Grifols’<br>production capacity by up to 3.3 million liters of plasma<br>equivalent per year.<br>Canada · Improvement of fractionation and<br>purification facilities<br>Work continues on upgrades to Grifols’ Quebec (Canada)<br>industrial complex, which includes a fractionation plant with<br>an annual capacity of 1.5 million liters of plasma and two<br>purification plants.<br>New production plants<br>+ More details on Grifols’ partnerships with Canada and Egypt in the chapter “Commitment to Donors and Patients” .<br>ACQUISITIONS AND CORPORATE<br>TRANSACTIONS<br>Acquisition of Access Biologicals<br>remaining capital<br>Grifols executed its call option, signed in 2017, to acquire<br>the remaining 51% of Access Biologicals capital. The<br>transaction will help drive the growth of Bio Supplies<br>by reinforcing and expanding its portfolio of biological<br>products, while boosting Grifols’ standing as a reputed<br>supplier of biological products for in-vitro diagnostics, cell<br>cultures and diagnostic R+D solutions.<br>Divestments<br>Grifols remained committed to its financial discipline plan,<br>including the divestment of non-strategic assets. In July<br>2022, it sold in cash all assets of its subsidiary Goetech<br>LLC, whose trade name is MedKeeper, for USD 100<br>million.<br>As part of its operational improvement plan, the company<br>closed 18 underperforming plasma donation centers in<br>the fourth quarter of 2022 out of the total 25 it plans<br>to sell or consolidate. Through these measures, Grifols<br>aspires to optimize the cost structure of its plasma<br>donation centers, as well as make them more efficient<br>and accessible for donors. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 157 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report· 157<br>On April 25, 2022, Grifols announced the closing of its acquisition<br>of all shares in Tiancheng (Germany) Pharmaceutical Holdings AG,<br>a German company that controlled 89.88% of Biotest AG ordinary<br>shares and 1.08% of preferred shares. Following the transaction,<br>Grifols now controls 97.13% of Biotest AG voting rights and holds<br>70.18% of its share capital.<br>Grifols’ strategic acquisition of Biotest AG will wield numerous<br>benefits, helping the company expand and diversify its plasma<br>supply; strengthen its operations and revenue in Europe, the Middle<br>East and Africa; and bolster its economic performance.<br>Biotest, a strategic acquisition<br>Grifols boosts its position as<br>the first European company in the industry to<br>Complementary capabilities: operational, industrial and scientific<br>Creation of the largest private European network of plasma centers with 91 centers: 33 Biotest and 58 Grifols<br>Leadership in fractionation capacity: 20+ million liters plasma/year<br>Improved profitability and revenue per liter of plasma<br>Increased revenue and margins from 2024 through new product launches<br>Complementarity and acceleration of R+D pipeline<br>Enhanced geographical balance in plasma supply and income<br>Greater availability of plasma therapies for the benefit of patients<br>The Grifols-Biotest collaboration will increase the availability of<br>plasma-based therapies for patients around the world<br>September 2021<br>O Grifols agrees to acquire the entire share<br>capital of Tiancheng (Germany) Pharmaceutical<br>Holdings AG for EUR 1,100 million. This<br>company holds 90% of Biotest AG ordinary<br>shares and 1% of preferred shares.<br>O Grifols launches a tender offer to all<br>shareholders to acquire Biotest’s outstanding<br>ordinary and preferred shares for EUR 43 and<br>EUR 37, respectively.<br>October 2021<br>O Bundesanstalt für Finanzdienstleistungsaufsicht<br>(“BaFin”), the German federal financial<br>supervisory authority, approves Grifols’ offer<br>document stipulating the terms and conditions<br>of the voluntary public tender offer, launched to<br>all Biotest AG shareholders.<br>O Grifols closes a EUR 2,000 million bond issue<br>in record time to finance the Biotest operation.<br>January 2022<br>O At the end of the tender offer acceptance<br>period, Grifols holds over 96% of the voting<br>rights and 69.7% of the share capital.<br>O The OPA put period for the outstanding<br>ordinary shares (with voting rights) ends on<br>April 21, 2022.<br>April 2022<br>O On April 25, 2022, Grifols closes the<br>acquisition of all the shares of Tiancheng<br>(Germany) Pharmaceutical Holdings AG.<br>O Upon completion of the takeover bid<br>and acquisition of Tiancheng (Germany)<br>Pharmaceutical Holdings AG, Grifols controls<br>97.13% of Biotest AG voting rights and<br>70.18% of its share capital.<br>TIMELINE OF THE BIOTEST INVESTMENT | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 158<br>Additional information<br>Treasury stock<br>Details of treasury stock operations during the 2021 fiscal year are<br>included in the consolidated financial statements at the end of this<br>report. As of December 31, 2022, Class A treasury shares totaled<br>3,944,430 and Class B treasury shares totaled 5,199,784 shares.<br>Public grants<br>The public grants received correspond largely to employee-training and<br>job-creation initiatives.<br>Thousands of euros Subsidies<br>Spain 464<br>United States 1,251<br>Corporate Governance Annual<br>Report<br>Grifols 2022 Annual Corporate Governance Report forms part of the<br>Consolidated Directors’ Report. It is available online on Grifols’ corporate<br>website and the Comisión Nacional del Mercado de Valores (Spanish<br>Stock Exchange Commission) site from the date of publication of Grifols’<br>consolidated financial statements.<br>Annual Directors’<br>Remuneration Report<br>Grifols 2022 Annual Directors’ Remuneration Report forms part of the<br>Directors’ Report. It is available on both the CNMV and Grifols websites<br>from the date of publication of the consolidated annual accounts. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 159 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>Subsequent events<br>On 15 February 2023, the Group announced a comprehensive<br>operational improvement plan with significant cost savings. The<br>plan includes the optimization of plasma costs and operations,<br>streamlining corporate functions, and enhancing other efficiencies<br>across the organization. It also includes a workforce optimization to<br>be implemented in 2023 that will affect approximately 8% of the<br>company’s employees, primarily in the U.S. plasma operations. The<br>Group estimates one-time restructuring charge of approximately<br>EUR 140 million to be accrued in the first quarter of 2023.<br>Grifols’ foreseeable evolution<br>Grifols is a large consolidated company with robust fundamentals<br>and a clear vision to strengthen its position moving forward. In<br>the coming years, its strategic road map centers on: efforts to<br>drive corporate growth, in which increased competitiveness will<br>continue to play a pivotal role; innovation, with a strong focus on<br>developing a differentiated product portfolio; customer orientation<br>to effectively respond to the evolving needs of patients and<br>healthcare professionals; continued global expansion; solid human<br>resources policy based on ongoing talent development, continuous<br>training, and the development of transversal initiatives and teams;<br>and promoting sustainability to continue reinforcing a long-term<br>business model that integrates and promotes environmental, social<br>and corporate governance (ESG) issues.<br>As part of this process, the company carried out an in-depth<br>analysis of its business areas and functions to discern where it<br>could achieve greater organizational efficiencies and profitability. In<br>this way, it aspires to not only bolster its financial performance, but<br>amplify its agility and response capacity.<br>The result is a wide-ranging operational improvement plan to be<br>implemented by 2023 along three core dimensions:<br>1) Plasma collection, including reorienting its U.S. plasma<br>operations to promote a more efficient, modern, reliable and<br>accessible network of plasma collection centers for donors.<br>Grifols will consolidate and relocate some of its U.S. plasma<br>donation centers, and close underperforming sites. In parallel,<br>the company is working on forging a digital plasma-collection<br>ecosystem to eliminate bottlenecks and offer donors a quicker<br>and more agile service to enhance the donor experience. It also<br>plans to streamline plasma-collection organizational structure to<br>make it more agile, efficient and results-oriented. The company<br>believes the cumulative effect of these changes will contribute to<br>reducing donor compensation.<br>2) Restructuring of corporate functions to optimize and simplify<br>reporting structures, automate workflows, consolidate suppliers,<br>implement shared services across all business units and, in<br>some cases, eliminate duplicate positions.<br>3) A general operational efficiency initiative focused mainly<br>on global purchasing, logistics and optimization of office space<br>(non-industrial).<br>Grifols continues to make inroads on its long-term sustainable growth<br>strategy, focused on improving its cash flow and expense profile,<br>reducing debt, capturing new sales opportunities, fully exploiting<br>Biotest synergies, and streamlining its organizational structure. In<br>addition, it continues to evaluate alternatives to reduce its debt level. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 160<br>Taxes in 2022: contributions, principles<br>and good practices<br>Grifols’ fiscal commitment<br>Grifols is committed to promoting economic, social and industrial<br>development by complying with the tax laws in its countries<br>of operation and paying its fair share in jurisdictions where it<br>creates value. The company’s corporate structures are based on<br>commercial and industrial bases and aligned with its business<br>activity. The company does not operate in territories qualified as tax<br>havens.<br>Grifols’ Tax Policy establishes the principles governing its fiscal<br>management.<br>As a core component of Grifols’ corporate responsibility, the Board<br>of Directors oversees all taxation issues, approving and regularly<br>monitoring the Group’s tax policy to ensure alignment with its<br>current business context and staunch commitment to sustainability.<br>Grifols’ senior management is responsible for developing the tax<br>strategy and tax compliance framework under the supervision of the<br>Board of Directors. Nonetheless, its implementation may entail other<br>corporate areas involved in routine and non-routine tasks.<br>The company does its utmost to develop cooperative relationships<br>with tax authorities grounded in respect, transparency and<br>mutual trust. To this end, on October 26, 2018, Grifols’ Board of<br>Directors adhered to Spain’s Code of Good Tax Practices, evidence<br>of its unequivocal commitment to transparency, good faith and<br>cooperation.<br>Grifols regularly provides information on its tax strategy and taxes<br>paid. In addition, it communicates and outlines taxation-related<br>disputes and possible litigation in its Consolidated Financial<br>Statements and informative reports submitted to market regulators.<br>Governance<br>Grifols’ Board of Directors approves the Risk Management Policy,<br>which outlines the basic principles and general framework to<br>identify, evaluate, control and manage all types of risks, including<br>tax risks, faced by the company and its subsidiaries.<br>The Audit Committee supervises the efficiency of the company’s<br>internal control, internal audit and risk management systems,<br>including tax risks, and periodically reviews the internal control<br>and risk management systems to ensure that the main risks are<br>adequately identified, managed and reported.<br>The Internal Audit Department assists the Audit Committee by:<br>O Guaranteeing adequate risk-management processes and<br>risk assessment<br>O Assessing risk-management processes, including oversight<br>of controls and procedures<br>The Corporate Risk Committee oversees the leadership’s<br>responsibilities in terms of risk assessment, management and<br>control risks, and integrates robust risk-management processes<br>throughout the organization.<br>Legal compliance<br>Grifols strictly complies with the tax legislation in its countries<br>of operation and with the OECD Guidelines for Multinational<br>Enterprises. In the U.S., the company complies with, subscribes to<br>and reports on the Tax Control Framework Questionnaire (2019)<br>prepared by the U.S. Treasury Department.<br>This initiative complements the OECD Model Control of Tax Risks<br>standard by including a self-assessment mechanism to cover the<br>essential elements in the tax risk management and control system.<br>The principles of Grifols’ risk management and control system<br>are subject to tax risks, which fall under the category of legal and<br>regulatory risks.<br>Grifols recognizes the vital<br>role of taxes in driving<br>social progress | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 161 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>Tax contribution<br>Grifols’ transparency is reflected in its forthright detailing of taxes<br>generated from three different areas: (1) contribution per tax type, (2)<br>distributed tax value and (3) taxes per geographic area. The company<br>uses the PwC Total Tax Contribution methodology (hereinafter referred<br>to as TTC) to measure the total impact of its tax payments.<br>This method aligns with the OECD approach, which emphasizes the<br>critical role of businesses in global tax systems, both as taxpayers<br>Source: PwC Source: PwC<br>51% taxes collected 85%<br>49% taxes borne<br>15%<br>TOTAL TAX CONTRIBUTION<br> €719 M<br>+29%<br> €556 M in 2021<br>Balance maintained<br>between taxes borne and collected<br>Taxes borne increase by<br>68% to €366 M<br>and taxes collected by 4% to €353 M.<br>Notable increase in corporate income tax.<br>Capital gains tax represents 43% of taxes paid<br>68% of taxes* are employment-related:<br>47% of taxes borne and<br>90% of taxes collected.<br>TOTAL TAX CONTRIBUTION AND TYPE TOTAL TAX CONTRIBUTION RATIO<br>(taxes borne) and third-party tax collectors (taxes collected). Grifols<br>analyzed and categorized its TTC in its five main countries of<br>operation, Spain, the United States, Ireland, Germany and United<br>Kingdom, as follows:<br>O Profit taxes: taxes on profits earned by companies such as<br>corporate income tax, business tax and taxes withheld on<br>payments to third parties<br>O Property taxes: taxes on the ownership, sale, transfer or<br>occupation of property<br>O Employment-related taxes: both paid and collected, which<br>include employee income tax withholdings or social security<br>payments made by both the employee and the company<br>O Taxes on products and services: these consider indirect<br>taxes on the production and consumption of goods and services,<br>including VAT, customs duties, etc.<br>O Environmental taxes: taxes on the supply, use or consumption<br>of products and services deemed to affect the environment<br>Maintaining the balance<br>between taxes borne and taxes<br>collected<br>Grifols paid €43 in taxes for<br>every €100 of profit<br>maintaining the ratio in 2022 vs 2021 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 162<br>Tax value distribution<br>Grifols’ various activities generate direct and collected taxes, paid to<br>global tax authorities. In general, these highly integrated activities can<br>be classified into net interest, wages and salaries, taxes (borne and<br>collected) and shareholder value.<br>The distributed tax value (DTV) ratio shows the percentage of the total<br>value generated by Grifols allocated to pay taxes borne and collected<br>from Public Administrations.<br>Contribution by geographic area<br>Grifols’ tax policy establishes a responsible approach to ensure good tax practices, embracing principles consistent with those set forth in OECD<br>Guidelines for Multinational Enterprises (2011). It expressly states that Grifols has no presence in territories classified as tax havens, and that its<br>business transactions with third parties in these territories or any other territories form part of its ordinary business activity.<br>Grifols is taxed on the profits generated in each country it operates. Spain, the United States, Ireland, Germany and United Kingdom account for<br>more than 70% of the Group’s global revenue, and its main industrial and R+D+i facilities are primarily located in these countries.<br>Taxes borne<br>Taxes Collected<br>Shareholder value<br>Net Interests<br>Wages and salaries<br>net of taxes<br>collected<br>10%<br>11%<br>51%<br>15%<br>13%<br>40%<br>14%<br>13%<br>18%<br>15%<br>DTV increases by 7%<br>rises from 25% to 27% globally<br>That is, 27% of Grifols’ value creation<br>was paid to the public treasury through taxes borne<br>(14%) and collected (13%).<br>Out of every €100 of value<br>generated in 2022, Grifols<br>paid €27 in taxes.<br>THOUSANDS OF EUROS Profit* Taxes paid** Total tax contribution*** %<br>Spain 30.0 8.0 175.1 62%<br>United States 308.4 85.3 446.1 24%<br>Ireland 87.8 11 49.7 7%<br>Germany (10.4) 6.5 44.6 6%<br>Rest of the world 15.8 6.8 N/A<br>* Profit after tax in 2022, excluding dividends and impairments or disposals in Group Companies.<br>** Net tax payable for 2022.<br>*** Exchange rate used 1,0591 euro/dollar.<br>U.S.<br>40%<br>Distributed tax value 25%<br>IRELAND<br>8%<br>Distributed tax value 19%<br>UK<br>72%<br>Distributed tax value 53%<br>SPAIN *<br>3,216%<br>Distributed tax value 32%<br>GERMANY<br>69%<br>Distributed tax value 44%<br>TAX CONTRIBUTION ACCORDING TO GRIFOLS’ OPERATIONS<br>* In Spain, the tax contribution ratio is distorted as a result of the negative pre-tax result in 2022. While this situation generates a negative accounting result, it does not affect<br>the payment of taxes. This decline is considered non-deductible for tax purposes, hence, does not affect the Group’s taxable income in Spain. Excluding its impact, Grifols’<br>tax contribution ratio in Spain would be close to 100%, representing an increase over 2021. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 163 CONTENTS<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About Grifols<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>9<br>About<br>this report<br>2022 Consolidated Directors’ Report · 163<br>Grifols’ tax policy<br>O Tax compliance is a pillar of Grifols’ economic contribution<br>and social commitment. Its policy on compliance and good<br>practices in fiscal matters is publicly available on its website. The<br>payment of required taxes fully aligns with the economic activities<br>in all jurisdictions where the Group operates.<br>O Grifols does not operate in territories classified as tax<br>havens. and its business transactions with third parties based<br>in these or any other territories form part of its ordinary industrial<br>and commercial activity.<br>O Grifols rejects artificially shifting results to these territories<br>or taking advantage of the information opacity that these<br>territories may offer in line with the taxation principles and<br>recommendations of the OECD’s Committee on Fiscal Affairs on<br>international taxation matters. Transparency in tax-related matters<br>is a core principle of Grifols’ tax policy.<br>O Grifols avoids significant tax risks through internal<br>information and control systems that enable us to manage tax<br>matters in an orderly and expert manner.<br>O Grifols’ tax policy is guided by the reasonable and careful<br>interpretation of the tax regulations in force in each jurisdiction.<br>O Grifols consults with reputable independent tax advisors<br>before making any business decision that may have fiscal<br>impacts.<br>O Grifols has a transfer pricing policy for all transactions with<br>related parties in line with the principles of the main competent<br>organizational bodies. This policy is reviewed annually to avoid<br>any deviation from these principles.<br>O Grifols understands and supports taxation that adequately<br>correlates with the structure and location of its activities,<br>resources, and human resources and the business risks<br>assumed.<br>O Grifols does not use artificial structures unrelated to its<br>activity with the aims of reducing its tax burden or profit sharing.<br>O Grifols fosters a cooperative and fluid relationship with<br>tax authorities based on respect for the law, trust, good faith,<br>reciprocity and cooperation.<br>O Grifols collaborates with the competent tax authorities to<br>seek solutions to achieve certainty and stability in the tax criteria<br>applied by public administrations and to prioritize non-litigious<br>means of resolving disputes.<br>O In reflection of its commitment to transparency,<br>Grifols does its utmost to provide complete information and<br>documentation requested by tax administrations in the shortest<br>timeframe possible.<br>O On October 26, 2018, Grifols’ Board of Directors adhered to the<br>Code of Good Tax Practices. | ||
| --- | ||
| About this report<br>Transparent<br>reporting<br>9 | ||
| --- | ||
| This annual report reflects Grifols’ commitment to transparency,<br>highlighting our continuous efforts to enhance our financial and<br>non-financial performance.<br>We are rigorous<br> Preparation principles<br>Standards<br>Materiality<br>Sustainability<br>Stakeholder inclusiveness<br>Completeness<br>Content<br>Financial Information<br>Non-Financial Information:<br>Materiality, Risk control and<br>management, GRI, SASB, Law<br>11/2018, SDGs<br>Methodologies: Input&OutPut,<br>Total Tax Contribution, SROI and<br>Gender Pay Gap | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 166<br>About this report<br>In its commitment to transparency and efficiency, Grifols has<br>prepared its Consolidated Directors’ Report based on the<br>recommendations contained in the “International Integrated<br>Reporting Framework” of the International Integrated Reporting<br>Council (IIRC) and the “International Integrated Reporting Council<br>(IIRC), the “Guidelines for Preparation of the Listed Company<br>Management Reports” of the Spanish National Securities Market<br>Commission. This Report presents Group’s financial and non-financial information which complies with the provisions of current<br>regulations .<br>This report also includes the Statement of Non-Financial Information<br>(see Annex I “Index of context required by Law 11/2018, of<br>December 28, regarding non-financial information and diversity”)<br>also presents the impact of its business on environmental and<br>social issues, as well as on workforce, on human rights and the<br>fight against corruption and bribery, including any measures that<br>may have been adopted to support the principle of equality and<br>opportunity among men and women, non-discrimination and<br>inclusion of the disabled and universal accessibility.<br>This report has been prepared in accordance with the GRI<br>standards, as detailed in Annex II “GRI Content Index”. In<br>addition, the SASB standards referring to the “Biotechnology and<br>Pharmaceuticals” sector have been included, as can be seen in<br>Annex III “SASB Content Index”.<br>In addition, this report shows Grifols’ commitment in relation to its<br>contribution to the Sustainable Development Goals. Annex IV “Index<br>of Grifols’ contribution to the SDGs” contains the list of the SDGs<br>to which it contributes, as well as a detail of the main contributions<br>made in 2022. Given the company’s formal adherence to the United<br>Nations Global Compact, with this report, Grifols complies with the<br>Communication on Progress (CoP).<br>The financial information presented in this report, unless expressly<br>stated to the contrary, coincides with the Consolidated Financial<br>Statements for the year ended December 31, 2022 and should<br>be read jointly with the 2022 Consolidated Financial Statements,<br>which have been subject to an external audit. Some of the financial<br>indicators and ratios are classified as Alternative Performance<br>Metrics (APMs) in accordance with European Securities Markets<br>Authority (ESMA) guidelines. Annex V, “Non-GAAP Measures<br>Reconciliation”, includes the reconciliation between the adjusted<br>figures and those corresponding to IFRS-EU financial information.<br>(1) Among others, the Commercial Code, the Consolidated Text of the Capital Companies Act and Law 11/2018, of December 28, which amends the Commercial Code, the<br>Consolidated Text of the Capital Companies Act and the Accounts Auditing Act with regard to non-financial information and diversity, and which transposes Directive 2014/95/EU<br>into Spanish law with regard to the disclosure of non-financial information. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 167 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Bases for the preparation of<br>the non-financial information<br>statement<br>In compliance with Law 11/2018, of December 28, regarding<br>non-financial information and diversity, Grifols includes its Non-Financial Information Statement (EINF, for its initials in Spanish)<br>in the Consolidated Directors’ Report for the period January 1 to<br>December 31, 2022 as a separate document from the consolidated<br>annual accounts. This report is public and can be consulted on the<br>corporate website www.grifols.com.<br>Grifols has analyzed the materiality of the requirements by Law<br>11/2018, taking into account the opinion of its main stakeholders.<br>As shown in Annex I, “Index of the contents required by Law<br>11/2018, of December 28”, the EINF has been prepared taking<br>into the standards of the Global Reporting Initiative (GRI) Standards<br>selected for those requirements considered material for the<br>business.<br>Principles<br>This report has been prepared in accordance with the GRI<br>Standards:<br>Stakeholder inclusiveness: Grifols maintains an ongoing<br>dialogue with its stakeholders. The group is able to effectively<br>address their expectations and interests by anticipating their needs.<br>Context of sustainability: Grifols aspire to contribute to<br>economic, environmental and social progress on local, regional<br>and global levels. Its 2022 performance is contextualized within its<br>countries of operation.<br>Materiality: This report features the corporate issues that had<br>the greatest economic, environmental and social impact, as well<br>as those that could significantly shape stakeholder decisions and<br>evaluations.<br>Completeness: The topics highlighted in this report adequately<br>reflect the group’s most significant social, economic and<br>environmental impacts, and allow stakeholders to assess their<br>effectiveness thro assess their effectiveness throughout the 2022<br>fiscal year. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 168<br>Scope of this report<br>This report covers the period from January 1 to December 31,<br>2022, corresponding to Grifols’ fiscal year.<br>For the purposes of this report, Grifols S.A. and all its subsidiaries<br>are considered as “Grifols”. The information reported includes all<br>subsidiaries with a shareholding of more than 51%, meaning all<br>companies over which Grifols has control and which are therefore<br>fully consolidated. A list of Grifols subsidiaries can be found in<br>Appendix I of the Consolidated Financial Statements for the year<br>ended December 31, 2022, the main new development is the<br>incorporation of Biotest since May.<br>The information reported for Biotest corresponds to the period from<br>May to December 2022, except for properly indicated exceptions.<br>Performance data for this company, mainly related to human<br>resources and the environment, are presented in separate tables<br>to allow comparability of the rest of the information with previous<br>years.<br>The scope of this report includes all Grifols operations, from<br>procurement (including plasma collection) and manufacturing to<br>commercial subsidiaries.<br>In the sections where historical data appears, figures for the last<br>three years (2020-2022) have been included where available.<br>The historical data presented in this report have not been<br>recalculated to adjust for changes in the scope of consolidation<br>that have occurred in each fiscal year. The only exceptions are<br>the carbon footprint data (Scope 3) which has been recalculated<br>for 2021 to include the same scope as in 2022. Also, due to the<br>reorganization of the company, the business units in 2022 do not<br>correspond to the divisions in which the information was broken<br>down in previous reports. In the following table you can see the<br>correspondence where information is reported broken down by unit,<br>historical data has been recalculated.<br>Business units 2022 Correspondence with former divisions<br>Plasma procurement Bioscience<br>Biopharma<br>Diagnostic Diagnostic<br>Bio Supplies Bio Supplies<br>Others Hospital and others<br>The financial information included in this report is derived from the<br>Consolidated Financial Statements for the year ended December<br>31, 2022.<br>Limitations of the scope:<br>Grifols believes that this report provides a reasonable and balanced<br>reflection of the company’s economic, environmental and social<br>performance because the exceptions to the scope of the report<br>described above do not significantly alter the consolidated<br>indicators and therefore do not affect the reader’s assessment of<br>the company’s performance.<br> • Due to the complexity and global distribution of Grifols’ activities,<br>the scope of some of the quantitative indicators differs from<br>the established standard, the scope being greater than 95% of<br>turnover or employees in all cases.<br>Chapter 7, Environmental responsibility:<br> • The data provided by Grifols in this section represents its total<br>production activity, and commercial activity, except for commercial<br>subsidiaries with fewer than 10 employees.<br> • As most of the manufacturing facilities are located in the U.S.<br>and Spain, the environmental information included in this section<br>is classified by division and region as US, Spain and Rest of the<br>world (RoW).<br>Chapter 5, Our People:<br> • Grifols has included figures for the last two years, sorted by<br>gender (female, male), age and region (U.S., Europe and RoW) in<br>all cases where historical figures were available. Europe includes<br>Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal,<br>Spain, Sweden, Switzerland and United Kingdom.<br> • The scope of the indicators related to remuneration includes the<br>workforce in Spain, Germany, U.S., Ireland, Italy, Poland, Portugal,<br>Sweden, Switzerland and the United Kingdom.<br> • The data provided by Grifols in relation to training hours includes<br>all group companies except Medion Grifols Dignostic, AG, Araclon<br>Biotech, S.L., Goetech, LLC, Grifols Dignostic, AG, Araclon<br>Biotech, S.L., Goetech, LLC, Grifols Worldwide Operations USA,<br>Inc, Alkahest, Inc, Grifols Inn and New Technologies Limited,<br>Plasmavita Healthcare GmbH, Plasmavita Healthcare II GmbH,<br>GigaGen Inc and Grifols Canada Therapeutics, Inc. The data<br>included represents 96.7% of the total Grifols workforce as of<br>December 31, 2022.<br> • The scope of the indicators for absenteeism, people with<br>disabilities and the calculation of accident rates only includes data<br>from the USA, Spain, Ireland and Germany.<br>The indicators included in this report have been compiled by Grifols.<br>This year, as a novelty, a systematized reporting tool (Sygris) has<br>been implemented which has increased the methodological rigor<br>compared to the previous year<br>GRI 2-1, GRI 2-2, GRI 20-3 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 169 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Stakeholder relations<br>Deeply aware of the vital role that stakeholders play in its success,<br>therefore, Grifols has identified them and established adequate<br>communication channels in order to ensure an open and fluid<br>dialogue and stay abreast of their needs and expectations.<br>This report is an additional channel to provide information to all<br>stakeholders in a clear, concise serves as yet another platform to<br>offer information to stakeholders in a clear, concise and ethical<br>manner.<br>Grifols uses a variety of communication channels to interact with<br>its stakeholder groups, including its corporate website. Grifols has<br>prepared this report and has defined its content in line with the<br>interest and expectations of its stakeholders. The following table<br>summarize the main channels of communication with several<br>stakeholders:<br>Stakeholders Communication channels<br>Patients, patient<br>organizations<br>Grifols has open lines for on-going communications (email, phone calls). It organizes monthly calls<br>with patient organizations to discuss key updates, topics and events.<br>Plasma donors<br>Grifols provides information to plasma donors through its website, educational videos and other<br>communication channels. Donors can communicate with Grifols through plasma collection centers<br>and the website.<br>Customers<br>Grifols engages with customers (public and private. wholesalers, distributors, group purchasing<br>organizations (GPOs), blood banks, hospitals and care institutions, National Health Systems) to provide<br>clear and honest information about all of our products.<br>Regulatory bodies<br>Grifols uses formal channels when engaging with regulatory bodies such as the FDA, EMA and<br>AEMPS and others, for matters related to clinical trials, plasma donation center authorizations,<br>validation of production facilities and other authorizations regarding the commercialization of<br>therapeutic treatments, including new drugs, indications.<br>Suppliers (non-plasma<br>materials)<br>Formal communication channels are used during certification processes, assessments and audits. For<br>daily operations, informal channels are also used.<br>Financial community<br>As appropriate, Grifols discloses material information in compliance with regulations of stock<br>exchanges where the company is listed (CNMV, SEC, NASDAQ, ISE, etc.) and uses the suitable<br>channel for each case.<br>Grifols communicates with all of its shareholders, investors, analysts and other stakeholders by organizing<br>and attending meetings, including General Shareholders’ Meetings, work meetings, conference calls<br>and roadshows. Furthermore, Grifols publishes an annual report and quarterly earnings releases, and<br>press releases on the Grifols corporate website and makes them available through distribution lists<br>when necessary.<br>Grifols hosts an annual capital-markets day designed specifically for investors and analysts that<br>features more in-depth management presentations.<br>Employees<br>Grifols maintains a continuously updated intranet site for employees, and has a screen system in their<br>facilities that displays information of general interest for its employees. It also publishes an in-house<br>magazine (Revista GO) and organizes biannual meetings, as well as engaging in informal day-to-day<br>communications with employees. Meetings with the employees’ legal representatives are also regularly<br>held.<br>Local community & NGOs Grifols works collaboratively and in partnership with numerous NGOs through its foundations and directly and supports a range of community initiatives in locations where the company operates.<br>Media<br>Grifols maintains clear and transparent communications with journalists and other media<br>representatives. The company publishes press releases to announce important events like quarterly<br>and annual results.<br>Scientific community,<br>research partners<br>Collaboration with research partners and other scientific institutions is essential to the ongoing<br>innovation of Grifols products and processes. Activities with the scientific community include<br>involvement in R&D+i projects, investments and partnerships.<br>Institutional bodies Institutional bodies, trade groups and other professional organizations are engaged in both formal and informal channels to organize forums, congresses and other business-related meetings. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 170<br>Materiality<br>During 2021 Grifols anticipated the effectiveness of the new GRI<br>(Global Reporting Initiative) and prepared a materiality study in<br>accordance with the new universal GRI standards, specifically GRI<br>3: Material topics, which has become effective this year.<br>With the aim of continuing to improve and anticipate regulatory<br>requirements, this year Grifols has extended its materiality<br>assessment to include the financial view. Thus, obtaining a double<br>materiality and aligning itself with the recommendations of EFRAG<br>(European Financial Reporting Advisory Group).<br>Both views and the result obtained are explained below:<br>MATERIALITY BY IMPACTS<br>Materiality by impacts performs an inside-out analysis, analyzing<br>the impacts caused by the company on the environment. This study<br>allows the company to know the material issues that represent the<br>most important impacts that the organization generates, or may<br>generate on the economy, the environment, and people, including<br>Human Rights.<br>The methodology followed for this study is based on the<br>methodology presented by GRI 3. It is divided into two blocks, on<br>the one hand, the identification and evaluation of impacts and<br>on the other hand, the determination of the material issues to be<br>reported. Within each of these, the following phases are broken<br>down:<br>1.1 Understand the<br>organization’scontext<br>1.2 Identify actual and<br>potential impacts<br>1.3 Assess the<br>significance of the<br>impacts<br>2.1 Prioritize the most significant<br>impacts for reporting 2.2 Determination of material aspects<br>PHASE 1. IDENTIFY AND ASSESS IMPACTS ON AN ONGOING BASIS PHASE 2. DETERMINE MATERIAL TOPICS FOR REPORTING<br>This study has identified Grifols’ material topics based on the<br>impacts generated or likely to be generated by the organization.<br>1. IDENTIFY AND ASSESS IMPACTS ON AN<br>ONGOING BASIS<br>1.1. Understand the organization’s context<br>The entire value chain of Grifols’ main businesses is analyzed.<br>Identifying the activities carried out by the company and the<br>commercial relationships, taking into account the company’s<br>stakeholders and business partners, as well as the sustainability<br>context in which they occur.<br>1.2. Identify actual and potential impacts<br>In order to identify the positive and negative impacts that Grifols can<br>generate with its activity, an analysis of the press, sector studies<br>and reports published globally and nationally on the sector is<br>carried out. At the same time, a benchmark is carried out with other<br>companies in the sector.<br>Based on this analysis and the results of the previous analysis, a list<br>is drawn up of the positive and negative, direct and indirect impacts<br>generated or likely to be generated by Grifols’ activities.<br>1.3. Assess the significance of the impacts<br>For each of the impacts listed above, the following is analyzed:<br>- The probability of that impact happening (for current impacts this<br>indicator is not evaluated).<br>- The severity of the impact, considering:<br> – Scale: level of severity of the impact.<br> – The scope, extent of the impact, e.g., the number of<br>individuals affected or the magnitude of environmental damage.<br> – Irremediability: the degree of difficulty involved in<br>counteracting or correcting the resulting damage.<br>The results of this assessment are validated by both Grifols<br>managers and industry experts<br>GRI 3-1 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 171 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>PHASE I:<br>IDENTIFICATION OF RISKS AND OPPORTUNITIES<br>PHASE II:<br>ASSESSMENT OF RISKS AND OPPORTUNITIES<br>2. DETERMINE MATERIAL TOPICS FOR<br>REPORTING<br>Based on the results of the evaluation of the previous phase, the<br>importance of the impacts is analyzed according to their probability<br>and severity, which allows us to identify those impacts with the<br>greatest importance. The most important impacts are grouped<br>and correlated with the different material issues, thus obtaining a<br>first list of material issues for Grifols according to the materiality of<br>impacts.<br>FINANCIAL MATERIALITY<br>Financial materiality consists of an analysis from the outside in,<br>analyzing the risks and opportunities that affect or may affect<br>the organization. In order to carry out the study from a financial<br>perspective, Grifols analyzes whether the environment triggers, or<br>may trigger, significant financial effects for the organization. In other<br>words, whether the environment generates or may generate more<br>significant risks or opportunities that influence or may influence<br>future cash flows and, therefore, the value of the company in the<br>short, medium, or long term.<br>The methodology is divided into two phases:<br>1. IDENTIFICATION OF RISKS AND OPPORTUNITIES<br>The first step is to understand the context of the company and the<br>sector. For this context analysis is considered.<br>- The impacts analyzed in the materiality by impacts of the previous<br>year.<br>- They are associated with the issues defined by EFRAG and,<br>- The main resources and business relationships necessary for<br>Grifols’ activity are recognized, analyzing all the company’s<br>business divisions.<br>Once the resources and business relationships have been identified,<br>the following is analyzed<br>- Trends in the sector and Grifols’ main resources.<br>- The regulatory, geopolitical and climatic context that may affect<br>both Grifols directly and its resources or business relationships.<br>This analysis makes it possible to identify various risks and<br>opportunities, these are classified according to.<br>- Whether they are risks or opportunities,<br>- Whether they are current or potential, and<br>- Whether they may occur in the short, medium or long term.<br>2. ASSESSMENT OF RISKS AND OPPORTUNITIES<br>In Phase II of this materiality analysis, Grifols evaluates the risks and<br>opportunities. For the evaluation, the probability of occurrence of<br>the potential risks or opportunities and the magnitude in the event<br>of their occurrence are assessed.<br>The followin g ranges are used to assess the probability:<br>- Very unlikely<br>- Unlikely<br>- Unlikely or improbable<br>- Probable<br>- Very probable<br>And finally, to value the magnitude, the following ranges are used:<br>- Minimum<br>- Low<br>- Significant<br>- Very significant<br>- Critical<br>The results of this assessment indicate the relevance of the risks<br>or opportunities. The results are validated both by Grifols managers<br>and by experts in the sector.<br>The selected risks and opportunities are grouped and correlated<br>with the different material issues, resulting in a list of material<br>issues for Grifols according to the financial vision.<br>GRI 3-1 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 172<br>Dual materiality matrix<br>The results of the financial materiality are crossed with the results of the impact materiality, giving rise to the dual materiality matrix included in chapter 1. About us<br>Material Aspects SASB GRI Standard SDG<br>Circular economy and resource<br>management<br>-<br>GRI 3<br>GRI 301<br>GRI 303<br>GRI 306<br>GRI 307<br>8. Decent work and eco-nomic growth<br>12. Responsible con-sumption and production<br>Climate change -<br>GRI 3<br>GRI 201<br>GRI 305<br>13. Climate Action<br>Energy efficiency - GRI 3 GRI 302<br>7. Affordable and clean<br>energy<br>12. Responsible con-sumption and production<br>Human rights HC-BP-210a.3 GRI 3 -<br>Ethical code and good business<br>practices<br>HC-BP-270a.2<br>HC-BP-510a.2<br>GRI 3<br>GRI 205<br>GRI 206<br>GRI 207<br>GRI 415<br>GRI 417<br>8. Decent work and eco-nomic growth<br>5. Gender equality<br>Health contribution (patients<br>and society)<br>HC-BP-000A<br>HC-BP-240a.1<br>HC-BP-240b.1<br>HC-BP-240b.2<br>HC-BP-240b.3<br>GRI 3<br>GRI 416<br>3. Good health and<br>well-being<br>Material Aspects SASB GRI Standard SDG<br>Employee commitment -<br>GRI 3<br>GRI 2<br>GRI 401<br>GRI 402<br>GRI 403<br>8. Decent work and eco-nomic growth<br>5. Gender equality<br>Data protection and cyberse-curity HC-BP-260a.1 GRI 3 GRI 418 -<br>Innovation and knowledge gen-eration HC-BP-330a.1 HC-BP-330a.2 HC-BP-000B GRI 3 GRI 404 9. Industry, innovation and infrastructure<br>Contribution to society -<br>GRI 3<br>GRI 201<br>GRI 203<br>9. Industry, innovation<br>and infrastructure<br>5. Gender equality<br>8. Decent work and eco-nomic growth<br>3. Good health and<br>well-being<br>Product safety and quality<br>HC-BP-250a.1<br>HC-BP-250a.2<br>HC-BP-250a.3<br>HC-BP-250a.4<br>HC-BP-250a.5<br>HC-BP-210a.1<br>GRI 3<br>GRI 416<br>3. Good health and<br>well-being<br>16. Peace, justice and<br>strong institutions<br>Plasma and donors HC-BP-210a.1 GRI 3 3. Good health and well-being<br>GRI 3-1, GRI 3-2 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 173 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Risk management and control<br>Supervised by the Board of Directors, Grifols’ risk management system involves identifying, evaluating and overseeing events that might<br>affect its operations and ability to reach its strategic objectives.<br>Grifols’ risk control and management policy includes rigorous systems to prevent, control and manage its exposure to risk, providing greater<br>security to patients, donors, employees, shareholders, customers, suppliers and other stakeholders. This policy is carried out through a<br>comprehensive risk control and management system based on COSO (Committee of Sponsoring Organizations of the Treadway Commission)<br>principles, and includes governance and culture, strategy and objectives, performance, review, information, communication and reporting.<br>Through the Audit Committee, the Board of Directors oversees the effectiveness of the risk control and management system. The Audit<br>Committee is assisted by the Internal Audit Department in these functions, providing a guarantee in relation to management of risk processes.<br>The corporate risk committee oversees the management’s responsibilities with regard to assessing, monitoring and controlling risks. The<br>enterprise risk management department assists the corporate risk committee in the development and implementation of risk management<br>policies and procedures. Therefore, the risk management function at Grifols is independent of commercial functions and other departments,<br>and serves to address risks throughout the organization, avoiding any potential conflicts of interest.<br>Grifols’ risk management system extends to all companies in the group, including investee firms.<br>Principles of Grifols’ risk control and<br>management system<br>1. Establishment of a risk tolerance framework, which<br>includes the levels of risk the company deems acceptable<br>and are consistent with its objectives.<br>2. Leadership from top management, which provides the<br>necessary resources.<br>3. Integration in management processes, especially those<br>related to strategy and planning.<br>4. Separation of duties between business areas and<br>supervision and assurance domains.<br>5. Comprehensive and harmonized management, with<br>all risks managed through a common process of<br>identification, assessment and treatment.<br>6. Continuous improvement via periodic reviews to ensure<br>the suitability and efficiency of the risk-management<br>system and implementation of best practices and risk-related recommendations. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 2022 Consolidated Directors’ R eport · 174<br>O Strategic risks: Risks that can affect the company’s business strategy and strategic<br>objectives, including market uncertainties and sociopolitical and reputational risks.<br>O Financial risks: Risks that can affect cash flows if not effectively managed, leading to a<br>loss in revenue, shareholder value or the overall stability of the organization. Financial risks<br>also include contingent liabilities and other off-balance sheet risks.<br>O Operational risks: Risks related to direct or indirect economic losses resulting from<br>inadequate internal procedures, technical failures, human error and specific external<br>events. Operational risks also include information technologies.<br>O Cybersecurity risks: Risk of breaches or attacks on information systems by malicious<br>insiders and outsiders of the organization.<br>O Environmental, social and governance (ESG) risks: ESG-related risks that may<br>impact the organization, including climate change, human capital and breaches of laws,<br>regulations, internal standards, ethical value and contracts. Governance risks also include<br>fraud and corruption risks.<br>O Legal and regulatory risks: Risks arising from new or modified legislation, regulation<br>and interpretation.<br>As of the date of preparing its consolidated financial statements, Grifols adopted measures it<br>deemed appropriate to mitigate possible effects arising from the aforementioned events.<br>Classification of Grifols’ risks by category: | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 175 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Annex I. Index of contents required by<br>Law 11/2018, of december 28<br>The selected GRI Disclosures below refer to those published in 2016, except those that<br>have undergone and in which case the year of publication is indicated.<br>Information requested by Law 11/2018 Materiality Page number(s) Reporting criteria: GRI (last version except indicated)<br>General information<br>A brief description of the business model that includes its business environment, its organization and<br>structure Material 11, 16-17 GRI 2-6 (2021)<br>Markets in which it operates Material 14-15 GRI 2-1 (2021) GRI 2-6 (2021)<br>Objectives and strategies of the organization Material 22, 24-25 GRI 2-1 (2021) GRI 2-22 (2021)<br>Main factors and trends that can affect its future evolution Material 173-174 GRI 3-3 (2021) GRI 2-22 (2021)<br>Reporting framework used Material 166-167 GRI 1 (2021)<br>Principle of materiality Material 23, 170-172 GRI 3-1 (2021) GRI 3-2 (2021)<br>Environmental Issues<br>Management approach: description and results of the policies related to these issues, as well as<br>the main risks related to those issues related to the group’s activities. Material 125-126, 234-235 GRI 3-3 (2021)<br>Detailed general information<br>Detailed information on the actual and predictable effects of the company’s activities on the environment<br>and, when applicable, health and safety. Material 130-131 GRI 3-3 (2021)<br>Environmental assessment or certification procedures Material 127 GRI 3-3 (2021)<br>Resources dedicated to the prevention of environmental risks Material 128-129 GRI 3-3 (2021)<br>Application of the precautionary principle Material 127-129 GRI 2-23 (2021)<br>Amount of provisions and guarantees for environmental risks Material 128 GRI 3-3 (2021) | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 176<br>Information requested by Law 11/2018 Materiality Page number(s) Reporting criteria: GRI (last version except indicated)<br>Contamination<br>Measures to prevent, reduce or repair emissions that seriously affect the environment; considering any form<br>of activity-specific air pollution, including noise and light pollution Material 132, 223 GRI 3-3 (2021) GRI 305-7<br>Circular-economy and waste-prevention management<br>Prevention, recycling, reutilization and other recovery and waste disposal measures. Material 138, 142-143, 231-233<br>GRI 306-1<br>GRI 306-2<br>GRI 306-4<br>GRI 306-5<br>Actions to fight food waste Not material - -<br>Sustainable use of resources<br>Water consumption and supply in accordance with the local limitations Material 140-141, 224-226, 227 GRI 303-1 a 303-5<br>Consumption of raw materials and measures taken to improve the efficiency of their use Material 139, 230-231, 234-235 GRI 301-1<br>Direct and indirect energy consumption Material 134-137, 228-230 GRI 302-1 GRI 302-3<br>Measures taken to improve energy efficiency Material 125-126, 234 GRI 3-3 (2021) GRI 201-2<br>Use of renewable energy Material 132, 137, 234 GRI 302-1<br>Climate change<br>Greenhouse gas emissions generated as a result of the company’s activities, including the use of the goods<br>and services it produces Material 132, 222-224<br>GRI 305-1<br>GRI 305-2<br>GRI 305-3<br>GRI 305-4<br>Measures taken to adapt to the consequences of climate change Material 125, 129, 130-131, 133, 222, 234 GRI 3-3 (2021) GRI 201-2<br>Voluntary measures for medium and long-term reduction goals to reduce greenhouse gas emissions and the<br>means implemented for this purpose Material 24, 234 GRI 3-3 (2021)<br>Biodiversity protection<br>Measures taken to preserve or restore biodiversity Material 144-145 GRI 3-3 (2021)<br>Impacts caused by activities or operations in protected areas Material 144-145 GRI 3-3 (2021)<br>Social and Personnel Matters<br>Management approach: description and results of the policies related to these matters as well as<br>the main risks related to those issues linked to the group’s activities. Material 87-89 GRI 3-3 (2021)<br>Employment<br>Total number and distribution of employees by country, gender, age and professional category Material 90, 203-209 GRI 405-1<br>Total number and distribution of employment contract modalities and annual average of indefinite contracts,<br>temporary contracts and part-time contracts by gender, age and professional category Material 202-209 GRI 2-7 (2021) | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 177 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Information requested by Law 11/2018 Materiality Page number(s) Reporting criteria: GRI (last version except indicated)<br>Number of dismissals by gender, age and professional classification Material 211-212 GRI 3-3 (2021) GRI 401-1<br>Average remuneration and its evolution disaggregated by sex, age and professional classification or equal<br>value Material 102, 217-218 GRI 3-3 (2021)<br>Gender gap, the remuneration of equal or average company jobs Material 100-101, 219-220 GRI 3-3 (2021) GRI 405-2<br>Average remuneration of directors and executives, including variable remuneration, allowances, allowances,<br>payment to long-term savings forecasting systems and any other perception disaggregated by sex Material 20, 218 GRI 3-3 (2021)<br>Implementation of policies work disconnection Material 89, 105 GRI 3-3 (2021)<br>Number of employees with disabilities Material 93, 221 GRI 3-3 (2021) GRI 405-1<br>Organization of work<br>Organization of working time Material 105 GRI 3-3 (2021)<br>Number of hours of absenteeism Material 213 GRI 3-3 (2021) GRI 403-9<br>Measures aimed at facilitating the enjoyment of conciliation and promoting the co-responsible exercise of<br>these by both parents Material 105 GRI 3-3 (2021) GRI 403-3<br>Occupational health and safety<br>Health and safety conditions at work Material 103-105<br>GRI 3-3 (2021)<br>GRI 403-1<br>GRI 403.3<br>GRI 403-4<br>GRI 403-5<br>GRI 403-6<br>GRI 403-7<br>Occupational accidents, their frequency and severity, as well as occupational diseases; disaggregated<br>by gender Material 105, 216 GRI 403-9 GRI 403-10<br>Social relationships<br>Organization of social dialogue including procedures for informing and consulting staff and negotiating<br>with them Material 102 GRI 3-3 (2021)<br>Mechanisms and procedures that the company has to promote the involvement of workers in the manage-ment of the company, in terms of information, consultation and participation Material 102 GRI 3-3 (2021)<br>Percentage of employees covered by collective agreement by country Material 102 GRI 2-30 (2021)<br>Balance of collective agreements, particularly in the field of health and safety at work Material 102 GRI 3-3 (2021) GRI 403-4<br>Training<br>Policies implemented in the field of training Material 94-96 GRI 404-2 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 178<br>Information requested by Law 11/2018 Materiality Page number(s) Reporting criteria: GRI (last version except indicated)<br>Total number of training hours by professional category Material 97, 214-215 GRI 3-3 (2021) GRI 404-1<br>Universal accessibility<br>Integration and universal accessibility of people with disabilities Material 93 GRI 3-3 (2021)<br>Equality<br>Measures taken to promote equal treatment and opportunities for women and men Material 89, 91, 93 GRI 3-3 (2021)<br>Equality plans, measures taken to promote employment, protocols against sexual and gender harassment Material 92-93 GRI 3-3 (2021)<br>Policy against all types of discrimination and, when applicable, diversity management Material 89, 92, 221 GRI 3-3 (2021)<br>Respect for human rights<br>Management approach: description and results of the policies related to these matters as well as<br>the main risks related to those issues linked to the group’s activities. Material 50-53 GRI 3-3 (2021)<br>Aplicación de procedimientos de diligencia debida<br>Application of due diligence procedures in the field of human rights and prevention of risks of violation of<br>human rights and, where appropriate, measures to mitigate, manage and repair possible abuses committed Material 53 GRI 2-23 (2021)<br>Complaints for cases of human rights violation Material 50, 52-53, 61 GRI 3-3 (2021) GRI 406-1 (2016)<br>Measures implemented to promote and comply with the provisions of the ILO fundamental conventions<br>related to respect for freedom of association and the right to collective bargaining; the elimination of discrimi-nation in employment and occupation; the elimination of forced or compulsory labor; the effective abolition of<br>child labor<br>Material 49, 51 GRI 3-3 (2021)<br>Fight against corruption and bribery<br>Management approach: description and results of the policies related to these matters as well as<br>the main risks related to those issues linked to the group’s activities. Material 50, 55-56 GRI 3-3 (2021)<br>Measures taken to prevent corruption and bribery Material 50, 55-61<br>GRI 3-3 (2021)<br>GRI 2-23 (2021)<br>GRI 205-1 a 205-3<br>Measures to fight money laundering Material 55<br>GRI 3-3 (2021)<br>GRI 2-23 (2021)<br>GRI 205-1 a 205-3 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 179 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Information requested by Law 11/2018 Materiality Page number(s) Reporting criteria: GRI (last version except indicated)<br>Contributions to foundations an NGOs Material 58-59, 68, 200-201<br>GRI 2-28 (2021)<br>GRI 201-1<br>GRI 415-1<br>Social Information<br>Management approach: description and results of the policies related to these matters as well as<br>the main risks related to those issues linked to the group’s activities. Material 107-108, 111-112 GRI 3-3 (2021)<br>Commitment to sustainable development<br>The impact of the company’s activity on employment and local development Material 112-117 GRI 3-3 (2021) GRI 203-2<br>The impact of society’s activity on local populations and in the territory Material 107, 111, 114 GRI 3-3 (2021)<br>The relations maintained with the actors of the local communities and the modalities of the dialogue with<br>these Material 108-117, 120-122 GRI 2-29 (2021)<br>Partnership or sponsorship actions Material 108-123, 200-201 GRI 3-3 (2021) GRI 201-1<br>Subcontracting and suppliers<br>Inclusion in the purchasing policy of social, gender equality and environmental issues Material 62-63 GRI 3-3 (2021)<br>Consideration in the relations with suppliers and subcontractors of their social and environmental responsi-bility Material 62, 63 GRI 2-6 (2021)<br>Supervision and audit systems and their results Material 63, 67-69 GRI 2-6 (2021)<br>Consumers<br>Measures for the health and safety of consumers Material 62, 64 GRI 3-3 (2021) GRI 416-1<br>Complaint systems, complaints received and resolution thereof Material 65 GRI 3-3 (2021) GRI 418-1<br>Tax information<br>Profit obtained country by country Material 162 GRI 3-3 (2021) GRI 207-4<br>Taxes earned on benefits paid (per country) Material 162<br>GRI 3-3 (2021)<br>GRI 201-1<br>GRI 207-4<br>Public grants received (per country) Material 158 GRI 3-3 (2021) | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 180<br>Annex II: GRI content index<br>GRI Standards GRI Disclosure Page number, URL and/or direct response Omission<br>Statement of use Grifols S.A. has reported in accordance with the GRI Standards for the period January 1st to December 31st of 2022.<br>GRI 1: Foundation 2021<br>General Disclosures<br>GRI 2: General<br>Disclosures 2021<br>The organization and its reporting practices<br> 2 - 1 Organizational details 14-15, 168<br> 2 - 2 Entities included in the organization’s sustainability reporting 168<br> 2 - 3 Reporting period, frequency and contact point 168<br> 2 - 4 Restatements of information All information with a temporal or organitzational scope other than 2021 is properly indicated and accompanied by a clarification.<br> 2 - 5 External assurance 241-242<br>Activities and workers<br> 2 - 6 Activities, value chain, and other business relationships 11-17, 62-64 No information available related to the requirement b-iii<br> 2 - 7 Employees 203-209 No information available related to the requirement b-iii<br> 2 - 8 Workers who are not employees - Not applicable since Grifols S.A do not ave workers who are not employees<br>Governance<br> 2 - 9 Governance structure and composition 18-22<br> 2 - 10 Nomination and selection of the highest governance body IAGC (section C) https://www.grifols.com/documents/3625622/5128964/2022-IAGC-en.pdf/4dcf52bb-17b9-497d-f72b-92d17190631d?t=1677235367882<br> 2 - 11 Chair of the highest governance body 19-21<br> 2 - 12 Role of the highest governance body in overseeing the management of impacts<br> “50<br>Climate Change Policy<br>https://www.grifols.com/documents/3625622/5132251/Climate+Change+Policy+.pdf/1f6e0159-<br>7798-6d49-e390-8ac95929fc2b?t=1677493449804<br>Sustainability Policy<br>https://www.grifols.com/documents/3625622/3684243/Politica+de+Sostenibilidad+Grifols-Dic+2020+-+EN.PDF/43bf357b-b54f-461f-b719-810db4be1072?t=1608130315510<br> 2 - 13 Delegation of responsibility for managing impacts Climate Change Policy https://www.grifols.com/documents/3625622/5132251/Climate+Change+Policy+.pdf/1f6e0159-<br>7798-6d49-e390-8ac95929fc2b?t=1677493449804<br> 2 - 14 Role of the highest governance body in sustainability reporting 170-171<br> 2 - 15 Conflicts of interest<br>173<br>IAGC (section D and G)<br>https://www.grifols.com/documents/3625622/5128964/2022-IAGC-en.pdf/4dcf52bb-17b9-497d-f72b-92d17190631d?t=1677235367882<br> 2 - 16 Communication of critical concerns 19<br>GRI 2-4<br>For the Content Index - Essentials Service, GRI Services reviewed that the GRI content index is clearly<br>presented, in a manner consistent with the Standards, and that the references for disclosures 2-1 to<br>2-5, 3-1 and 3-2 are aligned with the appropriate sections in the body of the report | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 181 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>GRI Standards GRI Disclosure Page number, URL and/or direct response Omission<br>GRI 2: General<br>Disclosures 2021<br> 2 - 17 Collective knowledge of the highest governance body 98<br> 2 - 18 Evaluation of the performance of the highest governance body IAGC (section C) https://www.grifols.com/documents/3625622/5128964/2022-IAGC-en.pdf/4dcf52bb-17b9-497d-f72b-92d17190631d?t=1677235367882<br> 2 - 19 Remuneration policies<br>20<br>Remuneration Policy for Directors of Grifols, S.A.<br>https://www.grifols.com/documents/3625622/4076106/20220610-Directors-Remuneration-Policy-proposal-EN.pdf/6d5fdb79-3f9d-d73a-39f9-753c1a4981e3?t=1654852418449<br> 2 - 20 Process to determine remuneration<br>20<br>Remuneration Policy for Directors of Grifols, S.A.<br>https://www.grifols.com/documents/3625622/4076106/20220610-Directors-Remuneration-Policy-proposal-EN.pdf/6d5fdb79-3f9d-d73a-39f9-753c1a4981e3?t=1654852418449<br> 2 - 21 Annual total compensation ratio - Not reported due to confidentiality constraints<br>Strategy, policies and practices<br> 2 -22 Statement on sustainable development strategy 5-7<br> 2 - 23 Policy commitments 49-60, 62-63, 87-89, 107, 125-126, 234-235<br> 2 - 24 Embedding policy commitments 49-60, 62-63, 87-89, 107 125-126, 234-235<br> 2 - 25 Processes to remediate negative impacts 56-57, 61, 64-66<br> 2 - 26 Mechanisms for seeking advice and raising concerns 50, 61<br> 2 - 27 Compliance with laws and regulations 54, 66, 128<br> 2 - 28 Membership associations 200-201<br>Stakeholder engagement<br> 2 - 29 Approach to stakegolder engagement 107, 167, 169<br> 2 - 30 Collective bargaining agreements 102<br>Material Topics<br>GRI 3: Material<br>Topics 2021<br> 3 - 1 Process to determine material topics 23, 170-172<br> 3 - 2 List of material topics 23, 170-172<br>Circular economy and resource management<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 125-126, 138-143 No information available related to the requirements a, b, d, e, f<br>GRI 301: Materials<br>2016 301-1 Materials used by weight or volume 230-231<br>Given the nature of the materials used by Grifols,<br>the breakdown by renewable and non-renewable<br>is not applicable.<br>GRI 303: Water and<br>Effluents 2018<br>303-1 Interactions with water as a shared resource 126, 140-141 No information available related to the requirement c.<br>303-2 Management of water discharge-related impacts 141<br>303-3 Water withdrawl 224-226 No information available related to the requirement c.<br>303-4 Water discharge 141, 227 No information available related to the requirements b, c.<br>303-5 Water consumption 140, 224-226 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 182<br>GRI Standards GRI Disclosure Page number, URL and/or direct response Omission<br>GRI 306: Waste<br>2020<br>306-1 Waste generation and significant waste-related impacts 138, 142-143<br>306-2 Management of significant waste-related impacts<br>138 ,142-143<br>Management platforms, tracking sheets, internal spreadsheets and reports<br>from waste managers are used to collect and track data associated with<br>waste quantities. This data is fed into the SAP Sustainability Performance<br>Management platform.<br>Information regarding significant waste-related<br>impacts is not available for publication in this<br>report. Specific measures are being taken in the<br>collection of information and the data processing<br>process to be able to provide this detail in the<br>next five years.<br>306-4 Waste diverted from disposal 231 -233 No information available related to the requirement d.<br>306-5 Waste directed to disposal 231 -233 No information available related to the requirement d.<br>Climate change<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 125-126, 130-133 No information available related to the requirements a, b, d, e, f<br>GRI 201: Economic<br>Performance 2016 201-2 Financial implications and other risks and opportunities due to climate change 130-131<br>GRI 305: Emissions<br>2016<br>305-1 Direct (Scope 1) GHG emissions 132, 222-224<br>305-2 Energy indirect (Scope 2) GHG emissions 132, 222-224<br>305-3 Other indirect (Scope 3) GHG emissions 132, 222-224<br>305-4 GHG emissions intensity 223<br>305-6 Emissions of ozone-depleting substances (ODS) 223 No information available related to the requirements a, c<br>305-7<br>Nitrogen oxides (NOX), sulfur oxides (SOX), and other<br>significant air<br>emissions<br>223 No information available related to the requirements a-iii, iv, v, vi<br>Energy Efficiency<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 125-126, 134-137 No information available related to the requirements a, b, d, e, f<br>GRI 302: Energy<br>2016<br>302-1 Energy consumption within the organization 134-137, 228-230<br>302-3 Energy intensity<br>228-230<br>All ratios are reported using energy consumption within the<br>organization<br>302-4 Reduction of energy consumption 134-137<br>Human rights<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 49-53 No information available related to the requirements a, b, d, e, f<br>Ethical code and good business practices<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 49, 55-57 No information available related to the requirements a, b, d, e, f | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 183 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>GRI Standards GRI Disclosure Page number, URL and/or direct response Omission<br>GRI 205: Anti-corruption 2016<br>205-1 Operations assessed for risks related to corruption 56<br>No information available related to the<br>requirement a) percentage of operations<br>assessed for risks related to corruption<br>205-2 Communication and training about anti-corruption policies and procedures 57 No information available related to the requirements a, c, d<br>205-3 Confirmed incidents of corruption and actions taken 56<br>GRI 207: Tax 2019<br>207-1 Approach to tax 160-163<br>207-2 Tax governance, control, and risk management 160-163<br>207-3 Stakeholder engagement and management of concerns related to tax 160-163<br>207-4 Country-by-country reporting 162, 203<br>No information available related to the<br>requirements a-i, a-ii, a-iv, a-v, a-vii, a-ix, a-x.<br>Breakdown of country-by-country information is<br>not available for publication in this report.<br>GRI 415 Public<br>Policy (2016) 415 -1 Political contributions 60<br>GRI 417 Marketing<br>and Labeling 2016 417-3 Incidents of non-compliance concerning marketing communications 66<br>Health contribution (patients and society)<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 40-47 No information available related to the requirements a, b, d, e, f<br>Employee commitment<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 87-89 No information available related to the requirements a, b, d, e, f<br>GRI 401:<br>Employment 2016 401-1 New employee hires and employee turnover<br>New hires by region:<br>United States: 10,399 employees, rate 61.78%<br>Europe: 1,136 employees, rate 17.02%<br>RoW: 93 employees, rate 17.25%<br>New hires by age group:<br> <30: 6,418 employees, rate 93.57%<br>30-50: 4,339 employees, rate 35.45%<br> >50: 811 employees, rate 16.73%<br>Total number of casualties and staff turnover rate by region:<br>United States: 9,514 employees, rate 56.85%<br>Europe: 950 employees, rate 14.23%<br>RoW: 118 employees, rate 21.89%<br>Total number of casualties and staff turnover rate by age group:<br> <30: 5,126 employees, rate 74.73%<br>30-50: 4,330 employees, rate 35.37%<br> >50: 1,126 employees, rate 23.23% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 184<br>GRI Standards GRI Disclosure Page number, URL and/or direct response Omission<br>GRI 401:<br>Employment 2016<br>401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees<br>All employees of the main locations with the exception of the US receive the<br>same benefits and labor benefits according to their category regardless of<br>the type of contract (full or part time). In the US, all full-time workers who<br>work an average of 30 hours or more a week, as well as their partner and<br>children, have various insurance policies (Life insurance, group accident<br>insurance, short-term work disability insurance). term and long-term<br>and work-related travel accident insurance). They also participate in the<br>Employee Assistance Program, a health and wellness program (LiveWell<br>Wellness Incentive Program and Gympass), 401k Match, reimbursement for<br>training, vacation pay (PTO Pay, Holiday Pay) and have adoption assistance.<br>Part-time workers receive 401k, work-related travel accident insurance,<br>participate in the Employee Assistance Program and the LiveWell Wellness<br>Incentive Program and Gympass.<br>401-3 Parental leave<br>100% of Grifols employees are entitled to maternity/paternity leave as long<br>as it is contemplated by state, federal, regional or local laws; In 2022, 405<br>women and 238 men between Spain, the United States and the Rest of the<br>world (considering Ireland and Germany) have taken parental leave. During<br>the reporting period, 619 people (388 women and 231 men) have returned<br>to work after finishing parental leave, which represents a return to work rate<br>of 87% (83% in women and 94% in men). Of the total number of people who<br>returned to work after finishing parental leave in 2021, 64% (56% women<br>and 80% men) continue to work for the company.<br>GRI 402: Labor/<br>management<br>relations 2016<br>402-1 Minimum notice periods regarding operational changes<br>Significant operational changes in the organization that may substantially<br>affect employees are notified with the minimum notice established in<br>compliance with applicable legislation and collective bargaining agreements.<br>GRI 405: Diversity<br>and Equal<br>Opportunity 2016<br>405-1 Diversity of governance bodies and employees 20, 206-208 No information available related to the requirement a-ii.<br>405-2 Ratio of basic salary and remuneration of women to men 219-220<br>GRI 406: Non-discrimination 2016 406-1 Incidents of discrimination and corrective actions taken 92, 221<br>GRI 403:<br>Occupational Health<br>and Safety 2018<br>403-1 Occupational health and safety management system 103, 105<br>403-3 Occupational health services 103, 105<br>403-4 Worker participation, consultation, and communication on occupational health and safety 102<br>403-5 Worker training on occupational health and safety 103<br>403-6 Promotion of worker health 103<br>403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships 103<br>403-9 Work-related injuries 216<br>403-10 Occupational diseases 105, 216<br>Data protection and cybersecurity<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 54 No information available related to the requirements a, b, d, e, f<br>GRI 418: Customer<br>Privacy 2016 418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data There have been no claims regarding breaches of privacy and loss of customer data | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 185 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>GRI Standards GRI Disclosure Page number, URL and/or direct response Omission<br>Innovation and knowledge generation<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 78-79, 87, 94-96 No information available related to the requirements a, b, d, e, f<br>GRI 404: Training<br>and education 2016<br>404-1 Average hours of training per year per employee<br>Average hours of training per employee by gender: Women 247.86 hours<br>and Men 153.71 hours.<br>By professional category:<br>Executives: 14.77h<br>Directors: 32.56h<br>Senior Management: 34.83h<br>Management: 34.51h<br>Senior Professional: 50.82h<br>Professional: 70.99h<br>Administrative/Manufacturing operators: 285.89h<br>Average hours of training per employee calculated from the cumulative<br>average workforce for the year (FTE average)<br>404-2 Programs for upgrading employee skills and transition assistance programs 94-96, 98<br>404-3 Percentage of employees receiving regular performance and career development reviews<br>In 2022, 74.02% of all subject employees have participated in a periodic<br>evaluation of performance and professional development.<br>Men: 87.1%<br>Women: 85%<br>Undeclared: 50%<br>By professional category:<br>Executives: 41.9%<br>Directors: 81.9%<br>Senior Management: 86.6%<br>Management: 89.1%<br>Senior Professional: 88.6%<br>Professional: 88.3%<br>Administrative/Manufacturing operators: 83.6%<br>Contribution to society<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 107, 111 No information available related to the requirements a, b, d, e, f<br>GRI 201: Economic<br>Performance 2016 201-1 Direct economic value generated and distributed 16-18, 162, 217-219 No information available related to the requirement a-iii.<br>GRI 203: Indirect<br>Economic Impacts<br>2016<br>203-1 Infrastructure investments and services supported 108, 111-117<br>203-2 Significant indirect economic impacts 160-162, 194<br>Product safety and quality<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics 62-66 No information available related to the requirements a, b, d, e, f<br>GRI 416: Customer<br>Health and Safety<br>2016<br>416-1 Assessment of the health and safety impacts of product and service categories 64, 67<br>416-2 Incidents of non-compliance concerning the health and safety impacts of products and services 65-66<br>Plasma and donors<br>GRI 3: Material<br>Topics 2021 3 - 3 Management of material topics<br>27-28, 32<br>Coverage: Within and outside the organization. The organization contributes<br>directly to the impact<br>No information available related to the<br>requirements a, b, d, e, f | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 186<br>Annex III: SASB content index<br>SASB Indicator Accounting metric Disclosure and/or references<br>Safety of Clinical Trial Participants<br>HC-BP-210a.1 Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials<br>54, 78-79<br>For more information please visit:<br>https://www.clinicaltrialsregister.eu/ctr-search/search/<br>https://www.clinicaltrials.gov/<br>https://eudract.ema.europa.eu/<br>HC-BP-210a.2 Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) Grifols has not received any FDA Sponsor Inspections related to clinical trial management and pharmaco- vigi lance that resulted in VAI or OAI.<br>HC-BP-210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in develo- ping countries There has not been any monetary loss as a result of legal proceedings associated with clinical trials in developing countries<br>Access to Medicines<br>HC-BP-240a.1 Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index 42-45<br>HC-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalifica- tion of Medicines Programme (PQP) Grifols has no products on the WHO List of Prequalified Medicinal Products.<br>Affordability & Pricing<br>HC-BP-240b.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/ or provisions to delay bringing an authorized generic product to market for a defined time period Grifols does not market generic products.<br>HC-BP-240b.2 Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year This information is not reported regarding confidentiality issues<br>HC-BP-240b.3 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year This information is not reported regarding confidentiality issues<br>Drug Safety<br>HC-BP-250a.1 List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database Information available on the FDA Safety Information and Adverse Event Reporting Program website: https://www.fda. gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program<br>HC-BP-250a.2 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System<br>Information available on the FDA Adverse Event Reporting System (FAERS) Public Dashboard: https://www.<br>fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event- re-porting-system-faers-public-dashboard<br>HC-BP-250a.3 Number of recalls issued, total units recalled 65<br>HC-BP-250a.4 Total amount of product accepted for takeback, reuse, or disposal We do not accept the return of products for reuse. We collect the products for disposal in accordance with the legal requirements of each country<br>HC-BP-250a.5 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type Grifols has not received any FDA enforcement action associated with warning letters, seizures, recalls or consent decrees in 2022. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 187 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>SASB Indicator Accounting metric Disclosure and/or references<br>Counterfeit Drugs<br>HC-BP-260a.1 Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting 66<br>HC-BP-260a.2 Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products<br>Grifols has an internal Policy for the prevention, detection and communication of counterfeiting. According<br>to this policy, suspected counterfeit drugs and confirmation of counterfeit product detection must be<br>notified to the corresponding regulatory authorities in a timely manner and in accordance with applicable<br>and current regulations.<br>HC-BP-260a.3 Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products Grifols is not aware of any actions that have led to raids, seizures, arrests and/or filing of criminal charges related to counterfeit products<br>Ethical Marketing<br>HC-BP-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims 66<br>HC-BP-270a.2 Description of code of ethics governing promotion of off-label use of products 66<br>Employee Recruit-ment, Develop-ment & Retention<br>HC-BP-330a.1 Discussion of talent recruitment and retention efforts for scientists and research and develop- ment personnel 94-95<br>HC-BP-330a.2 (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others 210<br>Supply Chain Ma-nagement<br>HC-BP-430a.1<br>Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in the Rx-360<br>International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit<br>programs for integrity of supply chain and ingredients<br>Grifols does not have facilities that participate in the Rx-360 International Pharmaceutical Supply Chain.<br>Consortium audit program or equivalent programs. However, our facilities are frequently audited by the<br>respective Health authorities of the countries in which we distribute our products. Our suppliers are<br>audited by our own teams of auditors that ensure compliance with all the requirements requested by the<br>health authorities.<br>Business Ethics<br>HC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery 56<br>HC-BP-510a.2 Description of code of ethics governing interactions with healthcare professionals 58<br>Activity metrics<br>HC-BP-000.A Number of patients treated 29<br>HC-BP-000.B Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3) 12-13; 77; 82 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 188<br>Annex IV: Index of Grifols’ SDG contributions<br>SDG Targets<br>Section within the<br>Integrated Annual<br>Report<br>Sub-section within<br>the Integrated Annual<br>Report<br>Detailed information on the contribution<br>Priority objectives<br>SDG 3<br>Good health<br>and well-being<br>3.3. End the epidemics of AIDS, tuberculosis,<br>malaria, and neglected tropical diseases and<br>combat hepatitis, water-borne diseases, and other<br>communicable diseases.<br>3.4. Reduce pre-mature mortality from non-communicable diseases (NCDs) by one-third<br>through prevention and treatment and promote<br>mental health and wellbeing.<br>1. About Grifols<br>2. Commitment to donors and patients<br>3. Ethical commitment<br>4. Innovation Treatment innovations · Main Projects in Development, p. 80<br> · Milestones and product launches, p. 81<br> · Other initiatives for Neurogenerative Diseases, p. 82<br> · Other advances in plasma therapies, p. 82<br> · GigaGen, Non-Plasma Innovations, p. 82<br>Diagnostic innovation · Milestones and launches, p. 83<br>6. Impact on society Support for NGOs and foundations · Probitas Foundation: improving the health of the most<br>vulnerable, p. 118-119<br>SDG 8<br>Decent work and<br>economic growth<br>8.5. Provide decent work for all women and<br>men, including young people and persons with<br>disabilities through full and productive employment<br>with equal pay.<br>5. Our people Growing with our team · Diversity and inclusion, p. 91<br> · Anti-discrimination principles and actions, p. 92<br> · Incorporating people with disabilities, p. 93<br> · Equal opportunities plan, p. 93<br> · A holistic approach to equality, p. 93<br>Fair compensation practices · Equal pay between man and women, p. 100<br> · Equality and gender pay gap, p. 101<br> · Remuneration system, p. 102<br>9. About this report Annex VI: Socioeconomic impact, p. 194<br>8.8. Protect labor rights and promote safe and<br>secure working environments for all workers.<br>5. Our people Occupational health and well-being · Comprehensive health and safety management, p. 103<br> · Performance in occupational health and safety, p. 105<br> · Work-life balance, p. 105<br> · Occupational safety as a core commitment, p. 105<br>SDG 9<br>Industry, innovation and<br>infrastructure<br>9.4. Upgrade infrastructure and retrofit industries<br>to make them sustainable and with increased<br>resources use efficiency and greater adoption of<br>clean and environmentally sound technologies and<br>industrial processes<br>2. Commitment to donors<br>and patients<br>Program to boost plasma self-sufficiency: leading the change, p. 31<br>4. Innovation A robust innovation system, p. 72<br>A solid organizational structure, p. 73<br>Digital innovation, p. 84<br>9.5 Enhance scientific research, upgrade the<br>technological capabilities of industrial sectors in<br>all countries, including encouraging innovation and<br>substantially increasing the number of research<br>and development workers and public and private<br>research and development spending.<br>4. Innovation R&D+i resource allocations, p. 74-75<br>Ethics, science and innovation · Our commitments, p. 79<br>Research support and collaboration · Sponsorship: ISR Program, p. 85<br> · The Grifols chair for the study of cirrhosis, p. 85<br> · Grifols Scientific Awards and research grants, p. 85<br> · Plasmatology Journal, p. 85 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 189 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>SDG Targets<br>Section within the<br>Integrated Annual<br>Report<br>Sub-section within<br>the Integrated Annual<br>Report<br>Detailed information on the contribution<br>Priority objectives<br>SDG 12<br>Responsible consumption<br>and production<br>12.2. Achieve sustainable management and<br>efficient use of natural resources.<br>7. Environmental<br>responsibility<br>Environmental management at<br>Grifols<br> · A cross-cutting and comprehensive approach, p. 126<br> · Environmental certifications, p. 127<br>A global organization to manage environmental risks, p. 128<br>Resources allocated to environmental management and climate change, p. 129<br>Electricity, p. 136-137<br>Circular economy · Consumption of raw materials, p. 139<br>Water cycle, p. 140<br>12.5. Substantially reduce waste generation<br>through prevention, reduction, recycling, and reuse.<br>7. Environmental<br>responsibility<br>Circular economy. 138<br>Waste, p. 142-143<br>SDG 13<br>Climate action<br>13.1. Strengthen resilience and adaptive capacity<br>to climate-related hazards and natural disasters in<br>all countries.<br>1. About Grifols Sustainability as a road map · Grifols 2030 Agenda, p. 24-25<br>7. Environmental<br>responsibility<br>Climate action · The impact of climate change on Grifols’ operations, p. 130-<br>131<br> · Emissions, p. 132-133 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 190<br>SDG Targets<br>Section within the<br>Integrated Annual<br>Report<br>Sub-section within<br>the Integrated Annual<br>Report<br>Detailed information on the contribution<br>Relevant objectives<br>SDG 4<br>Quality education<br>4.3. Ensure equal access for all women and men<br>to affordable and quality technical, vocational, and<br>tertiary education.<br>5. Our people We develop talent, p. 94-95<br>Continuous development, p.96-99<br>4.5. Eliminate gender disparities in education by<br>ensuring equal access to all levels of educational<br>and vocational training for the vulnerable, including<br>persons with disabilities, indigenous peoples, and<br>children in vulnerable situations.<br>6. Impact on society Social action and community<br>investment<br> · Health and well-being, p. 113<br> · Education, p. 116<br>Support for NGOs and foundations · Probitas Foundation: improving the health of the most<br>vulnerable, p. 118-119<br> · Victor Grífols Lucas Foundation: Bioethics as a principle, p.<br>120-121<br> · José Antonio Grífols Lucas Foundation: supporting donor<br>communities, p. 122-123<br>SDG 5<br>Gender equality<br>5.1. End all forms of discrimination against women<br>and girls everywhere.<br>5.5. Ensure equal opportunities for leadership and<br>full and effective participation for women at all<br>levels of decision-making in political, economic,<br>and public life.<br>5. Our people Growing with our team · Diversity and inclusion, p. 91<br> · Anti-discrimination principles and actions, p. 92<br> · Equal opportunities plan, p. 93<br> · A holistic approach to equality, p. 93<br>Fair compensation practices · Equal pay between man and women, p. 100<br> · Equality and gender pay gap, p. 101<br> · Remuneration system, p. 102<br>6. Impact on society Social action and community<br>investment<br> · Sponsorship: Supporting women’s football, p. 114<br>SDG 10<br>Reduced inequalities<br>10.2. Empower and promote the social, economic<br>and political inclusion of all irrespective of age,<br>sex, disability, race, ethnicity, origin, religion or<br>economic or other status.<br>2. Commitment to donors<br>and patients<br>Donation centers in dedicated communities, p. 37<br>Access to treatments, p. 42-43<br>Patient associations, p. 44-45<br>Positive impact on donors and local communities, p. 46-47<br>6. Impact on society We are community · Our principles, p. 107<br> · Our stakeholders, p. 107<br>Our social reach, p. 110<br>Promoting more sustainable public<br>health systems<br> · Improving health system costs, p. 109<br> · The value of our contributions, p. 109<br> · Supporting blood banks, p. 110<br>Social action and community investment, p. 111-117<br>Support for NGOs and foundations · Probitas Foundation: improving the health of the most<br>vulnerable, p. 118-118<br> · Victor Grífols Lucas Foundation: Bioethics as a principle,<br>p. 120-121<br> · José Antonio Grífols Lucas Foundation: supporting donor<br>communities, p. 122-123<br>SDG 16<br>Peace, justice and strong<br>institutions<br>16.5 Substantially reduce corruption and bribery in<br>all its forms.<br>3. Ethical commitment We promote integrity · Integrated anti-corruption model, p. 56-57<br>Grifols Ethics Helpline, p. 61<br>16.10 Ensure public access to information and<br>protect fundamental freedoms, in accordance with<br>national legislation and international agreements.<br>3. Ethical commitment Human rights: a core pillar, p. 51-53<br>We are transparent, p. 58-60 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 191 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>SDG Targets<br>Section within the<br>Integrated Annual<br>Report<br>Sub-section within<br>the Integrated Annual<br>Report<br>Detailed information on the contribution<br>Cross-cutting goal<br>SDG 17<br>Partnerships for the goals<br>17.6 Enhance the global partnership for<br>sustainable development, complemented by multi-stakeholder partnerships that mobilize and share<br>knowledge, expertise, technology and financial<br>resources, to support the achievement of the<br>sustainable development goals in all countries, in<br>particular developing countries.<br>2. Commitment to donors<br>and patients<br>Program to boost plasma self-sufficiency: leading the change, p.31<br>Access to treatments, p. 42-43<br>6. Impact on society Promoting more sustainable public health systems, p. 109-110<br>Support for NGOs and foundations · Probitas Foundation: improving the health of the most<br>vulnerable, p. 118-119<br> · Victor Grífols Lucas Foundation: Bioethics as a principle, p.<br>120-121<br> · José Antonio Grífols Lucas Foundation: supporting donor<br>communities, p. 122-123<br>17.16 Enhance the global partnership for<br>sustainable development, complemented by multi-takeholder partnerships that mobilize and share<br>knowledge, expertise, technology and financial<br>resources, to support the achievement of the<br>sustainable development goals in all countries, in<br>particular developing countries.<br>4. Innovation Treatment innovations · Main Projects in Development, p. 80<br> · Other initiatives for Neurogenerative Diseases, p. 82<br> · Other advances in plasma therapies, p.82<br> · GigaGen, Non-Plasma Innovations, p. 82<br>Digital innovation, p. 84<br>Research support and collaboration · Sponsorship: ISR Program, p. 85<br> · The Grifols chair for the study of cirrhosis, p. 85<br> · Grifols Scientific Awards and research grants, p. 85<br> · Plasmatology Journal, p. 85<br>5. Our people Continuous development · Professional development programs, p. 98<br> · The Grifols Academy, p. 99<br>17.17 Encourage and promote effective public,<br>public-private and civil society partnerships,<br>building on the experience and resourcing<br>strategies of partnerships.<br>6. Impact on society Promoting more sustainable public health systems, p. 109-110<br>Social action and community<br>investment<br> · Environmental issues, p. 117<br>7. Environmental<br>responsibility<br>Waste · Medication waste management, p.143<br>Biodiversity · Natural protected area in North Carolina, p. 144<br> · Besòs river basin in Barcelona, p.145 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 192<br>Annex V: NON-GAAP measures reconciliation<br>FY2022 - NET REVENUE RECONCILIATION CONSTANT CURRENCY<br>In thousands of euros 2022 2021 % Var<br>REPORTED NET REVENUE 6,063,967 4,933,118 22.9%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (518,222)<br>NET REVENUE AT CONSTANT CURRENCY 5,545,745 4,933,118 12.4%<br>In thousands of euros 2022 2021 % Var<br>REPORTED BIOPHARMA NET REVENUE 5,005,382 3,814,983 31.2%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (443,407)<br>REPORTED BIOPHARMA NET REVENUE AT CONSTANT<br>CURRENCY 4,561,975 3,814,983 19.6%<br>In thousands of euros 2022 2021 % Var<br>REPORTED DIAGNOSTIC NET REVENUE 671,292 779,108 (13.8%)<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (45,996)<br>REPORTED DIAGNOSTIC NET REVENUE AT CONSTANT<br>CURRENCY 625,296 779,108 (19.7%)<br>In thousands of euros 2022 2021 % Var<br>REPORTED BIO SUPPLIES NET REVENUE 146,076 115,811 26.1%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (15,003)<br>REPORTED BIO SUPPLIES NET REVENUE AT CONSTANT<br>CURRENCY 131,073 115,811 13.2%<br>In thousands of euros 2022 2021 % Var<br>REPORTED OTHER & INTERSEGMENTS NET REVENUE 241,217 223,216 (8.1%)<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (13,816)<br>REPORTED OTHER & INTERSEGMENTS NET REVENUE AT<br>CONSTANT CURRENCY 227,401 223,216 (1.9%)<br>In thousands of euros 2022 2021 % Var<br>REPORTED U.S. + CANADA NET REVENUE 3,855,607 3,154,548 22.2%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (433,392)<br>U.S. + CANADA NET REVENUE AT CONSTANT CURRENCY 3,422,215 3,154,548 8.5%<br>In thousands of euros 2022 2021 % Var<br>REPORTED EU NET REVENUE 1,032,210 906,449 13.9%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (3,630)<br>EU NET REVENUE AT CONSTANT CURRENCY 1,028,580 906,449 13.5%<br>In thousands of euros 2022 2021 % Var<br>REPORTED RoW NET REVENUE 1,176,150 872,121 34.9%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (81,199)<br>RoW NET REVENUE AT CONSTANT CURRENCY 1,094,951 872,121 25.6%<br>FY 2022 - NET REVENUE RECONCILIATION CONSTANT CURRENCY<br>EXCLUDING BIOTEST<br>In thousands of euros 2022 2021 % Var<br>REPORTED NET REVENUE 5,702,728 4,933,118 15.6%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (518,789)<br>NET REVENUE AT CONSTANT CURRENCY 5,183,939 4,933,118 5.1%<br>In thousands of euros 2022 2021 % Var<br>REPORTED BIOPHARMA NET REVENUE 4,644,143 3,814,983 21.7%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (443,974)<br>REPORTED BIOPHARMA NET REVENUE AT CONSTANT<br>CURRENCY 4,200,169 3,814,983 10.1%<br>In thousands of euros 2022 2021 % Var<br>REPORTED U.S. + CANADA NET REVENUE 3,853,487 3,154,548 22.2%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (433,392)<br>U.S. + CANADA NET REVENUE AT CONSTANT CURRENCY 3,420,095 3,154,548 8.4%<br>In thousands of euros 2022 2021 % Var<br>REPORTED EU NET REVENUE 851,795 906,449 (6.0%)<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (4,658)<br>EU NET REVENUE AT CONSTANT CURRENCY 847,137 906,449 (6.5%)<br>In thousands of euros 2022 2021 % Var<br>REPORTED RoW NET REVENUE 997,446 872,121 14.4%<br>VARIATION DUE TO EXCHANGE RATE EFFECTS (80,739)<br>RoW NET REVENUE AT CONSTANT CURRENCY 916,707 872,121 5.1% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 193 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>In thousands of euros 2022 2021 % Var<br>REPORTED GRIFOLS NET REVENUE 6,063,967 4,933,118 22.9%<br>BIOTEST NET REVENUE 361,239 - -<br>GRIFOLS NET REVENUE STAND-ALONE 5,702,728 4,933,118 15.6%<br>In thousands of euros 2022 2021 % Var<br>R&D RECURRENT EXPENSES IN P&L 361.1 354.9 1.8%<br>R&D CAPITALIZED 36.0 34.7 3.7%<br>R&D DEPRECIATION & AMORTIZATION & WRITE OFFS (43.9) (55.3) (20.6%)<br>R&D CAPEX FIXED ASSETS 0.9 1.3 (32.0%)<br>R&D EXTERNAL (2.8) (6.2) -<br>R&D NET INVESTMENT 351.3 329.3 6.7%<br>In thousands of euros 2022 2021 % Var<br>PP&E ADDITIONS 291,676 266,009 9.6%<br>SOFTWARE ADDITIONS 31,299 33,516 (6.6%)<br>INTEREST CAPITALIZED (25,184) (18,636) 35.1%<br>CAPEX 297,791 280,889 6.0%<br>In millions of euros except ratio 2022 2021<br>NET FINANCIAL DEBT 9,010.1 6,480.3<br>EBITDA ADJUSTED 12M 1,287.2 1,076.8<br>NET LEVERAGE RATIO(1) 7.13x 6.18x<br>(1) Excludes the impact of IFRS 16<br>In thousands of euros 2022 2021 % Var<br>EBIT 805,680 595,064 35.4%<br>D&A 415,339 366,435 13.3%<br>EBITDA REPORTED 1,221,019 961,499 27.0%<br>% NR 20.1% 19.5%<br>% NR without Biotest 21.4%<br>In thousands of euros 2022 2021 % Var<br>EBIT 805,680 595,064 35.4%<br>D&A 415,339 366,435 13.3%<br>NON-RECURRING COSTS (2) 25,866 52,405 (50.6%)<br>EBITDA ADJUSTED 1,246,885 1,013,904 23.0%<br>% NR 20.6% 20.6%<br>% NR without Biotest 21.9%<br>(2) 2022 non-recurring items mainly related to the capital gain due to the acquisition of the remaining Acces Biological's equity capital.<br>as well as the Biotest Next Level (BNL) project aimed at expanding production capacity in Dreieich. Germany. and to develop three key<br>R&D projects (IgG Next Gen. Trimodulin. Fibrinogen), To a lesser extent. includes restructuring. divestment and transaction costs,<br>In thousands of euros 2022 2021 % Var<br>EBIT 805,680 595,064 35.4%<br>D&A 415,339 366,435 13.3%<br>IFRS 16 (99,990) (78,147) 28.0%<br>NON-RECURRING ITEMS (3) 166,174 193,435 (14.1%)<br>EBITDA ADJUSTED 12M 1,287,203 1,076,787 (8.0%)<br>(3) Non-recurring items are mainly related to transaction. restructuring and divestitures costs. as well as the amount of cost savings.<br>operating improvements and synergies on a “run rate” | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 194<br>Annex VI: Socioeconomic impact<br>Grifols determined the socio-economic impact of its operations in<br>terms of wealth generation and job creation in the United States,<br>Spain, Germany, Ireland and United Kingdom. during 2022.<br>An input-output analysis was used for this purpose. Following this<br>approach, it is possible to estimate the outputs associated with<br>Grifols’ activities based on core inputs (expenditures on supplies<br>of goods and services, R&D+i and capital investments, main<br>taxes paid, financial expenses, dividend payments, and employee<br>expenditures based on wages received).<br>SPAIN IRELAND GERMANY: EXCEPT PLASMA CENTERS GERMANY PLASMA CENTERS TOTAL GERMANY % OF PLASMA CENTERS IN GERMANY<br>Economic impact (Millions of euros)<br>Direct 814 150 60 150 211 71%<br>Indirect 354 74 29 65 94 69%<br>Induced 364 81 27 59 86 68%<br>Total impact 1,532 305 117 275 392 70%<br>Impact on the employment (nº people)<br>Direct 4,217 331 124 1,460 1,584 92%<br>Indirect 13,025 1,050 576 1,429 2,005 71%<br>Induced 3,536 222 179 402 581 69%<br>Total employment 20,777 1,603 879 3,291 4,170 79%<br>US: EXCEPT PLASMA<br>CENTERS US: PLASMA CENTERS TOTAL US % OF PLASMA CENTERS IN US<br>Economic impact (Millions of dollars)<br>Direct 2,015 2,864 4,879 59%<br>Indirect 853 1,169 2,022 58%<br>Induced 721 1,040 1,761 59%<br>Total impact 3,589 5,072 8,661 59%<br>Impact on the employment (nº people)<br>Direct 4,132 12,531 16,663 75%<br>Indirect 38,505 100,446 138,951 72%<br>Induced 4,343 6,215 10,558 59%<br>Total employment 46,980 119,192 166,171 72%<br>UK<br>Economic impact (Millions of GBP)<br>Direct 55<br>Indirect 20<br>Induced 16<br>Total impact 91<br>Impact on the employment (nº people)<br>Direct 64<br>Indirect 352<br>Induced 69<br>Total employment 485<br>INPUT-OUTPUT MODEL<br>DIRECT<br>IMPACT<br>INDIRECT<br>IMPACT<br>INDUCED<br>IMPACT<br>MULTIPLIER IMPACT<br>TOTAL IMPACT<br>ECONOMIC IMPACT JOB CREATION<br>The input-output framework is an accounting instrument that<br>represents all production and distribution operations of an economy<br>in a given timeframe. This model enables observing the different<br>flows of intersectoral transactions in a specific economy in a<br>reference year. In addition, it allows us to observe a series of effects<br>about the production of the system, linked to the final demand,<br>exogenous to it, which appear broken down between the direct<br>or initial, indirect and total effects, which suppose the sum of the<br>previous ones. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 195 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Annex VII: Bases for the preparation: scope<br>and methodology – total tax contribution<br>Purpose and scope<br>The purpose of “Fiscal Contribution” section included in Chapter 8<br> “Financial Performance” is to provide information on the taxes paid<br>by the Grifols Group globally in 2022, in an understandable and<br>transparent manner. For this purpose, the information disclosed<br>includes data from the following territories: Spain, the United<br>States, Ireland, Germany and United Kingdom, as these are the<br>most relevant in terms of business volume and presence within the<br>Grifols Group.<br>The measurement has been performed using data obtained from<br>the information systems based on the criteria of PwC’s Total<br>Tax Contribution (CTT) methodology. In addition to the amounts<br>indicated, there may be other tax payments that have not been<br>taken into account because they are not individually identified in the<br>information systems or are not significant in terms of materiality.<br>TTC methodology<br>The Total Tax Contribution methodology measures the total impact<br>of a company’s tax payments. This assessment is made from the<br>point of view of the total contribution of taxes paid directly to the<br>different public administrations as a result of the Grifols’ Group<br>economic activity carried out.<br>In general, the CTT methodology allocates both input and output<br>taxes to each tax year on a cash basis.<br>The key points to be borne in mind in relation to this methodology are:<br>1. It distinguishes between taxes that are a cost to Grifols<br>and taxes collected<br>Taxes borne are those taxes that Grifols has paid to the<br>governments of the different countries in which it operates. These<br>taxes are those which have represented an effective cost for Grifols,<br>such as taxes on profits or certain environmental taxes.<br>Taxes collected are the taxes that have been paid as a result of<br>economic activities of Grifols, they are not the own costs of Grifols.<br>Here the company is collecting taxes from others, on behalf of<br>government, i.e. income taxes collected from employees under a<br>payroll system. However, these amounts are paid into the public<br>coffers as a result of the economic activity carried out by Grifols and<br>should therefore be included in the analysis as they represent tax<br>revenue due to the economic value generated by Grifols.<br>2. TTC Framework classifies taxes under 5 categories for<br>clarification purposes:<br>(i) Profit taxes: includes taxes borne on profits earned by companies<br>such as corporate income tax, business tax and taxes levied as<br>withholding taxes on payments to third parties.<br>(ii) Property taxes: are taxes on the ownership, sale, transfer or<br>occupancy of property.<br>(iii) People (or Employment Taxes): these are employment-related<br>taxes both borne and collected, which include employee income<br>tax withholdings or social security payments payable by both the<br>employee and the Company.<br>(iv) Taxes on Products and Services: take into account indirect<br>taxes on the production and consumption of goods and services,<br>including VAT, customs duties, etc.<br>(v) Planet (Environmental Taxes): taxes on the supply, use or<br>consumption of products and services deemed to affect the<br>environment.<br>3. It includes all tax payments made to Public<br>Administrations<br>In considering the figures contained in this report, it should be<br>taken into account that they include tax payments made to public<br>administrations for items which, due to their characteristics, are of<br>a tax nature, although for historical or cyclical reasons they are not<br>classified as such.<br>In this way, and in line with the philosophy implemented by the<br>OECD in the analysis of a country’s tax burden, contributions<br>to the different administrations in the form of “social security<br>contributions” have also been included in the above data, as<br>they are a compulsory contribution that generally constitutes<br>a significant part of a State’s income and which, due to its tax<br>configuration rather than its contributory nature, is clearly of a tax<br>nature in Spain.<br>The Mirrlees Report 1, which recommends an integration of taxes<br>on labor income and social insurance where these are of a tax<br>and non-contributory nature, takes a similar view. Likewise, the<br>so-called “Lagares Report” considers Social Security contributions<br>to be taxable in nature, when it includes them in its analysis for<br>the reform of the Spanish tax system, and defines them as “a tax<br>that falls directly on labor, although established with very peculiar<br>criteria, its economic effects are crucial for occupation and<br>employment in the Spanish economy”. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 196<br>On the other hand, with regard to the possibility of considering<br>surcharges and interest on late payment as a higher (or lower)<br>contribution, the OECD in its document on the classification as a<br>tax on the various payments to public administrations2, does not<br>expressly refer to interest on late payment and surcharges. In<br>line with this criterion, for the purposes of this report they are not<br>considered as a tax contribution. The same document also clearly<br>indicates how fines and penalties would not be considered as a<br>tax even though they are amounts paid to the Tax Authorities, and<br>therefore should not be considered as a higher contribution. In this<br>sense, we maintain the criterion followed by the OECD, and they are<br>not considered as a higher contribution either.<br>(1) The Mirrlees Report was commissioned by the UK’s IFS and published<br>after four years of work in 2011 under the title “Tax by Design, The Mirrlees<br>Review”. This same report has been studied by experts from the University<br>of Vigo and its conclusions have been included in the document entitled<br> “The Mirrlees Report and Environmental Taxation in Spain”. http://www.ifs.<br>org.uk/mirrleesReview/design<br>(2) https://www.oecd.org/tax/tax-policy/oecd-classification-taxes-interpretative-guide.pdf<br>4. Profit before taxes assumptions made during the<br>preparation of this report<br>The amount of profit before tax excludes intercompany dividends<br>in order to avoid double-counting of the same income of various<br>entities, if that income was distributed as dividends to the other<br>entities of the Group. Such calculation allows to reflect the objective<br>amount of profit before taxes at country levels, and to calculate<br>the objective ETRs since dividends are usually subject to beneficial<br>tax treatment compared to the other types of income (so-called<br> ‘participation exemption’ regime).<br>5. There are certain particularities with regard to Value<br>Added Tax and equivalent taxes<br>Value Added Tax (and equivalent taxes) is characterized as a tax on<br>products and services collected, the amount of which reflects the<br>result of the net payments made by Grifols to the tax authorities in<br>each of the jurisdictions in which it operates in the corresponding<br>period.<br>Therefore, considering the mechanics of VAT, the figure indicated<br>for a given country for this concept includes the positive amount<br>paid to the corresponding tax authorities, resulting from subtracting<br>the VAT accrued from the amount of VAT deducted. In case that<br>for the year as a whole and for a country, the net amount resulting<br>from subtracting VAT accrued from VAT deducted is negative as a<br>result of a refund, no figure shall be shown for this item.<br>On the other hand, VAT amounts that are not refundable because<br>the value chain cannot be continued by means of the reverse<br>charge instrument shall be considered as input tax on products and<br>services, as they represent a cost for the Company. In this regard,<br>in the process of preparing the report, we have been informed that<br>some items related to the net VAT position of companies resident<br>in the United States could not be reported for the purposes of<br>computing the TTC, as a result of the difficulty in obtaining them in<br>terms of time and resources. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 197 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Annex VIII: Social return on investment<br>(SROI) methodology<br>The Social Return on Investment (SROI) method aims to gain a<br>deeper understanding of an organization’s social, environmental<br>and economic impact. The SROI method offers Grifols a valuable<br>cost-benefit analysis, offering the leadership team and investors a<br>solid decision-making tool to assess and optimize the firm’s social<br>and environmental impacts.<br>The SROI uses individual assessments to measure the change in<br>stakeholders’ lives because of Grifols’ activities. The evaluations are<br>quantified and recorded on an impact map, and monetary value is then<br>assigned to the resulting social, environmental and economic impacts.<br>2022 global SROI analysis<br>In 2022, Grifols once again measured the value generated by its<br>U.S. and European donation centers and main plasma medicines<br>as treatment indications for alpha-1 antitrypsin to treat AATD.<br>immunoglobulins for primary immunodeficiencies (PIDD), secondary<br>immunodeficiencies (IDS), chronic inflammatory demyelinating<br>polyneuropathy (CIDP), primary immune thrombocytopenia (ITP),<br>Guillain Barré Syndrome and Myasthenia Gravis (MG). clotting factor<br>VIII. and albumin to treat acute liver disease, hepatorenal syndrome<br>and spontaneous bacterial peritonitis (SBP).<br>Grifols used the SROI (Social Return on Investment) methodology<br>to determine the value generated in 2022 for donors, local<br>communities and patients, and to estimate the global cost-benefit<br>of its treatments.<br> DATA INPUTS > SROI PROCESS > COST & BENEFIT OUTPUT<br>DONORS SROI IMPACT<br>SROI RATIO PATIENTS<br>LOCAL COMMUNITIES<br>SROI<br>METHODOLOGY<br>Developed from tradicional<br>cost-benefit analysis and social<br>accounting<br>Quantitative approach to<br>understand and manage the<br>social-value impacts by assigning<br>a monetary<br>value to the amount of change<br>created<br>ECONOM S Y OCIAL<br>HEALTH<br>VALUE<br>GENERATED<br>IN RELATION<br>TO THE<br>INVESTMENT | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 198<br>Analysis of impact on<br>patients in 2022<br>In 2022, Grifols remained committed to assessing the impact of<br>its main plasma medicines on patients. A study was conducted<br>by an independent expert using the SROI methodology, focusing<br>specifically on the Plasma Procurement and Biopharma business<br>units’ operations, dedicated to the plasma collection, as well as<br>manufacture and distribution of plasma proteins.<br>During this year, new scientific literature facilitated a better<br>demarcation and assessment of quality of life (QOL) indicators, the<br>most reliable metric to evaluate and quantify patients’ progress.<br>One QALY equals one year in perfect health. If an individual’s<br>health falls below this maximum, QALYs accumulate at a rate of<br>less than one per year. The formula for monetarily calculating<br>the improvement in the patient’s quality of life due to treatment<br>considers the value of living one year in perfect health (1 QALY),<br>weighted by the percentage increase of the patient’s improvement.<br>The following summarizes the different economic valuations used to<br>assess the changes in patients based on the variations experienced<br>in their quality of life (QALY), leveraging the distinct methodologies<br>of two sources:<br>- The Boston-based Institute for Clinical and Economic Review<br>(ICER)1. ICER’s latest value assessment framework states a<br>median value of $100,000 per QALY (with an established lower<br>range value of $50,000 and an upper range value of $150,000).<br>This indicator captures the heterogeneity of patients treated,<br>reflecting a global geographic dispersion.<br>- The proposed by Braithwaite et al.202 gives a QALY value of<br>$297,000 in its high range. This indicator mainly reflects the<br>reality of the US.<br>Euro-dollar exchange rate applied €: 1.0501 USD.<br>It is important to mention that this study was prepared in<br>accordance to the principle of prudence and thus, the impact<br>generated by Grifols is probably greater than that reported in this<br>report.<br>The study was carried out by Mr. Hugo Narrillos Roux - PhD with<br>honors in Economics from the Complutense University of Madrid<br>(Spain) – a specialist in social value, and the author of Economía<br>Social: Valoración y medición de la inversión social (método SROI)<br>(Social Economy: Valuation and Measurement of Social Investment<br>(SROI method)). His thesis was titled, “Social Return on Investment:<br>A Good Method to Measure the Social Value Created by Social<br>Firms.” Mr. Narrillos Roux is recognized as an Accredited SROI<br>practitioner from Social Value International, a member-led network<br>focused on social impact and social value. He teaches at several<br>universities and consults for leading global firms to help them<br>evaluate their social impact.<br>1. ICER Institute for Clinical and Economic Review website, icer-review. org.<br>2 . Braithwaite, R. Scott, Meltzer, David, King Jr., Joseph, John,<br>Leslie, Douglas, and Roberts, Mark S. Medical Care, Vol. 46, No. 4<br>(April, 2008), pp. 349-356.<br>Main references:<br>Alpha 1: Augmentation Therapy for<br>_1 Antitrypsin Deficiency: A Meta-Analysis. Chapman, K.R., Stockley, R.A., Dawkins, C., Wilkes, M. M.,<br>Navickis, R. J. COPD: Journal of Chronic Obstructive Pulmonary Disease,<br>6:177–184 (2009)<br>Factor VIII: Pasi, J., Hermans. C., Hakimi,Z., Nazir, J., Aballéa, S., Ezzalfani,<br>M., and Fatoye, F. (2022): Improvement in pain-related quality of life in<br>patients with hemophilia A treated with rFVIIIFc individualized prophylaxis:<br>post hoc analysis from the A-LONG study. Therapeutic Advances in<br>Hematology. 2022, Vol. 13: 1–9<br>PID: The impact of plasma-derived therapies in Europe. The health and<br>economic case for ensuring sustainable supply. Copenhagen Economics.<br>June 2021. Available at: https://www.copenhageneconomics.com/<br>publications/publication/the-impact-of-plasma-derived-therapies-in-europe<br>(website visited on January 25th, 2022).<br>CIDP: Hartung, H., Mallick, R., Bril, V., Lewis, R. A., Sobue, G., … Lawo,<br>J. (2019). Patient reported outcomes with subcutaneous immunoglobulin<br>in chronic inflammatory demyelinating polyneuropathy: the PATH Study.<br>European Journal of Neurology.<br>SID: Benbrahim, O., Viallard, J.-F., Choquet, S., Royer, B., Bauduer, F.,<br>Decaux, O., … Lévy, V. (2018). The use of octagam and gammanorm<br>in immunodeficiency associated with hematological malignancies: a<br>prospective study from 21 French hematology departments. Hematology,<br>24(1), 173–182.<br>ITP: Efficacy and mechanism of intravenous immunoglobulin treatment for<br>immune thrombocytopenia in adults. Ruqayyah J. Almizraq1, Donald R.<br>Branch. Annals of Blood. Vol 6 (March 2021).<br>GBS: Immunoglobulin Use for the Management of Painful Peripheral<br>Neuropathy: A Systematic Review and Meta-Analysis. Z. Panagiotis,<br>Liampas, A., Pozotou, T., Parperis, K., Artemiadis, A., Hadjigeorgiou, G.<br>(2022). Pain And Therapy (2022). 11:1219–1227<br>MG: Porras L.D., Homedes C., Alberti M.A., Santamaria V.V., Casasnovas C.<br>(2022). Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15<br>with Other Functional Scales. Journal of Clinical Medicine. 2022. 11(8).<br>HC: Runken, M. C., Caraceni, P., Fernandez, J., Zipprich, A., Carlton, R., &<br>Bunke, M. (2019). The cost-effectiveness of albumin in the treatment of<br>decompensated cirrhosis in Germany, Italy, and Spain. Health Economics<br>Review, 9(1). | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 199 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Annex IX: Methodology and calculation of the<br>adjusted and unadjusted wage gap<br>The following groups have been excluded from the calculation:<br> • Chairman of Honour<br> • Executive Chairman<br> • Co-Chief Executive Officers<br> • Partial retirees<br> • Expatriates or displaced employees<br> • Employees of foundations<br> • Non-declared employees<br> • Biotest, Plasmavita Healthcare, Grifols Canada, Grifols Canada<br>Therapeutics, Alkahest, GigaGen, Acces Biologicals LLC y Prometic<br>Plasma Res Inc, since these companies are still not 100%<br>integrated into Grifols’ systems and policy framework.<br>In total, 22,311 employees have been included in the wage gap<br>calculation, distributed by country as follows:<br> • United States: 16,459<br> • Spain: 4,138<br> • Germany: 1,386<br> • Ireland: 328<br>The methodology consisted of the use of econometric models that<br>compare the annual salaries at 100% of the occupancy rate of men<br>and women, isolating the effects generated by any and all possible<br>differences identified between the two (socioeconomic factors, job<br>characteristics, etc.).<br>In other words, the adjusted salary gap measures the difference in<br>retribution for the same job or one of equal value and is calculated<br>using the multiple lineal regression model as follows:<br> • For the calculation of the adjusted and unadjusted wage gap, the<br>gross annual fixed salaries of each person at full time have been<br>taken into account.<br> • For the econometric calculation of the adjusted wage gap, the<br>following variables were taken into account: age, seniority,<br>educational level, professional category, contract type, occupancy<br>rate, type of activity, geographical area and performance<br>evaluation.<br> • The results for each country are shown separately, so as not to<br>have to apply a currency exchange rate that distorts the result.<br> • For reasons of confidentiality and protection of personal data,<br>wage gap data are not shown for those professional categories in<br>which there is not a minimum of 3 persons of each sex.<br> • In the case of Ireland, Germany or other small groups, the<br>adjusted wage gap data is not shown because it was not possible<br>to obtain data with sufficient statistical significance using the<br>econometric model. For these cases, only the unadjusted wage<br>gap data is shown. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 200<br>Annex X: Alliances and associations<br>Main Alliances<br>O AECOC: Spanish Association of Manufacturers and Distributors<br>O AENE: Spanish Association of Manufacturers and Distributors of<br>Enteral Nutrition Products<br>O AmCham: American Chamber of Commerce in Spain, China<br>and Thailand<br>O ASEBIO: Spanish Association of Bio Companies<br>O BIOcom Life Sciences Organization of California: California<br>association of bioscience companies and research institutes<br>O Biotechnology Innovation Organization (BIO): the world’s premier<br>biotech trade association whose membership includes industry<br>firms, academic institutions and U.S. state-level centers<br>and organizations<br>O CAEME: Argentine Association for Pharmaceutical and<br>Biotech Products<br>O CBDL: Brazilian Chamber of In Vitro Diagnostics Companies<br>O EMIG: Ethical Medicines Industry Group<br>O EUCOPE: trade association representing small- to medium-sized<br>pharmaceutical and med-tech firms in Europe<br>O EURORDIS: non-governmental patient-driven alliance<br>representing 949 rare disease patient organizations in<br>73 countries<br>O Farmafluid: Spanish Association of Fluid Therapy and Parenteral<br>Nutrition Pharmaceutical Laboratories<br>O Farmaindustria: Italian Association of Pharmaceutical Companies<br>O Global Business Alliance: an association of globally focused U.S.<br>firms that promotes foreign investment in the country<br>O JACRI: Japanese Association of Clinical Reagents Industry<br>O LEEM: French industry association representing drug companies<br>operating in France<br>O MedTech Europe: Trade association representing the medical<br>technology industries, manufacturers of in vitro diagnostics<br>and medical devices operating in Europe and diverse national<br>associations<br>O National Health Council (U.S.): platform for diverse organizations<br>to forge consensus and drive patient-centered health policy<br>O North Carolina BIO: trade association for North Carolina’s life<br>science industry whose membership includes companies<br>and research institutions working in the pharmaceutical,<br>medical device, diagnostic, clinical research and agricultural<br>biotechnology sectors<br>O Pathology Technology Australia: Australian association of<br>manufacturers and distributors of in vitro diagnostic reagents and<br>systems.<br>O PPTA: Plasma Protein Therapeutics Association<br>O SIGRE: not-for-profit organization established to ensure proper<br>environmental management of medicines and their packaging in<br>the home<br>O SINDUSFARMA: Brazilian Association of Pharmaceutical<br>Companies<br>O United States-Spain Council: An organization of U.S. and Spanish<br>leaders who work to cultivate stronger ties between both<br>countries | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 201 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>The following table outlines Grifols’ most significant financial contributions in different industries:<br>ACTIVITY INVOLVEMENT / COMMITMENT 2022 CONTRIBUTION<br>PLASMA INDUSTRY Grifols supports various projects related to the plasma industry, including the joint promotion of a global code of conduct, educational campaigns, access to clinical treatments, procurement of plasma as a raw material, and awareness campaigns on rare diseases. €1,611,622<br>PHARMACEUTICAL INDUSTRY<br>Defense of policies and practices to promote the discovery of and access to life-enhancing medicines and vaccines for people around<br>the world. Efforts to reinforce regulatory systems to ensure maximum safety throughout the value chain, from production to patient<br>administration while acting ethically and professionally in alignment with Grifols Codes of Conduct.(1)<br> €236,054<br>MED-TECH INDUSTRY<br>Efforts to highlight the social value and contribution of medical technologies, facilitating their access to patients, healthcare<br>professionals, operators and healthcare systems. Promotion of value-based innovation to create more sustainable healthcare systems<br>and meet the growing needs and expectations of health and medical-care systems. Adherence to the highest ethical standards for all<br>training initiatives and interactions with healthcare professionals.(2)<br> €249,498<br>BIOTECHNOLOGY INDUSTRY Participation in national non-profit associations of several bio-tech firms, aimed at increasing their social awareness and promoting innovation by advocating for public policies that favor the growth of this essential industry.(3) €257,260<br>(1) IFPMA - Homepage: (https://www.ifpma.org/<br>(2) Medtech Europe – Homepage (https://www.medtecheurope.org/)<br>(3) ICBA – Homepage (https://internationalbiotech.org/about/)<br>Grifols advances social progress through<br>various collaborations with public- and<br>private-sector organizations. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 202<br>AVERAGE WORKFORCE BY COUNTRY<br>2022<br>U.S. 15,669<br>Spain 4,082<br>RoW 2,699<br>Total 22,450<br>AVERAGE WORKFORCE BY AGE<br>2022<br> <30 6,216<br>30-50 11,706<br> >50 4,528<br>Total 22,450<br>AVERAGE WORKFORCE BY REGION AND TYPE OF CONTRACT<br>2022<br>Permanent Temporary Total<br>U.S. 15,665 4 15,669<br>Europe 5,982 254 6,236<br>RoW 535 10 545<br>Total 22,181 268 22,450<br>AVERAGE WORKFORCE BY GENDER AND TYPE OF CONTRACT<br>2022<br>Permanent Temporary Total<br>Women 13,217 145 13,362<br>Men 8,938 124 9,062<br>Not declared 26 0 26<br>Total 22,181 268 22,450<br>AVERAGE WORKFORCE BY GENDER AND WORKING HOURS<br>2022<br>Full time Part time Total<br>Women 12,613 749 13,362<br>Men 8,778 283 9,062<br>Not declared 25 1 26<br>Total 21,417 1,033 22,450<br>AVERAGE WORKFORCE BY WORKING HOURS AND AGE<br>2022<br> <30 30-50 >50 Total<br>Full time 5,818 11,244 4,355 21,417<br>Part time 398 462 173 1,033<br>Total 6,216 11,706 4,528 22,450<br>AVERAGE WORKFORCE BY TYPE OF CONTRACT AND AGE<br>2022<br> <30 30-50 >50 Total<br>Permanent 6,125 11,577 4,478 22,181<br>Temporary 91 128 49 268<br>Total 6,216 11,706 4,528 22,450<br>AVERAGE WORKFORCE BY PROFESSIONAL CATEGORY AND GENDER<br>2022<br>% Women Men Not declared Total<br>Executives 22.4% 77.6% 0.0% 100%<br>Directors 41.2% 58.3% 0.5% 100%<br>Senior management 39.2% 60.8% 0.0% 100%<br>Management 47.4% 52.5% 0.0% 100%<br>Senior professionals 46.6% 53.3% 0.0% 100%<br>Professionals 52.3% 47.6% 0.1% 100%<br>Administrative staff / manufacturing operators 65.3% 34.6% 0.1% 100%<br>Total 60.0% 40.0% 0.0% 100%<br>AVERAGE WORKFORCE BY PROFESSIONAL CATEGORY AND TYPE OF CONTRACT<br>2022<br>Permanent Temporary Total<br>Executives 126 0 126<br>Directors 469 3 472<br>Senior management 568 4 572<br>Management 1,331 7 1,338<br>Senior professionals 1,998 19 2,016<br>Professionals 2,692 61 2,753<br>Administrative staff / manufacturing operators 14,997 175 15,172<br>Total 22,181 268 22,450<br>Annex XI: Tables related to Chapter 5. Our people<br>All tables are related to Grifols Stand-alone, except for those tables indicated in the title that are related to Biotest<br>AVERAGE WORKFORCE | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 203 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>AVERAGE WORKFORCE BY COUNTRY AND GENDER<br>2022<br>Women Men Not declared Total<br>U.S. 9,965 5,679 26 15,669<br>Spain 1,798 2,284 0 4,082<br>RoW 1,599 1,099 0 2,699<br>Total 13,362 9,062 26 22,450<br>AVERAGE WORKFORCE BY PROFESSIONAL CATEGORY AND AGE<br>2022<br>% <30 30-50 >50 Total<br>Executives 0.0% 36.9% 63.1% 100%<br>Directors 0.4% 45.5% 54.1% 100%<br>Senior management 0.6% 54.2% 45.2% 100%<br>Management 3.0% 65.5% 31.6% 100%<br>Senior professionals 8.5% 64.5% 27.0% 100%<br>Professionals 13.9% 65.5% 20.5% 100%<br>Administrative staff / manufacturing operators 37.0% 47.2% 15.8% 100%<br>Total 27.7% 52.1% 20.2% 100%<br>WORKFORCE DISTRIBUTION BY COUNTRY<br>2022 % 2021 % 2020 %<br>Spain 4,217 17.6% 4,163 17.9% 4,292 18.1%<br>U.S. 16,734 69.9% 16,306 70.2% 16,604 70.2%<br>RoW 2,996 12.5% 2,765 11.9% 2,759 11.7%<br>Total 23,947 100.0% 23,234 100% 23,655 100%<br>WORKFORCE DISTRIBUTION BY AGE<br>2022 2021 2020<br> <30 6,859 6,513 6,885<br>30-50 12,241 11,997 12,243<br> >50 4,847 4,724 4,527<br>Total 23,947 23,234 23,655<br>WORKFORCE DISTRIBUTION BY COUNTRY - BIOTEST<br>2022 %<br>Germany 1,796 75.9%<br>Spain 7 0.3%<br>U.S. 0 0.0%<br>RoW 564 23.8%<br>Total 2,367 100%<br>WORKFORCE DISTRIBUTION BY AGE - BIOTEST<br>2022<br> <30 434<br>30-50 1,272<br> >50 661<br>Total 2,367<br>AVERAGE WORKFORCE BY PROFESSIONAL CATEGORY AND WORKING HOURS<br>2022<br>Full time Part time Total<br>Executives 122 4 126<br>Directors 455 17 472<br>Senior management 558 14 572<br>Management 1,294 44 1,338<br>Senior professionals 1,949 67 2,016<br>Professionals 2,668 84 2,753<br>Administrative staff / manufacturing operators 14,370 802 15,172<br>Total 21,417 1,033 22,450<br>WORKFORCE DISTRIBUTION | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 204<br>WORKFORCE DISTRIBUTION BY REGION AND TYPE OF CONTRACT<br>2022 2021 2020<br>Permanent Temporary Total Permanent Temporary Total Permanent Temporary Total<br>U.S. 16,725 9 16,734 16,299 7 16,306 16,597 7 16,604<br>Europe 6,356 318 6,674 6,099 285 6,384 5,990 431 6,421<br>RoW 530 9 539 535 9 544 613 17 630<br>Total 23,611 336 23,947 22,933 301 23,234 23,200 455 23,655<br>WORKFORCE DISTRIBUTION BY GENDER AND TYPE OF CONTRACT<br>2022 2021 2020<br>Permanent Temporary Total Permanent Temporary Total Permanent Temporary Total<br>Women 14,206 182 14,388 13,831 146 13,977 13,921 221 14,142<br>Men 9,366 154 9,520 9,101 155 9,256 9,279 234 9,513<br>Not declared 39 0 39 1 0 1 0 0 0<br>Total 23,611 336 23,947 22,933 301 23,234 23,200 455 23,655<br>% 98.6% 1.4% 100.0% 98.7% 1.3% 100.0% 98.1% 1.9% 100.0%<br>WORKFORCE DISTRIBUTION BY REGION AND TYPE OF CONTRACT - BIOTEST<br>2022<br>Permanent Temporary Total<br>U.S. 000<br>Europe 2,156 209 2,365<br>RoW 202<br>Total 2,158 209 2,367<br>WORKFORCE DISTRIBUTION BY GENDER AND TYPE OF CONTRACT - BIOTEST<br>2022<br>Permanent Temporary Total<br>Women 1,112 157 1,269<br>Men 1,046 52 1,098<br>Total 2,158 209 2,367<br>% 91.2% 8.8% 100% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 205 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>WORKFORCE DISTRIBUTION BY GENDER AND WORKING HOURS<br>2022 2021 2020<br>Full time Part time Total Full time Part time Total Full time Part time Total<br>Women 13,266 1,122 14,388 12,844 1,133 13,977 12,999 1,143 14,142<br>Men 9,168 352 9,520 8,899 357 9,256 9,114 399 9,513<br>Not declared 36 3 39 1 0 1 0 0 0<br>Total 22,470 1,477 23,947 21,744 1,490 23,234 22,113 1,542 23,655<br>% 93.8% 6.2% 100.0% 93.6% 6.4% 100.0% 93.5% 6.5% 100.0%<br>WORKFORCE DISTRIBUTION BY WORKING HOURS AND AGE<br>2022 2021 2020<br> <30 30-50 >50 Total <30 30-50 >50 Total <30 30-50 >50 Total<br>Full time 6,243 11,648 4,579 22,470 5,852 11,418 4,474 21,744 6,172 11,665 4,276 22,113<br>Part time 616 593 268 1,477 661 579 250 1,490 713 578 251 1,542<br>Total 6,859 12,241 4,847 23,947 6,513 11,997 4,724 23,234 6,885 12,243 4,527 23,655<br>WORKFORCE DISTRIBUTION BY GENDER AND WORKING HOURS - BIOTEST<br>2022<br>Full time Part time Total<br>Women 912 357 1,269<br>Men 1,030 68 1,098<br>Total 1,942 425 2,367<br>% 82.0% 18.0% 100%<br>WORKFORCE DISTRIBUTION BY WORKING HOURS AND AGE - BIOTEST<br>2022<br> <30 30-50 >50 Total<br>Full time 377 1,044 521 1,942<br>Part time 57 228 140 425<br>Total 434 1,272 661 2,367 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 206<br>WORKFORCE DISTRIBUTION BY TYPE OF CONTRACT AND AGE<br>2022 2021 2020<br> <30 30-50 >50 Total <30 30-50 >50 Total <30 30-50 >50 Total<br>Permanent 6,763 12,113 4,735 23,611 6,425 11,880 4,628 22,933 6,715 12,052 4,433 23,200<br>Temporary 96 128 112 336 88 117 96 301 170 191 94 455<br>Total 6,859 12,241 4,847 23,947 6,513 11,997 4,724 23,234 6,885 12,243 4,527 23,655<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND GENDER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men<br>Not<br>declared Total Women Men Total<br>Executives 23.8% 76.2% 0.0% 122 28.2% 71.8% 0.0% 149 26.1% 73.9% 142<br>Directors 40.7% 58.9% 0.4% 484 37.6% 62.4% 0.0% 471 36.3% 63.7% 457<br>Senior management 38.8% 61.2% 0.0% 565 41.2% 58.8% 0.0% 582 40.6% 59.4% 584<br>Management 47.1% 52.7% 0.1% 1,337 46.7% 53.3% 0.0% 1,302 46.1% 53.9% 1,305<br>Senior professionals 47.4% 52.6% 0.0% 2,054 47.5% 52.5% 0.0% 2,071 46.0% 54.0% 2,063<br>Professionals 52.4% 47.6% 0.1% 2,799 52.4% 47.6% 0.0% 2,806 51.7% 48.3% 2,763<br>Administrative staff /<br>manufacturing operators 65.6% 34.2% 0.2% 16,586 66.0% 34.0% 0.0% 15,853 65.6% 34.4% 16,341<br>Total 60.1% 39.8% 0.2% 23,947 60.2% 39.8% 0.0% 23,234 59.8% 40.2% 23,655<br>WORKFORCE DISTRIBUTION BY TYPE OF CONTRACT AND AGE - BIOTEST<br>2022<br> <30 30-50 >50 Total<br>Permanent 346 1,173 639 2,158<br>Temporary 88 99 22 209<br>Total 434 1,272 661 2,367<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND GENDER - BIOTEST<br>2022<br>Women Men Total<br>Executives 29.7% 70.3% 37<br>Directors 46.9% 53.1% 209<br>Senior management 52.7% 47.3% 311<br>Management 53.4% 46.6% 191<br>Senior professionals 55.2% 44.8% 279<br>Professionals 80.6% 19.4% 330<br>Administrative staff / manufacturing operators 46.9% 53.1% 1,010<br>Total 53.6% 46.4% 2,367 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 207 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND AGE<br>2022 2021 2020<br> <30 30-50 >50 Total <30 30-50 >50 Total <30 30-50 >50 Total<br>Executives 0.0% 36.9% 63.1% 122 0.0% 38.9% 61.1% 149 0.7% 33.1% 66.2% 142<br>Directors 0.2% 44.0% 55.8% 484 0.6% 42.9% 56.5% 471 0.4% 41.8% 57.8% 457<br>Senior management 0.4% 54.0% 45.7% 565 0.9% 51.7% 47.4% 582 0.2% 52.4% 47.4% 584<br>Management 2.2% 64.9% 32.8% 1,337 2.8% 64.0% 33.2% 1,302 2.0% 64.7% 33.3% 1,305<br>Senior professionals 7.9% 64.0% 28.1% 2,054 8.1% 64.9% 27.0% 2,071 7.8% 65.2% 27.0% 2,063<br>Professionals 13.7% 64.8% 21.5% 2,799 13.6% 65.6% 20.8% 2,806 16.3% 63.9% 19.8% 2,763<br>Administrative staff /<br>manufacturing operators 37.9% 46.3% 15.8% 16,586 37.3% 46.8% 15.9% 15,853 38.2% 47.4% 14.4% 16,341<br>Total 28.6% 51.1% 20.2% 23,947 28.0% 51.6% 20.3% 23,234 29.1% 51.8% 19.1% 23,655<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND TYPE OF CONTRACT<br>2022 2021 2020<br>Permanent Temporary Total Permanent Temporary Total Permanent Temporary Total<br>Executives 121 1 122 148 1 149 139 3 142<br>Directors 481 3 484 467 4 471 455 2 457<br>Senior management 559 6 565 577 5 582 580 4 584<br>Management 1,318 19 1,337 1,289 13 1,302 1,293 12 1,305<br>Senior professionals 2,033 21 2,054 2,050 21 2,071 2,041 22 2,063<br>Professionals 2,728 71 2,799 2,723 83 2,806 2,666 97 2,763<br>Administrative staff /<br>manufacturing operators 16,371 215 16,586 15,679 174 15,853 16,026 315 16,341<br>Total 23,611 336 23,947 22,933 301 23,234 23,200 455 23,655<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND TYPE OF CONTRACT - BIOTEST<br>2022<br>Permanent Temporary Total<br>Executives 37 0 37<br>Directors 203 6 209<br>Senior management 281 30 311<br>Management 181 10 191<br>Senior professionals 262 17 279<br>Professionals 278 52 330<br>Administrative staff / manufacturing operators 916 94 1,010<br>Total 2,158 209 2,367 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 208<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND AGE - BIOTEST<br>2022<br> <30 30-50 >50 Total<br>Executives 0.0% 32.4% 67.6% 37<br>Directors 0.5% 49.3% 50.2% 209<br>Senior management 9.6% 59.8% 30.5% 311<br>Management 3.1% 70.7% 26.2% 191<br>Senior professionals 14.3% 68.1% 17.6% 279<br>Professionals 23.9% 52.4% 23.6% 330<br>Administrative staff / manufacturing operators 27.5% 46.8% 25.6% 1,010<br>Total 18.3% 53.7% 27.9% 2,367<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND WORKING HOURS<br>2022 2021 2020<br>Full time Part time Total Full time Part time Total Full time Part time Total<br>Executives 122 0 122 148 1 149 142 0 142<br>Directors 449 35 484 433 38 471 416 41 457<br>Senior management 557 8 565 577 5 582 578 6 584<br>Management 1,303 34 1,337 1,273 29 1,302 1,275 30 1,305<br>Senior professionals 2,001 53 2,054 2,014 57 2,071 2,006 57 2,063<br>Professionals 2,696 103 2,799 2,702 104 2,806 2,653 110 2,763<br>Administrative staff /<br>manufacturing operators 15,342 1,244 16,586 14,597 1,256 15,853 15,043 1,298 16,341<br>Total 22,470 1,477 23,947 21,744 1,490 23,234 22,113 1,542 23,655<br>WORKFORCE DISTRIBUTION BY PROFESSIONAL CATEGORY AND WORKING HOURS - BIOTEST<br>2022<br>Full time Part time Total<br>Executives 34 3 37<br>Directors 180 29 209<br>Senior management 229 82 311<br>Management 172 19 191<br>Senior professionals 220 59 279<br>Professionals 260 70 330<br>Administrative staff / manufacturing operators 847 163 1,010<br>Total 1,942 425 2,367 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 209 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>WORKFORCE DISTRIBUTION BY COUNTRY AND GENDER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men<br>Not<br>declared Total Women Men Total<br>U.S. 10,655 6,041 38 16,734 10,424 5,881 1 16,306 10,520 6,084 16,604<br>Spain 1,877 2,340 0 4,217 1,867 2,296 0 4,163 1,942 2,350 4,292<br>RoW 1,856 1,139 1 2,996 1,686 1,079 0 2,765 1,680 1,079 2,759<br>Total 14,388 9,520 39 23,947 13,977 9,256 1 23,234 14,142 9,513 23,655<br>EMPLOYEE NEW HIRES<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men<br>Not<br>declared Total Women Men Total<br>Total number of employees 14,388 9,520 39 23,947 13,977 9,256 1 23,234 14,142 9,513 23,655<br>Joiners* 8,296 3,208 64 11,568 7,073 2,306 0 9,379 3,041 1,921 4,962<br>Ratio (joiners/number<br>of employees) 57.7% 33.7% 164.1% 48.3% 50.6% 24.9% 0.0% 40.4% 21.5% 20.2% 21.0%<br>Note: Employees from acquisitions on the transaction date are not included as joiners.<br>WORKFORCE DISTRIBUTION BY COUNTRY AND GENDER - BIOTEST<br>2022<br>Women Men Total<br>Germany 840 956 1,796<br>Spain 5 2 7<br>U.S. 000<br>RoW 424 140 564<br>Total 1,269 1,098 2,367<br>EMPLOYEE NEW HIRES - BIOTEST<br>2022<br>Women Men Total<br>Total number of employees 1,269 1,098 2,367<br>Joiners* 362 220 582<br>Ratio (joiners/number of employees) 28.5% 20.0% 24.6%<br>*Note: Employees from acquisitions on the transaction date are not included as joiners.<br>JOINERS AND LEAVERS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 210<br>EMPLOYEE TURNOVER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men<br>Not<br>declared Total Women Men Total<br>Total number of employees 14,388 9,520 39 23,947 13,977 9,256 1 23,234 14,142 9,513 23,655<br>Leavers 7,666 2,885 31 10,582 7,673 2,814 0 10,487 5,552 2,136 7,688<br>Ratio (leavers/number<br>of employees) 53.3% 30.3% 79.5% 44.2% 54.9% 30.4% 0.0% 45.1% 39.3% 22.5% 32.5%<br>LEAVERS 2022<br>Voluntary Involuntary Total<br>Executives 7% 15% 21%<br>Directors 8% 9% 17%<br>Senior management 8% 6% 13%<br>Management 8% 5% 14%<br>Senior professionals 10% 5% 15%<br>Professionals 13% 7% 19%<br>Administrative staff / manufacturing operators 47% 10% 56%<br>Total 36% 9% 44%<br>LEAVERS BY PROFESSIONAL CATEGORY<br>2022<br>Executives 26<br>Directors 80<br>Senior management 75<br>Management 186<br>Senior professionals 308<br>Professionals 537<br>Administrative staff / manufacturing operators 9,370<br>Total 10,582<br>LEAVERS BY PROFESSIONAL CATEGORY - BIOTEST<br>2022<br>Executives 3<br>Directors 15<br>Senior management 43<br>Management 17<br>Senior professionals 17<br>Professionals 60<br>Administrative staff / manufacturing operators 177<br>Total 332<br>EMPLOYEE TURNOVER - BIOTEST<br>2022<br>Women Men Total<br>Total number of employees 1,269 1,098 2,367<br>Leavers 227 105 332<br>Ratio (leavers/number of employees) 17.9% 9.6% 14.0% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 211 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>DISMISSAL BY COUNTRY AND GENDER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men Total Women Men Total<br>Spain 25 40 0 65 83 47 130 10 17 27<br>U.S. 977 500 8 1,485 455 254 709 743 331 1,074<br>RoW 52 23 0 75 118 78 196 67 31 98<br>Total 1,054 563 8 1,625 656 379 1,035 820 379 1,199<br>% 64.9% 34.6% 0.5% 100.0% 63.4% 36.6% 100.0% 68.4% 31.6% 100.0%<br>DISMISSAL BY PROFESSIONAL CATEGORY AND COUNTRY<br>2022 2021 2020<br>Spain U.S. RoW Spain U.S. RoW Spain U.S. RoW<br>Executives 2 10 0 0 4 0 1 0 0<br>Directors 3 17 6 1 13 3 1 7 1<br>Senior management 9 8 2 1 8 4 2 4 1<br>Management 13 35 4 3 12 14 0 6 5<br>Senior professionals 9 53 5 7 22 20 1 16 4<br>Professionals 6 114 13 9 32 42 1 40 13<br>Administrative staff / manufacturing operators 23 1,248 45 109 618 113 21 1,001 74<br>Total 65 1,485 75 130 709 196 27 1,074 98<br>DISMISSALS BY COUNTRY AND GENDER - BIOTEST<br>2022<br>Women Men Total<br>Germany 14 17 31<br>Spain 0 0 0<br>U.S. 0 0 0<br>RoW 25 6 31<br>Total 39 23 62<br>% 62.9% 37.1% 100.0%<br>DISMISSALS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 212<br>DISMISSAL BY PROFESSIONAL CATEGORY AND COUNTRY - BIOTEST<br>2022<br>Germany Spain U.S. RoW<br>Executives 1 0 0 0<br>Directors 3 0 0 0<br>Senior management 0 0 0 2<br>Management 1007<br>Senior Professionals 1 0 0 0<br>Professionals 1 0 0 12<br>Administrative staff / Manufacturing operators 24 0 0 10<br>Total 31 0 0 31<br>DISMISSAL BY COUNTRY AND AGE<br>2022 2021 2020<br> <30 30-50 >50 Total <30 30-50 >50 Total <30 30-50 >50 Total<br>Spain 4 37 24 65 12 99 19 130 8 16 3 27<br>U.S. 606 680 199 1,485 272 339 98 709 523 446 105 1,074<br>RoW 14 34 27 75 46 102 48 196 29 47 22 98<br>Total 624 751 250 1,625 330 540 165 1,035 560 509 130 1,199<br>% 38.4% 46.2% 15.4% 100.0% 31.9% 52.2% 15.9% 100.0% 46.7% 42.5% 10.8% 100.0%<br>DISMISSAL BY COUNTRY AND AGE - BIOTEST<br>2022<br> <30 30-50 >50 Total<br>Germany 11 13 7 31<br>Spain 0 0 0 0<br>U.S. 0 0 0 0<br>RoW 8 16 7 31<br>Total 19 29 14 62<br>% 30.6% 46.8% 22.6% 100.0% | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 213 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>BREAKDOWN OF ABSEENTISM BY TYPE AND COUNTRY<br>2022 2021 2020<br>Spain U.S. RoW Total Spain U.S. RoW Total Spain U.S. RoW Total<br>Illness 380,924 586,913 315,499 1,283,336 370,163 548,671 234,421 1,153,255 311,932 564,523 293,958 1,170,413<br>Work accident 66,324 36,928 3,494 106,746 55,485 40,059 3,714 99,258 66,809 35,159 4,314 106,282<br>Maternity /<br>Paternity 127,633 112,717 135,339 375,689 94,018 157,978 120,017 372,013 81,363 145,309 116,389 343,061<br>Paid leave 50,080 120,422 36,336 206,838 83,644 259,507 18,002 361,153 115,581 425,152 11,919 552,652<br>Unpaid leave 1,582 177,047 26,371 205,000 1,958 193,785 16,322 212,065 1,870 254,972 18,137 274,979<br>Total 626,542 1,034,027 517,040 2,177,610 605,268 1,200,000 392,476 2,197,744 577,555 1,425,115 444,717 2,447,387<br>BREAKDOWN OF ABSEENTISM BY TYPE AND GENDER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women % Men % Women Men Total Women % Men % Women Men Total Women % Men %<br>Illness 905,342 377,063 932 1,283,337 71% 29% 802,452 350,803 1,153,255 70% 30% 838,705 331,708 1,170,413 72% 28%<br>Work accident 65,402 41,345 0 106,747 61% 39% 61,599 37,659 99,258 62% 38% 62,076 44,210 106,286 58% 42%<br>Maternity / Paternity 298,566 77,123 0 375,689 79% 21% 312,418 59,594 372,012 84% 16% 302,923 40,138 343,061 88% 12%<br>Paid leave 134,921 71,836 80 206,837 65% 35% 245,544 115,570 361,114 68% 32% 367,349 185,301 552,650 66% 34%<br>Unpaid leave 141,841 63,159 0 205,000 69% 31% 147,731 64,333 212,064 70% 30% 213,239 61,920 275,159 77% 23%<br>Total 1,546,072 630,526 1,012 2,177,610 71% 29% 1,569,744 627,959 2,197,703 71% 29% 1,784,292 663,277 2,447,569 73% 27%<br>BREAKDOWN OF ABSEENTISM BY TYPE AND COUNTRY - BIOTEST<br>Germany 2022*<br>Total<br>Illness 239,233<br>Work accident 4,269<br>Maternity / Paternity 117,082<br>Paid leave 104,505<br>Unpaid leave 3,994<br>Total 469,083<br>*Only German entities included<br>BREAKDOWN OF ABSEENTISM BY TYPE AND GENDER - BIOTEST<br>2022<br>Women Men Total Women % Men %<br>Illness 116,069 123,164 239,233 49% 51%<br>Work accident 554 3,715 4,269 13% 87%<br>Maternity / Paternity 104,782 12,300 117,082 89% 11%<br>Paid leave 37,850 66,655 104,505 36% 64%<br>Unpaid leave 2,164 1,830 3,994 54% 46%<br>Total 261,420 207,664 469,083 56% 44%<br>*Only german entities included<br>ABSENTEEISM | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 214<br>BREAKDOWN IN TRAINING HOURS BY PROFESSIONAL CATEGORY AND GENDER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men<br>Not<br>declared Total Women Men Total<br>Executives 512 1,349 0 1,861 707 1,482 0 2,189 611 1,453 2,064<br>Directors 6,432 8,889 46 15,367 4,060 7,024 0 11,084 4,533 6,970 11,503<br>Senior management 8,280 11,647 0 19,927 10,567 12,688 0 23,255 9,459 14,913 24,372<br>Management 20,143 26,018 12 46,173 20,183 23,960 0 44,143 19,925 24,643 44,568<br>Senior professionals 46,076 56,366 17 102,459 38,309 45,206 0 83,515 37,947 44,324 82,271<br>Professionals 102,709 92,304 434 195,447 122,234 105,079 0 227,313 52,807 60,317 113,124<br>Administrative staff /<br>manufacturing operators 3,127,749 1,196,391 13,440 4,337,580 1,699,131 728,586 231 2,427,948 1,106,114 631,046 1,737,160<br>Total 3,311,901 1,392,964 13,949 4,718,814 1,895,191 924,025 231 2,819,447 1,231,396 783,666 2,015,062<br>% by gender 70% 30% 0% 100% 67% 33% 0% 100% 61% 39% 100%<br>Average workforce 13,362 9,062 26 22,450 11,998 8,624 1 20,623 11,719 8,562 20,281<br>Ratio 247.66 153.71 536.5 938.07 157.96 107.15 231.00 136.71 105.08 91.53 99.36<br>BREAKDOWN IN TRAINING HOURS BY PROFESSIONAL CATEGORY AND GENDER - BIOTEST<br>2022<br>Women Men Total<br>Executives 218 545 763<br>Directors 2,058 2,352 4,409<br>Senior management 3,673 3,000 6,673<br>Management 2,298 1,860 4,158<br>Senior professionals 3,897 2,714 6,611<br>Professionals 6,919 1,392 8,311<br>Administrative staff / manufacturing operators 10,025 10,749 20,775<br>Total 29,088 22,612 51,700<br>% by gender 56% 44% 100%<br>TRAINING HOURS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 215 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>BREAKDOWN IN TRAINING HOURS BY COUNTRY AND GENDER<br>2022 2021 2020<br>Women Men<br>Not<br>declared Total Women Men<br>Not<br>declared Total Women Men Total<br>U.S. 3,105,514 1,190,597 13,949 4,310,060 1,681,538 730,020 231 2,411,789 988,337 543,680 1,532,017<br>Spain 115,414 153,995 0 269,409 99,756 133,292 0 233,048 153,864 173,571 327,435<br>RoW 90,972 48,373 0 139,345 113,897 60,713 0 174,610 89,195 66,415 155,610<br>Total 3,311,900 1,392,965 13,949 4,718,814 1,895,191 924,025 231 2,819,447 1,231,396 783,666 2,015,062<br>MANAGERS TRAINED IN LEADERSHIP<br>2022 2021 2020<br>Managers trained 583 481 594<br>BREAKDOWN IN TRAINING HOURS IN HEALTH, SAFETY AND ENVIRONMENT<br>2022 2021 2020<br>Total 170,240 141,418 116,410<br>BREAKDOWN IN TRAINING HOURS IN HEALTH, SAFETY AND ENVIRONMENT -<br>BIOTEST<br>2022<br>Total 5,230<br>THE GRIFOLS ACADEMY - PLASMAPHERESIS<br>2022 2021 2020<br>Employess trained 13,736 9,731 6,225<br>Participants on campuses 893 495 256<br>Distance participants 110 85 100<br>Online hours 39,099 42,492 23,783<br>Hours of distance training 2,468 1,631 1,496<br>THE GRIFOLS ACADEMY - IMMUNOHEMATOLOGY<br>2022 2021 2020<br>Professionals trained on transfussional medicine 5,518 4,939 3,575<br>Total educational programs 23 20 15<br>Webinar 19 19 15<br>Courses 2 0 0<br>Practical workshops 2 1 0<br>TRAINED STAFF<br>2022 2021 2020<br>Graduates 8 6 8<br>Grants awarded 403 428 449<br>THE GRIFOLS ACADEMY - PROFESSIONAL DEVELOPMENT<br>2022 2021 2020<br>Employee participants 2,001 2,068 3,706<br>Number of training sessions 135 163 249<br>Online training hours 4,467.75 5,630 6,398<br>BREAKDOWN IN TRAINING HOURS BY COUNTRY AND GENDER - BIOTEST<br>2022<br>Women Men Total<br>Germany 16,649 18,948 35,597<br>Spain 377 80 457<br>U.S. 0 0 0<br>RoW 12,062 3,584 15,646<br>Total 29,088 22,612 51,700 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 216<br>ACCIDENT RATE<br>U.S. 2022 U.S. 2021 Spain 2022 Spain 2021 Ireland 2022 Ireland 2021 Germany 2022 Germany 2021<br>Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men<br>Total number of work<br>accidents with leave* (LTI)<br>withour leave (NLTI) and<br>first aid (FA)<br> 928 373 605 222 90 122 87 130 7 3 1 2 63 13 53 14<br>Total number of work<br>accidents with leave** (LTI) 76 19 50 18 26 42 27 44 0 1 1 2 20 4 27 9<br>Hours worked 19,160,137 11,166,314 17,279,592 10,729,324 2,939,603 3,724,420 2,808,682 3,661,913 259,428 339,417 194,544 276,626 1,383,458 664,814 1,655,169 673,024<br>Accident Frequency<br>Index*** 4.0 1.7 2.9 1.7 8.8 11.3 9.6 12.0 0.00 2.9 5.1 7.2 14.5 6.0 16.3 13.4<br>Severity Index**** 0.11 0.09 0.04 0.06 0.29 0.31 0.21 0.35 0.00 0.00 0.07 0.03 0.14 0.10 0.22 0.13<br>Professional illnesses 0 0 - - 0 0 - - 0 0 - - 0 0 - -<br>ACCIDENT RATE - BIOTEST<br> 2022<br>Women Men<br>Total number of work accidents with leave* (LTI) without leave (NLTI) and first aid (FA) 61 26<br>Total number of work accidents with leave** (LTI) 9 23<br>Hours worked 1,451,784 1,792,284<br>Accident Frequency Index*** 6.2 12.8<br>Severity Index**** 0.26 0.05<br>*Only german entities are included<br>ACCIDENT RATE<br>*Total number of accidents with sick leave (non itinere) without sick leave and first aid.<br>**Total number of accidents with sick leave (non itinere) excluding COVID<br>***Number of occupational accidents with sick leave (non itinere) excluding COVID / total no, of actual hours worked *10^6<br>****Nº of days not worked due to occupational accidents with sick leave (non itinere) excluding COVID /nº of actual hours worked *10^3).<br>The days lost are counted as the difference between the calendar days (without discounting holidays or vacations in the calculation) between the date of discharge and the date of sick leave. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 217 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>SPAIN - EUROS<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br>Executives Women 287,311.2 212,963.7 236,614.2 Men 283,288.9 270,613.6 293,358.1<br>Directors Women 106,426.4 99,625.6 104,228.4 Men 122,761.5 120,321.9 124,396.9<br>Senior management Women 77,615.6 77,568.5 78,342.0 Men 82,403.3 81,002.8 80,413.0<br>Management Women 56,150.6 55,164.9 54,357.8 Men 59,679.4 59,317.4 58,921.7<br>Senior professionals Women 42,881.6 41,756.0 41,585.4 Men 46,370.8 45,345.3 44,829.2<br>Professionals Women 37,776.2 36,836.7 36,119.2 Men 39,319.5 38,559.2 37,893.0<br>Admin/manuf. operators Women 28,202.0 27,597.7 27,048.6 Men 28,774.1 28,136.4 27,700.6<br>U.S. - USD<br>Plasma centers<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br>Executives Women 423,128.9 377,434.2 352,263.5 Men 327,646.3 401,357.4 380,995.7<br>Directors Women 200,068.6 200,302.6 208,555.6 Men 227,863.1 214,532.9 217,271.4<br>Senior management Women 158,824.1 144,350.6 152,708.0 Men 162,299.8 158,173.6 150,236.0<br>Management Women 105,920.4 98,616.3 104,709.3 Men 111,852.3 108,925.6 110,151.9<br>Senior professionals Women 90,679.2 85,525.7 86,063.6 Men 93,429.4 91,855.2 90,880.2<br>Professionals Women 67,403.6 62,362.5 62,882.7 Men 70,289.3 65,102.4 66,155.5<br>Admin/manuf. operators Women 42,367.8 37,798.8 35,659.4 Men 41,653.4 37,421.6 35,017.3<br>U.S. - USD<br>Rest of activities<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br>Executives Women 431,673.0 303,731.8 303,731.8 Men 402,767.9 406,172.7 407,974.4<br>Directors Women 222,949.8 205,835.1 207,781.0 Men 230,487.9 217,810.3 219,348.1<br>Senior management Women 170,195.2 165,250.4 168,071.5 Men 177,603.8 166,667.3 168,751.0<br>Management Women 133,476.6 124,956.6 125,690.3 Men 139,899.7 131,632.8 132,194.5<br>Senior professionals Women 112,693.1 104,338.8 104,468.4 Men 112,378.6 105,809.3 106,722.8<br>Professionals Women 80,065.1 73,199.3 71,969.8 Men 83,287.4 77,673.7 77,004.3<br>Admin/manuf. operators Women 60,957.0 57,175.9 57,175.5 Men 63,889.0 61,328.9 59,884.6<br>IRELAND - EUROS<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br>Executives Women n/a n/a n/a Men n/a n/a n/a<br>Directors Women n/a n/a n/a Men n/a n/a n/a<br>Senior management Women 110,980.0 115,833.3 n/a Men 119,091.7 108,211.1 n/a<br>Management Women 70,401.7 69,802.4 68,352.2 Men 80,401.0 73,069.3 77,902.6<br>Senior professionals Women 55,616.3 52,880.6 52,791.0 Men 59,794.8 54,338.6 52,654.0<br>Professionals Women 45,099.1 43,448.2 44,874.8 Men 48,099.6 45,496.2 46,715.1<br>Admin/manuf. operators Women 37,382.6 37,401.8 36,471.1 Men 36,875.3 37,545.3 37,221.7<br>AVERAGE RETRIBUTIONS | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 218<br>GERMANY - EUROS<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br>Executives Women n/a n/a n/a Men n/a n/a n/a<br>Directors Women 172,301.1 175,768.2 172,018.2 Men 183,879.9 162,279.9 158,361.4<br>Senior management Women 91,136.0 97,142.7 93,098.6 Men 116,751.0 116,580.1 115,787.1<br>Management Women 83,347.3 76,584.4 75,927.0 Men 88,562.4 84,118.2 83,514.7<br>Senior professionals Women 58,765.4 57,413.9 55,902.3 Men 60,060.9 64,481.7 60,519.8<br>Professionals Women 62,654.9 60,365.9 59,479.1 Men 60,651.4 57,897.2 61,649.6<br>Admin./Manuf. Operators Women 34,632.7 28,882.8 28,349.3 Men 33,317.0 28,014.3 27,632.7<br>AVERAGE WAGE* BY AGE<br>SPAIN - EUROS<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br> <30 33,146.4 31,989.2 30,569.3<br>30-50 41,938.6 40,765.5 39,790.9<br> >50 58,172.8 59,117.1 58,703.3<br>AVERAGE WAGE* BY AGE<br>U.S. - USD<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br> <30 40,800.6 36,112.0 34,501.9<br>30-50 62,434.9 57,846.3 58,880.9<br> >50 89,849.2 86,462.3 92,155.3<br>AVERAGE WAGE* BY AGE<br>IRELAND - EUROS<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br> <30 48,304.7 46,946.5 44,382.0<br>30-50 57,997.7 55,937.7 56,338.7<br> >50 82,253.7 89,154.0 95,269.4<br>AVERAGE WAGE* BY AGE<br>GERMANY - EUROS<br>Fixed Wage-Average 2022 Fixed Wage- Average 2021 Fixed Wage- Average 2020<br> <30 36,957.2 30,948.0 30,762.5<br>30-50 44,162.1 39,398.9 38,132.7<br> >50 53,524.1 50,220.4 49,258.6<br>AVERAGE RETRIBUTION OF BOARD MEMBERS AND EXECUTIVES BY GENDER<br>Euros 2022 2021 2020<br>Women Men Total Women Men Total Women Men Total<br>Total average salary 250,329.3 292,935.3 277,054.2 223,249.3 278,680.7 259,405.0 217,543.0 273,101.7 254,582.0<br>Executives. employees and Board Members 186 313 499 177 332 509 170 340 510<br>Gender pay gap 14.50% 19.90% 20.30%<br>* To avoid distorting the results. the average fixed salary excludes salaries based on seniority or individual/personal events | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 219 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>SPAIN<br>Adjusted Gender<br>Pay Gap 2022<br>Gender Pay Gap<br>2022<br>Adjusted Gender<br>Pay Gap 2021<br>Gender Pay Gap<br>2021<br>Adjusted Gender<br>Pay Gap 2020<br>Gender Pay Gap<br>2020<br>Executives n/a -1.40% n/a 21.30% n/a 19.30%<br>Directors 6.50% 13.30% 17.20% 17.20% n/a 16.20%<br>Senior management 5.30% 5.80% 3.50% 4.20% 1.20% 2.60%<br>Management 4.40% 5.90% 6.30% 7.00% 6.80% 7.70%<br>Senior professionals 4.00% 7.50% 3.10% 7.90% 4.30% 7.20%<br>Professionals 3.00% 3.90% 2.30% 4.50% 3.90% 4.70%<br>Admin/manuf. operators 0.90% 2.00% 0.80% 1.90% 0.70% 2.40%<br>U.S. - Plasma centers<br>Adjusted Gender<br>Pay Gap 2022<br>Gender Pay Gap<br>2022<br>Adjusted Gender<br>Pay Gap 2021<br>Gender Pay Gap<br>2021<br>Adjusted Gender<br>Pay Gap 2020<br>Gender Pay Gap<br>2020<br>Executives n/a -29.10% n/a 6.00% n/a 7.50%<br>Directors 2.80% 12.20% -1.20% 6.60% n/a 4.00%<br>Senior management n/a 2.10% n/a 8.70% n/a -1.60%<br>Management 1.80% 5.30% 6.30% 9.50% n/a 4.90%<br>Senior professionals -0.60% 2.90% 5.40% 6.90% 5.00% 5.30%<br>Professionals 3.70% 4.10% 4.40% 4.20% 5.10% 4.90%<br>Admin/manuf. operators -2.50% -1.70% -1.50% -1.00% -1.50% -1.80%<br>CONTRIBUTION TO LONG-TERM SAVING SYSTEMS<br>Miles de euros 2022 2021 2020<br>Women Men Total Women Men Total Women Men Total<br>Spain 448.7 584.1 1,032.8 419.3 528.5 947.8 390.6 505.1 895.7<br>U.S. 15,406.4 15,652.4 31,058.8 12,426.1 13,539.4 25,965.5 12,431.0 14,462.0 26,893.0<br>RoW 384.4 412.2 796.6 435.0 403.6 838.6 298.3 289.1 587.4<br>Total 16,239.5 16,648.7 32,888.2 13,280.4 14,471.5 27,751.9 13,119.9 15,256.2 28,376.1<br>% 49.4% 50.6% 100.0% 47.9% 52.1% 100.0% 46.2% 53.8% 100.0%<br>GENDER GAP | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 220<br>U.S. - Rest of activities<br>Adjusted Gender<br>Pay Gap 2022<br>Gender Pay Gap<br>2022<br>Adjusted Gender<br>Pay Gap 2021<br>Gender Pay Gap<br>2021<br>Adjusted Gender<br>Pay Gap 2020<br>Gender Pay Gap<br>2020<br>Executives n/a -7.20% n/a 25.20% n/a 24.00%<br>Directors 1.30% 3.30% 5.20% 5.50% 4.60% 4.80%<br>Senior management 2.50% 4.20% -1.00% 0.90% -2.00% 0.40%<br>Management 6.70% 4.60% 4.50% 5.10% 5.00% 5.00%<br>Senior professionals 1.30% -0.30% 3.20% 1.40% 3.00% 1.90%<br>Professionals 2.30% 3.90% 1.80% 5.80% 5.90% 6.60%<br>Admins, / Manuf, Operators 4.50% 4.60% 5.20% 6.80% 3.60% 4.60%<br>IRELAND<br>Adjusted Gender<br>Pay Gap 2022<br>Gender Pay Gap<br>2022<br>Adjusted Gender<br>Pay Gap 2021<br>Gender Pay Gap<br>2021<br>Adjusted Gender<br>Pay Gap 2020<br>Gender Pay Gap<br>2020<br>Executives n/a n/a n/a n/a n/a n/a<br>Directors n/a n/a n/a n/a n/a n/a<br>Senior management n/a 6.80% n/a -7.00% n/a n/a<br>Management n/a 12.40% n/a 4.50% n/a 12.30%<br>Senior professionals 4.90% 7.00% -1.00% 2.70% n/a -0.30%<br>Professionals n/a 6.20% 1.80% 4.50% n/a 3.90%<br>Admins, / Manuf, Operators -1.00% -1.40% -1.00% 0.40% n/a 2.00%<br>GERMANY<br>%<br>Adjusted Gender<br>Pay Gap 2022<br>Gender Pay Gap<br>2022<br>Adjusted Gender<br>Pay Gap 2021<br>Gender Pay Gap<br>2021<br>Adjusted Gender<br>Pay Gap 2020<br>Gender Pay Gap<br>2020<br>Executives n/a n/a n/a n/a n/a n/a<br>Directors n/a 6.30% n/a -8.30% n/a -8.60%<br>Senior management n/a 21.90% n/a 16.70% n/a 19.60%<br>Management n/a 5.90% n/a 9.00% n/a 9.10%<br>Senior professionals n/a 2.20% 8.90% 11.00% n/a 7.60%<br>Professionals 2.10% -3.30% -0.70% -4.30% 3.50% 3.50%<br>Admins, / Manuf, Operators -1.40% -3.90% -4.20% -3.10% -1.30% -2.60%<br>For confidentiality and personal data protection reasons. no pay gap data is shown in those professional categories in which there is not a minimum of 3 people of each gender, The adjusted gender pay gap is not shown in those categories for which it is not<br>possible to obtain data with enough statistical significance through the econometric model, | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 221 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>PEOPLE WITH SOME TYPE OF DISABILITY<br>2022 2021 2020<br>People with some type of disability 899 772 599<br>PEOPLE WITH SOME TYPE OF DISABILITY - BIOTEST<br>2022<br>People with some type of disability 59<br>*Only German entities<br>NATIONALITY DIVERSITY<br>2022 2021 2020<br>Nationality diversity 94 98 88<br>NATIONALITY DIVERSITY - BIOTEST<br>2022<br>Nationality diversity 48<br>DIVERSITY | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 222<br>Annex XII: Tables related to Chapter 7.<br>Environmental responsibility<br>ENVIRONMENTAL EXPENSES AND INVESTMENTS<br>EMISSIONS<br>EXPENSES<br>In thousands of euros 2022 2021 2020<br>Waste management 17,544.51 13,236.70 14,845.40<br>Water cycle 7,893.98 6,975.50 5,159.10<br>Reducing atmospheric emissions<br>and energy 57.69 62.90 73.30<br>Others 290.63 367.20 416.70<br>Total 25,786.81 20,642.30 20,494.50<br>EXPENSES - BIOTEST<br>In thousands of euros 2022<br>Reducing atmospheric emissions<br>and energy 795.3<br>Total 795.3<br>EMISSIONS<br>T 2022 Spain U.S. RoW 2021** Spain U.S. RoW 2020 Spain U.S. RoW<br>Scope 1 95,242 30.4% 61.9% 7.7% 148,129 21.9% 71.2% 6.9% 111,435 31.0% 63.4% 5.6%<br>Scope 2* 105,068 9.3% 83.5% 7.3% 150,277 4.5% 84.7% 10.8% 127,596 8.2% 85.9% 5.9%<br>Scope 3 1,416,451 16.9% 64.4% 18.8% 1,323,454 24.4% 71.2% 4.6% 48,961*** 21.7% 73.6% 4.6%<br>EMISSIONS - BIOTEST<br>T 2022 Germany Spain U.S. RoW<br>Scope 1 12,283 99.4% 0.0% 0.0% 0.6%<br>Scope 2 6,523 94.8% 3.1% 0.0% 2.1%<br>Scope 3 n/a n/a n/a n/a n/a<br>INVESTMENTS<br>In thousands of euros 2022 2021 2020<br>Waste management 2,275.40 433.60 506.70<br>Water cycle 1,263.40 2,848.70 909.80<br>Reducing atmospheric emissions<br>and energy 1,502.60 1,580.60 1,096.00<br>Others 3,331.00 2,500.30 238.00<br>Total 8,372.40 7,363.20 2,750.50<br>All tables are related to Grifols Stand-alone, except for those tables indicated in the title that are related to Biotest<br>*Location based.<br>**2021 data has been recalculated using the ECOACT methodology also used in the text of the document.<br>***In 2020, only four categories of Scope 3 were considered. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 223 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>TOTAL EMISSIONS BY ORIGIN<br>T CO2 e 2022 2021 2020<br>Scope 1 95,242 148,129 111,435<br>Natural gas 82,536 86,403 76,629<br>Fugitive emissions 10,749 59,406 32,737<br>Other fuel ( gasoline. diesel and propane) 1,957 2,320 2,069<br>Scope 2 Location-based 105,068 150,276 127,596<br>Scope 2 Market-based 106,546 126,228<br>Electricity 103,322 147,975 125,300<br>Electricity (market-based) 104,800 123,927<br>District heating 1,746 2,301 2,296<br>Scope 3 1,416,451 1,323,454 48,961**<br>Purchased goods & services 765,443 697,287 -<br>Capital goods 198,034 237,955 -<br>Fuel & energy related activities 56,971 52,666 -<br>Upstream transportation* 216,062 172,501 6,995<br>Waste management 7,021 7,373 9,754<br>Business travel 22,780 10,062 3,904<br>Employee commuting 40,637 35,604 28,307<br>Upstream leased assets 21,860 14,347 -<br>Downstream transportation Not relevant Not relevant -<br>Processing of sold products n/a n/a -<br>Use of sold products 2,936 2,751 -<br>End of life treatment of sold products 4,065 2,581 -<br>Downstream leased assets n/a n/a -<br>Franchises n/a n/a -<br>Investments 80,643 90,327 -<br>Total*** 1,616,761 1,621,858 287,992<br>Source emission factors: GHG Protocol. Catalan Office of Climate Change. Environmental Protection Agency (US). Department for<br>Environment. Food & Rural Affairs (UK)<br>*Until 2021, only container transportation was considered.<br>**In 2020, only four categories of Scope 3 were considered.<br>***Including Scope 2 location-based.<br>TOTAL EMISSIONS BY ORIGIN - BIOTEST<br>T CO2 e 2022<br>Scope 1 12,283<br>Natural gas 11,424<br>Fugitive emissions 650<br>Other fuel (gasoline, diesel and propane) 209<br>Scope 2 6,523<br>Electricity 6,523<br>District heating -<br>Scope 3 -<br>Total 18,806<br>REFRIGERANT GAS LEAKS<br>Absolute value (T) 2022 2021 2020<br>HCFC 0.23 0.63 4.65<br>HFC 4.06 15.70 10.15<br>Others 0.02 1.24 0.40<br>OTHER EMISSIONS<br>Absolute value (T) 2022 2021 2020<br>NOx 59.31 74.14 59.96<br>CO 63.65 66.04 52.64<br>SO2 0.63 0.58 0.42<br>CO2 EMISSIONS RELATED TO TRANSPORTATION<br>2022 2021 2020<br>CO2 transportation emissions (t CO2) 279,478 218,167 39,207<br>CO2 transportation emissions (t CO2 / M €) 49.01 44.22 7.30<br>Emissions from container transport, employee commuting and business travel have been considered.<br>NOX EMISSIONS INTENSITY<br>T NOX/million of euros 2022 2021 2020<br>Total Grifols 0.01 0.02 0.01<br>SO2 EMISSIONS INTENSITY<br>T SO2/million of euros 2022 2021 2020<br>Total Grifols 0.00 0.00 0.00<br>CO EMISSIONS INTENSITY<br>T SO2/million of euros 2022 2021 2020<br>Total Grifols 0.01 0.01 0.01<br>Scope 1+2+3 CO2e EMISSIONS INTENSITY<br>T CO2e/million of euros 2022 2021 2020<br>Total Grifols 301.88 328.77 53.93<br>SCOPE 1+2 CO2e EMISSIONS INTENSITY<br>T CO2e/million of euros 2022 2021 2020<br>Total Grifols 53.50 60.49 44.76 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 224<br>METRIC TONS OF CO2e<br>Year Scope 1<br>Scope 2<br>(Location-based) Scope 1+2 Scope 3<br>disclosed estimate key disclosed estimate key disclosed estimate key upstream downstream undefined<br>2022** 95,242 n/a 105,068 n/a 200,310 n/a 1,328,807 87,644 n/a<br>2021** 148,129 n/a 150,276 n/a 298,405 n/a 1,227,795 95,659 n/a<br>2020* 111,435 n/a 127,596 n/a 239,031 n/a 2,170 14,580 32,211<br>*Criteria used: public data in IAR2020. The concepts are classified as: Undefined (employee commuting+business travel) / Downstream (Waste+exports from GI Parets) / Upstream (Imports to Spain managed from GI Parets, including plasma transport from USA and<br>other imports).<br>** Criteria used: GHG Protocol. Items are classified as: Upstream (Purchased goods and services, capital goods, fuel and electricity activities, transportation and distribution of upstream goods, Waste generated in operations, business travel, employee commuting,<br>upstream leased assets) / Downstream (Use of products placed on the market, end-of-life treatment of products placed on the market, investments).<br>SUSTAINABLE RESOURCE MANAGEMENT<br>WATER<br>BY BUSINESS UNIT<br>m3 2022 2021 2020<br>Plasma<br>Procurement 227,107 217,483 250,650<br>Biopharma 2,486,669 2,747,221 2,424,857<br>Diagnostic 110,446 130,374 165,422<br>Bio Supplies 11,992 10,890 19,390<br>Others 198,141 177,757 196,602<br>TOTAL 3,034,355 3,283,725 3,056,928<br>BY COUNTRY<br>m3 2022 2021 2020<br>Spain 881,131 866,181 864,079<br>U.S. 2,039,650 2,249,826 2,107,996<br>RoW 113,574 167,718 84,853<br>TOTAL 3,034,355 3,283,725 3,056,928<br>BY BUSINESS UNIT - BIOTEST<br>m3 2022<br>Plasma Procurement 6,610<br>Biopharma 333,221<br>TOTAL 339,831<br>Others 400<br>TOTAL 340,231<br>BY COUNTRY - BIOTEST<br>m3 2022<br>Germany 333,317<br>Spain 0<br>U.S. 0<br>RoW 6,447<br>TOTAL 339,764 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 225 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>VALUE RELATIVE TO SALES<br>m3/million<br>euros 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma<br> 584.00 777.12 630.82<br>Diagnostic 164.53 167.34 213.20<br>Bio Supplies 82.09 94.00 144.29<br>Others 792.00 611.42 813.97<br>TOTAL 532 666 573<br>VALUE RELATIVE TO PRODUCTION<br>m3/production<br>index 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma*<br> 0.061 0.069 0.058<br>Diagnostic** 164.53 167.34 213.20<br>Bio Supplies** 82.09 94.00 144.29<br>Others** 792.00 611.42 813.97<br>Production index: * liters of plasma: fractionated+ equivalent ** sales<br>Three decimal places are included for Plasma Procurement and Biopharma Business Units due to the nature of the data.<br>VALUE RELATIVE TO SALES - BIOTEST<br>m3/million euros 2022<br>Plasma Procurement 197<br>Biopharma 1,088<br>Others 97<br>TOTAL 1,088<br>VALUE RELATIVE TO PRODUCTION - BIOTEST<br>m3/production index 2022<br>Plasma Procurement* 0.0<br>Biopharma** 1<br>Production index: * liters of plasma: fractionated+ equivalent ** sales | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 226<br>BY SOURCE AND WATER STRESSED REGIONS<br>2022 2021 2020<br>Total By source By region Total By source By region Total By source By region<br>Ground-water Third party water<br>% of<br>consumption<br>in water-stressed<br>regions*<br>Ground-water Third party water<br>% of<br>consumption<br>in water-stressed<br>regions*<br>Ground-water Third party water<br>% of<br>consumption<br>in water-stressed<br>regions*<br>Water consumption (m3)<br>Plasma<br>Procure-ment 227,107 0 227,107 4.93% 217,483 0 217,483 4.35% 250,657 0 250,657 4.2%<br>Biopharma 2,486,669 234,824 2,251,845 20.33% 2,747,221 217,785 2,529,436 20.13% 2,424,857 187,582 2,237,275 19.74%<br>Diagnostic 110,446 0 110,446 26.15% 130,373 0 130,373 56.80% 165,422 0 165,422 61.50%<br>Bio<br>Supplies 11,992 0 11,992 26.93% 10,890 0 10,890 0.10% 19,390 0 19,390 0.04%<br>Others 198,141 120,943 77,198 29.63% 177,757 115,989 61,768 0.26% 196,602 122,967 73,635 0.00%<br>Total 3,034,355 355,767 2,678,588 20.02% 3,283,724 333,774 2,949,950 19.40% 3,056,928 310,549 2,746,379 19.30%<br>*Areas with high and extremely high risk according to World Resources Institute<br>BY SOURCE AND WATER STRESSED REGIONS - BIOTEST<br> 2022<br>Total By source<br>Groundwater Third party water<br>Water consumption (m3)<br>Plasma Procurement 5,040 0 5,040<br>Biopharma 333,150 84 333,066<br>Others 0 0 0<br>Total 338,190 84 338,106 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 227 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>WASTEWATER DISCHARGE BY SOURCE AND WATER STRESSED REGIONS<br>2022 2021 2020<br>By desti-nation By treatment By region By desti- nation By treatment By region By desti- nation By treatment By region<br>Total (pu-blic sewer<br>system)<br>No<br>internal<br>treatment*<br>Biological<br>systems<br>prior to<br>dischar-ge**<br>% of dis-charged<br>on wa-ter-stres-sed<br>regions***<br>Total (pu-blic sewer<br>system)<br>No<br>internal<br>treatment*<br>Biological<br>systems<br>prior to<br>dischar-ge**<br>% of dis-charged<br>on wa-ter-stres-sed<br>regions***<br>Total (pu-blic sewer<br>system)<br>No<br>internal<br>treatment*<br>Biological<br>systems<br>prior to<br>dischar-ge**<br>% of dis-charged<br>on wa-ter-stres-sed<br>regions***<br>Water discharged (m3)<br>Plasma<br>Procure-ment 225,099 225,099 0 4.08% 217,483 217,483 0 4.35% 250,280 250,280 0 4.04%<br>Biopharma 1,836,079 962,187 873,892 17.83% 1,976,546 1,089,611 886,935 25.48% 1,895,661 863,631 1,032,030 15.75%<br>Diagnostic 96,373 96,373 0 25.64% 107,044 107,044 0 55.87% 137,816 137,816 0 64.55%<br>Bio<br>Supplies 12,146 12,146 0 26.58% 10,815 10,815 0 0.10% 19,390 19,390 0 0.02%<br>Others 162,967 162,967 0 30.90% 122,602 122,602 0 0.38% 142,358 142,358 0 0.00%<br>Total 2,332,664 1,458,772 873,892 17.78% 2,434,490 1,547,555 886,935 23.60% 2,445,505 1,413,475 1,032,030 16.30%<br>* Wastewater discharged into the sewer system with subsequent treatment of municipal services<br>** Internal pretreatment processes<br>*** Areas with high and extremely high risk according to World Resources Institute<br>WASTEWATER DISCHARGE BY SOURCE AND WATER STRESSED REGIONS - BIOTEST<br> 2022<br>By destination By treatment<br>Total (public sewer system) No internal treatment Biological systems prior to discharge**<br>Water discharged (m3)<br>Plasma Procurement 0 0 0<br>Biopharma 299,186 299,186 0<br>Others 0 0 0<br>Total 299,186 299,186 0<br>COD DISCHARGED<br>2022 2021 2020<br>Total (T) 2,525 2,731 2,450<br>Relative to sales (T/million euros) 0.44 0.55 0.46<br>SUSPENDED SOLIDS DISCHARGED<br>2022 2021 2020<br>Total Grifols (T) 357 428 575<br>Relative to sales (T/million euros) 0.06 0.09 0.11 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 228<br>ELECTRICITY<br>BY BUSINESS UNIT<br>kWh 2022 2021 2020<br>Plasma<br>Procurement 120,422,380 101,589,024 108,324,100<br>Biopharma 274,349,821 291,041,998 263,080,403<br>Diagnostic 30,533,584 33,134,376 33,240,848<br>Bio Supplies 5,006,779 8,794,390 10,221,448<br>Others 20,363,388 13,998,104 13,519,475<br>TOTAL 450,675,952 448,557,892 428,386,274<br>CONSUMPTION VALUE RELATIVE TO SALES<br>kWh/<br>millon euros 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma<br> 85,004 102,918 87,568<br>Diagnostic 45,485 42,529 42,842<br>Bio Supplies 34,275 75,914 76,063<br>Others 81,400 48,148 55,973<br>TOTAL 79,029 90,928 80,222<br>CONSUMPTION VALUE RELATIVE TO PRODUCTION<br>kWh/<br>production<br>index 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma*<br> 8.91 9.16 8.12<br>Diagnostic** 45,485 42,529 42,842<br>Bio Supplies** 34,275 75,914 76,063<br>Others** 81,400 48,148 55,973<br>Production index: * liters of plasma: fractionated+ equivalent ** sales<br>BY COUNTRY<br>kWh 2022 2021 2020<br>Spain 92,681,455 93,187,332 91,596,849<br>U.S. 321,130,633 311,469,242 316,886,948<br>RoW 36,863,865 43,901,318 19,902,477<br>TOTAL 450,675,952 448,557,892 428,386,274<br>BY BUSINESS UNIT - BIOTEST<br>kWh 2022<br>Plasma Procurement 2,074,670<br>Biopharma 21,388,628<br>TOTAL 23,463,298<br>Others 400<br>TOTAL 23,463,698<br>CONSUMPTION VALUE RELATIVE TO SALES - BIOTEST<br>kWh/millon of euros 2022<br>Plasma Procurement 61,812<br>Biopharma 69,816<br>Others 97<br>TOTAL 131,725<br>CONSUMPTION VALUE RELATIVE TO PRODUCTION - BIOTEST<br>kWh/Production index 2022<br>Plasma Procurement* 6.3<br>Biopharma** 19<br> “Production index: * Liters of plasma collected<br>** Liters of plasma: fractionated + equivalent “<br>BY COUNTRY - BIOTEST<br>kWh 2022<br>Germany 22,279,317<br>Spain 5,186<br>U.S. 0<br>RoW 1,157,612<br>TOTAL 23,442,115 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 229 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>NATURAL GAS<br>BY BUSINESS UNIT<br>kWh 2022 2021 2020<br>Plasma<br>Procurement 22,924,665 18,394,582 14,084,519<br>Biopharma 383,791,223 410,355,915 359,446,305<br>Diagnostic 24,168,714 27,263,806 25,751,915<br>Bio Supplies 442,406 1,075,999 716,183<br>Others 20,825,195 17,191,989 20,629,846<br>TOTAL 452,152,203 474,282,291 420,628,768<br>CONSUMPTION VALUE RELATIVE TO SALES<br>kWh/million<br>euros 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma<br> 87,576 112,386 88,069<br>Diagnostic 36,003 34,994 33,190<br>Bio Supplies 3,029 9,288 5,329<br>Others 83,246 59,134 85,412<br>TOTAL 79,287 96,143 78,769<br>CONSUMPTION VALUE RELATIVE TO PRODUCTION<br>kWh/<br>production<br>index 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma*<br> 9.2 10.0 8.2<br>Diagnostic** 36,003 34,994 33,190<br>Bio Supplies** 3,029 9,288 5,329<br>Others** 83,246 59,134 85,412<br>Production index: * liters of plasma: fractionated+ equivalent ** sales<br>BY COUNTRY<br>kWh 2021 2021 2020<br>Spain* 143,376,530 168,964,411 172,171,007<br>U.S. 289,704,028 280,605,846 245,442,818<br>RoW 19,071,645 24,712,034 3,014,943<br>TOTAL 452,152,203 474,282,291 420,628,768<br>*Cogeneration plant natural gas consumption is included in Spain totals<br>BY BUSINESS UNIT - BIOTEST<br>kWh 2022<br>Plasma Procurement 456,548<br>Biopharma 50,916,230<br>TOTAL 51,372,778<br>CONSUMPTION VALUE RELATIVE TO SALES - BIOTEST<br>kWh/millon of euros 2022<br>Plasma Procurement 13,602<br>Biopharma 166,198<br>TOTAL 166,198<br>CONSUMPTION VALUE RELATIVE TO PRODUCTION - BIOTEST<br>kWh/Production index 2022<br>Plasma Procurement* 1<br>Biopharma** 154<br>Production index: * liters of plasma: fractionated+ equivalent/ ** Sales<br>BY COUNTRY - BIOTEST<br>kWh 2022<br>Germany 51,237,535<br>Spain 0<br>U.S. 0<br>RoW 60,705<br>TOTAL 51,298,240 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 230<br>CONSUMPTION VALUE RELATIVE TO SALES<br>kWh/milion<br>euros 2022 2021 2020<br>Plasma<br>Procurement &<br>Biopharma<br> 169,573 207,238 168,495<br>Diagnostic 81,570 77,592 76,101<br>Bio Supplies 48,071 131,167 120,658<br>Others 164,646 107,283 141,385<br>TOTAL 156,151 181,923 154,316<br>COGENERATION PLANT<br>COGENERATION 2022 2021 2020<br>Natural gas<br>consumed (kwh) 75,119,463 114,018,162 113,433,940<br>Total electricity<br>generate (kwh) 27,618,042 41,712,040 41,257,500<br>Useful heat recoverd<br>(kwh) 20,623,619 30,857,670 30,522,770<br>COGENERATION PLANT - BIOTEST<br>COGENERATION 2022<br>Natural gas consumed (kwh) 13,199,091<br>Total electricity generate (kwh) 4,770,118<br>Useful heat recoverd (kwh) 6,759,322<br>CONSUMPTION VALUE RELATIVE TO SALES - BIOTEST<br>kWh/millon of euros 2022<br>Plasma Procurement 76,635<br>Biopharma 237,947<br>Others 0<br>TOTAL 219,366<br>TOTAL ENERGY CONSUMPTION<br>MAIN MATERIALS<br>COGENERATION PLANT<br>TOTAL ENERGY CONSUMPTION<br>kWh 2022 2021 2020<br>Plasma<br>Procurement 155,299,475 119,983,606 122,408,619<br>Biopharma 632,222,407 670,626,538 592,237,763<br>Diagnostic 54,757,288 60,452,566 59,045,724<br>Bio Supplies 7,022,102 15,195,218 16,214,210<br>Others 41,188,602 31,190,360 34,149,321<br>TOTAL 890,489,874 897,448,288 824,055,637<br>MAIN MATERIALS CONSUMED - BIOPHARMA<br> Absolute<br>value (T) 2022 2021 2020<br>Sorbitol 1,164 1,163 1,405<br>Ethanol 3,225 2,730 3,071<br>Polyethylene glycol 1,720 1,749 1,597<br>Glass packaging 2,881 2,750 321<br>TOTAL 8,990 8,392 6,394<br>TOTAL ENERGY CONSUMPTION - BIOTEST<br>kWh 2022<br>Plasma Procurement 2,572,197<br>Biopharma 72,897,207<br>Others 0<br>TOTAL 75,469,405<br>MAIN MATERIALS CONSUMED - BIOPHARMA - BIOTEST<br> Absolute value (T) 2022<br>Sorbitol 0<br>Ethanol 1,462<br>Polyethylene glycol 0<br>Glass packaging 218<br>TOTAL 1,680 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 231 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>MAIN MATERIALS CONSUMED - DIAGNOSTIC<br> Absolute value (T) 2022 2021 2020<br>Circuit boards (units) 27,463 40,344 41,340<br>PP Plastic Cards 300 279 269<br>Glass packaging 21 28 33<br>Plastic reagent packaging 30 21 20<br>Red cell reagents (liters) 266,803 275,435 263,294<br>PVC pellets. flat tubes and sheets 14 121 505<br>MAIN MATERIALS CONSUMED - OTHERS<br>Absolute value (T) 2022 2021 2020<br>PP 979 832 931<br>Glucose 185 148 276<br>Sodium chloride 210 208 204<br>Glass packaging 526 238 1,162<br>TOTAL 1,900 1,426 2,573<br>WASTE<br>GENERATED WASTE BY TYPE AND DISPOSAL METHOD ABSOLUTE VALUE<br>T TREATMENT 2022 2021 2020<br>Waste diverted from disposal<br>Hazardous waste<br>Energy recovered and by-products 673 579 695<br>Reused 70 65 97<br>Recycled 1,100 2,509 2,745<br>Non-hazardous waste<br>Energy recovered and by-products 5,551 5,587 5,416<br>Reused 231 258 218<br>Recycled 12,930 13,376 9,080<br>Composted 2,195 1,882 2,025<br>Waste diverted to disposal<br>Hazardous waste<br>Incineration (with energy recovery) 336 244 0<br>Incineration (without energy recovery) 609 19 0<br>Landfill disposal 0 0 5<br>Other disposal treaments 7,053 5,416 6,809<br>Non-hazardous waste<br>Incineration (with energy recovery) 0 12 0<br>Incineration (without energy recovery) 16 18 27<br>Landfill disposal 13,097 14,129 20,076<br>Other disposal treaments 1,091 855 1,785<br>TOTAL 44,954 44,949 48,978 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 232<br>GENERATED WASTE BY TYPE AND DISPOSAL METHOD ABSOLUTE VALUE - BIOTEST<br>T TREATMENT 2022<br>Waste diverted from disposal<br>Hazardous waste<br>Energy recovered and by-products 84<br>Reused 0<br>Recycled 0<br>Non-hazardous waste<br>Energy recovered and by-products 36<br>Reused 0<br>Recycled 1<br>Composted 0<br>Waste diverted to disposal<br>Hazardous waste<br>Incineration (with energy recovery) 17<br>Incineration (without energy recovery) 19<br>Landfill disposal 1<br>Other disposal treaments 5,397<br>Non-hazardous waste<br>Incineration (with energy recovery) 657<br>Incineration (without energy recovery) 99<br>Landfill disposal 46<br>Other disposal treaments 251<br>TOTAL 6,607<br>GENERATED WASTE BY TYPE AND DISPOSAL METHOD RELATIVE VALUE<br>T/million euros TREATMENT 2022 2021 2020<br>Waste diverted from disposal<br>Hazardous waste<br>Energy recovered and by-products 0.12 0.12 0.13<br>Reused 0.01 0.01 0.02<br>Recycled 0.19 0.51 0.51<br>Non-hazardous waste<br>Energy recovered and by-products 0.97 1.13 1.01<br>Reused 0.04 0.05 0.04<br>Recycled 2.27 2.71 1.70<br>Composted 0.39 0.38 0.38<br>Waste diverted to disposal<br>Hazardous waste<br>Incineration (with energy recovery) 0.06 0.05 0.00<br>Incineration (without energy recovery) 0.11 0.00 0.00<br>Landfill disposal 0.00 0.00 0.00<br>Other disposal treaments 1.24 1.10 1.28<br>Non-hazardous waste<br>Incineration (with energy recovery) 0.00 0.00 0.00<br>Incineration (without energy recovery) 0.00 0.00 0.01<br>Landfill disposal 2.30 2.86 3.76<br>Other disposal treaments 0.19 0.17 0.33 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 233 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>GENERATED WASTE BY TYPE AND DISPOSAL METHOD RELATIVE VALUE - BIOTEST<br>T/million euros TREATMENT 2022<br>Waste diverted from disposal<br>Hazardous waste<br>Energy recovered and by-products 0.00<br>Reused 0.00<br>Recycled 0.00<br>Non-hazardous waste<br>Energy recovered and by-products 1.33<br>Reused 0.00<br>Recycled 0.00<br>Composted 0.00<br>Waste diverted to disposal<br>Hazardous waste<br>Incineration (with energy recovery) 16.94<br>Incineration (without energy recovery) 29,273.43<br>Landfill disposal 483.95<br>Other disposal treaments 0.00<br>Non-hazardous waste<br>Incineration (with energy recovery) 88,435.56<br>Incineration (without energy recovery) 6,018.18<br>Landfill disposal 44.04<br>Other disposal treaments 22,913.59<br>ABSOLUTE VALUE BY BUSINESS UNIT<br>T 2022 2021 2020<br>Plasma<br>Procurement 24,622 23,161 22,620<br>Biopharma 16,964 17,834 22,126<br>Diagnostic 1,242 1,342 1,302<br>Bio Supplies 802 1,309 1,763<br>Others 1,324 1,302 1,167<br>TOTAL 44,954 44,949 48,978<br>ABSOLUTE VALUE BY COUNTRY<br>T 2022 2021 2020<br> Spain 5,287 5,702 5,846<br> U.S. 37,784 37,577 41,689<br> RoW 1,883 1,669 1,443<br>TOTAL 44,954 44,949 48,978<br>ABSOLUTE VALUE BY BUSINESS UNIT - BIOTEST<br>T 2022<br> Plasma Procurement 282<br> Biopharma 6,325<br>TOTAL 6,607<br>ABSOLUTE VALUE BY COUNTRY - BIOTEST<br>kWh 2022<br> Germany 6,385<br> Spain 0<br> U.S. 0<br> RoW 222<br>TOTAL 6,607 | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 234<br>Annex XIII: 2022 environmental commitments:<br>progress and achievements<br>2020-2022 ENVIRONMENT PLAN<br>DEGREE OF<br>COMPLIANCE WITH<br>DEFINED ACTIONS<br>(STATUS 2022)<br>ATMOSPHERIC EMISSIONS<br>SCOPE 2<br>Reduce CO2e emissions by approximately 23,400 tons<br>per year by using 68 million kWh of renewable electric<br>energy<br>Construction of two photovoltaic plants of 100 and 150 kW in Murcia (Spain) for the Hospital Business unit<br>100.0%<br>Purchase of 18 million kWh of renewable electrical energy per year through a PPA (Power Purchasing Agreement) for the Bios-cience Business unit facilities in Barcelona<br>Purchase of 50 million kWh of renewable electricity per year between Grifols’ different plants. Savings of 17,000 tons of CO2e<br>Construction of a 220 kW photovoltaic plant at the Bioscience Business unit facilities in Barcelona (Spain) PL1 (P2)<br>SCOPE 1 AND 2<br>Reduce CO2e emissions by 6,700 tons per year through<br>the implementation of eco-efficiency measures in<br>existing facilities<br>Study improvements in the cooling system at the Bioscience Business unit facility in Barcelona (Spain)<br>77.9%<br>Increase in electrical energy generated and useful heat produced by the cogeneration plant at the Bioscience Business unit’s faci-lity in Barcelona (Spain).<br>Installation of a new variable speed compressor at the Bioscience Business unit facility in Clayton<br>Improvements in the compressed air network at the Hospital Business unit plant in Murcia (Spain)<br>Implementation of a centralized energy control system (BMS) at the work center in Madrid (Spain)<br>Replace refrigerant gases with lower Global Warming Potential (GWP) in cooling systems in the Haema (Germany) and Biomat<br>(Spain) facilities.<br>Apply energy efficiency measures in lighting and air conditioning systems in Grifols’ Italian offices and warehouse.<br>Replace existing lighting with LEDs at the Bioscience Business unit’s quality control building at Los Angeles (U.S.) facility.<br>Reduce CO2e emissions by 1,860 tons per year through<br>eco-efficiency projects in new facilities<br>Implement measures to obtain LEED Silver or Gold certification in the new building in Sant Cugat del Vallès (Barcelona, Spain) -<br>savings of 188,000 kWh per year compared to a standard building.<br>100% Earn Green Globe certification for the new Bioscience Business unit’s manufacturing buildings in Clayton (U.S.) - savings of 1,800 tons of CO2e<br>Installation of a new refrigeration plant using ammonia as a natural refrigerant gas at the Grifols International warehouse in Barce-lona (Spain) – Zero Global Warming Potential (GWP)<br>SCOPE 3 Minimizing carbon emissions in business trips and employee commutes<br>Increase remote working in all of Grifols facilities where feasible.<br>Increase the use of videoconferences to reduce business air travel 66.7%<br>Emission offsets for corporate travel with airlines and rental cars<br>STUDY OPTIONS TO BOOST ENERGY EFFICIENCY<br>SCOPE 2 Study options to increase energy efficiency<br>Carry out energy audits in the Haema facilities (Germany) and energy study in Biomat’s refrigeration chambers in Barcelona<br>(Spain). 80.0%<br>Implement good energy efficiency practices in the Raleigh facilities, North Carolina (U.S.). | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 235 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>2020-2022 ENVIRONMENT PLAN<br>DEGREE OF<br>COMPLIANCE WITH<br>DEFINED ACTIONS<br>(STATUS 2022)<br>WATER<br>Reduce water consumption by 87,700 m3 per year in<br>existing facilities.<br>Replace a reverse osmosis unit for process water treatment with a high-efficiency unit at the Bioscience Business unit facility in<br>Clayton’s (U.S.)<br>66.7%<br>Implement more efficient automated cleaning processes in some production areas of the Bioscience and Hospital divisions in<br>Spain<br>Implement water recovery projects in albumin pasteurization baths in the Bioscience Business unit in the USA and Ireland<br>Action to be carried out at one of the sites located in a water-stressed zone, California (U.S.)<br>Save 400 m3 per year in water consumption in new<br>facilities.<br>Implement consumption measures to reduce and reuse water in the new building in Sant Cugat del Vallès (Spain) as part of the<br>LEED Certification project. 100%<br>Study systems that reduce water consumption in various<br>production uses and outdoor facilities.<br>Study possibilities to save water for irrigation at the Bioscience Business unit facilities in Los Angeles (U.S.) and implement best<br>practices to save water at the Clayton production facilities (U.S.). Actions to be carried out at one of the sites located in a wa-ter-stressed zone, California. 15.0%<br>Reduce wastewater parameters<br>Expand Bioscience Business unit’s wastewater treatment plants in Barcelona (Spain) and Clayton (U.S.) to reduce levels of organic<br>matter discharged 75.0%<br>Reduce suspended solids and nitrogen discharged in the wastewater from Clayton’s facilities (U.S.) 50.0%<br>WASTE<br>Maintain 'Zero Waste to Landfill' certification Maintain certification at the Bioscience Business unit plant in Clayton (U.S) 100.0%<br>Reduce quantity of waste generated by 4,700 tons per<br>year<br>Expand capacity for storage and treatment of polyethylene glycol capacity at the Bioscience Business unit’s facilities in Barcelona<br>(Spain) 0.0%<br>Increase waste recycling by 500 tons per year. Install a new plastic bottle shredder and cleaning system at the Bioscience Business unit facility in Clayton (U.S.) to recycle all emptied plasma bottles 100.0%<br>Study more sustainable management alternatives for<br>628 tons of waste at the Bioscience and Diagnostic<br>divisions' facilities<br>Conduct a study to reduce 618 tons of hazardous waste at the Bioscience Business unit plant in Barcelona (Spain)<br>76.0%<br>Reduce the quantity of landfilled or incinerated waste by 9.5 tons per year at Los Angeles and Emeryville plants (California, U.S.)<br>New hazardous waste storage in Clayton Build a new 70-drum hazardous waste storage facility at the Bioscience Business unit’s facility in Clayton (U.S.) 0.0%<br>RAW MATERIAL CONSUMPTION<br>Increase alcohol recycling by 76 tons per year Improvements to the ethanol distillation tower at the Los Angeles (U.S.) plant to increase ethanol recycling by 8% 65.0%<br>Decrease caustic soda consumption by 28 tons per year Implement higher-efficiency automated cleaning reactors and production lines at the Bioscience and Hospital Business unit facili- ties in Barcelona (Spain) 66.7%<br>Reduce cardboard and plastic consumption by 1.1 tons<br>per year<br>Modify packaging of diagnostic products manufactured at the Diagnostic Business unit’s facilities in Barcelona (Spain) to reduce<br>the consumption of packaging materials 92.5%<br>OTHER<br>Develop biodiversity protection programs in natural areas<br>owned by Grifols and other areas of influence<br>Maintain protection, inventory and training programs, and Wildlife Habitat Area certification in the natural areas of Clayton (U.S.) 100%<br>Establish collaboration agreements to protect the biodiversity of Grifols’ areas of influence near its Barcelona (Spain) plants<br>Promote the use of clean energy and good commuting<br>practices Install a new charger for electric vehicle at the Hospital Business unit facilities in Murcia (Spain) 0%<br>Promote sustainable construction of new buildings: LEED<br>or Green Globe certifications.<br>Earn Silver or Gold LEED certification for the new corporate building in Sant Cugat del Vallès (Barcelona, Spain)<br>100%<br>Earn Green Globe certification for the new manufacturing buildings of the Bioscience Business unit in Clayton (U.S.) | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 236<br>Annex XIV: European taxonomy for<br>climate-change mitigation and adaptation<br>The European Sustainable Finance Taxonomy is a new classification of economic activities that contribute<br>to the EU’s environmental objectives, such as mitigating and adapting to climate change, and aims to<br>encourage investments that lead to sustainable growth.<br>To this end, the European Parliament and the Council of the European Union adopted the Taxonomy<br>Regulation1 in 2020. This regulation aims to increase transparency and consistency in the reporting of<br>economic activities that, by meeting specific criteria, can be considered environmentally sustainable.<br>In 2022, as required by Article 8 of the Taxonomy Regulation, Grifols has initiated a process of analysis<br>of its activities in order to identify those which could be considered environmentally sustainable. This<br>process has mainly consisted of two phases:<br>Phase 1. Eligible activities<br>In this first phase, an analysis has been carried out to determine whether or not any of Grifols’ economic<br>activities are considered eligible according to the European taxonomy.<br>Identification of all<br>Grifols’ activities<br>Correlation of their<br>activities with the NACE<br>codes (Nomenclature of<br>Economic Activities).<br>Assessment of the<br>selected NACE codes<br>with the list of eligible<br>activities according to<br>each environmental<br>objective (Annexes I2<br>and II3).<br>Phase 2. Aligned activities<br>Once the eligible activities had been identified, their suitability for the taxonomy was analysed. For this<br>analysis, the three conditions that an activity must meet in order to be considered environmentally<br>sustainable have been taken into account:<br>Substantial contribution<br>to at least one of the 6<br>objectives defined by the<br>Taxonomy<br>Principle of do no<br>significant harm to the<br>other defined objectives<br>Principle of do no<br>significant harm to the<br>other defined objectives<br>This process has led to the conclusion that all eligible activities identified in the first phase are aligned<br>with the EU Taxonomy for the environmental objective of Climate Change Mitigation. These are:<br> • 7.4. Installation, maintenance and repair of charging stations for electric vehicles in buildings (and in<br>parking spaces attached to buildings).<br> • 7.6. Installation, maintenance and repair of renewable energy technologies.<br>The proportion of eligible and non-eligible, aligned and non-aligned activities, according to the European<br>taxonomy, is shown below. The organisation’s income is not considered eligible, but some of its<br>investments and expenditures are. After a thorough analysis, these investments and expenses have been<br>considered insignificant in relation to the company’s total, as can be seen in the following tables.<br>The calculation of the main indicators for the identified activities is detailed below.<br>In relation to the taxonomic OpEx, the associated expenses taken into consideration for both activities are<br>composed only of non-capitalized direct costs related to research and development, short-term leases,<br>maintenance and repairs. For both activities, the results have been considered very insignificant.<br>With respect to CapEx, the Group has considered the weight of investments related to the above activity<br>in relation to total additions for the year, whether in Property, Plant and Equipment, software additions, as<br>active capitalized interest.<br>During the 2022 financial year, in terms of CapEx for activity 7.4 Installation, maintenance and repair of<br>charging stations for electric vehicles in buildings (and in the parking spaces attached to the buildings),<br>Grifols has not reported any amount. And with respect to activity 7.6 Installation, maintenance and repair<br>of renewable energy technologies, the result is considered very insignificant.<br>Due to the new information published in reference to the Taxonomy during the year, these results, number<br>of eligible activities and taxonomic KPIs, have undergone variations with respect to those published the<br>previous year.<br>(1) For more information; EU taxonomy for sustainable activities | European Commission (europa.eu)<br>(2) Annex I to the Commission delegated regulation supplementing Regulation (EU) 2020/852 (europa.eu)<br>(3) Annex II to the Commission delegated regulation supplementing Regulation (EU) 2020/852 (europa.eu) | |
| --- | ||
| 2022 Consolidated Directors’ Report · 237 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Substantial contribution criteria DNSH criteria<br>Economic activities<br>Code(s)<br>Absolute OpEx<br>Proportion of OpEx<br>Climate change mitigation<br>Climate change adaptation<br>of water and marine resources<br>Sustainable use and protection<br>Transition to a circular economy<br>Pollution prevention and control<br>biodiversity and ecosystems<br>Protection and restoration of<br>Climate change mitigation<br>Climate change adaptation<br>of water and marine resources<br>Sustainable use and protection<br>Transition to a circular economy<br>Pollution prevention and control<br>biodiversity and ecosystems<br>Protection and restoration of<br>Minimun safeguards<br>Taxonomy-aligned proportion of<br>OpEx, year 2022<br>Taxonomy-aligned proportion of<br>OpEx, year 2021<br>Category (enabling activity)<br>Category (transitional activity)<br> € % % % % % % % S/N S/N S/N S/N S/N S/N S/N % % F T<br>A. TAXONOMY ELIGIBLE ACTIVITIES<br>A.1. Environmentally sustainable activities (taxonomy-aligned)<br>"7.4. Installation, maintenance and repair of charging stations for electric vehicles in F42 2,450 0.0002% 0.0002% NA NA NA NA NA S NA NA NA NA S 50.8299% NA F<br>buildings (and parking spaces attached to buildings) " F42 2,370 0.0002% 0.0002% NA NA NA NA NA S NA NA NA NA S 49.1701% NA F<br>7.6. Installation, maintenance and repair of renewable energy technologies 4,820 0.0003% 0.0002% NA NA NA NA NA 100.00% NA<br>OpEx of environmentally sustainable activities (taxonomy-aligned) (A.1)<br>A.2. Taxonomy-eligible but not environmentally sustainable activities (not taxonomy-alig-ned activities) 0 0%<br>OpEx of taxonomy-eligible but not environmentally sustainable activities (not taxo-nomy-aligned activities) (A.2) 4,820 0.0003% 100.00% NA<br>Total (A.1 + A.2)<br>B. TAXONOMY-NON-ELIGIBLE ACTIVITIES 1,551,558,180 99.9997%<br>OpEx of taxonomy-non-eligible activities (B) 1,551,563,000 100%<br>Total (A + B)<br>Substantial contribution criteria DNSH criteria<br>Economic activities<br>Code(s)<br>Absolute OpEx<br>Proportion of OpEx<br>Climate change mitigation<br>Climate change adaptation<br>Sustainable use and protection of water<br>and marine resources<br>Transition to a circular economy<br>Pollution prevention and control<br>Protection and restoration of biodiversity<br>and ecosystems<br>Climate change mitigation<br>Climate change adaptation<br>Sustainable use and protection of water<br>and marine resources<br>Transition to a circular economy<br>Pollution prevention and control<br>Protection and restoration of biodiversity<br>and ecosystems<br>Minimun safeguards<br>Taxonomy-aligned proportion of OpEx,<br>year 2022<br>Taxonomy-aligned proportion of OpEx,<br>year 2021<br>Category (enabling activity)<br>Category (transitional activity)<br> € % % % % % % % S/N S/N S/N S/N S/N S/N S/N % % E T<br>A. TAXONOMY ELIGIBLE ACTIVITIES<br>A.1. Environmentally sustainable activities (taxonomy-aligned)<br>7.6. Instalación, mantenimiento y reparación de tecnologías de energía renovable F42 13,800 0.0046% 0.0046% NA NA NA NA NA S NA NA NA NA S 100.00% NA F<br>CapEx of environmentally sustainable activities (taxonomy-aligned) (A.1) 13,800 0.0046% 0.0046% NA NA NA NA NA 100.00% NA<br>A.2. Taxonomy-eligible but not environmentally sustainable activities (not taxono-my-aligned activities)<br>CapEx of taxonomy-eligible but not environmentally sustainable activities (not<br>taxonomy-aligned activities) (A.2)<br>0 0%<br>Total (A.1 + A.2) 13,800 0.0046% 100.00% NA<br>B. TAXONOMY-NON-ELIGIBLE ACTIVITIES<br>CapEx of taxonomy-non-eligible activities (B) 297,777,200 99.9954%<br>Total (A + B) 297,791,000 100%<br>CapEx<br>OpEx | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 238<br>Annex XV: Glossary and abbreviations<br>% Alpha-1 antitrypsin deficiency (AATD): Inherited disease<br>characterized by low levels of, or no alpha-1 antitrypsin (AAT)<br>in the blood. This protein made in the liver, reaches other<br>organs (such as the lungs), after being released into the blood<br>stream, enabling its normal function.<br>% Albumin: The most abundant protein found in plasma<br>(approximately 60% of human plasma). Produced in the liver,<br>it is important in regulating blood volume by maintaining the<br>oncotic pressure of the blood compartment.<br>% Alzheimer’s disease: This is the most common form<br>of dementia. This incurable, degenerative, and terminal<br>disease was first described by German psychiatrist and<br>neuropathologist Alois Alzheimer in 1906 and was named<br>after him.<br>% Anti-thymocyte globulin (ATG): blood serum that contains<br>antibodies that bind with human T cells. It is given to the patient<br>before a stem cell transplant to destroy T cells and decrease<br>the risk of graft-versus-host disease<br>% ASFA: American Society for Apheresis An organization of<br>physicians, scientists, and allied health professionals whose<br>mission is to advance apheresis medicine for patients, donors,<br>and professionals through education, evidence-based practice,<br>research, and advocacy<br>% Autoimmune disease: Condition in which the immune<br>system mistakenly attacks healthy cells.<br>% Babesiosis/Babesia virus: Disease caused by microscopic<br>parasites that infect red blood cells.<br>% Beta-amyloid: Protein strongly implicated in Alzheimer’s<br>diseases. Beta-amyloid is the main component of certain<br>deposits found in the brains of patients of Alzheimer’s<br>disease.<br>% Bullous pemphigoid: is an autoimmune disease that appears<br>when the immune system attacks the skin and causes blisters,<br>more common in the elderly<br>% CIDP (Chronic Inflammatory Demyelinating<br>Polyneuropathy): Neurological disorder which causes<br>gradual weakness, numbness, pain in arms and legs and<br>difficulty in walking.<br>% Cirrhosis: Medical condition which is a result of advanced<br>liver disease. It is characterized by the placement of liver<br>tissue by fibrosis (scar tissue) and regenerative nodules<br>(lumps that occur due to attempted repair of damaged<br>tissue).<br>% Cognitive impairment: Alterations in thinking, learning,<br>memory, judgment, and decision making<br>% COVID-19: Infectious disease caused by a new strain of<br>coronavirus. ‘CO’ stands for corona, ‘VI’ for virus, and ‘D’ for<br>disease.<br>% ELISA: Enzyme-linked immunosorbent assay.<br>% EMA: European Medicines Agency<br>% Factor VIII or FVIII: This is an essential blood clotting factor<br>also known as anti-hemophilic factor (AHF). In humans,<br>Factor VIII is encoded by the F8 gene.Defects in this gene<br>results in hemophilia A, a sexlinked disease that occurs<br>predominantly in males. FVIII concentrated from donated<br>blood plasma, or alternatively recombinant FVIII, or rFVIII can<br>be given to hemophiliacs to restore hemostasis.<br>% Factor IX: This is an important blood clotting factor also<br>known as Christmas factor or plasma thromboplastin<br>component (PTC). It is one of the serine proteases of the<br>coagulation system and belongs to the peptidase family S1.<br>In humans, a deficiency of this protein causes hemophilia B,<br>a sex-linked disease that occurs predominantly in males.<br>% FDA: Food and Drug Administration. U.S. Health Authority.<br>% Fibrin sealant: Surgical adhesive material derived from<br>plasma.<br>% Fibrinogen: Coagulation factor found in human plasma<br>crucial for blood clot formation.<br>% Fractionation: Process of separating plasma into its<br>component parts, such as albumin, immunoglobulin, alpha-1<br>antitrypsin and coagulation factors.<br>% GMP: Good manufacturing practice<br>% GPO: Group Purchasing Organization.<br>% HAE (Hereditary Angioedema): Rare but serious genetic<br>disorder characterized by recurrent episodes of severe<br>swelling (angioedema), particularly of the face and airways,<br>and abdominal cramping. It is caused by low levels or<br>improper function of the C1- esterase inhibitor protein.<br>% HBV: Hepatitis B Virus.<br>% HCV: Hepatitis C Virus.<br>% Hematocrit: value that is defined by the amount of blood<br>volume occupied by red blood cells, with respect to that<br>occupied by total blood. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 239 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>% Hematology: The study of blood, blood-forming organs, and<br>blood diseases.<br>% Hemoderivative: Proteins obtained by fractionation of<br>human blood plasma. See plasma derived proteins.<br>% Hemophilia: Genetic deficiency characterized by the lack of<br>one of the clotting factors. It has two main variants:<br> • Hemophilia A: genetic deficiency of coagulation Factor<br>VIII, which causes increased bleeding (usually affects males).<br> • Hemophilia B: genetic deficiency of coagulation Factor IX.<br>% Hemotherapy: Treatment of a disease using blood, blood<br>components and its derivatives.<br>% HIV: Human Immunodeficiency Virus.<br>% Hyperimmune globulins: type of immunoglobulins prepared<br>in a manner similar to human normal immunoglobulin, except<br>that the donor has high titers of antibodies against an organism<br>or antigen in their plasma.<br>% IA: Immunoassays. These are systems available in several<br>formats that may be used to detect antibodies, recombinant<br>proteins or a combination of the two.<br>% Intravenous: Administration of drugs or fluids directly into<br>a vein.<br>% Immunohematology: A branch of hematology related<br>to the study of recombinant proteins and antibodies and<br>their effects on blood and the relationships between blood<br>disorders and the immune system. Also referred to as<br>Transfusional Medicine – blood bank, its main activities<br>include blood typing, compatibility tests and crossmatching<br>and antibody identification.<br>% Immunology: This is a branch of biomedical science that<br>covers the study of all aspects of the immune system in<br>organisms. It deals with the physiological functioning of<br>the immune system in states of both health and disease.<br>malfunctions (autoimmune diseases, hypersensitivities,<br>immune deficiency, transplant rejection) and the physical,<br>chemical and physiological characteristics of the components<br>of the immune system in vitro, in situ, and in vivo.<br>% Immunoglobulin (IgG): Also known as antibodies, are<br>proteins derived from plasma. They control de body’s<br>immune response. They have multiple indications and some<br>of their main uses are to treat: (i) immune deficiencies,<br>(ii) inflammatory and autoimmune diseases and (iii)<br>acute infections. IVIG is an immunoglobulin administered<br>intravenously that contains IgG (immunoglobulin (antibody) G).<br>% ITP (Chronic immune thrombocytopenia): Autoimmune<br>disorder in which patients produce antiplatelet autoantibodies<br>and specialized white blood cells that destroy their<br>blood platelets. This results in a low blood platelet count<br>(thrombocytopenia) that may produce bruising or excessive<br>bleeding.<br>% IVD: In vitro Diagnostic.<br>% IV solutions/Intravenous solution: Medicine or<br>homogeneous mixture of a substance in liquid, enabling it to<br>be infused into the circulatory system through a needle.<br>% Lipemic plasma: plasma with a cloudy and/or milky<br>appearance, caused by excess lipids (hyperlipidemia) mainly<br>cholesterol and/or triglycerides in the blood, which in some<br>cases becomes evident.<br>% MRB: Marketing Research Bureau.<br>% Molecular Diagnostic: Discipline that studies genomic<br>(DNA) and proteomic (proteins)expression patterns and uses<br>the information to distinguish between normal, precancerous,<br>and canceroustissues at the molecular level.<br>% Monoclonal antibody (mAb): Antibody produced by a<br>single clone of cells typically used in immunotherapy (such<br>as in the treatment of autoimmune or inflammatory disorders<br>and cancer), diagnostic testing and cell identification<br>and tracking. Monoclonal antibodies are a cornerstone<br>of immunology and are increasingly coming into use as<br>therapeutic agents.<br>% Myasthenia Gravis (MG): Chronic autoimmune,<br>neuromuscular disease that causes weakness in the skeletal<br>muscles that worsens after periods of activity and improves<br>after periods of rest. These muscles are responsible for<br>functions involving breathing and moving parts of the body.<br>% NAT: Nucleic Acid Amplification Testing.<br>% Neurology: Science that deals with the anatomy, functions<br>and organic disorders of nerves and the nervous system.<br>% Northamerica: includes the U.S. and Canada.<br>% Ophthalmology: branch of medicine and surgery that deals<br>with the diagnosis and treatment of eye diseases<br>% Pandemic: The worldwide spread of a new disease.<br>% Parkinson’s Disease: complex neurodegenerative disorder<br>in which each patient experiences a different combination of<br>motor and non-motor symptoms.<br>% PCR: Polymerase chain reaction is a method widely used to<br>rapidly make millions to billions of copies of a specific DNA<br>sample, allowing scientists to take a very small sample of DNA<br>and amplify it to a large enough amount to study in detail.<br>% pdFVIII: Plasma-derived Factor VIII.<br>% Pharmacovigilance: Practice of monitoring the effects<br>of medical drugs after they have been licensed for use,<br>especially in order to identify and evaluate previously<br>unreported adverse reactions. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 240<br>% Plasma: Yellow-coloured liquid part of the blood, consisting<br>of a mix of a large number of proteins in solution.<br>% Plasma-derived proteins: Purified plasma proteins<br>with therapeutic properties that are obtained through the<br>fractionation of human plasma. Albumin, immunoglobulins,<br>factor VIII and alpha-1 antitrypsin are the main plasma<br>proteins.<br>% Plasma proteomic: describes the high-throughput analysis of<br>plasma biomarkers using very powerful, sensitive and specific<br>instruments<br>% Plasmapheresis: Plasmapheresis is a technique which<br>separates plasma from other blood components, such as<br>red blood cells, platelets and other cells. These unused blood<br>components are suspended in saline solution and immediately<br>reinjected back into the donor. Because the donor is only<br>providing plasma and not whole blood, the recovery process<br>is faster and better tolerated and the donor is able to make<br>donations more frequently. Plasmapheresis was developed<br>by Jose Antonio Grifols Lucas in the year 1951. It is the only<br>procedure that is capable of obtaining sufficientquantities of<br>plasma to cover the manufacturing needs for the different<br>plasma protein therapies.<br>% Pulmunology: is the specialty that takes care of the diagnosis<br>and treatment of respiratory diseases Pulmunologists treat<br>everything related to the respiratory system from asthma to<br>tuberculosis<br>% PPTA: Plasma Protein Therapeutics Association.<br>% Primary arthroplasty: Surgery performed to replace<br>damaged joints for various reasons, such as hip fractures,<br>osteoarthritis or other rheumatic diseases, by artificial joints<br>called prostheses<br>% Primary immunodeficiency: Inherited condition where<br>there is an impaired immune response, weakening the<br>immune system and allowing infections and other health<br>problems to occur more easily. It may be in one or more<br>aspects of the immune system.<br>% ProlastinR/ProlastinR -C: This is a concentrated form of<br>alpha-1 antitrypsin (AAT), derived from human plasma and<br>approved only for chronic, or ongoing, replacement therapy<br>in people with genetic AAT deficiency. Given as prescribed,<br>Prolastin raises the levels of AAT in the blood and lungs.<br>Raising the AAT level may help reduce the damage to the<br>lungs caused by destructive enzymes.<br>% Proteome: set of proteins that an organism synthesizes from<br>the genes it contains to give the cell its individual character.<br>This set of proteins determines what organisms are like, how<br>their bodies work and how they behave.<br>% Recombinant: Protein prepared by recombinant technology,<br>coded by the manipulated gene. Procedures are used to join<br>together segments in a cell-free system (an environment<br>outside a cell organism). They are known as highly potent<br>medicines that are safe from off-target side effects and take<br>a shorter time to develop than small molecules.<br>% Recovered plasma: plasma derived from whole blood<br>collected in blood donations<br>% rFVIII: Recombinant Factor VIII is the antihemophilic factor<br>A, obtained using recombinant DNA technology. With this<br>technology, pure factor is synthesized in the laboratory<br>instead of being extracted from blood plasma.<br>% Rh (Rhesus) blood group system: Most important blood<br>group system after ABO. The Rh blood group system consists<br>of 50 defined blood-group recombinant proteins, among<br>which the five recombinant proteins D,C, c, E and are the<br>most important. The commonly used terms Rh factor, Rh<br>positive and Rh negative refer to the D antigen only.<br>% RoW: Rest of the world<br>% SARS-CoV-2: Severe acute respiratory syndrome<br>coronavirus 2 is the strain of coronavirus that causes<br>coronavirus disease 2019 (COVID-19), the respiratory illness<br>responsible for the COVID-19 pandemic.<br>% Secondary immunodeficiency: Occurs when the immune<br>system is compromised due to an environmental factor.<br>Examples of these outside forces include HIV, chemotherapy,<br>severe burns or malnutrition.<br>% SCIG: subcutaneous immunoglobulin<br>% Single-cell transcriptomics: technique to characterize cell<br>identity.<br>% SubQ: Sub-cutaneous.<br>% Thrombin: Enzyme that presides over the conversion of a<br>substance called fibrinogen to fibrin, which promotes blood<br>clotting.<br>% Transfusion medicine: Branch of medicine that<br>encompasses among others, immunohematology, blood and<br>plasma screening and blood typing.<br>% West Nile Virus (WNV): Virus transmitted by mosquitoes.<br>Humans are mainly infected through mosquito bites, but<br>infection can occur through organ transplantation and blood.<br>% Von Willebrand Disease (vWD): This is the most common<br>hereditary coagulation abnormality described in humans,<br>although it can also be acquired as a result of other medical<br>conditions. It arises from a qualitative or quantitative<br>deficiency of von Willebrand factor (vWF), a multimeric protein<br>that is required for platelet adhesion.<br>% Zika virus: Infectious disease spread by the bite of an<br>infected Aedes species mosquito. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 241 CONTENTS<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>9<br>About<br>this report<br>1<br>About us<br>2<br>Commitment<br>to donors and<br>patients<br>3<br>Ethical<br>commitment<br>4<br>Innovation<br>5<br>Our people<br>6<br>Impact<br>on society<br>7<br>Environmental<br>responsibility<br>8<br>Financial<br>performance<br>Independent Review Report<br>GRI 2-5<br>KPMG Asesores S.L., a limited liability Spanish company and a member firm of the<br>KPMG global organization of independent member firms affiliated with KPMG<br>International Limited, a private English company limited by guarantee.<br>Paseo de la Castellana, 259C – Torre de Cristal – 28046 Madrid<br>KPMG Asesores, S.L.<br>Torre Realia<br>Plaça d’Europa, 41-43<br>08908 L’Hospitalet de Llobregat<br>Barcelona<br>Independent Assurance Report on the Consolidated Director’s<br>Report of Grifols, S.A. and subsidiaries for 2022<br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Reg. Mer Madrid, T. 14.972, F. 53, Sec. 8 , H. M -249.480, Inscrip. 1.ª<br>N.I.F. B-82498650<br>To the Shareholders of Grifols, S.A.:<br>We have been engaged by Grifols, S.A. management to perform a limited assurance review of the<br>accompanying Consolidated Directors’ Report of Grifols, S.A. (hereinafter, the Parent) and subsidiaries<br>(hereinafter, the Group) for the year ended 31 December 2022, prepared with reference to the<br>Sustainability Reporting Standards of the Global Reporting Initiative (GRI Standards) and with the<br>Sustainability Accounting Standards Board (SASB) Standards for Biotechnology & Pharmaceuticals<br>sector (hereinafter, the Report).<br>In addition, pursuant to article 49 of the Spanish Code of Commerce, we have performed a limited<br>assurance review to evaluate whether the Consolidated Non-Financial Information Statement<br>(hereinafter NFIS) of the Group for the year ended 31 December 2022, has been prepared in<br>accordance with prevailing mercantile legislation.<br>The Report includes additional information to that required by GRI Standards, by SASB Standards<br>and prevailing mercantile legislation concerning non-financial information, which has not been the<br>subject of our assurance work. In this respect, our work was limited exclusively to providing<br>assurance on the information contained in the “GRI Content Index”, in the “Appendix I. Table of<br>contents pursuant to Act 11/18 of 28 December on non-financial information and diversity” and in<br>the “SASB Content Index” of the accompanying Report.<br>Responsibility of the Parent’s Directors and Management ___________________<br>The Directors of the Parent are responsible for the content and authorisation for issue of the NFIS<br>included in the Report. The NFIS has been prepared in accordance with prevailing mercantile<br>legislation and selected GRI Standards based on each subject area in the “Appendix I. Table of<br>contents pursuant to Act 11/18 of 28 December on non-financial information and diversity” table of<br>the aforementioned Report.<br>Management of the Parent is responsible for the preparation and presentation of the Report in<br>accordance with the GRI Standards and SASB Standards for Biotechnology & Pharmaceuticals<br>sector in accordance with each subject area in the tables “GRI Content Index” and “SASB Content<br>Index” of the Report.<br>This responsibility also encompasses the design, implementation and maintenance of internal<br>control deemed necessary to ensure that the Report is free from material misstatement, whether<br>due to fraud or error.<br>The Directors of the Parent are also responsible for defining, implementing, adapting and maintaining<br>the management systems from which the information required to prepare the Report was obtained.<br><br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Our Independence and Quality Management _______________________________<br>We have complied with the independence and other ethical requirements of the International Code<br>of Ethics for Professional Accountants (including international independence standards) issued by<br>the International Ethics Standards Board for Accountants (IESBA), which is founded on fundamental<br>principles of integrity, objectivity, professional competence and due care, confidentiality and<br>professional behaviour.<br>Our firm applies current International Quality Standard and accordingly maintains a comprehensive<br>system of quality control including documented policies and procedures regarding compliance with<br>ethical requirements, professional standards and applicable legal and regulatory requirements.<br>The engagement team was comprised of professionals specialised in reviews of non-financial<br>information and, specifically, in information on economic, social and environmental performance.<br>Our Responsibility ________________________________________________________<br>Our responsibility is to express our conclusions in an independent limited assurance report based on<br>the work performed. We conducted our review engagement in accordance with the requirements of<br>the Revised International Standard on Assurance Engagements 3000, “Assurance Engagements<br>other than Audits or Reviews of Historical Financial Information” (ISAE 3000 (Revised)), issued by<br>the International Auditing and Assurance Standards Board (IAASB) of the International Federation of<br>Accountants (IFAC), and with the guidelines for assurance engagements on the Non-Financial<br>Information Statement issued by the Spanish Institute of Registered Auditors (ICJCE).<br>The procedures performed in a limited assurance engagement vary in nature and timing from, and<br>are less in extent than for, a reasonable assurance engagement, and consequently, the level of<br>assurance provided is also lower.<br>Our work consisted of making inquiries of management, as well as of the different units and areas of<br>the Group that participated in the preparation of the Report, reviewing the processes for compiling<br>and validating the information presented in the Report and applying certain analytical procedures and<br>sample review tests, which are described below:<br>- Meetings with the Group’s personnel to gain an understanding of the business model, policies<br>and management approaches applied, the principal risks related to these matters and to obtain<br>the information necessary for the external review.<br>- Analysis of the scope, relevance and completeness of the content of the Report based on the<br>materiality analysis performed by the Group and described in the “About this report” section,<br>considering the content required by prevailing mercantile legislation.<br>- Analysis of the processes for compiling and validating the data presented in the Report for 2022.<br>- Review of the information relative to the risks, policies and management approaches applied in<br>relation to the material aspects presented in the Report for 2022.<br>- Corroboration, through sample testing, of the information relative to the content of the Report<br>for 2022 and whether it has been adequately compiled based on data provided by the<br>information sources.<br>- Procurement of a representation letter from the Directors and management. | ||
| --- | ||
| 2022 Consolidated Directors’ Report · 242<br>GRI 2-5<br><br>(Translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails.)<br>Conclusion _______________________________________________________________<br>Based on the assurance procedures performed and the evidence obtained, nothing has come to our<br>attention that causes us to believe that:<br>a.) The Consolidated Directors’ Report of Grifols, S.A and subsidiaries for the year ended 31 December<br>2022 has not been prepared, in all material respects, with reference to the GRI Standards and<br>with the SASB Standards for Biotechnology & Pharmaceuticals sector as described in the “GRI<br>content index” and in “SASB content index”, respectively, of the aforementioned Report.<br>b.) The NFIS of Grifols, S.A. and subsidiaries for the year ended 31 December 2022 has not been<br>prepared, in all material respects, in accordance with prevailing mercantile legislation and<br>selected GRI Standards based on each subject area in the “Appendix I. Table of contents<br>pursuant to Act 11/18 of 28 December on non-financial information and diversity” of the Report.<br>Emphasis of Matter _______________________________________________________<br>Regulation (EU) 2020/852 of the European Parliament and of the Council of 18 June 2020 on the<br>establishment of a framework to facilitate sustainable investment stipulates the obligation to<br>disclose information on how and to what extent the undertaking’s activities are associated with<br>economic activities aligned to the objectives of climate change mitigation and climate change<br>adaptation. This obligation applies for the first time for the 2022 fiscal year, in addition to the<br>information related to eligible activities required in 2021. Consequently, the attached NFIS does not<br>contain comparative information on alignment. Furthermore, as much as the information on eligible<br>activities in 2021 was not required to be as detailed as in 2022, the disclosures on eligibility included<br>in the attached NFIS are not strictly comparable. The directors of Grifols, S.A. have included<br>information on the criteria that, in their opinion, best allow them to comply with the aforementioned<br>obligations, which are defined in annex XIV “European taxonomy for climate change mitigation and<br>adaptation” of the attached Report. Our conclusion is not modified in respect of this matter.<br>Use and Distribution ______________________________________________________<br>In accordance with the terms of our engagement letter, this Report has been prepared for Grifols,<br>S.A. in relation to its Consolidated Directors’ Report and for no other purpose or in any other context.<br>In relation to the Consolidated NFIS, this report has been prepared in response to the requirement<br>established in prevailing mercantile legislation in Spain, and thus may not be suitable for other<br>purposes and jurisdictions.<br>KPMG Asesores, S.L.4JHOFE PO PSJHJOBM JO 4QBOJTI<br><br>Patricia Reverter Guillot<br>27 February 2023 | ||
| --- | ||
| GRIFOLS, S.A. AND SUBSIDIARIES<br>(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)<br>At their meeting held on 23 February 2023, pursuant to legal requirements, the Directors<br>of Grifols, S.A. authorized for issue the consolidated annual accounts and consolidated<br>directors’ report for the period from 1 January 2022 to 31 December 2022. The<br>consolidated annual accounts comprise the documents that precede this certification.<br>Thomas Glanzmann<br>(signed)<br>Executive Chairman<br> Raimon Grifols Roura<br>(signed)<br>Chief Executive Officer<br> Víctor Grifols Deu<br>(signed)<br>Chief Executive Officer<br><br><br>Victor Grifols Roura<br> (signed)<br> Carina Szpilka Lázaro<br> (signed)<br> Tomás Dagà Gelabert<br> (signed)<br>Board member Board member Board member<br><br><br><br>Iñigo Sánchez-Asiaín<br>Mardones<br>(signed)<br> Enriqueta Felip Font<br>(signed)<br>Board member<br> James Costos<br>(signed)<br>Board member<br>Board member<br><br><br><br>Montserrat Muñoz<br>Abellana<br>(signed)<br> Susana González<br>Rodríguez<br>(signed)<br>Nuria Martín Barnés<br>(signed)<br>Secretary to the Board<br>Board member Board member | ||
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
| Grifols, S.A. | ||
|---|---|---|
| By: | /s/ David I. Bell | |
| Name: | David I. Bell | |
| Title: | Authorized Signatory |
Date: February 28, 2023